

Urinary stone management: Exploring innovative techniques and technologies

Plenary Session

05 April 2024
08:00 - 10:00

Location Green Area, eURO Auditorium 1
Chairs A. Bujons Tur, Barcelona (ES)
T. Knoll, Sindelfingen (DE)

08:00 - 08:01	Introduction T. Knoll, Sindelfingen (DE)
08:01 - 08:09	State-of-the-art lecture Radiation dose in endourology: How to achieve ALARA? E. Emiliani, Barcelona (ES)
08:09 - 08:17	State-of-the-art lecture Do we treat our patients right? Shared decision making and patient reported outcome measures in urolithiasis To be confirmed
08:17 - 08:34	Case discussion How I evaluate and counsel high-risk stone formers Moderator M. Straub, Munich (DE)
08:17 - 08:19	Case presentation M. Straub, Munich (DE)
08:19 - 08:34	Discussion Panel A. Skolarikos, Athens (GR) M. Monga, Cleveland (US) C.A. Wagner, Zurich (CH)
08:34 - 08:46	American Urological Association (AUA) lecture Role and outcomes of suction devices in ureteroscopy B. H. Eisner, Boston (US)
08:46 - 09:06	Debate URS with modern lasers for larger stones? Moderator M. Brehmer, Stockholm (SE)
08:46 - 08:48	Introduction M. Brehmer, Stockholm (SE)
08:48 - 08:53	Yes: URS for big stones Ö. Ulvik, Bergen (NO)
08:53 - 08:58	No: PCNL for big stones T.E. Şener, Istanbul (TR)
08:58 - 09:06	Discussion
09:06 - 09:16	Case-based video presentation PCNL troubleshooting in cases with previous renal surgery W. Gamal, Sohag (EG)
09:16 - 09:43	Case discussion The grey zone: The best treatment for a 1.5 cm pelvic stone is... Moderator T. Tailly, Ghent (BE)

Scientific Programme - EAU24

09:16 - 09:18	Case presentation T. Taily, Ghent (BE)
09:18 - 09:23	Ureteroscopy To be confirmed
09:23 - 09:28	Percutaneous nephrolithotomy J. Desai, Ahmedabad (IN)
09:28 - 09:33	Shock wave lithotripsy M.M. Popiolek, Örebro (SE)
09:33 - 09:43	Discussion
09:43 - 09:51	State-of-the-art lecture Status of robotics in ureteroscopy S.Y. Cho, Seoul (KR)
09:51 - 09:59	State-of-the-art lecture Follow-up imaging after stone treatment: Is standardisation of post-up imaging possible? A. Pietropaolo, Southampton (GB)
09:59 - 10:00	Closing remarks A. Bujons Tur, Barcelona (ES)

Controversies on GU cancer staging: Is it only imaging?

Plenary Session

05 April 2024
08:00 - 10:00

Location Purple Area, eURO Auditorium 2
Chairs M. Rouprêt, Paris (FR)
J. Walz, Marseille (FR)

08:00 - 08:03	Welcome and introduction
08:03 - 08:38	Controversies in initial staging for prostate cancer
	Disease characterisation
08:03 - 08:10	Advantages and pitfalls of molecular imaging K. Herrmann, Essen (DE)
08:10 - 08:17	Are biomarkers better? B.F. Chapin, Houston (US)
	The PSMA M1a positive patient
08:17 - 08:24	Treat as M1 C. Sweeney, Adelaide (AU)
08:24 - 08:31	Treat as M0 H.G. Van Der Poel, Amsterdam (NL)
08:31 - 08:38	Discussion
08:38 - 09:06	Controversies in initial staging for renal cell cancer
08:38 - 08:45	Evaluation with conventional imaging is enough J-C. Bernhard, Bordeaux (FR)
08:45 - 08:52	Evaluation with molecular imaging is the way to go P. Mulders, Nijmegen (NL)
08:52 - 08:59	Biopsy and pathology is the solution To be confirmed
08:59 - 09:06	Discussion
09:06 - 09:48	Controversies in initial staging for bladder cancer
09:06 - 09:13	No need for TURB, Vi-RADS makes the diagnosis V. Panebianco, Rome (IT)
09:13 - 09:20	TURB is mandatory before any treatment A.G. Van Der Heijden, Nijmegen (NL)
	Disease characterisation
09:20 - 09:27	FDG-PET for staging, is it mandatory? S. Shariat, Vienna (AT)
09:27 - 09:34	Histological variants, molecular phenotype and biomarkers are enough E. Compérat, Vienna (AT)
09:34 - 09:41	MRI in evaluation after neoadjuvant chemotherapy A. Necchi, Milan (IT)
09:41 - 09:48	Discussion

Scientific Programme - EAU24

09:48 - 09:58

The COPRA initiative (Comprehensive PSMA PET Reporting Recommendation)

A.S. Bjartell, Malmö (SE)

09:58 - 10:00

Closing remarks

Office management of male sexual dysfunction

ESU Course 01

05 April 2024
08:30 - 11:30

Location Purple Area, E01
Chair M.M. Fode, Herlev (DK)

Learning objectives

The course will enable participants to perform a basic diagnostic evaluation and give knowledge of advanced diagnostic methods. Participants will learn when testosterone replacement therapy is indicated and how to apply it and how to tailor PDE5-Is to the individual patient. Further, participants will gain insight into more advanced medical and mechanical ED treatments. The course will also include discussions of management/controversies regarding:

- Ejaculatory dysfunction
- Priapism
- Recurrent priapism
- Sexual rehabilitation following radical prostatectomy

Introduction

M.M. Fode, Herlev (DK)

Diagnostics: What is necessary?

D. Hatzichristou, Thessaloniki (GR)

Testosterone replacement

E.C. Şerefoğlu, Istanbul (TR)

Oral therapy for erectile dysfunction

M.M. Fode, Herlev (DK)

Therapy of erectile dysfunction when pills fail

D. Hatzichristou, Thessaloniki (GR)

Tips, tricks and questions from the audience

M.M. Fode, Herlev (DK)

D. Hatzichristou, Thessaloniki (GR)

E.C. Şerefoğlu, Istanbul (TR)

Management of ejaculatory dysfunction

E.C. Şerefoğlu, Istanbul (TR)

Peyronie's disease and priapism

D. Hatzichristou, Thessaloniki (GR)

What to do after radical prostatectomy?

M.M. Fode, Herlev (DK)

Chronic pelvic pain in men and women

ESU Course 02

05 April 2024
08:30 - 11:30

Location Purple Area, E03
Chair B. Parsons, Exeter (GB)

Learning objectives

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures, theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well-known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

Chronic pelvic pain, the basics: Mechanisms and terminology

P. Abreu-Mendes, Porto (PT)

Chronic pelvic pain in men: Case presentation and discussion

B. Parsons, Exeter (GB)

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment

B. Parsons, Exeter (GB)

Chronic pelvic pain in women: Case presentation and discussion

P. Abreu-Mendes, Porto (PT)

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment

P. Abreu-Mendes, Porto (PT)

The interdisciplinary approach: Team members and organisation

B. Parsons, Exeter (GB)

Male genital diseases

ESU Course 03

05 April 2024
08:30 - 11:30

Location Purple Area, E04
Chair S. Minhas, London (GB)

Learning objectives

This novel and revised course will give a state-of-the-art update on the variety of genital diseases that urologists will encounter in daily clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case-based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

- The aetiology, diagnosis and medical management of the common genital skin diseases including inflammatory conditions.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
- The surgical management of Peyronie's disease including plication procedures and grafting
- The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ-sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

Surgical management of Peyronie's disease

S. Minhas, London (GB)

Penile and scrotal dermatology for the urologist

M. Skrodzka, London (GB)

Circumcision, frenuloplasty and preputioplasty

A. Parnham, Manchester (GB)

The buried penis

S. Minhas, London (GB)

Management of genital lymphoedema

M. Skrodzka, London (GB)

Premalignant lesions of the penis and scrotum

S. Minhas, London (GB)

Penile cancer: Penile preserving surgery

M. Skrodzka, London (GB)

Penile cancer: Management of lymph nodes

A. Parnham, Manchester (GB)

Practical approach to paediatric urology

ESU Course 04

05 April 2024
08:30 - 11:30

Location Purple Area, E05
Chair F. O'Kelly, Dublin (IE)

Learning objectives

Many children with congenital anomalies will present to the adult urologist with long-term sequelae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what is expected and what should or can be done. It is also important to know how the urological follow-up of these patients should be done. The most common paediatric conditions will be explored by interactive case presentations.

- Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty.
- The clinical presentation of congenital anomalies of the urinary tract has changed, because of prenatal US, but sometimes adults may present with the classical symptoms.
- Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature. The treatment modalities and long-term outcomes depend on the pathophysiology.

Vesico-ureteral reflux (VUR)

F. O'Kelly, Dublin (IE)

Vesico-ureterale reflux and voiding dysfunction

F. O'Kelly, Dublin (IE)

Ureteropelvic junction (UPJ) obstruction

B. Burgu, Ankara (TR)

Most frequent penile abnormalities

B. Burgu, Ankara (TR)

Megaureter

B. Burgu, Ankara (TR)

Urethral valves

R.J.M. Lammers, Groningen (NL)

Neurogenic bladder

R.J.M. Lammers, Groningen (NL)

Ectopic ureter

F. O'Kelly, Dublin (IE)

Focal therapy in prostate cancer

ESU Course 05

05 April 2024
08:30 - 11:30

Location Purple Area, E06
Chair E. Barret, Paris (FR)

Learning objectives

Focal treatment (FT) is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates:

- understanding of the rationale for focal treatment and patient selection criteria.
- an update on principles, outcome and side effects of focal technologies.
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries.

As men with prostate cancer are getting younger, the side effects of whole-gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

Definition, rationale and role in the changing landscape of localised prostate cancer

C. Orczyk, London (GB)

Patient selection tools

J.I. Martínez Salamanca, Madrid (ES)

How to select the energy source?

E. Barret, Paris (FR)

The post-treatment monitoring

C. Orczyk, London (GB)

The outcomes and the ongoing trials

J.I. Martínez Salamanca, Madrid (ES)

Clinical cases: Real-life cases, stories of success and failure

E. Barret, Paris (FR)

Advanced course on laparoscopic renal surgery

ESU Course 06

05 April 2024
08:30 - 11:30

Location Purple Area, E07
Chair A. Breda, Barcelona (ES)

Learning objectives

Minimally-invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischaemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

Introduction

A. Breda, Barcelona (ES)

Transperitoneal renal surgery: Step by step

A. Breda, Barcelona (ES)

Retroperitoneal renal surgery: Step by step

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Complex kidney cases

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Intraoperative complications: Incidence and management

P.J. Zondervan, Amsterdam (NL)

Postoperative complications: Incidence and management

A. Breda, Barcelona (ES)

Special cases

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Urological patient presentations

Patient information session - Posters

05 April 2024
09:00 - 10:00

Location Green Area, W08
Chair E. Rogers, Roscommon (IE)

Learning objectives

The session seeks to highlight the needs of patients with urological disease; identify innovations in patient-centred care, and to listen to patients' voices as they report the outcomes and experiences of their treatment.

Presentations have a length of 5 minutes and are followed-up by 4 minutes discussion.

09:00 - 09:01

Introduction

PA1

How can patients be better supported when deciding on localised kidney cancer treatment?

Authors: Beyer K.¹, Venderbos L.D.F.¹, Roobol M.J.¹, Giles R.², Verhagen P.¹, Barod R.³, Wintner L.M.⁴, Van Hemelrijck M.⁵, Kinsella N.⁶

Institutes: ¹Erasmus MC Cancer Institute Erasmus University Medical Center Rotterdam, Dept. of Urology, Rotterdam, The Netherlands, ²International Kidney Cancer Coalition, Duivendrecht, The Netherlands, ³Royal Free Hospital, Specialist Centre for Kidney Cancer, London, United Kingdom, ⁴Medical University of Innsbruck, Dept. of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Innsbruck, Austria, ⁵King's College London, Translational Oncology and Urology Research TOUR, London, United Kingdom, ⁶Royal Marsden Hospital, Dept. of Urology, London, United Kingdom

PA2

Does video-based informed consent influence peri-operative experiences in patients who had undergone renal cancer surgery?

Authors: Marchetti M., Reissis D., Barod R.

Institutes: Royal Free Hospital, Renal and Urology Department, London, United Kingdom

PA3

Patient treatment experience in prostate cancer: Findings from a web-based survey

Authors: Moneer S.¹, Patch J.¹, Brown L.², Sutton L.³

Institutes: ¹ZERO Prostate Cancer, Patient Programs and Education, Alexandria, United States of America, ²Pfizer Inc., Global Medical Affairs Oncology, Colleagueville, United States of America, ³Duke University, Duke Cancer Network, Durham, United States of America

PA4 **Action on shared decision-making from a multi-stakeholder collaboration on continence care**

Authors: Van Poelgeest-Pomfret M.L.¹, Michalek T.¹, Blasco-Hernández P.², Castro-Diaz D.³, Rogers E.⁴, Martín-Martinez A.⁵, Bates F.⁶, Cruz F.⁷, Arlandis Guzmán S.⁸, van Kerrebroeck P.⁹

Institutes: ¹World Federation of Incontinence and Pelvic Problem, Bari, Italy, ²Sociedad Iberoamericana de Neurourología y Uroginecología, University Hospital Valme, Sevilla, Spain, ³International Continence Society, Universitario de Canarias, Tenerife, Spain, ⁴European Association of Urology, Patient Office, Arnhem, The Netherlands, ⁵Sociedad Iberoamericana de Neurourología y Uroginecología, Hospital Materno-Infantil de Canarias, Las Palmas de Gran Canaria, Spain, ⁶International Continence Society, Urology Wellness St Josephs Hospital, New Brunswick, Canada, ⁷Sociedad Iberoamericana de Neurourología y Uroginecología, Universidade de Porto, Porto, Portugal, ⁸Sociedad Iberoamericana de Neurourología y Uroginecología, La Fe University and Polytechnic Hospital, Valencia, Spain, ⁹European Association of Urology, Policy Office, Arnhem, The Netherlands

PA5 **Barriers and solutions for patient engagement in oncology research: Findings from Project RISE**

Authors: Bognanno T.¹, Geissler J.², Rogers E.³, Efstathiou E.⁴, Perkins T.⁵, Wolf Gianares B.⁶, Schuler K.⁷, Larsen V.⁸, Lobban D.⁹, Dormer L.¹⁰, Scott J.⁸, Daly J.¹¹

Institutes: ¹Alliance Practice, Alliance Practice, Springfield, United States of America, ²Patvocates, Munich, Germany, ³University College Hospital Galway, Dept. of Urology, Galway, Ireland, ⁴Houston Methodist Cancer Center, Genitourinary Medical Oncology, Houston, United States of America, ⁵Envision Pharma Group, Two Labs, Philadelphia, United States of America, ⁶Pfizer Inc., Pfizer Oncology, New York, United States of America, ⁷Pfizer Inc., Pfizer Oncology, Collegeville, United States of America, ⁸Legacy Health Strategies, Legacy Health Strategies, Del Mar, United States of America, ⁹Envision Pharma Group, Envision the Patient, Wilmslow, United Kingdom, ¹⁰Beclaris Publishing Ltd, Royston, United Kingdom, ¹¹East Galway and Midlands Cancer Support, Services, Ballinasloe, Ireland

PA6 **Why is the GU oncology clinic lagging in shared-decision making?**

Authors: Giles R.¹, Marconi L.², Jonasch E.³, Jewett M.⁴

Institutes: ¹International Kidney Cancer Coalition, Dept. of Advocacy, Duivendrecht, The Netherlands, ²Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ³University of Texas MD Anderson, Dept. of Medical Oncology, Houston, United States of America, ⁴University of Toronto, Dept. of Surgical Urology, Toronto, Canada

09:55 - 10:00

Closing remarks and announcement of prize winners

BPO surgery: Ablative surgical options

Abstract session 10

06 April 2024
12:00 - 13:30

Location Purple Area, S01
Chairs S. Madersbacher, Vienna (AT)
To be confirmed
To be confirmed

A0172

Benign prostatic hyperplasia surgery: A contemporary ten-year analysis of usage trends and costs from a large US database

Authors: Manfredi C.¹, Franco A.¹, Ditunno F.¹, Bologna E.¹, Licari L.¹, De Nunzio C.², Arcaniolo D.³, Romero-Otero J.⁴, Cindolo L.⁵, Antonelli A.⁶, Porphiglia F.⁷, De Sio M.³, Autorino R.¹

Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²Sant Andrea Hospital Sapienza University, Dept. of Urology, Rome, Italy, ³University of Campania Luigi Vanvitelli, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ⁴HM Hospitales, Dept. of Urology, Madrid, Spain, ⁵Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy, ⁶Azienda Ospedaliera Universitaria Integrata University of Verona, Dept. of Urology, Verona, Italy, ⁷San Luigi Gonzaga Hospital University of Turin, Dept. of Urology, Turin, Italy

A0165

Changing trends in the surgical management of BPO in Europe

Authors: Turney B.W.¹, Wetterauer C.², Sato R.³, Demaire C.³, Bruno L.³

Institutes: ¹University of Oxford, Dept. of Urology, Oxford, United Kingdom, ²University Hospital Basel, Dept. of Urology, Basel, Switzerland, ³Boston Scientific Corporation, Dept. of Urology, Marlborough, United States of America

A0163

The impact of the surgical waiting list for transurethral resection of the prostate on patient's clinical course: a single center investigation

Authors: Boeri L., Roberto D., Scanferla E., Molteni S., Marmiroli A., Nizzardo M., Nardini S., Quistini A., Zanetti S.P., Longo F., Albo G., Montanari E., De Lorenzis E.

Institutes: Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

A0160

Holmium Laser Enucleation of the Prostate (HoLEP) for very large benign prostatic hyperplasia (>200 ml):

long term outcome of a large series.

Authors: Tallè M., Mengoni F., Dente D., Orciani R., Papaveri A., Cafarelli A.

Institutes: Villa Igea Private Hospital, Dept. of Urology, Ancona, Italy

A0170

Day-case HOLEP : succes rate and predictive factor of D0 discharge after 10 years of clinical experience

Authors: Lacroix X., Klein C., Capon G., ALEZRA E., Blanc P., Estrade V., Bernhard J.C., Bladou F., Robert G.

Institutes: Bordeaux CHU, Gironde, Bordeaux, France

- A0168** **Impact of Laser energy and rate of enucleated prostate tissue in the early functional outcomes of Holmium Laser Enucleation of Prostate (HoLEP).**
Authors: Fernández-Pello Montes S., Gonzalez I., Rodríguez Villamil L., Blanco R., Martín L., Rivas M.
Institutes: Cabuenes University Hospital, Dept. of Urology, Gijón, Spain
- A0175** **Impact of total laser energy on functional outcome following Holmium Laser Enucleation of the prostate**
Authors: Westhofen T., Eismann L., Rodler S., Jokisch J.F., Becker A., Stief C.G., Weinhold P.
Institutes: University Hospital Großhadern Ludwig Maximilians University Munich, Dept. of Urology, Munich, Germany
- A0174** **Moses 2.0 Technology for holmium laser enucleation of the prostate in the treatment of BPH: Prospective randomized double-blind study**
Authors: Sun J., Xia S., Tricard T., Tong Z., Chen B.
Institutes: Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China
- A0162** **Analysis of the morcellation efficiency after HoLEP of the Multicut® device: the new standard of care?**
Authors: García Gómez B.¹, Gil Moradillo J.¹, Sola Galarza I.², Gimeno Collado A.², García González L.¹, González Ginel I.¹, Juste Álvarez S.¹, Rodríguez Antolín A.¹
Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Lyx Urología, Dept. of Urology, Madrid, Spain
- A0171** **Thulium Fiber Laser vs Thulium:YAG en-block laser enucleation of the prostate. A comparison of perioperative outcomes**
Authors: Perri D.¹, Besana U.¹, Pacchetti A.¹, Morini E.¹, Mazzoleni F.¹, Roche J.B.², Gozen A.S.³, Ribeiro De Oliveira T.⁴, Rocco B.⁵, Bozzini G.¹
Institutes: ¹Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²Clinique Saint-Augustin, Dept. of Urology, Bourdeaux, France, ³SLK-Kliniken, Dept. of Urology, Heilbronn, Germany, ⁴Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ⁵ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy
- A0169** **Thulium Laser energy versus Bipolar current in transurethral enucleation of large prostates; a multicenter prospective randomized study**
Authors: Yehia Abdelaziz A.¹, Eladawy M.S.², Abdelhamid M.¹
Institutes: ¹Cairo University, Dept. of Urology, Cairo, Egypt, ²Fayoum University, Dept. of Urology, Fayoum, Egypt

A0176

Real-world complications of anatomical endoscopic enucleation of the prostate: Lessons from the 6193 patients from the Refinement in Endoscopic Anatomical enucleation of Prostate (REAP) registry

Authors: Lim E.J.¹, Herrmann T.R.W.², Castellani D.³, Fong K.Y.⁴, Biligere S.⁵, Aslim E.J.¹, Tursunkulov A.N.⁶, Dellabella M.⁷, Sancha F.G.⁸, Sofer M.⁹, Enikeev D.¹⁰, Petov V.¹⁰, Gadzhiev N.¹¹, Elterman D.¹², Mahajan A.¹³, Socarrás M.R.⁸, Yunusov D.S.⁶, Nasirov F.⁶, Teoh J.¹⁴, Somani B.K.¹⁵, Gauhar V.⁵

Institutes: ¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Kantonspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, ³Università Politecnica delle Marche, Urology Unit, Ancona, Italy, ⁴National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁵Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁶AkfaMedline Hospital, Urology Division, Tashkent, Uzbekistan, ⁷INRCA Istituto Nazionale di Ricovero e Cura per Anziani, Dept. of Urology, Ancona, Italy, ⁸ICUA-Clínica CEMTRO, Dept. of Urology and Robotic Surgery, Madrid, Spain, ⁹Tel Aviv Sourasky Medical Center, Urology Division, Tel Aviv, Israel, ¹⁰Sechenov University, Dept. of Urology, Moscow, Russia, ¹¹Saint-Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ¹²University of Toronto, Division of Urology, Toronto, Canada, ¹³Sai Urology Hospital, Dept. of Urology, Aurangabad, India, ¹⁴The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, China, ¹⁵University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom

A0173

Endoscopic enucleation of large prostates > 80 cc in men aged 80 years and older. Double trouble? Outcomes from a global multicentre experience using different energy sources and techniques.

Authors: Pirola G.M.¹, Gökce M.I.², Fong K.Y.³, Gadzhiev N.⁴, Malkhasyan V.⁵, Naselli A.⁶, Mahajan A.⁷, Maheshwari P.N.⁸, Tursunkulov A.N.⁹, Nasirov F.⁹, Petov V.¹⁰, Lim E.J.¹¹, Socarras M.R.¹², Gomez-Sancha F.¹², Zawadzki M.¹³, Cormio L.¹⁴, Biligere S.¹⁵, Busetto G.M.¹⁶, Somani B.K.¹⁷, Enikeev D.¹⁸, Dellabella M.¹⁹, Sofer M.²⁰, Herrmann T.R.W.²¹, Gauhar V.¹⁵

Institutes: ¹IRCCS Multimedica, Dept. of Urology, Milan, Italy, ²Ankara University, Dept. of Urology, Ankara, Türkiye, ³National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁴Saint-Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁵Moscow State University of Medicine and Dentistry, Urology Unit, Dept. of Urology, Moscow, Russia, ⁶IRCCS Multimedica, Dept. of Urology, Milan, Italy, ⁷Sai Urology Hospital, Dept. of Urology, Aurangabad, India, ⁸Fortis Hospital Mulund, Dept. of Urology, Mumbai, India, ⁹AkfaMedline Hospital, Dept. of Urology, Tashkent, Uzbekistan, ¹⁰Sechenov University Institute for Urology and Reproductive Health, Dept. of Urology, Moscow, Russia, ¹¹Singapore University, Dept. of Urology, Singapore, Singapore, ¹²Clinica CEMTRO, Dept. of Urology, Madrid, Spain, ¹³St. Anna Hospital, Dept. of Urology, Piaseczno, Poland, ¹⁴Ospedale L. Bonomo, Dept. of Urology, Andria, Italy, ¹⁵Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁶University of Foggia, Dept. of Urology, Foggia, Italy, ¹⁷Southampton University, Dept. of Urology, Southampton, United Kingdom, ¹⁸Vienna University, Dept. of Urology, Vienna, Austria, ¹⁹IRCCS Inrca, Dept. of Urology, Ancona, Italy, ²⁰Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel, ²¹Kantonspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland

A0166

Risk of Acute Urinary Retention After-HoLEP – Results from a Prospective Trial

Authors: Capogrosso P.¹, Rosiello G.², Ventimiglia E.², Pozzi E.², Belladelli F.², Bertini A.², Schifano N.¹, Candela L.², Dehò F.¹, Briganti A.², Salonia A.², Montorsi F.²

Institutes: ¹ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi - University of Insubria, Dept. of Urology, Varese, Italy, ²IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

A0164

Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

Authors: Omidele O.O., Siegal A.S., Kaplan S.A.

Institutes: Icahn School of Medicine, Dept. of Urology, New York, United States of America

A0159

Waterjet ablation therapy (aquabeam) vs. urethral-sparing robot-assisted simple prostatectomy for large prostate volumes (>80 mL): results of a multicentric series according to the standardized BPH-6 achievement

Authors: Anceschi U.¹, Basile S.¹, Amparore D.², Siena G.³, Cocci A.³, Prata F.¹, De Cillis S.², Sessa F.³, Bove A.M.¹, Viola L.³, Ragusa A.¹, Brassetti A.¹, Tuderti G.¹, Mastroianni R.¹, Ferriero M.¹, Misuraca L.¹, Zampa A.¹, Quarà A.², Ortenzi M.², Checcucci E.², Fiori C.², Porpiglia F.², Minervini A.³, Simone G.¹

Institutes: ¹IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Luigi Gonzaga Hospital - University of Turin, Dept. of Urology, Orbassano, Italy, ³AOU Careggi - University of Florence, Dept. of Urology, Florence, Italy

A0167

Water vs. Water II 5-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30-80 cc and 80-150 cc prostates

Authors: Berjaoui M.B.¹, Nguyen D.D.¹, Almoussa S.², Barber N.³, Bidair M.³, Gilling P.⁴, Anderson P.⁵, Zorn K.C.², Badlani G.⁶, Humphreys M.⁷, Kaplan S.⁸, Kaufman R.⁹, Elterman D.¹, Desai M.¹⁰, Roehrborn C.¹¹, Bhojani N.²

Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Centre Hospitalier de l'Université de Montreal, Dept. of Urology, Montreal, Canada, ³McGill University, Dept. of Urology, Montreal, Canada, ⁴Bay of Plenty District Health Board Clinical School, Dept. of Urology, Tauranga, New Zealand, ⁵Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁶Wake Forest School of Medicine, Dept. of Urology, North Carolina, United States of America, ⁷Mayo Clinic, Dept. of Urology, Phoenix, United States of America, ⁸Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ⁹Albany Medical College, Dept. of Urology, Albany, United States of America, ¹⁰University of Southern California, Dept. of Urology, Los Angeles, United States of America, ¹¹UT Southwestern Medical Centre, Dept. of Urology, Texas, United States of America

A0161

Robot-Assisted Simple Prostatectomy versus Holmium Laser Enucleation for the Treatment of Benign Prostatic Hyperplasia in Large (>100 ml) Prostates: Updated Comparative Analysis from a High-Volume Center

Authors: Mottaran A.¹, Balestrazzi E.², Bravi C.A.², Nocera L.², Paciotti M.², Sarchi L.², Piramide F.², Ticonosco M.², Frego N.², Colla Ruvolo C.², Belmonte M.², Pissavini A.², Rebuffo S.², Sorce G.², De Groote R.³, De Naeyer G.³, Schatteman P.³, Mottrie A.²

Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ²ORSI Academy, Dept. of Urology, Ghent, Belgium, ³OLV Hospital, Dept. of Urology, Aalst, Belgium

Nutrition: Patients with cancer and the importance of nutrition

Patient information session - Roundtable

05 April 2024
10:15 - 11:15

Location

Green Area, W08

Chair

Patient Advocate - R.S. Greene, Amsterdam (NL)

Learning objectives

The roundtable, 'The Impact of Nutrition on Urological Cancers,' will feature insights from a medical professional, dietician/nutritionist, patient, and oncology nurse. Discussions include nutrition's importance, its role in a healthy lifestyle, its link to prostate cancer, and the oncology nurse's role in nutritional support. Participants will learn about challenges due to limited nutrition understanding. The conversation will explore customizing a healthy lifestyle, potentially through a five-step plan, to address nutritional challenges during and after prostate cancer treatment. The role of oncology nurses in providing nutritional support will be a key focus.

10:15 - 10:20

Welcome and introduction

Patient Advocate - R.S. Greene, Amsterdam (NL)

10:20 - 10:30

The significance of nutrition

To be confirmed

10:30 - 10:40

Role of nutrition in a healthy lifestyle

To be confirmed

10:40 - 10:50

Nutrition and prostate cancer

Patient Advocate - P.S. Huesmann, Milan (IT)

10:50 - 11:00

Benefits of multimodal prehabilitation interventions

B. Thoft Jensen, Aarhus (DK)

11:00 - 11:15

Q&A and closing

Patient Advocate - R.S. Greene, Amsterdam (NL)

Innovations in urolithiasis management

Video session 05

06 April 2024
12:00 - 13:30

Location Green Area, S04
Chairs To be confirmed
W. Krajewski, Wrocław (PL)
To be confirmed

- V033 **Ureterorenoscopic Thulium Laser Lithotripsy in the Treatment of Staghorn Calculi (TUNNEL's Technique)**
Authors: Nouri M., Abbass A.
Institutes: Achifaa Clinic Oujda, Dept. of Urology, Oujda, Morocco
- V034 **Laser for Stones Thulium is The Best?**
Authors: Martov A.G., Andronov A.S., Adilhanov M.M.
Institutes: Burnazyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Dept. of Urology and Andrology, Moscow, Russia
- V035 **Bilateral mini-percutaneous nephrolithotomy in a single surgical time: Step-by-step guided surgery and results from the experience of a high volume center**
Authors: Sanz - Gómez I., Kanashiro A., Sánchez R., Emiliani E., Palou J., Angerri O.
Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- V036 **Step-by-Step guide to Flexible And Navigable suction ureteric access Sheath (FANS)**
Authors: Gauhar V.¹, Ong C.¹, Traxer O.², Chew B.H.³, Gadzhiev N.⁴, Teoh J.⁵, Hamri S.⁶, Heng C.T.¹, Tiong H.Y.⁷, Castellani D.⁸, Somani B.K.⁹, Ragoori D.¹⁰
Institutes: ¹Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ²Sorbonne University, Dept. of Urology, Paris, France, ³University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁴Pavlov First Saint Petersburg State Medical University, Dept. of Urology, Saint Petersburg, Russia, ⁵S.H. Ho Urology Centre, Dept. of Urology, Hong Kong, Hong Kong, ⁶King Saud Bin Abdulaziz University for Health Sciences, Dept. of Urology, Riyadh, Saudi Arabia, ⁷National University Hospital, Dept. of Urology, Singapore, Singapore, ⁸Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ⁹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁰Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India
- V037 **Percutaneous cystolithotomy in an augmentation cystoplasty with Mitrofanoff**
Authors: Diéguez Aguirre L., Quiroz Y., Jiménez R., Bujons A.
Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- V038 **Robotic retrograde intrarenal surgery for urolithiasis**
Authors: Farré Alejo A., Casadevall M., Kanashiro A., Balanà J., Sánchez-Martin F., Millán F., Esteban E., Angerri O.
Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain

- V039** **The ILY Robotic Flexible Ureteroscopy: A comprehensive operative guide and demonstration**
Authors: Abou Chawereb E.¹, Zein M.¹, El Baba B.¹, Wahoud N.², El Hajj A.¹
Institutes: ¹American University of Beirut Medical Center, Dept. of Surgery Division of Urology, Beirut, Lebanon, ²American University of Beirut, Medical School, Beirut, Lebanon
- V040** **Robot-assisted flexible reno-ureteroscopy with the ILY® robot: First italian clinical experience**
Authors: Cossu M.¹, Quarà A.¹, Poggio M.¹, De Cillis S.¹, Amparore D.¹, Checcucci E.², Piana A.³, Piramide F.¹, Volpi G.², Verri P.¹, Sica M.¹, Burgio M.¹, Busacca G.¹, Ortenzi M.¹, Garzena V.¹, Turcan A.¹, Garino D.¹, Ferrando L.¹, Manfredi M.¹, Fiori C.¹, Porpiglia F.¹
Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy

Future-proofing urology: Large language models and E-Health

Abstract session 51

06 April 2024
12:00 - 13:30

Location Purple Area, E01
Chairs To be confirmed
K-F. Kowalewski, Mannheim (DE)
To be confirmed

12:00 - 12:30

E-health

A0183

Digital remote monitoring and machine learning (ML) modeling to predict survival following radical cystectomy for bladder cancer – a secondary outcome analysis of the iROC trial

Authors: Khetrapal P.¹, Liu Y.², Ambler G.¹, Williams N.R.¹, Sridhar A.³, Khan M.S.⁴, Ahmed I.⁵, Charlesworth P.⁶, Kotwal S.⁷, Rowe E.⁸, Koupparis A.⁸, Hanchanale V.⁹, Mcgrath J.¹⁰, Vasdev N.¹¹, Zhou Y.¹, Catto J.W.F.¹², Drobnjak I.², Kelly J.D.¹

Institutes: ¹University College London, Dept. of Urology, London, United Kingdom, ²University College London, Dept. of Computer Science, London, United Kingdom, ³University College London Hospital, Dept. of Urology, London, United Kingdom, ⁴Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁵University of Glasgow, CRUK Scotland Institute and the School of Cancer Sciences, Glasgow, United Kingdom, ⁶Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ⁷St James University Hospital, Dept. of Urology, Leeds, United Kingdom, ⁸North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ⁹Royal Liverpool University Teaching Hospital, Dept. of Urology, Liverpool, United Kingdom, ¹⁰Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ¹¹East and North Hertfordshire NHS Trust, Dept. of Urology, London, United Kingdom, ¹²University of Sheffield, School of Medicine and Population Health, Sheffield, United Kingdom

A0178

Electronic patient reported outcome measures (ePROM) collected through smartphone text messages.

Authors: Munk L., Kumasegaram V., Hyldgaard J., Jensen J.B., Lindgren M.S.

Institutes: Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark

A0182

A prospective multicenter clinical trial for efficacy of mobile uroflowmetry in benign prostatic hyperplasia undergoing transurethral resection: Interim results

Authors: Song S.H.¹, Park J.¹, Song J.¹, Jeong Y.¹, Ryu H.², Lee J.W.³, Lee S.C.¹

Institutes: ¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Ewha Womans University Medical Center, Dept. of Urology, Seoul, South Korea, ³Kyung Hee University Medical Center, Dept. of Urology, Seoul, South Korea

- A0189** **Opportunities of home uroflowmetry enabled by digital health technologies.**
Authors: Van Beeck Morales E.¹, Peters M.², Pauwels J.², Bladt L.³, Vermandel A.¹, De Wachter S.¹, De Win G.¹
Institutes: ¹University Hospital Antwerp, Dept. of Urology, Antwerp, Belgium, ²University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium, ³University of Antwerp, Faculty of Product Design, Antwerp, Belgium
- A0177** **Challenges in E-health: the effect of digitalisation of frequency voiding charts on compliance in paediatric patients. Randomised controlled trial comparing digital and paper frequency voiding charts.**
Authors: de Wall L.L.¹, Kragt E.A.M.¹, van de Wetering E.H.M.¹, Cobussen-Boekhorst J.G.L.¹, Mantel-Van Stel J.², Kortmann B.B.M.¹, Feitz W.F.J.¹, Bootsma-Robroeks C.M.H.H.T.³
Institutes: ¹Radboudumc, Amalia Children's Hospital, Dept. of Paediatric Urology, Nijmegen, The Netherlands, ²University Medical Center Groningen, Dept. of Paediatric Urology, Groningen, The Netherlands, ³University Medical Center Groningen, Dept. of Paediatric Nephrology, Groningen, The Netherlands
- A0186** **Use of a Novel Smartphone App for Audio Recording Consultations of Patients Seeking Genital Gender-Affirming Surgery: An Opportunity for Broader Application Throughout Urology**
Authors: Stelmar J.¹, Mallavarapu S.², Sandhu S.², Smith S.², Garcia M.²
Institutes: ¹University of California San Diego, Dept. of Medicine, San Diego, United States of America, ²Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America
- 12:30 - 13:00** **Large language models 1: Harnessing ChatGPT for enhanced clinical expertise**
- A0181** **Evaluating the efficacy of ChatGPT in answering e-consults from general practitioners to urologists: A pilot study**
Authors: Kommers M., Lagerveld B.W., Ruiter A.E.C., Boevé L.M.S., Kauer P.C., Van Haarst E.P.
Institutes: OLVG, Dept. of Urology, Amsterdam, The Netherlands
- A0179** **Performance of ChatGPT on the Fellow of the European Board of Urology (FEBU) Exams: A Comparative Analysis**
Authors: Schoch J.¹, Schmelz H.U.¹, Borgmann H.², Nestler T.¹
Institutes: ¹Federal Armed Forces Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ²Faculty of Health Sciences Brandenburg, Dept. of Urology, Brandenburg an der Havel, Germany
- A0180** **RARPKB: A Knowledge-guide Decision Support Platform for Personalized Robot-Assisted Surgery in Prostate Cancer**
Authors: Li J., Erman W., Tang T., Zhang Z., Zhang C., Zong H., Shen B., Wei Q.
Institutes: West China Hospital, Dept. of Urology, Chengdu, China

- A0187** **Automated Operative Reports for Robotic Radical Prostatectomy using Artificial Intelligence**
Authors: Khanna A.¹, Antolin A.², Zohar M.², Bar O.², Ben-Ayoun D.², Frank I.¹, Thompson R.H.¹, Krueger A.¹, Shah P.¹, Sharma V.¹, Boorjian S.¹, Wolf T.², Asselmann D.², Tollefson M.¹
Institutes: ¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Theator Inc, Palo Alto, United States of America
- A0184** **Large Language Models: The New AI-Powered Kidney Stone Experts? Comparative Study of Chat GPT 3.5, Chat GPT 4, Bard, and Bing AI**
Authors: Kalbit R., Vergara C.D., Lorenzo E.I., Agudera R., Quanico U., Aquino A., Mendoza M.C.
Institutes: Jose R. Reyes Memorial Medical Center, Dept. of Urology, Manila, Philippines
- A0194** **Validation of a Zero-Shot Learning Natural Language Processing Tool To Facilitate Data Abstraction for Urologic Research**
Authors: Kaufmann B., Busby D., Das C.K., Tillu N.T., Menon M.M., Tewari A.K.T., Gorin M.A.
Institutes: Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
- 13:00 - 13:30** **Large language models 2: Enhancing the quality of patient-centered communication**
- A0190** **Evaluation of the effectiveness of Smart Consent® in improving understanding of informed consent. Initial experience.**
Authors: Herrera Aranda N., San Martin Vilarino P., Merino Narro I., Arce Cuartango P., Ayerra Pérez H., Duque Martínez I., García De Garayo Pires N., Moctezuma Velázquez J., Cachi Fuentes G.R., Armijos León S., Extramiana Cameno J.
Institutes: Hospital Universitario Araba, Dept. of Urology, Vitoria-Gasteiz, Spain
- A0188** **Artificial Intelligence in Advancing Prostate Cancer Patient Care**
Authors: Khanmammadova N.¹, Gevorkyan R.², Epino M.¹, Jiang D.¹, Cumpas A.D.¹, Chu T.¹, Gomez R.K.¹, Xu H.¹, Myoung S.¹, Afyouni A.S.¹, O'leary M.¹, Nguyen T.T.³, Fung C.¹, Ali S.N.¹, Shahait M.⁴, Daneshvar M.¹, Ahlering T.E.¹, Lee D.¹
Institutes: ¹University of California Irvine, Dept. of Urology, California, United States of America, ²University of Southern California, Keck School of Medicine, California, United States of America, ³University of Medicine and Pharmacy, Dept. of Urology, Ho Chi Minh, Vietnam, ⁴Clemenceau Medical Center, Dept. of Urology, Dubai, United Arab Emirates

A0185

Characterizing the impact of novel patient-centered pathology reports: A randomized controlled trial of patients undergoing prostate biopsy

Authors: Kumar R.¹, Lajkosz K.², Silberman A.¹, Finelli A.¹, Fleshner N.¹, Hamilton R.¹, Kulkarni G.¹, Zlotta A.¹, Berlin A.³, Papadakos J.⁴, Ghai S.⁵, Deniffel D.⁵, Wiljer D.⁴, Alibhai S.⁶, Cafazzo J.⁷, Haider M.⁵, Lee O.⁸, Calicchia L.¹, Janusonis I.¹, Lovas M.⁸, Kreidstein J.¹, Hiemstra J.¹, Perlis N.¹

Institutes: ¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²University of Toronto, Dept. of Biostatistics, Toronto, Canada, ³University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, ⁴University of Toronto, Institute of Health Policy Management and Evaluation, Toronto, Canada, ⁵University of Toronto, Dept. of Medical Imaging, Toronto, Canada, ⁶University of Toronto, Dept. of Medicine, Toronto, Canada, ⁷University Health Network, Centre for Global eHealth Innovation, Toronto, Canada, ⁸University Health Network, Healthcare Human Factors, Toronto, Canada

A0191

Effectiveness of the medical chatbot PROSCA to inform patients about prostate cancer: Results of a randomized controlled trial

Authors: Baumgärtner K.¹, Schmid T.², Muschko M.², Woessner P.², Gerlach A.², Byczkowski M.², Hohenfellner M.¹, Görtz M.¹

Institutes: ¹Heidelberg University Hospital, Dept. of Urology, Heidelberg, Germany, ²SAP SE, SAP SE, Walldorf, Germany

A0192

Evaluating the effectiveness of ChatGPT in disseminating accurate and readable prostate cancer information

Authors: Eppler M.¹, Hershenhouse J.S.¹, Mokhtar D.¹, Rodler S.¹, Storino Ramacciotti L.¹, Gonjavi C.¹, Hom B.¹, Davis R.J.¹, Tran J.¹, Russo G.², Cocci A.³, Abreu A.¹, Gill I.¹, Desai M.¹, Cacciamani G.E.¹

Institutes: ¹Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, United States of America, ²University of Catania, Dept of Urology, Catania, Italy, ³University of Florence, Dept of Urology, Florence, Italy

A0193

Exploring the Efficiency of Generative Artificial Intelligence in Rapidly and Accurately Producing Patient Information for Urological Malignancy Treatments Aligned with the Latest EAU Guidelines

Authors: Rodler S.¹, Ramacciotti L.S.¹, Checcucci E.², De Backer P.³, Belenchon I.R.⁴, Taraktin M.⁵, Pulliatti S.⁶, Veccia A.⁷, Piazza P.⁸, Baekelandt L.⁹, Kowalewski K.F.¹⁰, Rivas J.G.¹¹, Abreu A.L.¹, Gill I.S.¹, Cacciamani G.E.¹

Institutes: ¹University of Southern California, Dept. of Urology, Los Angeles, United States of America, ²Candiolo Cancer Institute, Dept. of Surgery, Turin, Italy, ³Onze-Lieve-Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ⁴Virgen del Rocío University Hospital, Dept. of Urology, Sevilla, Spain, ⁵Sechenov University, Dept. of Urology, Moscow, Russia, ⁶University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁷Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ⁸IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ¹¹Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain

Urology & beyond: Inclusivity and healthy work environment

Abstract session 52

06 April 2024
12:00 - 13:30

Location Purple Area, E02
Chairs J. Baard, Amsterdam (NL)
To be confirmed
I. Rivero Belenchón, Seville (ES)

12:00 - 12:02

Introduction

A0196

Train the Trainers for the delivery of proficiency based progression training by the European Robotic Surgical Section Fellowship Centers

Authors: Frego N.¹, Ticonosco M.¹, Puliatti S.², Mazzone E.³, De Groot R.¹, Breda A.⁴, Van Der Poel H.⁵, Wagner C.⁶, Sorce G.¹, Collà Ruvolo C.¹, Rebuffo S.¹, Belmonte M.¹, Pissavini A.¹, Mottrie A.¹, Gallagher A.¹

Institutes: ¹ORSI Academy, Dept. of Urology, Melle, Belgium, ²University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ³San Raffaele Hospital - Milan - Italy, Dept. of Urology, Milan, Italy, ⁴Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁵Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands, ⁶St. Antonius Hospital Gronau, Dept. of Urology - Pediatric Urology and Urologic Oncology, Gronau, Germany

A0203

Trends of European School of Urology (ESU) Training and Resident Education: An overview of 2 decades of EAU Education Programme

Authors: Somani B.¹, Gomez-Rivas J.², Tiago O.³, Veneziano D.⁴, Brouwers T.⁵, Herrmann C.⁵, Sedelaar-Maaskant J.⁵, N'dow J.⁶, Palou J.⁷, Li N.⁵, Nedbal C.¹, Liatsikos E.⁸

Institutes: ¹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ²Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ³C.H.L.N. - Hospital de Santa Maria, Dept. of Urology, Lisbon, Portugal, ⁴The Smith Institute for Urology, Dept. of Urology, New York, United States of America, ⁵European Association of Urology, Dept. of Urology, Amsterdam, The Netherlands, ⁶University of Aberdeen, Dept. of Urology, Aberdeen, United Kingdom, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸University of Patras, Dept. of Urology, Patras, Greece

A0210

Emergency Urology Crash Course: Teaching Frontline Non-Urologists Pays Back

Authors: Desouky E.¹, Ibrahim M.², Koura M.², Dallash M.², Kalsi J.²

Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²Frimley Health NHS Trust, Dept. of Urology, Slough, United Kingdom

A0208

The Learning Styles of Graduating Canadian Urology Residents

Authors: Vanin Moreno N., Touma N.

Institutes: Queen's University, Dept. of Urology, Kingston, Canada

A0204

No Pressure: The Impact of Theatre Staff Education on Lithotomy Positioning

Authors: Xu J., Yim A., Thomson A.T., Qin K.Q., Bolton D., Liodakis P.L.

Institutes: Austin Health, Dept. of Urology, Melbourne, Australia

- A0200** **External validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in a sexual majority and minority population following robotic prostatectomy (RARP): NCT05772598**
Authors: MacAskill F.E.N.¹, Torres C.¹, Coker B.², Sahai A.¹, Shabbir M.¹, Yap T.¹
Institutes: ¹Guy's Hospital, Dept. of Urology, London, United Kingdom, ²King's College London, School of Life and Population Science, London, United Kingdom
- A0199** **Adverse Childhood Experiences and Prostate Cancer Screening**
Authors: Nguy M.¹, Chavez Santos E.², Puri D.³, Salmasi A.⁴, Santiago-Lastra Y.⁴
Institutes: ¹St. George's University, School of Medicine, St. George's, Grenada, ²University of Washington School of Public Health, Dept. of Health Systems and Population Health, Seattle, United States of America, ³University of California San Diego, School of Medicine, La Jolla, United States of America, ⁴University of California San Diego, Dept. of Urology, La Jolla, United States of America
- A0206** **Clinical impact of Social Determinants of Health (SDOH): Analysis of major uro-oncology surgical procedures using large national dataset**
Authors: Franco A.¹, Ditunno F.¹, Manfredi C.¹, Bologna E.¹, Licari L.C.¹, Pandolfo S.D.², Cherullo E.E.¹, Olweny E.¹, Leonardo C.³, De Nunzio C.⁴, Antonelli A.⁵, De Sio M.⁶, Autorino R.¹
Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴Sant'Andrea Hospital University La Sapienza of Rome, Dept. of Urology, Rome, Italy, ⁵University of Verona, Dept. of Urology, Verona, Italy, ⁶University of Campania Luigi Vanvitelli, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy
- A0211** **Care associated adverse events related to the use of laser in urological interventions: The French experience**
Authors: Abdessater M.¹, Michel P.², Avrillon V.³, Pogu B.⁴, Bart S.⁴
Institutes: ¹NOVO Hospital, Dept. of Urology, Pontoise, France, ²NOVO Hospital, Dept. of Epidemiology, Pontoise, France, ³French Association of Urology, Dept. of Statistics, Paris, France, ⁴French Association of Urology, Risk Management Department, Paris, France
- A0209** **Forgotten Antegrade Ureteric Stent: What can we do? – Inter-departmental safety net**
Authors: Desouky E.¹, Ibrahim M.², Maudgil D.³, Gill S.³, Bhardwa J.², Kalsi J.²
Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²Frimley Health NHS Trust, Dept. of Urology, Slough, United Kingdom, ³Frimley Health NHS Trust, Dept. of Radiology, Slough, United Kingdom

- A0198** **The practice of reflection by urologists on surgical mortality and the lessons learnt**
Authors: Qin S.¹, Mccahy P.²
Institutes: ¹Austin Health, Dept. of Urology, Melbourne, Australia, ²Royal Australasian College of Surgeons, Victorian Audit of Surgical Mortality, Melbourne, Australia
- A0205** **Investigating the ecological consequences of robotic surgery**
Authors: Tjahyadi G.¹, Treacy P.J.², Karunaratne S.², Bird J.², Alexander K.², Steffens D.², Chan L.¹, Leslie S.², Thanigasalam R.²
Institutes: ¹The University of Sydney, Concord Hospital Clinical School, Sydney, Australia, ²Surgical Outcomes Research Centre, SOuRCe, Sydney, Australia
- A0207** **Trial of a Self-TWOC pathway to reduce carbon footprint**
Authors: Louden H., Minto T., Voss J., Otto E., Plenty B.
Institutes: NorthBristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom
- A0195** **The Carbon Footprint of Reusable Versus Single Use Flexible Cystoscopes**
Authors: Lee A.¹, Hayne D.²
Institutes: ¹Fiona Stanley Hospital, Dept. of Urology, Perth, Australia, ²UWA Medical School, University of Western Australia, Perth, Australia
- A0197** **Parenthood among French urologists**
Authors: Stivalet Schoentgen N.¹, Methorst C.²
Institutes: ¹Bichat Claude Bernard Hospital, Dept. of Urology, Paris, France, ²Quatre Villes Hospital, Dept. of Surgery, Saint-Cloud, France
- A0202** **Family planning, pregnancy and parenthood during surgical training: experiences and perspectives from trainees and early career surgeons in Australia and New Zealand**
Authors: Xu J.¹, Basto M.², Ischia J.¹, Bolton D.¹, Dowling C.³, Woon D.¹
Institutes: ¹Austin Health, Dept. of Urology, Melbourne, Australia, ²Royal Brisbane and Women's Hospital, Dept. of Urology, Brisbane, Australia, ³Eastern Health, Dept. of Urology, Melbourne, Australia
- A0201** **Clinical hypnosis in urology: preliminary experience in the daily practice**
Authors: Cracco C.M., Casablanca C., Peretti D., Turco M., Scoffone C.M.
Institutes: Cottolengo Hospital, Dept. of Urology, Turin, Italy
- 13:27 - 13:30** **Expert summary**

Adrenal tumour and trauma

Abstract session 53

06 April 2024
12:00 - 13:30

Location Purple Area, E03
Chairs V. Gomez Dos Santos, Madrid (ES)
S.J. Hosseini, Tehran (IR)
To be confirmed
To be confirmed

12:00 - 12:50

Adrenal tumour

A0214

BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma

Authors: Numakura K., Muto Y., Sugiyama Y., Kobayashi M., Sekine Y., Kashima S., Yamamoto R., Nara T., Huang M., Saito M., Narita S., Habuchi T.

Institutes: Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan

A0225

Is size of an adrenal mass enough to indicate surgical examination?

Authors: Quintana L., Jiménez Alcaide E., García Fuentes C., Pérez Fernández E., Llorente C.

Institutes: Hospital Fundación de Alcorcón, Dept. of Urology, Madrid, Spain

A0212

Intratumor bacteria is associated with prognosis in adrenocortical carcinoma

Authors: Feng C.¹, Li Y.X.²

Institutes: ¹Huashan Hospital, Dept. of Urology, Shanghai, China, ²The University of Hong Kong, Chemistry and The Swire Institute of Marine Science, Hong Kong, Hong Kong

A0217

The European Network for the Study of Adrenal Tumors staging system (2015): a North American validation

Authors: Jannello L.M.I.¹, Incesu R.B.², Morra S.³, Scheipner L.⁴, Baudo A.⁵, de Angelis M.⁶, Siech C.⁷, Tian Z.⁸, Luzzago S.¹, Mistretta F.A.¹, Ferro M.¹, Saad F.⁸, Shariat S.F.⁹, Chun F.K.H.⁷, Briganti A.⁶, Tilki D.², Ahyai S.⁴, Carmignani L.⁵, Longo N.³, de Cobelli O.¹, Musi G.¹, Karakiewicz P.I.⁸

Institutes: ¹European Institute of Oncology, Dept. of Urology, Milan, Italy, ²Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ³Università di Napoli Federico II, Dept. of Urology, Naples, Italy, ⁴Medical University of Graz, Dept. of Urology, Graz, Austria, ⁵IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁷University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁸University of Montréal Health Center, Dept. of Urology, Montreal, Canada, ⁹Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0219

Minimally invasive adrenalectomy: Trends and outcomes analysis from a large population-based database

Authors: Ditunno F.¹, Franco A.¹, Manfredi C.¹, Bologna E.¹, Licari L.C.¹, Pandolfo S.D.², Cherullo E.E.¹, Olweny E.¹, Antonelli A.³, De Sio M.⁴, De Nunzio C.⁵, Porpiglia F.⁶, Autorino R.¹

Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ³University of Verona, Dept. of Urology, Verona, Italy, ⁴University of Campania Luigi Vanvitelli, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ⁵Sant'Andrea Hospital University La Sapienza of Rome, Dept. of Urology, Rome, Italy, ⁶University of Turin San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy

A0221

Is Partial Adrenalectomy a Viable Option in Treating Unilateral Primary Aldosteronism?

Authors: Lee T.N.¹, Chueh J.S.¹, Wu V.C.², Peng K.Y.², Tseng C.S.¹

Institutes: ¹National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, ²National Taiwan University Hospital, Dept. of Internal Medicine, Taipei City, Taiwan

A0220

Prognostic significance of lymph node count in surgically treated patients with T2-4 stage non-metastatic adrenocortical carcinoma

Authors: Assad A.¹, Barletta F.², Incesu R.B.³, Scheipner L.⁴, Morra S.⁵, Baudo A.⁶, Cano Garcia C.⁷, Tian Z.¹, Ahyai S.⁴, Longo N.⁵, Chun F.K.H.⁷, Tilki D.³, Briganti A.², Saad F.¹, Karakiewicz P.I.¹

Institutes: ¹CHUM, Dept. of Surgery, Montreal, Canada, ²IRCCS San Raffaele, Dept. of Surgery, Milan, Italy, ³University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Medical University of Graz, Dept. of Urology, Graz, Austria, ⁵University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁶Ospedale Galeazzi - Sant'Ambrogio, Dept. of Urology, Milan, Italy, ⁷University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany

A0222

Factors regarding metastasis risk of pheochromocytoma and paraganglioma

Authors: Wei T.T.-C., Chang Y-H., Chung H-J., Huang E. .Y.-H., Lin T.-P., Huang W.J.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

A0218

Influence of surgical technique on hemodynamic instability during minimally invasive surgery for pheochromocytoma

Authors: Chaman Baz A.H.¹, Van De Wal J.C.M.¹, Willems S.A.A.², d'Ancona F.¹, Zhu X.¹, Timmers J.L.M.³, Langenhuijsen J.F.¹

Institutes: ¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Anesthesiology, Nijmegen, The Netherlands, ³Radboudumc, Dept. of Endocrinology, Nijmegen, The Netherlands

A0228

Prognostic predictors of hypertension outcomes after adrenalectomy in primary aldosteronism

Authors: Fukushima H., Matsushima T., Harada J., Nakamura Y., Mitsunari K., Matsuo T., Ohba K., Mochizuki Y., Imamura R.

Institutes: Nagasaki University, Dept. of Urology, Nagasaki, Japan

12:50 - 13:30

Trauma

- A0215** **The seasonality of penile fractures: Results from the GRAND study**
Authors: Pyrgidis N., Chaloupka M., Volz Y., Pfitzinger P., Apfelbeck M., Weinhold P., Stief C., Marcon J., Schulz G.B.
Institutes: University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany
- A0213** **When Urologists go to war – Workload of German Urological Surgeons in a deployed U.S. Facility in Afghanistan**
Authors: Schoch J.¹, Matthies C.M.², Holger H.H.³, Diehm J.¹, Hans-Ulrich H.-U. .S.¹, Ruf C.R.⁴, Nestler T.N.¹
Institutes: ¹Federal Armed Forces Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ²Federal Armed Forces Hospital Hamburg, Dept. of Urology, Hamburg, Germany, ³Federal Armed Forces Hospital Berlin, Dept. of Urology, Berlin, Germany, ⁴Federal Armed Forces Hospital Ulm, Dept. of Urology, Ulm, Germany
- A0227** **EmERgency UrEteric InJury Management: A Year LOng NatIoNal Audit (BAUS REJOIN AUDIT)**
Authors: MacASkill F.E.N.¹, Belal M.², Kujawa M.³, Faure Walker N.⁴, Harding C.⁵, Fowler S.⁶, Hermans L.⁶, Dickinson A.⁷, Sahai A.¹
Institutes: ¹Guy's Hospital, Dept. of Urology, London, United Kingdom, ²Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom, ³Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom, ⁴King's College NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ⁶British Association of Urological Surgeons, Dept. of Urology, London, United Kingdom, ⁷University Hospitals Plymouth NHS Trust, Dept. of Urology, Plymouth, United Kingdom
- A0216** **Ureteral injuries in cytoreductive and hyperthermic intraperitoneal chemotherapy surgery: An analysis of incidence and risk factors**
Authors: Alonso Grandes M.¹, Arroyo Rojas Y.E.¹, Roldán Testillano R.¹, Márquez Negro A.M.¹, Cernuda Pereira C.¹, Herranz Yagüe J.A.¹, Martín Way D.A.¹, Dorado Valentín M.¹, Ripalda Ferretti E.A.¹, Manzanedo Romero I.², Páez Borda A.¹
Institutes: ¹University Hospital of Fuenlabrada, Dept. of Urology, Madrid, Spain, ²University Hospital of Fuenlabrada, Dept. of General Surgery, Madrid, Spain
- A0223** **Intermittent catheters with integrated amphiphilic surfactant associated with less urethral microtrauma in ex vivo model**
Authors: Barbieri L.¹, Ung M.S.², Neessen J.T.², Ali A.¹, Pytel R.Z.², Smith Callahan L.A.²
Institutes: ¹Convatec Ltd, Dept. of Continence Care, Deeside, United Kingdom, ²Convatec Ltd, Dept. of Advanced Biomaterials, Lexington, United States of America
- A0224** **An integrated guidewire Urethral Catheterisation Device (UCD®) for Difficult Urethral Catheterisation in the Emergency department**
Authors: Combes A.¹, McClintock G.², Jeffery N.¹, Dinh M.³, Smith Hanratty B.⁴, Boothroyd C.⁴, Berendsen Russell S.³
Institutes: ¹Nepean Hospital, Dept. of Urology, Sydney, Australia, ²Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia, ³Royal Prince Alfred Hospital, Emergency Department, Sydney, Australia, ⁴Blue Mountains Hospital, Emergency Department, Sydney, Australia
-

A0226

Acute imaging practices after pediatric renal trauma: the Multi-Institutional Pediatric Acute Renal Trauma Study (Mi-PARTS) experience

Authors: Neuville P., Hagedorn J.

Institutes: University of Washington, Dept. of Urology, Seattle, United States of America

A0229

Renal preservation in patients undergoing surgical exploration for grade IV renal trauma.

Authors: Charalampos F., Stamatakis P.V., Papadimitriou E., Leventi A., Pinitas A., Papadopoulos G., Stathouros G., Ntoumas K.

Institutes: GNA G. Gennimatas, Dept. of Urology, Athens, Greece

Chronic pelvic pain & male stress incontinence

Abstract session 54

06 April 2024
12:00 - 13:30

Location Purple Area, E04
Chairs W.A. Hübner, Korneuburg (AT)
H.C. Kuo, Hualien (TW)
To be confirmed

12:00 - 12:25

Chronic pelvic pain: basic research & epidemiology

A0235

Metagenomic Sequencing of the Urinary Microbiome of Postmenopausal Women with Recurrent Urinary Tract Infection and Type 2 Diabetes

Authors: Papp S.¹, Neugent M.², Sharon B.², Zimmern P.E.¹, De Nisco N.²

Institutes: ¹UT Southwestern, Dept. of Urology, Dallas, United States of America, ²University of Texas at Dallas, Dept. of Biological Sciences, Richardson, United States of America

A0233

Controlled release of microorganisms from engineered living materials for the treatment of urinary tract infections

Authors: Sivaperuman Kalairaj M.¹, George I.², Rivera-Tarazona L.¹, Zimmern P. .E.³, Subashchandrabose S.², Ware T. .H.¹

Institutes: ¹Texas A and M University, Dept. of Biomedical Engineering, College Station, United States of America, ²Texas A and M University, Dept. of Veterinary Pathobiology, College Station, United States of America, ³The University of Texas Southwestern, Dept. of Urology, Dallas, United States of America

A0239

Intradetrusor plasmid VEGF165-gene therapy in comparison with botulinum toxin type A in rats with cyclophosphamide-induced cystitis.

Authors: Kasyan G.¹, Isaev A.², Grigoryan B.¹, Golubev A.², Pushkar D.¹

Institutes: ¹Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ²Human Stem Cells Institute, Dept. of Cells, Moscow, Russia

A0234

The potential role of macrophage polarization in the progression of Hunner type interstitial cystitis

Authors: Lee S.¹, Ko K.J.¹, Lee K.S.¹, Kim G.H.²

Institutes: ¹Samsung Medical Center, Dept. of Urology, Seoul, South Korea, ²Samsung Medical Center, Samsung Genome Institute, Seoul, South Korea

A0243

Chronic prostatitis enhances the incidence of the subsequent benign prostatic hyperplasia: A population-based cohort study

Authors: Lin T.Y.¹, Huang Y.C.², Cheng I.H.¹, Weng H.Y.², Lin Y.C.², Ou C.H.², Li C.Y.³, Cheng Y-S.²

Institutes: ¹National Cheng Kung University Hospital Dou-Liou Branch, Dept. of Urology, Yunlin, Taiwan, ²National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ³National Cheng Kung University, Dept. of Public Health, Tainan, Taiwan

12:25 - 12:50

Chronic pelvic pain: clinic

- A0236** **Clinical significance of interstitial cystitis/bladder pain syndrome with metabotropic glutamate receptor**
Authors: Park J.¹, Kim A.¹, Kim H.G.¹, Lee M.², Seok J.³, Kwak Y.³, Cho S-G.³, Yoon H.⁴, Kim B.⁵
Institutes: ¹Konkuk University Medical center, Dept. of Urology, Seoul, South Korea, ²Konkuk university, Dept. of Advanced Translational Medicine, Graduate School of Konkuk University, Seoul, South Korea, ³Konkuk university, Dept. of Stem Cell and Regenerative Biotechnology, Seoul, South Korea, ⁴Ewha Womans University school of medicine, Dept. of Urology, Seoul, South Korea, ⁵Konkuk University Medical center, Dept. of Pathology, Seoul, South Korea
- A0245** **Brimapitide (BRM), potential novel treatment for bladder pain syndrome (BPS/IC), is safe and well tolerated. Report from a phase 1/2a study**
Authors: Heesakkers J.¹, Taubert E.², Van Der Aa F.³
Institutes: ¹Maastricht University Medical Center, Dept. of Urology, Maastricht, The Netherlands, ²Slingeland Hospital, Dept. of Urology, Doetinchem, The Netherlands, ³UZ Leuven, Dept. of Urology, Leuven, Belgium
- A0244** **Classification of non-Hunner's interstitial cystitis by maximal bladder capacity and grade of glomerulation – association with urinary inflammatory biomarker levels and implication of treatment outcome**
Authors: Jiang Y-H., Jhang J.F., Chang T-L., Liu M.C., Yang C.C., Kuo H.C.
Institutes: Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan
- A0241** **Effects of Onabotulinum toxin-A injection on sexual function in women with refractory interstitial cystitis/bladder pain syndrome**
Authors: Karaburun M.C.¹, Kubilay E.², Oztuna D.³, Gokce M.I.⁴, Suer E.⁴, Gülpinar O.⁴
Institutes: ¹Acipayam State Hospital, Dept. of Urology, Denizli, Türkiye, ²Near East University, Dept. of Urology, Lefkosa, Cyprus, ³Ankara University, Dept. of Biostatistics, Ankara, Türkiye, ⁴Ankara University, Dept. of Urology, Ankara, Türkiye
- A0237** **Efficacy and Safety of Intravesical Interferon Instillation for Women with Refractory Bladder Pain Syndrome/Interstitial Cystitis: A Prospective Study**
Authors: Shen S.H., Peng L., Zeng X., Shen H., Luo D.Y.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- 12:50 - 13:30** **Male stress incontinence**

A0242

Early continence recovery after robot-assisted radical prostatectomy: a multicenter analysis on the role of prostatic shape

Authors: Carilli M.¹, Iacovelli V.¹, Sandri M.², Forte V.³, Antonelli A.⁴, Celia A.⁵, Falabella R.⁶, Leonardo C.⁷, Minervini A.⁸, Pastore A.L.⁹, Patruno G.¹⁰, Secco S.¹¹, Verze P.¹², Bertolo R.G.⁴, Vittori M.¹, Petta F.¹, Signoretti M.¹, Cipriani C.¹, Finazzi Agrò E.¹³, Bove P.¹

Institutes: ¹San Carlo di Nancy Hospital, Dept. of Urology, Rome, Italy, ²University of Brescia, Big and Open Data Innovation Laboratory, Brescia, Italy, ³San Carlo di Nancy Hospital, Dept. of Radiology, Rome, Italy, ⁴University of Verona, Dept. of Urology, Verona, Italy, ⁵S. Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy, ⁶San Carlo Hospital, Dept. of Urology, Potenza, Italy, ⁷Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁸University of Florence, Urological Oncologic Minimally Invasive Robotic Surgery and Andrology, Florence, Italy, ⁹ICOT Sapienza University of Rome, Dept. of Urology, Latina, Italy, ¹⁰San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy, ¹¹ASST Niguarda Hospital, Dept. of Urology, Milan, Italy, ¹²University of Salerno, Dept. of Urology, Baronissi, Italy, ¹³Tor Vergata University of Rome, Dept. of Urology, Rome, Italy

A0240

Unveiling the Long-term Survival Outcomes of Artificial Urinary Sphincter: A Twelve-Year Study from the French National Health Insurance Database

Authors: Lenfant L.¹, Taille Y.², Chartier-Kastler E.¹, Lukacs B.³, Beaugerie A.¹, Vicaut E.², Mozer P.C.¹

Institutes: ¹Hopital Pitié Salpêtrière - AP-HP- Sorbonne Université, Dept. of Urology, Paris, France, ²Lariboisière Hospital - APHP - Université de Paris, Dept. of Clinical Research, Paris, France, ³APHP, Health Data Hub, Paris, France

A0231

Artificial urinary sphincter (AUS) Implantation with Transcorporal versus Standard technique: an international multicenter retrospective study on high-risk patients

Authors: Maiolino G.¹, Hevia Palacios M.², Białek L.³, Skrzypczyk M.³, Peri Cusi L.⁴, Costa Grau M.⁴, Medina Polo J.⁵, García-Rojo E.⁶, Martínez-Salamanca J.I.⁷, Oliveira Curvo R.⁷, Lledó García E.⁸, Sánchez Ochoa M.A.⁸, Zucchi A.⁹, Perotti A.⁹, Ignacio M.¹⁰, Zaccaro C.¹⁰, Pankaj M J.¹¹, Hirepan Arment A.¹¹, Gómez De Vicente J.M.¹², Alonso Bartolomé M.B.¹², Fernández-Pascual E.¹², Szyperski P.¹³, Romero-Otero J.⁶, Fraile Poblador A.²

Institutes: ¹The Lyx Institution, Dept. of Urology, Madrid, Spain, ²Ramón y Cajal Hospital, Dept. of Urology, Madrid, Spain, ³Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, ⁴Hospital Clinic of Barcelona, Dept. of Urology, Barcelona, Spain, ⁵12 de Octubre University Hospital, Dept. of Urology, Madrid, Spain, ⁶ROC Clinic and HM Hospitals, Dept. of Urology, Madrid, Spain, ⁷Hospital Universitario Puerta De Hierro-Majadahonda, Dept. of Urology, Madrid, Spain, ⁸Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁹University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy, ¹⁰Hospital Universitario La Zarzuela, Dept. of Urology and Robotic Surgery, Madrid, Spain, ¹¹UROKUL, Dept. of Urology, Pune, India, ¹²Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹³Hospital St. Luke, Dept. of Urology, Bydgoszcz, Poland

A0246

Artificial urinary sphincter with or without prior male slings in patients with post-prostatectomy incontinence: 15-year experience from a referral center

Authors: Chow P-M.¹, Agrawal S.², Emrich Accioly J.P.², Wood H.², Angermeier K.²

Institutes: ¹National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ²Cleveland Clinic, Dept. of Urology, Cleveland, United States of America

A0230

Effect of action and feedback observation training (AFOT) in the achievement of urinary continence in men after robot-assisted laparoscopic prostatectomy (RALP): a randomized controlled trial

Authors: Russo F.¹, Cifoletti D.¹, Benaglia E.¹, Franzini C.², Temporiti F.¹, Buffi N.M.¹, Lughezzani G.¹, Lazzeri M.³, Casale P.³, Fasulo V.³, Paciotti M.³, Gatti R.¹

Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Physiotherapy Unit, Rozzano, Italy, ³IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0247

The new artificial urinary sphincter UroActive™: results of the first in man study at 3 months post-activation (SOPHIA study)

Authors: Beaugerie A.¹, Perrouin-Verbe M.A.², Denormandie A.¹, Cotte J.¹, Poinard F.¹, Plassais C.¹, Mozer P.¹, Chartier-Kastler E.¹

Institutes: ¹University Hospital La Pitie-Salpetriere, Dept. of Urology, Paris, France, ²University Hospital of Nantes, Dept. of Urology, Nantes, France

A0232

Third implantation of artificial urinary sphincter in male patients with two previous explantations : is it doomed to failure?

Authors: Meyer F.¹, Cotte J.², Bento L.³, Nicaud G.⁴, Dubois A.⁵, Werth H.⁶, Saussine C.⁶, Chartier-Kastler E.², Gamé X.³, Hermieu J.F.⁴, Desgrandchamps F.¹, Peyronnet B.⁵, Cornu J-N.L.⁷

Institutes: ¹CHU Saint Louis, Dept. of Urology, Paris, France, ²CHU Pitie Salpetriere, Dept. of Urology, Paris, France, ³CHU de Toulouse, Dept. of Urology, Toulouse, France, ⁴CHU Bichat, Dept. of Urology, Paris, France, ⁵CHU de Rennes, Dept. of Urology, Rennes, France, ⁶NHC - CHU de Strasbourg, Dept. of Urology, Strasbourg, France, ⁷CHU de Rouen, Dept. of Urology, Rouen, France

A0238

SATURN 1 year follow-up: European prospective multicentre registry for surgical procedures in males with stress urinary incontinence.

Authors: Martens F.¹, Heesakkers J.², Thiruchelvam N.³, Hamid R.⁴, Witjes W.⁵, Caris C.⁵, Van Der Aa F.⁶

Institutes: ¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²MUMC, Dept. of Urology, Maastricht, The Netherlands, ³Addenbrookes Hospital, Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, ⁴University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁵European Association of Urology, Dept. of Research Foundation, Arnhem, The Netherlands, ⁶University Hospital Leuven, Dept. of Urology, Leuven, Belgium

Combatting urological infections: Advances in treatment and prophylaxis strategies

Abstract session 55

06 April 2024
12:00 - 13:30

Location Purple Area, E05
Chairs G. Bonkat, Basel (CH)
J. Kranz, Aachen (DE)
To be confirmed
To be confirmed

- A0254** **Assessing the long-term efficacy and safety of MV140 sublingual bacterial vaccine in the initial cohort: A 9-year study in the UK for treating recurrent urinary tract infections in men and women**
Authors: Kanabar S., Foley S., Yang B.
Institutes: Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom
- A0257** **Comparison of the clinical efficacy of guideline-based and culture-based antibiotic therapy for chronic bacterial prostatitis**
Authors: Ismailov R.S.¹, Kogan M.I.¹, Ibishev K.H.S.¹, Naboka Y.U.L.², Gudima I.A.², Ferzauli A.K.H.¹, Naber K.³
Institutes: ¹Rostov State Medical University, Dept. of Urology and Pediatric Urology, Rostov-on-Don, Russia, ²Rostov State Medical University, Dept. of Microbiology and Virology No1, Rostov-on-Don, Russia, ³Technical University of Munich School of Medicine, Dept. of Urology, Munich, Germany
- A0256** **Computer-assisted optimisation of perioperative antibiotic prophylaxis in urologic surgery**
Authors: Blanc P.¹, Denis de Senneville B.², Haeuser L.¹, Boulenger De Hauteclouque A.¹, Estrade V.¹, Robert G.¹
Institutes: ¹University Hospital Bordeaux, Dept. of Urology and Renal Transplantation, Bordeaux, France, ²University of Bordeaux, Mathematical Institute of Bordeaux, Talence, France
- A0258** **Prediction of Antibiotic Prescription for Acute Uncomplicated Cystitis: Insights from Two Randomized Clinical Trials**
Authors: Alidjanov J.F.¹, Hoch S.¹, Steindl H.¹, Abramov-Sommariva D.², Höller M.³, Wimmelbacher V.³, Naber K.⁴, Wagenlehner F.M.E.⁵, Abels C.⁶
Institutes: ¹Bionorica SE, Research and Development Biostatistics and Data Science Unit, Neumarkt in der Oberpfalz, Germany, ²Bionorica SE, Dept. of Medical Relations, Neumarkt in der Oberpfalz, Germany, ³Bionorica SE, Dept. of Clinical and Scientific Affairs, Neumarkt in der Oberpfalz, Germany, ⁴Technical University of Munich, Dept. of Urology, Munich, Germany, ⁵Justus-Liebig University of Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany, ⁶Bionorica SE, Research and Development Department, Neumarkt in der Oberpfalz, Germany

- A0255** **Antibiotic therapy for pre-operative positive urine culture: how can we improve our practice?**
Authors: Garnier T.¹, Lesprit P.², Pavese P.², Sarrazin C.¹, Descotes J.L.¹, Fiard G.¹
Institutes: ¹Centre Hospitalier Universitaire de Grenoble-Alpes, Dept. of Urology, Grenoble, France, ²Centre Hospitalier Universitaire de Grenoble-Alpes, Dept. of Infectious Disease, Grenoble, France
- A0263** **Efficacy and safety of cefepime/enmetazobactam as compared to frequently used antibiotics in patients with complicated urinary tract infections including acute pyelonephritis: A Bayesian network meta analysis**
Authors: Wagenlehner F.M.E.¹, Caballero V.R.², Maheshwari V.³, Biswas A.⁴, Ruiz L.⁵, Cure S.⁶
Institutes: ¹Justus Liebig University Giessen, Clinic of Urology, Pediatric Urology and Andrology, Giessen, Germany, ²Hospital Clinic of Barcelona, Infectious Disease Department, Barcelona, Spain, ³Parexel International, HEOR, Hyderabad, India, ⁴Parexel International, HEOR, Bangalore, India, ⁵Advanz Pharma, Dept. of Market Access, London, United Kingdom, ⁶Advanz Pharma, HEOR, London, United Kingdom
- A0264** **Elevating quality of life: Autovaccination strategies for reducing hospitalizations and emergency visits in neurogenic bladder patients**
Authors: Ortiz Salvador J.B., Bonillo Garcia M.A., Colet Guitert J.O., Quereda Flores F., Bevia Romero A.J., Espinosa Vano J., Castillo Anton D., Moran Pascual E.J., Martinez Cuenca E., Broseta Rico E., Arlandis Guzman S., Budia Alba A.
Institutes: Hospital Universitario y Politécnico La Fe, Dept. of Urology, Valencia, Spain
- A0260** **Ureterostomy vs ileal conduit : comparative study of Urinary tract infections (UTIs) after external urinary diversion for radical cystectomy.**
Authors: Saidani B.¹, Chakroun M.¹, Saadi A.¹, Bedoui M.A.¹, Hermi A.¹, Boussaffa H.¹, Mokadem S.¹, Zaghbib S.¹, Ayed H.¹, Ferjani A.², Boutiba I.², Ben Slama R.¹
Institutes: ¹Tunis Charles Nicolle Hospital, Dept. of Urology, Tunis, Tunisia, ²Tunis Charles Nicolle Hospital, Dept. of Bacteriology, Tunis, Tunisia
- A0262** **Management tactics of patients with symptomatic gestational ureterohydronephrosis**
Authors: Kotov S.V., Perov R., Nizin P.
Institutes: Pirogov Russian National Research Medical University, Urology and Andrology of Medical Faculty, Moscow, Russia

- A0253** **Predictors of Additional Intervention in Prostate Abscess: A Multicenter Study and Prostate Abscess Complexity Score Proposal**
Authors: Pallares-Mendez R.¹, Bove A.M.¹, Armillas-Canseco F.², Martinez D.E.³, Cervantes-Miranda D.E.⁴, Hernandez-Aranda K.L.⁵, Badillo-González M.K.⁵, Molgado-Garza V.M.⁵, Garcia-Saucedo J.⁵, Castillejos-Molina R.A.², Becerra-Cardenas J.³, Simone G.¹, Gutierrez-Gonzalez A.⁵
Institutes: ¹IRCCS Regina Elena, Dept. of Urology, Rome, Italy, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Dept. of Urology, Mexico City, Mexico, ³Hospital Civil Fray Antonio Alcalde, Dept. of Urology, Guadalajara, Mexico, ⁴Instituto Nacional de Cancerología, Dept. of Urology, Mexico City, Mexico, ⁵Hospital Universitario Dr. Jose Eleuterio Gonzalez, Dept. of Urology, Monterrey, Mexico
- A0252** **The Outcomes of Three Different Techniques of Prostatic Abscess Drainage: A Retrospective Single Center Experience.**
Authors: Zoeir A., Eissa A., Mamdoh H., Gameel T., Mousa A.
Institutes: Tanta University, Dept. of Urology, Tanta, Egypt
- A0251** **Prognostic factors and clinical outcomes in fournier's gangrene: A retrospective study of 35 patients**
Authors: Chanhee P., Jeongwoo L., Hanbee H., Woonkyung J.
Institutes: Keimyung University Dongsan Hospital, Dept. of Surgery, Daegu, South Korea
- A0261** **Predicting the risk factors for severity and long-term ICU stay in patients with emphysematous pyelonephritis: a five-year experience from a tertiary center**
Authors: Kumar Pal A., Dorairajan L.N., Kalra S., Sah S.K., Narkhede V., Sreenivasan S.K.
Institutes: Jawaharlal Institute of Post Graduate Medical Education and Research, Dept. of Urology, Puducherry, India
- A0249** **Treatment outcome of intravesical platelet rich plasma injections in patients with interstitial cystitis/bladder pain syndrome of different clinical phenotype**
Authors: Yu W-R.¹, Jiang Y.H.², Jhang J.F.², Chang T-L.², Liu M.C.², Yang C.C.², Kuo H.C.²
Institutes: ¹Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan, ²Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan
- A0250** **Intravesical instillation of epidermal growth factor could ameliorate urothelial inflammation and down-regulate oxidative stress in rats with LPS-induced interstitial cystitis**
Authors: Yang C.H.¹, Tung M.C.¹, Ou Y.C.¹, Lin C.C.²
Institutes: ¹Tungs' Taichung MetroHarbor Hospital, Division of Urology, Dept. of Surgery, Taichung City, Taiwan, ²National Chung Hsing University, Institute of Biomedical Science The iEGG and Animal Biotechnology Center, Taichung, Taiwan

A0259

Intravesical Gentamicin: Is it the new Gold Standard to manage Refractory Urinary Tract

infections? – Experience from a dedicated complex UTI clinic

Authors: Chitteti P., Ekpeno I., Morris-Laverick J., Benzemer S., Mccune V., Kubelka I., Nadeem M.

Institutes: James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom

A0248

Bladder-pain predominance is associated with satisfactory outcome to intravesical botulinum toxin A injection for patients with interstitial cystitis/bladder pain syndrome

Authors: Yu W-R.¹, Jiang Y.H.², Jhang J.F.², Chang T-L.², Liu M.C.², Yang C.C.², Kuo H.C.²

Institutes: ¹Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan, ²Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan

Basic research and trials : renal tumours

Abstract session 56

06 April 2024
12:00 - 13:30

Location Purple Area, E06
Chairs K. Junker, Homburg (DE)
To be confirmed
G. Lucarelli, Bari (IT)
To be confirmed

12:00 - 12:02

Introduction

A0276

Establishment of intratumor bacteria as biomarkers in renal clear cell carcinoma

Authors: [Feng C.](#)¹, Zhang D.², Li Y.¹, Li Y.X.²

Institutes: ¹Huashan Hospital Fudan University, Dept. of Urology, Shanghai, China, ²The University of Hong Kong, Chemistry and The Swire Institute of Marine Science, Hong Kong, Hong Kong

A0278

Molecular correlates of clinical response to combination immunotherapy in advanced fumarate hydratase deficient renal cell carcinoma

Authors: [Xu Y.](#), Xue W., Zhang J., Huang Y.

Institutes: Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Dept. of Urology, Shanghai, China

A0279

Commensal Lachnospiraceae bacterium-derived Propionate Inhibites Tumorigenesis in Clear cell renal cell carcinoma

Authors: [Zhai W.](#), Xu J., Xue W., Zheng J.

Institutes: Renji Hospital of School of Medicine in Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

A0280

A preliminary study on the prognostic effects of aging microenvironment on clear cell renal cell cancer based on transcriptomic data analysis

Authors: [Zou J.](#), Zhang G., Chen X., Zou X.

Institutes: Institute of Urology Gannan Medical University, Dept. of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China

A0281

A randomized controlled trial assessing the release of circulating tumor and mesenchymal cells in no-touch radical nephrectomy

Authors: [Palmela Leitão T.M.](#)¹, [Correadeira P.](#)², [Rodrigues C.R.](#)³, [Pairo P.P.](#)³, [Miranda M.M.](#)¹, [Cavaco A.](#)², [Kucharczac S.K.](#)⁴, [Antunes M.](#)⁵, [Peixoto S.P.](#)¹, [Palma Dos Reis J.P.R.](#)¹, [Lopes T.L.](#)¹, [Dieguez L.](#)³, [Costa L.](#)¹

Institutes: ¹Centro Hospitalar Universitário Lisboa Norte, Dept. of Urology, Lisbon, Portugal, ²Instituto de Medicina Molecular Joao Lobo Antunes, Luis Costa Lab, Lisbon, Portugal, ³International Iberian Nanotechnology Laboratory, Dept. of Medical Devices, Braga, Portugal, ⁴Norwegian University of Science and Technology Faculty of Medicine and Health Sciences, Dept. of Clinical and Molecular Medicine, Trondheim, Norway, ⁵CEAUL - Centro de Estatística e Aplicações, Dept. of Biostatistics, Lisbon, Portugal

- A0269** **FOXM1D interacts with HCFC1 to regulate YY1-mediated transcription of immune checkpoint molecules in renal cancer**
Authors: Wang Y., Zhang W., Feng T., Tian X., Chang K., Ye D.
Institutes: fudan university shanghai cancer center, Dept. of Urology, Shanghai, China
- A0267** **Clinical and biohumoral markers of AKI predictive of mid-term renal function after kidney surgery**
Authors: Paladini A., Cochetti G., La Mura R., Rizzo D., Tancredi A., Massa G., Pastore F., Esposito R., Vitale A., Maiolino G., Mearini E.
Institutes: University of Perugia, Dept. of Medicine and Surgery- Urology Clinic, Perugia, Italy
- A0270** **A potential tumor-marker from urinary microbiota – focusing on renal cell carcinoma**
Authors: Kajjoka S.¹, Okabe A.², Okada T.², Toyoda M.³, Shiota M.², Inokuchi J.², Takei M.⁴, Yokomizo A.⁴, Yoshida A.⁵, Etoh M.²
Institutes: ¹International University of Health and Welfare, Dept. of Pharmacy, Ookawa, Japan, ²Kyushu University, Dept. of Urology, Fukuoka, Japan, ³Kyushu University, Dept. of Periodontology, Fukuoka, Japan, ⁴Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, ⁵Matsumoto Dental College, Dept. of Microbiology, Matsumoto, Japan
- A0274** **ARPP19 a key lactylation-related gene, associated with prognosis and immunogenicity of clear cell renal cell carcinoma**
Authors: Song N., Ji C.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- A0273** **Tumor Characteristics Associated with Detectable Circulating Tumor DNA Preoperatively in Patients With Renal Masses Suspicious for RCC**
Authors: Ben David R.¹, Alerasool P.², Kalola H.K.¹, Tillu N.T.¹, Che-Kai T.², Galsky M.G.², Kyrollis A.K.¹, Sfakianos J.S.¹, Wiklund P.W.¹, Waingankar N.W.¹, Mehrazin R.M.¹
Institutes: ¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, United States of America
- A0275** **Impact of heavy metals, trace elements, and oxidative stress in the pathogenesis of renal cell carcinoma**
Authors: Arulraj K.¹, Nayak B.¹, Quadri J.A.², Pandit S.¹, Panaiyadiyan S.¹, Singh P.¹, Shariff A.², Seth A.¹
Institutes: ¹All India Institute of Medical Sciences, Dept. of Urology, New Delhi, India, ²All India Institute of Medical Sciences, Dept. of Anatomy, New Delhi, India
- A0268** **Construction of Cuproptosis Signature based on bioinformatics and experimental validation in Clear Cell Renal Cell Carcinoma**
Authors: Tian X., Shuxuan Z., Qu Y., Hailiang Z., Dingwei Y.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

- A0271** **Enhancing immunotherapy in renal cell carcinoma by engineering cytotoxic T lymphocytes with chimeric costimulatory switch proteins**
Authors: Linxweiler J.¹, Aman C.², Mink J.¹, Mosetter B.², Junker K.¹, Nößner E.²
Institutes: ¹Saarland University, Dept. of Urology, Homburg, Germany, ²Helmholtz Center Munich, Dept. of Immunoanalytics - Tissue Control of Immunocytes, Munich, Germany
- A0277** **Untargeted Metabolomics Study of Plasma and Tissue in Renal Cell Carcinoma Patients with Von Hippel-Lindau Syndrome**
Authors: Zhang Z.¹, Yang W.¹, Wang Y.², Zhou X.³, Gong K.¹
Institutes: ¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Beijing International Center for Mathematical Research, Dept. of Mathematical Research, Beijing, China, ³Peking University, Dept. of Biostatistics, Beijing, China
- A0272** **Evaluation of genetic mutations in clear cell renal cell carcinoma with tumor necrosis**
Authors: Davis L.¹, Omil-Lima D.², Bell S.², Calaway A.¹, Kutikov A.², Uzzo R.², Ponsky L.¹, Abbosh P.², Bukavina L.¹
Institutes: ¹University Hospitals Cleveland Medical Center, Dept. of Urology, Cleveland, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America
- A0266** **Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics**
Authors: Shiqi Y., Xi T., Anwaier A., Jiaqi S., Shuxuan Z., Yuanyuan Q., Wenhao X., Hailiang Z., Dingwei Y.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- A0265** **Multi-omics profiling demonstrates dynamic changes of cancer-associated fibroblasts and their derived extracellular vesicles during prostate cancer progression**
Authors: Hu C.¹, Zhang Y.², Du X.¹, Wu T.¹, Zhu H.H.², Dong L.¹, Xue W.¹
Institutes: ¹Shanghai Jiao Tong University School of Medicine, Dept. of Urology Renji Hospital, Shanghai, China, ²Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Oncogenes and Related Genes, Renji-Med-X Stem Cell Research Center, Shanghai Cancer Institute, Dept. of Urology, Ren Ji Hospital, Shanghai, China
- 13:27 - 13:30** **Expert summary**
To be confirmed

Pathology at biopsy: grade group assignment, risk prediction

Abstract session 57

06 April 2024
12:00 - 13:30

Location Purple Area, E07
Chairs To be confirmed
J.P. Radtke, Düsseldorf (DE)
R.C.N. Van Den Bergh, Utrecht (NL)

12:00 - 12:02

Introduction

12:02 - 12:22

Cribriform and Intraductal subtypes

A0286

Undetected Cribriform and Intraductal Prostate Cancer in Grade Group 2 False Negative Biopsies and Their Impact on Post-Prostatectomy Pathological Results

Authors: Marques Bernardino R.M.¹, Yin B.², Lajkosz K.³, Cockburn J.¹, Sayyid R.¹, Wettstein M.¹, Randhawa H.¹, Campos Pinheiro L.⁴, Henrique R.⁵, Van Der Kwast T.⁶, Fleshner N.¹

Institutes: ¹Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, ²University of Toronto, Temerty, Toronto, Canada, ³Princess Margaret Cancer Centre, Dept. of Statistics, Toronto, Canada, ⁴Centro Hospitalar Universitário Lisboa Central, Dept. of Urology, Lisbon, Portugal, ⁵IPO Porto, Dept. of Pathology, Porto, Portugal, ⁶Princess Margaret Cancer Centre, Dept. of Pathology, Toronto, Canada

A0290

The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

Authors: Binyu W.¹, Yao F.², Mengxia C.¹, Shan P.², Giancarlo M.³, Junlong Z.¹, Shiwei Z.¹, Hongqian G.¹, Xuefeng Q.¹

Institutes: ¹Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Pathology, Nanjing, China, ³San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy

A0284

Is prostate biopsy a reliable method for detecting cribriform and intraductal carcinoma?

Authors: Marques Bernardino R.M.¹, Sayyid R.¹, Lajkosz K.², Al-Daqqaq Z.¹, Cockburn J.¹, Chavarriaga J.¹, Abedi S.¹, Berlin A.³, Van Der Kwast T.⁴, Fleshner N.¹

Institutes: ¹University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, ²Princess Margaret Cancer Centre, Dept. of Statistics, Toronto, Canada, ³Princess Margaret Cancer Centre, Dept. of Radiation Oncology, Toronto, Canada, ⁴Princess Margaret Cancer Centre, Dept. of Pathology, Toronto, Canada

A0292

The Clinical Trajectory of Patients Afflicted by Rare Histological Variants of Prostate Carcinoma

Authors: Artamonova N.¹, Gallee L.¹, Neuwirt H.², Steiner E.¹, Bektic J.¹, Horninger W.¹, Heidegger I.¹

Institutes: ¹Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Medical University Innsbruck, Dept. of Nephrology, Innsbruck, Austria

12:22 - 12:47

Risk prognosis

A0283

Comparison of the utility of worst vs. global Gleason grade group in MRI-US fusion biopsy for predicting postprostatectomy biochemical recurrence

Authors: Kobayashi M., Yoshitomi K., Fan B., Fujiwara M., Nakamura Y., Ishikawa Y., Fukuda S., Waseda Y., Tanaka H., Yoshida S., Fujii Y.

Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

A0288

Quantification of perineural cancer invasion on systematic needle core biopsy of the prostate is useful for risk stratification in patients with Grade Group 2 or 3 cancer, but not in those with Grade Group 4-5 cancer

Authors: Teramoto Y.¹, Wang Y.¹, Miyamoto H.²

Institutes: ¹University of Rochester Medical Center, Dept. of Pathology, Rochester, United States of America, ²University of Rochester Medical Center, Dept. of Pathology and Urology, Rochester, United States of America

A0291

The Highest Grade Group Does Not Drive the Risk of Advanced Stage when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Results from a Large Multi-Institutional Series

Authors: Scuderi S.L.A.¹, Tin A.², Gaffney C.³, Bianchi L.⁴, Kesch C.⁵, Marra G.⁶, Soeterik T.⁷, Ploussard G.⁸, Ettala O.⁹, Stroomberg H.V.¹⁰, Fiard G.¹¹, Hiten P.¹², Gopal G.N.¹², Yonover P.M.¹³, Zhuang J.¹⁴, Poyet C.¹⁵, Zattoni F.¹⁶, Rajwa P.¹⁷, Stabile A.¹, Eastham J.A.³, Montorsi F.¹, Briganti A.¹, Gandaglia G.¹, Vickers A.J.²

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America, ³Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America, ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁵Essen University Hospital, Dept. of Urology, Essen, Germany, ⁶Città della Salute e della Scienza- University of Turin, Dept. of Urology, Turin, Italy, ⁷Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁸Saint Jean Languedoc - La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ⁹Turku University Hospital and University of Turku, Dept. of Urology, Turku, Finland, ¹⁰Copenhagen Prostate Cancer Center-, Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark, ¹¹Grenoble Alpes University Hospital, Université Grenoble Alpes, Dept. of Urology, Grenoble, France, ¹²Loyola University Medical Center, Dept. of Urology, Maywood, United States of America, ¹³UroPartners, LLC, Chicago, United States of America, ¹⁴Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹⁵University Hospital Zurich, University of Zurich, Dept. of Urology, Zürich, Switzerland, ¹⁶University of Padova, Dept. of Surgery-Oncology and Gastroenterology, Urologic Unit, Padua, Italy, ¹⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria

- A0285** **Risk estimation of metastatic recurrence after prostatectomy : new preoperative risk stratification tools including cancer location and size at MRI, targeted biopsy and percent of grade 4/5.**
Authors: Bommelaere T.¹, Villers A.¹, Puech P.², Leroy X.³, Olivier J.¹
Institutes: ¹CHU de Lille, Dept. of Urology, Lille, France, ²CHU de Lille, Imaging, Lille, France, ³CHU de Lille, Dept. of Pathology, Lille, France
- A0298** **Peritumoral inflammation in prostate biopsy core predict Biochemical recurrence after active treatment for prostate cancer.**
Authors: Guzzi F.¹, Falagario U.G.¹, Fanelli A.¹, Ninivaggi A.¹, Troiano F.¹, Montrone L.¹, Selvaggio O.¹, Annese P.¹, Busetto G.M.¹, Bettocchi C.¹, Sanguedolce F.², Carrieri G.¹, Cormio L.¹
Institutes: ¹Hospital of Foggia, Dept. of Urology and Kidney transplantation, Foggia, Italy, ²Hospital of Foggia, Dept. of pathological anatomy, Foggia, Italy
- 12:47 - 13:27** **Pathologic examination**
- A0282** **An assessment of WHO Group 1 Prostate Cancer in Irish Hospitals, an analysis of 6816 newly diagnosed prostate cancer cases using the IPCOR database.**
Authors: Galvin D.J.¹, Dooley C.², Gordon N.G.², Murphy A.², Watson W.W.², Sharp L.S.³, Sullivan F.S.⁴, Mcdermott R.M.C.D.⁵
Institutes: ¹Mater and St. Vincent's University Hospitals, Dept. of Urology, Dublin, Ireland, ²University College Dublin, IPCOR, Dublin, Ireland, ³Newcastle University, Dept. of Epidemiology, Newcastle, United Kingdom, ⁴Galway University, Dept. of Radiotherapy, Galway, Ireland, ⁵St Vivent's University hospital, Dept. of Medical Oncology, Dublin, Ireland
- A0297** **Interim Analysis of the FAST – Study Frozen section Analysis assisted MRI-Targeted Biopsy for Prostate Cancer Diagnosis – a Prospective, Randomized Study**
Authors: Jahnen M.¹, Amiel T.¹, Schwamborn K.², Sauter A.³, Gschwend J.E.¹
Institutes: ¹Klinikum rechts der Isar School of Medicine Technical University of Munich, Dept. of Urology, Munich, Germany, ²Klinikum rechts der Isar School of Medicine Technical University of Munich, Institute of Pathology, Munich, Germany, ³Klinikum rechts der Isar School of Medicine Technical University of Munich, Dept. of Diagnostic and Interventional Radiology, Munich, Germany
- A0293** **A “green biopsy” expedited prostate cancer diagnostic pathway: Carbon footprint assessment and clinical outcomes**
Authors: Storino Ramacciotti L., Kaneko M., Rodler S., Mohideen M., Aron M., Hopstone M., Cacciamani G.E., Gill I., Abreu A.L.
Institutes: University of Southern California, Institute of Urology, Los Angeles, United States of America
- A0289** **Defining Prostate Cancer with High Gleason Score by Prostate fluid Metabolic Fingerprint Based Multi-Modal Recognition**
Authors: Peng Z.¹, Wang Y.², Wu X.¹, Du X.¹, Hu C.¹, Chen Q.¹, Ge Y.¹, Dong Y.¹, Qian K.², Dong L.¹, Xue W.¹
Institutes: ¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, ²Shanghai Jiaotong University, School of Biomedical Engineering, Shanghai, China
-

A0296

Upgrading risk in prostate cancer after combined prostate biopsy according to the site of positive cores: results in 658 patients treated with robot-assisted radical prostatectomy in tertiary referral centers

Authors: Bianchi A.¹, Califano G.², Morra S.², Gallina S.¹, Collà Ruvolo C.², Ornaghi P.I.¹, Di Bello F.², Ditonno F.¹, Montanaro F.¹, Cerruto M.A.¹, Imbimbo C.², Antonelli A.¹, Longo N.²

Institutes: ¹Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ²University of Naples Federico II, Dept. of Urology, Naples, Italy

A0287

Optimizing Detection and Prediction of Prostate Cancer After Positive MRI and Negative Biopsies.

Authors: Zattoni F.¹, Gandaglia G.², C N Van Den Bergh R.³, Marra G.⁴, Valerio M.⁵, Olivier J.⁶, Puche Sanzi I.⁷, Rajwa P.⁸, Maggi M.⁹, Campi R.¹⁰, Amparore D.¹¹, De Cillis S.¹¹, Guo H.¹², Veccia A.¹³, Ditonno F.¹³, Pereira L.J.P.¹⁴, Barletta F.², Leni R.², Rivas J.G.¹⁵, Remmers S.¹⁶, J. Roobol M.¹⁶, Antonelli A.¹³, Dal Moro F.¹, Novara G.¹

Institutes: ¹University of Padua, Dept. of Urology, Padua, Italy, ²URI IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ³Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ⁴Molinette Hospital, Dept. of Urology, Turin, Italy, ⁵Geneva University Hospital, Dept. of Urology, Geneva, Switzerland, ⁶Lille University, Dept. of Urology, Lille, France, ⁷Hospital Universitario Virgen de las Nieves, Dept. of Urology, Granada, Spain, ⁸Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ¹⁰Unit of Urological Robotic Surgery and Renal Transplantation Careggi Hospital, Dept. of Urology, Florence, Italy, ¹¹San Luigi Gonzaga Hospital, School of Medicine Division of Urology, Orbassano, Italy, ¹²Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ¹³Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ¹⁴Sint Antonius Hospital, Dept. of Urology, Utrecht-Nieuwegein, The Netherlands, ¹⁵Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ¹⁶Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

A0294

Predicting pathological tumor and prostate volume in prostate cancer patients based on micro-ultrasound and MRI findings

Authors: Richemond A.¹, Vietti Violi N.², Matthey J.², Peters M.³, Schaer S.¹, Dagher J.⁴, Roth B.¹, Valerio M.⁵, Rakauskas A.¹

Institutes: ¹Lausanne University Hospital CHUV, Dept. of Urology, Lausanne, Switzerland, ²Lausanne University Hospital CHUV, Dept. of Radiology, Lausanne, Switzerland, ³University Medical Center Utrecht, Dept. of Radiotherapy, Utrecht, The Netherlands, ⁴Lausanne University Hospital CHUV, Institute of Pathology, Lausanne, Switzerland, ⁵Geneva University Hospital HUG, Dept. of Urology, Geneva, Switzerland

A0295

Pathological features of prostatic false-positive lesions on 68Ga-PSMA-11 PET/CT

Authors: Li R., Fu Y.

Institutes: Nanjing Drum Tower Hospital, Dept. of Urology Surgery, Nanjing, China

13:27 - 13:30

Expert summary

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.13

06 April 2024
12:00 - 12:55

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.14

06 April 2024
12:00 - 12:55

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Semi-live session: PCNL updates

Thematic Session

05 April 2024
10:45 - 11:45

Location Green Area, eURO Auditorium 1
Chairs O. Angerri Feu, Barcelona (ES)
A. Skolarikos, Athens (GR)

10:45 - 10:55	Semi-live video presentation Endoscopic Combined Intrarenal Surgery (ECIRS) for horseshoe kidney stones C.M. Cracco, Turin (IT)
10:55 - 11:00	Discussion
11:00 - 11:10	Semi-live video presentation Prone Combined Intrarenal Surgery (ECIRS) for diverticular stones P. Kallidonis, Patras (GR)
11:10 - 11:15	Discussion
11:15 - 11:25	Semi-live video presentation Percutaneous nephrolithotripsy in patients with severe skeletal anomalies J. Desai, Ahmedabad (IN)
11:25 - 11:30	Discussion
11:30 - 11:40	Semi-live video presentation Bilateral synchronous percutaneous nephrolithotripsy E. Emiliani, Barcelona (ES)
11:40 - 11:45	Discussion

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.15

06 April 2024
12:00 - 12:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

EAU Data Initiatives

Thematic Session

06 April 2024
12:15 - 13:45

Location Green Area, N04
Chairs J. N'Dow, Aberdeen (GB)
V. Sakalis, Thessaloniki (GR)

12:15 - 12:25	EAU Data Initiatives: Foundations and looking to the future J. N'Dow, Aberdeen (GB)
12:25 - 12:40	EAU UroEvidenceHub: Building a platform for future RWE research P. Cornford, Liverpool (GB)
12:40 - 12:50	Patient engagement in EAU data initiatives: Why it is essential E. Briers, Hasselt (BE)
12:50 - 13:05	How real world evidence can complement traditional evidence synthesis & guideline development To be confirmed
13:05 - 13:15	Real world evidence analysis of the adverse events of systemic treatment in patients with mHSPC: Results of the 3rd PIONEER Studyathon P. Rajwa, Zabrze (PL)
13:15 - 13:25	Guidelines-based decision support tools & there impact on guidelines adherence M.J. Roobol, Rotterdam (NL)
13:25 - 13:40	Piloting the European Health Data Space: Methods, challenges and opportunities encountered M. Jendrossek, Paris (FR)
13:40 - 13:45	Session take home messages V. Sakalis, Thessaloniki (GR)

MRI, Micro-US and TEP for biopsy targeting

Abstract session 11

06 April 2024
12:15 - 13:45

Location Green Area, W03
Chairs N. Fossati, Lugano (CH)
To be confirmed
To be confirmed

12:15 - 13:00

MRI

A0315

Can systemic biopsies be avoided in biopsy-naïve patients with very high suspicious lesion at multiparametric MRI? A single institution analysis

Authors: [Avolio P.P.](#)¹, Maffei D.¹, Paciotti M.¹, Fasulo V.¹, Saitta C.¹, De Carne F.¹, Lazzeri M.², Casale P.², Buffi N.M.¹, Lughezzani G.¹

Institutes: ¹Humanitas University, Biomedical Science, Pieve Emauele, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0307

Incidence of significant prostate cancer after positive MRI and negative targeted and systematic biopsies.

Authors: [Siebert C.](#)¹, Nguyen T.A.¹, Fourcade A.¹, Zambon A.¹, Saout K.¹, Deruelle C.¹, Joulin V.¹, Tissot V.², Doucet L.³, Fournier G.¹, Valeri A.¹

Institutes: ¹CHU Brest, Dept. of Urology, Brest, France, ²CHU Brest, Dept. of Radiology, Brest, France, ³CHU Brest, Dept. of Anatomopathology, Brest, France

A0313

The Impact of Multiple Lesions in Prostate MRI – Insights from the YAU Prostate Cancer Group

Authors: [Zattoni F.](#)¹, Novara G.¹, Marra G.², Kasivisvanathan V.³, Carletti F.¹, Ploussard G.⁴, Olivier J.⁵, K Chiu P.⁶, Valerio M.⁷, Marquis A.², Gontero P.², Guo H.⁸, Zhuang J.⁸, Barletta F.⁹, Leni R.⁹, Cirulli G.⁹, Kretschmer A.¹⁰, Apfelbeck M.¹⁰, Kesch C.¹¹, Van Den Bergh R.¹², Briganti A.⁹, Dal Moro F.¹, Gandaglia G.⁹

Institutes: ¹Urology Clinic University of Padua, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy, ²University of Turin, Molinette Hospital, Turin, Italy, ³University College London Hospitals NHS Foundation Trust, Division of Surgery and Interventional Science, Dept. of Urology, London, United Kingdom, ⁴La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ⁵Lille University, Dept. of Urology, Lille, France, ⁶The Chinese University of Hong Kong, Dept. of Surgery, Division of Urology, Hong Kong, ⁷Lausanne University Hospital, Dept. of Urology, Lausanne, Switzerland, ⁸Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Nanjing Drum Tower Hospital, Nanjing, China, ⁹IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology URI, Milan, Italy, ¹⁰University Hospital Munich Campus Großhadern Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, ¹¹University Hospital Essen, Dept. of Urology, Essen, Germany, ¹²St Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands

- A0309** **Bimodal imaging: Detection Rate of clinically significant Prostate Cancer is higher in MRI lesions visible by transrectal ultrasound**
Authors: Falkenbach F.¹, Ahmad-Sterkau F.¹, Kachanov M.², Beyersdorff D.³, Köhler D.³, Ambrosini F.⁴, Ortner G.¹, Maurer T.⁵, Graefen M.¹, Budäus L.¹
Institutes: ¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Institute of Human Genetics, Hamburg, Germany, ³University Medical Center Hamburg-Eppendorf, Dept. of Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Germany, ⁴IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ⁵University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany
- A0299** **Predicting clinically significant prostate cancer following mpMRI - Analyses from a high-volume center**
Authors: Jahnen M.¹, Hausler T.², Ankerst D.P.², Meissner V.H.¹, Gschwend J.E.¹, Herkommer K.¹
Institutes: ¹School of Medicine and Health Technical University of Munich Rechts der Isar University Hospital, Dept. of Urology, Munich, Germany, ²School of Computation Information and Technology Technical University of Munich, Dept. of Mathematics, Munich, Germany
- A0303** **Clinically significant MRI-negative prostate cancer: a matched-paired analysis to evaluate radiological, histological and molecular features**
Authors: Oderda M.¹, Marquis A.M.¹, Bertero L.², Dematteis A.¹, Callaris G.C.¹, Gatti M.G.³, Marra G.M.¹, Ruggirello I.R.², Vissio E.V.², Faletti R.F.³, Cassoni P.², Gontero P.G.¹
Institutes: ¹Division of Urology, Dept. of Surgical Sciences Molinette Hospital University of Turin, Turin, Italy, ²Division of Pathology, Dept. of Medical Sciences Molinette Hospital University of Turin, Turin, Italy, ³Division of Radiology, Dept. of Surgical Sciences Molinette Hospital University of Turin, Turin, Italy
- A0302** **Diagnostic value of the Prostate Health Index and ADC values based on PI-RADSv2.1 in prostate cancer with PSA4-20ng/ml**
Authors: Ziaho L., Hua H., Yang L., Ma Y., Yuanjie N., Yong W.
Institutes: The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China
- A0312** **Mid-term follow up analysis of a cohort of patients with initial MRI at suspicion of prostate cancer. How it can be useful for exclusion of PC and avoid unnecessary biopsies.**
Authors: Tagalos Munoz A.C., Fernandez Conejo G., Fernandez Mardomingo A., López Plaza J.A., Subiela Henríquez J.D., Mata Alcaraz M., Mínguez Ojeda C., López Curtis D., Rodríguez-Patrón Rodríguez R., Sanz Mayayo E., García Barreras S., Fraile Poblador A., Burgos Revilla F.J.
Institutes: Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain
- A0301** **NMR-based metabolomics discriminate between prostate biopsy-positive and biopsy-negative patients suspicious for prostate cancer.**
Authors: Ladurner M.¹, Ameismeier T.², Klocker H.¹, Steiner E.¹, Hauffe H.¹, Wittmann J.², Drettwan D.², Eder I.¹
Institutes: ¹Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Lifespın GmbH, Regensburg, Germany

13:00 - 13:25

Micro-US

A0304

Retrospective Analysis of Microultrasound Accuracy in Prostate Cancer diagnosis: Results from a High-Volume Referral Center

Authors: Frego N., Maffei D., Fasulo V., Avolio P.P., Arena P., Beatrici E., Saitta C., Chiarelli G., Sordelli F., De Carne F., Garofano G., Dagnino F., Aljoulani M., Paciotti M., Saita A.R., Lazzeri M., Hurle R., Buffi N.M., Casale P., Lughezzani G.

Institutes: IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0305

Pathologic Gleason Upgrading Following High-resolution Micro-Ultrasound, Conventional Ultrasound and MRI Fusion Biopsy Techniques: A Comparative Study

Authors: Lokeshwar S., Choksi A., Smani S., Kong V., Sundaresan V., Brito J., Renzulli J., Sprenkle P., Michael M.

Institutes: Yale University, Dept. of Urology, New Haven, United States of America

A0308

“Histofusion” biopsy of the prostate: analysis of multicenter national data in real-life settings

Authors: Govorov A., Kim Y., Arutyunyan P., Kuzin B., Vasiliyev A., Kolontarev K., Pushkar D.

Institutes: Botkin Hospital, Dept. of Urology, Moscow, Russia

A0300

Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: a single-center prospective analysis

Authors: Dagnino F. D.¹, Avolio P.¹, Maffei D.M.¹, Aljoulani M.¹, Piccolini A.P.¹, De Carne F.¹, Moretto S.M.¹, Fasulo V. .F.¹, Paciotti M. .P.², Saitta C.S.¹, Beatrici E.¹, Saita A.², Hurle R.H.², Lazzeri M.L.², Casale P.², Buffi N.M.¹, Lughezzani G. .L.¹

Institutes: ¹Humanitas University, Dept. of Biomedical sciences, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0314

Prostate cancer detection rate with the ExactVu System in biopsy-naïve patients with high clinical suspicion and negative multiparametric MRI: Update from a large single-center experience.

Authors: Avolio P.P.¹, Maffei D.¹, Fasulo V.¹, Paciotti M.¹, Saitta C.¹, De Carne F.¹, Beatrici E.¹, Lazzeri M.², Casale P.², Buffi N.M.¹, Lughezzani G.¹

Institutes: ¹Humanitas University, Biomedical Science, Pieve Emanuele, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

13:25 - 13:45

PET/CT

A0310

Use of PSMA PET/CT in Detecting Primary Prostate Cancer: evaluation of the diagnostic accuracy in prebiopsy setting

Authors: Cisero E.¹, Amparore D.¹, Checcucci E.², De Cillis S.T.¹, Piramide F.¹, Volpi G.², Piana A.³, Sica M.¹, Verri P.¹, Burgio M.¹, Quarà A.¹, Sterrantino A.¹, Ortenzi M.¹, Garzena V.¹, Bignante G.¹, Garino D.¹, Rosi F.¹, Ziani N.¹, Ribolzi B.S.¹, Venezia A.E.M.¹, Manfredi M.¹, Fiori C.¹, Di Dio M.⁴, Porpiglia F.¹

Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁴Annunziata Hospital, Division of Urology - Dept. of Surgery, Cosenza, Italy

A0311

Comparing detection rates of PSMA PET/CT target biopsy vs. mpMRI targeted biopsy in detection of clinically significant prostate cancer

Authors: Piramide F.¹, Cisero E.¹, Amparore D.¹, Checcucci E.², De Cillis S.T.¹, Piana A.³, Volpi G.², Sica M.¹, Verri P.¹, Burgio M.¹, Meziere J.¹, Quarà A.¹, Busacca G.¹, Sterrantino A.¹, Ortenzi M.¹, Mesterca A.G.¹, Mandaletti M.¹, Bignante G.¹, Garino D.¹, Rosi F.¹, Manfredi M.¹, Di Dio M.⁴, Fiori C.¹, Porpiglia F.¹

Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁴Annunziata Hospital, Division of Urology - Dept. of Surgery, Cosenza, Italy

A0306

The new long-half-life probe 123I-PSMA-7 guided real-time intraoperatively biopsy in patients with suspected prostate cancer

Authors: Niu S.¹, Liu Y.², Ding X.³, Zhang X.¹

Institutes: ¹Chinese PLA General hospital, Dept. of Urology, Beijing, China, ²Chinese PLA General hospital, Dept. of Nuclear Medicine, Beijing, China, ³Chinese PLA General hospital, Dept. of Pathology, Beijing, China

A0316

Additive utility of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography in prostate cancer diagnosis: Is there a case for “seeing is believing”?

Authors: Chin J.¹, Tan Y.G.¹, Lee A.¹, Ng T.K.¹, Law Y.M.², Tang C.³, Lam W.³, Shi R.⁴, Tuan J.⁵, Ho H.¹, Yuen J.¹, Chen K.¹

Institutes: ¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Singapore General Hospital, Dept. of Diagnostic Radiology, Singapore, Singapore, ³Singapore General Hospital, Dept. of Nuclear Medicine and Molecular Imaging, Singapore, Singapore, ⁴Singapore General Hospital, Dept. of Anatomical Pathology, Singapore, Singapore, ⁵National Cancer Centre Singapore, Dept. of Radiation Oncology, Singapore, Singapore

The evolving landscape of kidney cancer and transplantation: Insights and innovations

EGPT 05

06 April 2024
12:15 - 13:45

Location EGPT
Chairs M.C. Mir Maresma, Valencia (ES)
S. Psutka, Seattle (US)

12:15 - 12:27

Screen A:

- P142** **Anti-inflammatory dietary index and risk of renal cell carcinoma**
Authors: Taj T.¹, Sundqvist P.², Fall K.¹, Ugge H.²
Institutes: ¹Örebro University Hospital, Dept. of Clinical Epidemiology and Biostatistics, Örebro, Sweden, ²Örebro University Hospital, Dept. of Urology, Örebro, Sweden
- P129** **Prognostic significance of body mass index in patients with metastatic renal cell carcinoma treated with first-line therapies**
Authors: Sato K., Takemura K., Oki R., Urasaki T., Yoneoka Y., Fujiwara R., Yasuda Y., Oguchi T., Numao N., Yamamoto S., Yonese J., Yuasa T.
Institutes: The Cancer Institute Hospital of JFCR, Dept. of Genitourinary Oncology, Tokyo, Japan
- P136** **Risk factors for kidney cancer and socio-occupational category: Significant impact of chlorinated solvents (ProCCR 111 study)**
Authors: Ferragu M.¹, Bernhard J.C.², Fontenil A.³, Guillotreau J.⁴, Branger N.⁵, Belas O.⁶, Patard J.J.⁷, Audenet F.⁸, Surlemont L.⁹, Malle R.¹⁰, Waeckel T.¹¹, Bigot P.¹
Institutes: ¹Angers University Hospital, Dept. of Urology, Angers, France, ²Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ³Nimes University Hospital, Dept. of Urology, Nimes, France, ⁴Pasteur Clinic Toulouse, Dept. of Urology, Toulouse, France, ⁵Tenon Hospital, Dept. of Urology, Paris, France, ⁶Paoli Calmettes Institute, Dept. of Urology, Marseille, France, ⁷Mont-de-Marsan Hospital, Dept. of Urology, Mont-de-Marsan, France, ⁸Hopital Europeen Georges Pompidou, Dept. of Urology, Paris, France, ⁹Rouen University Hospital, Dept. of Urology, Rouen, France, ¹⁰Francheville Polyclinic, Dept. of Urology, Francheville, France, ¹¹Caen Normandy University Hospital, Dept. of Urology, Caen, France
- P120** **Influence of body composition, nutritional, and systemic inflammatory status on prognosis in patients with metastatic renal cell carcinoma**
Authors: Tsuchiya N., Yagi M., Naito S., Takai Y., Fukuhara H., Narisawa T., Nishida H., Kanno H., Yamagishi A., Takai S., Horie S.
Institutes: Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan

12:27 - 12:42

Screen B:

- P145** **Preoperative or intraoperative renal biopsy increases the accuracy in predicting lymph node invasion in patients with renal cell carcinoma**
Authors: Belladelli F.¹, Re C.¹, Cei F.¹, Musso G.¹, Rosiello G.¹, Cignoli D.¹, Canibus D.¹, Fiorio F.¹, Bertini R.¹, Salonia A.¹, De Cobelli F.², Brembilla G.², Roupert M.³, Esposito A.², Palmisano A.², Piccolo C.¹, Gambirasio M.¹, Lucianò R.⁴, Tenace N.⁴, Briganti A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Experimental Oncology - Urological Research Institute, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy, ³Sorbonne University - AP-HP, Hopital Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy
- P144** **Renal Biopsy does not affect mortality in Renal Mass Patients When Confronted with Upfront Surgery: a Propensity Score Adjusted Analysis**
Authors: Belladelli F.¹, Re C.¹, Cei F.¹, Musso G.¹, Rosiello G.¹, Cignoli D.¹, Piccolo C.¹, Salerno L.¹, Iannace F.¹, Canibus D.¹, Fiorio F.¹, Matloob R.¹, Bertini R.¹, Salonia A.¹, De Cobelli F.², Brembilla G.², Gusmini S.², Guazzarotti G.², Gambirasio M.¹, Briganti A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Experimental Oncology - Urological Research Institute, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy
- P124** **Shifting the Paradigm: Improving Renal Cell Carcinoma Staging Within the AJCC System by Adding C-Reactive Protein-Analysis of the INMARC Registry**
Authors: Saitta C.¹, Afari J.¹, Lane B.², Tanaka H.³, Patil D.⁴, Yuen K.¹, Cortes J.¹, Mahmood M.¹, Matian J.¹, Mansour M.¹, Hakimi K.¹, Wang L.¹, Meagher M.¹, Nguyen M.¹, Puri D.¹, Nicaise E.⁴, Nahar I.⁴, Greenwald R.⁴, Cerrato C.¹, Kobayashi M.³, Fukuda S.³, Fujii Y.³, Master V.⁴, Derweesh I.¹
Institutes: ¹UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ²Spectrum Health, Dept. of Urology, Grand Rapids, United States of America, ³Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ⁴Emory University, Dept. of Urology, Atlanta, United States of America

P135

Mismatch between clinical and pathological T stage among patients with suspected renal cell carcinoma undergoing surgery: potential implications for target volume delineation and stereotactic body radiotherapy (SBRT) implementation for localized renal masses.

Authors: Francolini G.¹, Breda A.², Gallioli A.², Territo A.², Simone G.³, Anceschi U.³, Marchioni M.⁴, Pavan N.⁵, Erdem S.⁶, Capitanio U.⁷, Montorsi F.⁷, Palumbo C.⁸, Sharma G.⁹, Pandolfo S.D.¹⁰, Minervini A.¹¹, Warren H.¹², Wu Z.¹³, Ciccamese C.¹⁴, Roussel E.¹⁵, Amparore D.¹⁶, Pecoraro A.¹⁷, Bertolo R.¹⁸, Campi R.¹¹

Institutes: ¹Radiation Oncology Unit, Dept. of Oncology, Florence, Italy, ²Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴G. d'Annunzio University of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ⁵University of Palermo, Dept. of Surgical Oncological and Stomatological Sciences, Section of Urology, Palermo, Italy, ⁶Istanbul University, Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Türkiye, ⁷IRCCS San Raffaele Scientific Institute Vita-Salute San Raffaele University, Unit of Urology Division of Experimental Oncology Urological Research Institute, Milan, Italy, ⁸University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy, ⁹Medanta Hospital, Dept. of Urologic Oncology and Robotic Surgery, Gurugram, India, ¹⁰University of L'Aquila, Dept. of Urology, L'Aquila, Italy, ¹¹Unit of Urological Robotic Surgery and Renal Transplantation Careggi Hospital University of Florence, Dept. of Experimental and Clinical Medicine University of Florence, Florence, Italy, ¹²University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, ¹³Changay Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ¹⁴Comprehensive Cancer Center Fondazione Policlinico Universitario A. Gemelli IRCCS, Medical Oncology Unit, Rome, Italy, ¹⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁶San Luigi Gonzaga Hospital University of Turin, Dept. of Urology, Orbassano, Italy, ¹⁷Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy, ¹⁸University of Verona Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy

P126

Diagnostic Performance of Multiparametric Magnetic Resonance Imaging before Renal Biopsy using Clear Cell Likelihood Score (ccLS)

Authors: Re C.¹, Brembilla G.², Pennella R.², Russo T.², Cosenza M.², Cei F.¹, Belladelli F.¹, Cignoli D.¹, Musso G.¹, Basile G.¹, Rosiello G.¹, Canibus D.¹, Fiorio F.¹, Bertini R.¹, Verze P.³, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Larcher A.¹, De Cobelli F.², Capitanio U.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Experimental Oncology - Urological Research Institute, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Radiology, Milan, Italy, ³University of Salerno, Unit of Urology, Dept. of Medicine and Surgery, Salerno, Italy

12:42 - 12:54

Screen C:

- P143** **Postoperative recurrence factors in patients with pT3N0M0 clear cell renal cell carcinoma, called the M0 intermediate-high-risk group of the KEYNOTE 564 trial**
Authors: Naito H.¹, Homare O.¹, Ryou I.², Tomoko H.¹, Yu O.¹, Yohei A.¹, Yoichiro T.¹, Yuki M.¹, Takuma K.¹, Rikiya T.¹, Nobufumi U.¹, Reiji H.², Mikio S.¹
Institutes: ¹Kagawa University Faculty of Medicine, Dept. of Urology, Kagawa, Japan, ²Kagawa University Faculty of Medicine, Dept. of Diagnostic Pathology, Kagawa, Japan
- P139** **Predicting positive surgical margins in patients treated with robot-assisted partial nephrectomy: results from a prospectively maintained dataset of a single tertiary referral center**
Authors: Salamone V., Cadenar A., Sandulli A., Grosso A.A., Lambertini L., Massaro E., Gajo L., Coco S., Bacchiani M., Giudici S., Di Maida F., Fantechi R., Vittori G., Minervini A., Mari A.
Institutes: University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy
- P130** **Incremental value of Radiomics with Machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma**
Authors: Wang Z.J.
Institutes: The First Affiliated Hospital with Nanjing Medical University, Dept. of Urology, Nanjing, China
- P121** **Development and validation of prognostic nomograms and integrated software incorporating preoperative CRP level for predicting survival outcomes in patients with nonmetastatic clear cell renal cell carcinoma: INMARC study**
Authors: Chen W.¹, Tanaka H.¹, Kobayashi M.¹, Fukuda S.¹, Nakayama A.², Meagher M.³, Greenwald R.⁴, Schmeusser B.⁴, Waseda Y.¹, Yoshida S.¹, Derweesh I.H.³, Master V.A.⁴, Fujii Y.¹, Saito K.²
Institutes: ¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Dokkyo Medical University Saitama Medical Center, Dept. of Urology, Saitama, Japan, ³University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ⁴Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America

12:54 - 13:09

Screen D:

- P128** **Surveillance interruption and need for active treatment in Von Hippel-Lindau disease: implications for clinical management and trial design**
Authors: Cei F.¹, Re C.¹, Belladelli F.¹, Salerno L.¹, Falini A.², Calloni S.², De Cobelli F.³, Guazzarotti G.³, Mortini P.⁴, Capitanio J.F.⁴, Bailo M.⁴, Bandello F.⁵, Lattanzio R.⁵, Falconi M.⁶, Partelli S.⁶, Muffatti F.⁶, Castellino L.⁷, Piccioni L.O.⁸, Battista R.A.⁸, Rowe I.¹, Montorsi F.¹, Capitanio U.¹, Larcher A.¹, Salonia A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Urology and Division of Experimental Oncology - VHL Cancer Center - URI Urological Research Institute, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Neuroradiology - VHL Cancer Center, Milan, Italy, ³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Radiology - VHL Cancer Center, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Neurosurgery - VHL Cancer Center, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Ophthalmology - VHL Cancer Center, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Pancreatic Surgery - VHL Cancer Center, Milan, Italy, ⁷IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Endocrinology - VHL Cancer Center, Milan, Italy, ⁸IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Department of Department of Otolaryngology - Head and Neck Surgery - VHL Cancer Center, Milan, Italy
- P140** **The new 2019 Bosniak classification of complicated renal cysts. Radiopathological correlation and critical review**
Authors: Alfambra Fernandez H.¹, Sebastià C.², Ajami T.¹, Jiménez S.², Rodríguez L.³, López R.³, Nicolau C.², Alcaraz A.¹, Musquera M.¹
Institutes: ¹Hospital Clínic, Dept. of Urology, Barcelona, Spain, ²Hospital Clínic, Dept. of Radiology, Barcelona, Spain, ³Hospital Clínic, Dept. of Pathology, Barcelona, Spain
- P125** **Revealing patterns in spontaneous hemorrhagic risks and growth of angiomyolipomas: Is strict follow-up warranted?**
Authors: Lopez Curtis D.¹, Artiles Medina A.¹, Subiela Henríquez J.D.¹, Fernández-Mardomingo Díaz A.¹, González Tello F.², Brasero Burgos J.¹, Sánchez González A.¹, Gomez Dos Santos V.¹, Jimenez Cidre M.A.¹, Burgos Revilla F.J.¹
Institutes: ¹Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Ramón y Cajal, Dept. of Radiology, Madrid, Spain
- P138** **Epithelioid renal angiomyolipoma: clinical features, treatment modalities, and oncologic outcomes – a systematic review of 221 case reports**
Authors: Haselhoff E., Fankhauser C.D., Mattei A., Affentranger A.
Institutes: Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland

P141 **Growth Kinetics of Oncocytic Neoplasms on Active Surveillance and Impact on Renal Function**
Authors: Raveendran L.¹, Tsang J.T.¹, Cheung D.C.¹, Martin L.J.M.², Komisarenko M.K.², Prendeville S.P.³, Finelli A.F.²
Institutes: ¹University Health Network, Dept. of Surgery, Toronto, Canada, ²Princess Margaret Cancer Centre - University Health Network, Dept. of Surgical Oncology, Toronto, Canada, ³Princess Margaret Cancer Centre, Dept. of Genitourinary Oncology, Toronto, Canada

13:09 - 13:21

Screen E:

P133 **Urologists & Kidney Transplantation: The residents' perspective**
Authors: Pecoraro A.¹, Territo A.², Boissier R.³, Hevia V.⁴, Prudhomme T.⁵, Piana A.⁶, Banuelos B.⁷, Afferi L.⁸, Carrion D.⁹, Falagario U.¹⁰, Goujon A.¹¹, Piramide F.¹², Enrique Ortega Polledo L.¹³, Breda A.², Serni S.¹, Checcucci E.¹², Campi R.¹
Institutes: ¹Careggi University Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³La Conception University Hospital, Dept. of Urology and Renal Transplantation, Marseille, France, ⁴Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain, ⁵Rangueil University Hospital, Dept. of Urology, Kidney Transplantation and Andrology, Toulouse, France, ⁶Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁷Hospital Universitario El Clínico San Carlos, Division Renal Transplantation and Reconstructive Urology, Madrid, Spain, ⁸Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁹Torrejon University Hospital, Dept. of Urology, Madrid, Spain, ¹⁰Policlinico Riuniti, Dept. of Urology and Renal Transplantation, Foggia, Italy, ¹¹Rennes University Hospital, Dept. of Urology, Rennes, France, ¹²San Luigi Gonzaga Hospital, Division of Urology, Turin, Italy, ¹³Hospital Universitario Príncipe de Asturias, Dept. of Urology, Alcalá de Henares, Spain

P131

Perioperative Surgical Complications in Robot-Assisted vs. Pure Laparoscopic Living Donor Nephrectomy: A European Robotic Urology Section (ERUS) RAKT working group study

Authors: Campi R.¹, Pecoraro A.², Gallioli A.³, Territo A.³, Basile G.³, Berlin C.⁴, Etcheverry B.⁵, Musquera M.⁶, Vangeneugden J.⁴, Orteved M.⁷, Zeuschner P.⁸, Volpe A.⁹, Garcia-Baquero R.¹⁰, Kocak B.¹¹, Idu M.¹², Fornara P.⁸, Rohrsted M.⁷, Alcaraz A.⁶, Doumerc N.¹³, Vignes F.⁵, Decaestecker K.⁴, Serni S.², Breda A.¹

Institutes: ¹Careggi University Hospital, Unit of Urological Minimally Invasive Robotic Surgery and Kidney Transplantation, Florence, Italy, ²Careggi University Hospital, Dept. of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ³Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁴University Hospital Ghent, Dept. of Urology, Ghent, Belgium, ⁵Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ⁶Hospital Clinic-IDIBAPS, Dept. of Urology, Barcelona, Spain, ⁷Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark, ⁸Medical Faculty of Martin Luther University Halle-Wittenberg, Clinic of Urology and Transplantation, Halle, Germany, ⁹University of Eastern Piedmont, Division of Urology, Novara, Italy, ¹⁰Hospital Universitario Puerta del Mar, Dept. of Urology, Cádiz, Spain, ¹¹Koç University Hospital Organ Transplant Center, Dept. of Urology, Istanbul, Türkiye, ¹²Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands, ¹³University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France

P132

Outcomes of robot-assisted kidney transplantation (RAKT) using right- vs left grafts from living donors: update from the ERUS-RAKT working group

Authors: Pecoraro A.¹, Gallioli A.², Territo A.², Basile G.², Berquin C.³, Etcheverry B.⁴, Musquera M.⁵, Lopez De Mesa Rodriguez B.⁵, Vignolini G.¹, Prudhomme T.⁶, Volpe A.⁷, Garcia-Baquero R.⁸, Kocak B.⁹, Idu M.¹⁰, Fornara P.¹¹, Rohrsted M.¹¹, Alcaraz A.⁵, Doumerc N.⁶, Vignes F.⁴, Decaestecker K.³, Serni S.¹, Breda A.², Campi R.¹

Institutes: ¹Careggi University Hospital, Unit of Urological Minimally Invasive Robotic Surgery and Kidney Transplantation, Florence, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³University Hospital Ghent, ERN eUROGEN Accredited Centre, Dept. of Urology, Ghent, Belgium, ⁴Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ⁵Hospital Clinic-IDIBAPS, Dept. of Urology, Barcelona, Spain, ⁶University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, ⁷University of Eastern Piedmont, Division of Urology, Novara, Italy, ⁸Hospital Universitario Puerta del Mar, Kidney Transplant Unit, Cádiz, Spain, ⁹Koç University Hospital Organ Transplant Center, Dept. of Urology, Istanbul, Türkiye, ¹⁰Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands, ¹¹Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark

- P134** **Deceased Donor Robotic-Assisted Kidney Transplantation: The ERUS-RAKT Experience**
Authors: Musquera M.¹, Prudhomme T.², Peri L.¹, Pecoraro A.³, Territo A.⁴, Etcheverry B.⁵, Orved M.⁶, Roder A.⁶, Mirza I.⁷, Vignolini G.³, Rohrsted M.⁶, Doumerc N.², Vignes F.⁵, Breda A.⁴, Alcaraz A.¹, Serni S.³, Campi R.³
Institutes: ¹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ²Rangueil University Hospital, Dept. of Urology, Toulouse, France, ³Careggi Hospital - University of Florence, Unit of Urological Minimally Invasive - Robotic Surgery and Kidney Transplantation, Florence, Italy, ⁴Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁵Hospital Universitari de Bellvitge, Le'Hospitalet de Llobregat, Dept. of Urology, Barcelona, Spain, ⁶Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ⁷Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands
- 13:21 - 13:33** **Screen F:**
- P137** **Renal allograft management with urolithiasis: A multicentric study. On behalf of the Renal Transplant group of the Spanish Urological Association**
Authors: Sierra Del Rio A.¹, Etcheverry B.², Alvarez-Maestro M.³, Lopez J.M.¹, Fiol M.², Torrecilla C.², Vigués F.², Martínez C.¹, Carbonell E.¹, Martínez-Perez S.³, Alcaraz A.¹, Luque M.P.¹, Musquera M.¹
Institutes: ¹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ²Hospital de Bellvitge, Dept. of Urology, Hospitalet, Spain, ³Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain
- P122** **Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes. A systematic review by the EAU-YAU Kidney Transplantation working group**
Authors: Prudhomme T.¹, Boissier R.², Hevia V.³, Campi R.⁴, Pecoraro A.⁴, Piana A.⁵, Banuelos B.⁶, Dönmez M.I.⁷, Sallusto F.¹, Breda A.⁸, Territo A.⁸
Institutes: ¹Toulouse University Hospital, Dept. of Urology, Toulouse, France, ²La Conception University Hospital, Dept. of Urology, Marseille, France, ³University Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain, ⁴Florence University Hospital, Dept. of Urology, Florence, Italy, ⁵San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁶Hospital Universitario El Clínico San Carlos, Division Renal Transplantation and Reconstructive Urology, Madrid, Spain, ⁷Istanbul Faculty of Medicine, Division of Pediatric Urology, Istanbul, Türkiye, ⁸Puigvert Foundation, Dept. of Oncology and Renal Transplant units, Barcelona, Spain
- P123** **Impact of donating the larger kidney by CT volumetry on the kidney function, 5-years after living donation**
Authors: Kyaw L.¹, Hong M.P.², Ong S.², Gan A.², Goh B.¹, Lu J.¹, Tiong H.Y.¹
Institutes: ¹National University Hospital, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore

P127

Renal volumetry as a predictor of residual renal function after nephrectomy in living donors

Authors: Simón Nieto D., Parra López M.L., Rivero Belenchón I., León Duenas E., Medina López R.A.

Institutes: Hospital Universitario Virgen del Rocío, Dept. of Urology, Sevilla, Spain

Joint session of the EAU, EANM, ESMO and ESTRO: A collaborative approach - Multidisciplinary tumour boards in stage II seminoma

Thematic Session

06 April 2024
12:30 - 14:00

Location Chairs

Purple Area, eURO Auditorium 2
M. Albersen, Leuven (BE)
N. Naoun, Villejuif (FR)
D. Oprea-Lager, Amsterdam (NL)
P. Ost, Ghent (BE)

12:30 - 13:25

Case discussion Stage IIb seminoma (3-5cm): Spoilt for choice?

12:30 - 12:35

Case presentation

I. Anselmo da Costa Santiago, Berlin (DE)

12:35 - 12:42

Standard of care: BEP

To be confirmed

12:42 - 12:49

Role of PET-imaging in seminoma

D. Oprea-Lager, Amsterdam (NL)

12:49 - 12:56

mi-RPLND + carbo

W. Cazzaniga, London (GB)

12:56 - 13:03

Modern radiotherapy to affected node + carbo

A. Papachristofilou, Basel (CH)

13:03 - 13:10

Surgery first, primum non nocere

Y. Che, Düsseldorf (DE)

13:10 - 13:25

Panel discussion

13:25 - 13:35

State-of-the-art lecture Is progression free survival a correct endpoint in stage II seminoma trials?

L. Nappi, Vancouver (CA)

13:35 - 13:45

State-of-the-art lecture Long term toxicity in testicular cancer and AYA: Premature mortality and morbidity illustrated

To be confirmed

13:45 - 13:55

State-of-the-art lecture Ongoing trials and novel tools in the toolbox for metastatic TGCT

To be confirmed

13:55 - 14:00

Discussion

10th ESO Prostate Cancer Observatory 2024

Thematic Session

06 April 2024
15:00 - 17:00

Location Purple Area, eURO Auditorium 2
Chairs P. Cornford, Liverpool (GB)
F. Peccatori, Bellinzona (CH)
U. Vogl, Bellinzona (CH)

15:00 - 15:05	Welcome and introduction
15:05 - 15:13	The nurse's perspective C.N. Tillier, Amsterdam (NL)
15:13 - 15:21	The urologist's perspective on active surveillance P. Cornford, Liverpool (GB)
15:21 - 15:29	The imaging specialist's perspective on MRI To be confirmed
15:29 - 15:37	The imaging specialist's perspective on PSMA-PET/CT To be confirmed
15:37 - 15:45	The pathologist's perspective E. Compérat, Vienna (AT)
15:45 - 15:53	The urologist's perspective on surgery S. Joniau, Leuven (BE)
15:53 - 16:01	The radiation oncologist's perspective K. Rans, Leuven (BE)
16:01 - 16:09	The urologist's perspective on focal therapy R. Sanchez-Salas, Montreal (CA)
16:09 - 16:17	The medical oncologist's perspective U. Vogl, Bellinzona (CH)
16:17 - 16:25	The geneticist's perspective E. Castro, Madrid (ES)
16:25 - 16:33	The patient advocate's perspective To be confirmed
16:33 - 16:58	Panel discussion Hottest topics in Prostate cancer 2024
16:58 - 17:00	Closing remarks

French contributions to urology

Special Session

06 April 2024
15:00 - 17:00

Location

Purple Area, N01

Chairs

To be confirmed

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

Several major innovations in Urology were developed in France. These still have impact on the actual urological practice, and hence are still relevant today. Different aspects of these developments will be presented and discussed.

15:00 - 15:10

Introduction

15:10 - 15:25

Stone cutters of old France

E. Chartier-Kastler, Paris (FR)

15:25 - 15:30

Discussion

15:30 - 15:45

Urology as a surgical specialty: A French revolution?

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

15:45 - 15:50

Discussion

15:50 - 16:05

'Mon cher collegue...' : French influence on Britain's most famous urologist

J.C. Goddard, Leicester (GB)

16:05 - 16:10

Discussion

16:10 - 16:25

Famous French urologic patients

D. Schultheiss, Giessen (DE)

16:25 - 16:30

Discussion

16:30 - 16:45

The 'Belle Epoque' of Urology

J. Mattelaer, Kortrijk (BE)

16:45 - 16:50

Discussion

16:50 - 17:00

Conclusions and closure

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

YUORDay24: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part II

Special Session

<p>06 April 2024 15:00 - 17:00</p>	<p>Location Green Area, W06 Chairs E. Checcucci, Candiolo (IT) J.L. Vásquez, Copenhagen (DK)</p>
	<p>Challenging the guidelines: Controversial topics Moderators E.C. Bujoreanu, Cluj Napoca (RO) S.T. De Cillis, Turin (IT) B. Pradere, Toulouse (FR)</p>
<p>15:00 - 15:20</p>	<p>PSMA for prostate cancer diagnosis</p>
<p>15:00 - 15:08</p>	<p>Pro F. Ceci, Milano (IT)</p>
<p>15:08 - 15:16</p>	<p>Con M. Emberton, London (GB)</p>
<p>15:16 - 15:20</p>	<p>Conclusion by expert S. Shariat, Vienna (AT)</p>
<p>15:40 - 16:00</p>	<p>PDD for bladder cancer diagnosis</p>
<p>15:40 - 15:48</p>	<p>Pro A. Masson-Lecomte, Paris (FR)</p>
<p>15:48 - 15:56</p>	<p>Con R. Heer, London (GB)</p>
<p>15:56 - 16:00</p>	<p>Conclusion by expert M. Rouprêt, Paris (FR)</p>
<p>16:00 - 16:45</p>	<p>Guidelines cup Guideline masters M.J. Ribal Caparros, Barcelona (ES) J.L. Vásquez, Copenhagen (DK) Guideline cup finalists To be confirmed To be confirmed To be confirmed</p>
<p>16:45 - 17:00</p>	<p>Prizes and awards Moderators L. Afferi, Luzern (CH) E. Checcucci, Candiolo (IT) J.L. Vásquez, Copenhagen (DK)</p>
<p>16:45 - 16:50</p>	<p>First prize: Best abstract by a resident To be confirmed</p>
<p>16:50 - 16:55</p>	<p>Second prize: Best abstract by a resident To be confirmed</p>
<p>16:55 - 17:00</p>	<p>Third prize: Best abstract by a resident To be confirmed</p>

The infertile couple: Urological aspects

ESU Course 26

06 April 2024
15:00 - 18:00

Location Purple Area, E07
Chair M. Dinkelman-Smit, Rotterdam (NL)

Learning objectives

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility.

In terms of therapy, this course will provide updated information on evidence-based data and discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation.

We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

Diagnostic work-up, medical treatment

A. Salonia, Milan (IT)

Pathophysiology, diagnosis and treatment of varicocele

M. Dinkelman-Smit, Rotterdam (NL)

Microsurgical refertilisation

M. Dinkelman-Smit, Rotterdam (NL)

Sperm retrieval techniques and genetic aspects of IVF/ICSI

A. Salonia, Milan (IT)

The Management of genitourethral complications

Meeting of the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

06 April 2024
15:15 - 18:15

Location Green Area, N03
Chair D.J. Ralph, London (GB)

Learning objectives

This year we have lectures on the management of complications of penile prosthesis implantation from our associates. This is followed by straightening the penis in different congenital conditions. We all have nightmare cases in reconstruction and some will be presented here. Can balloon dilatation replace urethroplasty- we will debate this. There will also be updates in male incontinence and urethral strictures together with the problems of mesh in females.

15:15 - 16:03

Penile prosthesis 101

Moderators A. Cocci, Florence (IT)
D.J. Ralph, London (GB)

15:15 - 15:21

Antibiotics to be replaced by antiseptics during penile prosthesis implantation?

J. Romero-Otero, Madrid (ES)

15:21 - 15:27

Extra tunical grafting with IPP in treating Peyronie's Disease waisting

E. Lledó García, Madrid (ES)

15:27 - 15:33

Techniques to prevent IPP reservoir herniation

D. Osmonov, Kiel (DE)

15:33 - 15:39

The management of penile prosthesis aneurysms

F-X.M. Madec, Suresnes (FR)

15:39 - 15:45

Total vs single component change for IPP mechanical failure

L.A. Micol, Lausanne (CH)

15:45 - 15:51

Is the mini jupette still a good option to treat climaturia?

F. Chierigo, Genova (IT)

15:51 - 15:57

The use of mesh in penile prosthesis insertion

W.G. Lee, London (GB)

15:57 - 16:03

The management of intraoperative and post operative tunical perforation in IPP surgery

P. Gordon, Leeds (GB)

16:03 - 16:27

Penile reconstruction: Making it straight but not narrow

Moderators I. Moncada Iribarren, Madrid (ES)
J. Romero-Otero, Madrid (ES)

16:03 - 16:09

Straightening the congenital penile curvature

D. Schlager, Freiburg (DE)

16:09 - 16:15

Straightening the exstrophy penis

G. De Win, Edegem (BE)

16:15 - 16:21

Straightening the hypospadias penis

M.Y. Ortega González, San Cristóbal de La Laguna (ES)

16:21 - 16:27	The current grafts used in Peyronie's Disease: What has changed? S.C. Morgenstern, Frankfurt am Main (DE)
16:27 - 16:57	Reconstruction nightmares Moderators R. Dahlem, Hamburg (DE) E. Kocjancic, Chicago (US)
16:27 - 16:33	Total/partial loss of phallus after penile prosthesis W.G. Lee, London (GB)
16:33 - 16:39	Stenosis of neovagina To be confirmed
16:39 - 16:45	Recurrence of bulbar urethral stricture To be confirmed
16:45 - 16:51	Fistulae after robotic surgery T.J. Greenwell, London (GB)
16:51 - 16:57	Medico-legal aspects of reconstruction: In depth medico-legal cross examination of case 6 L. De Kort, Utrecht (NL)
16:57 - 17:47	Lower urinary tract hot topics Moderators To be confirmed L.G. Smyth, Dublin (IE)
16:57 - 17:07	Debate Paclitaxel balloon dilatation of recurrent bulbar urethral stricture versus urethroplasty Panel F. Campos Juanatey, Santander (ES) M.W. Vetterlein, Hamburg (DE)
17:07 - 17:15	Mesh related urinary tract injuries and their management H. Gresty, London (GB)
17:15 - 17:23	The outcomes of female urethroplasty from the EFG collaborative and future research directions M. Waterloos, Gent (BE)
17:23 - 17:31	Urinary diversion techniques in 2024 To be confirmed
17:31 - 17:39	Acute and long-term management of the obstructed ureter J. Sairanen, Helsinki (FI)
17:39 - 17:47	Setting up a GURS practice in a L-M income health care setting M.J. Abalajon, Antipolo City (PH)
17:47 - 18:11	Decision making in reconstructive urology Moderators O. Kose, Sakarya (TR) A.O. Noah, London (GB)
17:47 - 17:55	Artificial urinary sphincter or sling in men with stress urinary incontinence W. Verla, Ghent (BE)

Scientific Programme - EAU24

17:55 - 18:03	Urethroplasty for men with bulbar artificial urinary sphincter A.E. Zumrutbas, Denizli (TR)
18:03 - 18:11	Fistula repair in women J. Ockrim, London (GB)
18:11 - 18:15	Discussion and closing remarks D.J. Ralph, London (GB)

Rapid-fire debates: Common problems and controversies in bladder cancer

Thematic Session

05 April 2024
10:45 - 12:45

Location Purple Area, eURO Auditorium 2
Chairs A.M. Kamat, Houston (US)
A. Stenzl, Tübingen (DE)

Learning objectives

1. Describe the complexities related to the diagnosis and management of bladder cancer.
2. Apply existing treatment options to appropriate patients across the spectrum of disease, from non-muscle invasive to advanced, metastatic bladder cancer.
3. Select appropriate patients for de-intensification of interventions.
4. Identify the importance of variant histology in bladder cancer management.
5. Compare management strategies in BCG-unresponsive bladder cancer.
6. Cite evidence-based approaches to surgical treatment of bladder cancer.
7. Discuss evidence supporting current bladder preservation paradigms in non-muscle invasive and muscle-invasive bladder cancer.

10:45 - 10:48

Session introduction

A.M. Kamat, Houston (US)

10:48 - 11:07

Rapid Fire Debate 1: Is there any role for urinary markers other than cytology in era of modern cystoscopy in surveillance of patients? What about to decrease frequency of cystoscopy?

Moderator J Palou, Barcelona (ES)

10:48 - 10:50

Case presentation

J Palou, Barcelona (ES)

10:50 - 10:54

No, cytology is sufficient

E. Compérat, Vienna (AT)

10:54 - 10:58

Yes, urinary markers are needed

T. Zuiverloon, Rotterdam (NL)

10:58 - 11:07

Discussion/Q&A

11:07 - 11:26

Rapid Fire Debate 2: How do we manage a patient with frequent recurrence of LG papillary tumours in the bladder despite intravesical chemotherapy and BCG therapy? No clinical trial available

Moderator M. Babjuk, Prague (CZ)

11:07 - 11:09

Case presentation

M. Babjuk, Prague (CZ)

11:09 - 11:13

Repeated TUR +/- chemo is necessary

K. Chen, Singapore (SG)

11:13 - 11:17	Time to do surveillance/de-escalate therapy P. Spiess, Tampa (US)
11:17 - 11:26	Discussion/Q&A
11:26 - 11:45	Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What is the best treatment option? What if mixed histologic subtypes in addition to micropapillary? Moderator P. Gontero, Turin (IT)
11:26 - 11:28	Case presentation P. Gontero, Turin (IT)
11:28 - 11:32	Intravesical therapy best option B. Pradere, Toulouse (FR)
11:32 - 11:36	Upfront radical cystectomy is best A.M. Kamat, Houston (US)
11:36 - 11:45	Discussion/Q&A
11:45 - 12:04	Rapid Fire Debate 4: Patient with MIBC after radical cystectomy – can we use ctDNA to guide decisions on adjuvant chemo/IO? What about utDNA for Bladder Sparing after NAC? Moderator A. Necchi, Milan (IT)
11:45 - 11:47	Case presentation A. Necchi, Milan (IT)
11:47 - 11:51	No, ctDNA/utDNA is not ready for prime-time use P. Black, Vancouver (CA)
11:51 - 11:55	Yes, ctDNA/utDNA should be used to make treatment decisions J. Bjerggaard Jensen, Aarhus (DK)
11:55 - 12:04	Discussion/Q&A
12:04 - 12:23	Rapid Fire Debate 5: The age-old debate – what is the best treatment – oncological and QOL – for young healthy patient with MIBC? What about health care related costs? Moderator J.A. Witjes, Nijmegen (NL)
12:04 - 12:06	Case presentation J.A. Witjes, Nijmegen (NL)
12:06 - 12:10	Clearly XRT A.J Birtle, Preston (GB)
12:10 - 12:14	Clearly, radical cystectomy J.W.F. Catto, Sheffield (GB)
12:14 - 12:23	Discussion/Q&A
12:23 - 12:42	Rapid Fire Debate 6: Patient with non-invasive, high grade upper tract disease in setting of prior radical cystectomy – what is optimal management? What if GFR ~ 50 instead of 80? Moderator M. Rouprêt, Paris (FR)
12:23 - 12:25	Case presentation M. Rouprêt, Paris (FR)

12:25 - 12:29	Conservative management should be offered S. Psutka, Seattle (US)
12:29 - 12:33	Nephroureterectomy is needed A. Stenzl, Tübingen (DE)
12:33 - 12:42	Discussion/Q&A
12:42 - 12:45	Closing remarks A. Stenzl, Tübingen (DE)

Influence of chatGPT and AI in urology

Thematic Session

06 April 2024
15:15 - 16:45

Location Green Area, N04
Chairs K.A.O. Tikkinen, Helsinki (FI)
J. Walz, Marseille (FR)

Learning objectives

1. Understand AI's role in decision support, data analysis, and prediction tools
2. Explore AI's applications in diagnostic assistance, emphasizing AI diagnostics in imaging and pathology
3. Learn about AI's integration into surgical planning through augmented reality and robotics for enhanced surgical precision
4. Discover AI's, specifically ChatGPT's, role in patient education and support
5. Learn about AI's and chatGPT's role in grant applications, scientific publications and congresses

This programme was developed with the help of ChatGPT

15:15 - 15:34

Decision support

15:15 - 15:22

AI analysis of data and AI prediction tools

To be confirmed

15:22 - 15:29

Literature research with AI/ChatGPT

G. Cacciamani, Los Angeles (US)

15:29 - 15:34

Discussion

15:34 - 15:53

Diagnostic assistance

15:34 - 15:41

AI diagnostics imaging

J.J. Futterer, Nijmegen (NL)

15:41 - 15:48

AI diagnostics pathology

To be confirmed

15:48 - 15:53

Discussion

15:53 - 16:12

Surgical planning and guidance

15:53 - 16:00

AI and augmented reality

R. Autorino, Chicago (US)

16:00 - 16:07

AI and robotics

S. Secco, Milan (IT)

16:07 - 16:12

Discussion

16:12 - 16:19

Patient education and support

16:12 - 16:19

ChatGPT and the patient

J. Ghith, New York (US)

16:19 - 16:45

Research and data analysis

16:19 - 16:26

Grant application

A.S. Bjartell, Malmö (SE)

Scientific Programme - EAU24

16:26 - 16:33

Communication: Scientific publication

A. Briganti, Milan (IT)

16:33 - 16:40

Communication: Scientific congress

P. Albers, Düsseldorf (DE)

16:40 - 16:45

Discussion

Female urology: stress urinary incontinence and more

Abstract session 12

06 April 2024
15:15 - 16:45

Location Purple Area, S01
Chairs S. Arlandis, Valencia (ES)
M. Wong, Singapore (SG)
E. Costantini, Perugia (IT)
To be confirmed

A0326

Direct comparison of novel vaginal meshes developed for use in the treatment of stress urinary incontinence in an improved pre-clinical rabbit model

Authors: Ozturk S.¹, Roman Regueros S.², Zeybek D.³, Bozdemir O.³, Gultekinoglu- Bayram M.¹, Hearnden V.², Macneil S.², Ulubayram K.¹, Mangir N.⁴

Institutes: ¹Hacettepe University School of Pharmacy, Dept. of Basic Pharmaceutical Sciences, Ankara, Türkiye, ²University of Sheffield, Dept. of Materials Science and Engineering, Sheffield, United Kingdom, ³Hacettepe University School of Medicine, Dept. of Histology and Embryology, Ankara, Türkiye, ⁴Hacettepe University School of Medicine, Dept. of Urology, Ankara, Türkiye

A0321

Treatment of Female Stress Urinary Incontinence with Allograft slings from Human Umbilical Vessels in Patients with complicated mid-urethral synthetic slings: intermediate Analysis

Authors: Chartier-Kastler E.¹, Ruffion A.², Perrouin-Verbe M.A.E.³, Pinar U.¹, Barnouin L.⁴

Institutes: ¹Hospital la Pitié Salpêtrière, Dept. of Urology, Paris, France, ²Hospices Civils de Lyon, Dept. of Urology, Lyon, France, ³Hotel Dieu Hospital, Dept. of Urology, Nantes, France, ⁴Tissue Bank of France, Dept. of Engineering, Mions, France

A0320

Low-intensity pulsed ultrasound promotes urethral smooth muscle regeneration by modulating the immune microenvironment

Authors: Song C., Shujie X., Yiping Z., Wenhao W., Shiyun L.

Institutes: Shanghai General Hospital, Dept. of Urology, Shanghai, China

A0331

Design and Prototyping of a Shape-Adjustable Sling for the Treatment of Stress Urinary Incontinence

Authors: Tasmim S.¹, Baten A.², Sivaperuman Kalairaj M.¹, Zimmern P.E.³, Ware T.¹

Institutes: ¹Texas A and M University, Dept. of Biomedical Engineering, College Station, United States of America, ²Texas A and M University, Dept. of Materials Science and Engineering, College Station, United States of America, ³The University of Texas Southwestern, Dept. of Urology, Dallas, United States of America

A0330

A randomized controlled trial: TOT and transurethral bulking agent in naive stress incontinence

Authors: Illiano E., Felici G., Rossi De Vermandois J.A., Gioè M., Vacilotto G., Costantini E.

Institutes: Santa Maria Terni Hospital University of Perugia, Andrological and Urogynecological Clinic, Terni, Italy

- A0329** **Adjustable continence therapy device versus polyacrylamide hydrogel peri-urethral injections in elderly women with non-neurogenic stress urinary incontinence**
Authors: Chapuis M., Guerin S., Hascoet J., Peyronnet B.
Institutes: CHU Rennes, Dept. of Urology, Rennes, France
- A0324** **Outpatient periurethral injections of polyacrylamide hydrogel under local anesthesia in the office: a prospective single-center series**
Authors: Faurie B.¹, Hascoet J.H.¹, Richard C.R.¹, Haudebert C.H.¹, Nyangoh Timoh K.N.T.², Peyronnet B.P.¹
Institutes: ¹University of Rennes, Dept. of Urology, Rennes, France, ²University of Rennes, Dept. of Obstetrics and Gynecology, Rennes, France
- A0323** **Long-term Midurethral Mesh Sling Survival For Women With Stress Urinary Incontinence**
Authors: Laude M.¹, Bentellis I.², Fabre R.³, Ahallal Y.², Durand M.², Tibi B.², Chauleur C.¹, Peyronnet B.⁴, Bailly L.³
Institutes: ¹CHU Saint-Etienne, Dept. of Gynecology, Saint-Étienne, France, ²CHU de Nice, Dept. of Urology, Nice, France, ³CHU de Nice, Public Health Department, Nice, France, ⁴CHU de Rennes, Dept. of Urology, Rennes, France
- A0317** **Have I placed the single incision sling correctly? Transperineal ultrasound could have the answer**
Authors: Espinosa J., Castillo D.J., Morán E.J., Ortiz J.B., Quereda F., Beviá A.J., Munoz J., Puhar N., Martínez-Barbero J., Ramada E., Bonillo M.A., Martínez-Cuenca M.E., Colet J.O., Luján S., Rogel R., Broseta E., Arlandis S., Budía A.
Institutes: Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain
- A0318** **The long-term rate of re-operation after mid-urethral sling insertion among women with urinary incontinence: Population-based study**
Authors: Cho J.Y.¹, Park J.J.¹, Kim Y.J.¹, Kim M.N.², Song S.H.¹, Choo M-S.¹, Park J.H.¹
Institutes: ¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Hanmi Pharm, Data science Team, Seoul, South Korea
- A0325** **Late presentation of complications of mid-urethral sling and outcomes after sub-urethral sling removal**
Authors: Suzman E., Shah A., Alhalabi F., Christie A., Zimmern P.E.
Institutes: University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America
- A0328** **The Impact of the Colposacropexy Learning Curve on Mesh Complications**
Authors: Illiano E., Rossi De Vermandois J.A., Felici G., Gioè M., Vacilotto G., Costantini E.
Institutes: Santa Maria Terni Hospital University of Perugia, Andrological and Urogynecological Clinic, Terni, Italy

- A0332** **Robotic assisted colposuspension for female stress urinary incontinence (SUI). A 2-year multicentre prospective study**
Authors: Clark C.¹, Ramalingam A.R.², Joshi S.², Tan N.², Folkard S.¹, Umari P.², Qazi H.², Issa R.², Walker R.², Sharma D.², Malde S.¹, Sri D.², Sahai A.¹, Seth J.²
Institutes: ¹Guys and St Thomas' NHS Trust, Dept. of Urology, London, United Kingdom, ²St Georges NHS Trust, Dept. of Urology, London, United Kingdom
- A0334** **Trends in the use of female artificial urinary sphincter in Europe: preliminary data from the VENUS study**
Authors: Peyronnet B.¹, Chartier-Kastler E.², Lopez-Fando L.³, Perrouin-Verbe M.A.⁴, Wagner L.⁵, Sievert K.D.⁶, Karsenty G.⁷, Witjes W.⁸, biardeau X.⁹, Thiruchelvam N.¹⁰, Van Der Aa F.¹¹
Institutes: ¹University of Rennes, Dept. of Urology, Rennes, France, ²Hopital Pitie Salpetriere, Dept. of Urology, Paris, France, ³Hospital la Princesa, Dept. of Urology, Madrid, Spain, ⁴University of Nantes, Dept. of Urology, Nantes, France, ⁵University of Nimes, Dept. of Urology, Nimes, France, ⁶Klinikum Lippe, Dept. of Urology, Detmold, Germany, ⁷University of Marseille, Dept. of Urology, Marseille, France, ⁸European Association of Urology, Dept. of Research Foundation, Arnhem, The Netherlands, ⁹University of Lille, Dept. of Urology, Lille, France, ¹⁰University Of Cambridge, Dept. of Urology, Cambridge, United Kingdom, ¹¹University of Leuven, Dept. of Urology, Leuven, Belgium
- A0333** **Impact of robotic artificial urinary sphincter implantation in female patients on quality of life and patients-reported outcomes**
Authors: Dubois A.¹, Lethuillier V.¹, Berthelot L.P.², Richard C.¹, Haudebert C.¹, Voiry C.³, Freton L.⁴, Hascoet J.¹, Manunta A.¹, Peyronnet B.¹
Institutes: ¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Private Hospital of Cote d'Armor, Dept. of Urology, Plérin, France, ³Rennes University Hospital, Dept. of Physical and Rehabilitation, Rennes, France, ⁴Private Hospital of Cote d'Armor, Dept. of Urology, Rennes, France
- A0322** **Use Cluster Analysis to Develop an Accurate and Practical Diagnostic Method for Detrusor Underactivity in Female Patient without Bladder Outlet Obstruction**
Authors: Chen J-C., Lin C.C., Fan Y.H., Lin A.T.L., Huang W.J.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- A0327** **Inter-observer reproducibility for determination of female urethral narrowing on voiding cystourethrogram**
Authors: Carlton C.E.¹, Al-Kinani M.², Khatri G.², Bishop K.², Huang T.², Christie A.L.³, Zimmern P.E.¹
Institutes: ¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²University of Texas Southwestern Medical Center, Dept. of Radiology, Dallas, United States of America, ³University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center Biostatistics, Dallas, United States of America
-

A0319

Therapeutic efficacy of transurethral bladder neck incisions for female voiding dysfunction

Authors: Chiang C-H., Jiang Y.H., Chang T-L., Liu M.C., Yang C.C., Kuo H.C.

Institutes: Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan

Infections in urology

Meeting of the EAU Section of Infections in Urology (ESIU)

06 April 2024
15:15 - 18:15

Location Purple Area, S03
Chairs T. Cai, Trento (IT)
F.M.E. Wagenlehner, Giessen (DE)

Learning objectives

Infections of the urogenital tract are amongst the most frequent infections inside the hospital but also in outpatients. This session on infections in urology combines urgent and ongoing topics, highly relevant for practicing urologists. Participants will learn strategies how to prevent infections, how to deal with infections in kidney transplant patients, and how to deal with the most severe infections in urology, namely urosepsis.

15:15 - 15:16

Introduction

F.M.E. Wagenlehner, Giessen (DE)

15:16 - 15:55

Kidney transplant resolving the myths about catheters: Lively Debate and development of a consensus

Chair V. Gomez Dos Santos, Madrid (ES)

Moderator C. Ohyama, Hiroasaki (JP)

15:16 - 15:24

Introduction and findings from national registries

T.E. Bjerklund Johansen, Oslo (NO)

15:24 - 15:29

Is early removal of catheters a must?

F. McCaig, London (GB)

15:29 - 15:34

What about ureteral catheters: are they mandatory and when to remove them?

V. Díez Nicolás, Madrid (ES)

15:34 - 15:39

Use a SPC and have no problems!

J. Medina-Polo, Madrid (ES)

15:39 - 15:52

Roundtable discussion: Can we reach a pragmatic consensus? (voting)

T. Cai, Trento (IT)

L. Schneidewind, Rostock (DE)

15:52 - 15:55

Closing remarks and summary of the session

T.E. Bjerklund Johansen, Oslo (NO)

15:55 - 16:55

How do I do it to prevent and deal with infections in urological surgery?

Moderators R. Bartoletti, Pisa (IT)

M. Vallée, Poitiers (FR)

F.M.E. Wagenlehner, Giessen (DE)

15:55 - 16:00

Introduction and background

F.M.E. Wagenlehner, Giessen (DE)

16:00 - 16:10

Penile implantation: Can antibiotics be removed? (5 min. presentation + 5 min. video)

To be confirmed

16:10 - 16:20	Fascial Sling: Do I need to use antibiotics? (5 min. presentation + 5 min. video) E. Costantini, Perugia (IT)
16:20 - 16:30	Prostate biopsies without antibiotics (5 min. presentation + 5 min. video) A. Pilatz, Giessen (DE)
16:30 - 16:40	PCNL: Who are patients that don't need antibiotic prophylaxis? (5 min. presentation + 5 min. video) B. Somani, Southampton (GB)
16:40 - 16:55	Debate all Can we agree to reduce antibiotics around prophylaxis? (voting) Moderator M. Vallée, Poitiers (FR)
16:55 - 17:21	Vaccines - Immunomodulation in urology: Is this the future? Moderators F. Bruyere, Tours (FR) T. Cai, Trento (IT)
16:55 - 17:03	Host response to UTIs: The basics B. Wullt, Helsingborg (SE)
17:03 - 17:11	Immunoprophylaxis of UTIs: Basics let's go to the drawing board M. Ingersoll, Paris (FR)
17:11 - 17:16	How will immunoprophylaxis reshape the management of UTIs F. Bruyere, Tours (FR)
17:16 - 17:21	Wrap up and key points T. Cai, Trento (IT)
17:21 - 18:15	Severe infections in Urology: Early detection and management? Moderators S.E. Geerlings, Amsterdam (NL) J. Kranz, Aachen (DE) Z. Tandoğdu, London (GB)
17:21 - 17:26	Introduction Z. Tandoğdu, London (GB)
17:26 - 17:34	Updates from the latest guidelines on management of urosepsis J. Kranz, Aachen (DE)
17:34 - 17:42	Biomarkers role in urosepsis F.M.E. Wagenlehner, Giessen (DE)
17:42 - 17:50	How and when is rapid point of diagnostic tools to arrive and reshape management of urosepsis? To be confirmed
17:50 - 17:58	From PCNL to Sepsis? Why? How? Can we prevent? Can we predict? E. De Lorenzis, Milan (IT)
17:58 - 18:06	Tackling complexity: Approaches to UTI management in pregnancy J. Currie, Bristol (GB)

18:06 - 18:14

ICU for the urologist in managing urosepsis

To be confirmed

18:14 - 18:15

Closing remarks

T. Cai, Trento (IT)

Enucleation is enucleation is enucleation

Video session 06

06 April 2024
15:15 - 16:45

Location Green Area, S04
Chairs To be confirmed
K. Lehrich, Berlin (DE)
To be confirmed

- V041** **STAR-P – Suprapubic Transvesical Adenoma Resection of the Prostate - original technique for surgical treatment of BPH: A novel urethra-sparing strategy for any prostatic volume**
Authors: Bucca B.¹, Gobbi L.M.¹, Asero V.¹, Scornajenghi C.M.¹, Alviani F.¹, Licari L.C.¹, Bologna E.¹, Gozzi C.²
Institutes: ¹Sapienza University of Rome Policlinico Umberto I Hospital, Urology Unit, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²City Clinic, Dept. of Urology, Bolzano, Italy
- V042** **En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success.**
En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success.
En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success.
Authors: Rodríguez Socarrás M.E., Guzman Barraza J.D., Fernandez Del Alamo J., Reinoso Elbers J., Carrion Monsalve D., Gomez Rivas J.A., Llanes Gonzalez L., Ruiz Grana S., Cuadros Rivera V., Gomez Sancha F.
Institutes: Instituto de Cirugia Urologica Avanzada ICUA, Clinica Cemtro, Dept. of Urology, Madrid, Spain
- V043** **Combined HoLEP and transvesical Single port robotic simple prostatectomy**
Authors: Wang Y., Arora S., Bazzi M., Zhuo J., Leavitt D., Rogers C.G.
Institutes: Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America
- V044** **Plasmakinetic enucleation of the prostate with apical precut (APC-PKEP): a modified electrode and en bloc technique for anatomic transurethral prostatectomy**
Authors: Wu J., Lin H.X., Wu J.Y., Cai W.H., Lin Y.C., Z Q.G., Ye L.F.
Institutes: Shengli Clinical Medical College of Fujian Medical University, Dept. of Urology, Fuzhou, China
- V045** **Robotic anatomical enucleation of the prostate (RAEP) without irrigation and with suprapubic tube only for massively enlarged obstructive prostate**
Authors: Sarychev S.¹, Klein J-T.²
Institutes: ¹Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ²Spital Thurgau AG, Dept. of Urology, Münsterlingen, Switzerland
- V046** **Robotic Single port Transvesical Enucleation of the Prostate (STEP): technique and early single center experience**
Authors: Franco A., Ditunno F., Bologna E., Licari L.C., Manfredi C., Cherullo E.E., Vourganti S., Chow A.K., Autorino R.
Institutes: Rush University Medical Center, Dept. of Urology, Chicago, United States of America

V047

Robot-Assisted Simple Prostatectomy (RASP): step by step technique, complications and peri-operative results

Authors: Blezien O., de Broucker C., Bentellis I., Shaikh A., Tibi B., Ahallal Y., Durand M.

Institutes: CHU Nice, Hopital Pasteur 2, Dept. of Urology, Andrology and Kidney Transplantation, Nice, France

Penile cancer dynamics: Targeting progress in diagnostics and therapy

Abstract session 13

06 April 2024
15:15 - 16:45

Location Green Area, W01
Chairs To be confirmed
A. Necchi, Milan (IT)
To be confirmed

15:15 - 15:17

Introduction

15:17 - 15:37

Tumor micro-environment, liquid biopsies and new targets

A0345

Single-cell trajectory analysis reveals distinct differentiation of epithelial cells highlighting a more aggressive phenotype in HPV-negative and TP53 mutated penile cancer

Authors: Elst L.¹, Philips G.², Bassez A.², Vandermaesen K.¹, Boeckx B.², Spans L.³, Vanden Bempt I.³, Jacomen G.⁴, Van Rompuy A.S.⁵, Baldewijns M.⁵, Lambrechts D.², Albersen M.¹

Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²VIB KU Leuven Center for Cancer Biology, Laboratory of Translational Genetics, Leuven, Belgium, ³University Hospitals Leuven, Dept. of Human Genetics, Leuven, Belgium, ⁴AZ. Sint-Maarten, Dept. of Pathological Anatomy, Mechelen, Belgium, ⁵University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium

A0346

Single-cell transcriptomics reveals B cells-IgA-PIGR axis improving overall survival in HPV-associated penile squamous cell carcinomas

Authors: Tao T., Xiao J.

Institutes: The First Affiliated Hospital of USTC of China, Dept. of Urology, Hefei, China

A0350

Checkpoint-related proteins in liquid biopsies and their association with prognostic factors in penile cancer

Authors: Glombik D., Carlsson J., Kirrander P., Davidsson S.

Institutes: Faculty of Medicine and Health, Örebro University, Dept. of Urology, Örebro, Sweden

A0342

TROP-2 – a promising new therapeutic target in penile squamous cell carcinoma

Authors: Weiten R.¹, Kessler C.², Meisl C.³, Spohn H.E.², Storz E.², Pfister D.², Nestler T.⁴, Tolkach Y.⁵, Linden F.⁶, Wirtz R.⁶, Von Brandenstein M.², Krausewitz P.¹, Heidenreich A.²

Institutes: ¹University Hospital Bonn, Dept. of Urology and Paediatric Urology, Bonn, Germany, ²University Hospital Cologne, Dept. of Urology, Cologne, Germany, ³Charité Hospital Berlin, Dept. of Urology, Berlin, Germany, ⁴Federal Armed Services Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ⁵University Hospital Cologne, Institute of Pathology, Cologne, Germany, ⁶STRATIFYER Molecular Pathology GmbH, STRATIFYER Molecular Pathology GmbH, Cologne, Germany

15:37 - 16:07

Evolutions in diagnosis

A0344

Snap diagnosis: pilot study of artificial intelligence powered smartphone application for penile cancer detection from the comfort of your home

Authors: Liu J.¹, O'Brien J.S.¹, Nandakishor K.², Chen K.³, Teh J.⁴, Kelly B.D.⁴, Manning T.⁵, Niranjana S.⁶, Murphy D.G.⁴, Bolton D.⁵, Chee J.⁷, Marimuthu P.², Lawrentschuk N.¹

Institutes: ¹EJ Whitten Prostate Cancer Research Centre, Dept. of Urology, Melbourne, Australia, ²The University of Melbourne, Dept. of Electrical and Electronic Engineering, Melbourne, Australia, ³Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ⁴Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ⁵Austin Health, Dept. of Surgery, Melbourne, Australia, ⁶The Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁷MURAC Health, Dept. of Urology, Melbourne, Australia

A0351

First evaluation of one-step nucleic acid amplification (OSNA) for rapid molecular detection of lymph node metastases in penile cancer patients

Authors: Engels S.¹, Michalik B.¹, Dirks L.¹, Henke R.P.², Wawroschek F.¹, Winter A.¹

Institutes: ¹Carl Von Ossietzky University Oldenburg, University Hospital for Urology, Oldenburg, Germany, ²Institute of Pathology Oldenburg, Oldenburg, Germany

A0339

Evaluation of the use of serum Squamous cell carcinoma Antigen for staging of penile cancer

Authors: Vreeburg M.T.A.¹, Tomassen Y.¹, Kessel R.², Graafland N.¹, Hendricksen K.¹, Van Rhijn B.W.G.¹, Brouwer O.R.¹

Institutes: ¹The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Biometrics, Amsterdam, The Netherlands

A0340

Assessment and outcome of intraoperative frozen section examination of surgical resection margins in the management of penile cancer

Authors: Yunis M.¹, Pang K.H.², Haider A.³, Freeman A.³, Hadway P.⁴, Nigam R.⁵, Rees R.⁶, Muneer A.², Alnajjar H.M.²

Institutes: ¹King's College London, Dept. of Life Sciences and Medicine, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Institute of Andrology, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Histopathology, London, United Kingdom, ⁴Royal Berkshire NHS Foundation Trust, Dept. of Urology, Reading, United Kingdom, ⁵Royal Surrey NHS Foundation Trust, Dept. of Urology, Guildford, United Kingdom, ⁶University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

A0348

Comprehensive Evaluation of MRI Accuracy in Local Staging of Penile Cancer

Authors: Shendy M.¹, Iqbal M.¹, Brown G.¹, McClune A.², Shanahan A.¹

Institutes: ¹Royal Glamorgan hospital, Dept. of Urology, Cardiff, United Kingdom, ²Leighton hospital, Dept. of Urology, Crewe, United Kingdom

- A0335** **Does the “10% rule” apply to sentinel node biopsies for penile squamous cell carcinoma?**
Authors: Yan S., Ayres B., Ni Raghallaigh H., Oliver R., Watkin N.
Institutes: St George's University Hospital, Dept. of Urology, London, United Kingdom
- 16:07 - 16:22** **Epidemiology and prognosis**
- A0343** **Human papillomavirus (HPV) does not modify the prognostic significance of tumour stage and grade of differentiation in penile carcinoma. A retrospective study spanning 50 years from a Norwegian tertiary centre.**
Authors: Moen C.A.¹, Nordanger I.M.¹, Thorkelsen T.K.¹, Honoré A.¹, Juliebø-Jones P.¹, Bostad L.², Beisland C.¹
Institutes: ¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²Haukeland University Hospital, Dept. of Pathology, Bergen, Norway
- A0337** **Penile Intraepitheliale Neoplasia (PeIN) in the Netherlands: A Comprehensive 15-Year Study on Incidence, Recurrence, and Progression to Invasive Malignancy**
Authors: Avitan O.¹, Van Maaren L.C.¹, Vreeburg M.¹, Bekers E.², Van Der Poel H.¹, Brouwer O.¹
Institutes: ¹The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute, Dept. of Pathology, Amsterdam, The Netherlands
- A0341** **Penile cancer, epidemiological data can determine the disease trend and how to conduct prevention and treatment?**
Authors: Rodrigues A.F.¹, Lima G.S.¹, Barbosa J.P.O.¹, Monteiro C.R.A.², Rodrigues D.P.³, Leao F.F.¹
Institutes: ¹Hospital Israelita Albert Einstein, Dept. of Urology, Goiania, Brazil, ²Hospital Edmundo Vasconcelos, Dept. of Urology, Sao Paulo, Brazil, ³Hospital Universitario Sao Francisco na Providencia de Deus, Dept. of Urology, Branganca Paulista, Brazil
- 16:22 - 16:42** **Therapy & outcomes**
- A0349** **Outcome of videoendoscopic inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in patients with penile Cancer: A retrospective comparative study**
Authors: Jalan A., Pokhrel G.P., Gharti B.B., Nepal U., Lamichhane N.
Institutes: B P Koirala Memorial Cancer Hospital, Dept. of Surgical Oncology, Bharatpur, Nepal
- A0347** **Organ Preservation and Oncological Efficacy of Penoscopically Controlled CO2 Laser Excision of Penile Squamous Cell Carcinoma: Early and Late Results in a High-Volume Center**
Authors: Silvani C.¹, Lorusso V.¹, Nazzani S.¹, Macchi A.¹, Torelli T.¹, Stagni S.¹, Tesone A.¹, Claps M.², Giannatempo P.², Zimatore M.², Cattaneo L.³, Paolini B.³, Darisi R.¹, Montanari E.⁴, Nicolai N.¹
Institutes: ¹Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Dept. of Oncology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Dept. of Pathology, Milan, Italy, ⁴Fondazione IRCCS Ca' Granda Policlinico di Milano, Dept. of Urology, Milan, Italy
-

A0338

Quality of life after penile cancer surgery: comparison between amputative and penile-sparing surgery.

Authors: [Vreeburg M.T.A.](#)¹, Van Harten M.J.¹, de Vries H-M.¹, de Ligt K.M.², Van Muilekom E.¹, Van Kesteren J.¹, Van Der Poel H.G.¹, Elzevier H.W.³, Nicolai M.¹, Brouwer O.R.¹

Institutes: ¹The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Division of Psychosocial Research and Epidemiology, Amsterdam, The Netherlands, ³Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands

A0336

Optimising surveillance imaging in high risk nodal (N+) penile cancer: Proposal of an updated surveillance protocol

Authors: Kynaston T.¹, Yan S.W.L.¹, [Ayres B.E.](#)¹, Ager M.², Watkin N.A.¹, Pathmanathan A.³

Institutes: ¹St George's University Hospital, Dept. of Urology, London, United Kingdom, ²Charing Cross Hospital, Dept. of Urology, London, United Kingdom, ³Royal Marsden Hospital, Dept. of Oncology, London, United Kingdom

16:42 - 16:45

Expert summary

Imaging guided surgeries

Meeting of the EAU Section of Urological Imaging (ESUI)

06 April 2024
15:15 - 18:15

Location Green Area, W03
Chair F. Sanguedolce, Barcelona (ES)

Learning objectives

Which are the latest advances in imaging technology that will support urological surgical training, surgical planning, and real-time intervention guidance?

15:15 - 15:19

Welcome and introduction

F. Sanguedolce, Barcelona (ES)

15:19 - 16:16

Joint-session with EULIS

Moderators P. Martino, Bari (IT)
V. Scattoni, Milan (IT)
C.C. Seitz, Vienna (AT)

15:19 - 15:30

Dual energy CT scan for stone characterization

E.X. Keller, Zürich (CH)

15:30 - 15:41

Training in urolithiasis interventions: from simulation to virtual reality

K. Ahmed, London (GB)

15:41 - 15:52

Image-tracked renal puncture for PCNL

E.A. Rodrigues De Lima, Braga (PT)

15:52 - 16:03

Augmented reality for renal puncture during PCNL

E. Checcucci, Candiolo (IT)

16:03 - 16:16

Discussion

16:16 - 17:13

Joint-session with ESUT

Moderators L. Budäus, Hamburg (DE)
C. Fiori, Orbassano (IT)
To be confirmed

16:16 - 16:27

BPH: Aquablation, the WATER trials

N. Barber, Camberley (GB)

16:27 - 16:38

BPH/focal therapy: TULSA, an option for several indications

L.H. Klotz, Toronto, ON (CA)

16:38 - 16:49

Surgical planning and fusion guidance technologies for precise focal therapy of PCa

F. Sanguedolce, Barcelona (ES)

16:49 - 17:00

Focal therapy Registry: A European call

E. Barret, Paris (FR)

17:00 - 17:13

Discussion

17:13 - 18:10

Joint-session with ERUS

Moderators A. Breda, Barcelona (ES)
M.C. Kriegmair, Planegg (DE)

- 17:13 - 17:24 **Real-time assessment of surgical margins after robotic radical prostatectomy: Confocal microscopy vs. Histolog scanner**
G. Shaw, London (GB)
- 17:24 - 17:35 **PSMA guided salvage lymphadenectomy**
T. Maurer, Hamburg (DE)
- 17:35 - 17:46 **Sentinel lymphadenectomy in PCa with 99mTcnanocolloid: Myth or reality?**
C.D. Vera Donoso, Valencia (ES)
- 17:46 - 17:57 **Surgical planning and augmented reality during partial nephrectomy**
A. Breda, Barcelona (ES)
- 17:57 - 18:10 **Discussion**
- 18:10 - 18:15** **Closing remarks**
F. Sanguedolce, Barcelona (ES)

Basic research and trials: Oncology

EGPT 06

06 April 2024
15:15 - 16:45

Location EGPT
Chairs R.T. Bryan, Birmingham (GB)
To be confirmed
To be confirmed

15:15 - 15:27

Screen A: Bladder cancer

P146

Urinary proteomics for microbiome identification and its implication in bladder cancer pathogenesis

Authors: Stamatakos P.V.¹, Fragkoulis C.¹, Zoidakis I.², Stathouros G.¹, Papadopoulos G.¹, Dellis A.³, Papatsoris A.⁴, Ntoumas K.¹

Institutes: ¹GNA G. Gennimatas, Dept. of Urology, Athens, Greece, ²Biomedical Research Foundation Academy of AthenS, Proteomics Laboratory, Athens, Greece, ³Aretaieion Hospital School of Medicine National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ⁴School of Medicine Sismanoglio Hospital National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece

P164

Bladder cancer organoids serve as a useful system to mirror the characteristics of parental tumours

Authors: Zhao H., Liu K., Chen X., Wu H., Chiu P.K-F., Ng C.F., Teoh J.Y.C.

Institutes: The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong

P172

A zebrafish xenograft model for evaluating efficacy of cisplatin in muscle-invasive bladder cancer

Authors: Sugino Y.¹, Sekito S.¹, Kageyama T.¹, Sasaki T.¹, Masui S.¹, Nishikawa K.¹, Tanaka T.², Shimada Y.³, Zang L.⁴, Inoue T.¹

Institutes: ¹Mie University, Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan, ²Mie University, Graduate School of Medicine, Dept. of Systems Pharmacology, Tsu, Japan, ³Mie University, Graduate School of Medicine, Dept. of Integrative Pharmacology, Tsu, Japan, ⁴Mie University, Graduate School of Regional Innovation, Tsu, Japan

P155

Low-absent expression of TROP-2 in sarcomatoid subtype of bladder cancer: immunohistochemical evaluation of TROP-2 in a series of muscle invasive bladder cancer

Authors: Cimadamore A.¹, Franzese C.², Giannarini G.², Miani B.¹, Moschini M.³, Cesselli D.¹, Di Loreto C.¹, Crestani A.²

Institutes: ¹University of Udine, Dept. of Medicine DAME, Udine, Italy, ²Ospedale Santa Maria della Misericordia di Udine, Dept. of Urology, Udine, Italy, ³Urological Research Institute Vita Salute San Raffaele, Dept. of Urology, Milan, Italy

15:27 - 15:39

Screen B: Bladder cancer

- P165** **Discovery of Biomarker for BCG-unresponsive Non-Muscle Invasive Bladder Cancer Using Single-cell RNA Sequencing**
Authors: Park J.¹, Koh D.², Jeong H.O.³, Lee K.J.³, Kim J.¹, Jang W.S.¹, Lee S.H.¹, Lee S.³, Ham W.S.¹
Institutes: ¹Yonsei University College of Medicine, Dept of. Urology and Urological Science Institute, Seoul, South Korea, ²Konyang University, Dept of. Urology, Daejeon, South Korea, ³Ulsan National Institute of Science and Technology, Dept of. Biomedical Engineering, Ulsan, South Korea
- P163** **Expression of CYTOR in Cancer-Associated Fibroblasts Is Associated with the Prognosis and Immunotherapeutic Response in Bladder Cancer**
Authors: Wu Y., He S., Gong Y., Li X., Zhou L.
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China
- P152** **Combined analysis of molecular patterns and clinical factors for the prediction of immune checkpoint inhibitor therapy in advanced urothelial carcinoma**
Authors: Szarvas T.¹, Varadi M.¹, Horvath O.², Soos E.², Fazekas T.¹, Csizmarik A.¹, Nemeth B.¹, Gyorffy B.³, Kenessey I.⁴, Reis H.⁵, Koll F.⁶, Olah C.⁷, Hadaschik B.⁷, Krafft U.⁷, Mairinger F.⁸, Wessolly M.⁸, Hoffmann M.⁹, Grunewald C.⁹, Niegisch G.⁹, Maraz A.¹⁰, Kuthi L.¹¹, Furka A.¹², Nyirady P.¹
Institutes: ¹Semmelweis University, Dept. of Urology, Budapest, Hungary, ²National Institute of Oncology, Dept. of Genitourinary Medical Oncology and Pharmacology, Budapest, Hungary, ³Semmelweis University, Research Centre for Natural Sciences, Dept. of Pediatrics and Dept. of Bioinformatics Institute of Enzymology, Budapest, Hungary, ⁴Semmelweis University, Institute of Pathology, Budapest, Hungary, ⁵Goethe University Frankfurt, Dr. Senckenberg Institute of Pathology, Frankfurt am Main, Germany, ⁶Goethe University, Dept. of Urology, Frankfurt am Main, Germany, ⁷University of Duisburg-Essen, Dept. of Urology, Essen, Germany, ⁸University of Duisburg-Essen, Institute of Pathology, Essen, Germany, ⁹Heinrich-Heine University, Dept. of Urology, Düsseldorf, Germany, ¹⁰University of Szeged, Dept. of Oncotherapy, Szeged, Hungary, ¹¹University of Szeged, Institute of Pathology, Szeged, Hungary, ¹²University of Miskolc, Dept. of Clinical Radiology, Miskolc, Hungary
- P171** **Cancer-derived exosomal prothymosin- α triggers muscle wasting via regulating TLR4-NF- κ B-E3 ubiquitin ligase signaling pathway**
Authors: Hu C.-Y.¹, Wu C.L.², Shiau A.L.³, Ou C.H.¹, Tsai Y.S.¹, Shieh G.S.¹
Institutes: ¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, Dept. of Biochemistry and Molecular Biology, Tainan, Taiwan, ³National Cheng Kung University, Dept. of Microbiology and Immunology, Tainan, Taiwan

15:39 - 15:54

Screen C: Bladder cancer

- P149** **PHF6 promotes bladder cancer malignant progression via facilitating P53 ubiquitination**
Authors: Diao W., Mo W., Hu H., Wei F., Chen Y., Zhang B., Xu G., Li D., Zhang Q., Guo H.
Institutes: Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China
- P154** **AIRD1A Knockouts in Bladder Cancer Cell Lines Leads to MYC and E2F Activation Implicated in More Aggressive Tumor Behavior**
Authors: Magnani C.J.¹, DAndrea V.D.¹, Stawiski K.², Stelter I.², Hanlon T.², Jia L.¹, Kibel A.S.¹, Mossanen M.¹, Preston M.A.¹, Clinton T.N.¹, Mouw K.W.², Carvalho F.L.F.¹
Institutes: ¹Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, ²Dana-Farber Cancer Institute, Dept. of Radiation Oncology, Boston, United States of America
- P153** **The m6A reader IGF2BP3 promotes bladder cancer progression via enhancing HSP90AB1 expression**
Authors: Ding M., Chen X., Guo H.
Institutes: Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China
- P159** **The histone methyltransferase KMT9 regulates proliferation and migration of bladder cancer cells and is a novel target for treatment of muscle invasive bladder cancer (MIBC)**
Authors: Totonji S., Metzger E., Urban S., Willmann D., Bauer H., Sum M., Schüle R.
Institutes: Universitätsklinik Freiburg, Dept. of Urology, Freiburg, Germany
- P158** **YTHDC1 reduces M2 macrophage infiltration by regulating tumor senescence to suppress lymph node metastasis of bladder cancer**
Authors: Su Y., Niu H.
Institutes: The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China
- 15:54 - 16:09** **Screen D: Prostate cancer**
- P160** **Generation of a new transgenic mouse model to explore the role of oncofetal CRIPTO in lethal prostate cancer**
Authors: Rodrigues Sousa E.¹, De Brot S.², Zoni E.¹, Scarpa M.³, La Manna F.¹, Brunello A.¹, Abey Alexander A.¹, Klima I.¹, Freeman D.⁴, Thalmann G.⁵, Spike B.⁴, Chouvardas P.¹, Kruithof-De Julio M.³
Institutes: ¹University of Bern, Dept. of Biomedical Research, Urology Research Laboratory, Bern, Switzerland, ²Institute of Animal Pathology, Dept. of Infectious Diseases and Pathobiology, Bern, Switzerland, ³University of Bern, Dept. of BioMedical Research, Translational Organoid Research, Bern, Switzerland, ⁴Huntsman Cancer Institute, Dept. of Oncological Sciences, Salt Lake City, United States of America, ⁵University Hospital of Bern, Dept. of Urology, Bern, Switzerland

- P150** **Investigating prostate cancer cellular heterogeneity and treatment response at single-cell level**
Authors: Parmentier R.¹, Roux J.², Dolgos R.¹, Servant R.¹, Mertz K.³, Subotic S.⁴, Seifert H.⁵, Bubendorf L.⁶, Rentsch C.⁵, Le Magnen C.¹
Institutes: ¹University Hospital Basel, University Basel, Dept. of Urology - Institute of Medical Genetics and Pathology - Dept. of Biomedicine, Basel, Switzerland, ²University of Basel, Dept. of Biomedicine, Basel, Switzerland, ³Kanton Baselland Liestal Hospital, Institute of Pathology, Liestal, Switzerland, ⁴Kanton Baselland Liestal Hospital, Clinic for Urology, Liestal, Switzerland, ⁵University Hospital Basel, Dept. of Urology, Basel, Switzerland, ⁶University Hospital Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland
- P169** **Exploring the genomic blueprint of de novo neuroendocrine prostate cancer: Insights for innovative therapies from spatial gene expression analysis**
Authors: Watanabe R.¹, Miura N.¹, Kurata M.², Kitazawa R.³, Kikugawa T.¹, Saika T.¹
Institutes: ¹Ehime University Graduate School of Medicine, Dept. of Urology, Toon, Japan, ²Ehime University Graduate School of Medicine, Dept. of Analytical Pathology, Toon, Japan, ³Ehime University Hospital, Division of Diagnostic Pathology, Toon, Japan
- P162** **Melatonin Induces P53 Phosphorylation to Enhance SLC7A11-Mediated Ferroptosis and Inhibit Prostate Cancer Progression**
Authors: Huang H., Luo T.
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- P161** **Androgen receptor mediated tumor-associated macrophages drives prostate cancer progression to castration-resistant prostate cancer.**
Authors: Cheng B.S., Huang H.
Institutes: Sun Yat sen Memorial Hospital Sun Yat-sen University, Dept. of Urology, Guangzhou, China
- 16:09 - 16:21** **Screen E: Prostate cancer**

- P151** **Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk biochemically recurrent prostate cancer (BCR) following radical prostatectomy (RP) or radiation therapy (RT): EMBARK post hoc analysis**
Authors: De Giorgi U.¹, Freedland S.J.², Rannikko A.³, Ramirez-Backhaus M.⁴, Villers A.⁵, Gleave M.⁶, Tarazi J.⁷, Tang Y.⁸, Haas G.P.⁹, Rosales M.⁹, Shore N.D.¹⁰
Institutes: ¹IRST Dino Amadori, Dept. of Medical Oncology, Meldola, Italy, ²Samuel Oschin Comprehensive Cancer Institute, Dept. of Urology, Los Angeles, United States of America, ³University of Helsinki and Helsinki University Hospital, Dept. of Urology and Research Program in Systems Oncology, Helsinki, Finland, ⁴Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ⁵University of Lille, Dept. of Urology, Lille, France, ⁶University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ⁷Pfizer Inc., Dept. of Global Product Development, Collegeville, United States of America, ⁸Pfizer Inc., Dept. of Global Product Development, San Francisco, United States of America, ⁹Astellas Pharma Inc., Dept. of Global Product Development, Northbrook, United States of America, ¹⁰Carolina Urologic Research Center, Dept. of Surgical Oncology and Urology, Myrtle Beach, United States of America
- P168** **Uncovering somatic genetic susceptibility factors in prostate cancer through comprehensive genome-wide analysis**
Authors: Lin L., Wu K., Li X.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- P148** **Unveiling the Hidden Role of Spermine: Targeting HMOX1-induced Mitophagy in Prostate Cancer Therapy**
Authors: Sun J.¹, Chiu P.K-F.¹, Xie T.¹, Teoh J.Y.C.¹, Huang P.², Ho V.W.S.¹, Ng C.F.¹
Institutes: ¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ²Okayama University, Dept. of Urology, Okayama, Japan
- P166** **T cells subset in tumor-draining lymph nodes and blood from patients with prostate cancer**
Authors: Saudi A.Z.S.¹, Banday V.², Selinger M.³, Henriksson J.³, Waldén M.⁴, Alamdari F.⁵, Aljabery F.¹, Winqvist O.⁶, Sherif A.²
Institutes: ¹Medical Faculty, Linköping University, Dept. of Urology and Experimental Medicine, Linköping, Sweden, ²Umeå University, Division of Urology and Andrology, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ³Umeå Centre for Microbial Research, Dept. of Molecular Biology, Umeå, Sweden, ⁴Central Hospital of Karlstad, Dept. of Urology, Karlstad, Sweden, ⁵Västmanland Hospital, Dept. of Urology, Västerås, Sweden, ⁶ABC Labs, Campus Solna, BioClinicum, Stockholm, Sweden
- 16:21 - 16:36** **Screen F: Kidney cancer**
-

- P167** **Targeting glutamine addiction to induce ferroptosis with potent drug combination therapy for renal cell carcinoma**
Authors: Takeuchi A.¹, Sumitomo M.¹, Yoshimura A.², Watanabe T.³, Yanagi H.⁴, Sugihara E.³, Zennami K.¹, Takahara K.¹, Saya H.³, Shiroki R.¹
Institutes: ¹Fujita Health University, Dept. of Urology, School of Medicine, Aichi, Japan, ²Fujita Health University, Advanced Medical Research Center for Animal Models of Human Diseases, Aichi, Japan, ³Fujita Health University, Fujita Cancer Center, Aichi, Japan, ⁴Fujita Health University, Dept. of Clinical Oncology School of Medicine, Aichi, Japan
- P156** **Carbonic anhydrase IX in renal cell carcinoma: a relevant biomarker and promising therapeutic target**
Authors: Barathova M.¹, Csaderova L.¹, Grossmannova K.¹, Belvoncikova P.¹, Pastorek J.², Breza Jr. J.³, Breza Sr. J.⁴
Institutes: ¹Biomedical Research Center, Slovak Academy of Sciences, Dept. of Cancer Biology, Bratislava, Slovakia, ²Mabpro, Bratislava, Slovakia, ³National Institute of Childrens Diseases, Dept. of Pediatric Urology, Bratislava, Slovakia, ⁴Slovak Medical University, Bratislava, Slovakia
- P157** **Prognostic role of PD-L1 in tumor tissue and liquid biopsy in clear cell renal cell carcinoma**
Authors: Junk K.¹, Jaschkowitz G.¹, Stahl P.², Stöckle M.¹, Junker K.¹, Zeuschner P.¹
Institutes: ¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ²Saarland University, Dept. of Pathology, Homburg, Germany

P170

Effect of HLA genotype on anti-PD-1 antibody treatment for advanced renal cell carcinoma

Authors: Tanegashima T.¹, Shiota M.¹, Miyake H.², Takahashi M.³, Oya M.⁴, Tsuchiya N.⁵, Masumori N.⁶, Matsuyama H.⁷, Obara W.⁸, Shinohara N.⁹, Fujimoto K.¹⁰, Nozawa M.¹¹, Ohba K.¹², Ohyama C.¹³, Hashine K.¹⁴, Akamatsu S.¹⁵, Kamba T.¹⁶, Mita K.¹⁷, Gotoh M.¹⁸, Tatarano S.¹⁹, Fujisawa M.²⁰, Tomita Y.²¹, Tokunaga S.²², Eto M.¹

Institutes: ¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Hamamatsu University, Dept. of Urology, Hamamatsu, Japan, ³Tokushima University, Dept. of Urology, Tokushima, Japan, ⁴Keio University, Dept. of Urology, Tokyo, Japan, ⁵Yamagata University, Dept. of Urology, Yamagata, Japan, ⁶Sapporo Medical University, Dept. of Urology, Sapporo, Japan, ⁷Yamaguchi University, Dept. of Urology, Ube, Japan, ⁸Iwate Medical University, Dept. of Urology, Iwate, Japan, ⁹Hokkaido University, Dept. of Urology, Sapporo, Japan, ¹⁰Nara Medical University, Dept. of Urology, Kashihara, Japan, ¹¹Kindai University, Dept. of Urology, Osaka, Japan, ¹²Nagasaki University, Dept. of Urology, Nagasaki, Japan, ¹³Hirosaki University, Dept. of Urology, Hirosaki, Japan, ¹⁴National Hospital Organization Shikoku Cancer Center, Dept. of Urology, Ehime, Japan, ¹⁵Kyoto University, Dept. of Urology, Kyoto, Japan, ¹⁶Kumamoto University, Dept. of Urology, Kumamoto, Japan, ¹⁷Hiroshima City Asa Citizens Hospital, Dept. of Urology, Hiroshima, Japan, ¹⁸Nagoya University, Dept. of Urology, Nagoya, Japan, ¹⁹Kagoshima University, Dept. of Urology, Kagoshima, Japan, ²⁰Kobe University, Dept. of Urology, Kobe, Japan, ²¹Niigata University, Dept. of Urology, Niigata, Japan, ²²Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

P147

Metallothionein 1 X is a tumor suppressor gene and inhibits metastasis in clear cell renal cell carcinoma

Authors: Rui R., He S., Li X., Zhou L.

Institutes: Institute of Urology Peking University, Dept. of Urology, Beijing, China

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.17

06 April 2024
15:30 - 16:25

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.18

06 April 2024
15:30 - 16:25

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.19

06 April 2024
15:30 - 16:25

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

05 April 2024
10:45 - 12:45

Location
Chairs

Purple Area, N01
R. Kumar, New Delhi (IN)
J.O.R. Sønksen, Herlev (DK)

10:45 - 10:48	Welcome and introduction
10:48 - 11:45	Urology sans the robot: Semi-live techniques
10:48 - 10:58	Vesicovaginal fistulae: The African experience To be confirmed
10:58 - 11:08	Sperm retrieval: The surgeon matters C.F.S. Jensen, Herlev (DK)
11:08 - 11:18	Truly progressive perineal urethroplasty M. Fisch, Hamburg (DE)
11:18 - 11:28	Laparoscopic pediatric pyeloplasty To be confirmed
11:28 - 11:38	Adrenalectomy: The least invasive way R. Kumar, New Delhi (IN)
11:38 - 11:45	Discussion
11:45 - 12:42	The next decade of urology
11:45 - 11:55	Not cutting for stone: Flexible ureteroscopy for all seasons O. Traxer, Paris (FR)
11:55 - 12:05	Invasion of the robots J. Lee, Seoul (KR)
12:05 - 12:15	AI solutions: Will the prostate biopsy be redundant? C. Moore, London (GB)
12:15 - 12:25	Out-patient surgery for BPH D. Elterman, Toronto (CA)
12:25 - 12:35	The artificial bladder To be confirmed
12:35 - 12:42	Discussion
12:42 - 12:45	Closing remarks

Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript

ESU Course 20

06 April 2024
16:00 - 18:00

Location Purple Area, E01
Chairs A. Briganti, Milan (IT)
D.R. Siemens, Kingston, Ontario (CA)

Learning objectives

This ESU course is a collaboration between *European Urology* and the *Journal of Urology*

This course will offer an expansive and interactive overview of the entire scholarly publishing procedure, specifically focusing on the writing process and what it means to be an outstanding author. The Faculty will offer instruction on how to construct a well-written introduction and methods section for your manuscript, learn how to present statistical analyses, understand key points when writing and how to use Social Media to best promote important work. Participants will obtain insight directly from editors on what they expect to see. The course will be structured into two modules including lectures and breakout sessions.

- To learn how to write a full length article from the Author and Editor perspective
- To understand systematic reviews and meta-analysis.
- Using Social Media platforms in a responsible and successful manner.
- To learn from experienced editors.

Welcome and introduction

A. Briganti, Milan (IT)

How to capture the Editor’s attention

D.R. Siemens, Kingston, Ontario (CA)

Performing and reporting the perfect statistics

R. L. Dunn, Ann Arbor (US)

Beyond the scientific manuscript: The role of social media in 2024

D. Murphy, Melbourne (AU)

Small group sessions (20 minutes per group)

What did I do wrong? Practical examples on "How to improve the methodological approach to your research question"

R. L. Dunn, Ann Arbor (US)

Captivating the reader: Unlocking the power of abstracts and introductions

L. Bukavina, Philadelphia (US)

Contextualising results and crafting impactful conclusions in discussion

B.F. Chapin, Houston (US)

Conclusion Reports from the group

Laparoscopy for beginners

ESU Course 21

06 April 2024
16:00 - 18:00

Location Purple Area, E02
Chair D. Veneziano, New York (US)

Learning objectives

Over the past decades laparoscopy has played a major role in the therapeutic options of most urological conditions. Nevertheless, the steep learning curve associated with laparoscopic surgery makes it a challenging technique to master.

The aim of this ESU course is to provide you not only the basics of laparoscopic surgery, but also the tips and tricks to develop your laparoscopic skills.

- Peritoneal access and pneumoperitoneum
- How to choose and use the best laparoscopic instruments
- Indications and contraindications of the laparoscopic approach
- How to prevent and manage complications

Video and lively discussions will aid beginners shortening their learning curve and optimizing the success of their laparoscopic procedures.

Laparoscopy: Historical perspective

D. Veneziano, New York (US)

Basic principles of laparoscopic surgery and pneumoperitoneum

T.M. Ribeiro De Oliveira, Lisbon (PT)

Laparoscopic equipment and trocar placement

D. Veneziano, New York (US)

Indications for laparoscopic surgery in urology

T.M. Ribeiro De Oliveira, Lisbon (PT)

Managing complications in laparoscopic surgery

D. Veneziano, New York (US)

Modern treatment in testicular cancer

ESU Course 22

06 April 2024
16:00 - 18:00

Location Purple Area, E03
Chair D. Nicol, London (GB)

Learning objectives

This course will cover the diagnosis and treatment of germ cell tumours of the testis. Lectures will cover the potential role of the new marker miRNA-371 in testicular cancer and provide an overview of both early stage and advanced disease. Case based discussions with audience interaction will cover common scenarios and issues in clinical practice. Learning objectives will be to understand the promise and current limitations on a new marker in testicular cancer, management of early stage disease including adjuvant treatments, the role and use of chemotherapy and surgery in advanced and relapsed disease.

Introduction

D. Nicol, London (GB)

Whats new? The role of the new diagnostic marker miR-371

R. Leão, Coimbra (PT)

Testis cancer: Early stages

D. Nicol, London (GB)

Testis cancer: Case discussion

D. Nicol, London (GB)

R. Leão, Coimbra (PT)

T. Tandstad, Trondheim (NO)

Testis cancer: Advanced stages

T. Tandstad, Trondheim (NO)

Testis cancer: Case discussion

D. Nicol, London (GB)

R. Leão, Coimbra (PT)

T. Tandstad, Trondheim (NO)

Discussion and conclusion

D. Nicol, London (GB)

Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 23

**06 April 2024
16:00 - 18:00**

Location Purple Area, E04
Chair J.M. Gaya Sopena, Barcelona (ES)

Learning objectives

Patient positioning and trocar placement

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic adenomectomy and radical prostatectomy

P. Kallidonis, Patras (GR)

Laparoscopic radical cystectomy

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy

P. Kallidonis, Patras (GR)

Identify and solve complications

J.M. Gaya Sopena, Barcelona (ES)

How we manage upper tract tumours

ESU Course 24

06 April 2024
16:00 - 18:00

Location Purple Area, E05
Chair S. Shariat, Vienna (AT)

Learning objectives

This course will address contemporary concepts and controversies in UTUC such as:

- Accurate staging and its role in clinical decision-making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

Epidemiology, diagnosis, evaluation

A. Masson-Lecomte, Paris (FR)

Prognostic and predictive factors, pathology

S. Shariat, Vienna (AT)

Treatment of low-risk cancer (high grade Ta, T1 and carcinoma in situ (CIS))

A. Masson-Lecomte, Paris (FR)

Treatment of localised high-risk (invasive) and metastatic cancer

S. Shariat, Vienna (AT)

Update EAU Guidelines 2024 – Sexual health, infections and penile and testicular cancer: What has changed?

ESU Course 25

**06 April 2024
16:00 - 18:00**

Location Purple Area, E06
Chair G. Bonkat, Basel (CH)

Urological infections

Updated from the 2024 Infections Guidelines – recurrent UTI, ABU and the EMA stance on fluoroquinolones

G. Bonkat, Basel (CH)

Testicular cancer

Principles of systemic therapy in testicular cancer across disease stages

A. Patrikidou, Villejuif (FR)

Sexual and reproductive health panel

Penile size abnormalities and dysmorphophobia – does size matter? Summary of the Guidelines

M. Falcone, Torino (IT)

Penile cancer

EAU ASCO Penile Cancer guidelines one year on – key recommendations and questions

O.R. Brouwer, Amsterdam (NL)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.21

06 April 2024
16:30 - 17:25

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.22

06 April 2024
16:30 - 17:25

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.23

06 April 2024
16:30 - 17:25

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

From diagnosis to management: Comprehensive insights into non-Muscle invasive bladder cancer

Abstract session 14

06 April 2024
17:00 - 18:30

Location Green Area, N04
Chairs To be confirmed
To be confirmed
To be confirmed
To be confirmed

17:00 - 17:02

Introduction

17:02 - 17:27

Quality of life of patients with non-muscle invasive bladder cancer

A0368

Development of the Bladder Utility Symptom Scale (BUSS Utility): A novel tool to measure utilities and quality of life in bladder cancer patients

Authors: Kulkarni G.¹, Perlis N.¹, Cheung D.¹, Bremner K.E.¹, Papasideris M.¹, Lajkosz K.¹, Power N.², Nam R.K.¹, Tomlinson G.³

Institutes: ¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²Western University, Dept. of Urology, London, Canada, ³University of Toronto, Dept. of Biostatistics, Toronto, Canada

A0356

Quality of life and utility measurement in bladder cancer patients

Authors: Papasideris M.P.¹, Bremner K.E.¹, Cheung D.C.², Black P.C.³, Kassouf W.⁴, Wong W.L.⁵, Kulkarni G.S.²

Institutes: ¹University Health Network, Toronto General Hospital Research Institute, Toronto, Canada, ²University Health Network, Dept. of Surgical Oncology, Toronto, Canada, ³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁴McGill University, Dept. of Surgery, Urology, Montreal, Canada, ⁵University of Waterloo, School of Pharmacy, Kitchener, Canada

A0364

Effect of pregabalin on catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor

Authors: Mosbahi B.¹, Hariz A.¹, Khalifa C.¹, Fakhfakh H.¹, Chaker K.², Ouanes Y.², Madani M.A.², Karmous J.², Bibi M.², Mrad Dali K.², Rahoui M.², Nouria Y.², Ammous A.¹

Institutes: ¹La Rabta Hospital, Dept. of Anesthesiology, Tunis, Tunisia, ²La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

A0367

Effect of Intravesical Bacillus Calmette-Guerin (BCG) Induction Therapy on Sperm Paramaters in Sexually Active Male Patients Diagnosed With Non Muscle Invasive Bladder Cancer

Authors: Sahin S., Canitez I.O., Dusunus Y.E., Yentur S., Ulus I., Temiz M.Z., Semercioz A.

Institutes: University of Health Sciences Istanbul Bagcilar Training and Research Hospital, Dept. of Urology, Istanbul, Türkiye

A0355

Impact of chronic kidney disease on prognosis in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant induction bacillus Calmette-Guérin therapy

Authors: Fujita N.¹, Momota M.M.¹, Narita T.N.¹, Ito H.I.², Yoneyama T.Y.¹, Hashimoto Y.H.¹, Yoshikawa K.Y.³, Ohyama C.O.¹, Hatakeyama S.H.¹

Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

17:27 - 17:42

Urinary markers in the surveillance setting of non-muscle invasive bladder cancer

A0359

Clinical Validation and Performance Assessment of a TERT/FGFR3/KRAS Mutation screening urinary biomarker test for recurrence surveillance in non-muscle invasive bladder cancer

Authors: Ramos P.¹, Brás J.P.², Dias C.², Bessa-Gonçalves M.², Botelho F.¹, Silva J.¹, Matins-Silva C.¹, Pacheco-Figueiredo L.³

Institutes: ¹Sao Joao University Hospital Center, Dept. of Urology, Porto, Portugal, ²University of Porto, Health Investigation and Innovation Institute i3S, Porto, Portugal, ³University of Minho, Institute for Research in Life and Health Sciences ICVS, Braga, Portugal

A0358

Reducing the number of flexible cystoscopies in patients undergoing follow-up for non-muscle invasive bladder cancer with either flexible cystoscopy or the urinary biomarker test Bladder Cancer Monitor: a secondary outcome from a randomised clinical trial

Authors: Dreyer T.¹, Brandt S.², Fabrin K.³, Azawi N.⁴, Vásquez J.L.⁴, Ernst A.¹, Dyrskjøt L.⁵, Jensen J.B.¹

Institutes: ¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ³Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁴Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, ⁵Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark

A0361

Results from the prospective randomized UroFollow trial comparing marker-guided vs. cystoscopy-based standard follow-up in patients with low/intermediate risk bladder cancer.

Authors: Schmitz-Dräger B.¹, Bismarck E.², Roghmann F.³, Von Landenberg N.³, Noldus J.³, Jahn D.⁴, Kernig K.⁴, Hakenberg O.⁴, Goebell P.J.¹, Hennenlotter J.R.⁵, Erne E.⁵, Stenzl A.⁵, Rowinski M.⁶, Schiffhorst G.⁶, Baranek T.⁷, Benderska-Söder N.²

Institutes: ¹Friedrich-Alexander University, Dept. of Urology and Pediatric Urology, Erlangen, Germany, ²St. Theresienkrankenhaus, Dept. of Urology 24, Nuremberg, Germany, ³Marien Hospital Herne, Dept. of Urology, Herne, Germany, ⁴University of Rostock, Dept. of Urology, Rostock, Germany, ⁵Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ⁶IGES Institute, Dept. of Biostatistics, Berlin, Germany, ⁷University of applied Sciences and Arts, Dept. of Clinical Research, Hannover, Germany

17:42 - 18:27

Oncological outcome of patients with non-muscle invasive bladder cancer

A0366

Long-term oncological outcomes of de novo bladder cancer in kidney transplant recipients: results from a large multicenter international cohort

Authors: Livoti S.¹, Soria F.¹, Rosazza M.¹, Dutto D.¹, Colucci F.¹, D'Andrea D.², Laukhtina E.², Teoh J.Y.³, Marcq G.⁴, Segquier D.⁴, Pichler R.⁵, Lackner F.⁵, Martin R.⁶, Roumeguere T.⁶, Albisinni S.⁷, Mesnard B.⁸, Krajewski W.⁹, Shariat S.F.², Gontero P.¹

Institutes: ¹AOU Città della Salute e della Scienza di Torino - University of Turin School of Medicine, Dept. of Urology, Turin, Italy,

²Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³S.H. Ho Urology Centre - Department of Surgery - The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ⁴Claude Huriez Hospital, Centre Hospitalier Universitaire de Lille, Dept. of Urology, Lille, France, ⁵Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁶Jules Bordet Institute-Erasme Hospital - Hopital Universitaire de Bruxelles, Dept. of Urology, Brussels, Belgium, ⁷Tor Vergata University Hospital, University of Rome Tor Vergata, Dept. of Surgical Sciences, Urology Unit, Rome, Italy, ⁸Hotel Dieu Hospital, University of Nantes, Dept. of Urology, Nantes, France, ⁹University Center of Excellence in Urology, Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland

A0362

Evaluation of the long term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.

Authors: Chan A.¹, Lajkosz K.², Villegas E.¹, Vitug C.¹, Din S.¹, Kuk C.¹, Gao B.³, Hemminiki O.³, Kot D.³, Misurka J.³, Black P.⁴, Jewett M.³, Soloway M.S.⁵, Roupret M.⁶, Comperat E.⁷, Shen J.⁸, Sweet J.⁹, Seisen T.⁶, Fleshner N.E.³, Wrana J.⁸, Van Der Kwast T.H.⁹, Kulkarni G.S.³, Zlotta A.R.¹

Institutes: ¹Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, ²University Health Network, Dept. of Biostatistics, Toronto, Canada, ³University Health Network, Dept. of Surgery, Toronto, Canada, ⁴University of British Columbia, Division of Urology, Vancouver, Canada, ⁵Memorial Healthcare System, Division of Urology, Hollywood, United States of America, ⁶Hopital Pitie-Salpetriere - Sorbonne Université, Dept. of Urology, Paris, France, ⁷Hopital Tenon - Sorbonne Université, Dept. of Pathology, Paris, France, ⁸Lunenfeld-Tanenbaum Research Institute - Mount Sinai Hospital, The Centre for Systems Biology, Toronto, Canada, ⁹University Health Network, Laboratory Medicine Program, Toronto, Canada

A0360

Defining intermediate-risk non-Muscle invasive bladder cancer: a comparative study of EAU and IBCG criteria

Authors: Scilipoti P.¹, Avesani G.¹, Longoni M.¹, De Angelis M.¹, Re C.¹, Bertini A.¹, Quarta L.¹, Burgio G.¹, Basile G.¹, Rosiello G.¹, Pellegrino F.¹, Necchi A.², Raggi D.², Lucianò R.³, Gandaglia G.¹, Capitanio U.¹, Colombo R.¹, Salonia A.¹, Montorsi F.¹, Briganti A.¹, Moschini M.¹

Institutes: ¹IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy

A0354

Towards Defining Follow-up Strategies for Patients with Primary (First Diagnosis) EAU2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Authors: Contieri R.¹, Beijert I.¹, Martini A.², Camperat E.M.³, Hernandez V.⁴, Bruins H.M.⁵, Dominguez-Escrig J.L.⁶, Liedberg F.⁷, Masson-Lecomte A.⁸, Cohen D.⁹, Mostafid H.¹⁰, Shariat S.F.³, Roupret M.¹¹, Pradere B.³, Zigeuner R.¹², Soria F.¹³, Soukup V.¹⁴, Palou Redorta J.¹⁵, Capoun O.¹⁴, Burger M.¹⁶, Gontero P.¹³, Sylvester R.¹⁷, Mertens L.¹, Van Rhijn B.W.G.¹

Institutes: ¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ³Medical University of Vienna, Dept. of Pathology, Vienna, Austria, ⁴Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ⁵Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁶Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ⁷Lund University, Institution of Translational Medicine, Malmö, Sweden, ⁸Université de Paris, Dept. of Urology, Paris, France, ⁹Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹⁰Royal Surrey Hospital, Dept. of Urology, Guildford, United Kingdom, ¹¹Sorbonne University, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, ¹²Medical University of Graz, Dept. of Urology, Graz, Austria, ¹³University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ¹⁴Charles University, Dept. of Urology, Prague, Czech Republic, ¹⁵Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁶University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹⁷European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands

A0363

Real-world outcomes of bladder sparing treatments (BSTs) in patients with high-risk non-muscle invasive bladder cancer, who failed or were intolerant to BCG therapy

Authors: Day E.¹, Aquilina R.², Ta A.¹, Sridhar A.N.¹, Kelly J.D.¹, Szabados B.E.¹

Institutes: ¹University College London Hospital, Dept. of Urology, London, United Kingdom, ²University College London, Medical School, London, United Kingdom

A0365

Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG

Authors: De Angelis M.¹, Basile G.¹, Scilipoti P.¹, Longoni M.¹, Re C.¹, Avesani G.¹, Leni R.¹, Robesti D.¹, Quarta L.¹, Bertini A.¹, Burgio G.¹, Rosiello G.¹, Necchi A.², Raggi D.², Lucianò R.³, Gandaglia G.¹, Colombo R.¹, Capitanio U.¹, Salonia A.¹, Montorsi F.¹, Briganti A.¹, Moschini M.¹

Institutes: ¹IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy

A0352

Development and external validation of an artificial intelligence-based tool for PROgression Risk assessment in Non-muscle invasive Bladder Cancer (PROGRxN-BCa)

Authors: Kwong J.¹, Al-Daqqaq Z.², Chelliahpillai Y.², Lee S.², Kim K.², Ringa M.³, Ali A.³, Feifer A.³, Wettstein M.¹, Kassouf W.⁴, Black P.C.⁵, Breau R.H.⁶, Lodde M.⁷, Fairey A.⁸, Lattouf J.B.⁹, Jeldres C.¹⁰, Rendon R.¹¹, Alimohamed N.¹², Chung P.¹³, Fleshner N.E.¹⁴, Finelli A.¹⁴, Zlotta A.R.¹⁵, Johnson A.E.W.¹⁶, Kulkarni G.S.¹⁴

Institutes: ¹University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada, ²University of Toronto, Temerty Faculty of Medicine, Toronto, Canada, ³Trillium Health Partners, Division of Urology, Dept. of Surgery, Mississauga, Canada, ⁴McGill University Health Centre, Dept. of Urology, Montreal, Canada, ⁵University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁶The Ottawa Hospital, Division of Urology, Dept. of Surgery, Ottawa, Canada, ⁷CHU de Québec, Université Laval, Division of Urology, Dept. of Surgery, Quebec City, Canada, ⁸University of Alberta, Division of Urology, Dept. of Surgery, Edmonton, Canada, ⁹Centre Hospitalier de l'Université de Montréal, Division of Urology, Dept. of Surgery, Montreal, Canada, ¹⁰Université de Sherbrooke, Division of Urology, Dept. of Surgery, Sherbrooke, Canada, ¹¹Dalhousie University, Dept. of Urology, Halifax, Canada, ¹²University of Calgary, Dept. of Oncology, Calgary, Canada, ¹³Princess Margaret Cancer Centre - University Health Network, Radiation Medicine Program, Toronto, Canada, ¹⁴Princess Margaret Cancer Centre - University Health Network, Division of Urology, Dept. of Surgical Oncology, Toronto, Canada, ¹⁵Mount Sinai Hospital - Sinai Health System, Division of Urology, Dept. of Surgery, Toronto, Canada, ¹⁶University of Toronto, Division of Biostatistics - Dalla Lana School of Public Health, Toronto, Canada

A0357

TERT C228T and KDM6A alterations are potential predictive biomarkers in non muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin

Authors: Sun J., Xia Q-D., Liu Z., Wang S.

Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

A0353

En bloc vs. conventional transurethral resection of bladder tumor: Two-year oncological follow-up of a single-center prospective, randomized, controlled, non-inferiority trial

Authors: Diana P.¹, Gallioli A.¹, Territo A.¹, Rodriguez-Faba S.¹, Gaya J.M.¹, Sanguedolce F.¹, Huguet J.¹, Parada R.¹, Sanz I.¹, Sanchez R.¹, Farré A.¹, Algaba F.², Palou J.¹, Breda A.¹

Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain,

²Fundació Puigvert, Dept. of Pathology, Barcelona, Spain

18:27 - 18:30

Expert summary

Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

05 April 2024
10:45 - 12:45

Location Chairs

Green Area, N03
L. Shah (IN)
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

At this session, attendees will be able to:
Learn about the latest developments in uro-oncology and reconstructive urology.
Get tips on the clinical approach to asymptomatic renal stones.
Hear from the experts on complex problems in pediatric urology.
Be informed about new possibilities for treatment in female and male urology.

Introduction

10:50 - 11:30

Uro-oncology and reconstructive urology

10:50 - 11:00

Mantra Robot-India's Pride

S. Rawal, Delhi (IN)

11:00 - 11:10

Update on reconstructive surgery in uro-oncology

To be confirmed

11:10 - 11:20

Radical Perineal prostatectomy: revisited and improved

H. Goel, New Delhi (IN)

11:20 - 11:30

Challenges and intricacies in the management of pan-anterior urethral strictures

B.T. Enganti, Hyderabad (IN)

11:30 - 11:40

Urolithiasis

11:30 - 11:40

Asymptomatic renal stones –when to treat?

D. Ragoori, hyderabad (IN)

11:40 - 12:00

Pediatric Urology

11:40 - 11:50

Pediatric urolithiasis: a nuanced understanding

V. Krishnamoorthy, Bangalore (IN)

11:50 - 12:00

Valve Bladder syndrome

A.K. Chawla, Manipal (IN)

12:00 - 12:40

Male and female urology

12:00 - 12:08

Prosthetics in uro-andrology

V.S. Karthikeyan, Chennai (IN)

12:08 - 12:16

Orthotopic ureteric meatoplasty: Shah's technique to avoid ureteric reimplant in VVF in urogynae section

L. Shah (IN)

12:16 - 12:24

Varicocelectomy: improvisations for better outcomes

V. K.V., Trivandrum (IN)

12:24 - 12:32

Urodynamics 2024

S. Arlandis, Valencia (ES)

12:32 - 12:40

Complex vesico-vaginal fistulae: beyond primary repair

S. Patwardhan, Mumbai (IN)

Closing remarks

Neurourology & female urology miscellaneous

Abstract session 15

06 April 2024
17:00 - 18:30

Location Purple Area, S01
Chairs To be confirmed
To be confirmed
To be confirmed

17:00 - 17:10

Neurourology: basic research

A0386

The role of 5-hydroxytryptamine neurons in the mouse raphe nucleus for controlling the micturition reflex

Authors: Gu B., Li M.

Institutes: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

A0380

5-HT_{2A/2C} receptor agonist DOI improve detrusor sphincter dyssynergia by inhibiting L-type voltage-gated calcium channels in spinal cord injury rats

Authors: Gu B., Lv R.

Institutes: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

17:10 - 17:45

Neurourology clinical

A0382

HAP-PEE, a Danish national registry study of women with neuromuscular diseases' s ability to urinate when away from home, prevalence of lower urinary tract symptoms and the impact on quality of life

Authors: Thoft Jensen B.¹, Handberg C.², Kristensen B.², Glerup S.³, Phrao A.V.³, Strøm J.³, Werlauff U.²

Institutes: ¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²National Rehabilitation Centre for Neuromuscular Diseases, Dept. of Research, Aarhus, Denmark, ³National Rehabilitation Centre for Neuromuscular Diseases, Patient Information Panel, Aarhus, Denmark

A0376

Remote Programming in Phase I Sacral Neuromodulation: A Multi-Center Feasibility Study

Authors: Jing J.¹, Lingfeng M.¹, Yaoguang Z.¹, Xinhao W.¹, Wen Z.², Qingwei W.², Li L.³, Wei S.⁴, Yifei Z.⁵, Yan L.⁶, Jiaying N.¹, Haoran W.¹

Institutes: ¹Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Dept. of Urology, Beijing, China, ²The First Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China, ³Sun Yat-Sen University, Sixth Affiliated Hospital, General Surgery, Guangzhou, China, ⁴Shandong Provincial Hospital, Dept. of Urology, Jinan, China, ⁵The First Affiliated Hospital of Anhui Medical University, Dept. of Urology, Hefei, China, ⁶Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China

- A0377** **Survey in a young autism spectrum disorder population on bladder and bowel dysfunctions.**
Authors: Gubbiotti M.¹, Zoccante L.², Marchiafava M.³, Bedetti C.⁴, Rosadi S.¹, Rubilotta E.⁵
Institutes: ¹Ospedale Santa Maria alla Gruccia, Dept. of Urology, Montevarchi, Italy, ²A.O.U.I. Verona University, Dept. of Child Neuropsychiatry, Verona, Italy, ³ASL Roma 5, Dept. of Mental Health and Pathological Addictions, Rome, Italy, ⁴Città di Castello Hospital, Stroke Unite Neurology, Perugia, Italy, ⁵AOUI Verona, Dept. of Urology, Verona, Italy
- A0375** **Positive Impact of a Patient Support Programme on Intermittent Catheterisation Outcomes**
Authors: Azuero Perdomo J.J.¹, Cabrera C.², Ariza M.², Jarava I.²
Institutes: ¹Fundación Santa Fe de Bogotá, Dept. of Urology, Bogotá, Colombia, ²ConvaCare Clinics, Continence Program, Bogotá, Colombia
- A0370** **Comparative cost-consequence study between supra pubic catheter and cystectomy with ileal conduit derivation for patients with neurogenic bladder**
Authors: de Broucker C.¹, Bulsei J.², Declémy A.¹, Fontas E.², Karsenty G.³, Ahallal Y.¹, Durand M.¹, Peyronnet B.⁴, Bentellis I.¹
Institutes: ¹CHU de Nice, Dept. of Urology, Nice, France, ²CHU de Nice, DRCl, Nice, France, ³La Conception, Dept. of Urology, Marseille, France, ⁴CHU de Rennes, Dept. of Urology, Rennes, France
- A0373** **Urodynamics: Imposition or not as bad as it seems? Secondary analyses from a randomized controlled trial**
Authors: Gross O.¹, Kasten M.², Wettstein M.³, Anderson C.E.⁴, Birkhäuser V.¹, Borer J.¹, Koschorke M.¹, Liechti M.D.¹, Mccallin S.¹, Mehnert U.¹, Röthlisberger R.¹, Sadri H.¹, Stächele L.¹, Van Der Lely S.¹, Kessler T.M.¹, Leitner L.¹
Institutes: ¹Balgrist University Hospital, University of Zurich, Dept. of Neuro-Urology, Zürich, Switzerland, ²Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ³University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada, ⁴University of Lucerne, Dept. of Swiss Paraplegic Research, Nottwil, Switzerland
- A0379** **A prospective paired comparison trial on mirabegron and anticholinergics in patients with low bladder compliance**
Authors: Son H.S., Kim J.H.
Institutes: Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea
- 17:45 - 18:00** **Neuromodulation in neurogenic patients**
- A0385** **Efficacy of sacral nerve modulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.**
Authors: Carolus B.¹, Olivier L.¹, Hafez S.², Perrouin-Verbe M.A.², Peyronnet B.³, Capon G.⁴, Biardeau X.¹
Institutes: ¹Lille University Hospital, Dept. of Urology, Lille, France, ²Nantes University Hospital, Dept. of Urology, Nantes, France, ³Rennes University Hospital, Dept. of Urology, Rennes, France, ⁴Bordeaux University Hospital, Dept. of Urology, Bordeaux, France
-

- A0384** **Wearable dorsal genital nerve stimulation to control neurogenic detrusor over-activity after spinal cord injury**
Authors: Knigh S.L.¹, Nobrega R.¹, Martinez E.¹, Doherty S.², Duffell L.²
Institutes: ¹Royal National Orthopaedic Hospital, Dept. of Neuro-Urology, Stanmore, United Kingdom, ²University College London, Dept. of Medical Physics and Bioengineering, London, United Kingdom
- A0372** **Transcutaneous spinal cord stimulation and pelvic floor rehabilitation: a randomised controlled trial to investigate effect on lower urinary tract function after spinal cord injury**
Authors: Knigh S.L., Houlston H., Vasquez N., Nobrega R.P.
Institutes: Royal National Orthopaedic Hospital, Dept. of Neuro-urology, Stanmore, United Kingdom
- 18:00 - 18:30** **Female urology: miscellaneous topics**
- A0381** **Voiding diary data, patient-reported outcomes and safety through 6 months after sacral neuromodulation implantation in non-obstructive urinary retention patients**
Authors: Malde S.¹, Goudelocke C.², Lavin V.³, Peyronnet B.⁴, Elterman D.⁵, Perrouin-Verbe M.A.⁶, Shah S.⁷, Bukkapatnam R.⁸, Xavier K.⁹, Smits M.¹⁰, Noel K.¹¹, Keller D.U.J.¹², Sahai A.¹
Institutes: ¹Guys and St Thomas NHS FDN Trust-St Thomas, Dept. of Urology, London, United Kingdom, ²Ochsner Medical Center, Dept. of Urology, New Orleans, United States of America, ³The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁴Centre Hospitalier Universitaire de Rennes, Dept. of Urology, Rennes, France, ⁵University of Toronto, Division of Urology, Toronto, Canada, ⁶Centre Hospitalier Universitaire de Nantes, Dept. of Urology, Nantes, France, ⁷East Coast Institute for Research LLC, Dept. of Urology, Jacksonville, United States of America, ⁸Florida Urology Partners, Dept. of Urology, Arlington, United States of America, ⁹Urology Partners of North Texas, Dept. of Urology, Arlington, United States of America, ¹⁰Maastricht Universitair Medisch Centrum, Dept. of Urology, Maastricht, The Netherlands, ¹¹Medtronic, Dept. of Statistics, Minneapolis, United States of America, ¹²Medtronic, Dept. of Clinical Research, Tolochenaz, Switzerland
- A0374** **Natural Orifice Uterine Suspension (NOUS): An easier way to treat advanced uterine prolapse in elderly patients (IDEAL Phase 2a)**
Authors: Zhang C., Shen H., Luo D.Y.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- A0383** **Using urinary biomarkers and machine learning models to develop predictive factors for long-term treatment outcome in the patients with interstitial cystitis/bladder pain syndrome**
Authors: Jhang J-F.¹, Jiang Y.H.¹, Yu W.R.², Chang T-L.¹, Liu M-C.¹, Yang C.C.¹, Kuo H.C.²
Institutes: ¹Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan, ²Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan
-

A0369

A Mussel Inspired Bio-Adhesive for Early Correction of Pelvic Floor Detachment

Authors: Taylor A.¹, Cockerill I.¹, Luo Y.¹, Soto-Garcia L.¹, Xu J.¹, Yang Z.¹, Nguyen T.¹, Tang L.¹, Zimmern P.E.², Liao J.¹, Hong Y.¹

Institutes: ¹The University of Texas at Arlington, Dept. of Biomedical Engineering, Arlington, United States of America, ²UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

A0378

Robot-assisted sacrocolpopexy versus trans-vaginal prolapse repair: impact on lower bowel tract function

Authors: Pastore A.L.¹, Antonioni A.¹, Suraci P.P.¹, Rera O.A.¹, Sequi M.B.¹, Valenzi F.M.¹, Graziani D.¹, Martoccia A.¹, Martino G.¹, Gianfrancesco F.¹, Scalzo S.¹, Fuschi A.¹, Al Salhi Y.¹, Sciarra A.², De Berardinis E.², Lombardo R.³, De Nunzio C.³, Carbone A.¹, Cervigni M.¹

Institutes: ¹Sapienza University of Rome Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies Urology, Rome, Italy, ²Sapienza University of Rome, Dept. of Urology, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy

A0371

Erogenous and Aversive Sensation Throughout the Vulva, Vagina, and Breasts in Cis-Gender Women: Anatomic “Heat-Maps” to Assess Effect of Treatment on Erogenous Sensation

Authors: Stelmar J.¹, Zaliznyak M.², Smith S.³, Lee G.³, Mallavarapu S.³, Sandhu S.³, Garcia M.³

Institutes: ¹University of California San Diego, Dept. of Medicine, San Diego, United States of America, ²University of Washington, Dept. of Medicine, St Louis, United States of America, ³Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America

The cutting edge of prostate surgery: New techniques and technologies

Video session 07

06 April 2024
17:00 - 18:30

Location Green Area, S04
Chairs F. Gómez Veiga, Salamanca (ES)
To be confirmed
To be confirmed

- V048 **Peritoneal flap following lymph node dissection in robotic radical prostatectomy: A novel “Bunching” technique**
Authors: Mohamed A.G., Covas Moschovas M., Jaber A.R., Saikali S., Patel E., Patel E., Rogers T., Patel V.
Institutes: Adventhealth-GRI, Dept. of Urology-Oncology, Orlando, United States of America
- V049 **Robot-assisted transperineal radical prostatectomy: Surgical technique and analysis of intraoperative and postoperative outcomes**
Authors: Almeida-Magana R.¹, Al-Hammouri T.², So C.³, Shaw G.², Ogden C.⁴
Institutes: ¹University College London, Dept. of Targeted Intervention, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, ³Princess Grace Hospital, Dept. of Surgery, London, United Kingdom, ⁴The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- V050 **Robotic assisted prostatectomy in a patient with a pre-existing inflatable penile prosthesis –a novel suspensory technique**
Authors: McDonald J., Clarebrough E., Kapoor J., Goad J.
Institutes: St Vincent's Hospital Melbourne, Dept. of Urology, Melbourne, Australia
- V051 **Impact of a novel anterior suspension stitch on return of urinary continence after Robotic Radical Prostatectomy (RRP), with description of surgical technique**
Authors: Arora S., Wang Y., Wilder S., Fisher E., Stephens A., Peabody J.O., Jeong W.
Institutes: Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America
- V052 **Surgical and new generation imaging tips and tricks to maximize robotic radical prostatectomy outcomes**
Authors: Piramide F.¹, Amparore D.¹, Checucci E.², De Cillis S.¹, Piana A.³, Volpi G.², Sica M.¹, Verri P.¹, Burgio M.¹, Meziere J.¹, Busacca G.¹, Cisero E.¹, Marsero L.¹, Quarà A.¹, Colombo M.¹, Mandaletti M.¹, Garzena V.¹, Ribolzi B.¹, Manfredi M.¹, Fiori C.¹, Porpiglia F.¹
Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy
- V053 **IP8-FLUORESCENCE: Fluorescence Confocal Microscopy for Rapid Evaluation of Surgical Margins**
Authors: Mayor N., Silvanto A., Light A.J.W., Cullen E., Shah V., Ng C., Connor M.J., Shah T.T., Ahmed H.U., Winkler M.
Institutes: Imperial College London, Dept. of Urology, London, United Kingdom

- V054** **Lateral versus anterior approach for bladder neck dissection during robot-assisted radical prostatectomy: impact on surgical margins and early urinary continence.**
Authors: Oderda M., Marquis A., Sasia A., Calleris G., Dematteis A., D Agate D., Falcone M., Lavagno F., Marra G., Montefusco G., Gontero P.
Institutes: Molinette Hospital and University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy
- V055** **Robot assisted radical prostatectomy: SSI Mantra**
Authors: Pratihari S.K., Khanna A., Singh A., Rawal S.
Institutes: Rajiv Gandhi Cancer Institute and Research Centre, Dept. of Urooncology and Robotics, New Delhi, India

Urolithiasis: Basic research and metabolic management

Abstract session 16

06 April 2024
17:00 - 18:30

Location Green Area, W01
Chairs B. Geavlete, Bucharest (RO)
To be confirmed
To be confirmed
To be confirmed

- A0396** **Microplastics exposure influence the formation of calcium oxalate kidney stone through inducing renal injury**
Authors: Chen Y.¹, Han B.¹, Chen L.²
Institutes: ¹The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ²Tianjin University, Academy of Medical Engineering and Translational Medicine, Tianjin, China
- A0395** **Urinary Metabolic Disturbances and VDR Gene Polymorphisms as Prognostic Factors for Recurrence of Calcium Oxalate Renal Calculi: A prospective controlled trial.**
Authors: Abolazm A.E., Elshal A.M., Eltabey N.A., Bazeed M.A., Shoma A.M.
Institutes: Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt
- A0387** **The urinary microbiota composition and functionality of calcium oxalate stone formers**
Authors: Xie J., Zhang X.Q., Guo J.N., Yuan Y.Q., Yuan Q., Xiao K.F.
Institutes: Shenzhen People's Hospital, Dept. of Urology, Shenzhen, China
- A0400** **Comparison of the intestinal microbiota of patients with primary hyperparathyroidism with and without urinary system stone disease**
Authors: Mammadov M.¹, Erturk B.², Cennet O.³, Sendur S.N.², Gudeloglu A.¹
Institutes: ¹Hacettepe University Faculty of Medicine, Dept. of Urology, Ankara, Türkiye, ²Hacettepe University Faculty of Medicine, Dept. of Endocrinology, Ankara, Türkiye, ³Hacettepe University Faculty of Medicine, Dept. of General Surgery, Ankara, Türkiye
- A0403** **Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: a comparative study with stone-free subjects**
Authors: Lu Y.¹, Lim P.², Toh K.Y.², Chong T.W.¹
Institutes: ¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²AMILI Singapore, Dept. of Research, Singapore, Singapore
- A0393** **Cross-species multi-omics analysis using human GWAS and a mouse model reveals novel urolithiasis-associated molecules CRYAB and SHROOM3 acting in collecting duct principal cells**
Authors: Chaya R.¹, Taguchi K.¹, Yanase T.¹, Sue Y.¹, Hattori T.¹, Okada T.¹, Kawase K.¹, Hamamoto S.¹, Okada A.¹, Okada Y.², Yasui T.¹
Institutes: ¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ²Osaka University Graduate School of Medicine, Dept. of Statistical Genetics, Osaka, Japan

- A0391** **Long-term sodium deficiency reduces sodium excretion but impairs renal function and increases stone formation in hyperoxaluric calcium oxalate rats**
Authors: Huang Y.C., Liu C.J., Lu Z.H., Huang H.S.
Institutes: National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan
- A0390** **Preliminary study on PKA/STAT3 in the formation mechanism of kidney stones induced by nanobacteria mediated by CaSR-Claudin-14 pathway**
Authors: Zou J., Qian B., Luo P., Zou X., Zhang G.
Institutes: Institute of Urology Gannan Medical University, Dept. of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
- A0399** **Exosomal miR-146a-5p, the hope within Pandora's Box for CaOx stones**
Authors: Yang Y., Miao L.T.M., Sihan Z.S.H., Wang S.G.W.
Institutes: Tongji Hospital, Dept. of Urology, Wuhan, China
- A0401** **Exploring the Pandora's box—exosomes derived from HK2 cells**
Authors: Yang Y., Miao L.T.M., Wang S.G.W.
Institutes: Tongji Hospital, Dept. of Urology, Wuhan, China
- A0402** **Urinary glycated uromodulin of diabetic nephropathy patients accelerate more crystal aggregation and kidney stone formation**
Authors: Tseng Y.S.
Institutes: Far Eastern Memorial Hospital, Dept. of Urology, New Taipei City, Taiwan
- A0398** **Urinary stones associated with elevated levels of Lead, Cadmium, Aluminum, Zinc, and Boron: investigation of mitochondrial dysfunction and oxidative stress as possible pathogenic pathways**
Authors: Ali-El-Dein B.¹, Soliman A.A.¹, Elkady M.E.¹, El-Shal A.M.¹, Helmy T.S.¹, Saleh H.H.¹, Abdelgawad M.²
Institutes: ¹Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Dept. of Urology, Mansoura, Egypt, ²Toshka Endoscopy and Urology Center, Dept. of Urology, Mansoura, Egypt
- A0397** **Results of the effect of a food supplement containing Agropyronrepens, Mannitol and Magnesium on upper urinary tract stone volume and surface compared to placebo: The AMMOS study.**
Authors: Sountoulides P.¹, Mutomba W.F.¹, Daniel G.², Pagalidou E.³, Baniotis P.¹, Pyrgidis N.¹, Mykoniatis I.¹, Langas G.¹, Dimitriadis G.¹
Institutes: ¹Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ²Aristotle University of Thessaloniki, Dept. of Radiology, Thessaloniki, Greece, ³Aristotle University of Thessaloniki, Dept. of Preventive Medicine and Biostatistics, Thessaloniki, Greece
- A0389** **Ammonium urate urinary stones – a rare subtype of unknown significance**
Authors: Shpitzer S.A., Ehrlich Y., Darawsha A.E., Lifshitz D.
Institutes: Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel
-

A0392

Efficacy and side effects of low dose indapamide vs hydrochlorothiazide for the treatment of patients with idiopathic hypercalciuria: A randomized prospective trial.

Authors: Peraire Lores M.¹, Guimera Garcia J.², Bauza Quetglas P.L.², Martínez Moreno A.², Coello Tora I.¹, Grases Freixedas F.³, Pieras Ayala E.²

Institutes: ¹Joan XXIII Universitary Hospital, Dept. of Urology, Tarragona, Spain, ²Son Espases Universitary Hospital, Dept. of Urology, Palma de Mallorca, Spain, ³Illes Balears University, Dept. of Urology, Palma de Mallorca, Spain

A0394

Correlation analysis between urinary crystals and upper urinary calculi

Authors: Song N., Xi Z.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A0404

Visual assessment of Randall's plaque during flexible ureteroscopy and its correlation with stone analysis and metabolic evaluation: A prospective study

Authors: Shrestha A., Chitrakar A.

Institutes: National Academy of Medical Sciences, Dept. of Urology, Kathmandu, Nepal

A0388

What is the compliance rate with metabolic evaluation in surgically treated nephrolithiasis patients?

Authors: Shpitzer S.A., Tamir H., Ehrlich Y., Darawsha A.E., Lifshitz D.

Institutes: Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel

Surgery and devices in andrology

EGPT 07

**06 April 2024
17:00 - 18:30**

Location EGPT
Chairs A. Cocci, Florence (IT)
S. Minhas, London (GB)

17:00 - 17:00

Screen A: Surgical approaches for male infertility

- P188** **Microscopic surgery for the repair of painful varicocele—efficacy, and predictors of successful outcomes**
Authors: Bercovich S., Hendel H.H., Ventura Y.V., Shmueli Y.S., Shoshany O. .S.
Institutes: Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel
- P177** **Day-Case Vasectomy Reversal Under Local Anaesthesia: Evaluating Feasibility, Safety and Effectiveness**
Authors: Mukherjee A., Jesuraj N., Shaw W., Jesuraj M.
Institutes: Best Life Clinic, Best Life Clinic, Stockton on Tees, United Kingdom
- P179** **Risk factor analysis including ductus deferens lavage for lingering sperm post vasectomy**
Authors: Lu C.H., Hsu C.Y., Ou Y.C., Tung M.C.
Institutes: Tungs' Taichung Metroharbor Hospital, Division of Urology, Dept. of Surgery, Taichung, Taiwan
- P185** **The Necessity of Improvement in Micro-TESE for Male Infertility based on Current Literature: the Clinical Investigation of a New Imaging Modality**
Authors: Çam H.K.¹, Sahin B.¹, Çelik Özneci Ç.², Yücel S.Y.¹, Canpolat M.C.³
Institutes: ¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ²Koç University School of Medicine, Dept. of Histology and Embriology, Istanbul, Türkiye, ³Akdeniz University School of Medicine, Dept. of Biophysics, Antalya, Türkiye
- P197** **Hormonal changes following microdissection testicular sperm extraction in men with non-obstructive azoospermia - findings from a real-life multi-centric study**
Authors: Pozzi E.¹, Negri F.¹, Boeri L.², Bertini A.¹, Belladelli F.¹, Corsini C.¹, Raffo M.¹, Candela L.¹, Fallara G.³, Matloob R.¹, Sacca' A.⁴, Capogrosso P.⁵, Deho' F.⁵, D'Arma A.¹, Ramasamy R.⁶, Montorsi F.¹, Salonia A.¹
Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Ca Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ³IEO Istituto Europeo di Oncologia, Dept. of Urology, Milan, Italy, ⁴ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ⁵ASST dei Sette Laghi, Dept. of Urology, Varese, Italy, ⁶Desai Sethi Urology Institute, Dept. of Urology, Miami, United States of America
- P201** **Predictive factors in the success of surgical sperm retrieval techniques**
Authors: Ayllón H., Solano P., Fernández-Pascual E., Girón M., Gómez R., González-Peramato P., Alonso-Bartolomé M.B., Yebes A., Toribio C., Martínez-Pérez S., Martínez-Pineiro L.
Institutes: Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain

- P183** **Clinical outcomes of intracytoplasmic sperm injection using ejaculated or testicular sperm in patients with AZFc deletions**
Authors: Fang Y.¹, Zhang L.², Li R.², Hong K.¹
Institutes: ¹Peking University Third Hospital, Dept. of Urology, Beijing, China, ²Peking University Third Hospital, Center for Reproductive Medicine, Beijing, China
- 17:00 - 17:18** **Screen B: Erectile restoration with penile prosthesis**
- P180** **"Comparing Chlorhexidine 0.05% Antiseptic Monotherapy to Conventional Combined Antibiotic Irrigation During Penile Prosthesis Implantation: A Two-Center Prospective Randomized Controlled Non-Inferiority Study " (Preliminary Data)**
Authors: Desouky E.¹, Tsambarlis P.¹, Levine L.A.²
Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²Uropartners Solaris Health, Dept. of Urology, Chicago, United States of America
- P189** **The Road to Penile Prosthesis: Unveiling Factors Linked to Early Surgery - Insights from a Real-Life Cross-Sectional Study**
Authors: Pozzi E.¹, Sandler M.¹, Aden S.², Yanes J.¹, Ramasamy R.¹
Institutes: ¹Desai Sethi Urology Institute, Dept. of Urology, Miami, United States of America, ²Herbert Wertheim College of Medicine, Dept. of Urology, Miami, United States of America
- P173** **Perioperative outcomes and evolution of penile prosthesis implantation in Germany: Results from the GRAND study**
Authors: Pyrgidis N., Schulz G.B., Chaloupka M., Volz Y., Pfitzinger P., Rodler S., Berg E., Weinhold P., Jokisch F., Stief C., Becker A., Marcon J.
Institutes: University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany
- P200** **Penile prosthesis with contemporary plastic procedures in obese patients: complication and satisfaction rate in day case surgery setting**
Authors: Maiolino G., Fernandez Pascual E., Lledó García E., Serrano J., Balmori C., Martínez-Salamanca J.I.
Institutes: The Lyx Institution, Dept. of Urology, Madrid, Spain
- P192** **Long-term outcomes and risk factors for reintervention after Penile Prosthesis Implantation**
Authors: Zouari S., Mendel L., Morrone A., Barthe F., Haider R., Chavallier D., Ahallal Y., Durand M., Bentellis I.
Institutes: CHU Nice, University of Nice-Sophia Antipolis, Hôpital Pasteur 2, Dept. of Urology, Nice, France
- P176** **Male genital image and quality of life after penile prosthesis implantation: a patient perspective**
Authors: García Formoso N.¹, Meza Huamán A.², Herrera Aranda N.³, Calleja Hermosa P.¹, Varea Malo R.¹, Giral Villalta P.¹, Cáceres Rodríguez F.³, Gorría Cardesa O.², Campos Juanatey F.¹
Institutes: ¹Marques de Valdecilla University Hospital, Dept. of Urology, Santander, Spain, ²Navarra University Hospital, Dept. of Urology, Pamplona, Spain, ³Araba University Hospital, Dept. of Urology, Vitoria, Spain
- 17:18 - 17:39** **Screen C: Peyronie's disease and priapism**
-

- P175** **What do patients with Peyronie's disease expect from therapy? A prospective multi-center study**
Authors: Schaefer L.¹, Cremers J.², Witschel B.¹, Schuettfort V.¹, Nieder T.O.³, Koenig F.¹, Vetterlein M.W.¹, Gild P.¹, Dahlem R.¹, Fisch M.¹, Kliesch S.², Soave A.¹
Institutes: ¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Medical Center Muenster, Center of Reproductive Medicine and Andrology, Muenster, Germany, ³University Medical Center Hamburg-Eppendorf, Institute for Sex Research Sexual Medicine and Forensic Psychiatry, Hamburg, Germany
- P182** **Severity of penile curvature in patients with Peyronie's disease and erectile dysfunction does not correlate with dynamic colour Doppler duplex ultrasound parameters: findings from a real-life cross-sectional study**
Authors: Pozzi E.¹, Belladelli F.¹, Corsini C.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Cattafi F.¹, Oddo M.¹, Malvestiti M.¹, Ramadani R.¹, Candela L.¹, Capogrosso P.², Boeri L.³, Zahiti L.⁴, Mattei A.⁴, d'Arma A.¹, Montorsi F.¹, Salonia A.¹
Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland
- P199** **Multicenter evaluation of Multi-Incision Technique (MIT) with Malleable Prosthesis in Peyronie's Disease: a Lengthening Strategy in patients with or without Erectile Dysfunction**
Authors: Maiolino G.¹, Fraile Poblador A.², Fernández-Pascual E.³, Hevia Palacios M.², Martínez-Salamanca J.I.¹
Institutes: ¹The Lyx Institution, Dept. of Urology, Madrid, Spain, ²Ramón y Cajal Hospital, Dept. of Urology, Madrid, Spain, ³La Paz University Hospital, Dept. of Urology, Madrid, Spain
- P187** **Lengthening Corporoplasty with TachoSil® in Peyronie's Disease – A National Multicentric Analysis**
Authors: Costa Silva A.¹, Ye A.², Vinagre N.³, Marques-Pinto A.³, Louro N.³, Oliveira P.², Morgado A.¹, Tomada N.⁴
Institutes: ¹Centro Hospitalar Universitário de Sao Joao, Dept. of Urology, Porto, Portugal, ²Centro Hospitalar Universitário de Lisboa Norte, Dept. of Urology, Lisbon, Portugal, ³Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal, ⁴Hospital da Luz, Dept. of Urology, Porto, Portugal
- P191** **Shockwave therapy and Platelet Rich Plasma for the treatment of Peyronie's disease**
Authors: Epifanova M.V.¹, Artemenko S.¹, Kostin A.¹, Epifanov A.²
Institutes: ¹RUDN University, Dept. of Urology and Operative Nephrology with Oncourology Course, Moscow, Russia, ²FSBEI HE A.I. Yevdokimov MSMSU MOH Russia, Dept. of Stomatology, Moscow, Russia

- P198** **Outcomes of superselective transcatheter embolization in high-flow priapism**
Authors: Biasatti A.¹, Piasentin A.¹, Rizzo M.¹, Rossin G.¹, Traunero F.¹, Ongaro L.¹, Claps F.², Bucci S.¹, Trombetta C.¹, Liguori G.¹
Institutes: ¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Pisa, Dept. of Urology, Pisa, Italy
- P184** **Quality of life outcomes for penile prosthesis insertion post-priapism – Satisfaction guaranteed?**
Authors: Dighero I., Looney A., Naylor K., Mount C., Johnson M., Holden F., Ralph D., Sangster P.
Institutes: University College London Hospital, Dept. of Andrology, London, United Kingdom
- 17:39 - 17:57** **Screen D: Post-prostatectomy ED and rehabilitation**
- P181** **An exploratory clinical trial of alginate gel combined with polyglycolic acid nerve sheets for restoring erectile function following cavernous nerve injury during radical prostatectomy**
Authors: Narita N.¹, Kobayashi M.K.¹, Kashima S.K.¹, Yamamoto R.Y.¹, Kazuyuki N.K.¹, Sekine Y.S.¹, Sato H.S.¹, Saito M.S.¹, Suzuki Y.S.², Habuchi T.H.¹
Institutes: ¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Kitano Hospital, Dept. of Plastic Surgery, Osaka, Japan
- P178** **Transcutaneous mechanical nerve stimulation as rehabilitation of sexual function following nerve-sparing radical prostatectomy: A pilot study**
Authors: Fode M.M., Nolsøe A.B.R., Durukan E., Østergren P.B., Jensen C.F.S., Sønksen J.
Institutes: Copenhagen University Hospital Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark
- P194** **Evaluation of the consequences of direct current stimulation (DCS) treatment in patients undergoing robot-assisted radical prostatectomy with nerve-sparing technique**
Authors: Scarciglia E., Totaro A., Campetella M., Ragonese M., Nigro D., Bizzarri F.P., Gavi F., Fettucciari D., Cavarra V., Creti A., Cosenza L., Bellavia F., D'Amico L., Fantasia F., Marino F., Filomena G.B., Vocino S., Foti M., Ruocco R., Sanesi D., Gulino G., Sacco E., Racioppi M.
Institutes: Agostino Gemelli Hospital Foundation IRCCS Catholic University Medical School, Dept. of Urology, Rome, Italy
- P195** **Low-intensity extracorporeal shockwave therapy is safe immediately following robotic-assisted radical prostatectomy (NCT03862599)**
Authors: MacAskill F.E.N.¹, Sluzar P.¹, Sammy I.¹, Bertoncilli Tanaka M.², Megson M.³, Qazi H.⁴, Yap T.¹
Institutes: ¹Guy's Hospital, Dept. of Urology, London, United Kingdom, ²Imperial College NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University College NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴St Georges NHS Foundation Trust, Dept. of Urology, London, United Kingdom

- P186** **Urethral Sparing versus Trans-vesical Robot-Assisted Simple Prostatectomy: A Comparative Analysis of Perioperative, Postoperative Outcomes and Ejaculatory function**
Authors: Kim H.J.¹, Hwang W.¹, Jo S.B.¹, Kim J.W.¹, Oh M.M.¹, Park H.S.¹, Moon D.G.¹, Shin Y.S.², Ahn S.T.¹
Institutes: ¹Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea, ²Jeonbuk National University Medical School, Dept. of Urology, Jeonju, South Korea
- P196** **Preoperative prostatic urethral length in MRI is associated with the risk of climacturia after robotic radical prostatectomy**
Authors: Munoz Calahorro C., García-Sánchez C., Parra López L., Lozano Blasco J.M.A., Medina López R.A.
Institutes: Hospital Virgen del Rocío, Dept. of Urology, Sevilla, Spain
- 17:57 - 18:09** **Screen E: ESWT**
- P193** **Comparison of three focal shockwave protocols for the treatment of erectile dysfunction**
Authors: Corredor Ayala H.A., Sandoval C., Martinez J.M.
Institutes: Elexial research, Dept. of Urology and Sexology, Bogota, Colombia
- P190** **Erectile dysfunction treatment by platelet-rich plasma and extracorporeal shock wave therapy**
Authors: Epifanova M.V.¹, Artemenko S.¹, Kostin A.¹, Epifanov A.²
Institutes: ¹RUDN University, Dept. of Urology and Operative Nephrology with Oncourology Course, Moscow, Russia, ²FSBEI HE A.I. Yevdokimov MSMSU MOH Russia, Dept. of Stomatology, Moscow, Russia
- P202** **Correlation between comorbidities and the response of erectile dysfunction (ED) to low-intensity extracorporeal shock wave therapy (LI-ESWT): a prospective study**
Authors: Quaresima L.¹, Fasanella D.², Mariani L.¹, Giannubilo W.¹
Institutes: ¹Civitanova Marche Hospital, Urology Division, Civitanova Marche, Italy, ²University of L'Aquila, Dept. of Life Health and Environmental Sciences, L'Aquila, Italy
- P174** **The effect of combination treatment with low-intensity shockwave therapy and daily low-dose tadalafil on severe erectile dysfunction: A double-blind, randomized, sham-controlled clinical trial**
Authors: Kalyvianakis D.¹, Mykoniatis I.¹, Pyrgidis N.², Kapoteli P.¹, Zilotis F.¹, Hatzichristou D.¹
Institutes: ¹Institute for the Study of Urological Diseases, Dept. of Urology, Thessaloniki, Greece, ²University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

History of urology

Abstract session 17

06 April 2024
17:15 - 18:45

Location Purple Area, N01
Chairs J. Angulo Cuesta, Getafe (ES)
J.C. Goddard, Leicester (GB)
D. Schultheiss, Giessen (DE)

17:15 - 17:17

Introduction

A0409

Of Monkeys and Men: Britain's rejuvenators and the decade of the testicle

Authors: Hill J., Hodgson D.

Institutes: Queen Alexandra hospital, Dept. of Urology, Portsmouth, United Kingdom

A0421

Abracadabra! Bladder Stones, Birds` Eggs, Wild Horses and Joseph-Émile Cornay

Authors: Badawi J.K.¹, Goddard J.C.²

Institutes: ¹Medical Faculty of Mannheim, Dept. of Urology, Mannheim, Germany, ²University Hospitals of Leicester NHS Trust, Dept. of Urology, Leicester, United Kingdom

A0419

Self-harm and simulation of genital diseases in forensic medicine - a historical-forensic overview

Authors: Albrecht K.

Institutes: Institute of Legal Medicine Brandenburg, Dept. of Legal Medicine, Potsdam, Germany

A0415

Fernand Cathelin (1873-1960): eminent urologist and pioneer of sacral anaesthesia

Authors: Schultheiss D.

Institutes: Protestant Hospital, Dept. of Urology, Giessen, Germany

A0411

Sir Peter Freyer: The man who popularized prostatectomy and his love affair with India

Authors: Sharma P., Talwar H.S.

Institutes: Medanta The Medicity, Dept. of Urology, Gurugram, India

A0420

Revision of the case of the first human kidney transplantation: the original article by Yurii Voronoy

Authors: Medina-Polo J., Rodríguez-Antolín A.

Institutes: Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain

A0418

Nudity and sexual symbology in Romanesque baptismal fonts in medieval Spain

Authors: Angulo Cuesta J., Mattelaer J.

Institutes: Universidad Europea, Dept. of Urology, Madrid, Spain

A0417

Historicization in Urology: The Viennese and Austrian Model

Authors: Moll F.¹, Halling T.¹, Shariat S.², Krischel M.¹

Institutes: ¹Heinrich Heine University Duesseldorf, Dept. of History Theory and Ethics of Medicine Centre for Health and Society, Düsseldorf, Germany, ²MedUni Vienna, Dept. of Urology, Vienna, Austria

A0416

August Socin (1837 –1899) a pioneer in Urology from a small University

Authors: Taussky D.

Institutes: Centre Hospitalier Université de Montréal, Dept. of Radiation Oncology, Montreal, Canada

- A0407** **Involvement of the Medical Profession in the promotion of anti-masturbation measures: A Historical Perspective**
Authors: Sankaran S., Coscione A.
Institutes: Addenbrookes hospital, Dept. of Urology, Cambridge, United Kingdom
- A0405** **history and evolution of percutaneous nephrolithotomy**
Authors: Chatar A., Amoch A., Lakmichi M.A., Dahami Z., Sarf I.
Institutes: Cadi Ayyad University King Mohammad the VIth University Hospital of Marrakech, Dept. of Urology, Marrakesh, Morocco
- A0413** **A pioneer turkish urologist-medical historian and his one-century-old review about prostate with integration effort of Turkish republic to Europe**
Authors: Verit A., Karaman M.I.
Institutes: University of Health Sciences, Dept. of Urology, Istanbul, Türkiye
- A0410** **Charles Brenton Huggins: a historical review of the Nobel laureate's pioneering contributions to hormonal treatment for prostate cancer**
Authors: Benadada F.¹, Saad F.², Delouya G.¹, Tausky D.¹
Institutes: ¹Centre Hospitalier de l'Université de Montréal, Dept. of Radiation Oncology, Montreal, Canada, ²Centre Hospitalier de l'Université de Montréal, Division of Urology, Montreal, Canada
- A0408** **Historical aspects of the relationship between Peruvian and French urology**
Authors: Corrales Riveros J.
Institutes: Clinica Ricardo Palma Quiron Salud, Dept. of Urology, Lima, Peru
- A0414** **What is new at the deepest point of human civilization for andrologic point of view?**
Authors: Yagmur I.¹, Verit A.²
Institutes: ¹Harran University Medical School, Dept. of Urology, Sanliurfa, Türkiye, ²Univ. of Health Sciences, Dept. of Urology, Istanbul, Türkiye
- A0406** **Bhutan: The divine madman and his phallic legacy.**
Authors: Baby A., Mahesan T.
Institutes: East Surrey Hospital, Dept. of Urology, Redhill, United Kingdom

Improved risk stratification before local treatment of prostate cancer

Abstract session 18

06 April 2024
17:15 - 18:45

Location Green Area, W06
Chairs To be confirmed
Z. Krstanoski, Slovenj Gradec (SI)
To be confirmed
R.J. Karnes, Rochester (US)

17:15 - 17:17

Introduction

17:17 - 17:32

Type of treatment and outcome

A0424

Patterns of treatment in men with intermediate-, high-, and very high-risk prostate cancer according to their modelled life expectancy

Authors: Irenaeus S.¹, Garmo H.², Gedeberg R.², Robinson D.³, Stattin P.², Beckmann K.⁴

Institutes: ¹Uppsala University, Dept. of Immunology Genetics and Pathology, Uppsala, Sweden, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ³Highland Hospital, Dept. of Urology, Eksjö, Sweden, ⁴Cancer Epidemiology and Population Health Research group, University of South Australia, Adelaide, Australia

A0428

The Impact of Radical Prostatectomy versus Radiation Therapy on Cancer-Specific-Mortality for Non-Metastatic Prostate Cancer: analysis of an Other-Cause-Mortality Matched Cohort

Authors: Finati M.¹, Corsi N.J.², Chiarelli G.¹, Cirulli G.O.¹, Stephens A.³, Tinsley S.¹, Davis M.¹, Butaney M.¹, Arora S.¹, Sood A.⁴, Buffi N.⁵, Lughezzani G.⁵, Briganti A.⁶, Salonia A.⁶, Montorsi F.⁶, Bettocchi C.⁷, Carrieri G.⁷, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ³Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ⁴The James Cancer Hospital and Solove Research Institute, Ohio State's Comprehensive Cancer Center, Dept. of Urology, Columbus, United States of America, ⁵IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy, ⁷University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy

A0422

The impact of radical prostatectomy versus radiation therapy on cancer-specific mortality for patients with localized prostate cancer and positive nodal disease: an analysis of other cause mortality weighted cohort.

Authors: Tinsley S.A.¹, Stephens A.², Marco F.¹, Chiarelli G.¹, Cirulli G.O.¹, Davis M.³, Corsi N.⁴, Sood A.⁵, Buffi N.⁶, Lughezzani G.⁶, Bettocchi C.⁷, Salonia A.⁸, Briganti A.⁸, Montorsi F.⁸, Carrieri G.⁷, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ²Henry Ford Health, Dept. of Public Health Sciences, Detroit, United States of America, ³Rutgers New Jersey Medical School, Dept. of Urology, Newark, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁵The Ohio State University, Dept. of Urology, Columbus, United States of America, ⁶Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ⁷University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, United States of America, ⁸Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy

17:32 - 17:47

Defining risk

A0431

Impact of time interval between diagnosis and radical prostatectomy on treatment outcome

Authors: Yee C.H.¹, Wong R.¹, Chan B.¹, Chau H.², Lam T.³, Ng A.⁴, Kan C.F.⁵, Leung L.H.⁶, So H.S.⁷, Chiu P.K-F.¹, Teoh J.Y.C.¹, Ng C.F.¹

Institutes: ¹S.H. Ho Urology Centre, the Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Tune Mun Hospital, Dept. of Surgery, Hong Kong, Hong Kong, ³Princess Margaret Hospital, Dept. of Surgery, Hong Kong, Hong Kong, ⁴Queen Mary Hospital, the University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁵Queen Elizabeth Hospital, Dept. of Surgery, Hong Kong, Hong Kong, ⁶Kwong Wah Hospital, Dept. of Surgery, Hong Kong, Hong Kong, ⁷United Christian Hospital, Dept. of Surgery, Hong Kong, Hong Kong

A0435

The Impact of Omitting Contralateral Systematic Biopsy on the Surgical Planning of Patients with a Unilateral Suspicious Lesion on Pre-operative MRI undergoing Robot-Assisted Radical Prostatectomy for Prostate Cancer

Authors: van den Kroonenberg D.L.¹, Stöter J.D.¹, Jager A.¹, Veerman H.², Hagens M.J.², Schoots I.G.³, Postema A.W.², Hoekstra R.J.⁴, Oprea-Lager D.E.⁵, Nieuwenhuijzen J.A.¹, Van Leeuwen P.J.², Vis A.N.¹

Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ⁴Catharina Hospital, Dept. of Urology, Eindhoven, The Netherlands, ⁵Amsterdam UMC, Dept. of Radiology and Nuclear medicine, Amsterdam, The Netherlands

A0429

Long-Term Oncological Outcomes of Surgically Managed Very High-Risk Prostate Cancer Patients According to the STAMPEDE Trial Definition: Implications for the Selection of Candidates for Clinical Trials

Authors: Pellegrino A.¹, Scuderi S.¹, Mazzone E.¹, Stabile A.¹, Quarta L.¹, Santangelo A.¹, Cucchiara V.¹, Longoni M.¹, Scilipoti P.¹, Zaurito P.¹, Mannazzu A.¹, Viti A.¹, Barletta F.¹, Lucianò R.², Tenace N.², Robesti D.¹, Leni R.¹, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

17:47 - 18:42

Staging of the lymph nodes

A0425

A novel machine learning-based model predicting lymph node metastasis at robotic assisted radical prostatectomy

Authors: Fulgini D.¹, Castellani D.¹, Lucarelli L.², Teoh J.Y.C.³, Leung D.³, Bugis A.⁴, Azhar R.A.⁴, Ghouse S.M.⁵, Gautam G.⁶, Gauhar V.⁷, Campobasso D.⁸, Campi R.⁹, Sakamoto S.¹⁰, Palagonia E.¹¹, Bocciard A.M.¹¹, Lee H.Y.¹², Rubilotta E.¹³, Antonelli A.¹³, Pastore A.L.¹⁴, Vasdev N.¹⁵, Gómez Rivas J.¹⁶, Cormio L.¹⁷, Ferretti S.¹⁸, Galosi A.B.¹

Institutes: ¹Azienda Ospedaliero Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ²Università Politecnica delle Marche, Dept. of Computer and Automation Engineering, Ancona, Italy, ³Prince of Wales Hospital, the Chinese University, Division of Urology, Dept. of Surgery, Hong Kong, China, ⁴King Abdulaziz University Hospital, Dept. of Urology, Jeddah, Saudi Arabia, ⁵Asian Institute of Nephrology and Urology, Urology Unit, Hyderabad, India, ⁶Medanta The Medicity, Dept. of Urologic Oncology, Gurgaon, India, ⁷Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁸Azienda Ospedaliero-Universitaria di Parma, Division of Urology, Parma, Italy, ⁹Careggi Hospital University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹⁰Chiba University Graduate School of Medicine, Dept. of Urology, Chiba, Japan, ¹¹ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ¹²Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan, ¹³A.O.U.I. Verona University, Dept. of Urology, Verona, Italy, ¹⁴Faculty of Pharmacy and Medicine Sapienza University of Rome, Dept. of Medical-Surgical Sciences and Biotechnologies, Latina, Italy, ¹⁵Lister Hospital East and North Herts NHS Trust, Dept. of Urology, Stevenage, United Kingdom, ¹⁶Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ¹⁷Bonomo Teaching Hospital University of Foggia, Dept. of Urology, Andria, Italy, ¹⁸University of Modena e Reggio Emilia, Dept. of Urology, Modena, Italy

A0437

PSMA PET/CT and nodal staging in prostate cancer: comparison between the diagnostic accuracy of different PSMA- ligand radiopharmaceuticals. A single institutional analysis

Authors: Arena P.¹, Fasulo V.¹, Dagnino F.¹, Piccolini A.¹, Chiarelli G.¹, Frego N.¹, Maffei D.¹, Paciotti M.², Gelardi F.¹, Jandric J.³, Muraglia L.³, Rodari M.³, Evangelista L.¹, Saita A.², Hurle R.², Lazzeri M.², Buffi N.M.¹, Casale P.², Lughezzani G.¹

Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ²IRCCS Humanitas Reserch Hospital, Dept. of Urology, Rozzano, Italy, ³IRCCS Humanitas Research Hospital, Dept. of Nuclear Medicine, Rozzano, Italy

A0430

External Validation of the Available Nomograms for the Identification of Candidates for a Staging Extended Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy in Prostate Cancer Patients Preoperatively Staged with PSMA PET

Authors: Barletta F.M.¹, Gandaglia G.¹, Scuderi S.¹, Robesti D.¹, Rajwa P.², Soeterik T.F.W.³, Bianchi L.⁴, Meijer D.⁵, Darr C.⁶, Guo H.⁷, Zattoni F.⁸, Fendler W.⁹, Marra G.¹⁰, Joniau S.¹¹, Schiavina R.⁴, Mattei A.¹², Fiori C.¹⁰, Porpiglia F.¹⁰, Picchio M.¹³, Van Den Bergh R.³, Shariat S.F.², Chiti A.¹³, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³St Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁵Amsterdam University - VU University, Prostate Cancer Network Netherlands, The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁶West German Cancer Center- University of Duisburg-Essen and German Cancer Consortium- University Hospital Essen, Dept. of Urology, Essen, Germany, ⁷Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ⁸University of Padova, Dept. of Surgery-Oncology and Gastroenterology, Urologic Unit, Padua, Italy, ⁹University of Duisburg-Essen, Dept. of Nuclear Medicine, Essen, Germany, ¹⁰Città della Salute e della Scienza- University of Turin, Dept. of Urology, Turin, Italy, ¹¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹²Luzerner Kantonsspital, Dept. of Urology, Luzener, Switzerland, ¹³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Nuclear Medicine, Milan, Italy

A0423

The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT NOM0 intermediate/high-risk prostate cancer - an international cohort study

Authors: Van Leeuwen P.J.¹, Berrens A-C.¹, Vis A.², Yaxley J.³, Meijer D.², Siriwardana A.³, Wit E.¹, Van Der Noort V.⁴, Morton A.³, Franklin A.³, Yaxley J.⁵, Wong D.⁶, Goughlin G.⁶, Gianduzzo T.⁶, Kua B.⁶, Emmett L.⁷, Zuur L.¹, Van Der Poel H.¹, Roberts M.³

Institutes: ¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam University Medical Centers Location VUmc, Dept. of Urology, Amsterdam, The Netherlands, ³Royal Brisbane and Women's Hospital, Dept. of Urology, Brisbane, Australia, ⁴Netherlands Cancer Institute, Dept. of Statistics, Amsterdam, The Netherlands, ⁵Aquesta Pathology, Dept. of Pathology, Brisbane, Australia, ⁶Wesley Hospital, Dept. of Urology, Brisbane, Australia, ⁷St Vincent's Hospital, Dept. of Nuclear Medicine, Sydney, Australia

A0438

A prospective randomized multicenter study on the impact of 18F-Choline PET/CT versus conventional imaging for staging intermediate- to high-risk prostate cancer

Authors: Evangelista L.¹, Zattoni F.², Borsasti E.³, Trifiro G.⁴, Farsad M.⁵, Trenti E.⁶, Chierichetti F.⁷, Bartolomei M.⁸, Cracco E.⁹, Bombardieri E.¹⁰, Dal Moro F.², Del Bianco P.¹¹, Magni G.¹¹, De Salvo G.L.¹¹, Novara G.²

Institutes: ¹University of Padua, Nuclear Medicine Unit, Padua, Italy, ²University of Padua, Dept. of Urology, Padua, Italy, ³IRCCS CRO, Nuclear Medicine Unit, Aviano, Italy, ⁴ICS Maugeri SpA SB IRCCS, Nuclear Medicine Unit, Pavia, Italy, ⁵Central Hospital Bolzano-Bozen, Nuclear Medicine Unit, Bolzano, Italy, ⁶Hospital of Bolzano SABES-ASDAA, Dept. of Urology, Bolzano, Italy, ⁷S. Chiara Hospital, Nuclear Medicine Unit, Trento, Italy, ⁸University of Ferrara, Nuclear Medicine Unit Diagnostic Imaging and Laboratory Medicine Department, Ferrara, Italy, ⁹Hospital of Angelo, Nuclear Medicine Unit, Venice Mestre, Italy, ¹⁰Humanitas Gavazzeni, Nuclear Medicine Unit, Bergamo, Italy, ¹¹Istituto Oncologico Veneto IOV IRCCS, Clinical Research Unit, Padua, Italy

A0434

“The More You See the More You miss”. PSMA PET/CT Is Still Affected by a Substantial Risk of Underestimation in Prostate Cancer Patients Undergoing Radical Prostatectomy

Authors: Zaurito P.¹, Barletta F.M.¹, Gandaglia G.¹, Rajwa P.², Gomez Rivas J.³, Soeterik T.F.W.⁴, Bianchi L.⁵, Kesch C.⁶, Darr C.⁶, Guo H.⁷, Moreno-Sierra J.³, Marra G.⁸, Joniau S.⁹, Brunocilla E.⁵, Mattei A.¹⁰, Dal Moro F.¹¹, Fiori C.⁸, Porpiglia F.⁸, Picchio M.¹², Chiti A.¹², Van Den Bergh R.⁴, Shariat S.F.², Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ⁴St Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁶West German Cancer Center-University of Duisburg- Essen and German Cancer Consortium-University Hospital Essen, Dept. of Urology, Essen, Germany, ⁷Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ⁸Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰Luzerner Kantonsspital, Dept. of Urology, Luzener, Switzerland, ¹¹University of Padova, Dept. of Surgery- Oncology and Gastroenterology, Urologic Unit, Padua, Italy, ¹²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Nuclear Medicine, Milan, Italy

A0436

PSMA Radio-Guided Surgery to Detect Nodal Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Updated Results of a Planned Interim Analysis of a Prospective Phase 2 Study.

Authors: Quarta L.¹, Mazzone E.¹, Gandaglia G.¹, Stabile A.¹, Pellegrino A.¹, Cucchiara V.¹, Barletta F.¹, Scuderi S.¹, Robesti D.¹, Leni R.¹, Cannoletta D.¹, Zaurito P.¹, Samanes Gajate A.M.², Picchio M.², Chiti A.², Brembilla G.³, De Cobelli F.³, Van Oosterom M.N.⁴, Van Leeuwen F.W.B.⁴, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ³Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁴Leiden University Medical Center, Dept. of Radiology, Leiden, The Netherlands

A0433

Oncological Outcomes of pN1 Prostate Cancer Patients Treated with Radical Prostatectomy: Does Molecular Imaging Have a Prognostic Impact? Results of a Large, Multi-Institutional Series

Authors: Barletta F.M.¹, Gandaglia G.¹, Rajwa P.², Gomez-Rivas J.³, Afferi L.⁴, Kesch C.⁵, Darr C.⁵, Zhuang J.⁶, Zattoni F.⁷, Lanzafame H.⁵, Marra G.⁸, Huebner N.⁹, Joniau S.¹⁰, Cabrera M.³, Brunocilla E.¹¹, Mattei A.⁴, Fiori C.¹², Checcucci E.¹³, Picchio M.¹⁴, Chiti A.¹⁴, Van Den Bergh R.¹⁵, Shariat S.F.¹⁶, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁴Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁵Essen University Hospital, Dept. of Urology, Essen, Germany, ⁶Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ⁷University of Padua, Dept. of Surgery - Oncology and Gastroenterology, Padua, Italy, ⁸Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ⁹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁰University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ¹²School of Medicine - San Luigi Hospital - University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ¹³Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University Hospital S Giovanni Battista, Turin, Italy, ¹⁴IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹⁵Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ¹⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0427

Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: Implication for imaging and oncologic follow-up of 2705 lymph-node positive patients

Authors: Falkenbach F.¹, Kachanov M.², Leyh-Bannurah S.R.³, Maurer T.⁴, Knipper S.¹, Köhler D.⁵, Graefen M.¹, Sauter G.⁶, Budäus L.¹

Institutes: ¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Institute of Human Genetics, Hamburg, Germany, ³St. Antonius-Hospital Gronau, Prostate Center Northwest, Gronau, Germany, ⁴University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Radiology and Nuclear Medicine, Hamburg, Germany, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Pathology, Hamburg, Germany

A0426

Correlation Between the Location of the Index Tumour and the Location of Positive Lymph Nodes in High-Risk Prostate Cancer – A Monocentric Positive Lymph Node Mapping Study

Authors: Declodt H.¹, Jacobs B.¹, Giesen A.¹, Matthias V.¹, Gevaert T.¹, Baldewijns M.², Battaglia A.¹, Laenen A.³, Van Den Broeck T.¹, Moris L.¹, Albersen M.¹, Claessens F.⁴, Lerut E.², Haustermans K.⁵, Van Poppel H.¹, De Meerleer G.⁵, Everaerts W.¹, Joniau S.¹

Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium, ³KU Leuven, Leuven Biostatistics and Statistical Bioinformatics Center, Leuven, Belgium, ⁴KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ⁵University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium

A0432

Prostate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?

Authors: Aldaz Acin A.¹, De Pablos-Rodríguez P.², Claps F.³, Gómez Ferrer A.², Boronat Catalá J.², Calatrava Fons A.⁴, Coy García A.², Casanova-Ramón Borja J.², Ramírez Backhaus M.²

Institutes: ¹Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, ²Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ³University of Trieste, Dept. of Medicine Surgery and Health Sciences, Trieste, Italy, ⁴Instituto Valenciano de Oncología, Dept. of Pathology, Valencia, Spain

18:42 - 18:45

Expert summary

Personalised approaches in high-risk and metastatic prostate cancer

Plenary Session

07 April 2024
08:00 - 10:00

Location Green Area, eURO Auditorium 1
Chairs A. Briganti, Milan (IT)
S. Gillessen Sommer, Bellinzona (CH)

08:00 - 08:10	State-of-the-art lecture Morphologic and genomic features of high-risk prostate cancer: Implications for treatment To be confirmed
08:10 - 08:20	State-of-the-art lecture Staging high-risk prostate cancer with PET PSMA: Strengths and pitfalls I. Burger, Baden (CH)
08:20 - 08:25	Discussion
08:25 - 08:47	Case discussion Negative staging PSMA in high-risk disease: Can we skip extended PLND?
08:25 - 08:27	Case presentation I. Heidegger, Innsbruck (AT)
08:27 - 08:32	Yes, we can D. Murphy, Melbourne (AU)
08:32 - 08:37	No, we cannot A. De La Taille, Créteil (FR)
08:37 - 08:42	The guidelines' view C.J. Stranne, Göteborg (SE)
08:42 - 08:47	Discussion
08:47 - 08:57	State-of-the-art lecture Clinical and molecular stratification of men with biochemical recurrence after radical prostatectomy R.C.N. Van Den Bergh, Utrecht (NL)
08:57 - 09:19	Case discussion High-risk biochemical recurrence after radical prostatectomy and negative PSMA PET: What to do?
08:57 - 08:59	Case presentation G. Gandaglia, Milan (IT)
08:59 - 09:04	RT + ADT in all patients T. Zilli, Genève (CH)
09:04 - 09:09	Systemic therapy alone A.S. Rannikko, Helsinki (FI)
09:09 - 09:14	The guidelines' view D. Tilki, Hamburg (DE)
09:14 - 09:19	Discussion
09:19 - 09:29	State-of-the-art lecture How to personalise treatment in mHSPca? More than just counting metastases K. Fizazi, Villejuif (FR)

09:29 - 09:39	State-of-the-art lecture Local therapy in mHSPCa: Who does really benefit? A. Bossi, Villejuif (FR)
09:39 - 09:44	Discussion
09:44 - 10:00	Case discussion PARP-I only for patients with alterations in DNA repair genes: Yes vs. no
09:44 - 09:46	Case presentation S. Merler, Verona (IT)
09:46 - 09:51	Yes E. Castro, Madrid (ES)
09:51 - 09:56	No F. Saad, Montréal (CA)
09:56 - 10:00	The guidelines' view M. De Santis, Berlin (DE)

How to deal with complications?

Plenary Session

07 April 2024
08:00 - 10:00

Location Purple Area, eURO Auditorium 2
Chairs J. Boormans, Rotterdam (NL)
J. Rassweiler, Krems - Stein (DE)

Learning objectives

Over the last decade, the concept of this session has been very well received by the delegates. This year we are happy to be able to invited the key-opinion leaders and surgeons in the respective field to comment and discuss the management of complications in basically all important fields of minimally invasive surgery in urology.

Since the possibility of personal interaction of the audience is relatively limited in a plenary session, we have chosen this format. The expert will challenge the young presenter of the respective complication and both can then discuss all important steps of managing and preventing the pitfalls.

08:00 - 08:12

Video-based PowerPoint presentation Robotic management of vascular complications

C. Schwentner, Stuttgart (DE)
C. Fankhauser, Lucerne (CH)

08:12 - 08:24

Discussion

08:24 - 08:36

Video-based PowerPoint presentation Rectal injury during pelvic surgery: How do I deal with it?

P. Wiklund, Stockholm (SE)
G. Pignot, Marseille (FR)

08:36 - 08:48

Discussion

08:48 - 09:00

Video-based PowerPoint presentation The case of ureteral avulsion during ureteroscopy and its management

O. Traxer, Paris (FR)
J. Baard, Amsterdam (NL)

09:00 - 09:12

Discussion

09:12 - 09:24

Video-based PowerPoint presentation Nightmares in percutaneous renal surgery

E. Liatsikos, Patras (GR)
S. Proietti, Milan (IT)

09:24 - 09:36

Discussion

09:36 - 09:48

Video-based PowerPoint presentation What can go wrong during enucleation of the prostate?

C.M. Scoffone, Turin (IT)
I. Schwartzmann, Barcelona (ES)

09:48 - 10:00

Discussion

Prostate cancer update: 2023-2024

ESU Course 27

07 April 2024
08:30 - 11:30

Location Purple Area, E01
Chair F. Montorsi, Milan (IT)

Learning objectives

This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

Clinical implications of basic research

F. Montorsi, Milan (IT)

Screening: Novel biomarkers and strategies

C.P. Evans, Sacramento (US)

Diagnosis: Role of mpMRI and PET PSMA in detecting prostate lesions. Fusion biopsies

F. Montorsi, Milan (IT)

Staging: Imaging and predictive models

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Radical prostatectomy

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Focal therapy

F. Montorsi, Milan (IT)

Treatment of localised prostate cancer: Radiation therapy

M. Graefen, Hamburg (DE)

Management of recurrence after curative treatment

M. Graefen, Hamburg (DE)

Management of hormone sensitive metastatic prostate cancer

C.P. Evans, Sacramento (US)

Management of castration-resistant prostate cancer

C.P. Evans, Sacramento (US)

Adrenalectomy course: Elevate your surgical expertise

ESU Course 28

07 April 2024
08:30 - 11:30

Location Purple Area, E02
Chair J.F. Langenhuijsen, Nijmegen (NL)

Learning objectives

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

Introduction

J.F. Langenhuijsen, Nijmegen (NL)

Indications and patient preparation (medical and surgical)

J.F. Langenhuijsen, Nijmegen (NL)

Surgical anatomy of adrenals

C. Fiori, Orbassano (IT)

How I do it; step by step operative procedure, technical tips and tricks

- Transperitoneal

J.F. Langenhuijsen, Nijmegen (NL)

- Retroperitoneal and prone

- Mini-laparoscopic

C. Fiori, Orbassano (IT)

Partial adrenalectomy and challenging cases in adrenalectomy

J.F. Langenhuijsen, Nijmegen (NL)

Complications and management

Discussion and interaction

N. Knežević, Zagreb (HR)

J.F. Langenhuijsen, Nijmegen (NL)

C. Fiori, Orbassano (IT)

Meeting of the Young Academic Urologists (YAU)

Special Session

05 April 2024
10:45 - 14:45

Location Green Area, N04
Chair J. Gómez Rivas, Madrid (ES)

Learning objectives

In this session tailored for young academics, participants can expect to gain a comprehensive understanding of new insights in urological conditions. The session will delve into current research trends, innovative technologies, and emerging treatments in the field. Delegates will have the opportunity to explore the intersection of urology with cutting-edge medical advancements, fostering a dynamic environment for knowledge exchange and collaboration. By the end of the session, participants will be equipped with insights that bridge theoretical knowledge with practical applications in urological research and patient care.

10:45 - 11:20

Overview of the Young Academics

Moderators J. Gómez Rivas, Madrid (ES)
J.L. Vásquez, Copenhagen (DK)

10:45 - 11:00

The EAU Young Academics Where are we?

J. Gómez Rivas, Madrid (ES)

11:00 - 11:10

Non-oncology groups Update on the latest news

A. Pietropaolo, Southampton (GB)

11:10 - 11:20

Oncology groups Update on the latest news

A. Larcher, Milan (IT)

11:20 - 11:30

YAU awards

Moderators J. Gómez Rivas, Madrid (ES)
J.L. Vásquez, Copenhagen (DK)

Best paper published in 2023 by a YAU group

To be confirmed

Best poster at EAU24 by a YAU group

To be confirmed

YAU reviewer of the year

To be confirmed

11:30 - 13:00

Multidisciplinary team discussion on daily cases

Moderators I. Heidegger, Innsbruck (AT)
A. Sierra Del Rio, Barcelona (ES)

11:30 - 11:58

B. Somani, Southampton (GB)

T.E. Şener, Istanbul (TR)

L.A. 't Hoen, Rotterdam (NL)

Case I Kidney stones in a child with urinary diversion

Case presenter To be confirmed

	Take-home messages To be confirmed		
12:00 - 12:28	To be confirmed C. Manfredi, Naples (IT) C.V. Kesch, Essen (DE) Case II Enlarged prostate, rising PSA with negative prostate biopsies: What's next?	Case presenter	A. Ribeiro Morgado, Porto (PT)
12:30 - 12:58	Take-home messages A. Ribeiro Morgado, Porto (PT) A. Muneer, London (GB) C. Fankhauser, Lucerne (CH) G.I. Russo, Catania (IT) Case III HPV-related localised penile cancer	Case presenter	I. Anselmo da Costa Santiago, Berlin (DE)
13:00 - 13:45	Take-home messages I. Anselmo da Costa Santiago, Berlin (DE) Artificial intelligence and new technologies Moderators	M. Moschini, Milan (IT) I. Rivero Belenchón, Seville (ES)	
13:00 - 13:10	AI to predict and detect residual stones B.M. Zeeshan Hameed, Mangaluru (IN)		
13:10 - 13:20	Artificial intelligence applications using MRI features for detection & staging in prostate cancer G. Cacciamani, Los Angeles (US)		
13:20 - 13:30	Machine learning modeling in urothelial cancer detection and characterisation B. Pradere, Toulouse (FR)		
13:30 - 13:45	Discussion		
13:45 - 14:40	Training session Moderators	N.I. Osman, Steeton (GB) M.W. Vetterlein, Hamburg (DE)	
13:45 - 13:55	Standardisation in academic reconstructive urology: Where are we now and where are we going? N. Lumen, Ghent (BE)		
13:55 - 14:05	Which is the best pathway for a young urologist to be trained in kidney transplant? A. Territo, Barcelona (ES)		
14:05 - 14:15	Surveys in clinical research: Are they worthwhile? K.A.O. Tikkinen, Helsinki (FI)		

14:15 - 14:25

Treatment of genitourinary tumours in 2023: A multidisciplinary perspective

R. Campi, Florence (IT)

14:25 - 14:40

Discussion

14:40 - 14:45

Closing remarks

J. Gómez Rivas, Madrid (ES)

Tips and tricks in cystectomy

ESU Course 29

07 April 2024
08:30 - 11:30

Location Purple Area, E03
Chair J Palou, Barcelona (ES)

Learning objectives

The aim of this course is to describe the surgical technique of radical cystectomy.

There are different approaches for radical surgery depending on the expertise and economical possibilities of the centers, and even there are some differences on the results, it is important to follow some basic principles.

The main differences according to the surgical approach will be described (open, laparoscopic and robotic).

Tips and tricks of each approach will be presented in order to show the most important steps of each procedure, and also according to execute a nerve sparing or and organ spring procedure.

Finally the most common complications will be analysed in order prevent and improve their management.

Objectives:

- Describe the rational to choose an specific urinary diversions
- Describe the main details of the different approaches and treatment anatomy related to nerve sparing, organ sparing, intracorporeal diversion
- Provide tips and tricks to improve the efficacy and results of the operation
- Explain the complications including their prevention and management

Introduction

J Palou, Barcelona (ES)

Which diversion for which patient?

J Palou, Barcelona (ES)

Open cystectomy in male (nerve and no nerve sparing)

B. Ali-El-Dein, Mansoura (EG)

Laparoscopic female cystectomy (organ and non- organ sparing)

M. Karavitakis, Pagkrati - Athens (GR)

Robotic intracorporeal ileal conduit and neobladder diversion

C. Wijburg, Arnhem (NL)

Global tricks to decrease complications

J Palou, Barcelona (ES)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 30

07 April 2024
08:30 - 11:30

Location Purple Area, E04
Chair A. Skolarikos, Athens (GR)

Learning objectives

The aim of this course is to describe the surgical techniques of all available treatment options in percutaneous surgery of renal stones in details. In addition to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on prevention and proper management.

Objectives:

- describe the main indications for percutaneous nephrolithotomy and the best clinical practice based on the EAU Guidelines
- Describe the basic percutaneous nephrolithotomy techniques step by step
- Provide tips and tricks to improve the efficacy of the operation
- Identify associate complications including their management

Guidelines on stone treatment

E.K. Bres-Niewada, Pruszkow (PL)

PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

E.K. Bres-Niewada, Pruszkow (PL)

From skin to stone: Step-by-step access using only fluoroscopy (Prone position)

A. Skolarikos, Athens (GR)

From skin to stone: Step-by-step access using ultrasonography (US) and fluoroscopy (Supine position)

O. Angerri Feu, Barcelona (ES)

MiniPerc- Indications, equipment and technique

A. Skolarikos, Athens (GR)

Tips and tricks in PCNL

O. Angerri Feu, Barcelona (ES)

Round table: Complications of PCNL: Diagnosis, management, prevention

O. Angerri Feu, Barcelona (ES)

E.K. Bres-Niewada, Pruszkow (PL)

A. Skolarikos, Athens (GR)

Enhanced recovery after surgery (ERAS) in urological surgery

ESU Course 31

07 April 2024
08:30 - 11:30

Location Purple Area, E05
Chair J. Walz, Marseille (FR)

Learning objectives

Enhanced recovery after surgery (ERAS) has become a mainstay in modern surgical management. The aim of this concept is to optimize and standardize perioperative management to reduce the risk of complications, and promote faster recovery and shorter hospital stays. Key elements of ERAS include increasing the use of minimally invasive surgical approaches and standardized clinical pathways starting before surgery and continuing through recovery, as well as a proactive approach to increasing patient mobilization and return to oral nutrition. ERAS is grounded in a multidisciplinary approach to proactively facilitating recovery. The course provides a detailed overview of the current standard ERAS protocols and pathways as well as practical tips on how to get started with an ERAS programme.

The concept of ERAS

J. Walz, Marseille (FR)

The surgical tools

C. Fankhauser, Lucerne (CH)

The organizational tools

S. Psutka, Seattle (US)

The anesthesia tools

J. Walz, Marseille (FR)

Protocols for endoscopy

C. Fankhauser, Lucerne (CH)

Protocols for nephrectomy

S. Psutka, Seattle (US)

Protocols for radical prostatectomy

J. Walz, Marseille (FR)

Protocols for cystectomy

C. Fankhauser, Lucerne (CH)

Personalized risk stratification

S. Psutka, Seattle (US)

How to get started with ERAS?

J. Walz, Marseille (FR)

Questions and answers

Metabolic workup and non-surgical management of urinary stone disease

ESU Course 32

07 April 2024
08:30 - 11:30

Location Purple Area, E06
Chair T. Tailly, Ghent (BE)

Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:

- Identify patients that would benefit from metabolic workup.
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.

Who needs a metabolic evaluation and why should this be done

M. Straub, Munich (DE)

How to do a metabolic evaluation, step-by-step

K. Thomas, London (GB)

Common stone types: What abnormalities might we find on investigation?

T. Tailly, Ghent (BE)

Stone and diet: What advice should we give?

M. Straub, Munich (DE)

Medical treatment for stones: What works?

T. Tailly, Ghent (BE)

Interactive case discussions

K. Thomas, London (GB)

T. Tailly, Ghent (BE)

M. Straub, Munich (DE)

Practical neuro-urology

ESU Course 33

07 April 2024
08:30 - 11:30

Location Purple Area, E07
Chair T.M. Kessler, Zurich (CH)

Learning objectives

- Learn which nerve centres control the lower urinary tract, and the general principles of how functions change in neurological disease
- Understand key aspects of neuro-urological assessments as described in the EAU guidelines
- Discuss key factors when deciding on therapy

Introduction: What can go wrong with the lower urinary tract?

T.M. Kessler, Zurich (CH)

Neuro-urological assessments

S.T. De Cillis, Turin (IT)

Treatment: Key issues

N. Sihra, London (GB)

Clinical case discussion

T.M. Kessler, Zurich (CH)

S.T. De Cillis, Turin (IT)

N. Sihra, London (GB)

Conclusion

T.M. Kessler, Zurich (CH)

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.03

07 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Urology Beyond Europe

05 April 2024
10:45 - 12:45

Location Purple Area, S01
Chairs T. Karmouni, Rabat (MA)
B. Malavaud, Toulouse (FR)

10:45 - 10:50

Welcome and introduction
B. Malavaud, Toulouse (FR)
T. Karmouni, Rabat (MA)

10:50 - 11:30

Balancing ureteral stone management
Moderators To be confirmed
P.L. Chlosta, Krakow (PL)

Debate Stone and pregnancy

10:50 - 11:00

Pro
To be confirmed

11:00 - 11:10

Con
P.L. Chlosta, Krakow (PL)

Stone management, a balanced approach to sustainability

11:10 - 11:20

Organising care to control costs in ureteral stone management
C.M. Cracco, Turin (IT)

11:20 - 11:30

Taking care of the planet: Disposable vs. reusable ureteroscopes
B.M.C. Rocco, Milan (IT)

11:30 - 12:10

Looking beyond LUTS
Moderators J.L. Domínguez Escrig, Valencia (ES)
To be confirmed

Debate Sex and surgery for BPO

11:30 - 11:40

Pro
S. Lekouaghet, Annaba (DZ)

11:40 - 11:50

Con
J-N.L. Cornu, Rouen (FR)

Debate The case for pre-emptive surgery in enlarged prostate

11:50 - 12:00

Pro
J.L. Domínguez Escrig, Valencia (ES)

12:00 - 12:10

Con
To be confirmed

12:10 - 12:45

A video collection of some challenges in penile surgery
Moderators To be confirmed
G.Y. Robert, Bordeaux (FR)
A. Salonia, Milan (IT)

12:10 - 12:20

Video presentation: The Management of posterior urethral disruption due to pelvic trauma
To be confirmed

Scientific Programme - EAU24

12:20 - 12:30

Video presentation: Challenges in the correction of penile curvature

A. Salonia, Milan (IT)

12:30 - 12:40

Video presentation: Challenges in the surgery of penile trauma

To be confirmed

12:40 - 12:45

Concluding remarks

B. Malavaud, Toulouse (FR)

T. Karmouni, Rabat (MA)

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.08

07 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Urolithiasis: Laser, heat and pressure

Abstract session 19

07 April 2024
10:30 - 12:00

Location Purple Area, N01
Chairs To be confirmed
S. Ferretti, Modena (IT)
To be confirmed

A0450

A comparison between Vapor Tunnel and Virtual Basket for the treatment of proximal ureteral stones using Holmium:YAG laser (Cyber Ho): which is the best tool to reduce retropulsion?

Authors: Perri D.¹, Besana U.¹, Pacchetti A.¹, Morini E.¹, Mazzoleni F.¹, Maltagliati M.¹, Romero Otero J.², Sighinolfi M.C.³, Rocco B.³, Bozzini G.¹

Institutes: ¹Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²12 de Octubre University Hospital, Dept. of Urology, Madrid, Spain, ³ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy

A0453

Pulsed Thulium:YAG laser – What is the lithotripsy ablation efficiency for stone dust from human urinary stones? Results from an in-vitro PEARLS study

Authors: Kwok J.L.¹, Ventimiglia E.², De Coninck V.³, Panthier F.⁴, Barghouthy Y.⁵, Danilovic A.⁶, Shrestha A.⁷, Smyth N.⁸, Schmid F.⁹, Hunziker M.⁹, Poyet C.⁹, Daudon M.¹⁰, Traxer O.⁴, Eberli D.⁹, Keller E.X.⁹

Institutes: ¹Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ²IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ³AZ Klina, Dept. of Urology, Brasschaat, Belgium, ⁴Hopital Tenon, Sorbonne Universite GRC n20 Groupe de Recherche Clinique sur la Lithiase Urinaire, Paris, France, ⁵Centre Hospitalier de Valenciennes, Dept. of Urology, Valenciennes, France, ⁶Universidade de Sao Paulo Hospital das Clínicas, Dept. of Urology, Sao Paulo, Brazil, ⁷Bir Hospital, Dept. of Urology, Gwarko Lalitpur, Nepal, ⁸University Hospital Monklands, Dept. of Urology, Airdrie, United Kingdom, ⁹University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ¹⁰Hopital Tenon CRISTAL Laboratory, Sorbonne University, Paris, France

A0446

In-Vitro Comparison of Stone Ablation Volume Using Pulsed Thulium:YAG and Modulated Pulsed Holmium:YAG Lasers

Authors: Bravo Balado A.C., Sánchez-Puy A., Izquierdo P., Diana P., Piana A., Kanashiro A.S., Balanà J., Millán F.L., Gallioli A., Gracia S., Angerri O., Emiliani E.

Institutes: Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain

- A0449** **Prospective Evaluation of Efficacy, Safety, Cumulative Laser Energy, and Stone-Free Rates in the Post-Market Thulium Fiber Laser (SOLTIVE™ SuperPulsed Laser System) Registry: Insights from Team of Worldwide Endourological Researchers' (T.O.W.E.R.) Research Consortium**
Authors: Chew B.H.¹, Humphreys M.R.², Molina W.R.³, Knudsen B.E.⁴, Gupta M.⁵, Baldwin D.D.⁶, Koo K.⁷, Wong K.F.V.¹, Kronenberg P.⁸, Osther P.J.⁹, Traxer O.¹⁰
Institutes: ¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America, ³Kansas University, Dept. of Urology, Kansas City, United States of America, ⁴Ohio State University, Dept. of Urology, Columbus, United States of America, ⁵Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁶Loma Linda University, Dept. of Urology, Loma Linda, United States of America, ⁷Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁸Hospital CUF Descobertas, Dept. of Urology, Lisbon, Portugal, ⁹University of Southern Denmark, Dept. of Urology, Vejle, Denmark, ¹⁰Sorbonne University Tenon Hospital, Dept. of Urology, Paris, France
- A0455** **A prospective clinical trial on temperature profiles during flexible ureteroscopic laser lithotripsy**
Authors: Asoy M.S.R., Juliebø-Jones P., Beisland C., Ulvik Ø.
Institutes: Haukeland University Hospital, Dept. of Urology, Bergen, Norway
- A0456** **Impact of ureteral access sheath size on intrarenal pressure evaluated by LithoVue Elite single use ureteroscope**
Authors: Kayano S.¹, Yanagisawa T.², Tomomasa N.², Yata Y.², Kawano S.², Kimura T.²
Institutes: ¹Ota Memorial Hospital, Dept. of Urology, Ota, Japan, ²Jikei University School of Medicine, Dept. of Urology, Mnato-ku, Japan
- A0444** **Clinical results analysis of the first disposable intrarenal pressure measuring flexible ureteroscope in China**
Authors: Liu Y.B., Song H.F., Li J.X.
Institutes: Beijing Tsinghua Changgung Hospital, Dept. of Urology, Beijing, China
- A0445** **Pharmacological modulation of intrarenal pressure using a novel isoprenaline eluting guidewire ("IsoWire")**
Authors: John J.¹, Wellman M.¹, Dixon C.², Kellerman T.², Wisniewski P.¹, Kopeć K.³, Trzciński J.W.³, Kopeć D.³, Ciach T.³, Fieggan G.⁴, Kaestner L.¹, Lazarus J.¹
Institutes: ¹University of Cape Town, Dept. of Urology, Cape Town, South Africa, ²University of Stellenbosch, Dept. of Pharmacology, Cape Town, South Africa, ³Warsaw University of Technology, Dept. of Chemical and Process Engineering, Warsaw, Poland, ⁴University of Cape Town, Dept. of Neurosurgery, Cape Town, South Africa

A0439

A multicentre RCT assessing the influence of pressure bag versus manual-pump irrigation on intrarenal pressure during retrograde intrarenal surgery

Authors: Croghan S.M.¹, O'meara S.², Cunnane E.M.³, O'brien F.J.⁴, Walsh M.T.³, Manecksha R.P.⁵, Mcguire B.B.⁶, Breen K.J.⁶, Davis N.F.¹

Institutes: ¹Royal College of Surgeons in Ireland, Dept. of Urology, Dublin, Ireland, ²Blackrock Clinic, Dept. of Urology, Dublin, Ireland, ³University of Limerick, Dept. of Biomedical Engineering, Limerick, Ireland, ⁴Royal College of Surgeons in Ireland, Dept. of Tissue Engineering, Dublin, Ireland, ⁵Tallaght University Hospital, Dept. of Urology, Dublin, Ireland, ⁶St. Vincent's Hospital Group, Dept. of Urology, Dublin, Ireland

A0441

Expert consensus on high intra-renal pressure during ureteroscopy: A pan-European Delphi panel

Authors: Somani B.¹, Davis N.², Emiliani E.³, Gökce M.I.⁴, Jung H.U.⁵, Keller E.X.⁶, Miernik A.⁷, Proietti S.⁸, Turney B.⁹, Wiseman O.¹⁰, Bosworth Smith A.¹¹, Caterino M.¹¹, Saunders R.¹¹, Boulmani M.¹², Traxer O.¹³

Institutes: ¹University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ²Beaumont Hospital, Dept. of Urology, Dublin, Ireland, ³Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁴Ankara University School of Medicine, Dept. of Urology, Ankara, Türkiye, ⁵Hospital Lillebaelt, Dept. of Urology, Vejle, Denmark, ⁶University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ⁷University of Freiburg Medical Center, Dept. of Urology, Freiburg, Germany, ⁸San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁹University of Oxford, Dept. of Urology, Oxford, United Kingdom, ¹⁰Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, ¹¹Coreva Scientific, Dept. of Health Economics, Koenigswinter, Germany, ¹²Boston Scientific, Dept. of Urology and Pelvic Health, Paris, France, ¹³Lithiase Urinaire Sorbonne Université, Dept. of Urology, Paris, France

A0447

The Dusting Utilizing Suction Technique (DUST) Ureteroscope: In vitro evaluation of a novel multichannel continuous flow ureteroscope

Authors: Ghani K.¹, Plott J.²

Institutes: ¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Biomedical Engineering, Ann Arbor, United States of America

A0454

Novel dual action pump (DAP) shows promise to reduce intra-renal pressure and improve irrigant flow in flexible ureteroscopy.

Authors: Wellmann M., Lazarus J., Kaestner L.

Institutes: Groote Schuur Hospital University of Cape Town, Division of Urology, Cape Town, South Africa

A0452

Multi-centre study comparing outcomes of RIRS using traditional suction ureteral access sheath (SUAS) and flexible-navigable suction UAS (FANS)

Authors: Ong C.¹, Somani B.K.², Chew B.H.³, Fong K.Y.⁴, Bin Hamri S.⁵, Sridharan V.⁶, Ragoori D.⁷, Soebhali B.⁸, Tiong H.Y.⁹, Heng C.T.¹, Gadzhiev N.¹⁰, Teoh J.Y.C.¹¹, Castellani D.¹², Traxer O.¹³, Gauhar V.¹

Institutes: ¹Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ³University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁴National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁵King Saud Bin Abdulaziz University for Health Sciences, Dept. of Surgery, Riyadh, Saudi Arabia, ⁶Sree Paduka Speciality Hospital, Dept. of Urology, Tamil Nadu, India, ⁷Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ⁸Abdul Wahab Sjahranie Hospital, Dept. of Urology, Indonesia, Indonesia, ⁹National University Hospital, Dept. of Urology, Singapore, Singapore, ¹⁰Pavlov First Saint Petersburg State Medical University, Dept. of Urology, Saint Petersburg, Russia, ¹¹S.H. Ho Urology Centre, Dept. of Surgery, Hong Kong, Hong Kong, ¹²Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ¹³Sorbonne University, Dept. of Urology, Paris, France

A0451

24 hours after retrograde intrarenal surgery for solitary renal calculi using a flexible and navigable suction access sheath (fans) : Results from a prospective global multicentre study by the eau section on urolithiasis (eulis)

Authors: Gauhar V.¹, Traxer O.², Castellani D.³, Fong K.Y.⁴, Bin Hamri S.⁵, Gökce M.I.⁶, Nariman G.⁷, Corrales M.², Malkhasyan V.⁸, Ragoori D.⁹, Boyke S.¹⁰, Tan K.¹¹, Chai C.A.¹², Tursunkulov A.N.¹³, Tanidir Y.¹⁴, Persaud S.¹⁵, Elshazly M.¹⁶, Kamal W.¹⁷, Tefik T.¹⁸, Zawadzki M.¹⁹, Shrestha A.²⁰, Chew B.H.²¹, Seitz C.²², Somani B.K.²³

Institutes: ¹Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ²Sorbonne University Tenon, Dept. of Urology, Paris, France, ³Azienda Ospedaliero-Universitaria delle Marche Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ⁴Yong Loo Lin School of Medicine, National University of Singapore, Dept. of Urology, Singapore, Singapore, ⁵Specialised Medical Center, Dept. of Urology, Riyadh, Saudi Arabia, ⁶Ankara University, Dept. of Urology, Ankara, Türkiye, ⁷Pavlov First Saint Petersburg State Medical University, Dept. of Urology, Saint Petersburg, Russia, ⁸Moscow State University of Medicine and Dentistry, Urology Unit, Dept. of Urology, Moscow, Russia, ⁹Asian Institute of Nephrology and Urology, Dept. Of Urology, Hyderabad, India, ¹⁰Abdul Wahab Sjahranie Hospital Medical Faculty Mulawarman University, Dept. of Urology, East Java, Indonesia, ¹¹Veterans Memorial Medical Center, Dept. of Urology, Qezon City, Philippines, ¹²University Malaya, Dept. of Urology, Kuala Lumpur, Malaysia, ¹³AkfaMedline Hospital, Dept. of Urology, Tashkent, Uzbekistan, ¹⁴Marmara University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ¹⁵University of the West Indies, Dept. of Urology, St. Augustine, Trinidad and Tobago, ¹⁶Menoufia University, Dept. of Urology, Shibin el Kom, Egypt, ¹⁷King Fahd General Hospita, Dept. of Urology, Jeddah, Saudi Arabia, ¹⁸Istanbul University, Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Türkiye, ¹⁹St. Anna Hospital, Dept. of Urology, Piaseczno, Poland, ²⁰National Academy for Medical Sciences, Bir Hospital, Dept. of Urology, Kathmandu, Nepal, ²¹University of British Columbia, Dept. of Urology, Vancouver, Canada, ²²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

A0448

Direct in scope suction (DISS) or suction via an ureteric access sheath (SUAS): Which is the better option for retrograde intra-renal surgery? A multi-centre validation study

Authors: Ragoori D.¹, S M.², So W.Z.³, Traxer O.⁴, Tiong H.Y.³, Teoh J.Y.C.⁵, Castellani D.⁶, Heng C.T.³, Somani B.⁷, Nanjappa K.⁸, Chew B.H.⁹, Gauhar V.³

Institutes: ¹Asian Institute of Nephrourology, Dept. of Urology, Hyderabad, India, ²APIS Kidney Stone Institute, Dept. of Urology, Mangalore, India, ³National University Hospital, Dept. of Urology, Singapore, Singapore, ⁴Sorbonne University Tenon Hospital, AP-HP, Dept. of Urology, Paris, France, ⁵The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ⁶Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ⁷University hospital NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁸Cauvery Uroderm Centre, Dept. of Urology, Mumbai, India, ⁹University of British Columbia, Dept. of Urology, Vancouver, Canada

A0443

Introducing a novel 7.5Fr single-use ureteroscope with self-vacuum suction in lowering intrarenal pressure: an in vitro study

Authors: Linh L., Lin L.D., Zhou L., Li H., Wang K.J.

Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

A0440

Four dimension analysis of heat generation during Ho:YAG and thulium fiber laser activation: an in vitro thermographic study

Authors: Robesti D.¹, Corsini C.¹, Candela L.¹, Fantin M.¹, Villa L.¹, Goumas I.K.², Proietti S.¹, Giusti G.¹, Cracco C.³, Soffocone C.³, Traxer O.⁴, Keller E.⁵, Montorsi F.¹, Salonia A.¹, Saccomandi P.⁶, Ventimiglia E.¹

Institutes: ¹Urological Research Institute IRCCS San Raffaele Scientific Institute Vita-Salute San Raffaele University, Division of Urology, Dept. of Experimental Oncology, Milan, Italy, ²Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ³Cottolengo Hospital, Dept. of Urology, Turin, Italy, ⁴Hopital Tenon Sorbonne Universite, Urinary Lithiasis Clinical Research Group, Paris, France, ⁵University Hospital Zurich, University of Zurich, Dept. of Urology, Zürich, Switzerland, ⁶Politecnico di Milano, Dept. of Mechanical Engineering, Milan, Italy

A0442

Feasibility of laser lithotripsy in robotic-assisted retrograde intrarenal surgery using Zamenix in an in-vitro model

Authors: Kim J.¹, Ketsuwan C.², Song K.S.¹, Kim J.C.¹, Kim J.¹, Park H.³, Kwon D.S.⁴, Lee J.Y.⁵, Cho S.Y.³

Institutes: ¹ROEN Surgical, Research Institute, Daejeon, South Korea, ²Ramathibodi Hospital, Division of Urology, Bangkok, Thailand, ³Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ⁴Korea Advanced Institute of Science and Technology, Dept. of Mechanical Engineering, Daejeon, South Korea, ⁵Severance Hospital, Dept. of Urology, Seoul, South Korea

Deciphering small renal masses: Advances in diagnosis, intervention, and active surveillance

Abstract session 20

**07 April 2024
10:30 - 12:00**

Location Green Area, N03
Chairs To be confirmed
 To be confirmed
 Z . Wu, Shanghai (CN)

A0471

Reclassification of small renal masses according to the EAU Guidelines newly-proposed TNM classification for suspected renal cell carcinoma: implications for decision-making

Authors: Palumbo C.¹, Amparore D.², Pecoraro A.³, Bertolo R.⁴, Erdem S.⁵, Marchioni M.⁶, Pandolfo S.⁷, Pavan N.⁸, Roussel E.⁹, Sharma G.¹⁰, Warren H.¹¹, Wu Z.¹², Breda A.¹³, Capitanio U.¹⁴, Minervini A.¹⁵, Simone G.¹⁶, Campi R.¹⁷

Institutes: ¹University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy, ²University of Turin San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy, ³Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy, ⁴University of Verona Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁵Istanbul University, Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Türkiye, ⁶University G. d'Annunzio, Dept. of Medical Oral and Biotechnological Sciences Urology Unit, Chieti, Italy, ⁷University of Naples Federico II, Dept. of Neurosciences Science of Reproduction and Odontostomatology, Naples, Italy, ⁸University of Palermo, Dept. of Surgical Oncological and Stomatological Sciences, Section of Urology, Palermo, Italy, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰Medanta Hospital, Division of Urology, Gurugram, India, ¹¹University College London Royal Free Hospital, Specialist Centre for Kidney Cancer, London, United Kingdom, ¹²Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ¹³Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁴IRCCS San Raffaele Scientific Institute Vita-Salute San Raffaele University, Unit of Urology Division of Experimental Oncology Urological Research Institute, Milan, Italy, ¹⁵Careggi Hospital, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ¹⁶IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁷Careggi Hospital University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy

A0468

A national study of the rate of benign pathology after partial nephrectomy for T1 renal cell carcinoma: should we be satisfied?

Authors: Van Den Brink L.¹, Debelle T.², Gietelink L.³, Lagerveld B.⁴, Widdershoven C.V.¹, Graafland N.M.⁵, Ruiter A.E.C.⁴, Bex A.⁵, Beerlage H.P.¹, Van Moorselaar R.J.A.², Zondervan P.J.¹

Institutes: ¹Amsterdam UMC location AMC, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam UMC location VUmc, Dept. of Urology, Amsterdam, The Netherlands, ³Alrijne Ziekenhuis, Dept. of Urology, Leiderdorp, The Netherlands, ⁴OLVG, Dept. of Urology, Amsterdam, The Netherlands, ⁵Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

A0464

Small renal masses in young adults: Insights from a large contemporary multi-institutional Registry

Authors: Amparore D.¹, Pecoraro A.², Bertolo R.³, Marchioni M.⁴, Roussel E.⁵, Pavan N.⁶, Erdem S.⁷, Wu Z.⁸, Sharma G.⁹, Pandolfo S.D.¹⁰, Warren H.¹¹, Caliò A.¹², Carbonara U.¹³, Breda A.¹⁴, Simone G.¹⁵, Capitanio U.¹⁶, Minervini A.¹⁷, Campi R.¹⁸, Palumbo C.¹⁹

Institutes: ¹San Luigi Gonzaga Hospital - University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ²Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy, ³Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁴G. d'Annunzio - University of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶University of Palermo, Dept. of Surgical oncological and Stomatological Sciences, Palermo, Italy, ⁷Istanbul University, Dept. of Urology, Istanbul, Türkiye, ⁸Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ⁹Medanta The Medicity, Dept. of Urologic Oncology and Robotic Surgery, Gurugram, India, ¹⁰University of L'Aquila, Dept. of Urology, L'Aquila, Italy, ¹¹Royal Free Hospital - University College London, Specialist Centre for Kidney Cancer, London, United Kingdom, ¹²University of Verona, Dept. of Diagnostic and Public Health - Section of Pathology, Verona, Italy, ¹³University of Bari, Depy. of Emergency and Organ Transplantation-Urology - Andrology and Kidney Transplantation Unit, Bari, Italy, ¹⁴Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁵IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁶Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, ¹⁷Careggi Hospita, University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ¹⁸Careggi Hospital - University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹⁹Maggiore della Carità Hospital - University of Eastern Piedmont, Division of Urology, Dept. of Translational Medicine, Novara, Italy

- A0457** **Diagnostic accuracy of contrast-enhanced ultrasonography for the assessment of small renal mass: A prospective study**
Authors: Kang J.K.¹, Lim J.S.¹, Yun O.J.¹, Lee S.H.¹, Oh J.S.¹, Park S.Y.², Ha Y.S.¹, Choi S.H.¹, Lee J.N.¹, Kim B.S.¹, Kim H.T.¹, Kim T.H.¹, Yoo E.S.¹, Kim S.H.², Yoon G.S.³, Kwon T.G.¹, Chung J.W.¹
Institutes: ¹Kyungpook National University School of Medicine, Urology, Daegu, South Korea, ²Kyungpook National University School of Medicine, Radiology, Daegu, South Korea, ³Kyungpook National University School of Medicine, Pathology, Daegu, South Korea
- A0463** **GA68-FAPI PET/CT for the primary evaluation of a localized renal mass; a pilot study**
Authors: Aviv T.¹, Bernstine H.², Nadu A.¹, Groshar D.², Baniel J.¹, Golan S.¹
Institutes: ¹Rabin Medical Center, Beilinson Hospital, Institute of Urology, Petah Tikva, Israel, ²Rabin Medical Center, Beilinson Hospital, Dept. of Nuclear Medicine, Petah Tikva, Israel
- A0465** **Diagnostic accuracy of 99mTc Sesta-MIBI SPECT/CT for preoperative differentiation of oncocytoma from renal cell carcinoma**
Authors: Singh U.P., Surekha S., Shukla A., Raj H.
Institutes: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology and Renal Transplantation, Lucknow, India
- A0462** **Incremental value of machine learning-based radiomics for preoperative discrimination between malignant and benign small renal masses**
Authors: Wang Z.J.
Institutes: The First Affiliated Hospital with Nanjing Medical University, Dept. of Urology, Nanjing, China
- A0461** **A MRI-based radiomics model for differentiation of benign and malignant small renal masses (≤4 cm)**
Authors: Dong W., Fang C.
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- A0459** **Decoding Benign Renal Cortical Lesions: A Machine Learning Approach from the INMARC Registry**
Authors: Saitta C.¹, Afari J.¹, Tanaka H.², Patil D.³, Hakimi K.¹, Wang L.¹, Nguyen V.¹, Meagher M.¹, Liu F.¹, Nguyen M.¹, Puri D.¹, Cerrato C.¹, Yuen K.¹, Kobayashi M.², Fukuda S.², Fujii Y.², Master V.³, Lughezzani G.⁴, Buffi N.⁴, Bagrodia A.¹, Derweesh I.¹
Institutes: ¹UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ²Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ³Emory Medical Center, Dept. of Urology, Atlanta, United States of America, ⁴Humanitas Clinical Research Hospital, Dept. of Urology, Rozzano, Italy
- A0458** **Artificial intelligence links pre-operative multi-phase CT images to pathologic features, survival outcomes and biological behaviors of renal masses using real-world data**
Authors: Xiong Y.¹, Shuo W.S.², Guo G.J.M.¹
Institutes: ¹Zhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China, ²School of Basic Medical Sciences, Fudan University, Digital Medical Research Center, Shanghai, China
-

A0469

How to Perform The Optimal Renal Biopsy: a Machine Learning-Based Indication

Authors: Belladelli F.¹, Re C.¹, Cei F.¹, Musso G.¹, Rosiello G.¹, Cignoli D.¹, Canibus D.¹, Fiorio F.¹, Bertini R.¹, Salonia A.¹, De Cobelli F.², Brembilla G.², Esposito A.², Palmisano A.², Piccolo C.¹, Gambirasio M.¹, Lucianò R.³, Tenace N.³, Briganti A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Experimental Oncology - Urological Research Institute, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy

A0460

The role of biopsy in small renal masses <4cm: A european modified delphi consensus statement

Authors: Bernstein D. E.¹, Warren H.¹, Santiapillai J.¹, Fox G.², Wildgoose W.H.¹, Stewart G.D.³, Armitage J.⁴, Le Roux P.⁵, Keeley Jr F.X.⁶, Campain N.⁷, Challacombe B.⁸, Warburton H.⁹, Palumbo C.¹⁰, Muselaers C.H.J.¹¹, Yu D.¹², Oliveira P.¹³, Calio A.¹⁴, El-Sheikh S.¹⁵, Wah T.¹⁶, Campi R.¹⁷, Bex A.¹, Barod R.¹, Gurusamy K.¹⁸, Tran M.¹

Institutes: ¹Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, London, United Kingdom, ²Kidney Cancer UK, Surrey, United Kingdom, ³University of Cambridge, Dept. of Surgery, Cambridgeshire, United Kingdom, ⁴Addenbrookes Hospital, Dept. of Urology, Cambridgeshire, United Kingdom, ⁵Epsom and St Hellier NHS Trust, Dept. of Urology, Surrey, United Kingdom, ⁶Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ⁷Royal Devon and Exeter NHS Foundation Trust, Dept. of Urology, Exeter, United Kingdom, ⁸Guys and St Thomas NHS Trust, Dept. of Urology, London, United Kingdom, ⁹Wythenshawe Hospital, Dept. of Urology, Manchester, United Kingdom, ¹⁰Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, ¹¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ¹²Royal Free London NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ¹³The Christie NHS Foundation Trust, Dept. of Histopathology, Manchester, United Kingdom, ¹⁴University of Verona, Dept. of Diagnostics and Public Health, Verona, Italy, ¹⁵University College London, Dept. of Research Dept. of Pathology, London, United Kingdom, ¹⁶The Leeds Teaching Hospital NHS Trust, Dept. of Radiology, Leeds, United Kingdom, ¹⁷University Hospital, Unit of Urologic Robotic Minimally Invasive Surgery and Renal Transplantation of Careggi, Florence, Italy, ¹⁸University College London, Division of Surgery and Interventional Science, London, United Kingdom

A0472

Malignant progression outcomes of Bosniak graded renal cysts in the modern era of better imaging and uro-radiology subspecialisation

Authors: Speck F., Egiz A., Barrass B., Ramkumar S., Khan F., Pushkaran A.

Institutes: Luton and Dunstable Hospital NHS Foundation trust, Dept. of Urology, Luton, United Kingdom

- A0473** **Contemporary outcomes of Bosniak categorised cystic renal lesions in a cohort of 379 cases; A UK based series**
Authors: Egiz A., Speck F., Barrass B., Ramkumar S., Khan F., Pushkaran A.
Institutes: Luton and Dunstable Hospital NHS Foundation trust, Dept. of Urology, Luton, United Kingdom
- A0466** **Assessing the Impact of Renal Mass Biopsy on the Outcomes of Active Surveillance for Small Renal Masses**
Authors: Abdelaziz A.¹, Bhandari M.², Trecarten S.¹, Dalla E.E.¹, Noel O.¹, Pruthi D.¹, Liss M.A.¹, Dursun F.¹, Mansour A.M.¹
Institutes: ¹The University of Texas Health Science Center, San Antonio, Dept. of Urology, San Antonio, United States of America, ²The University of Texas Health Science Center, San Antonio, Dept. of Population Health Science, San Antonio, United States of America
- A0467** **Progression rates in prospective series of Small Renal Masses treated with Active Surveillance according to the newly-proposed cT1a classification**
Authors: Nicolazzini M., Palumbo C., Abdulvagabov A., Del Galdo M.T., Berra M., Bondonno G., De Angelis P., Zacchero M., Volpe A.
Institutes: University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy
- A0474** **Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors:**
Contemporary results after Fourteen-Year Experience of the DISSRM Prospective Comparative Study
Authors: Alkhatib K.¹, Cheaib J.², Pallauf M.², Wlajnitz T.², Singla N.², Chang P.³, Wagner A.³, Pavlovich C.², Mckiernan J.⁴, Guzzo T.¹, Allaf M.², Pierorazio P.¹
Institutes: ¹University of Pennsylvania, Division of Urology, Philadelphia, United States of America, ²The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ³Beth Israel Deaconess Medical Center, Division of Urology, Boston, United States of America, ⁴Columbia University Medical Center, Dept. of Urology, New York, United States of America
- A0470** **Does the Timing of Intervention Affect Overall Survival? A Comparative Study of Early versus Delayed Interventions for Small Renal Masses.**
Authors: Abdelaziz A.¹, Bhandari M.², Trecarten S.¹, Dalla E.E.¹, Noel O.¹, Pruthi D.¹, Liss M.A.¹, Dursun F.¹, Mansour A.M.¹
Institutes: ¹The University of Texas Health Science Center, San Antonio, Dept. of Urology, San Antonio, United States of America, ²The University of Texas Health Science Center, San Antonio, Dept. of Population Health Science, San Antonio, United States of America

Robotics at its best

Meeting of the EAU Robotic Urology Section (ERUS)

07 April 2024
10:30 - 12:30

Location Green Area, N04
Chair A. Breda, Barcelona (ES)

Learning objectives

To provide an update on the latest technology applications in robotic surgery as well as surgical procedures.

10:30 - 10:35

Welcome and introduction

10:35 - 10:55

New technology

Moderators S. Nathan, London (GB)
H.G. Van Der Poel, Amsterdam (NL)

10:35 - 10:45

New technologies in robotic surgery

V. Patel, Celebration (US)

10:45 - 10:55

New robotic platforms: Who's next?

A. Mottrie, Aalst (BE)

10:55 - 11:25

Prostate cancer

Moderators B.M.C. Rocco, Milan (IT)
To be confirmed

10:55 - 11:05

Different approaches to RALP. How do I choose?

A. De La Taille, Créteil (FR)

11:05 - 11:15

Retzius sparing prostatectomy: A step by step approach

S. Secco, Milan (IT)

11:15 - 11:25

Robotic radical prostatectomy using Japanese-original surgical robots "hinotori" system

R. Shiroki, Aichi (JP)

11:25 - 11:55

Renal cancer

Moderators B.J. Challacombe, London (GB)
N.N. Harke, Hannover (DE)

11:25 - 11:35

Tips and tricks of retroperitoneal surgery

A. Breda, Barcelona (ES)

11:35 - 11:55

Extreme renal surgery: Video session

J-C. Bernhard, Bordeaux (FR)
S.C. Crivellaro, Chicago (US)

11:55 - 12:27

Bladder cancer and benign

Moderators M. Musquera Felip, Barcelona (ES)
C. Wijburg, Arnhem (NL)

11:55 - 12:03

Single vs. multiport cystectomy

P. Wiklund, Stockholm (SE)

12:03 - 12:11

Female intracorporeal neobladder: Tips and tricks

A. Minervini, Florence (IT)

12:11 - 12:19

Fistula repair after abdominal surgery

H. John, Winterthur (CH)

Scientific Programme - EAU24

12:19 - 12:27

Robotic sacrocolpopexy

V. Phé, Paris (FR)

12:27 - 12:30

Closing remarks

A. Breda, Barcelona (ES)

Radical cystectomy revisited: prognostic factors, surgical innovations, and quality of life assessments

Abstract session 21

07 April 2024
10:30 - 12:00

Location Purple Area, S01
Chairs To be confirmed
L.S. Mertens, Amsterdam (NL)
N. Vasdev, Stevenage (GB)

10:30 - 10:32

Introduction

10:32 - 11:12

Perioperative outcomes in radical cystectomy

A0485

Diagnostic accuracy and inter-reader agreement of nac-VIRADS scoring system: a prospective validation study

Authors: Messina E.¹, Deghanpour A.¹, Pecoraro M.¹, Del Giudice F.², Santini D.¹, Simone G.³, Panebianco V.¹

Institutes: ¹Sapienza University, Dept. of Radiological Sciences Oncology and Pathology, Rome, Italy, ²Sapienza University, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0487

Standardized assessment of Perioperative outcomes of robot-assisted radical cystectomy assessed using the EAU guidelines for collecting and reporting complications

Authors: Pellegrino F.¹, Re C.¹, Scilipoti P.¹, Longoni M.¹, De Angelis M.¹, Burgio G.¹, Quarta L.¹, Musso G.¹, Avesani G.¹, Leni R.¹, Basile G.¹, Rosiello G.¹, Gandaglia G.¹, Capitanio U.¹, Necchi A.², Raggi D.², Lucianò R.³, Akre O.⁴, Wiklund P.⁴, Colombo R.¹, Salonia A.¹, Francesco M.¹, Briganti A.¹, Moschini M.¹

Institutes: ¹IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy, ⁴Karolinska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden

A0490

Early gender-related outcomes in radical cystectomy: Perioperative, postoperative and health-related quality of life outcomes comparison from a single centre randomized controlled trial

Authors: Mastroianni R., Tuderti G., Anceschi U., Bove A.M., Brassetti A., D'Annunzio S., Ferriero M., Misuraca L., Guaglianone S., Gallucci M., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0481

Impact of the race-coefficient to estimate eGFR on the management of Muscle Invasive Bladder Cancer

Authors: Khan A.¹, Wang S.¹, Choudhry R.¹, Phelan M.¹, Onukwugha E.², Barry K.H.³, Siddiqui M.M.¹

Institutes: ¹University of Maryland, Dept. of Surgery, Baltimore, United States of America, ²University of Maryland, Dept. of Pharmacy, Baltimore, United States of America, ³University of Maryland, Dept. of Epidemiology and Public Health, Baltimore, United States of America

- A0486** **Ureteroenteric strictures of open vs robot-assisted radical cystectomy with totally intracorporeal urinary diversion: single centre prospective randomised controlled trial**
Authors: Mastroianni R., Tuderti G., Anceschi U., Bove A.M., Brassetti A., D'Annunzio S., Ferriero M., Misuraca L., Guaglianone S., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- A0484** **Intraoperative ICG fluorescence as a method of prevention of postoperative strictures of ureteroileoanastomoses during robot-assisted radical cystectomy**
Authors: Pavlov V., Urmantsev M., Denevko A., Papoyan A.
Institutes: Bashkir State Medical University, Dept. of Urology, Ufa, Russia
- A0477** **Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with Double J stent versus nephrostomy tube prior to radical cystectomy**
Authors: De Angelis M.¹, Soria F.², Pradere B.³, Afferi L.⁴, Montorsi F.¹, Briganti A.¹, Shariat S.³, Wiklund P.⁵, D'Andrea D.³, Albissini S.⁶, Mari A.⁷, Del Giudice F.⁸, Krajewski W.⁹, Laukhtina E.³, Teoh J.Y.C.¹⁰, Mori K.¹¹, Mertens L.S.¹², Gallioli A.¹³, Pichler R.¹⁴, Cimadamore A.¹⁵, Moschini M.¹
Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ²University of Studies of Torino, Urology Division, Dept. of Surgical Sciences, Turin, Italy, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁵Karolinska Institutet, Dept. of Urology, Stockholm, Sweden, ⁶Institut Jules Bordet, Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, ⁷Careggi Hospital, University of Florence, Oncologic Minimally Invasive Urology and Andrology Unit, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁸Policlinico Umberto I Hospital, Sapienza University of Rome, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ⁹Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ¹⁰The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ¹¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ¹²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹³Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁴Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁵University of Udine, Dept. of Medical Area - Institute of Pathological Anatomy, Udine, Italy
- A0478** **Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer**
Authors: Hüge Y.A.M.¹, Rydell H.², Eriksson V.², Johansson M.², Alamdari F.³, Svensson J.⁴, Aljabery F.¹, Sherif A.M.²
Institutes: ¹Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, ²Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ³Västmanlands Sjukhus, Dept. of Urology, Västerås, Sweden, ⁴Umeå University, Umeå School of Business, Dept. of Statistics, Umeå, Sweden
- 11:12 - 11:42** **Prognostic risk factors for adverse outcome after radical cystectomy**
-

- A0488** **Prognostic Variations Between "Primary" and "Progressive" Muscle-Invasive Bladder Cancer Following Radical Cystectomy: A Novel Propensity Score-based Multicenter Cohort Study**
Authors: Shicong L.¹, Jianyong L.², Lai C-H.¹, Samuel S.³, Haopu H.¹, Mingrui W.¹, Hao H.¹, Tao X.¹
Institutes: ¹Peking University People's Hospital, Dept. of Urology, Beijing, China, ²Beijing Hospital, Dept. of Urology, Beijing, China, ³Lancaster University, Faculty of Health and Medicine, Beijing, China
- A0476** **Metformin - A Risk Factor for Metabolic Acidosis After Radical Cystectomy with Ileal Conduit or Continent Diversion? A National Claims Database Analysis**
Authors: Pallauf M.¹, Rezaee M.¹, Kohn T.P.¹, Mcnamara M.¹, Broenimann S.¹, Hoffman-Censits J.², Smith A.¹, Singla N.¹
Institutes: ¹Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Johns Hopkins University School of Medicine, Dept. of Oncology, Baltimore, United States of America
- A0475** **High androgen expression is linked to poor prognosis in male patients with muscle-invasive urothelial carcinoma of the bladder**
Authors: Plage H.¹, Hofbauer S.¹, Furlano K.¹, Roßner F.², Schallenberg S.², Elezkurtaj S.², Kluth M.³, Lennartz M.³, Marx A.H.⁴, Samtleben H.⁴, Fisch M.⁵, Rink M.⁶, Slojewski M.⁷, Kaczmarek K.⁷, Klatte T.⁸, Koch S.⁹, Burandt E.³, Minner S.³, Simon R.³, Sauter G.³, Zecha H.¹⁰, Schlomm T.¹, Ecke T.⁸
Institutes: ¹Charite Urology Berlin, Dept. of Urology, Berlin, Germany, ²Charité Pathology Berlin, Dept. of Pathology, Berlin, Germany, ³University Medical Center Hamburg-Eppendorf, Dept. of Pathology, Hamburg, Germany, ⁴Academic Hospital Fürth, Dept. of Pathology, Fürth, Germany, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁶Marienkrankehaus Hamburg, Dept. of Urology, Hamburg, Germany, ⁷Pomeranian Medical University, Dept. of Urology and Urological Oncology, Szczecin, Poland, ⁸Helios Hospital, Dept. of Urology, Bad Saarow, Germany, ⁹Helios Hospital, Dept. of Pathology, Bad Saarow, Germany, ¹⁰Albertinen Hospital, Dept. of Urology, Hamburg, Germany
- A0479** **Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer - a Swedish retrospective multicenter study**
Authors: Eriksson V.¹, Holmlund J.¹, Wiberg E.¹, Johansson M.¹, Huge Y.A.M.², Alamdari F.³, Svensson J.⁴, Aljabery F.², Sherif A.M.¹
Institutes: ¹Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ²Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, ³Västmanlands Sjukhus, Dept. of Urology, Västerås, Sweden, ⁴Umeå University, Umeå School of Business USBE, Dept. of Statistics, Umeå, Sweden

A0480

Does pre-cystectomy anemia following neoadjuvant chemotherapy in muscle invasive bladder cancer affect survival?

Authors: Eriksson V.¹, Elfving-Long J.¹, Johansson M.¹, Huge Y.A.M.², Alamdari F.³, Aljabery F.², Svensson J.⁴, Banday V.¹, Sherif A.M.¹

Institutes: ¹Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ²Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, ³Västmanlands Sjukhus, Dept. of Urology, Västerås, Sweden, ⁴Umeå University, Umeå School of Business USBE, Dept. of Statistics, Umeå, Sweden

A0483

Pre-existing morbidity is a risk factor for mortality post-cystectomy in elderly urology patients: An Australian and New Zealand Audit of Surgical Mortality (ANZASM) study

Authors: Qin S., Tempo J., Ischia J., Ranasinghe W., Woon D., Bolton D.

Institutes: Austin Health, Dept. of Urology, Melbourne, Australia

11:42 - 11:57

Outcomes after radical cystectomy for muscle-invasive bladder cancer

A0482

Real-world oncological outcomes of a nationwide, prospective bladder cancer cohort

Authors: van Hoogstraten L.¹, Kiemeny L.A.L.M.², Meijer R.P.³, Witjes J.A.⁴, Aben K.K.H.¹

Institutes: ¹Netherlands Comprehensive Cancer Organisation, Dept. of Research and Development, Utrecht, The Netherlands, ²Radboud University Medical Center, Dept. of Health Evidence, Nijmegen, The Netherlands, ³University Medical Center Utrecht, Dept. of Oncological Urology, Utrecht, The Netherlands, ⁴Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands

A0491

Stage-specific Recurrence Rates Post-Radical Cystectomy: A Path to Personalized Oncological Follow-up

Authors: Wettstein M.S.¹, Antonelli L.², Martini A.³, Bologna E.⁴, Guano G.⁵, Veccia A.⁶, Tully K.⁷, Umari P.⁸, Pochet C.⁹, Lambertini L.¹⁰, Pichler R.¹¹, Pavan N.¹², Teoh J.Y.C.¹³, Schulz G.B.¹⁴, Soria F.¹⁵, Bieri U.¹⁶, Alrumayyan M.¹⁷, Rink M.¹⁸, Lonati C.¹⁹, Sessa F.²⁰, Roupret M.²¹, Lavalley L.²², Moschini M.²³, Fankhauser C.D.²

Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ³University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁴Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁵IRCCS Ospedale Policlinico S. Martino, Dept. of Urology, Genoa, Italy, ⁶Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ⁷Marien Hospital Herne, Dept. of Urology and Neurourology, Bochum, Germany, ⁸St. George University Hospital, Dept. of Urology, London, United Kingdom, ⁹Hopital Universitaire de Bruxelles, Dept. of Urology, Brussels, Belgium, ¹⁰Careggi Hospital, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ¹¹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹²University of Trieste, Dept. of Urology, Trieste, Italy, ¹³The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ¹⁴LMU Munich, Dept. of Urology, Munich, Germany, ¹⁵AOU città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy, ¹⁶University Hospital Zürich, Dept. of Urology, Zürich, Switzerland, ¹⁷Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, ¹⁸Marienkrankenhaus Hamburg, Dept. of Urology, Hamburg, Germany, ¹⁹ASST Spedali Civili di Brescia, Dept. of Urology, Brescia, Italy, ²⁰Careggi Hospital, Dept. of Urology, Florence, Italy, ²¹Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, ²²University of Ottawa and Ottawa Hospital Research Institute, Dept. of Urology, Ottawa, Canada, ²³Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy

A0489

Female sexual function after radical cystectomy

Authors: Milling R.V., Seyer-Hansen A.D., Graugaard-Jensen C., Jensen J.B., Kingo P.S.

Institutes: Aarhus Univeristy Hospital, Dept. of Urology, Aarhus, Denmark

11:57 - 12:00

Expert summary

Less common urologic diseases and treatments

Abstract session 22

07 April 2024
10:30 - 12:00

Location Purple Area, S03
Chairs D. Eberli, Zürich (CH)
To be confirmed
To be confirmed

10:30 - 10:32

Introduction

10:32 - 10:42

Urethral cancer

A0504

Outcomes of Invasive Primary Urethral Cancer in Women: An Analysis from the National Cancer Database

Authors: Ganiyani M.A.¹, Podder V.¹, Pon Avudaiappan A.², Khosla A.A.¹, Prabhakar P.², Ozair A.¹, Ahmad S.¹, Rubens M.³, Roy M.³, Manoharan M.², Garje R.⁴

Institutes: ¹Miami Cancer Institute, Dept. of Medical Oncology, Miami, United States of America, ²Miami Cancer Institute, Dept. of GU Surgical Oncology, Miami, United States of America, ³Miami Cancer Institute, Dept. of Office of Clinical Research, Miami, United States of America, ⁴Miami Cancer Institute, Dept. of GU Medical Oncology, Miami, United States of America

A0500

Treatment Strategies and Survival Outcomes in Non-Invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database

Authors: Ganiyani M.A.¹, Podder V.¹, Khosla A.A.¹, Ahmad S.¹, Pon Avudaiappan A.², Ozair A.¹, Prabhakar P.², Roy M.³, Rubens M.³, Manoharan M.², Garje R.⁴

Institutes: ¹Miami Cancer Institute, Dept. of Medical Oncology, Miami, United States of America, ²Miami Cancer Institute, Dept. of GU Surgical Oncology, Miami, United States of America, ³Miami Cancer Institute, Dept. of Office of Clinical Research, Miami, United States of America, ⁴Miami Cancer Institute, Dept. of GU Medical Oncology, Miami, United States of America

10:42 - 10:57

Uncommon prostate cancer types

A0494

Survival outcomes and prognostic factors in the patients with clear cell adenocarcinoma of the prostate: a case-control study for this uncommon cancer type

Authors: Wei Y.¹, Sijin C.²

Institutes: ¹Fujian Provincial Hospital, Dept. of Urology, Fuzhou, China, ²The First Affiliated Hospital of Hunan Normal University, Dept. of Urology, Changsha, China

A0492

Clinicopathological analysis and effective prognostic evaluation system of signet ring-like cell carcinoma of prostate: A mixed-method study

Authors: Yi L.

Institutes: Peking Union Medical College Hospital, Dept. of Urology, Beijing, China

- A0495** **A Comprehensive Comparative Study on Mortality and Risk Factors in Prostate Adenocarcinoma Variants and Transitional Cell Carcinoma**
Authors: Wei Y.¹, Yiming J.²
Institutes: ¹Fujian Medical University, Dept. of Urology, Fuzhou, China, ²Juntendo University School of Medicine, Dept. of Urology, Tokyo, Japan
- 10:57 - 11:07** **Retroperitoneal conditions**
- A0498** **Tertiary lymphoid structures in retroperitoneal sarcoma correlates with improved prognosis**
Authors: Kokubun H.¹, Takada-Owada A.², Kijima T.¹, Kotouno M.¹, Goto K.¹, Mamiya D.¹, Shimoda H.¹, Okubo N.¹, Kurashina R.¹, Uematsu T.¹, Takei K.¹, Betsunoh H.¹, Yashi M.¹, Ishida K.², Kamai T.¹
Institutes: ¹Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, ²Dokkyo Medical University, Dept. of Diagnostic Pathology, Tochigi, Japan
- A0503** **Conditional cancer-specific survival in surgically treated retroperitoneal liposarcoma and leiomyosarcoma patients: a stage-specific analysis**
Authors: Baudo A.¹, Scheipner L.², Jannello L.M.I.³, de Angelis M.⁴, Siech C.⁵, Di Bello F.⁶, Morra S.⁶, Tian Z.⁷, Acquati P.¹, Ahyai S.², de Cobelli O.³, Briganti A.⁴, Chun F.⁵, Longo N.⁶, Saad F.⁷, Shariat S.⁸, Carmignani L.⁹, Karakiewicz P.⁷
Institutes: ¹IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ²Medical University of Graz, Dept. of Urology, Graz, Austria, ³Istituto Europeo di Oncologia, Dept. of Urology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁵Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁶Università di Napoli Federico II, Dept. of Urology, Naples, Italy, ⁷Research Center Du Chum, Dept. of Urology, Montreal, Canada, ⁸Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁹IRCCS Ospedale Galeazzi - Sant'Ambrogio, Dept. of Urology, Milan, Italy
- 11:07 - 11:17** **Less common disease types or treatments of bladder cancer**
- A0507** **Neoadjuvant PD-1 inhibitor plus etoposide and cisplatin in neuroendocrine bladder carcinoma: a single-center, real-world study**
Authors: Chen H.¹, Lei Q.¹, Tianxiang Z.¹, Ruiyun Z.¹, Di J.¹, Jun X.², Guangyu W.³, Ming C.¹, Lianhua Z.¹
Institutes: ¹Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, ²Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Pathology, Shanghai, China, ³Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Radiology, Shanghai, China
- A0499** **Stapled W-shaped Hautmann orthotopic ileal neobladder. Functional results and complications over a 13-year period.**
Authors: Cormio A.C.¹, d'Altilia N.², Calò B.³, Falagarìo U.G.², Cinelli F.², Mancini V.², Busetto G.M.², Bettocchi C.², Carrieri G.², Cormio L.³
Institutes: ¹University of Ancona, Dept. of Urology, Ancona, Italy, ²University of Foggia, Dept. of Urology, Foggia, Italy, ³Bonomo Hospital, Dept. of Urology, Andria, Italy
- 11:17 - 11:27** **Less common uro-onco**
-

- A0501** **Tumor size predicts survival for urachal cancer – Findings from a nationwide multicenter cohort study in Norway**
Authors: Akhtar S.N.¹, Haug E.S.², Carlsen B.³, Aarsaether E.J.⁴, Karlsvik A.K.⁵, Kjoebli E.⁵, Hannestad I.⁶, Müller S.⁶, Hopland O.A.⁷, Dimmen M.⁸, Juliebø-Jones P.¹, Beisland C.¹, Gudbrandsdottir G.¹
Institutes: ¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²Vestfold Hospital Trust, Dept. of Urology, Tønsberg, Norway, ³Vestfold Hospital Trust, Dept. of Pathology, Tønsberg, Norway, ⁴University Hospital in Tromsø, Dept. of Urology, Tromsø, Norway, ⁵St. Olavs University Hospital, Dept. of Urology, Trondheim, Norway, ⁶Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ⁷Oslo University Hospital, Dept. of Urology, Oslo, Norway, ⁸Bodø Hospital, Dept. of Urology, Bodø, Norway
- A0508** **The tumor molecular characteristic and microenvironmental heterogeneity between rare non-urothelial carcinoma of bladder and urothelial carcinoma**
Authors: Chen X., Peng S., Chen Z., Zhang Y., Huang J., Lin T.
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- 11:27 - 11:57** **Less common benign urology miscellaneous**
- A0506** **Genitourinary toxicity following radiation therapy is not just about haematuria- lessons from 7 years of a specialist radiation cystitis clinic.**
Authors: Kam J., Abu-Ghanem Y., Mensah E., Nair R., Khan S., Thurairaja R.
Institutes: Guy's Hospital, Dept. of Urology, London, United Kingdom
- A0493** **Predictive factors for failure of surgical treatment of vesicovaginal fistulas**
Authors: Chaker K.¹, Ouanes Y.¹, Marrak M.¹, Gharbia N.¹, Mosbahi B.², Fakhfakh H.², Hariz A.², Chbeb O.², Bibi M.¹, Mrad Dali K.¹, Rahoui M.¹, Abid K.¹, Ammous A.², Nouira Y.¹
Institutes: ¹La Rabta Hospital, Dept. of Urology, Tunis, Tunisia, ²La Rabta Hospital, Dept. of Anesthesiology, Tunis, Tunisia
- A0505** **Urinary incontinence is associated with the level of the demyelinating lesions in patients with multiple sclerosis: findings from a prospective cross-sectional study**
Authors: Tutolo M.¹, Salerno R.², Filippi M.³, Montorsi F.¹, Salonia A.¹, Del Carro U.³
Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ³IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Neurology, Milan, Italy
- A0496** **Assessing perioperative complications in native nephrectomy as a therapeutic approach for symptomatic polycystic kidney disease: a comprehensive study**
Authors: Helal Birjandi A., Tezval H., Idais H.
Institutes: Hannover Medical School, Dept. of Urology and Urologic Oncology, Hannover, Germany

A0497

Fournier's gangrene prognosis: peri-umbilical cutaneous involvement as a vital warning sign.

Authors: Ouanes Y., Lachnani M., Marrak M., Chaker K., Rahoui M., Mourad Dely K., Bibi M., Abid K., Noura Y.

Institutes: La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

A0502

3D augmented reality robot-assisted segmental ureterectomy with buccal mucosa graft repair: technique description and short-term outcomes

Authors: Piramide F.¹, Piana A.², Amparore D.¹, Manfredi M.¹, Checcucci E.³, Alessio P.³, De Cillis S.T.¹, Volpi G.³, Sica M.¹, Verri P.¹, Burgio M.¹, Meziere J.¹, Quara' A.¹, Cisero E.¹, Busacca G.¹, Marsero L.¹, Colombo M.¹, Mesterca A.G.¹, Sterrantino A.¹, Ribolzi B.S.¹, Di Dio M.⁴, Fiori C.¹, Porpiglia F.¹

Institutes: ¹AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ²Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ³Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ⁴Annunziata Hospital, Division of Urology - Dept. of Surgery, Cosenza, Italy

11:57 - 12:00

Expert summary

The frontier of transplant urology: Robotic techniques and complex cases

Video session 08

07 April 2024
10:30 - 12:00

Location Green Area, S04
Chairs To be confirmed
F. McCaig, London (GB)
To be confirmed

- V056** **Robotic-assisted nephrectomy in ADPKD: a single-center experience**
Authors: Labate C., Marzio S. .M.A.R.Z.I.O., Rella L. .R.E.L.L.A., Vulpi M. .V.U.L.P.I., Mizio D., Lippolis G., Filograsso F.M., Falsetti F., Gerbasi S., Lopinto M., Lospalluto M., Soldano S., Carbonara U., Forte S., Tedeschi M., Spilotros M., Lucarelli G., Ditonno P.
Institutes: University of Bari, Dept. of Emergency and Organ Transplantation-Urology and Andrology section, Bari, Italy
- V057** **Robot assisted transplant graft nephrectomy**
Authors: Mathew J., Bhargava Boppana V.B., Menon R.P., Prabhakaran S.P., Sodhi B.S., S R., Soman S., T A K.
Institutes: Aster Medcity Kochi, Dept. of Urology, Kochi, India
- V058** **Orthotopic robot-assisted laparoscopic kidney transplantation with living donor: First case**
Authors: Al-Emadi I.¹, Prudhomme T.¹, Sallusto F.¹, Hebral A.L.², Lagarde S.³, Thoulouzan M.¹, Game X.¹, Kamar N.², Soulie M.¹, Roumiguie M.¹, Doumerc N.¹
Institutes: ¹Centre Hospitalier Universitaire de Toulouse, Dept. of Urology and Renal Transplantation, Toulouse, France, ²Centre Hospitalier Universitaire de Toulouse, Dept. of Nephrology and Organ Transplantation, Toulouse, France, ³Centre Hospitalier Universitaire de Toulouse, Dept. of Radiology, Toulouse, France
- V059** **Orthotopic robot-assisted kidney transplantation: surgical technique and preliminary results**
Authors: Pecoraro A.¹, Etcheverry B.², Gaya J.M.¹, Territo A.¹, Gallioli A.¹, Berquin C.¹, Basile G.¹, Diana P.¹, Prudhomme T.³, Doumerc N.³, Vigués F.², Breda A.¹
Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ³University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France
- V060** **Learning curve in Robot-Assisted Kidney Transplantation (RAKT): a single centre experience.**
Authors: Gerbasi S., Vulpi M., Magistro R., Matera M., Miacola C., Michele T., Palella G., Lospalluto M., Lopinto M., Filograsso F.M., Falsetti F., Soldano S., Mizio D., Rella L., Lippolis G., Marzio S., Forte S., Carbonara U., Spilotros M., Battaglia M., Lucarelli G., Ditonno P.
Institutes: University of Bari, Dept. of Emergency and Organ Transplantation Urology and Andrology section, Bari, Italy
- V061** **Approach to splitting a donor horseshoe kidney for transplantation**
Authors: Lu J., Li B., Luke P.
Institutes: Western University, Dept. of Urology, London, Canada

- V062** **Transplanting horseshoe kidneys: A challenge for the urologist**
Authors: Mata Alcaraz M., Gomez Dos Santos V., Lopez Perez E., Diez Nicolas V., Laso Garcia I., Alvarez Rodriguez S., Hevia Palacios V., Subiela Henriquez J.D., Jimenez Cidre M.A., Arias Funez F., Burgos Revilla F.J.
Institutes: Ramón y Cajal University Hospital, Dept. of Urology, Madrid, Spain
- V063** **Robot-assisted uretero-calyceal-anastomosis using native ureter as an alternative technique for treatment of complex ureteral strictures in transplanted kidney**
Authors: Facco M., Zattoni F., Gardi M., Betto G., Taverna A., Novara G., Dal Moro F.
Institutes: Urology Clinic - University of Padua, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy

Local salvage options for recurring prostate cancer

Abstract session 23

07 April 2024
10:30 - 12:00

Location Green Area, W01
Chairs To be confirmed
A.S. Zribi, Tunis (TN)
To be confirmed
T. Steuber, Hamburg (DE)

10:30 - 10:32

Introduction

10:32 - 11:02

Salvage treatment for radio-recurrent prostate cancer

A0517

PSA response after Radiotherapy. Is there a definition of PSA persistence after RT?

Authors: Falagario U.G.¹, Pellegrino F.², Abbadi A.³, Björnebo L.³, Valdman A.⁴, Carrieri G.⁵, Briganti A.², Montorsi F.², Akre O.¹, Aly M.¹, Eklund M.³, Nordström T.³, Grönberg H.³, Wiklund P.⁶, Lantz A.¹

Institutes: ¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²IRCCS San Raffaele Hospital, Urology Unit Division of Oncology, Milan, Italy, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, ⁵University of Foggia, Dept. of Urology and kidney transplantation, Foggia, Italy, ⁶Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

A0514

Treatment free survival and the pattern of follow-up treatments after curative prostate cancer treatment, a reflection of electronic health record data

Authors: Denijs F.B., Remmers S., Van Den Bergh R.C.N., Roobol M.J.
Institutes: Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands

A0520

Multicentric evaluation of the oncological outcomes and management of recurrence after brachytherapy for prostate cancer

Authors: Benchimol Y.¹, Taussky D.², Thiounn N.³, Bouche G.⁴, Ramiandrisoa F.⁴, Delouya G.², Taha F.¹, Meynard C.⁵, Giraud P.⁵, Bibault J.E.⁵, Kreps S.⁵, Timsit M.O.³, Méjean A.³, Larré S.¹, Dariane C.³

Institutes: ¹Hopital Robert Debré, Dept. of Urology, Reims, France, ²Centre Hospitalier Université de Montréal, Dept. of Radiation Oncology, Montreal, Canada, ³Hopital Européen Georges-pompidou, Dept. of Urology, Paris, France, ⁴Institut Jean Godinot, Dept. of Radiotherapy, Reims, France, ⁵Hopital Européen Georges-pompidou, Dept. of Radiotherapy, Paris, France

A0523

Enhancing patient selection for salvage radical prostatectomy: a new risk-stratification model from a large retrospective cohort

Authors: Callaris G.¹, Marra G.¹, Benfant N.², Rajwa P.³, Ahmed M.⁴, Ghoreifi A.⁵, Abreu A.⁵, Ribeiro L.⁶, Westhofen T.⁷, Tourinho-Barbosa R.⁸, Raskin Y.⁹, Smith J.A.¹⁰, Oderda M.¹¹, Van Der Poel H.¹², Joniau S.⁹, Sanchez-Salas R.⁸, Kretschmer A.⁷, Cathcart P.⁶, Gill I.⁵, Karnes R.J.⁴, Tilki D.¹³, Shariat S.F.¹⁴, Touijer K.², Gontero P.¹¹

Institutes: ¹Politecnico di Torino, Dept. of Surgical Sciences, Turin, Italy, ²Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ³Medical University of Silesia, Dept. of Urology, Zabrze, Poland, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁵USC Institute of Urology, Dept. of Urology, Los Angeles, United States of America, ⁶Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁷Ludwig-Maximilians University of Munich, Dept. of Urology, Munich, Germany, ⁸Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰Vanderbilt University, Dept. of Urology, Nashville, United States of America, ¹¹Università degli Studi di Torino, Dept. of Surgical Sciences, Turin, Italy, ¹²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹³Martini-Klinik Prostate Cancer, Dept. of Urology, Hamburg, Germany, ¹⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0518

Optimal approach for salvage radical prostatectomy in radiorecurrent prostate cancer

Authors: Ghaffar U.G., Sharma V., Reitano G., Basourakos S.P., Henning G.M., Karnes R.J.

Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America

A0510

Current clinical practice patterns with robotic salvage radical prostatectomy: Oncological results from 10 high-volume robotic centers

Authors: Wenzel M.¹, Di Maida F.², Gomez Rivas J.³, Ibanez L.³, Bravi C.A.⁴, De Groote R.⁵, Piramide F.⁶, Turri F.⁷, Kowalczyk K.⁸, Würnschimmel C.⁹, Sharma G.¹⁰, Andras I.¹¹, Lambert E.⁵, Liakos N.¹², Darlington D.¹³, Paciotti M.⁵, Sorce G.¹⁴, Galfano A.¹⁵, Dell'Oglio P.¹⁵, Mottrie A.⁵, Patel V.¹⁶, Chun F.¹, Moschovas M.C.¹⁶, Larcher A.¹⁴

Institutes: ¹Goethe University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Careggi Hospital Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ³Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁴The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵Onze-Lieve-Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ⁶San Luigi Gonzaga Hospital University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ⁷ASST Santi Paolo e Carlo University of Milan, Dept. of Urology, Milan, Italy, ⁸MedStar Georgetown University Hospital, Dept. of Urology, Washington, United States of America, ⁹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ¹⁰Medanta The Medicity, Dept. of Urologic Oncology, Gurgaon, India, ¹¹Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ¹²Medical Centre of the University of Freiburg, Dept. of Urology, Freiburg, Germany, ¹³Royal Surrey County Hospital, Dept. of Urology, Stokes Centre for Urology, Guildford, United Kingdom, ¹⁴IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ¹⁵ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ¹⁶AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America

11:02 - 11:27

Focal therapy and salvage

A0525

Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: a matched-pair analysis

Authors: Ambrosini F.¹, Hagemann J.², Nagaraj Y.², Pose R.², Maurer T.², Heinzer H.², Michl U.², Steuber T.², Budäus L.², Terrone C.¹, Tennstedt P.², Haese A.², Tilki D.², Graefen M.², Salomon G.²

Institutes: ¹IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ²Martini-Klinik Prostate Cancer Center - University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0513

Effect of prior focal therapy vs radiation on the outcomes of salvage robotic radical prostatectomy

Authors: Ghoreifi A., Storino Ramacciotti L., Kaneko M., Cacciamani G.E., Djaladat H., Sotelo R., Desai M., Gill I., Aron M., Abreu A.L.

Institutes: University of Southern California, Institute of Urology, Los Angeles, United States of America

A0509

HIFI-2 study: salvage HIFU for local recurrence after first-line radiotherapy for localized prostate cancer in 531 patients.

Authors: Rischmann P.¹, Ploussard G.², Chevallier T.³, Fiard G.⁴, Mathieu R.⁵, Houédé N.⁶, Villers A.⁷, Coloby P.⁸

Institutes: ¹Rangueil University Hospital, Dept. of Urology, Renal Transplant and Andrology, Toulouse, France, ²La Croix du Sud Clinic, Dept. of Urology, Quint-Fonsegrives, France, ³Nimes University Hospital, Dept. of Epidemiology and Biostatistics, Nimes, France, ⁴Grenoble University Hospital, Dept. of Urology, Grenoble, France, ⁵Rennes University Hospital, Dept. of Urology, Rennes, France, ⁶Nimes University Hospital, Dept. of Oncology, Nimes, France, ⁷Lille University Hospital, Dept. of Urology, Lille, France, ⁸Pontoise Hospital, Dept. of Urology, Pontoise, France

A0515

US-guided Targeted Focal Salvage Cryoablation: a feasible and effective treatment for prostate cancer recurrence after radiotherapy.

Authors: Altobelli E., de Jong I.J.

Institutes: University Medical Centre Groningen - UMCG, Dept. of Urology, Groningen, The Netherlands

A0521

Salvage focal ablation versus radical prostatectomy for localized radiorecurrent prostate cancer: a propensity-score matched comparison

Authors: Light A.¹, Callaris G.², Gontero P.², Ahmed H.U.¹, Marra G.², Shah T.T.¹

Institutes: ¹Imperial College London, Imperial Prostate Department, London, United Kingdom, ²University of Turin, Dept. of Surgical Sciences, Turin, Italy

11:27 - 11:57

Salvage after radical prostatectomy

A0516

Time to death and clinical characteristics of patients who died for Prostate cancer after robot-assisted radical prostatectomy: 20 years' report from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Authors: Falagario U.G.¹, Pellegrino F.², Moschovas M.C.³, Knipper S.⁴, Martini A.⁵, Akre O.¹, Egevad L.⁶, Aly M.¹, Bravi C.A.⁷, Tran J.⁸, Heiniger Y.⁹, Von Kempis A.⁹, Schaffar R.¹⁰, Carrieri G.¹¹, Briganti A.², Montorsi F.², Rochat C.H.¹⁰, Mottrie A.⁷, Ahlering T.E.⁸, John H.⁹, Patel V.³, Graefen M.⁴, Wiklund P.¹²

Institutes: ¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²IRCCS San Raffaele Hospital, Unit of Urology, Division of Oncology, Milan, Italy, ³University of Central Florida, AdventHealth Global Robotics Institute, Orlando, United States of America, ⁴University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ⁵MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶Karolinska Institutet, Dept. of Oncology and Pathology, Stockholm, Sweden, ⁷Onze-Lieve-Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ⁸University of California Irvine Medical Center, Dept. of Urology, Orange, United States of America, ⁹Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ¹⁰Clinique Générale Beaulieu, Dept. of Urology, Geneva, Switzerland, ¹¹University of Foggia, Dept. of Urology, Foggia, Italy, ¹²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

A0522

Long-term biochemical recurrence in patients with lymph node invasion undergoing radical prostatectomy and lymph node dissection.

Authors: Preisser F., Abrahms-Pompe R.S., Graefen M., Tilki D.
Institutes: University Hospital Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany

A0519

Identify the optimal candidates for adjuvant androgen deprivation therapy among patients with detectable PSA after radical prostatectomy.

Authors: Pellegrino F.¹, Falagario U.G.², Knipper S.³, Martini A.⁴, Akre O.², Aly M.², Moschovas M.C.⁵, Bravi C.A.⁶, Tran J.⁷, Heiniger Y.⁸, Von Kempis A.⁸, Schaffar R.⁹, Carrieri G.¹⁰, Briganti A.¹, Montorsi F.¹, Rochat C.H.⁹, Mottrie A.⁶, Ahlering T.E.⁵, John H.⁸, Patel V.¹¹, Graefen M.³, Wiklund P.²

Institutes: ¹IRCCS San Raffaele Hospital, Unit of Urology, Division of Oncology, Milan, Italy, ²Karolinska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ³University Hospital Hamburg Eppendorf, Martini Klinik Prostate Cancer Center, Hamburg, Germany, ⁴MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁵AdventHealth Global Robotics Institute, Dept. of Urology, Orlando, United States of America, ⁶OLV Hospital, Dept. of Urology, Aalst, Belgium, ⁷University of California, Dept. of Urology, Orange, United States of America, ⁸Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ⁹Clinique Générale Beaulieu, Dept. of Urology, Geneva, Switzerland, ¹⁰University of Foggia, Dept. of Urology, Foggia, Italy, ¹¹AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America

A0524

Duration of Use of Androgen Deprivation Therapy After Radical Therapy for Prostate Cancer: Nationwide, Population-based Study

Authors: Lin E.¹, Garmo H.¹, Robinson D.², Stattin P.¹

Institutes: ¹Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ²Höglandssjukhuset, Dept. of Urology, Eksjö, Sweden

A0512

Comparison of EAU and EMBARK criteria for high-risk biochemical recurrence after radical prostatectomy.

Authors: Server Gomez G.¹, Coy García A.², Lopez Abad A.³, Loyola Maturana J.P.², Giménez Andreu I.S.⁴, Guardiola Ruiz I.¹, de Pablos Rodríguez P.², Boronat Catalá J.², Casanova Ramón-Borja J.², Gómez-Ferrer A.², Collado Serra A.², Calatrava Fons A.⁵, Ramirez Backhaus M.²

Institutes: ¹Santa Lucia's Hospital, Dept. of Urology, Cartagena, Spain, ²Instituto Valenciano De Oncología, Dept. of Urology, Valencia, Spain, ³Virgen de la Arrixaca Hospital, Dept. of Urology, Murcia, Spain, ⁴Miguel Servet Hospital, Dept. of Urology, Zaragoza, Spain, ⁵Instituto Valenciano De Oncología, Dept. of Anatomical Pathology, Valencia, Spain

A0511

Age-Dependent Effect of Early Salvage Radiotherapy for Biochemical Recurrence in Prostate Cancer Patients Treated with Radical Prostatectomy

Authors: Pellegrino A., Barletta F., Gandaglia G., Scuderi S., Scilipoti P., Longoni M., Stabile A., Cannoletta D., Quarta L., Mazzone E., Viti A., Santangelo A., Zaurito P., Leni R., Cirulli G.O., Cucchiara V., Robesti D., Montorsi F., Briganti A.

Institutes: IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

11:57 - 12:00

Expert summary

Hot research topics I

Abstract session

07 April 2024
10:30 - 12:00

Location Green Area, W03
Chairs A.M. Autran-Gomez, Veracruz (MX)
C. Le Magnen, Basel (CH)
E.S. Martens-Uzunova, Rotterdam (NL)

10:30 -

Patient derived models for tailored therapy

A0527

Patient derived renal cell carcinoma organoids and isolated autologous tumor infiltrating lymphocytes as cancer in vitro models for immunotherapy agents screening

Authors: [Hevia Palacios V.](#)¹, [García-Donas J.](#)², [García-Rojo E.](#)¹, [Rodríguez-Moreno J.F.](#)², [Feltes J.](#)¹, [Sevillano E.](#)², [Duque G.](#)¹, [Grazioso T.](#)², [Brime R.](#)¹, [Barquin A.](#)², [Quiralte M.](#)², [Romero J.](#)¹, [Navarro P.](#)²

Institutes: ¹Hospital Universitario HM Sanchinarro, Dept. of Urology - Kidney Division, Madrid, Spain, ²CIOCC Hospital Universitario HM Sanchinarro, Dept. of Clinical Oncology, Traslational Oncology Lab, Madrid, Spain

A0528

Identification of new therapeutic targets in penile squamous cell carcinoma using patient-derived in-vitro and in-vivo models

Authors: [Linxweiler J.](#)¹, [Ayoubian H.](#)¹, [Mink J.](#)¹, [Pongratanakul P.](#)², [Skowron M.A.](#)², [Kotthoff M.](#)², [Stöckle M.](#)¹, [Nettersheim D.](#)², [Junker K.](#)¹

Institutes: ¹Saarland University, Dept. of Urology, Homburg, Germany, ²Heinrich Heine University Düsseldorf, Dept. of Urology - Urological Research Laboratory - Translational UroOncology - Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany

A0526

A patient-derived bladder cancer organoid biobank for translational research and precision oncology

Authors: [Garioni M.](#)¹, [Tschan V.J.](#)², [Elyan A.](#)³, [Wang J.](#)¹, [Pueschel H.](#)³, [Vlajnic T.](#)⁴, [Bubendorf L.](#)⁴, [Seifert H.H.](#)³, [Rentsch C.](#)³, [Le Magnen C.](#)¹

Institutes: ¹University Hospital Basel, University Basel, Dept. of Urology - Institute of Medical Genetics and Pathology - Dept. of Biomedicine, Basel, Switzerland, ²University Hospital Basel, University Basel, Dept. of Biomedicine, Basel, Switzerland, ³University Hospital Basel, University Basel, Dept. of Urology, Basel, Switzerland, ⁴University Hospital Basel, University Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland

A0529

Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

Authors: Servant R.¹, Parmentier R.¹, Dolgos R.¹, Wang J.¹, Diamantopoulou Z.², Roma L.³, Stenner F.⁴, Templeton A. J.⁵, Aceto N.², Bubendorf L.³, Seifert H.⁶, Rentsch C.A.⁶, Le Magnen C.¹

Institutes: ¹University Hospital Basel, University Basel, Dept. of Urology - Institute of Medical Genetics and Pathology - Dept. of Biomedicine, Basel, Switzerland, ²Swiss Federal Institute of Technology, Institute of Molecular Health Sciences, Dept. of Biology, Zürich, Switzerland, ³University Hospital Basel, University Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland, ⁴University Hospital Basel, Division of Medical Oncology, Basel, Switzerland, ⁵St. Claraspital Basel, Division of Medical Oncology, Basel, Switzerland, ⁶University Hospital Basel, Dept. of Urology, Basel, Switzerland

10:30 -

The role of extracellular vesicles in cell-cell communication

A0530

M2-like macrophage promotes prostate cancer metastasis by horizontal transfer of TXNDC5 mRNA via extracellular vesicles

Authors: Hu C., Wu T., Du X., Peng Z., Chen Q., Zhu Y., Dong B., Pan J., Dong L., Xue W.

Institutes: Shanghai Jiao Tong University School of Medicine, Dept. of Urology Renji Hospital, Shanghai, China

A0531

Identification of novel snoRNA-based biomarkers from urine-derived extracellular vesicles for non-invasive detection of clear cell renal cell carcinoma

Authors: Grützmann K.¹, Salomo K.², Krüger A.³, Lohse-Fischer A.², Erdmann K.², Seifert M.¹, Baretton G.⁴, Aust D.⁴, Schröck E.⁵, Thomas C.², Füssel S.²

Institutes: ¹TU Dresden, Institute for Medical Informatics and Biometry, Dresden, Germany, ²University Hospital Dresden, Dept. of Urology, Dresden, Germany, ³NCT Dresden, Core Unit for Molecular Tumor Diagnostics, Dresden, Germany, ⁴TU Dresden, Institute of Pathology, Dresden, Germany, ⁵TU Dresden, Institute for Clinical Genetics, Dresden, Germany

ERN eUROGEN: Update on rare & complex urology

Thematic Session

05 April 2024
10:45 - 12:15

Location Purple Area, S03
Chairs M. Batty, Nijmegen (NL)
W.F.J. Feitz, Nijmegen (NL)

10:45 - 11:15	ERN eUROGEN Patient Advocacy Group (ePAG)
10:45 - 10:55	Testicular/penile cancer support from the patient perspective (WS3) R. Cornes, London (GB)
10:55 - 11:05	Interstitial cystitis: When chronic pain invades the mind (WS2) A. De Santis, Rome (IT)
11:05 - 11:15	ePAG and experts discussion: Future perspectives and patients expectation management
11:15 - 11:45	ERN eUROGEN Workstream 1: Rare congenital uro-recto-genital anomalies
11:15 - 11:25	Urethral duplications: The complexity of diagnosis and management A. El-Ghoneimi, Paris (FR)
11:25 - 11:35	Long term care in posterior hypospadias A. Morlacco, Padova (IT)
11:35 - 11:45	Post-hypospadias urethral strictures: The challenge is not only the surgery F. Campos Juanatey, Santander (ES)
11:45 - 11:55	ERN eUROGEN Workstream 2: Functional urogenital conditions requiring highly specialised surgery
11:45 - 11:55	Urethral stenosis in women: Diagnosis, pitfalls, management options M. Mancini, Padua (IT)
11:55 - 12:05	ERN eUROGEN Workstream 3: Rare urogenital tumours
11:55 - 12:05	Sentinel lymph-node staging in testicular cancer patients Y. Che, Düsseldorf (DE)
12:05 - 12:15	Take home message on rare urology: Practice approaches and innovations

Basic research and trials: metastatic prostate cancer

Abstract session 24

07 April 2024
10:30 - 12:00

Location Green Area, W06
Chairs To be confirmed
I. Heidegger, Innsbruck (AT)
To be confirmed

A0542

Preclinical assessment of integrin receptors as therapeutic targets in advanced treatment-resistant prostate cancer

Authors: Tsauro I.¹, Saar M.², Juengel E.³, Vakhrusheva O.³, Slade K.S.³, Michaelis M.⁴, Rothweiler F.⁵, Cinatl Jr. J.⁵, Menger M.D.⁶, Linxweiler J.⁷, Blaheta R.A.³

Institutes: ¹University of Tuebingen, Dept. of Urology, Tübingen, Germany, ²University Hospital RWTH Aachen, Dept. of Urology and Pediatric Urology, Aachen, Germany, ³University Medicine Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ⁴University of Kent, School of Biosciences, Canterbury, United Kingdom, ⁵Goethe-University, Dept. of Medical Virology, Frankfurt, Germany, ⁶Saarland University, Institute for Clinical and Experimental Surgery, Homburg, Germany, ⁷Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany

A0540

Cofilin-1 is implicated in the progression of prostate cancer under long-term exposure to leptin

Authors: Hu M., Chen X., Zhou Q., Hu J., Wu Y., Zhang L., Jiang H.

Institutes: Huashan Hospital Fudan University, Dept. of Urology, Shanghai, China

A0541

Cancer-associated fibroblast exosomes promote prostate cancer metastasis through miR-500a-3p/FBXW7/HSF1 axis under hypoxic microenvironment

Authors: Liu Z.¹, Lin Z.², Jiang M.¹, Zhu G.², Xiong T.¹, Cao F.³, Cui Y.⁴, Niu Y.¹

Institutes: ¹Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China, ²Beijing Shijitan Hospital, Dept. of Urology, Beijing, China, ³Cancer Hospital Chinese Academy of Medical Science, ICU, Beijing, China, ⁴Beijing Chaoyang Hospital, Dept. of Urology, Beijing, China

- A0547** **Clinical translation of the albumin-binding radioligand 177Lu-(S)-Ibu-DAB-PSMA in patients with mCRPC: enhancing clinical efficacy of PSMA-targeted RLT**
Authors: Fernandez R.¹, Nicolai H.², Ritt P.³, Soza-Ried C.¹, Rogers A.⁴, Qin Y.³, Meckel M.³, Fliegert F.³, Ceballos M.¹, Wettlin J.¹, Amaral H.⁵, Zhernosekov K.³, Borgna F.⁶, Deberle L.M.⁶, Schibli R.⁶, Müller C.⁶, Martinez C.², Del Castillo C.⁷, Kramer V.¹
Institutes: ¹Center for Nuclear Medicine - PETCT, Positronmed, Providencia - Santiago, Chile, ²Universidad de Chile, Dept. of Urology, Santiago, Chile, ³ITM Medical Isotopes GmbH, Garching, Munich, Germany, ⁴Universidad de Chile, Hospital Clinic, Santiago, Chile, ⁵Positronpharma SA, Providencia, Santiago, Chile, ⁶Paul Scherrer Institute, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Villigen-PSI, Switzerland, ⁷Hospital Clínico San Borja Arriaran, Dept. of Oncology, Santiago, Chile
- A0548** **Single-cell transcriptome analysis reveals the diverse mechanisms of castration resistance development in prostate cancer**
Authors: Peng Q., Xie T., Ho V.W.S., Teoh J.Y.C., Ng C.F., Chiu P.K-F.
Institutes: The Chinese University of Hong Kong, Dept. of Surgery, Sha Tin, Hong Kong
- A0545** **Epidermal growth factor-like domain 7 inhibit immune response in metastatic castration resistant prostate cancer by de-activation of endothelial intercellular adhesion molecule-1**
Authors: Lee Y.H., Kim J.Y., Yoo S., Lee D., Lee S.S., Song W.H., Nam J.K., Park S.W.
Institutes: Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan-si, South Korea
- A0544** **Characterization of the tumor microenvironment in prostate cancer progression**
Authors: Bonollo F.¹, Cheng W.¹, Sampson N.², Chouvardas P.¹, Thalmann G.³, Kruithof-De Julio M.¹, Karkampouna S.¹
Institutes: ¹University of Bern, Dept. of BioMedical Research, Bern, Switzerland, ²Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ³University Hospital of Bern-Inselspital, Dept. of Urology, Bern, Switzerland
- A0546** **Melatonin inhibits tumor growth and metastasis by promoting NRF2-mediated iron death activated via increase of liquid-liquid phase separation behavior of androgen receptor in prostate cancer**
Authors: Yi X., Li J., Ai J.
Institutes: Institute of Urology, West China Hospital Sichuan University, Dept. of Urology, West China Hospital Sichuan University, Chengdu, China
- A0543** **Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers**
Authors: Villa M.¹, Cazzaniga G.¹, Bolognesi M.¹, Crippa V.¹, Malighetti F.¹, Aroldi A.¹, Perri D.², Mazzoleni F.², Bozzini G.², Pagni F.¹, Piazza R.¹, Mogni L.¹, Ramazzotti D.¹
Institutes: ¹University of Milano-Bicocca, Dept. of Medicine and Surgery, Milan, Italy, ²Sant'Anna Hospital, Dept. of Urology, Como, Italy

A0537

FeS-functionalized bacteria-derived outer membrane vesicle as a novel immunotherapeutic nanodrug for prostate cancer

Authors: Du X.¹, Chen H.², Hu C.¹, Wu X.¹, Liu J.², Dong L.¹, Xue W.¹

Institutes: ¹Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Institute of Molecular Medicine, Shanghai, China

A0538

Elevated Circulating PMN-MDSC Levels Predict Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients.

Authors: Kobayashi T.¹, Nagata M.¹, Hachiya T.², Wakita H.¹, Yan L.¹, Ikehata Y.¹, Takahashi K.¹, Ide H.³, Horie S.¹

Institutes: ¹Juntendo University Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ²Juntendo University Graduate School of Medicine, Dept. of Advanced Informatics for Genetic Diseases, Tokyo, Japan, ³Juntendo University Graduate School of Medicine, Dept. of Digital Therapeutics, Tokyo, Japan

A0536

Investigation of the tumor-macrophage crosstalk to identify palmitic acid as modulator of macrophage reprogramming in prostate cancer.

Authors: Lughezzani G.¹, Marelli G.², Buffi N.M.¹, Casale P.³, Saita A.³, Hurle R.³, Fasulo V.¹, Paciotti M.¹, Finocchiaro A.¹, Colombo P.⁴, Maria G.M.⁴, Carriero R.⁵, Iovino M.⁵, Kunde-franco P.⁵, Morosi C.⁵, Di Mitri D.⁵, Lazzeri M.³

Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²Humanitas Research Hospital, Dept. of Immunology, Milan, Italy, ³Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ⁴Humanitas Research Hospital, Dept. of Pathology, Milan, Italy, ⁵Humanitas Research Hospital, Dept. of Biology, Milan, Italy

A0535

Cell-Free DNA Genomic Profiling and its Clinical Implementation in Advanced Prostate Cancer

Authors: Roma L.¹, Bratic Hench I.¹, Conticelli F.², Bubendorf L.¹, Calgua B.¹, Le Magnen C.³, Piscuoglio S.⁴, Rubin M.⁵, Chirindel A.⁶, Nicolas G.P.⁶, Vlajnic T.¹, Zellweger T.⁷, Templeton A.J.⁸, Stenner F.⁹, Ruiz C.¹, Rentsch C.¹⁰, Bubendorf L.¹

Institutes: ¹University Hospital of Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland, ²University of Naples Federico II, Dept. of Public Health, Naples, Italy, ³University Hospital of Basel, Institute of Medical Genetics and Pathology, Dept. of Urology and Dept. of Biomedicine, Basel, Switzerland, ⁴University Hospital of Basel, Institute of Medical Genetics and Pathology, Dept. of Biomedicine, Basel, Switzerland, ⁵University of Bern, Bern Center for Precision Medicine, Precision Oncology Laboratory, Dept. for Biomedical Research, Bern, Switzerland, ⁶University Hospital of Basel, Dept. of Theragnostics, Basel, Switzerland, ⁷Claraspital, Dept. of Urology, Basel, Switzerland, ⁸Claraspital, Dept. of Oncology, Basel, Switzerland, ⁹University Hospital of Basel, Division of Oncology, Basel, Switzerland, ¹⁰University Hospital of Basel, Dept. of Urology, Basel, Switzerland

A0539

Preclinical evidence for the use of anti-TROP-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer

Authors: Weiten R.¹, Niemann M.¹, Below E.¹, Friker L.L.², Ralser D.J.³, Toma M.⁴, Kristiansen G.⁴, Hahn O.⁵, Zechel S.⁶, Grünwald V.⁷, Bald T.⁸, Siewert J.⁸, Pietsch T.², Ritter M.¹, Hölzel M.⁸, Eckstein M.⁹, Alajati A.¹, Krausewitz P.¹, Klümper N.¹

Institutes: ¹University Hospital Bonn, Dept. of Urology and Paediatric Urology, Bonn, Germany, ²University Hospital Bonn, Institute of Neuropathology, Bonn, Germany, ³University Hospital Bonn, Dept. of Gynaecology and Gynaecological Oncology, Bonn, Germany, ⁴University Hospital Bonn, Institute of Pathology, Bonn, Germany, ⁵University Hospital Göttingen, Dept. of Urology, Göttingen, Germany, ⁶University Hospital Göttingen, Institute of Neuropathology, Göttingen, Germany, ⁷University Hospital Essen, Dept. of Interdisciplinary Genitourinary Oncology, West-German Cancer Center, Essen, Germany, ⁸University Hospital Bonn, Institute of Experimental Oncology, Bonn, Germany, ⁹University Hospital Erlangen, Institute of Pathology, Erlangen, Germany

A0532

ZBTB46 complex increasing intracellular Calcium level promote Epithelial-to-

ZBTB46 Complex Increasing Intracellular Calcium Level Promotes Epithelial-to-Mesenchymal Transition in Neuroendocrine Prostate Cancer

Authors: Ho Y.¹, Liu Y.N.², Chen W-Y.³, Hsiao M.⁴, Wen Y.C.¹

Institutes: ¹Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Medical University, Graduate Institute of Cancer Biology and Drug Discovery, Taipei, Taiwan, ³Wan Fang Hospital, Dept. of Pathology, Taipei, Taiwan, ⁴Academia Sinica, Research Center, Taipei, Taiwan

A0533

Loss of glucocorticoid receptor expression in diagnostic biopsies of metastatic prostate cancer is associated with poor response to sequential docetaxel treatment

Authors: Moll J.M.¹, Mout L.¹, Kweldam C.F.², Wissing M.³, de Morrée E.M.¹, Van Leenders G.J.L.H.², Jenster G.W.¹, Van Weerden W.M.¹

Institutes: ¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ³LUMC, Dept. of Medical Oncology, Leiden, The Netherlands

A0534

Chemotherapeutic effects of luteolin and the regulatory mechanism of androgen receptor splice variant 7 by miR-8080 in castration-resistant prostate cancer

Authors: Naiki-Ito A.¹, Naiki T.², Murakami A.¹, Kato H.¹, Aoki M.², Yasui T.², Takahashi S.¹

Institutes: ¹Nagoya City University Graduate School of Medical Sciences, Dept. of Experimental Pathology and Tumor Biology, Nagoya, Japan, ²Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

The evolving landscape of muscle-invasive bladder cancer: Clinical trials, surgical techniques, and treatment outcomes

EGPT 08

**07 April 2024
10:30 - 12:00**

Location EGPT
Chairs A.K. Czech, Kraków (PL)
To be confirmed
To be confirmed

10:30 - 10:51

Screen A: Translational research in muscle-invasive bladder cancer

P223

B7-Family Score improves high tumor mutation burden harbored urothelial carcinoma patients response to PD-L1 blockade

Authors: Liu Z.¹, Wang Z.², Jin K.², Xu Z.³, Zhu Y.¹, Xu J.³

Institutes: ¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Zhongshan Hospital of Fudan University, Dept. of Urology, Shanghai, China, ³School of Basic Medical Sciences, Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China

P213

Loss of MTAP expression by immunohistochemistry is a surrogate marker for homozygous 9p21.3 deletion in urothelial carcinoma

Authors: Vlajnic T.¹, Chijioke O.¹, Roma L.¹, Savic Prince S.¹, Zellweger T.², Rentsch C.³, Bubendorf L.¹

Institutes: ¹University Hospital Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland, ²St. Clara Hospital, Division of Urology, Basel, Switzerland, ³University Hospital Basel, Dept. of Urology, Basel, Switzerland

P222

KMT2D missense mutation identifies urothelial carcinoma subtype with distinct genomic characteristics and clinical outcomes

Authors: Xu Z.¹, Liu Z.², Wang Z.³, Jin K.³, Zhu Y.², Xu J.¹

Institutes: ¹School of Basic Medical Sciences, Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Zhongshan Hospital of Fudan University, Dept. of Urology, Shanghai, China

P221

Boron Neutron Capture Therapy for Experimental Bladder Cancer: Systemic or Intravesical Approach

Authors: Teke K.¹, Özer C.², Bayrak Yaprak B.³, Reyhancan I.A.⁴, Vural C.³, Kasap M.⁵, Karabey A.Ü.⁶, Akpınar G.⁵, Bosnali E.¹, Koyuncu Gürsu N.⁴, Avci I.E.¹, Erbay O.⁴, Kiziltas M.S.⁴, Hunc F.⁷, Camtakan Z.⁴, Kara O.¹, Aksu G.⁶, Dillioglugil O.¹

Institutes: ¹Kocaeli University, Dept. of Urology, Kocaeli, Türkiye, ²Kocaeli University, Experimental Medicine Research Laboratory, Kocaeli, Türkiye, ³Kocaeli University, Dept. of Pathology, Kocaeli, Türkiye, ⁴Istanbul Technical University, Dept. of Energy Institutes, Istanbul, Türkiye, ⁵Kocaeli University, Dept. of Molecular Biology, Kocaeli, Türkiye, ⁶Kocaeli University, Dept. of Radiation Oncology, Kocaeli, Türkiye, ⁷Kocaeli University, Dept. of Biochemistry, Kocaeli, Türkiye

- P228** **Pathological complete response to neoadjuvant chemotherapy improves antitumor immune response through reduction of regulatory T cells in muscle-invasive bladder cancer.**
Authors: Ikarashi D.I.¹, Kitano S.², Shiomi E.¹, Matsuura T.¹, Maekawa S.¹, Kato R.¹, Kanehira M.¹, Sugimura J.¹, Obara W.¹
Institutes: ¹Iwate medical university, Dept. of. Urology, Iwate, Japan, ²The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Advanced Medical Development, Tokyo, Japan
- P224** **B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer**
Authors: Zhu Y., Liu Z., Ye D.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- P230** **Hypoxia-induced LINC00941/IMP2 drives chemoresistance of basal/squamous bladder cancer through m6A-mediated stabilization of IPO4**
Authors: Yilin Y., Zhengnan H., Bing S., Shujie X.
Institutes: Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China
- 10:51 - 11:06** **Screen B: Clinical trials in muscle-invasive bladder cancer**
- P218** **A Prospective Multinational and Multi-institutional Analysis of Radical Cystectomy for Bladder Cancer in the Nordic Countries (NorCys – trial)**
Authors: Venhomaa T.¹, Nikulainen I.¹, Bläckberg M.², Bro L.³, Buchardt Brandt S.⁴, Ettala O.¹, Fabrin K.⁵, Gudjonsson S.⁶, Haug E.S.⁷, Högerman M.¹, Hyldgaard J.M.⁴, Jerlström T.⁸, Koskinen I.⁹, Lam G.¹⁰, Leskinen M.¹¹, Liedberg F.¹², Nordström Joensen U.¹³, Seikkula H.¹⁴, Ströck V.¹⁵, Virta V.¹⁶, Bjerggaard Jensen J.⁴, Boström P.¹
Institutes: ¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Helsingborgs Hospital, Dept. of Urology, Helsingborg, Sweden, ³Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁴Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁵Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁶Landspítali University Hospital, Dept. of Urology, Reykjavik, Iceland, ⁷Vestfold Hospital Trust, Dept. of Urology, Vestfold, Norway, ⁸Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ⁹Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ¹⁰Herlev Hospital, Dept. of Urology, Herlev, Denmark, ¹¹Central Hospital of Seinäjoki, Dept. of Surgery, Seinäjoki, Finland, ¹²Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ¹³Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ¹⁴Central Hospital of Jyväskylä, Dept. of Surgery, Jyväskylä, Finland, ¹⁵Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ¹⁶Oulu University Hospital, Dept. of Urology, Oulu, Finland
- P204** **The Hidden Landscape: A Lymph Node Mapping Study in Unilateral Muscle-Invasive Bladder Cancer**
Authors: Baekelandt L.¹, Decloedt H.¹, Giesen A.¹, Gajdos T.¹, Muilwijk T.¹, Akand M.¹, Van Den Broeck T.², Gevaert T.³, Joniau S.¹
Institutes: ¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²GZA Hospitals, Dept. of Urology, Antwerp, Belgium, ³AZ Klina, Dept. of pathology, Brasschaat, Belgium
-

- P214** **Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: prospective surgical assessment from the NURE-Combo Trial**
Authors: Re C.¹, Pellegrino F.¹, Longoni M.¹, Scilipoti P.¹, De Angelis M.¹, Avesani G.¹, Mercinelli C.², Cigliola A.², Patanè D.², Raggi D.², Lucianò R.³, Colombo R.¹, Gandaglia G.¹, Briganti A.¹, Montorsi F.¹, Necchi A.², Moschini M.¹
Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy
- P229** **A real-world study from two centers regarding the combination treatment of Disitamab vedotin and immune checkpoint inhibitors for locally advanced bladder urothelial carcinoma: a novel bladder-preserving strategy**
Authors: Wei Y.¹, Jianhui C.²
Institutes: ¹Fujian Provincial Hospital, Dept. of Urology, Fuzhou, China, ²Fujian Medical University Union Hospital, Dept. of Urology, Fuzhou, China
- P225** **Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial).**
Authors: Racioppi M.¹, Moosavi S.K.¹, Bizzarri F.P.¹, Scarciglia E.¹, Russo P.¹, Palermo G.¹, Sparagna I.², Allitto A.R.³, Ciccacese C.⁴, Tagliaferri L.³, Boldrini L.³, Gambacorta M.A.³, Valentini V.³, Tortora G.⁴, Iacovelli R.⁴
Institutes: ¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Urology, Rome, Italy, ²Università Cattolica del Sacro Cuore, Dept. of Medical Oncology, Rome, Italy, ³Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Radiation Therapy Department, Rome, Italy, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Medical Oncology, Rome, Italy
- 11:06 - 11:27**
- P216** **Stentless Florence Robotic Intracorporeal Neobladder (FloRIN), a feasibility prospective randomized clinical trial.**
Authors: Lambertini L., Di Maida F., Cadenar A., Nardoni S.N., Francesca V.F., Grosso A.A.G., Gajo L.G., Coco S., Paganelli D.P., Sandulli A.S., Fantechi R.F., Tuccio A., Vittori G.V., Mari A.M., Minervini A.M.
Institutes: Careggi Hospital University of Florence, Dept. of Experimental and Clinical Medicine Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy

- P212** **Temporal Trends in Urinary Diversion Among Patients Undergoing Radical Cystectomy from 1986 to 2022: Single-Center Evaluation of 2,224 Cases**
Authors: Duwe G.¹, Wiesmann C.¹, Banasiewicz K.E.¹, Wagner I.¹, Fischer N.D.¹, Frey L.J.¹, Haack M.¹, Mager R.¹, Höfner T.², Sparwasser P.³, Tsaour I.³, Kamal M.M.¹, Thomas C.⁴, Brandt M.P.¹, Haferkamp A.¹
Institutes: ¹University Medical Center of the Johannes Gutenberg-University Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²Ordensklinikum Linz Elisabethinen, Dept. of Urology, Linz, Austria, ³University Hospital and Faculty of Medicine Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ⁴University Hospital Carl Gustav-Carus TU Dresden, Dept. of Urology, Dresden, Germany
- P217** **Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: Is time for a paradigm shift in surgical treatment?**
Authors: Flammia R.S., Tuderti G., Mastroianni R., Brassetti A., Bove A.M., Proietti F., Misuraca L., D'Annunzio S., Chiacchio G., Minore A., Basile S., Anceschi U., Ferriero M.C., Guaglianone S., Leonardo C., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- P205** **Oncological Impact of Perioperative Blood Transfusion in Bladder Cancer Patients Undergoing Radical Cystectomy: Do We Need to Consider Storage Time of Blood Units, Donor Age or Gender Matching?**
Authors: Ebner B.¹, Franka F.¹, Volz Y.¹, Eismann L.¹, Hermans J.¹, Buchner A.¹, Enzinger B.¹, Weinhold P.¹, Wichmann C.², Stief C.G.¹, Humpe A.², Pyrgidis N.¹, Schulz G.B.¹
Institutes: ¹Ludwig Maximilians University, Dept. of Urology, Munich, Germany, ²Ludwig Maximilians University, Transfusion Medicine - Cell Therapeutics - Haemostaseology, Munich, Germany
- P211** **Radical cystectomy in patients over 80 years of age: comparison of age and common preoperative geriatric assessment scores in predicting 30-days postoperative morbidity in a monocentric cohort of 429 patients**
Authors: Duwe G.¹, Wagner I.¹, Banasiewicz K.E.¹, Frey L.J.¹, Fischer N.D.¹, Rölz N.¹, Haack M.¹, Mager R.¹, Sparwasser P.², Tsaour I.², Kamal M.M.¹, Haferkamp A.¹, Brandt M.P.¹, Höfner T.³
Institutes: ¹University Medical Center of the Johannes Gutenberg-University Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Hospital and Faculty of Medicine Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ³Ordensklinikum Linz Elisabethinen, Dept. of Urology, Linz, Austria
- P219** **Long-term follow-up of capsule-preserving radical cystectomy: a multicenter experience**
Authors: Xu P.¹, Chen C.X.¹, Cheng J.Z.¹, Chen B.S.¹, Liu C.X.¹, Chi N.², Chen C.Q.³, Xu A.B.¹
Institutes: ¹Zhujiang Hospital, Dept. of Urology, Guangzhou, China, ²Inner Mongolia Autonomous Region People's Hospital, Dept. of Urology, Hohhot, China, ³Ningde Municipal hospital of Ningde Normal university, Dept. of Urology, Ningde, China
-

- P210** **Utility of intravenous indocyanine green to evaluate distal ureteral vascularity during robot-assisted radical cystectomy with intracorporeal urinary diversion**
Authors: Carbonell E., Muní M., Martínez C., Alfambra H., Pagès R., Villalba E., Peradejordi M., Tello A., Mercader C., Sierra A., Vilaseca A., Ribal M.J., Alcaraz A., Musquera M., Martos R.
Institutes: Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain
- 11:27 - 11:57** **Screen D: Oncological outcomes of patients with muscle-invasive bladder cancer**
- P231** **Assessing Predictive Factors for Disease-Free Survival (DFS) and Overall Survival (OS) in Patients Eligible for Adjuvant Immunotherapy (IO) Following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC).**
Authors: Foschi N.¹, Ciccicarese C.², Russo P.¹, Marino F.¹, Rossi F.¹, Maioriello G.¹, Anghelone A.², Filomena G.B.¹, Fantasia F.¹, Tortora G.², Iacovelli R.²
Institutes: ¹Gemelli Hospital, Dept. of Urology, Rome, Italy, ²Gemelli Hospital, Dept. of Oncology, Rome, Italy
- P208** **Comparison of the Efficacy of PD-1/L1 Antibodies in Conventional Bladder Cancer and Bladder Cancer with Histological Variations**
Authors: Shiwang H., Jia K., Shen C., Zhang Z., Niu Y., Hu H.
Institutes: Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China
- P206** **What is the real-world eligibility rate for bladder preservation treatment in patients with muscle-invasive bladder cancer?**
Authors: Abu Ghanem Y.¹, Omar K.², Kam J.¹, Mensah E.¹, Mohamed G.¹, Nair R.¹, Thurairaja R.¹, Khan S.¹
Institutes: ¹Guys and St Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²King's College Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- P226** **Addition of neoadjuvant chemotherapy to a quadrifecta composite improves the oncologic outcomes reporting of patients treated with radical cystectomy for bladder cancer**
Authors: Mancon S.¹, Soria F.², Moschini M.³, Laukhtina E.⁴, Hurle R.⁵, Antonelli A.⁶, Yuen-Chun Teoh J.⁷, Shariat S.F.⁴, Pradere B.⁸, D'Andrea D.⁴
Institutes: ¹Humanitas University, Biomedical Science, Pieve Emanuele, Italy, ²Torino School of Medicine, Dept. of Urology, Turin, Italy, ³Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵IRCCS Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ⁶Azienda Ospedaliera Universitaria Integrata Di Verona, Dept. of Urology, Verona, Italy, ⁷The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁸Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

P227

The impact of venous thromboembolism on bladder cancer patients undergoing open or minimally-invasive radical cystectomy in the united states: perioperative outcomes and health-care costs from insurance claims data

Authors: Del Giudice F.¹, Tresh A.², Basran S.², Belladelli F.³, De Berardinis E.¹, Asero V.¹, Scornajenghi C.M.¹, Carino D.¹, Ferro M.³, Busetto G.M.⁴, Crocetto F.⁵, Balsamo R.⁶, Barone B.⁵, Pradere B.⁷, Krajewski W.⁸, Nowak L.⁸, Szydelko T.⁹, Moschini M.¹⁰, Mari A.¹¹, Rane A.¹², Challacombe B.¹³, Nair R.¹³, Chung B.I.²

Institutes: ¹Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ²Stanford University, Dept. of Urology, Stanford, United States of America, ³IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴Azienda Ospedaliera Universitaria Ospedali Riuniti di Foggia, Dipartimento di Scienze Mediche e Chirurgiche dell'Università di Foggia, Foggia, Italy, ⁵Reproductive Sciences and Odontostomatology University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁶AORN Ospedali dei Colli Monaldi Hospital, Unit of Urology, Naples, Italy, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Wroclaw Medical University, Dept. of Urology, Wrocław, Poland, ⁹4th Clinical Military Hospital, Clinical Department of Urology, Wrocław, Poland, ¹⁰IRCCS San Raffaele Hospital, Urological Research Institute, Milan, Italy, ¹¹University of Florence, Dept. of Experimental and Clinical Medicine Oncologic Minimally Invasive Urology and Andrology Unit, Florence, Italy, ¹²East Surrey Hospitals, Dept. of Urology, Surrey, United Kingdom, ¹³Guy's and St. Thomas Hospitals, Dept. of Urology, London, United Kingdom

P207

Is adjuvant immunotherapy following cystectomy a bandage for inadequate surgery?

Authors: Kjøbli E.¹, Salvesen Ø.², Gharib-Alhaug B.³, Gudbrandsdottir G.⁴, Karlsvik A.K.¹, Lilleaasen G.⁵, Larsen M.⁶, Roaldsen M.⁶, Mueller S.⁵, Haug E.S.⁷, Beisland C.⁴

Institutes: ¹St. Olavs Hospital Trondheim University Hospital Trondheim, Dept. of Surgery, Trondheim, Norway, ²Norwegian University of Science and Technology NTNU, Dept. of Clinical and Molecular Medicine, Trondheim, Norway, ³Oslo University Hospital, Dept. of Urology, Oslo, Norway, ⁴Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ⁵Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ⁶Tromsø University Hospital of North Norway, Dept. of Urology, Tromsø, Norway, ⁷Vestfold Hospital Trust, Dept. of Urology, Tønsberg, Norway

Impact of EAU Prostate Cancer Guidelines

Thematic Session

07 April 2024
10:45 - 12:15

Location Green Area, eURO Auditorium 1
Chairs P. Cornford, Liverpool (GB)
S. Gillessen Sommer, Bellinzona (CH)

10:45 - 10:47	Introduction P. Cornford, Liverpool (GB)
10:47 - 11:22	Case discussion Active surveillance vs. focal therapy intermediate-risk disease
10:47 - 10:52	Case presentation D. Eberli, Zürich (CH)
10:52 - 11:02	Active surveillance S. Carlsson, New York (US)
11:02 - 11:12	Focal therapy H.U. Ahmed, London (GB)
11:12 - 11:17	The patient perspective E. Briers, Hasselt (BE)
11:17 - 11:22	Conclusion: What do the guidelines say D. Eberli, Zürich (CH)
11:22 - 12:12	Case discussion Management of nodal disease (N1/cN1)
11:22 - 11:32	Role of modern imaging (PSMA-PET) in managing nodal disease D. Oprea-Lager, Amsterdam (NL)
11:32 - 11:37	Case presentation P. Cornford, Liverpool (GB)
11:37 - 11:47	The role of surgery D. Tilki, Hamburg (DE)
11:47 - 11:57	The role of radiotherapy V. Fonteyne, Ghent (BE)
11:57 - 12:07	The role of systemic therapy S. Gillessen Sommer, Bellinzona (CH)
12:07 - 12:12	Conclusion: What do the guidelines say P. Cornford, Liverpool (GB)
12:12 - 12:15	Session summary P. Cornford, Liverpool (GB)

Controversies on EAU Guidelines: Neurourology, pediatric urology and infections

Thematic Session

07 April 2024
10:45 - 12:15

Location Purple Area, eURO Auditorium 2
Chairs B. Blok, Rotterdam (NL)
G. Bogaert, Leuven (BE)
G. Bonkat, Basel (CH)

Learning objectives

Treatment of varicocele in adolescents is still discussed quite controversially. The panelists will present different scenarios and present current evidence based data to support the various treatment options. Special emphasis will focus on possible long term consequences and outcome. Participants should be able to leave the session with a better evidence based knowledge of how to address different clinical presentations of adolescent varicocele.

10:45 - 10:47

Introduction

G. Bonkat, Basel (CH)

10:47 - 11:16

Case discussion Surgical treatment for detrusor sphincter dyssynergia (DSD) is the way to go

Moderator B. Blok, Rotterdam (NL)

10:47 - 10:50

Case presentation

B. Blok, Rotterdam (NL)

10:50 - 10:58

Yes

S. Musco, Firenze (IT)

10:58 - 11:06

No

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

11:06 - 11:16

Discussion

11:16 - 11:45

Case discussion Is varicocele treatment in teenagers of any benefit at all?

Moderator G. Bogaert, Leuven (BE)

11:16 - 11:19

Case presentation

M.S. Skott, Aarhus (DK)

11:19 - 11:27

Yes

J.S.L.T. Quaedackers, Groningen (NL)

11:27 - 11:35

No

U.K. Kennedy, Zurich (CH)

11:35 - 11:45

Discussion

11:45 - 12:14

Case discussion Vaccination and oestrogen therapy for treatment of recurrent UTIs: Does the evidence support this?

Moderator G. Bonkat, Basel (CH)

11:45 - 11:48

Case presentation

G. Bonkat, Basel (CH)

Scientific Programme - EAU24

11:48 - 11:56

Evidence for vaccination

J. Kranz, Aachen (DE)

11:56 - 12:04

Evidence for hormone replacement

F.M.E. Wagenlehner, Giessen (DE)

12:04 - 12:14

Voting & discussion

12:14 - 12:15

Closing remarks

G. Bogaert, Leuven (BE)

Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC)

Thematic Session

07 April 2024
13:30 - 15:30

Location Green Area, eURO Auditorium 1
Chairs S. Gillessen Sommer, Bellinzona (CH)
B. Tombal, Brussels (BE)

13:30 - 13:35	Introduction and background S. Gillessen Sommer, Bellinzona (CH)
13:35 - 14:50	Synchronous mHSPC: What are the treatment options and what are the goals of treatment?
13:35 - 13:40	Case presentation F. Turco, Turin (IT)
13:40 - 13:50	What is the evidence for systemic therapy in synchronous low-volume mHSPC K. Fizazi, Villejuif (FR)
13:50 - 14:00	What is the evidence for RT T. Zilli, Genève (CH)
14:00 - 14:10	What is the evidence for surgery N. Fossati, Lugano (CH)
14:10 - 14:20	Germline genetic testing necessary and/or helpful? E. Castro, Madrid (ES)
14:20 - 14:30	What to test before start of hormonal treatment and what to monitor A. Omlin, Zürich (CH)
14:30 - 14:40	How to treat a frail and elderly patient in the same situation? S. Chowdhury, London (GB)
14:40 - 14:45	Summary B. Tombal, Brussels (BE)
14:45 - 14:50	Q&A
14:50 - 15:20	PSA persistence after radical prostatectomy
14:50 - 14:55	Case presentation P. Rajwa, Zabrze (PL)
14:55 - 15:05	Is all PSA persistence created equal? Definition and diagnostic work-up D. Tilki, Hamburg (DE)
15:05 - 15:15	Optimal treatment in the case of PSA persistence To be confirmed
15:15 - 15:20	Summary and Q&A K. Fizazi, Villejuif (FR)
15:20 - 15:30	Outlook for APCCC 2024 S. Gillessen Sommer, Bellinzona (CH)

New developments and innovations in endourology

Meeting of the EAU Section of Urolithiasis (EULIS)

07 April 2024
13:30 - 15:30

Location Purple Area, N01
Chair C.C. Seitz, Vienna (AT)

Learning objectives

Continuous technological innovation alongside with the effective application in endourology influences treatment concepts. This EULIS session takes a close look on new insights particularly on stone recurrences, metabolomics and future orientated developments and their application in practice demonstrated by experts sharing their tips and tricks.

13:30 - 13:31

Welcome and introduction

C.C. Seitz, Vienna (AT)

13:31 - 13:52

Developments in stone metabolics

Moderators O.R. Durutovic, Belgrade (RS)
C.A. Wagner, Zurich (CH)

13:31 - 13:38

Definition and prediction of kidney stone recurrence

J. Sayer, Newcastle upon Tyne (GB)

13:38 - 13:45

The role of metabolomics in kidney stone disease

P.M. Ferraro, Verona (IT)

13:45 - 13:52

What does the urologist need to know about new developments in hyperoxaluria?

To be confirmed

13:52 - 14:20

Challenging the guidelines

Moderators A. Bujons Tur, Barcelona (ES)
B. Somani, Southampton (GB)

13:52 - 13:59

Should we use cumulative stone diameter or stone volume for guidance in stone treatment?

T. Taily, Ghent (BE)

13:59 - 14:06

Quality of life in endourology: Impact on treatment decisions?

G. Mazzon, Bassano del Grappa (IT)

14:06 - 14:13

Are fluoroscopy-free procedures to come in endourology?

A. Skolarikos, Athens (GR)

14:13 - 14:20

Follow-up imaging strategies - Overdetection of fragments: An issue?

V. Jahrreiss, Vienna (AT)

14:20 - 14:48

Evolution of percutaneous nephrolithotomy

Moderators G.M. Kamphuis, Amsterdam (NL)
E. Liatsikos, Patras (GR)

14:20 - 14:27

Lapaxy in percutaneous nephrolithotomy: From physics to the OR

E. De Lorenzis, Milan (IT)

14:27 - 14:34

Non-papillary puncture: An evolutionary step for percutaneous nephrolithotomy

P. Kallidonis, Patras (GR)

14:34 - 14:41	Is there still a place for percutaneous nephrolithotomy in current times? From classic to special indications A. Budía Alba, Valencia (ES)				
14:41 - 14:48	Robotic surgery complementary or an alternative to percutaneous nephrolithotomy? E. Montanari, Milan (IT)				
14:48 - 15:18	Advances in technology Moderators P.J.S. Osther, Vejle (DK) A. Pietropaolo, Southampton (GB)				
14:48 - 14:58	Debate Is vacuum assisted stone surgery a game changer in endourology? <table><tr><td>Yes</td><td>V. Gauhar, Singapore (SG)</td></tr><tr><td>No</td><td>M. Straub, Munich (DE)</td></tr></table>	Yes	V. Gauhar, Singapore (SG)	No	M. Straub, Munich (DE)
Yes	V. Gauhar, Singapore (SG)				
No	M. Straub, Munich (DE)				
14:58 - 15:03	Robotics in ureteroscopy L.B. Dragoş, Cambridge (GB)				
15:03 - 15:08	Optimal laser settings for stones E.X. Keller, Zürich (CH)				
15:08 - 15:13	Precision medicine: Robotic guided percutaneous access, never have a stressed puncture again? U. Nagele, Wörgl (AT)				
15:13 - 15:18	Burst-wave lithotripsy: All set? M. Özsoy, Vienna (AT)				
15:18 - 15:28	Video presentations: Ureteroscopy/percutaneous nephrolithotomy Moderators K. Sarica, Istanbul (TR) C.C. Seitz, Vienna (AT)				
15:18 - 15:23	Flexible ureteroscopy: Traditional ureteral access sheath vs. Suction ureteral access sheath? G.H. Zeng, Guangzhou (CN)				
15:23 - 15:28	Percutaneous nephrolithotomy - Puncture W. Gamal, Sohag (EG)				
15:28 - 15:30	Closing remarks C.C. Seitz, Vienna (AT)				

Uro-Technology welcomes computer-assisted systems and artificial intelligence applications

Meeting of the EAU Section of Uro-Technology (ESUT)

07 April 2024
13:30 - 15:30

Location Green Area, N04
Chair To be confirmed

13:30 - 13:35	Introduction To be confirmed
13:35 - 14:03	Current Innovations and minimally invasive therapy options in laparoscopy (New technologies in laparoscopy theatre) Moderators F. Porpiglia, Turin (IT) D. Veneziano, New York (US)
13:35 - 13:42	Mentoring platforms and their applications in surgical training D. Veneziano, New York (US)
13:42 - 13:49	The Place of Metaverse 3D surgical planning in minimally invasive laparoscopic surgery C. Fiori, Orbassano (IT)
13:49 - 13:56	Intra-operative visual guidance through artificial Intelligence P. De Backer, Ghent (BE)
13:56 - 14:03	New computer-assisted miniaturized surgical platforms: Is this the future? To be confirmed
14:03 - 14:52	New technologies and innovations in endoscopic surgery Moderators To be confirmed J. Rassweiler, Krems - Stein (DE)
14:03 - 14:10	Computer-aided platforms for percutaneous kidney access P. Kallidonis, Patras (GR)
14:10 - 14:17	Auris Monarch platform for advanced endoscopic stone surgery M.M. Desai, Los Angeles (US)
14:17 - 14:24	ILY robotic ureteroscopy W. Krajewski, Wrocław (PL)
14:24 - 14:31	Avicenna Roboflex ureteroscopy robot K. Sarica, Istanbul (TR)
14:31 - 14:38	Virtuoso, mini endoscopic-robotic arms for transurethral surgeries D. Herrell, Nashville (US)
14:38 - 14:45	Endoluminal surgical system and applications in urology B. Geavlete, Bucharest (RO)
14:45 - 14:52	Computer-assisted, image-guided waterjet ablation of the prostate To be confirmed
14:52 - 15:30	Computer-assisted imaging and navigation in urology Moderators G. Bozzini, Gallarate (IT) P.J. Zondervan, Amsterdam (NL)

Scientific Programme - EAU24

14:52 - 14:59	Image-guided focal therapy in urology: What is new E. Barret, Paris (FR)
14:59 - 15:06	Artificial intelligence applications and imaging for bladder pathologies during endoscopic operations G.M. Kamphuis, Amsterdam (NL)
15:06 - 15:13	Virtual biopsy for urologic malignancies G. Cacciamani, Los Angeles (US)
15:13 - 15:20	Artificial intelligence-based visual intelligence systems F. Porpiglia, Turin (IT)
15:20 - 15:30	Discussion and closing remarks To be confirmed

Kidney transplant: Andrology issues, research, paediatric KT, surgical and clinical scenarios to teach young urologists

Meeting of the EAU Section of Transplantation Urology (ESTU)

07 April 2024
13:30 - 16:30

Location Green Area, W01
Chairs To be confirmed
E. Lledó García, Madrid (ES)
M. Musquera Felip, Barcelona (ES)

13:30 - 13:35

Welcome and introduction

13:35 - 14:20

Kidney transplant and andrology issues

Moderators C. Bettocchi, Foggia (IT)
E. Lledó García, Madrid (ES)
K. Van Renterghem, Hasselt (BE)

13:35 - 13:45

Prevalence or erectile dysfunction in patients before/after kidney transplant

G.I. Russo, Catania (IT)

13:45 - 13:55

Male infertility in ESRD patients: What are the best options for treatment?

J.M. Corral Molina, Barcelona (ES)

13:55 - 14:05

Surgical treatment in erectile dysfunction KT patients: Still the third line?

P. Capogrosso, Varese (IT)

14:05 - 14:15

Female sexual dysfunction with ESRD/Kidney Tx

A. Zachariou, Ioannina (GR)

14:15 - 14:20

Conclusions

14:20 - 14:45

Kidney transplant and research: The lab and the clinic

Moderators J.D.J.M. Branchereau, Nantes (FR)
V. Gomez Dos Santos, Madrid (ES)

14:20 - 14:30

Artificial intelligence and kidney transplantation

To be confirmed

14:30 - 14:40

New options in organ perfusion preservation

S. Hosgood, Cambridge (GB)

14:40 - 14:45

Conclusions

14:45 - 15:10

Kidney transplant and nephrological issues

14:45 - 14:55

To be confirmed
Motivations and challenges to self-management in kidney transplant recipients: The importance of the attitude of the patient

Moderator J. Pascual, Madrid (ES)

14:55 - 15:05	J. Pascual, Madrid (ES) The immunosuppression of the 21st century	Moderator	To be confirmed
15:05 - 15:10	Conclusions		
15:10 - 15:40	Kidney transplant and the young urologists: Urological and nephrological problems		
	Moderators	J. Gómez Rivas, Madrid (ES) J.D. Olsburgh, London (GB) J. Pascual, Madrid (ES) A. Territo, Barcelona (ES)	
15:10 - 15:20	NHBD initially non-functioning KT: How to manage?		To be confirmed
15:20 - 15:30	Urinary leak in the first week: Surgery vs. non-surgery?		M.I Dönmez, Istanbul (TR)
15:30 - 15:40	Hypertension 2 years after kidney transplant: An arterial stenosis		L. Peri Cusi, Barcelona (ES)
15:40 - 16:00	Conference of the big master		
	Moderators	To be confirmed E. Lledó García, Madrid (ES)	
15:40 - 16:00	My journey in kidney transplant		G. Ciancio, Miami (US)
16:00 - 16:15	Rene-Küss Prize 2024		
16:15 - 16:30	Closing remarks		

How to individualize therapy in uro-oncology

Joint meeting of the EAU Section of Uro-pathology (ESUP) and the EAU Section of Urological Research (ESUR)

07 April 2024
13:30 - 16:30

Location Green Area, W03
Chairs M. Colecchia, Milan (IT)
C. Jeronimo, Porto (PT)

13:30 - 13:35

Welcome and introduction

C. Jeronimo, Porto (PT)

13:35 - 14:25

Clinical and biological rationale of combination therapies in renal cell carcinoma

Moderators M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)

13:35 - 13:47

Checkpoint inhibition and TKI: Clinical evidence

R. Pichler, Innsbruck (AT)

13:47 - 13:59

Immunological rationale of combination with VEGF/VEGFR inhibition

E. Nossner, Munich (DE)

13:59 - 14:11

Any advance with the new WHO classification of renal tumours?

A. Lopez-Beltran, Lisbon (PT)

14:11 - 14:25

Discussion

14:25 - 15:00

The role of chemo- (and radiation) therapy for ICI in bladder cancer: Sequence or combination?

Moderators M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)

14:25 - 14:37

Clinical evidence

T. Powles, London (GB)

14:37 - 14:49

Biological rationale

S. Lerner, Houston (US)

14:49 - 15:00

Discussion

15:00 - 16:25

New approaches to individualise therapy

Moderators I. Ahmad, Glasgow (GB)
To be confirmed
K.A. Tasken, Oslo (NO)

15:00 - 15:10

Histological subtyping: The role of molecular pathologist

M. Brunelli, Verona (IT)

15:10 - 15:20

Deep learning in cancer pathology: A new generation of clinical biomarkers

To be confirmed

15:20 - 15:30

Spatial transcriptomics/proteomics: Understanding the tumour heterogeneity

C. Le Magnen, Basel (CH)

15:30 - 15:40

Spatial transcriptomics/proteomics: Understanding the tumour complexity

M. Eckstein, Erlangen (DE)

Scientific Programme - EAU24

15:40 - 15:55	Discussion
15:55 - 16:05	In vitro model systems to select the best therapy for each patient To be confirmed
16:05 - 16:15	In vivo model systems to select the best therapy for each patient J. Paramio, Madrid (ES)
16:15 - 16:25	Discussion
16:25 - 16:30	Closing remarks M. Colecchia, Milan (IT)

Surgical innovations: New techniques for safer procedures

Video session 01

05 April 2024
10:45 - 12:15

Location Green Area, S04
Chairs To be confirmed
To be confirmed
To be confirmed

- V001** **Endoscopic treatment of ureteral strictures with use of self-expanding ureteral stents.**
Authors: Kowalski F., Kuffel B., Lipowski P., Ostrowski A., Wilamowski J., Adamowicz J., Drewa T.
Institutes: A.Jurasz Memorial University Hospital No 1, Dept. of Urology, Bydgoszcz, Poland
- V002** **Ileal Ureter Replacement and ileocystoplasty for the Treatment of Bilateral Ureteral Strictures and bladder contracture: Technique and Outcomes**
Authors: Wenzhi G., Xuesong L.
Institutes: Peking University First Hospital Miyun Hospital, Dept. of Urology, Beijing, China
- V003** **Negative Predictive Value of Intraoperative Fluorescence-guided Surgery of PSMA-Positive Prostate Cancer During Prostatectomy**
Authors: Contieri R.¹, de Barros H.A.¹, Stibbe J.A.², Vahrmeijer A.L.², Burggraaf J.², Van Der Poel H.G.¹
Institutes: ¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Leiden University Medical Center, Dept. of Surgery, Leiden, The Netherlands
- V004** **Laser Speckle Contrast Imaging to detect prostatic artery during RALP**
Authors: Saikali S., Jaber A., Gamal A., Covas Moschovas M., Rogers T., Patel E., Patel V.
Institutes: Global Robotic Institute Adventhealth, Dept. of Uro-Oncology, Celebration, United States of America
- V005** **Prophylactic Lymphovenous Bypass during Inguinal Lymphadenectomy for Penile Cancer: A Promising Strategy to Prevent Lymphedema of the Lower Extremities**
Authors: Di Nardo N.¹, Scaglioni M.², Zahiti L.¹, Mattei A.¹, Fankhauser C.D.¹
Institutes: ¹Lucerne Cantonal Hospital, Dept. of Urology, Lucerne, Switzerland, ²Lucerne Cantonal Hospital, Dept. of Plastic Surgery and Hand Surgery, Lucerne, Switzerland
- V006** **Utility of 3D-models in the planning and outcome assessment of laparoscopic resolution of urinary tract complications after kidney transplantation**
Authors: Burgos Revilla F.J., Sanz-Mayayo E., Lorca J., Laso I., López-Curtis D., Díez-Nicolás V., Arias F., Gómez-Dos-santos V.
Institutes: Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Dept. of Urology, Madrid, Spain
- V007** **Robotic excision of extruded mid-urethral sling and concomitant bladder neck fascial sling placement**
Authors: Haudebert C., Richard C., Hascoet J., Peyronnet B.
Institutes: Hospital Center of Rennes, Dept. of Urology, Rennes, France

V008

Robotical transperitoneal release of both pudendal and cluneal nerves for entrapment neuralgias

Authors: Celhay O., Calvarin E., Gomez C.G., Susperregui J.S., Pasticier G.P., Palamara C.P., Monleon L.M., Michiels C.M.

Institutes: Clinique Tivoli, Dept. of Urology, Bordeaux, France

Take 'that' antibiotic away!

Thematic Session

07 April 2024
13:45 - 15:15

Location Purple Area, eURO Auditorium 2
Chairs G. Bonkat, Basel (CH)
Z. Tandođdu, London (GB)

13:45 - 14:20	Combatting antimicrobial resistance in urology: Innovations, challenges, and strategies for a resilient future
13:45 - 13:50	Case presentation: Introduction, background and urosepsis with MDR pathogens H.M. Çek, Edirne (TR)
13:50 - 14:00	Point of diagnosis to direct treatment: Emerging technologies To be confirmed
14:00 - 14:10	State-of-the-art lecture Non-antibiotic options for management of rUTIs: New evidence from a RCT C. Harding, Newcastle upon Tyne (GB)
14:10 - 14:20	Do we need more evidence to change practice for the guidelines? Methanime hippurate the old kid back on the block F.M.E. Wagenlehner, Giessen (DE)
14:20 - 14:40	Case discussion Management of rUTIs: Strategies to employ to reduce burden of antibiotics
14:20 - 14:25	Case presentation I & II To be confirmed M. Vallée, Poitiers (FR)
14:25 - 14:40	Discussion
	Panel
	F.M.E. Wagenlehner, Giessen (DE) C. Harding, Newcastle upon Tyne (GB) T.E. Bjerklund Johansen, Oslo (NO)
14:40 - 14:45	Implementation of the EAU Guidelines on infection: IMAGINE N.M. Pereira Azevedo, Porto (PT)
14:45 - 15:15	How to avoid complications and sepsis due to prostate biopsies
14:45 - 14:50	Guidelines recommendation: Transperineal R.C.N. Van Den Bergh, Utrecht (NL)
14:50 - 14:55	Challenge the guidelines: Transrectal is still safe enough P. Albers, Düsseldorf (DE)
14:55 - 15:00	Statement on current literature and trials in progress J. Kranz, Aachen (DE)
15:00 - 15:15	Discussion

EAU Guidelines: Artificial intelligence and new clinical insights

Abstract session 25

07 April 2024
13:45 - 15:15

Location Green Area, N03
Chairs To be confirmed
M.C. Lapitan, Manila (PH)
M.I. Omar, Aberdeen (GB)
M.J. Ribal Caparros, Barcelona (ES)

13:45 - 13:47

Introduction

A0857

Quality of information and appropriateness of ChatGPT outputs for urological trauma

Authors: Gallo G., Mancini E., Lombardo R., Turchi B., Fiasconaro D., Stira J., Gravina C., Tema G., Nacchia A., Guarnotta G., Cicione A., Pastore A., Al Salhi Y., Carbone A., Franco G., Sciarra A., Tubaro A., Romagnoli M., Santoro G., De Nunzio C.

Institutes: Sapienza University of Rome, Dept. of Urology, Rome, Italy

A0850

The role of artificial intelligence in urological cancers: An overview of systematic reviews.

Authors: Sakalis V.¹, Pang K.², Rai B.³, Moris L.⁴, Yuan Y.⁵, N'dow J.⁶, Omar M.I.⁶

Institutes: ¹Hippokrateion General Hospital of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ²University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Freeman Hospital The Newcastle upon Tyne Hospitals NHS Foundation Trust, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ⁴University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁵McMaster University, Division of Gastroenterology Cochrane UGPD Group, Medicine Health Sciences Center, Hamilton, Canada, ⁶University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom

A0855

Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric MRI (PIRADS/Likert 3-5) and negative initial biopsy. A systematic review

Authors: Grivas N.¹, Lardas M.², Linares Espinós E.³, Lam T.⁴, Rouviere O.⁵, Mottet N.⁶, Van Den Bergh R.⁷, Tilki D.⁸, Cornford P.⁹

Institutes: ¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²National and Kapodistrian University of Athens Sismanogleion Hospital, Dept. of Urology, Athens, Greece, ³Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ⁴Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, ⁵Hopital Edouard Herriot, Dept. of Urinary and Vascular Imaging, Lyon, France, ⁶University Hospital St. Etienne, Dept. of Urology, St. Etienne, France, ⁷Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁸Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ⁹Liverpool University Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom

A0852

Development of Prostate Cancer Typical Case Presentations and Their Usage in OPTIMA's Guideline Based Decision Support Tool

Authors: Murray C.¹, Beyer K.², Gandaglia G.³, Stabile A.³, Auweter S.⁴, Morariu A.⁴, Santiago I.⁵, Maclennan S.¹, Maclennan S.¹, Thomas M.⁶, Bjartell A.⁷, Cornford P.⁸, Kruger H.⁹, N'dow J.¹, Roobol M.², Omar M.I.¹

Institutes: ¹University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ³Vita-Salute San Raffaele University, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ⁴Smart Reporting, Dept. of Smart Reporting, Munich, Germany, ⁵European Association of Urology, Guidelines Office, Arnhem, The Netherlands, ⁶Roche, Basel, Switzerland, ⁷Lund University, Dept. of Translational Medicine, Lund, Sweden, ⁸Liverpool University Hospitals Foundation Trust, Dept. of Urology, Liverpool, United Kingdom, ⁹Pfizer, Medical Affairs, Berlin, Germany

A0844

Active Surveillance Follow-Up for Prostate Cancer: From Guidelines to Real-World Clinical Practice

Authors: Chiarelli G.¹, Cirulli G.O.¹, Finati M.¹, Stephens A.¹, Tinsley S.¹, Butaney M.¹, Arora S.¹, Sood A.², Carrieri G.³, Briganti A.⁴, Montorsi F.⁴, Lughezzani G.⁵, Buffi N.⁵, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Health System, VUI Center for Outcomes Research Analysis and Evaluation, Detroit, United States of America, ²MD Anderson, Dept. of Urology, Houston, United States of America, ³University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁴Università Vita-Salute San Raffaele, Division of Oncology - Unit of Urology, Milan, Italy, ⁵Humanitas University, Dept. of Urology, Milan, Italy

A0856

Patient- and tumour-related prognostic factors for urinary incontinence after radical prostatectomy for nonmetastatic prostate cancer: A systematic review and meta-analysis

Authors: Grivas N.¹, Lardas M.², Zattoni F.³, Berridge C.⁴, Cumberbatch M.⁵, Van Den Broeck T.⁶, Mottet N.⁷, Tilki D.⁸, Cornford P.⁹

Institutes: ¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²National and Kapodistrian University of Athens Sismanogleion Hospital, Dept. of Urology, Athens, Greece, ³Santa Maria della Misericordia University Hospital, Dept. of Urology, Udine, Italy, ⁴Worcestershire Acute Hospitals NHS Trust, Dept. of Urology, Redditch, United Kingdom, ⁵University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁶University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁷University Hospital St. Etienne, Dept. of Urology, St. Etienne, France, ⁸Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ⁹Royal Liverpool and Broadgreen Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom

A0851

Critical Appraisal of Systematic Reviews Cross-Referenced by the European Association of Urology (EAU) 2023 Guidelines on Prostate Cancer 2023 with AMSTAR 2 Tool

Authors: Alebraheem A., Imran A., Cheriyan A., Maclennan S., Omar M.I.

Institutes: University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom

A0859

AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer

Authors: Beyer K.¹, Bhattacharya Y.², Murray C.³, Smith E.J.², Boissier R.⁴, Borkowetz A.⁵, Dabestani S.⁶, Willemsse P.P.M.⁷, Maresca G.², Rivas J.G.M.², Rajwa P.², Lardas M.², Grivas N.², Sakalis V.², Evans-Axelsson S.⁸, Maclennan S.³, Auweter S.⁹, Thomas M.¹⁰, Bjartell A.¹¹, Cornford P.¹², Kruger H.¹³, N'dow J.³, Roobol M.¹, Omar M.I.³

Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²European Association of Urology, Guidelines Office, Arnhem, The Netherlands, ³University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁴Aix-Marseille Université, Dept. of Urology and Renal transplantation, Marseille, France, ⁵Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ⁶Kristianstad Central Hospital, Dept. of Urology, Kristianstad, Sweden, ⁷University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands, ⁸Bayer AG, Berlin, Germany, ⁹Smart Reporting, Dept. of Smart Reporting, Munich, Germany, ¹⁰Roche, Basel, Switzerland, ¹¹Lund University, Dept. of Translational Medicine, Lund, Sweden, ¹²Liverpool University Hospitals Foundation Trust, Dept. of Urology, Liverpool, United Kingdom, ¹³Pfizer, Medical Affairs, Berlin, Germany

A0853

OPTIMA prostate cancer care pathways - bridging clinical practice guidelines, real world evidence and artificial intelligence to enhance decision-making

Authors: Anselmo da Costa Santiago I.¹, Gómez Rivas J.², Maclennan S.³, Beyer K.⁴, Murray C.³, Smith E.J.⁵, Auweter S.⁶, Thomas M.⁷, Krüger H.⁸, N'dow J.³, Bjartell A.⁹, Cornford P.¹⁰, Roobol M.⁴, Omar M.I.³

Institutes: ¹Klinikum am Urban, Dept. of Urology, Berlin, Germany, ²Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ³University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁴Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ⁵European Association of Urology, Guidelines Office, Arnhem, The Netherlands, ⁶Smart Reporting GmbH, Optima Project, Munich, Germany, ⁷Roche Headquarters, Dept. of Integrated Health Care Solutions, Basel, Switzerland, ⁸Pfizer, Dept. of Oncology, Berlin, Germany, ⁹Lund University, Dept. of Urology, Lund, Sweden, ¹⁰University of Liverpool, Dept. of Urology, Liverpool, United Kingdom

A0849

Oncologic surveillance after surgical treatment for clinically localized kidney cancer – time for a revision? (OroCCR N.129)

Authors: Martini A.¹, Bernhard J.C.², Falagario U.G.³, Herman G.², Geshkovska A.², Khene Z.E.⁴, Audenet F.⁵, Champy C.⁶, Bruyere F.⁷, Rolland M.⁸, Waeckel T.⁹, Lorette M.¹⁰, Doumerc N.¹¹, Surlemont L.¹², Parier B.¹³, Tricard T.¹⁴, Branger N.¹⁵, Michel C.¹⁶, Fiard G.¹⁷, Fontenil A.¹⁸, Vallée M.¹⁹, Guillotreau J.²⁰, Bigot P.²¹, Beauval J.B.¹

Institutes: ¹La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ²CHU Bordeaux, Dept. of Urology, Bordeaux, France, ³University of Foggia, Dept. of Urology, Foggia, Italy, ⁴CHU Rennes, Dept. of Urology, Rennes, France, ⁵HEGP Paris, Dept. of Urology, Paris, France, ⁶CHU Henri-Mondor, Dept. of Urology, Créteil, France, ⁷CHU Tours, Dept. of Urology, Tours, France, ⁸CHU Lyon, Dept. of Urology, Lyon, France, ⁹CHU Caen, Dept. of Urology, Caen, France, ¹⁰CHU Lille, Dept. of Urology, Lille, France, ¹¹CHU Rangueil, Dept. of Urology, Toulouse, France, ¹²CHU Rouen, Dept. of Urology, Rouen, France, ¹³CHU Kremlin Bicetre, Dept. of Urology, Le Kremlin-Bicêtre, France, ¹⁴CHU Strasbourg, Dept. of Urology, Strasbourg, France, ¹⁵Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ¹⁶Hospital St Joseph, Dept. of Urology, Paris, France, ¹⁷CHU Grenoble, Dept. of Urology, Grenoble, France, ¹⁸CHU Nimes, Dept. of Urology, Nimes, France, ¹⁹CHU Poitiers, Dept. of Urology, Poitiers, France, ²⁰Pasteur Hospital, Dept. of Urology, Toulouse, France, ²¹CHU Angers, Dept. of Urology, Angers, France

A0854

Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

Authors: Mertens L.S.¹, Bruins H.M.², Contieri R.¹, Babjuk M.³, Bhavan R.⁴, Carrion Puig A.⁵, Dominguez Escrig J.L.⁶, Gontero P.⁷, Van Der Heijden A.G.⁸, Liedberg F.⁹, Mariappan P.¹⁰, Masson-Lecomte A.¹¹, Meijer R.P.¹², Mostafid H.¹³, Neuzillet Y.¹⁴, Pradere B.¹⁵, Van Rhijn B.W.G.¹, Roupret M.¹⁶, Seisen T.¹⁶, Soria F.⁷, Viktor S.³, Thalmann G.¹⁷, Xylinas E.¹⁸, Witjes F.⁸

Institutes: ¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Zuyderland Hospital, Dept. of Urology, Heerlen, The Netherlands, ³Charles University, Urological Clinic, Dept. of Urology, Prague, Czech Republic, ⁴Newcastle's Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁵Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ⁶Fundacion I.V.O., Dept. of Urology, Valencia, Spain, ⁷AOU Citta della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy, ⁸Radboud UMC, Dept. of Urology, Nijmegen, The Netherlands, ⁹Lund University, Dept. of Urology, Lund, Sweden, ¹⁰Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ¹¹Hopital Saint-Louis AP-HP, Dept. of Urology, Paris, France, ¹²UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹³Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, ¹⁴Hopital Foch, Dept. of Urology, Suresnes, France, ¹⁵Clinique La Croix du Sud, Dept. of Urology, Toulouse, France, ¹⁶AP-HP Sorbonne University, Dept. of Urology, Paris, France, ¹⁷University Hospital Inselspital, Dept. of Urology, Bern, Switzerland, ¹⁸Hopital Bichat, Dept. of Urology, Paris, France

A0858

The diagnostic accuracy of cystoscopy for detecting bladder cancer in adults presenting with haematuria: A Systematic Review from the European Association of Urology Guidelines Office

Authors: Devlies W.¹, Jong J.J.D.², Hofmann F.³, Bruins H.M.⁴, Zuiverloon T.C.M.², Smith E.J.⁵, Yuan Y.⁶, Van Rhijn B.W.G.⁷, Mostafid H.⁸, Santesso N.⁹, Violette P.¹⁰, Omar M.I.¹¹

Institutes: ¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ³Umeå University, Dept. of Urology, Luleå, Sweden, ⁴Zuyderland Medical Center, Dept. of Urology, Sittard-Geleen, The Netherlands, ⁵European Association of Urology, Guidelines Office, Arnhem, The Netherlands, ⁶McMaster University, Dept. of Medicine, Ontario, Canada, ⁷Netherlands Cancer Institute, Dept. of Surgical Oncology, Amsterdam, The Netherlands, ⁸Royal Surrey Hospital, Dept. of Urology, Guildford, United Kingdom, ⁹McMaster University, Dept. of Health Research Methods Evidence and Impact, Hamilton, Canada, ¹⁰McMaster University, Dept. of Surgery and Health Research Methods Evidence and Impact, Hamilton, Canada, ¹¹University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom

A0847

Clinical Application of Bladder MRI and Vesical Imaging-Reporting And Data System

Authors: Panebianco V.¹, Briganti A.², Boellaard T.N.³, Catto J.⁴, Compera E.⁵, Efstathiou J.⁶, Van Der Heijden A.G.⁷, Giannarini G.⁸, Girometti R.⁹, Mertens L.¹⁰, Takeuchi M.¹¹, Muglia V.F.¹², Narumi Y.¹³, Novara G.¹⁴, Pecoraro M.¹⁵, Roupret M.¹⁶, Sanguedolce F.¹⁷, Santini D.¹⁸, Shariat S.F.¹⁹, Simone G.²⁰, Vargas H.A.²¹, Woo S.²¹, Barentsz J.O.²², Witjes J.A.⁷

Institutes: ¹Sapienza University of Rome, Dept. of Radiological Sciences, Rome, Italy, ²Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ³Netherlands Cancer Institute, Dept. of Radiology, Nijmegen, The Netherlands, ⁴University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ⁵Sorbonne University, Dept. of Pathology, Paris, France, ⁶Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America, ⁷Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁸Academic Medical Centre Santa Maria della Misericordia, Urology Unit, Udine, Italy, ⁹Academic Medical Centre Santa Maria della Misericordia, Institute of Radiology, Udine, Italy, ¹⁰Netherlands Cancer Institute, Dept. of Surgical Oncology, Amsterdam, The Netherlands, ¹¹Radiolonet Tokai, Dept. of Radiology, Nagoya, Japan, ¹²University of Sao Paulo, Dept. of Medical Images, Ribeirao Preto, Brazil, ¹³Tachibana University, Dept. of Healthcare, Kyoto, Japan, ¹⁴University of Padua, Urology Clinic, Padua, Italy, ¹⁵Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ¹⁶Sorbonne University, Dept. of Urology, Paris, France, ¹⁷Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁸Sapienza University, Dept. of Oncology, Rome, Italy, ¹⁹Medical University Vienna, Dept. of Urology, Vienna, Austria, ²⁰IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²¹NYU Grossman School of Medicine, Dept. of Radiology, New York, United States of America, ²²Radboudumc, Dept. of Radiology and Nuclear Medicine, Nijmegen, The Netherlands

A0845

Individual Patient Data Validation of the Definitions of BCG Failure in Patients with Non-muscle Invasive Urothelial Carcinoma of the Bladder: an international multi-centre retrospective study

Authors: Gontero P.¹, Soria F.¹, Babjuk M.², Burger M.³, Comperat E.⁴, Mostafid H.⁵, Palou Redorta J.⁶, Roupert M.⁷, Van Rhijn B.W.⁸, Zigeuner R.⁹, Shariat S.F.¹⁰, Cohen D.¹¹, Masson-Lecomte A.¹², Xylinas E.¹³, Mariappan P.¹⁴, Rai B.P.¹⁵, Capoun O.², Soukup V.², Thalmann G.¹⁶, Pradere B.¹⁷, Seisen T.¹⁸, Dominguez-Escrig J.L.¹⁹, Liedberg F.²⁰, Sylvester R.J.²¹

Institutes: ¹Torino School of Medicine, Division of Urology, Turin, Italy, ²Teaching Hospital Motol and 2nd Faculty of Medicine Charles University, Dept. of Urology, Prague, Czech Republic, ³Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ⁴Medical University of Vienna, Dept. of Pathology, Vienna, Austria, ⁵The Stokes Centre for Urology Royal Surrey Hospital, Dept. of Urology, Guildford, United Kingdom, ⁶Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁷Sorbonne University AP-HP, Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, ⁸Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Surgical Oncology, Dept. of Urology, Amsterdam, The Netherlands, ⁹Medical University of Graz, Dept. of Urology, Graz, Austria, ¹⁰Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹¹Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹²Université de Paris APHP Saint Louis Hospital, Dept. of Urology, Paris, France, ¹³Bichat-Claude Bernard Hospital, Dept. of Urology, Paris, France, ¹⁴Edinburgh Bladder Cancer Surgery, Dept. of Urology, Edinburgh, United Kingdom, ¹⁵Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ¹⁶University Hospital Inselspital, Dept. of Urology, Berne, Switzerland, ¹⁷UroSud Clinique La Croix du Sud, Dept. of Urology, Toulouse, France, ¹⁸GRC 5 Predictive Onco-Uro, Dept. of Urology, Paris, France, ¹⁹Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ²⁰Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ²¹European Association of Urology, Arnhem, The Netherlands

A0846

Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria

Authors: Rai B.P.¹, Escrig J.L.D.², Vale L.S.³, Capoun O.⁴, Soukup V.⁴, Bruins H.M.⁵, Yuan Y.⁶, Violette P.D.⁷, Santesso N.⁷, Rhijn B.W.G.V.⁸, Mostafid A.H.⁹, Omar M.I.¹⁰

Institutes: ¹Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ²Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ³University of Porto, Dept. of Urology, Porto, Portugal, ⁴General University Hospital First Faculty of Medicine Charles University, Dept. of Urology, Prague, Czech Republic, ⁵Zuyderland Medical Center, Dept. of Urology, Heerlen, The Netherlands, ⁶McMaster University, Health Science Centre, Dept. of Medicine, Hamilton, Canada, ⁷McMaster University, Health Research Methods Evidence and Impact, Hamilton, Canada, ⁸Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Surgical Oncology, Dept. of Urology, Amsterdam, The Netherlands, ⁹Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, ¹⁰University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom

A0848

Mirabegron versus Placebo and other therapeutic modalities in the treatment of patients with Overactive Bladder Syndrome – A Systematic Review

Authors: Dey A.¹, Georgiadis G.², Umezurike J.¹, Yuan Y.³, Farag F.⁴, N'dow J.¹, Omar M.I.¹, Mamoulakis C.²

Institutes: ¹University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ²University of Crete, University General Hospital of Heraklion, Crete, Greece, ³McMaster University, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, Hamilton, Canada, ⁴Sohag University Hospital, Dept. of Urology, Sohag, Egypt

15:07 - 15:10

Expert summary

Prostate cancer diagnosis: Genetics, liquid biomarkers, node staging

Abstract session 26

07 April 2024
13:45 - 15:15

Location Purple Area, S01
Chairs To be confirmed
P.K-F. Chiu, Hong Kong (HK)
B. Malavaud, Toulouse (FR)
F. Preisser, Hamburg (DE)

13:45 - 13:47

Introduction

13:47 - 14:17

Genetics for classification

A0549

Clinical Significance of SCHLAP1:UBE2E3 Gene Fusion Compared to TMPRSS2:ERG Gene Fusion in Localized Prostate Cancer: Insights from a Korean Cohort

Authors: Kang B.¹, Kim S.H.¹, Jang K.H.¹, Seong W.S.¹, Kim K.H.¹, Ha H.K.¹, Lee C.H.², Lee H.S.²

Institutes: ¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Busan Paik Hospital, Inje University College of Medicine, Dept. of Urology, Busan, South Korea

A0557

Gene expression-based molecular classifier is associated with biochemical recurrence and proves independent of heterogeneity in primary prostate cancer

Authors: Axcrona K.¹, Johannessen B.², Myklebust T.³, Bakken A.C.², Maltau A.M.V.², Jareid M.², Lothe R.A.², Axcrona U.⁴, Skotheim R.I.²

Institutes: ¹Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ²Oslo University Hospital-Radiumhospitalet, Dept. of Molecular Oncology, Oslo, Norway, ³Cancer Registry of Norway, Dept. of Analysis and Research, Oslo, Norway, ⁴Oslo University Hospital-Radiumhospitalet, Dept. of Pathology, Oslo, Norway

A0558

Insights into the impact of neuropsychiatric disorders on prostate diseases: A two-sample Mendelian randomization study

Authors: Han Z., Yi X., Li J., Zhang T., Ai J.

Institutes: West China Hospital, Dept. of Urology, Chengdu, China

A0562

First description of a Collagen score outperforming PSA, age and mpMRI in diagnosis of significant prostate cancer

Authors: Heidegger I.¹, Frantzi M.², Salcher S.³, Tymoszyk P.⁴, Gomez-Gomez E.⁵, Lendinez Cano G.⁶, Mischak H.², Vlahou A.⁷, Pircher A.³

Institutes: ¹Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Mosaiques diagnostics GmbH, Dept. of Biomarker Research, Hannover, Germany, ³Medical University Innsbruck, Dept. of Hematology and Oncology, Innsbruck, Austria, ⁴Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁵University of Cordoba, Maimonides Institute of Biomedical Research of Cordoba, Cordoba, Spain, ⁶University Hospital Virgen del Rocío, Dept. of Urology, Seville, Spain, ⁷Academy of Athens, Systems Biology Center Biomedical Research Foundation, Athens, Greece

- A0552** **Evaluation of Chimeric RNA Expression in Urine Samples as a Non-invasive Method for the Detection and Molecular Classification of Prostate Cancer**
Authors: Huang H., Luo T.
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- A0560** **The 17-gene Genomic Prostate Score test as a predictor of treatment selection in men with favorable intermediate-risk prostate cancer**
Authors: Margolis E.M.¹, Lowentritt B.H.L.², Pieczonka C.M.P.³, John J.P.B.⁴, Marina M.P.⁴, Zambon J.P.Z.⁵, Groskopf J.G.⁵, Uchio E.⁶
Institutes: ¹Hackensack Meridian School of Medicine, Dept. of Urology, Nutley, United States of America, ²Chesapeake Urology, Dept. of Urology, Towson, United States of America, ³Associated Medical Professionals of New York, Dept. of Urology, Syracuse, United States of America, ⁴Exact Sciences Corporation, Dept. of Oncology, Redwood City, United States of America, ⁵mdx Health, Dept. of Clinical Affairs, Irvine, United States of America, ⁶University of California Irvine, Dept. of Urology, Newport Beach, United States of America
- 14:17 - 14:47** **Liquid biomarkers**
- A0553** **Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds**
Authors: Kawada T.¹, Shim S.R.², Quhal F.³, Rajwa P.³, Pradere B.⁴, Yanagisawa T.⁵, Bekku K.¹, Laukhina E.³, Von Deimling M.⁶, Araki M.¹, Shahrokh F.S.³
Institutes: ¹Okayama University Hospital, Dept. of Urology, Okayama, Japan, ²Konyang University, Dept. of Biomedical Informatics, Daejeon, South Korea, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ⁵The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- A0561** **Platelet RNAs as Potential Biomarkers in Prostate Cancer Detection: Highlighting Differential Expression of hsa-miR-627, hsa-miR-22, and hsa-miR-190**
Authors: Wang X.K.¹, Guo T.Y.¹, Gu J.Y.², Burke E.¹, Davies C.R.¹, Feng N.H.², Lu Y.J.¹
Institutes: ¹Barts Cancer Institute, Queen Mary University of London, Dept. of Molecule Oncology, London, United Kingdom, ²Jiangnan University Affiliated Central Hospital, Dept. of Urology, Wuxi, China

A0563

A Novel Approach to Identify Aggressive Prostate Cancer via DNA-Methylation Signatures from Prostate Needle Biopsy

Authors: Kaneko M.¹, Sekino Y.¹, Li H.¹, Zhou X.¹, Jin M.², Guo W.², Yang X.³, Bhasin J.², Fujihara A.¹, Iwata T.¹, Ramacciotti L.S.¹, Paralkar D.¹, Cacciamani G.E.¹, Aron M.⁴, Ukimura O.⁵, Gill I.S.¹, Liang G.¹, Abreu A.L.¹

Institutes: ¹University of Southern California, Institute of Urology, Center for Image-Guided Surgery Focal Therapy and Artificial Intelligence for Prostate Cancer, Los Angeles, United States of America, ²Zymo Research Corporation, Dept. of Bioinformatics, Irvine, United States of America, ³Zymo Research Corporation, Epigenetic Department, Irvine, United States of America, ⁴University of Southern California, Dept. of Pathology, Los Angeles, United States of America, ⁵Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan

A0555

A Highly Sensitive Methylation Assay for Prostate Cancer Diagnosis

Authors: Zhong X-Y., Wang S.G.

Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department and Institute of Urology, Wuhan, China

A0565

Assessing the Potential of Cystatin 4 as a Blood Biomarker for Prostate Cancer Diagnosis and Prognosis: A Prospective Single-center Study

Authors: Keles A.¹, Demirtas B.¹, Hamid-Zada I.¹, Kado A.², Isman F.K.², Yildirim A.¹

Institutes: ¹Istanbul Medeniyet University, School of Medicine, Goztepe Prof Dr Suleyman Yalcin City Hospital, Dept. of Urology, Istanbul, Türkiye, ²Istanbul Medeniyet University, School of Medicine, Goztepe Prof Dr Suleyman Yalcin City Hospital, Dept. of Biochemistry, Istanbul, Türkiye

A0550

Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene Genomic Prostate Score assay

Authors: Nguyen A.N.¹, Carter G.C.², Wilson L.A.W.³, Zambon J.P.Z.⁴, Canfield S.⁵

Institutes: ¹OPTUM, Dept. of Provider Advancement, Eden Prairie, United States of America, ²Exact Sciences Corporation, Dept. of Health Economics and Outcomes Research, Indianapolis, United States of America, ³Exact Sciences Corporation, Dept. of Health Economics and Outcomes Research, Houston, United States of America, ⁴mdx Health, Dept. of Clinical Affairs, Randolph, United States of America, ⁵UT Medical School, Dept. of Urology, Houston, United States of America

14:47 - 15:12

Node staging

A0551

The conventional Briganti 2018 nomogram is superior to its side-specific adaptation in identifying candidates for extended pelvic lymph node dissection at radical prostatectomy

Authors: Ortner G.¹, Falkenbach F.¹, Kachanov M.¹, Maurer T.², Knipper S.¹, Graefen M.¹, Budäus L.¹

Institutes: ¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0554

POPCORN Study: Application of the “One-Step Nucleic Acid Amplification” (OSNA) Method for the Detection of Nodal Metastasis in Patients with Prostate Cancer

Authors: Cuadras Sole M.¹, Semidey M.E.², de Torres I.S.M.², Planas J.¹, Medina R.³, Marcilla D.⁴, Martínez-Pineiro L.⁵, González-Peramato P.⁶, Leivar A.⁵, Carrato C.⁷, Areal J.⁸, Fernández P.L.⁷, Ramírez M.⁹, Calatrava A.¹⁰, Vázquez-Martul D.O.¹¹, Queipo F.¹², Moreno J.¹³, Luque R.¹⁴, Álvarez J.L.¹⁵, Catalina I.¹⁶, Ramón Y Cajal S.², Trilla E.¹, Morote J.¹

Institutes: ¹Hospital Universitario Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ²Hospital Universitario Vall d'Hebron, Dept. of Pathology, Barcelona, Spain, ³Hospital Universitario Virgen del Rocío, Dept. of Urology, Sevilla, Spain, ⁴Hospital Universitario Virgen del Rocío, Dept. of Pathology, Sevilla, Spain, ⁵Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ⁶Hospital Universitario La Paz, Dept. of Pathology, Madrid, Spain, ⁷Hospital Universitario Germans Trias i Pujol, Dept. of Pathology, Badalona, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Dept. of Urology, Badalona, Spain, ⁹Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ¹⁰Instituto Valenciano de Oncología, Dept. of Pathology, Valencia, Spain, ¹¹Complejo Hospitalario Universitario A Coruna, Dept. of Urology, A Coruna, Spain, ¹²Complejo Hospitalario Universitario A Coruna, Dept. of Pathology, A Coruna, Spain, ¹³Hospital Universitario de Jaén, Dept. of Urology, Jaén, Spain, ¹⁴Hospital Universitario de Jaén, Dept. of Pathology, Jaén, Spain, ¹⁵Hospital Universitario Puerta del Mar, Dept. of Urology, Cádiz, Spain, ¹⁶Hospital Universitario Puerta del Mar, Dept. of Pathology, Cádiz, Spain

A0559

More Micrometastases, More Recurrence? Assessing the Role of Quantitative rtPCR of PSA from Lymph Nodes Post-Prostatectomy in Predicting Biochemical Recurrence - An Experimental Study

Authors: Troidl J., Fehr A., Gür M., Jandrig B., Schostak M.

Institutes: University Hospital Magdeburg, Dept. of Urology, Magdeburg, Germany

A0564

Modified use of Briganti 2019 nomogram to assess lymph node metastasis risk in patients with in-bore biopsy detected prostate cancer

Authors: Madendere S.¹, Kilic M.¹, Igdem A.², Balbay D.³, Vural M.⁴, Esen T.³

Institutes: ¹VKV American Hospital, Dept. of Urology, Istanbul, Türkiye, ²VKV American Hospital, Dept. of Pathology, Istanbul, Türkiye, ³Koç University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ⁴VKV American Hospital, Dept. of Radiology, Istanbul, Türkiye

A0556

The diagnostic performance of indocyanine green for sentinel node biopsy in prostate cancer: a systematic review and meta-analysis

Authors: Sun J., Ma S., Xia Q., Wang S.

Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

15:12 - 15:15

Expert summary

Translational andrology: Improving understanding and advancing treatment

Abstract session 27

07 April 2024
13:45 - 15:15

Location Purple Area, S03
Chairs To be confirmed
To be confirmed
N. Sofikitis, Ioannina (GR)
To be confirmed

13:45 - 13:47

Introduction

13:47 - 14:05

Interrogating the tissue micro-environment in andrology

A0568

Targeting and enhancing digestive capacity in Sertoli cells to ameliorate late-onset hypogonadism

Authors: [Zhao L.](#)

Institutes: The Fifth Affiliated Hospital of Sun Yat-Sen University, Dept. of Urology, Zhuhai, China

A0566

Anatomical transcriptome atlas of the male mouse Anatomical Transcriptome Atlas of the Male Mouse Reproductive System During Aging

Authors: [Huang Y.](#)¹, Xie Y.²

Institutes: ¹Shanghai Jiao Tong University School of Medicine Renji Hospital, Dept. of Urology and Andrology, Shanghai, China, ²The First Affiliated Hospital Sun Yat-Sen University, Dept. of Urology and Andrology, Guangzhou, China

A0567

A single-cell analysis deciphers the molecular characteristics of low semen quality in seminoma

Authors: [Chen G.](#)¹, Wang W.², Qu R.¹, Dai Y.¹, Hu Y.¹, Liu Y.¹, He S.¹, Wei R.¹, Luo X.¹, Yang L.¹

Institutes: ¹West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu Sichuan P. R. China., Dept. of Urology and Pelvic Surgery, Chengdu, China, ²West China Hospital Sichuan University Chengdu, Dept. of Urology, Institute of Urology, Chengdu, China

14:02 - 14:05

Summary

14:05 - 14:25

Translational research in testicular function

A0577

Physio-pharmacological Mechanisms Underlying Ejaculation in Human Seminal Vesicle

Authors: [Kajjoka S.](#)¹, Okabe A.², Okada T.², Shiota M.², Inokuchi J.², Etoh M.²

Institutes: ¹International University of Health and Welfare, Dept. of Pharmacy at Fukuoka, Ookawa, Japan, ²Kyushu University, Dept. of Urology, Fukuoka, Japan

A0573

Epididymal RNase T2 contributes to astheno-teratozoospermia and intergenerational metabolic disorder through epididymosome-sperm interaction

Authors: [Xin Z.](#)¹, Ding Z.², Liu Y.²

Institutes: ¹Shanghai Changzheng Hospital, Dept. of Urology, Shanghai, China, ²Shanghai Key Laboratory for Reproductive Medicine, Dept. of Histology Embryology Genetics and Developmental Biology, Shanghai, China

- A0574** **Testosterone Synthesis Pathway in Non-Obstructive Azoospermic Men: Aberrant CYP17A1/HSD17B3 activity**
Authors: Huang I.S.¹, Li L.H.², Chen W-J.¹, Juan C.C.³, Huang W.J.¹
Institutes: ¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Pathology, Taipei, Taiwan, ³National Yang Ming Chiao Tung University, Dept. of Physiology, Taipei, Taiwan
- A0582** **The expression of PDE11A in sperm and the potential role of its inhibitors in sperm motility regulating**
Authors: Zi-Jue Z.J., Li Z.
Institutes: Shanghai General Hospital, Dept. of Andrology, Shanghai, China
- 14:25 - 14:55** **Translational research in erectile function**
- A0576** **Comprehensive analysis of biological landscape of oxidative stress-related genes in diabetic erectile dysfunction**
Authors: Yuan P., Meng Q., Cui L., Li T., Wei Y.
Institutes: The First Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China
- A0570** **Erectile dysfunction in non-bacterial chronic prostatitis is induced via suppressing PI3K/AKT/CREB and Nrf2/Keap1 pathways**
Authors: Xiong Y., Changjing W., Wei W., Shiyu Z., Feng Q., JiuHong Y.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- A0575** **Studies on the mechanism of methyltransferase METTL3 regulating GLP-1R m6A modification in the pathogenesis of diabetic erectile dysfunction**
Authors: Yuan P., Meng Q., Cui L., Li T., Wei Y., Sun T.
Institutes: The First Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China
- A0569** **Acute sleep deprivation impairs erectile function via activating RhoA/ROCK signaling pathway**
Authors: Xiong Y., Fuxun Z., Wei W., Feng Q., JiuHong Y.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- A0579** **Orexin receptors in paraventricular nucleus influence sexual behavior via regulating the sympathetic outflow in males**
Authors: Song N., Jiaochen L.
Institutes: Jiangsu Province Hospital, Dept. of Urology, Nanjing, China
- A0580** **New biomarker for erectile dysfunction: soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK)**
Authors: İplikci A.¹, Efiloglu O.¹, Kado A.², Erman H.², Yildirim A.¹
Institutes: ¹Istanbul Medeniyet University, Dept. of Urology, Istanbul, Türkiye, ²Istanbul Medeniyet University, Dept. of Biochemistry, Istanbul, Türkiye
- 14:55 - 15:15** **Preclinical evidence for novel therapeutics**
- A0578** **Lacosamide alleviates bilateral cavernous nerve injury-induced erectile dysfunction in the rat model by ameliorating pathological changes in the corpus cavernosum**
Authors: Song N., Liangyu Y.
Institutes: Jiangsu Province Hospital, Dept. of Urology, Nanjing, China
-

A0571

Role of adipose-derived stem cells in healing of surgically induced trauma of rat's tunica albuginea

Authors: Sharqawi A.¹, Mansour M.F.¹, Elatrash G.A.¹, Ismail E.A.¹, Ralph D.R.², El-Sakka A.I.¹

Institutes: ¹Suez Canal University, Dept. of Urology, Ismailia, Egypt, ²University College London Hospitals, The Institute of Urology, London, United Kingdom

A0572

Effects of different doses of human umbilical cord-derived mesenchymal stem cells on the recovery of erectile function in rats

Authors: Wei W.¹, Ying L.², Han C.¹

Institutes: ¹Southeast University Affiliated Xuzhou Hospital, Dept. of Andrology, Xuzhou, China, ²Xuzhou Central Hospital, Dept. of Andrology, Xuzhou, China

A0581

Effect of near-infrared laser treatment on improving erectile function in aging rats

Authors: Yang L.¹, Liu G.X.¹, Jiang D.L.¹, Lin G.T.², Ren Z.J.¹, Fan H.T.¹, Yang B.¹, Mu L.Y.¹, Lue T.F.², He D.L.¹

Institutes: ¹Xian Jiaotong University, Dept. of Urology, Xi'an, China, ²University of California, Dept. of Urology, San Francisco, United States of America

15:15 - 15:17

Expert summary

Advances in genital reconstruction

Video session 09

07 April 2024
13:45 - 15:15

Location Green Area, S04
Chairs To be confirmed
To be confirmed
S.C. Morgenstern, Frankfurt am Main (DE)

- V064** **Transmeatal Dorsal Inlay Buccal Mucosa Graft Augmentation for Fossa Navicularis Strictures: Technical Nuances and Short-term Functional Outcomes.**
Authors: Enganti B.T., Chiruvella M., Wani A., Nanavati P., Madduri V., Ghose S., Tak G.
Institutes: Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India
- V065** **Female Urethral Stricture - A Reconstructive Surgery**
Authors: Ottaiano A., Simoes G.C., De Oliveira C., Di Domenico B.R., Junior F.F.O., Rubez A.C., Salles L.C., Pereira A.B., Ferrucio A.A., Gon L.M., Riccetto C.L.Z.
Institutes: Universidade Estadual de Campinas - UNICAMP, Dept. of Urology, Campinas, Brazil
- V066** **Medium to Long Term Outcomes of Female VOBMG Urethroplasty**
Authors: Toia B.¹, Gresty H.¹, Noah A.¹, Nobrega R.¹, Pakzad M.¹, Kose O.², Ockrim J.¹, Greenwell T.¹
Institutes: ¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²Sakarya University, Dept. of Urology, Sakarya, Türkiye
- V067** **Robot-assisted gonadal vein excision for chronic abdominal pain after varicocele embolization: a case series**
Authors: Panio E., Sighinolfi C., Assumma S., Calcagnile T., Sarchi L., Macchione N., Sangalli M., Turri F., Rocco B.
Institutes: ASST SANTI PAOLO E CARLO, Dept. of Urology, Milan, Italy
- V068** **Configuration of pudendal thigh flap in recurring perineal urethrostomy stenosis**
Authors: Falcone M., Preto M.P., Ferro I.F., Lavagno F.L., Cirigliano L., Peretti F.P., Plamadeala N.P., Scavone M.S.
Institutes: Città della Salute e della Scienza, Dept. of Urology, Turin, Italy
- V069** **Urethral polyps: Hidden flow obstructors after PFUI repair**
Authors: Navarro J., Ocampo M.A., Tapallikar A., Barot P., Anand A., Joshi P.M., Kulkarni S.B.
Institutes: UROKUL Kulkarni Uro Surgery Institute, Dept. of Reconstructive Urology, Pune, India
- V070** **Gender affirmation vulvovaginoplasty with inverted penile skin, scrotal graft and peritoneal flap technique**
Authors: Lethuillier V.¹, Richard C.R.¹, Zhao L.Z.², Peyronnet B.P.¹, Freton L.¹
Institutes: ¹CHU Rennes, Dept. of Urology, Rennes, France, ²NYU, Dept. of Urology, New York, United States of America

V071

The outcomes of inflatable penile prosthesis implantation in the context of GGAS in AFAB patients: a comparative study between cis-gender modified and single cylinder transgender PP

Authors: Falcone M., Preto M., Peretti F., Cirigliano L., Ferro I., Plamadeala N., Scavone M., Gontero P.

Institutes: AOU Città della Salute e della Scienza di Torino, Dept of Urology, Turin, Italy

Basic research and trials - Non muscle invasive bladder cancer

Abstract session 28

07 April 2024
13:45 - 15:15

Location Green Area, W06
Chairs To be confirmed
T. Strandgaard, Aarhus (DK)
To be confirmed

13:45 - 13:47

A0597

Introduction

Results from SunRISe-1 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 monotherapy

Authors: [Necchi A.](#)¹, [Jacob J.M.J.](#)², [Daneshmand S.](#)³, [Simone G.S.](#)⁴, [Xylinas E.X.](#)⁵, [Morris D.S.M.](#)⁶, [Spiegelhalder P.S.](#)⁷, [Zainfeld D.Z.](#)⁸, [Kang T.W.K.](#)⁹, [Matulay J.T.M.](#)¹⁰, [Belkoff L.H.B.](#)¹¹, [Decaestecker K.](#)¹², [Arentsen H.](#)¹³, [Hampras S.H.](#)¹⁴, [Cutie C.J.](#)¹⁵, [Sweiti H.S.](#)¹⁶, [Stromberg K.S.](#)¹⁴, [Martin J.M.](#)¹⁷, [Shulka A.](#)¹⁵, [Van Der Heijden M.S.V.D.H.](#)¹⁸

Institutes: ¹IRCCS San Raffaele Hospital-Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Upstate Medical University, Dept. of Urology, Syracuse, United States of America, ³University of Southern California, Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁴Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁵Bichat-Claude Bernard Hospital, Assistance Publique Hopitaux de Paris, Université de Paris Cité, Dept. of Urology, Paris, France, ⁶Urology Associates, Dept. of Urology, Nashville, United States of America, ⁷Urologie Neandertal-Gemeinschaftspraxis für Urologie, Dept. of Urology, Mettmann, Germany, ⁸Urology San Antonio, Dept. of Urology, San Antonio, United States of America, ⁹Chonnam National University Medical School-Chonnam National University Hospital, Dept. of Urology, Gwangju, South Korea, ¹⁰Atrium Health Levine Cancer Institute, Dept. of Urology, Charlotte, United States of America, ¹¹MidLantic Urology-Solaris Health, Dept. of Urology, Bala Cynwyd, United States of America, ¹²Ghent University Hospital, AZ Maria Middelaes, Dept. of Urology, Ghent, Belgium, ¹³AZ Sint-Jan Hospital Brugge-Oostende, Dept. of Urology, Bruges, Belgium, ¹⁴Janssen Research and Development, Dept. of Clinical Oncology, Raritan, United States of America, ¹⁵Janssen Research and Development, Dept. of Clinical Oncology, Lexington, United States of America, ¹⁶Janssen Research and Development, Dept. of Research and Development, Spring House, United States of America, ¹⁷Janssen Research and Development, Dept. of Research and Development, High Wycombe, United Kingdom, ¹⁸Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands

A0595

SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non-muscle-invasive bladder cancer

Authors: Catto J.W.F.¹, Necchi A.N.², Powles T.P.³, Guerrero-Ramos F.G.-R.⁴, Simone G.S.⁵, Shore N.S.⁶, Salinas J.S.⁷, Merseburger A.S.M.⁸, Roumiguie M.R.⁹, Hiroshi K.H.¹⁰, Morris D.M.¹¹, Qiang W.Q.¹², Korke F.K.¹³, Hasan M.H.¹⁴, Jin S.J.¹⁵, Maffeo J.M.¹⁵, Hammond C.H.¹⁴, Sweiti H.S.¹⁴, Somer R.S.¹⁴, Chang S.S.¹⁶

Institutes: ¹University of Sheffield, Sheffield Teaching Hospitals NHS Trust, Dept. of Urology, Sheffield, United Kingdom, ²Vita-Salute San Raffaele University-Medical Oncology Unit-IRCCS San Raffaele Hospital and Scientific Institute, Dept. of Urology, Milan, Italy, ³Barts Cancer Centre, Queen Mary University of London, London, United Kingdom, ⁴12 de Octubre University Hospital, Dept. of Urology, Madrid, Spain, ⁵Regina Elena National Cancer Institute IRCCS, Dept. of Oncologic Urology, Rome, Italy, ⁶Carolina Urologic Research Center, Myrtle Beach, United States of America, ⁷CEMAIC Private Medical Center, Dept. of Oncology, Cordoba, Argentina, ⁸University Hospital Schleswig-Holstein-Campus Lübeck, Dept. of Urology, Lübeck, Germany, ⁹Andrology and Kidney Transplantation-Institut Universitaire du Cancer de Toulouse Oncopole CHU, Dept. of Urology, Toulouse, France, ¹⁰Graduate School of Medicine and Pharmaceutical Sciences for Research-University of Toyama, Dept. of Urology, Toyama, Japan, ¹¹Urology Associates PC, Dept. of Urology, Nashville, United States of America, ¹²West China Hospital-Sichuan University, Dept. of Urology, Chengdu, China, ¹³Faculdade de Medicina do ABC, Santo André-Hospital Albert Einstein, Dept. of Urology, Sao Paulo, Brazil, ¹⁴Janssen Research and Development, Dept. of Research and Development, Spring House, United States of America, ¹⁵Janssen Research and Development, Dept. of Research and Development, Lexington, United States of America, ¹⁶Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America

A0596

First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations

Authors: Vilaseca A.¹, Jayram G.J.², Raventos C.R.³, Shore N.D.S.⁴, Zainfeld D.Z.⁵, Kang T.W.K.⁶, Ku J.H.K.⁷, Meeks J.M.⁸, Rodríguez Faba O.R.-F.⁹, Roghmann F.R.¹⁰, Daneshmand S.¹¹, Beeharry N.B.¹², Cost C.R.¹², Kalota A.¹², Lauring J.L.¹², Peterson M.R.P.¹³, Quiroz M.Q.¹², Stone N.L.S.¹², Zhu W.Z.¹³, Gurrero-Ramos F.G.-R.¹⁴

Institutes: ¹Hospital Clínic de Barcelona, Uro-oncology Unit, Barcelona, Spain, ²Urology Associates, Dept. of Urology, Nashville, United States of America, ³Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ⁴Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁵Urology San Antonio, Dept. of Urology, San Antonio, United States of America, ⁶Chonnam National University Medical School-Chonnam National University Hospital, Dept. of Urology, Gwangju, South Korea, ⁷Seoul National University Hospital- Seoul National University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁸Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America, ⁹Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁰Ruhr-University Bochum-Marien Hospital, Dept. of Urology, Herne, Germany, ¹¹University of Southern California, Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ¹²Janssen Research and Development, Dept. of Research and Development, Spring House, United States of America, ¹³Janssen Research and Development, Dept. of Research and Development, Raritan, United States of America, ¹⁴University Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain

A0583

Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial

Authors: Boorjian S.A.¹, Narayan V.M.², Konety B.R.³, Master V.A.², Shore N.D.⁴, Kamat A.M.⁵, Bivalacqua T.J.⁶, Kates M.R.⁷, Montgomery J.S.⁸, Crispen P.L.⁹, Steinberg G.D.¹⁰, Agarwal P.K.¹¹, Schuckman A.K.¹², Karsh L.I.¹³, Bjurlin M.A.¹⁴, Brown G.A.¹⁵, Lotan Y.¹⁶, Inman B.A.¹⁷, Williams M.B.¹⁸, Cookson M.S.¹⁹, Chang S.S.²⁰, Kim E.H.²¹, Sankin A.I.²², Dinney C.⁵

Institutes: ¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ³University of Minnesota and Allina Health Cancer Institute, Dept. of Urology, Minneapolis, United States of America, ⁴Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁵The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Dept. of Urology, Baltimore, United States of America, ⁷The James Buchanan Brady Urological Institute and Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ⁸University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁹University of Florida, Dept. of Urology, Gainesville, United States of America, ¹⁰Rush University, Dept. of Urology, Chicago, United States of America, ¹¹University of Chicago, Dept. of Surgery, Section of Urology, Chicago, United States of America, ¹²USC Institute of Urology Norris Comprehensive Cancer Center University of Southern California, Dept. of Urology, Los Angeles, United States of America, ¹³The Urology Center of Colorado, Dept. of Urology, Denver, United States of America, ¹⁴University of North Carolina, Dept. of Urology, Chapel Hill, United States of America, ¹⁵New Jersey Urology, Dept. of Urology, Bloomfield, United States of America, ¹⁶University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹⁷Western University, Division of Urology, London, Canada, ¹⁸Urology of Virginia, Dept. of Urology, Virginia Beach, United States of America, ¹⁹University of Oklahoma Health Sciences Center, Dept. of Urology, Oklahoma City, United States of America, ²⁰Vanderbilt University, Division of Urologic Oncology, Nashville, United States of America, ²¹Barnes-Jewish Hospital, Siteman Cancer Center, St. Louis, United States of America, ²²Montefiore Medical Center, Dept. of Urology, Bronx, United States of America

A0599

Intravesical instillation of nanoparticle-loaded toll like receptor (TLR) 3/9 agonists triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.

Authors: Ji J.¹, Bao J.², Lai C-H.¹, Wang L.², Hu H.¹

Institutes: ¹Peking University People's Hospital, Dept. of Urology, Beijing, China, ²Chinese Academy of Sciences, Process of Engineering, Beijing, China

A0594

Comprehensive analysis of immune activation and suppression markers in peripheral blood and tumor tissue in NMIBC.

Authors: Albers E.M.¹, Celada Luis G.¹, Romero La Orden N.², Velasco Balanza C.¹, San José Manso L.A.¹, Alfranca González A.³, Olivier Gomez C.¹

Institutes: ¹Hospital Universitario de La Princesa, Dept. of Urology, Madrid, Spain, ²Hospital Universitario de La Princesa, Dept. of Oncology, Madrid, Spain, ³Hospital Universitario de La Princesa, Dept. of Immunology, Madrid, Spain

A0590

Validation of FGFR screening by uromonitor® and thescreen in FFPE tissue in bladder cancer in the context of the clinical-pathological real-world registry study "Bladder BRIDGister"

Authors: Ecke T.¹, Veltrup E.², Linden F.², Prazeres H.³, Brás J.⁴, Dias C.⁴, Hake R.⁵, Eidt S.⁵, Vinagre J.⁶, Soares P.⁶, Koch S.⁷, Roggisch J.⁷, Barski D.⁸, Gössl A.⁸, Otto T.⁸, May M.⁹, Kravchuk A.⁹, Gagel N.¹⁰, Friedersdorff F.¹⁰, Sommerfeldt L.¹⁰, Stöhr R.¹¹, Wirtz R.²

Institutes: ¹Helios Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ²STRATIFYER, Dept. of Molecular Pathology, Cologne, Germany, ³Uromonitor, Dept. of Molecular Pathology, Maia, Portugal, ⁴Ipatimup, University of Porto, Dept. of Molecular Pathology and Immunology, Porto, Portugal, ⁵St. Elisabeth Krankenhaus, Dept. of Pathology, Cologne, Germany, ⁶University of Porto, Medical Faculty, Porto, Portugal, ⁷Helios Hospital Bad Saarow, Dept. of Pathology, Bad Saarow, Germany, ⁸Rheinlandklinikum Neuss, Dept. of Urology, Neuss, Germany, ⁹Klinikum St. Elisabeth, Dept. of Urology, Straubing, Germany, ¹⁰Ev. Krankenhaus Königin Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ¹¹University of Erlangen, Dept. of Pathology, Erlangen, Germany

A0588

Utility of a 23-Gene Prognostic Signature for Predicting Progression and BCG Response in Non-Muscle-Invasive Bladder Cancer

Authors: Piao X.M.¹, Byun Y.J.¹, Kim S.K.¹, Park S.H.², Zheng C.M.¹, Moon S.³, Kim K.³, Min K.⁴, Park H.⁴, Kang H.W.³, Kim W.T.³, Yun S.J.³

Institutes: ¹Chungbuk National University, Dept. of Urology, Cheongju - Chungbuk, South Korea, ²University of Science and Technology, Department of Bioscience, Daejeon, South Korea, ³Chungbuk National University Hospital, Department of Urology, cheongju, South Korea, ⁴Gwangju Institute of Science and Technology, Department of Biomedical Science and Engineering, Gwangju, South Korea

A0591

Multiple activation of apoptosis, ferroptosis cuproptosis and disulfidptosis by iridium based complex for bladder cancer therapy

Authors: Zhen J.¹, Zhang A.¹, Xu Y.¹, Qin X.¹, Zhao S.¹, Li L.¹, Zhao Z.¹, Wang K.N.², Yu N.¹

Institutes: ¹Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China, ²Shandong University, State Key Laboratory of Crystal Materials, Jinan, China

- A0587** **Association between genetic variants of antioxidant enzymes and levels of organic pollutants analyzed in bladder cancer**
Authors: Martin Way D.A.¹, Tamayo Gómez A.², Puche Sanz I.², Martínez González L.J.³, Zafra Gómez A.⁴, Álvarez Cubero M.J.³
Institutes: ¹Hospital Universitario de Fuenlabrada, Dept. of Urology, Fuenlabrada, Spain, ²Hospital Universitario Virgen de las Nieves, Dept. of Urology, Granada, Spain, ³Centro Pfizer, University of Granada Junta de Andalucía de Genómica e Investigación Oncológica GENYO, Dept. of Genomics, Granada, Spain, ⁴University of Granada, Dept. of Analytical Chemistry, Granada, Spain
- A0586** **A novel molecular classification of non-muscle-invasive bladder cancer based on HLA class I expression: Associations with immune infiltration and prognosis**
Authors: Yu M.¹, Goel A.¹, Ward D.G.¹, Gordon N.S.¹, Abbotts B.¹, Zeegers M.P.², Cheng K.K.³, James N.D.⁴, Bryan R.T.¹, Arnold R.¹
Institutes: ¹Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, ²Maastricht University, Dept. of Complex Genetics and Epidemiology, Maastricht, The Netherlands, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Cancer Research, Institute of Cancer Research, London, United Kingdom
- A0585** **Analysis of the tumor microenvironment (TME) in High-Grade Ta (HG Ta) Bladder Cancer reveals an immune and stromal enriched subtype which demonstrates poor prognosis with concurrent carcinoma-in situ (CIS)**
Authors: Mark F.¹, Jacob T.², Pietzak E.²
Institutes: ¹New York Presbyterian Weill Cornell, Dept. of Urology, New York, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America
- A0584** **Differential urinary microbiome and its metabolic footprint in bladder cancer patients following BCG treatment**
Authors: Min K.¹, Piao X.M.², Byun Y.J.², Zheng C.M.², Kim S.K.³, Park S.H.³, Moon S.⁴, Kim K.⁴, Kang H.W.⁴, Kim W.T.⁴, Yun S.J.⁴, Park H.¹
Institutes: ¹Gwangju Institute of Science and Technology, Department of Biomedical Science and Engineering, Gwangju, South Korea, ²College of Medicine Chungbuk National University, Urology, Cheongju, South Korea, ³University of Science and Technology, Department of Bioscience, Daejeon, South Korea, ⁴Chungbuk National University Hospital, Urology, Cheongju, South Korea
- A0593** **The novel Immunotherapy for BCG-resistant Bladder Cancer by ImmuneNanoVaccine**
Authors: Huang P.¹, Lin W.², Zhou T.², Igawa K.³, Kasai T.³, Sadahira T.², Michiue H.³, Araki M.²
Institutes: ¹Okayama University, Urology and Neutron Therapy Research Center, Okayama, Japan, ²Okayama University, Dept. of Urology, Okayama, Japan, ³Okayama University, Neutron Therapy Research Center, Okayama, Japan
-

A0598

Guiding adjuvant instillation in intermediate risk non-muscle invasive bladder cancer by drug screens in patient derived organoids

Authors: Egger M.¹, De Menna M.², Lyatoshinsky P.³, Blarer J.¹, Hösli R.¹, Abt D.¹, Kruithof-De Julio M.², Seiler R.¹

Institutes: ¹Spitalzentrum Biel, Dept. of Urology, Biel, Switzerland, ²University of Bern, Dept. of BioMedical Research, Bern, Switzerland, ³Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland

A0592

A pre-clinical organoid model to select suitable bladder cancer patients for targeting EZH2 treatment

Authors: Zhao H.¹, Liao J.², Liu K.¹, Chen X.¹, Wu H.¹, Chiu P.K-F.¹, Ng C.F.¹, Teoh J.Y.C.¹

Institutes: ¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Dept. of Chemical Pathology, Hong Kong, Hong Kong

A0589

Development and evaluation of gemcitabine-loaded liposomes in an orthotopic mouse bladder cancer model

Authors: Wee C.¹, Maeng S.¹, Tae J.H.¹, Choi S.Y.¹, Kim M.J.², Lee H.J.², Kim J.H.¹, Chang J.H.¹

Institutes: ¹Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea, ²Seoun National University Bundaung Hospital, Dept. of Radiology, Seongnam, South Korea

15:12 - 15:15

Expert summary

Prostate cancer management: from the beginning to the end

EGPT 09

07 April 2024
13:45 - 15:15

Location	EGPT
Chairs	To be confirmed
	To be confirmed

13:45 - 13:54

Screen A: Initial diagnosis

P251

Pre-diagnostic prostate-specific antigen testing and clinical characteristics in men deceased from Prostate Cancer

Authors: [Arvendell M.](#)¹, [Björnebo L.](#)², [Eklund M.](#)², [Giovanni Falagarlo U.](#)³, [Akre O.](#)¹, [Grönberg H.](#)², [Nordström T.](#)², [Lantz A.](#)¹

Institutes: ¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³University of Foggia, Dept. of Urology, Foggia, Italy

P243

Cost effectiveness of prostate cancer testing incorporating Stockholm3 and MRI versus standard of care

Authors: [Mcleod O.](#)¹, [Palsdottir T.](#)¹, [Walz J.](#)², [Tilki D.](#)³, [Briganti A.](#)⁴, [Stabile A.](#)⁴, [Vigmostad M.N.](#)⁵, [Mortezavi A.](#)⁶, [Elyan A.](#)⁶, [Dudderidge T.](#)⁷, [Grönberg H.](#)¹, [Vigneswaran H.T.](#)¹

Institutes: ¹Karolinska institutet, Dept. of Medical Epidemiology and Biostatistics, Solna, Sweden, ²Institut Paoli-Calmettes Cancer Center, Dept. of Surgery, Marseille, France, ³Martini Klinik, Dept. of Urology, Hamburg, Germany, ⁴Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁵Universitetet i Stavanger, Dept. of Medical Oncology, Stavanger, Norway, ⁶Universitätsspital Basel, Dept. of Urology, Basel, Switzerland, ⁷University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

P239

Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial

Authors: Meissner V.H.¹, Dinkel A.², Kron M.³, Schiele S.¹, Lakes J.⁴, Radtke J.P.⁴, Kuczyk M.⁵, Harke N.⁵, Debus J.⁶, Körber S.⁶, Antoch G.⁷, Schimmöller L.⁷, Kristiansen G.⁸, Krilaviciute A.⁹, Seibold P.⁹, Behrens S.¹⁰, Benner A.¹¹, Arsov C.⁴, Hadaschik B.¹², Becker N.¹⁰, Kaaks R.¹¹, Albers P.¹⁰, Gschwend J.E.¹, Herkommer K.¹

Institutes: ¹Technical University of Munich - School of Medicine and Health - Klinikum rechts der Isar, Dept. of Urology, Munich, Germany, ²Technical University of Munich - School of Medicine and Health - Klinikum rechts der Isar, Dept. of Psychosomatic Medicine and Psychotherapy, Munich, Germany, ³University of Ulm, Institute of Epidemiology and Medical Biometrics, Ulm, Germany, ⁴Heinrich-Heine University Duesseldorf, University Hospital, Medical Faculty, Dept. of Urology, Düsseldorf, Germany, ⁵Medical University Hannover, Dept. of Urology, Hannover, Germany, ⁶Ruprecht Karls University Heidelberg - Heidelberg University Hospital, Dept. of Radiation Oncology, Heidelberg, Germany, ⁷Heinrich-Heine University Duesseldorf, Medical Faculty, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ⁸University Hospital Bonn, Institute of Pathology, Bonn, Germany, ⁹German Cancer Research Center DKFZ, Division of Personalized Early Detection of Prostate Cancer, Heidelberg, Germany, ¹⁰German Cancer Research Center DKFZ, Division of Cancer Epidemiology, Heidelberg, Germany, ¹¹German Cancer Research Center DKFZ, Division of Biostatistics, Heidelberg, Germany, ¹²University of Duisburg-Essen and German Cancer Consortium, Dept. of Urology, Essen, Germany

13:54 - 14:06

Screen B: Local management with active surveillance and focal therapy

P247

Do Incidental Prostate Cancer Patients Managed with Active Surveillance Exhibit Different Disease Features and Outcomes Compared to Their Biopsy-Diagnosed Counterparts? Results of a Multi-Institutional Study

Authors: Leni R.¹, Stabile A.¹, Capitanio U.¹, Roscigno M.², La Croce G.², Da Pozzo L.F.², Olivier J.³, Zattoni F.⁴, Facco M.⁴, Dal Moro F.⁴, Van Den Bergh R.⁵, Soeterik T.⁵, Bianchi L.⁶, Lampariello L.⁶, Salonia A.¹, Montorsi F.¹, Briganti A.¹, Vickers A.⁷, Gandaglia G.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²ASST Papa Giovanni XXIII-Milano-Bicocca University-School of Medicine, Dept. of Urology, Bergamo, Italy, ³Lille University, Dept. of Urology, Lille, France, ⁴University of Padova, Dept. of Surgery-Oncology and Gastroenterology, Urologic Unit, Padua, Italy, ⁵St Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁷Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

- P236** **Validation of a Blood-Based Sphingolipid Panel for Men with Prostate Cancer on Active Surveillance**
Authors: [Gregg J.R.](#)¹, Irajizad E.¹, Newcomb L.², Wu R.¹, Dennison J.¹, Davis J.W.¹, Pettaway C.¹, Pisters L.¹, Ward J.F.¹, Chapin B.F.¹, Chery L.¹, Urkmez A.¹, Troncso P.¹, Daniel C.R.¹, Hahn A.W.¹, Liu M.², Zheng Y.², Lin D.², Hanash S.¹, Fahrman J.¹
Institutes: ¹UT MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²University of Washington, Dept. of Urology, Seattle, United States of America
- P232** **Initial non-curative treatment for favorable intermediate-risk prostate cancer: Findings from a population-based database**
Authors: [Shangguan X.](#), Han B.
Institutes: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China
- P241** **MRI-guided transurethral ultrasound ablation (TULSA) for the treatment of organ-confined primary prostate cancer: A single-center retrospective clinical service evaluation of 300 patients**
Authors: [Engelage L.](#)¹, Behnel N.¹, Doerwald P.², Muschter R.¹, Lumiani A.³
Institutes: ¹ALTA clinic, Dept. of Urology, Bielefeld, Germany, ²Profound Medical, Dept. of Clinical Science, Hamburg, Germany, ³ALTA clinic, Dept. of Radiology, Bielefeld, Germany
- 14:06 - 14:27** **Screen C: Local management with surgery**
- P246** **Prostate cancer and solid organ transplantation: Patient management and outcomes**
Authors: [Lazarovich A.Y.](#)¹, Kristof T.W.¹, Dahmaen A.¹, Steadman S.², Morgan T.², Eggener S.¹
Institutes: ¹University of Chicago Medical Center, Dept. of Urology, Chicago, United States of America, ²University of Michigan Health, Dept. of Urology, Ann Arbor, United States of America

- P253** **Radical Prostatectomy for non-metastatic Prostate Cancer in Renal Transplant Recipients: outcomes from a large contemporary cohort and matched-paired analysis with non-transplanted patients**
Authors: Tappero S.¹, Marquis A.², Barletta F.³, Allasia M.², Oderda M.², Dariane C.⁴, Timsit O.⁴, Branchereau J.⁵, Mesnard B.⁵, Tilki D.⁶, Olsburgh J.⁷, Kulkarni M.⁷, Kasivisvanathan V.⁸, Lebacle C.⁹, Breda A.¹⁰, Galfano A.¹, Gandaglia G.³, Briganti A.³, Montorsi F.³, Biancone L.¹¹, Gontero P.², Marra G.²
Institutes: ¹ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ²Città della Salute e della Scienza and University of Turin, Dept. of Surgical Sciences, Division of Urology, Turin, Italy, ³IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ⁴Hopital Européen Georges Pompidou, Dept. of Urology, Paris, France, ⁵Institut de Transplantation Urologie et Néphrologie and Centre Hospitalier Universitaire de Nantes, Dept. of Urology, Nantes, France, ⁶Martini Klinik, Dept. of Urology, Hamburg, Germany, ⁷Guy s Hospital, Dept. of Urology, London, United Kingdom, ⁸University College London, Dept. of Urology, London, United Kingdom, ⁹Kremlin-Bicetre Hospital, Dept. of Urology, Paris, France, ¹⁰Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹¹Città della Salute e della Scienza and University of Turin, Dept. of Nephrology, Turin, Italy
- P242** **The risk of venous thromboembolic events in men operated with laparoscopic or open radical prostatectomy - A nationwide population-based cohort study**
Authors: Björklund J., Rautiola J., Zelic R., Vincent P.H., Wiklund P., Aly M., Akre O.
Institutes: Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden
- P256** **Learning Curve For Single-Port Robot-Assisted Urological Surgery: Implications for Surgical Adoption**
Authors: Pellegrino A.¹, Sauer Calvo R.², Cannoletta D.¹, Morgantini L.², Pellegrino F.¹, Torres Anguiano J.², Briganti A.¹, Crivellaro S.²
Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²University of Illinois Chicago, Dept. of Urology, Chicago, United States of America

- P255** **The relationship between mental wellbeing and functional outcomes in the first year of a prostate cancer diagnosis**
Authors: Brunckhorst O.¹, Liszka J.¹, James C.¹, Fanshawe J.², Hammadeh M.², Thomas R.³, Khan S.⁴, Sheriff M.⁵, Ahmed H.⁶, Van Hemelrijck M.⁷, Muir G.⁸, Stewart R.⁹, Dasgupta P.¹, Ahmed K.¹
Institutes: ¹King's College London, MRC Centre for Transplantation, London, United Kingdom, ²Queen Elizabeth Hospital, Dept. of Urology, London, United Kingdom, ³Bedfordshire Hospitals NHS Foundation Trust, The Primrose Oncology Unit, Bedford, United Kingdom, ⁴East Surrey Hospital, Dept. of Urology, Redhill, United Kingdom, ⁵Medway NHS Foundation Trust, Dept. of Urology, Gillingham, United Kingdom, ⁶Imperial College London, Imperial Prostate Department, London, United Kingdom, ⁷King's College London, Dept. of Translational Oncology and Urology Research, London, United Kingdom, ⁸King's College Hospital, Dept. of Urology, London, United Kingdom, ⁹King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom
- P252** **Predictors for improvement of lower urinary tract symptoms (LUTS) in prostate cancer patients treated with robot assisted laparoscopic prostatectomy (RALP)**
Authors: Qvigstad L.F.¹, Diep L.M.², Eri L.M.¹, Berge V.¹
Institutes: ¹Oslo University Hospital, Dept. of Urology, Oslo, Norway, ²Oslo University Hospital, Research Support, Oslo, Norway
- P258** **A Randomized Comparison of 9 months' Maximum Androgen Blockage versus Bicalutamide 150 mg as Adjuvant Therapy for High-risk Localized Prostate Cancer: Long-Term Update of the CU1005**
Authors: Chang K., Qin X., Ye D.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- 14:27 - 14:45** **Screen D: Estimate outcome**
- P260** **Radiomics-based prognostic model guided by artificial intelligence to predict lymph node invasion and biochemical recurrence in patients with high-grade prostate cancer**
Authors: Touma N.¹, Larose M.², Brodeur R.², Desroches F.², Raymond N.³, Bédard-Tremblay D.¹, Leblanc D.², Rasekh F.¹, Hovington H.¹, Neveu B.¹, Vallières M.³, Archambault L.², Pouliot F.¹
Institutes: ¹Centre de Recherche du Centre Hospitalier Universitaire de Québec et Université Laval, Quebec City, Canada, ²Université Laval, Dept. of Physics, Engineering physics, and Optics, Quebec City, Canada, ³Université de Sherbrooke, Dept. of Computer Science, Sherbrooke, Canada
- P234** **Does prostate cancer without cribriform pattern have metastatic potential?**
Authors: Kroon L.¹, Remmers S.², Hollemans E.¹, Bangma C.², Roobol M.², Van Leenders G.¹
Institutes: ¹Erasmus Medical Center, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands
-

- P254** **Prostatic ductal adenocarcinoma and comparison to high-risk acinar adenocarcinoma of the prostate in patients undergoing robotic radical prostatectomy (RARP): A prostate cancer referral centre review**
Authors: Reddy S.K.¹, Covas Moschovas M.¹, Saikali S.¹, Gamal A.¹, Sandri M.², Harvey T.¹, Kenneth R.¹, Patel V.¹
Institutes: ¹AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²University of Brescia, Data Methods and Statistics, Brescia, Italy
- P257** **Impact of RAS Inhibitors on prostate cancer aggressiveness – a retrospective multicenter analysis by the Young academic urologists Prostate cancer group**
Authors: Artamonova N.¹, Kafka M.¹, Faiss L.¹, Avetisyan D.², Puche Sanz I.², La Bombarda G.³, Iacono G.³, Zattoni F.², Steiner E.¹, D'Elia C.⁴, Pycha A.⁴, Gandaglia G.⁵, Horninger W.¹, Heidegger I.¹
Institutes: ¹Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Hospital Universitario Virgen de las Nieves, UGC Urología, Granada, Spain, ³University of Padova, Dept. of Urology, Padua, Italy, ⁴Zentralkrankenhaus Bozen, Dept. of Urology, Bolzano, Italy, ⁵Urological Research Institute Vita-Salute University and San Raffaele Hospital, Dept. of Urology, Milan, Italy
- P259** **Association of Area Deprivation Index and Race with Prostate Cancer-Specific Mortality among Non-Hispanic Black and Non-Hispanic White men in a contemporary North American population.**
Authors: Cirulli G.O.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Tinsley S.¹, Butaney M.¹, Etta P.¹, Arora S.¹, Morrison C.¹, Lughezzani G.³, Buffi N.³, Carrieri G.⁴, Salonia A.⁵, Briganti A.⁵, Montorsi F.⁵, Rogers C.¹, Abdollah F.¹
Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation - Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁴University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁵IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy
- P248** **Assessment of Significant Clinical and Pathological Tumor Volume Cutoffs Pre vs Post RARP**
Authors: Nguyen M.X., Tran J., Zeidan Z., Haddadin E.A., Yeagyeong YH, Zhang W., Epino M., Huang E., Fung C., Ahlering T.
Institutes: University of California Irvine, Dept. of Urology, Orange, United States of America
- 14:45 - 14:57** **Screen E: Recurrent prostate cancer**
-

- P238** **Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: Analysis from a national database**
Authors: Bologna E.¹, Licari L.C.¹, Franco A.², Ditunno F.³, Manfredi C.⁴, De Nunzio C.², Antonelli A.³, Simone G.⁵, De Sio M.⁴, Pandolfo S.D.⁶, Cherullo E.E.⁷, Autorino R.⁷
Institutes: ¹Sapienza University Rome Policlinico Umberto I Hospital, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²Sant'Andrea Hospital Sapienza University, Dept. of Urology, Rome, Italy, ³Azienda Ospedaliera Universitaria Integrata Verona University of Verona, Dept. of Urology, Verona, Italy, ⁴University of Campania Luigi Vanvitelli, Unit of Urology, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ⁵Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁶University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ⁷Rush University, Dept. of Urology, Chicago, United States of America
- P244** **Detection of prostate cancer recurrences with Prostate-Specific Membrane Antigen Positron Emission Tomography after curative radiotherapy: a call for reconsideration of the Phoenix Criteria.**
Authors: van Altena E.¹, Jansen B.H.E.¹, Korbee M.², Luining W.¹, Leeuwen P.³, Wondergem M.⁴, Oprea-Lager D.¹, Vis A.¹
Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Noordwest Ziekenhuisgroep Alkmaar, Dept. of Urology, Alkmaar, The Netherlands, ³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴Noordwest Ziekenhuisgroep Alkmaar, Dept. of Nuclear Medicine, Amsterdam, The Netherlands
- P245** **Strong association between the intraoperative numeric gamma probe signal and the maximum standardized uptake value (SUVmax) on PSMA PET/CT in patients with recurrent prostate cancer**
Authors: Berrens A.C.¹, Sorbi M. .A.¹, Donswijk M.L.², de Barros H.A.¹, Azargoshasb S.³, Van Oosterom M. .N.³, Rietbergen D. .D. .D.⁴, Bekers E.M.⁵, Van Der Poel H. .G.¹, Van Leeuwen F. .W. .B.³, Van Leeuwen P. .J.¹
Institutes: ¹Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ³Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Dept. of Radiology, Leiden, The Netherlands, ⁴Leiden University Medical Centre, Dept. of Nuclear Medicine, Leiden, The Netherlands, ⁵Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands

- P250** **Assessing The Impact and Timing of Salvage Radiation Therapy In Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy and Negative PSMA PET**
Authors: Cannoletta D.¹, Mazzone E.¹, Gandaglia G.¹, Stabile A.¹, Cucchiara V.¹, Picchio M.², Cozzarini C.³, Chiti A.², Scilipoti P.¹, Longoni M.¹, Sorce G.¹, Pellegrino F.¹, Cirulli G.O.¹, Robesti D.¹, Leni R.¹, Quarta L.¹, Necchi A.⁴, Raggi A.⁴, Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Radiation Oncology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy
- 14:57 - 15:12** **Screen F: Metastatic prostate cancer**
- P249** **Inter-lesional response heterogeneity in paired PSMA and FDG PET strongly associated with conventional progression-free survival in metastatic castration resistant prostate cancer treated with abiraterone: a prospective study**
Authors: Pan J., Wu J., Ye D., Zhu Y.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- P235** **Cardiovascular Risk associated with LHRH analogue treatment and assessing those at risk: A Retrospective Cohort Study**
Authors: Gibson J.¹, Bromage S.²
Institutes: ¹East Lancashire Hospitals NHS Trust, Dept. of Urology, Blackburn, United Kingdom, ²Stockport NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
- P233** **Patient and Physician Preferences for Treatments of Metastatic Castrate Resistant Prostate Cancer**
Authors: Castro E.¹, Jones R.², Machtens S.³, Uemura H.⁴, Mclaurin K.⁵, Yeh N.⁶, Payne S.⁶, Cain T.⁶, Collacott H.⁷, Gabriela F.⁷, Heidenreich S.⁸, Morgans A.⁹
Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Oncology, Madrid, Spain, ²University of Glasgow, School of Cancer Sciences, Glasgow, United Kingdom, ³GFO Kiniken Rhein-Berg, Dept. of Urology and Paediatric Urology, Cologne, Germany, ⁴Yokohama City University Medical Center, Dept. of Oncology, Yokohama, Japan, ⁵AstraZeneca, Dept. of Oncology Outcomes Research, Gaithersburg, United States of America, ⁶AstraZeneca, Dept. of Oncology Outcomes Research, Cambridge, United Kingdom, ⁷Evidera, Dept. of Patient-Centered Research, Bethesda, United States of America, ⁸Evidera, Dept. of Patient-Centered Research, London, United Kingdom, ⁹Harvard University, Dana Farber Cancer Institute, Boston, United Kingdom
- P237** **A Phase IV Study Investigating the Contemporary Risk of Fragility Fractures Among Men with Advanced Prostate Cancer on Androgen Deprivation Therapy**
Authors: Hird A.E., Jayalath J., Matta R., Golding H., Saskin R., Wilton A.S., Neu S., Herschorn S., Nam R.K.
Institutes: University of Toronto, Dept. of Urology, Toronto, Canada
-

P240

Comparative Analysis of the Expression of Clinically Available Contemporary Antibody-Drug Conjugate Targets in Varied Prostate Cancer Types

Authors: Mulati Y., Fan Y., Tian Y., Yao K., Shen Q., Yu W., Zhang Q., He Z.

Institutes: Institute of Urology of Peking University, Dept. of Urology of Peking University First Hospital, Beijing, China

Retropubic radical prostatectomy: Tips, tricks and pitfalls

ESU Course 34

07 April 2024
14:30 - 17:30

Location Purple Area, E01
Chair G. Thalmann, Bern (CH)

Learning objectives

In many parts of Europe, open retropubic radical prostatectomy remains an alternative to robotic prostatectomy for treating localised prostate cancer for practical and financial reasons. Novel competitive treatment options should encourage urologists to optimally perform the surgical resection. This teaching course offers a refresher on the anatomy, a step-by-step demonstration of the important stages of the intervention and how to cope with specific complications. The course may benefit the elder resident and the younger urologist as well as trained urologists who do not treat many patients with localised prostate cancer.

Introduction

G. Thalmann, Bern (CH)

Surgical anatomy

I. Varkarakis, Athens (GR)

Step by step radical retropubic prostatectomy

G. Thalmann, Bern (CH)

Tips, tricks and pitfalls

I. Varkarakis, Athens (GR)

Treatment of complications

G. Thalmann, Bern (CH)

Discussion and interaction

I. Varkarakis, Athens (GR)

All about the current BPO surgical therapy

ESU Course 35

07 April 2024
14:30 - 17:30

Location Purple Area, E02
Chair T.R.W. Herrmann, Frauenfeld (CH)

Learning objectives

Subject of the course is the content of the surgical chapter of the EAU Non Neurogenic Male Luts Guidelines.

The Course will display:

- The surgical treatment algorithm of the EAU Guidelines
- The Rational behind the subdivision in Vaporisation, Resection and Enucleation
- Positioning and leverage of each surgical modality and evidence
- Enucleating modalities: endoscopic enucleation, vs Robotic / laparoscopic adenomectomy vs. Open adenomectomy
- Treatment related side effects, esp. QOL, sexual function

Surgical treatment of BPO: Current EAU guidelines.

L. Lusuardi, Salzburg (AT)

What (not) to know about lasers for BPO treatment?

T.R.W. Herrmann, Frauenfeld (CH)

Is there still a role for TUIP and TURP?

L. Lusuardi, Salzburg (AT)

Endoscopic Enucleation of the Prostate: Surgical principles & outcomes

T.R.W. Herrmann, Frauenfeld (CH)

Defining the role of laparoscopic and robotic surgery in BPO surgery

N. Barber, Camberley (GB)

Ejaculation-preserving techniques: TURP & EEP vs. MIST-techniques

T.R.W. Herrmann, Frauenfeld (CH)

Minimally invasive surgical (ablative) techniques (Rezum & Aquablation)

N. Barber, Camberley (GB)

Minimally invasive surgical (non-ablative) techniques (i-Tind, Urolift, PAE)

L. Lusuardi, Salzburg (AT)

Interactive case discussions

N. Barber, Camberley (GB)

L. Lusuardi, Salzburg (AT)

T.R.W. Herrmann, Frauenfeld (CH)

Advanced vaginal reconstruction

ESU Course 36

07 April 2024
14:30 - 17:30

Location Purple Area, E03
Chair T.J. Greenwell, London (GB)

Learning objectives

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetic tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion. Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

Introduction

T.J. Greenwell, London (GB)

Mostly vaginal surgery for stress urinary incontinence (SUI)

T. Tarcan, Üsküdar/ İstanbul (TR)

Mostly vaginal repair of pelvic organ prolapse (POP)

K-D. Sievert, Detmold (DE)

Management of mesh complications

K-D. Sievert, Detmold (DE)

Surgery for female urethral stricture and loss

T. Tarcan, Üsküdar/ İstanbul (TR)

Surgery for urethral diverticulum

T.J. Greenwell, London (GB)

Vesico-vaginal fistulae

T.J. Greenwell, London (GB)

Discussion and conclusions

T.J. Greenwell, London (GB)

Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

05 April 2024 10:45 - 12:45	Location Chairs	Green Area, W01 HE. O'Connell AO, Melbourne (AU) M.J. Ribal Caparros, Barcelona (ES)
10:45 - 10:50	Introduction	
10:50 - 11:13	Mesh cases: Exploring recent advances and best practices Moderators	To be confirmed C. Harding, Newcastle upon Tyne (GB)
10:50 - 10:55	Mesh complications and management strategies: Discuss the latest advancements in understanding and managing complications	To be confirmed
10:55 - 11:00	Emerging techniques and technologies: Explore innovative approaches and technologies related to mesh procedures	To be confirmed
11:00 - 11:05	Regulatory updates and guidelines: Provide an overview of the current regulatory landscape and guidelines governing mesh usage	E. Costantini, Perugia (IT)
11:05 - 11:13	Panel discussion	
11:13 - 11:31	Debate Focal therapy in prostate cancer improves functional outcomes Moderators	P. Cornford, Liverpool (GB) C. Varol, Sydney (AU)
11:13 - 11:20	Pro	J. Grummet, Melbourne (AU)
11:20 - 11:27	Con	G. Ploussard, Toulouse (FR)
11:27 - 11:31	Rebuttal	Pro J. Grummet, Melbourne (AU) Con G. Ploussard, Toulouse (FR)
11:31 - 11:51	Symphyseal fistula: Diagnosis, management, and future directions Moderators	To be confirmed V.W.M. Tse, Sydney (AU)
11:31 - 11:36	Evaluation and prevention of symphyseal fistula: Explore the current diagnostic methods and evaluation techniques for symphyseal fistula	V.W.M. Tse, Sydney (AU)
11:36 - 11:41	Multidisciplinary management and collaboration: Emphasize the importance of a multidisciplinary approach in managing symphyseal fistula	L. Peri Cusi, Barcelona (ES)

11:41 - 11:46	Surgical management L. Peri Cusi, Barcelona (ES)
11:46 - 11:51	Panel discussion
11:51 - 12:11	PPI including radiotherapy: Functional outcomes Moderators E. Chartier-Kastler, Paris (FR) To be confirmed
11:51 - 11:56	Functional pelvic floor US for pre and post radical prostatectomy L. Chan, Sydney (AU)
11:56 - 12:01	Role of UDS in post prostatectomy incontinence M. Costa Grau, Barcelona (ES)
12:01 - 12:06	Long term outcomes of AUS in men with prior radiotherapy A. Collado Serra, Valencia (ES)
12:06 - 12:11	Discussion including picking early diversion rather than urethral surgery V.W.M. Tse, Sydney (AU)
12:11 - 12:31	Functional aspects of urothelial cancer management Moderators D. Bolton, Heidelberg (AU) P. Gontero, Turin (IT)
12:11 - 12:16	Development and evaluation of NMIBC-SYMPTOM index M. Patel, Westmead (AU)
12:16 - 12:21	PROMS and PREMS in bladder cancer P. Mariappan, Edinburgh (GB)
12:21 - 12:26	Complications of intravesical therapy for NMIBC K. Zimmermann, Andernach (DE)
12:26 - 12:31	Complications of radiotherapy for MIBC N. Lawrentschuk, Victoria (AU)
12:31 - 12:47	Women's outcome with urothelial cancer: Identifying challenges and seeking solutions Moderators To be confirmed J.A. Witjes, Nijmegen (NL)
12:31 - 12:36	Diagnostic challenges and early detection L.S. Mertens, Amsterdam (NL)
12:36 - 12:41	Treatment approaches and individualized care J.W.F. Catto, Sheffield (GB)
12:41 - 12:47	Discussion: Long term functional outcomes bladder preservation S. Sengupta, Box Hill (AU)
	Closing remarks M.J. Ribal Caparros, Barcelona (ES) HE. O'Connell AO, Melbourne (AU)

Lower urinary tract dysfunction and urodynamics

ESU Course 37

07 April 2024
14:30 - 17:30

Location Purple Area, E04
Chair S. Musco, Firenze (IT)

Learning objectives

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics.
- Be able to assess the quality of a urodynamic trace.
- Recognise common artefacts and know how to correct them.
- Know the indications for urodynamic studies in men, women and neurological patients.

Urodynamics: Philosophy, scientific basis and technique

M.K. Przydacz, Cracow (PL)

Urodynamics in men

S. Musco, Firenze (IT)

Urodynamics in female urology

M.K. Przydacz, Cracow (PL)

Urodynamics in neurourology

S. Musco, Firenze (IT)

Theranostics in prostate cancer

ESU Course 38

07 April 2024
14:30 - 17:30

Location Purple Area, E05
Chair B.A. Hadaschik, Essen (DE)

Learning objectives

Recently theranostics, the combination of diagnosis and treatment based on the same concept, was introduced in the management of prostate cancer based on nuclear medicine technologies. This is an emerging field with promising clinical data being published very recently. The concept of theranostics has the potential to change the management of prostate cancer and to become an essential part of our armamentarium. The aim of the course is to provide an in-depth overview on these new concepts and to critically assess their performance, efficacy and limitations.

Diagnosis and initial staging of prostate cancer

Diagnosis of the primary

B.A. Hadaschik, Essen (DE)

Initial staging of prostate cancer

W.J.G. Oyen, Arnhem (NL)

The EAU guidelines perspective on early PET imaging

P. Cornford, Liverpool (GB)

Biochemical recurrence

Staging of biochemical recurrence with PET imaging

W.J.G. Oyen, Arnhem (NL)

Treatment options and risk stratification for salvage treatment

B.A. Hadaschik, Essen (DE)

What to do with the information?

P. Cornford, Liverpool (GB)

Metastatic disease

Use of PET in the management of metastatic prostate cancer

B.A. Hadaschik, Essen (DE)

Radioligand treatment for metastatic prostate cancer

W.J.G. Oyen, Arnhem (NL)

The place of radioligand treatment in the M1 prostate cancer arena

P. Cornford, Liverpool (GB)

Practical management of non-muscle-invasive bladder cancer (NMIBC)

ESU Course 39

07 April 2024
14:30 - 17:30

Location Purple Area, E06
Chair E.N. Xylinas, Paris (FR)

Learning objectives

Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities and then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

Introduction

E.N. Xylinas, Paris (FR)

Diagnosis, markers and innovations

E.N. Xylinas, Paris (FR)

TUR technique: Tips and tricks; problems; En bloc resection; TUR and the location, including diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI etc.: With several cases and videos

P. Gontero, Turin (IT)

Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.

L.S. Mertens, Amsterdam (NL)

Risk groups and guideline treatment: What is clearly established

P. Gontero, Turin (IT)

Standard of care treatment including BCG shortage and new treatment modalities on the block

E.N. Xylinas, Paris (FR)

Complications of intravesical therapy, including case

L.S. Mertens, Amsterdam (NL)

Follow-up of NMIBC

P. Gontero, Turin (IT)

How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations

L.S. Mertens, Amsterdam (NL)

Questions, answers and conclusion
E.N. Xylinas, Paris (FR)

Advanced course on upper tract laparoscopy: Kidney, ureteropelvic junction (UPJ), ureter and stones

ESU Course 40

07 April 2024
14:30 - 17:30

Location Purple Area, E07
Chair F. Porpiglia, Turin (IT)

Learning objectives

Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.

Approach: Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.

Procedures: Ablative, reconstruction, stone surgery.

Presentation: Power-point, interactive, videos, tips and tricks, complications.

- For surgery of the kidney, the da Vinci robot is often overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.
- Choice of the perfect approach makes the respective surgery easier and safer.
- Standard laparoscopy is greatly facilitated by 3D vision.
- When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

Approach: Transperitoneal, retroperitoneoscopy

B. Petrut, Cluj Napoca (RO)

Kidney: Nephrectomy, management of cysts

M.C. Mir Maresma, Valencia (ES)

Ureter: Nephroureterectomy, end-to-end anastomosis, replacement

F. Porpiglia, Turin (IT)

Pyeloplasty: Indication – techniques – problems

F. Porpiglia, Turin (IT)

Stone surgery

M.C. Mir Maresma, Valencia (ES)

Complication management

B. Petrut, Cluj Napoca (RO)

Questions, tips and tricks

M.C. Mir Maresma, Valencia (ES)

F. Porpiglia, Turin (IT)

B. Petrut, Cluj Napoca (RO)

European Urology Surgery in Motion: Novel robotic approaches for challenging benign cases

Thematic Session

07 April 2024
15:30 - 17:00

Location Chairs

Purple Area, eURO Auditorium 2
A. Briganti, Milan (IT)
R. De Groot, Aalst (BE)
N.N. Harke, Hannover (DE)
A. Mottrie, Aalst (BE)

Learning objectives

This session will deal with the extension of indications of robotic surgery, mainly in the field of challenging benign cases. We aim to widen your interest in robotics so that you will adopt minimally invasive surgery, also for non-oncological surgery for the benefit of your patients. Experts will give tips and tricks on how to optimally set the indication and perform the surgery.

15:30 - 15:35

Welcome and introduction

15:35 - 16:15

Modern management of ureteric strictures

15:35 - 15:45

Proximal ureteric strictures

B. McGuire, Dublin (IE)

15:45 - 15:55

Is there still a place for ureteral reimplantation and how?

R. Nair, London (GB)

15:55 - 16:05

Extended ureteral stricture: Ileal interposition

A. Minervini, Florence (IT)

16:05 - 16:15

Extended ureteral stricture: Renal autotransplantation

To be confirmed

16:15 - 16:25

Use of technology in benign robotic surgery: ICG, Augmented reality, Tilepro and stapling

A. Mottrie, Aalst (BE)

16:25 - 16:55

Prosthetic surgery in the robotic era

16:25 - 16:35

Male bladder neck AUS

M.A. Perrouin Verbe, Nantes (FR)

16:35 - 16:45

Female AUS

B. Peyronnet, Rennes (FR)

16:45 - 16:55

Mesh sacrocolpopexy

E. Costantini, Perugia (IT)

16:55 - 17:00

Conclusion

Intensify treatment for better prostate cancer control

Abstract session 29

07 April 2024
15:30 - 17:00

Location Green Area, N03
Chairs J. Gadu Campos Salcedo, Mexico City (MX)
W. Loidl, Linz (AT)
A.S. Rannikko, Helsinki (FI)
To be confirmed

15:30 - 15:32

Introduction

15:32 - 15:47

Neoadjuvant treatment

A0602

Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.

Authors: Devos G.T.¹, Tosco L.¹, Baldewijns M.², Giesen A.¹, Gevaert T.², Goffin K.³, Petit V.⁴, Mai C.⁴, Raskin Y.¹, Van Haute C.¹, De Meerleer G.⁵, Berghen C.⁵, Devlies W.¹, Van Poppel H.¹, Claessens F.⁶, Everaerts W.¹, Joniau S.¹

Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium, ³University Hospitals Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ⁴University Hospitals Leuven, Dept. of Radiology, Leuven, Belgium, ⁵University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium, ⁶University Hospitals Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium

A0604

Two-year quality of life (QoL) outcomes of the randomized phase II trial ARNEO: neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

Authors: Giesen A.¹, Devos G.¹, Tosco L.¹, Baldewijns M.², Gevaert T.¹, Goffin K.³, Petit V.⁴, Mai C.⁴, Raskin Y.¹, Van Haute C.¹, Goeman L.⁵, De Meerleer G.⁶, Berghen C.⁶, Devlies W.¹, Claessens F.⁷, Van Poppel H.¹, Everaerts W.¹, Joniau S.¹

Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium, ³University Hospitals Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ⁴University Hospitals Leuven, Dept. of Radiology, Leuven, Belgium, ⁵KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ⁶University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium, ⁷KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium

A0613

Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: results of a prospective study.

Authors: Zhuang J.¹, Zhang S.², Qiu X.², Zhou F.³, Guo H.²

Institutes: ¹Affiliated Drum Tower hospital, Dept. of Urology, Nanjing, China, ²Affiliated Drum Tower hospital, Dept. of Urology, Nanjing, China, ³The First Affiliated Hospital School of Medicine Zhejiang University, Dept. of Urology, Hangzhou, China

15:47 - 16:12

Adjuvant treatment

A0608

Which Is the Optimal Multimodal Management of pN1 Patients with PSA Persistence After Radical Prostatectomy and Extended Nodal Dissection? Results of a Large, Multi-Institutional Database

Authors: Scuderi S.L.A.¹, Marra G.², Olivier J.³, Stabile A.¹, Mazzone E.¹, Afferi L.⁴, Mattei A.⁴, Malkiewicz B.⁵, Gallina S.⁶, Antonelli A.⁶, Zattoni F.⁷, Van Den Bergh R.⁸, Rajwa P.⁹, Shariat S.F.⁹, Cathelineau X.¹⁰, Nicoletti R.¹¹, Campi R.¹¹, Ahmed M.¹², Karnes R.J.¹², Heidegger I.¹³, Montorsi F.¹, Gontero P.², Briganti A.¹, Gandaglia G.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ³Lille University Hospital, Dept. of Urology, Lille, France, ⁴Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁵University Center of Excellence in Urology, Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ⁶University of Verona - Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁷University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁸Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁹Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ¹⁰Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ¹¹Unit of Urological Robotic Surgery and Renal Transplantation - Careggi Hospital, Dept. of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹³Innsbruck University Hospital, Dept. of Urology, Innsbruck, Austria

A0614

Early oncological outcomes following radical prostatectomy of patients with pelvic lymph node-positive prostate cancer at preoperative PSMA PET/CT

Authors: Zuur L.G.¹, de Bie K.², Vis A.N.², Van Der Poel H.G.¹, Donswijk M.L.³, Oprea-Lager D.E.⁴, Roberts M.⁵, Van Leeuwen P.J.¹

Institutes: ¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁴Amsterdam University Medical Center, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁵Royal Brisbane and Women's Hospital, Dept. of Urology, Brisbane, Australia

A0605

Natural history of pN1 prostate cancer after radical prostatectomy: competing risk analysis from a large multi-institutional series

Authors: Milonas D.¹, Giesen A.², Lorenzo T.², Annouschka L.³, Zilvinas V.¹, Devos G.², Alberto B.⁴, Gontero P.⁵, Graefen M.⁶, Chlosta P.⁷, Gratzke C.⁸, Marchioro G.⁹, Sanchez-Salas R.¹⁰, Tombal B.¹¹, Van Der Poel H.¹², Van Poppel H.², Karnes R.J.¹³, Spahn M.¹⁴, De Meerleer G.¹⁵, Joniau S.²

Institutes: ¹Lithuanian University of Health Sciences, Dept of. Urology, Kaunas, Lithuania, ²University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ³KU Leuven, Leuven Biostatistics and Statistical Bioinformatics Center, Leuven, Belgium, ⁴Vita Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁵University of Studies of Torino, Dept of. Urology, Turin, Italy, ⁶Martini Klinik, Dept. of Urology, Hamburg, Germany, ⁷Jagiellonian University, Dept. of Urology, Krakow, Poland, ⁸Ludwig-Maximilians-Universität München, Dept. of Urology, Munich, Germany, ⁹Azienda Ospedaliero Universitaria Maggiore della Carità, Dept of. Urology, Novara, Italy, ¹⁰Institute Mutualiste Montsouris, Dept. of Urology, Paris, France, ¹¹Université Catholique de Louvain, Dept. of Urology, Brussels, Belgium, ¹²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹⁴Universitätsspital Bern, Dept. of Urology, Bern, Switzerland, ¹⁵University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium

A0609

Adjuvant or Early Salvage Radiotherapy in Node Positive Prostate Cancer Patients: Development of a Novel Risk Score to Identify the Optimal Candidate for Early Intensification Approaches Based on a Large, Multi-Institutional Series.

Authors: Barletta F.M.¹, Marra G.², Olivier J.³, Grogg J.B.⁴, Hermanns T.⁴, Afferi L.⁵, Mattei A.⁵, Malkiewicz B.⁶, Antonelli A.⁷, Zattoni F.⁸, Dal Moro F.⁸, Van Den Bergh R.⁹, Rajwa P.¹⁰, Shariat S.F.¹⁰, Cathelineau X.¹¹, Nicoletti R.¹², Campi R.¹², Ahmed M.¹³, Karnes R.J.¹³, Heidegger I.¹⁴, Montorsi F.¹, Gontero P.², Briganti A.¹, Gandaglia G.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ³Lille University Hospital, Dept. of Urology, Lille, France, ⁴University Hospital Zürich, Dept. of Urology, Zürich, Switzerland, ⁵Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁶University Center of Excellence in Urology, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ⁷University of Verona - Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁸University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁹Antonius Hospital Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹⁰Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹¹Institut Mutualiste Montsouris and Paris Descartes University, Dept. of Urology, Paris, France, ¹²Careggi Hospital - University of Florence, Dept. of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹⁴University Hospital of Innsbruck, Dept. of Urology, Innsbruck, Austria

A0601

Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials

Authors: Nabid A.¹, Carrier N.², Martin A.G.³, Vigneault E.³, Nguyen T.V.⁴, Bahary J.P.⁴, Vavassis P.⁵, Bahoric B.⁶, Brassard M.A.⁷, Vass S.⁷, Archambault R.⁸, Vincent F.⁹, Bettahar R.¹⁰, Duclos M.¹¹, Wilke D.¹², Souhami L.¹¹

Institutes: ¹CIUSSS de l'Estrie - CHUS, Dept. of Radiation Oncology, Sherbrooke, Canada, ²CIUSSS de l'Estrie - CHUS, Dept. of Statistics, Sherbrooke, Canada, ³Centre Hospitalier Universitaire de Québec, Dept. of Radiation Oncology, Quebec City, Canada, ⁴Centre Hospitalier Universitaire de Montréal, Dept. of Radiation Oncology, Montreal, Canada, ⁵Hopital Maisonneuve-Rosemont de Montreal, Dept. of Radiation Oncology, Montreal, Canada, ⁶Jewish General Hospital, Dept. of Radiation Oncology, Montreal, Canada, ⁷Centre de Santé et de Service Sociaux de Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada, ⁸Hopital de Gatineau, Dept. of Radiation Oncology, Gatineau, Canada, ⁹Centre Hospitalier Régional de Trois-Rivières, Dept. of Radiation Oncology, Trois-Rivières, Canada, ¹⁰Centre Hospitalier Régional de Rimouski, Dept. of Radiation Oncology, Rimouski, Canada, ¹¹McGill University Health Centre, Dept. of Radiation Oncology, Montreal, Canada, ¹²Nova Scotia Cancer Center, Dept. of Radiation Oncology, Halifax, Canada

16:12 - 16:27

Time and PSA kinetics for risk stratification for biochemical recurrence

A0611

Avoiding Overtreatment using PSA Doubling Time Kinetics: Long-Term Management of BCR Following RARP

Authors: Tran J., Hassas N., Gevorkyan R., Huang E., Fung C., Ahlering T.

Institutes: University of California Irvine, Dept. of Urology, Orange, United States of America

A0612

PSA Doubling Time Thresholds in Predicting Clinical Recurrence after Biochemical Recurrence in Surgically Treated Prostate Cancer Patients. The Impact of Nodal Status and Adjuvant Radiotherapy

Authors: Nocera L., Mazzone E., Scuderi S., Barletta F., Cannoletta D., Quarta L., Pellegrino A., Pellegrino F., Scilipoti P., Sorce G., Leni R., Longoni M., Cirulli G.O., Cucchiara V., Robesti D., Gandaglia G., Montorsi F., Briganti A.

Institutes: IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

A0615

The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment.

Authors: Pellegrino F.¹, Falagarino U.G.¹, Abbadi A.², Björnebo L.², Valdman A.³, Carrieri G.⁴, Briganti A.⁵, Montorsi F.⁵, Akre O.¹, Aly M.¹, Eklund M.², Nordström T.², Grönberg H.², Lantz A.¹, Wiklund P.¹

Institutes: ¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, ⁴University of Foggia, Dept. of Urology and kidney Transplantation, Foggia, Italy, ⁵IRCCS San Raffaele Hospital, Unit of Urology, Division of Oncology, Milan, Italy

16:27 - 16:57

Metastasis directed therapy and recurrence

A0603

PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized controlled trial

Authors: Belliveau C.¹, Saad F.², Duplan D.³, Petit C.⁴, Delouya G.¹, Daniel T.¹, Barkati M.¹, Lambert C.¹, Beauchemin M.C.¹, Clavel S.³, Mok G.³, Igidbashian L.³, Nguyen T.V.⁵, McLaughlin P.Y.⁶, Keu K.V.⁷, DaSilva J.⁸, Juneau D.⁹, Ménard C.¹⁰

Institutes: ¹Centre Hospitalier de l'Université de Montréal, Radiation-Oncology, Montréal, Canada, ²Centre Hospitalier de l'Université de Montréal, Urology, Montréal, Canada, ³Centre Intégré de Santé et de Services Sociaux de Laval, Radiation-Oncology, Laval, Canada, ⁴Institut Paoli Calmettes, Radiothérapie, Marseille, France, ⁵Hopital de Charles-Le Moyne, Radiation-Oncology, Longueuil, Canada, ⁶Hopital de Gatineau, Radiation-Oncology, Montréal, Canada, ⁷Hopital de la Cité-de-la-Santé, Nuclear Medicine, Laval, Canada, ⁸Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Radiochimie et cyclotron, Montréal, Canada, ⁹Centre Hospitalier de l'Université de Montréal, Nuclear Medicine, Montréal, Canada, ¹⁰Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Radiation-Oncology, Montréal, Canada

A0610

Identifying the optimal definition of PSA response after metastasis directed therapy in Men With oligo-recurrent prostate cancer detected at PSMA PET.

Authors: Mazzone E.¹, Gandaglia G.¹, Pellegrino F.¹, Stabile A.¹, Scuderi S.¹, Barletta F.¹, Cannoletta D.¹, Robesti D.¹, Pellegrino A.¹, Longoni M.¹, Scilipoti P.¹, Samanes Gajate A.M.², Picchio M.², Chiti A.², Ghezzi S.¹, Mapelli P.², Necchi A.³, Raggi D.³, Karakiewicz P.I.⁴, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Nuclear Medicine, Milan, Italy, ³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Oncology, Milan, Italy, ⁴University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

A0616

Prostate-specific Membrane Antigen-radioguided Surgery Salvage Lymph Node Dissection: Experience with Fifty Oligorecurrent Prostate Cancer Patients in a Single Center

Authors: Mayr R.¹, Engelmann S.U.¹, Yang Y.¹, Maximilian H.¹, Schnabel M.J.¹, Breyer J.¹, Burger M.¹, Eiber M.², Schmidt D.³, Hellwig D.³, Moosbauer J.³, Grosse J.³

Institutes: ¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²Technical University of Munich Rechts der Isar Medical Center, Dept. of Nuclear Medicine, Munich, Germany, ³University of Regensburg, Dept. of Nuclear Medicine, Regensburg, Germany

A0600

PSICHE trial (NCT05022914): PSMA guided approach for biochemical relapse after prostatectomy- a prospective trial

Authors: Francolini G.¹, Di Cataldo V.¹, Garlatti P.², Detti B.¹, Bertini N.², Ilaria B.², Caini S.³, Franzese C.⁴, Scorsetti M.⁴, Simoni N.⁵, Colombo F.⁵, Chiti A.⁶, Serni S.⁷, Campi R.⁷, Minervini A.⁸, Vaggelli L.⁹, Burchini L.², Frosini G.², Loi M.¹, Simontacchi G.¹, Desideri I.², Meattini I.², Valicenti R.K.¹⁰, Livi L.²

Institutes: ¹Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy, ²University of Florence, Dept. of Biomedical Experimental and Clinical Sciences Mario Serio, Florence, Italy, ³Institute for Cancer Research Prevention and Clinical Network ISPRO, Cancer Risk Factors and Lifestyle Epidemiology Unit, Florence, Italy, ⁴Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ⁵Azienda Ospedaliera Universitaria, Radiotherapy Unit, Parma, Italy, ⁶IRCCS San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ⁷University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ⁸University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Florence, Italy, ⁹Careggi University Hospital, Nuclear Medicine Division, Florence, Italy, ¹⁰UC Davis, Dept. of Radiation Oncology, Davis, United States of America

A0607

Prognostic factors of long-term survival rates after PSMA/PET-based salvage whole pelvic radiotherapy for recurrent prostate cancer.

Authors: Grivas N.¹, Zuur L.¹, Van Leeuwen P.¹, Wit E.¹, Vis A.², Nieuwenhuijzen J.², Vogel W.³, Pos F.³, Van Der Poel H.¹

Institutes: ¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²VU University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Radiation Oncology, Amsterdam, The Netherlands

A0606

Prostate re-irradiation after previous definitive or salvage radiotherapy (RE-START). A study on behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Authors: Francolini G.¹, Matrone F.², Donofrio A.², Marvaso G.³, Jereczek-Fossa B.A.³, Belgioia L.⁴, D'angelo E.⁵, Mazzola R.⁶, Ingargiola R.⁷, Fontana A.⁸, Cacciola A.⁹, Scipilliti E.¹⁰, Miszczyk M.¹¹, Di Cataldo V.¹, Livi L.¹

Institutes: ¹Azienda Ospedaliero Universitaria Careggi, Dept. of Radiation Oncology, Florence, Italy, ²Centro di Riferimento Oncologico di Aviano IRCCS, Division of Radiation Oncology, Aviano, Italy, ³IEO European Institute of Oncology IRCCS, Dept. of Radiation Oncology, Milan, Italy, ⁴IRCCS Ospedale Policlinico San Martino, Dept. of Radiotherapy, Genoa, Italy, ⁵Azienda Ospedaliero Universitaria di Modena, Radiotherapy Unit, Modena, Italy, ⁶IRCCS Sacro Cuore Don Calabria Hospital, Dept. of Advanced Radiation Oncology, Verona, Italy, ⁷National Center for oncological hadrontherapy, Radiation Oncology Unit, Pavia, Italy, ⁸Santa Maria Goretti Hospital, Dept. of Radiotherapy, Latina, Italy, ⁹University of Messina, Radiation Oncology Unit, Dept. of Biomedical Dental Sciences and Morphological and Functional Images, Messina, Italy, ¹⁰Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Dept. of Radiation Oncology, Naples, Italy, ¹¹Maria Skłodowska-Curie National Research Institute of Oncology, 3rd Radiotherapy and Chemotherapy Department, Gliwice, Poland

16:57 - 17:00

Expert summary

Responsible and affordable medicine

Thematic Session

07 April 2024
15:30 - 17:00

Location Purple Area, S01
Chairs R. Hovhannisyanyan, Yerevan (AM)
G. Karazanashvili, Tbilisi (GE)

Learning objectives

The session is about to make medical care widely affordable without compromising the highest standards of medical care

15:30 - 15:35	Introduction: Value based health care & oncology R. Hovhannisyanyan, Yerevan (AM)
15:35 - 15:40	When there is no MRI for PCa diagnosis: Extended biopsy? R. Sosnowski, Warsaw (PL)
15:40 - 15:45	When there is no MRI for PCa diagnosis: Ultrasound? G. Karazanashvili, Tbilisi (GE)
15:45 - 15:55	Added value of expensive oncological medication, non-histology based medical oncological treatment To be confirmed
15:55 - 16:15	Debate Upfront orchiectomy for metastatic PCa
15:55 - 16:05	Pro M. Arslan, Istanbul (TR)
16:05 - 16:15	Con R.J.A. Van Moorselaar, Amsterdam (NL)
16:15 - 16:25	Telemonitoring allows better and cheaper patient contact and patient care as compared to face to face visits H. Borgmann, Brandenburg an der Havel (DE)
16:25 - 16:35	Understanding the urology needs of countries with limited access to resources S.M. Gueye, Dakar (SN)
16:35 - 16:55	Debate Disposable cystoscope
16:35 - 16:45	No M. Baboudjian, Marseille Cedex (FR)
16:45 - 16:55	Yes To be confirmed
16:55 - 17:00	Closing remarks G. Karazanashvili, Tbilisi (GE)

From techniques to outcomes: Navigating kidney cancer care in the modern era

Abstract session 30

**07 April 2024
15:30 - 17:00**

Location Purple Area, S03
Chairs M. Eto, Fukuoka (JP)
To be confirmed
G. Pignot, Marseille (FR)

A0628

Renal function after CT-guided cryoablation of small renal tumours in patients with solitary kidney - An Analysis of European Multinational Prospective EuRECA Registry

Authors: Pietersen P.I.¹, Junker T.¹, Stougaard S.¹, Keeley F.X.², Lagerveld B.W.³, Breen D.⁴, King A.⁴, Nielsen T.K.⁵, Van Strijen M.⁶, Garnon J.⁷, Alcorn D.⁸, de Kerviler E.⁹, Zondervan P.J.¹⁰, Wah T.M.¹¹, Graumann O.¹

Institutes: ¹Odense University Hospital, Dept. of Radiology, Odense, Denmark, ²North Bristol NHS Trust, Bristol Urological Institute, Bristol, United Kingdom, ³OLVG, Dept. of Urology, Amsterdam, The Netherlands, ⁴Southampton University Hospitals, Dept. of Radiology, Southampton, United Kingdom, ⁵Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁶St Antonius Hospital, Dept. of Radiology, Nieuwegein, The Netherlands, ⁷Nouvel Hopital Civil France, Dept. of Interventional Radiology, Strasbourg, France, ⁸Gartnavel General Hospital, Dept. of Interventional Radiology, Glasgow, United Kingdom, ⁹Saint-Louis Hospital, Dept. of Radiology, Paris, France, ¹⁰Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ¹¹Leeds Teaching Hospitals Trust - St. James's University Hospital, Dept. of Diagnostic and Interventional Radiology, Leeds, United Kingdom

A0619

A detailed analysis about perioperative complications, length of stay, readmission rates and treatment time after percutaneous thermal ablation for small renal masses

Authors: Piccinelli M.L.¹, Luzzago S.¹, Mistretta F.A.¹, Mauri G.², Vaccaro C.¹, Tozzi M.¹, Guglielmo O.¹, Graps G.¹, Fallara G.¹, Cioffi A.¹, Cordima G.¹, Matei D.V.¹, Ferro M.¹, Orsi F.², Musi G.¹, De Cobelli O.¹

Institutes: ¹European Institute of Oncology, Dept. of Urologic Surgery, Milan, Italy, ²European Institute of Oncology, Division of Interventional Radiology, Milan, Italy

A0627

Comparison of survival outcomes following surgical treatment and local nonsurgical treatment of kidney cancer patients with a history of radical nephrectomy: a population study based on the SEER database

Authors: Ruiyi D., Nienie Q., Jingcheng Z., Jianhui Q., Lin C., Kan G.
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

A0623

Quality metrics for renal cell carcinoma (RCC) surgical care: Insights from a large contemporary multi-institutional Registry

Authors: Campi R.¹, Pecoraro A.¹, Bertolo R.², Marchioni M.³, Roussel E.⁴, Pavan N.⁵, Erdem S.⁶, Palumbo C.⁷, Wu Z.⁸, Gopal S.⁹, Simone G.¹⁰, Capitanio U.¹¹, Mari A.¹², Pandolfo S.¹³, Warren H.¹⁴, Pecoraro A.¹⁵, Borregales L.¹⁶, Muselaers S.¹⁷, Breda A.¹⁸, Minervini A.¹², Serni S.¹, Amparore D.¹⁹

Institutes: ¹Careggi University Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ²Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ³SS Annunziata Hospital, Unit of Urology, Chieti, Italy, ⁴UZ Leuven, Dept. of Urology, Leuven, Belgium, ⁵University of Trieste, Dept. of Medical Surgical and Health Science, Trieste, Italy, ⁶University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Türkiye, ⁷University of Eastern Piedmont, Division of Urology, Dept. of Translational Medicine, Novara, Italy, ⁸Changhai Hospital, Dept. of Urology, Shanghai, China, ⁹Medanta Hospital, Dept. of Urology, Gurugram, India, ¹⁰IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹¹San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹²Careggi University Hospital, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ¹³VCU Health System, Division of Urology, Richmond, United States of America, ¹⁴Guys and St Thomas NHS Foundation Trust, Urology Centre, London, United Kingdom, ¹⁵Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy, ¹⁶New York-Presbyterian Hospital, Dept. of Urology, New York, United States of America, ¹⁷Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ¹⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁹San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy

A0633

Prospective quality assessment using Patient Reported Outcomes (PROMS) of nurse-led coordinated pathways of care for Robotic Assisted Partial Nephrectomy (RAPN) (UroCCR 25)

Authors: Margue G., Klein C., Khaddad A., Ricard S., Calde E., Alezra E., Capon G., Bladou F., Robert G., Bernhard J.C.

Institutes: Bordeaux University Hospital, Dept. of Urology, Bordeaux, France

A0631

Exploring the associations between hospital volume and complications in renal cancer surgery

Authors: Akerlund J., Mansson M.M., Grenabo Bergdahl A.G.B.

Institutes: University of Gothenburg, Dept. of Urology, Gothenburg, Sweden

A0626

Urinary fistulae after robotic partial nephrectomy – analysis of a multicenter database

Authors: Fuhrmann C.¹, Katzendorn O.¹, Schiefelbein F.², Schoen G.³, Wiesinger C.⁴, Pfuner J.⁴, Ubrig B.⁵, Gloger S.⁵, Nuhn P.⁶, Eraky A.⁶, Wagner C.⁷, Ayanle A.⁷, Kesch C.⁸, Al-Nader M.⁸, Hadaschik B.A.⁸, Kuczyk M.A.¹, Faraj Tabrizi P.¹, Siemer S.⁹, Stöckle M.⁹, Zeuschner P.⁹, Harke N.N.¹

Institutes: ¹Hannover Medical School, Dept. of Urology and Urological Oncology, Hannover, Germany, ²Klinikum Wuerzburg Mitte, Missioklinik, Dept. of Urology, Wuerzburg, Germany, ³Urologische Klinik Muenchen-Planegg, Dept. of Urology, Munich, Germany, ⁴Klinikum Wels-Grieskirchen GmbH, Dept. of Urology, Wels, Austria, ⁵University Witten-Herdecke - Augusta-Kranken-Anstalt Bochum, Chair and Department of Urology, Bochum, Germany, ⁶University of Schleswig Holstein Campus Kiel, Dept. of Urology, Kiel, Germany, ⁷St. Antonius Hospital Gronau, Dept. of Urology, Gronau, Germany, ⁸University Hospital Essen, Dept. of Urology, Essen, Germany, ⁹Saarland University, Dept. of Urology and Pediatric Urology, Homburg Saar, Germany

A0624

SAFE: Multi-institutional study of time to complications after robot-assisted partial nephrectomy, selection of a population eligible for outpatient management (UroCCR 90)

Authors: Barthe F.¹, Bentellis I.¹, Benhard J.C.², Bensalah K.³, Champy C.⁴, Doumerc N.⁵, Olivier J.⁶, Audenet F.⁷, Parier B.⁸, Brenier M.⁹, Long J.A.¹⁰, Nouhaud F.X.¹¹, Branger N.¹², Lang H.¹³, Bossier R.¹⁴, Durand M.¹, Ahallal Y.¹

Institutes: ¹CHU de Nice, Dept. of Urology, Andrology and Kidney Transplantation, Nice, France, ²CHU Bordeaux, Dept. of Urology, Bordeaux, France, ³CHU Rennes, Dept. of Urology, Rennes, France, ⁴CHU Henri-Mondor, Dept. of Urology, Paris, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France, ⁶CHU Lille, Dept. of Urology, Lille, France, ⁷Hopital Europeen Georges Pompidou, Dept. of Urology, Paris, France, ⁸Le Kremlin Bicetre, Dept. of Urology, Paris, France, ⁹Saint Joseph, Dept. of Urology, Paris, France, ¹⁰CHU Grenoble, Dept. of Urology, Grenoble, France, ¹¹CHU Rouen, Dept. of Urology, Rouen, France, ¹²Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ¹³CHU Strasbourg, Dept. of Urology, Strasbourg, France, ¹⁴CHU la Conception, Dept. of Urology, Marseille, France

A0622

Robotic partial nephrectomy is associated with a significantly decreased rate of postoperative pseudoaneurysm as compared to open and laparoscopic partial nephrectomy

Authors: Mahmud H., Haitovich B., Zilberman D., Rozenswig B., Laufer M.L., Friedman E.F., Zohar D.Z.

Institutes: Sheba Tel-HaShomer Medical Centre, Dept. of Urology, Ramat Gan, Israel

A0620

Does robot-assisted partial nephrectomy / nephrectomy has favourable perioperative cytokine response compared to laparoscopic / open renal surgery? : A Prospective study .

Authors: Mete U.¹, Thakur A.¹, Aggarwal R.²

Institutes: ¹PGIMER, Dept. of Urology, Chandigarh, India, ²PGIMER, Dept. of Immunopathology, Chandigarh, India

- A0618** **Incidence and risk factors for urinary fistula in patients undergoing partial nephrectomy: results of a single-center cohort study (UroCCR n°170)**
Authors: Margue G., Klein C., Geshkovska A., Alezra E., Estrade V., Capon G., Bladou F., Robert G., Bernhard J.C.
Institutes: Bordeaux University Hospital, Dept. of Urology, Bordeaux, France
- A0621** **Clinical characteristics of patients with renal cancer do impact more than ischemia time on post-operative renal function**
Authors: Rosiello G., Musso G., Re C., Cei F., Belladelli F., Trevisani F., Cignoli D., Salerno L., Basile G., Bertini A., Rowe I., Ferrara A., Mazzone E., Gandaglia G., Bertini R., Montorsi F., Briganti A., Salonia A., Larcher A., Capitanio U.
Institutes: IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology - Urological Research Institute, Milan, Italy
- A0617** **Comparative analysis of mortality and progression to end-stage renal disease between surgically induced-chronic kidney disease versus medical chronic kidney disease - Multicenter hospital-based cohort study**
Authors: Jung G.¹, Song S.H.², Han J.H.³, Oh K.H.⁴, Byun S.S.², Jeong C.W.³
Institutes: ¹Hanyang University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ³Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ⁴Seoul National University Hospital, Dept of. Nephrology, Seoul, South Korea
- A0634** **Development and temporal external validation of a simple risk classification tool with location index and tumor volume for the prediction of renal function after robotic partial nephrectomy**
Authors: Ohsugi H., Ikeda J., Takayasu K., Takizawa N., Taniguchi H., Yanishi M., Kinoshita H.
Institutes: Kansai Medical University Hospital, Dept. of Urology and Andrology, Osaka, Japan
- A0630** **Predictors of renal function improvement after partial nephrectomy**
Authors: Afari J.¹, Saitta C.S.¹, Yuen K.L.¹, Puri D.P.¹, Nguyen M.V.¹, Meagher M.M.¹, Wang L.W.¹, Kevin K.H.¹, Roberts J.R.¹, Liu F.L.¹, Nicaise E.², Greenwald R.², Imtiaz N.², Patil D.², Fujii Y.F.³, Derweesh I.H.¹
Institutes: ¹University of California San Diego, Dept. of Urology, San Diego, United States of America, ²Emory University, Dept. of Urology, Atlanta, United States of America, ³Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan
- A0632** **Incorporating C-Reactive Protein into the Trifecta: Implications for Survival and Functional Outcomes Following Partial Nephrectomy**
Authors: Afari J., Saitta C., Yuen K., Meagher M., Nguyen M., Hakimi K., Wang L., Cortes J., Mahmood M., Matian J., Mansour M., Puri D., Cerrato C., Derweesh I.
Institutes: UC San Diego Health System, Dept. of Urology, San Diego, United States of America
-

A0629

Surgical Experience and Functional Outcomes after Laparoscopic and Robot-Assisted Partial Nephrectomy: Results from a Multi-Institutional Collaboration

Authors: Bravi C.A.¹, Tappero S.², Dell'Oglio P.², Campi R.³, Bertolo R.⁴, Da Pozzo L.F.⁵, Simone G.⁶, Suardi N.⁷, Schiavina R.⁸, Bensalah K.³, Canda E.⁹, Zhang X.¹⁰, Terrone C.¹¹, Shariat S.¹², Porpiglia F.¹³, Antonelli A.⁴, Kaouk J.¹⁴, Badani K.¹⁵, Minervini A.³, Derweesh I.¹⁶, Breda A.¹⁷, Mottrie A.¹⁸, Montorsi F.¹⁹, Larcher A.¹⁹

Institutes: ¹The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ³University of Florence Careggi Hospital, Dept. of Urology, Florence, Italy, ⁴Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁵Milano Bicocca University School of Medicine, Dept. of Urology, Milan, Italy, ⁶IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁷Spedali Civili, Dept. of Urology, Brescia, Italy, ⁸IRCCS Azienda Ospedaliera Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ⁹Koç University, Dept. of Urology, Istanbul, Türkiye, ¹⁰Chinese PLA General Hospital, Dept. of Urology, Beijing, China, ¹¹IRCCS Policlinico San Martino, Dept. of Urology, Genoa, Italy, ¹²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹³San Luigi Hospital, Dept. of Urology, Turin, Italy, ¹⁴Glickman Urological and Kidney Institute, Dept. of Urology, Cleveland, United States of America, ¹⁵Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁶University of California, Dept. of Urology, San Diego, United States of America, ¹⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁸OLV Hospital, ORSI Academy, Dept. of Urology, Aalst, Belgium, ¹⁹IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy

A0625

The effect of metabolic syndrome on long-term renal function after partial nephrectomy

Authors: Scilipoti P.¹, Rosiello G.¹, Trevisani F.¹, Bettiga A.¹, Musso G.¹, Re C.¹, Cei F.¹, Belladelli F.¹, Salerno L.¹, Iannace F.¹, Stattin P.², Ventimiglia E.¹, Necchi A.³, Raggi D.³, Rowe I.¹, Alfano M.¹, Bertini R.¹, Montorsi F.¹, Salonia A.¹, Larcher A.¹, Capitanio U.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Experimental Oncology - Urological Research Institute, Milan, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Medical Oncology, Milan, Italy

Exploring options in minimally invasive ureteroplasty

Video session 10

07 April 2024
15:30 - 17:00

Location Green Area, S04
Chairs To be confirmed
To be confirmed
To be confirmed

- V072 **Intravesical Laparoscopic Cohen's cross trigonal bilateral ureteric reimplant**
Authors: [Thangarasu M.](#)¹, T N.S.¹, Ratheesh R.², S R.¹
Institutes: ¹Asian Institute of Nephrology and Urology, Dept. of Urology, Chennai, India, ²Texas Tech University, Dept. of Internal Medicine, Richmond, United States of America
- V073 **Robot Assisted Excisional Tapering and Ureteric Re-implantation: Surgical tips and tricks**
Authors: Sharma A.P., [Bora G.S.](#), Mavuduru R., Devana S., Mete U.
Institutes: Postgraduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India
- V074 **Robot-assisted surgical treatment for ureteral stenosis: Comparison of different techniques**
Authors: Annino F., [Chiaramonti E.](#), Bianchi B., Verdelli L., DI COSTANZO R.
Institutes: San Donato Hospital, Dept. of Urology, Arezzo, Italy
- V075 **Robotic-assisted repair of complex ureteral stricture after kidney transplantation. 3D virtual models and intraoperative laparoscopic ultrasound are essential tools in the planning and performance of surgery**
Authors: [Burgos Revilla F.J.](#), Sanz-Mayayo E., Laso I., Lorca J., Del Olmo P., Diez-Nicolás V., Arias F., Gómez-Dos-santos V.
Institutes: Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Dept. of Urology, Madrid, Spain
- V076 **Robot-assisted pyeloplasty with direct pyelo-ureteral anastomosis for retrocaval ureter**
Authors: [Mottaran A.](#), Scarlatti R., Presutti M., Salvador M., Piazza P., Droghetti M., Bianchi L., Schiavina R., Brunocilla E.
Institutes: IRCCS Azienda ospedaliero-univeritaria di Bologna, Dept. of Urology, Bologna, Italy
- V077 **Laparoscopic appendiceal interposition techniques for the management of ureteral stricture disease.**
Authors: [Karavitakis M.](#), Leotsakos I., Katafigiotis I., Grivas N., Zabaftis C., Ntoutsias A.
Institutes: Lefkos Stavros the Athens Clinic, Dept. of Laparoscopy and Endourology, Athens, Greece
- V078 **Robotic-assisted laparoscopic ureteroplasty using a non-transecting side-to-side technique for distal ureteral strictures.**
Authors: Gonzalez Jauregui R., Bhalla R.G.B., Coddington N., [Flynn B.](#)
Institutes: University of Colorado, Dept. of Surgery, Aurora, United States of America
- V079 **Techniques and Outcomes of Minimally Invasive Augmentation Ureteroplasty using Buccal Mucosal Graft for Ureteric Strictures**
Authors: [Nanavati P.](#), Wani A., Madduri V., Ghouse S.M., Chiruvella M.
Institutes: Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India

Metastatic prostate cancer

Abstract session 31

07 April 2024
15:30 - 17:00

Location Green Area, W06
Chairs G. Baciarello, Rome (IT)
B.F. Chapin, Houston (US)
To be confirmed

15:30 - 16:05

A0644

mHSPC

PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): 24-months toxicity results of a randomized phase II trial

Authors: Zilli T.¹, Shankar S.², Brabrand S.³, Dirix S.⁴, Liefhooghe S.⁵, Otte F.X.⁶, Gomez-Iturriaga A.⁷, Everaerts W.⁸, Shelan M.⁹, Conde-Moreno A.¹⁰, López Campos F.¹¹, Papachristofilou A.¹², Guckenberger M.¹³, Scorsetti M.¹⁴, Zapatero A.¹⁵, Villafranca Iturre A.E.¹⁶, Eito C.¹⁷, Counago F.¹⁸, Muto P.¹⁹, Van De Voorde L.²⁰, Mach N.²¹, Fonteyne V.²², Dries R.²³, Ost P.²⁴

Institutes: ¹Oncology Institute of Southern Switzerland, Dept. of Radiation Oncology, Bellinzona, Switzerland, ²University of Melbourne, Dept. of Radiation Oncology, Melbourne, Australia, ³Oslo University Hospital, Dept. of Radiation Oncology, Oslo, Norway, ⁴Iridium Network GZA Ziekenhuizen, Dept. of Radiation Oncology, Antwerp, Belgium, ⁵AZ Groeninge, Dept. of Radiation Oncology, Kortrijk, Belgium, ⁶Jules Bordet Institute, Dept. of Radiation Oncology, Brussels, Belgium, ⁷Hospital Universitario Cruces, Dept. of Radiation Oncology, Barakaldo, Spain, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹Bern University Hospital, Dept. of Radiation Oncology, Bern, Switzerland, ¹⁰Hospital Universitari i Politècnic la Fe, Dept. of Radiation Oncology, Valencia, Spain, ¹¹Hospital Universitario Ramón y Cajal, Dept. of Radiation Oncology, Madrid, Spain, ¹²Universitätsspital Basel, Dept. of Radiation Oncology, Basel, Switzerland, ¹³University Hospital Zurich, Dept. of Radiation Oncology, Zürich, Switzerland, ¹⁴Humanitas Clinical and Research Hospital IRCSS, Dept. of Radiotherapy and Radiosurgery, Dept. of Radiation Oncology, Milan, Italy, ¹⁵University Hospital La Princesa, Dept. of Radiation Oncology, Madrid, Spain, ¹⁶Complejo Hospitalario de Navarra, Dept. of Radiation Oncology, Navarra, Spain, ¹⁷Instituto Oncológico Clínica Universitaria IMQ, Dept. of Radiation Oncology, Bilbao, Spain, ¹⁸University Hospital Quironsalud, Dept. of Radiation Oncology, Madrid, Spain, ¹⁹Napoli Istituto Nazionale Tumori IRCCS Fondazione Pascale, Dept. of Radiation Oncology, Naples, Italy, ²⁰AZ St-Lucas Ghent, Dept. of Radiation Oncology, Ghent, Belgium, ²¹Geneva University Hospital, Dept. of Medical Oncology, Geneva, Switzerland, ²²Ghent University, Dept. of Human Structure and Repair, Radiation Oncology, Ghent, Belgium, ²³Ghent University, Dept. of Applied Mathematics Computer Science and Statistics, Ghent, Belgium, ²⁴Ghent University, Dept. of Human structure and repair, Dept. of Radiation Oncology, Ghent, Belgium

A0639

Impact of Disease Volume on Survival Efficacy of Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis

Authors: Matsukawa A.¹, Rajwa P.¹, Kensuke B.¹, Laukhtina E.¹, Klemm J.¹, Pradere B.¹, Mori K.¹, Karakiewicz P.², Kimura T.³, Chlosta P.⁴, Shariat S.¹, Yanagisawa T.¹

Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Montreal Health Center, Division of Urology, Montreal, Canada, ³The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴Jagiellonian University, Dept. of Urology, Krakow, Poland

A0643

Development of a predictive model for death amongst patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) treated with one of the approved treatment plans, on characteristics present at admission using Big data: preliminary results from the European network of excellence for big data in prostate cancer (PIONEER).

Authors: Nicoletti R.¹, Gomez Rivas J.², Ibáñez L.², Steinbeisse C.³, de Meulder B.⁴, Ayman H.⁵, Golozar A.⁶, Snijder R.⁷, Van Hemelrijck M.⁸, Beyer K.⁸, Willemse P.P.⁹, Murtola T.¹⁰, Roobol M.J.¹¹, Moreno-Sierra J.², Campi R.¹, Gacci M.¹, Mottet N.¹², Merseburger A.¹³, Cornford P.¹⁴, Ndow J.¹⁵

Institutes: ¹University of Florence, Dept. of Experimental and Clinical Biomedical Science, Florence, Italy, ²Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ³Teinbeisser Project Management, Munich, Germany, ⁴CIRI UMR5308 CNRS ENS UCBL INSERM, European Institute for Systems Biology and Medicine, Lyon, France, ⁵Eötvös Loránd University, Budapest, Hungary, ⁶Johns Hopkins Bloomberg School of Public Health, Regeneron Pharmaceuticals, Baltimore, United States of America, ⁷Astellia Pharma, Tokyo, Japan, ⁸King s College London, Dept. of Research, London, United Kingdom, ⁹Cancer Center University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹⁰Tampere University Hospital, Dept. of Urology, Tampere, Finland, ¹¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ¹²Hospitalier Universitaire de Saint-Étienne, Dept. of Urology, Saint-Étienne, France, ¹³University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany, ¹⁴Liverpool University Hospital, Dept. of Urology, Liverpool, United Kingdom, ¹⁵University of Aberdeen, Dept. of Urology, Aberdeen, United Kingdom

A0641

Analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer. A comparative study of patients from clinical trials to patients from real life using 'Big Data'.

Authors: Ibanez Vazquez L.¹, Gómez Rivas J.¹, Nicoletti R.², Golozar A.³, Steinbeißer C.⁴, De Meulder B.⁵, Snijder R.⁶, Axelsson S.E.⁴, Ayman H.⁵, Feng Q.⁶, Bjartell A.⁷, Cornford P.⁸, Murtola T.J.⁹, Willemse P.¹⁰, Moreno Sierra J.¹, N'dow J.¹¹

Institutes: ¹Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ²Careggi Hospital. University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ³Odysseus Data Services, Dept. of Data Services, New York, United States of America, ⁴Bayer AG, Berlin, Germany, ⁵Association EISBM, EISBM, Vourles, France, ⁶Astellhas Pharma Europe, Leiden, The Netherlands, ⁷Lund University, Dept. of Translational Medicine, Division of Urological Cancers, Lund, Sweden, ⁸Liverpool University Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom, ⁹Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland, ¹⁰University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹¹University of Aberdeen, Urology Unit, Aberdeen, United Kingdom

A0638

Understanding variation in treatment intensification for de novo metastatic castration sensitive prostate cancer (mCSPC): A population-based cohort study

Authors: Wallis C.J.D.¹, Satkunasivam R.², Nguyen D.D.¹, Aminoltehari K.¹, Hird A.¹, Roy S.³, Morgan S.⁴, Malone S.⁴, Shayegan B.⁵, Breau R.⁶

Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Houston Methodist, Dept. of Urology, Houston, United States of America, ³Rush Medicine, Dept. of Radiation Oncology, Chicago, United States of America, ⁴University of Ottawa, Dept. of Radiation Oncology, Ottawa, United States of America, ⁵McMaster University, Dept. of Urology, Hamilton, Canada, ⁶University of Ottawa, Dept. of Urology, Ottawa, Canada

A0645

Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data

Authors: Jones C.¹, Dutey-Magni P.², Murphy L.², Murray M.², Brown J.³, McCloskey E.³, Parmar M.K.B.², Parker C.⁴, Attard G.⁵, James N.D.⁴, Sydes M.R.², Brown L.C.², Clarke N.W.¹, Sachdeva A.¹

Institutes: ¹Christie Hospital NHS Trust, Dept. of Urology, Manchester, United Kingdom, ²University College London, MRC Clinical Trials Unit, London, United Kingdom, ³University of Sheffield, Dept. of Bone Metabolism, Sheffield, United Kingdom, ⁴Institute of Cancer Research, Dept. of Oncology, London, United Kingdom, ⁵University College London, Cancer Institute, London, United Kingdom

A0647

Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial

Authors: Tombal B.¹, Hussain M.², Saad F.³, Fizazi K.⁴, Shore N.⁵, Kopyltsov E.⁶, Bögemann M.⁷, Mendez-Vidal M.J.⁸, Littleton N.⁹, Srinivasan S.¹⁰, Verhoken F.¹¹, Smith M.R.¹²

Institutes: ¹Saint Luc University Clinics, Division of Urology, Brussels, Belgium, ²Northwestern University, Feinberg School of Medicine, Dept. of Oncology, Chicago, United States of America, ³University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada, ⁴Institut Gustave Roussy University of Paris-Saclay, Dept. of Oncology, Villejuif, France, ⁵Carolina Urologic Research Center-Genesis Care, Dept. of Urology, Myrtle Beach, United States of America, ⁶Clinical Oncological Dispensary of Omsk Region, Dept. of Oncology, Omsk, Russia, ⁷Münster University Medical Center, Dept. of Urology, Münster, Germany, ⁸Maimonides Institute for Biomedical Research of Cordoba Reina Sofia University Hospital, Dept. of Oncology, Cordoba, Spain, ⁹Bayer Ltd., Dept. of Oncology, Dublin, Ireland, ¹⁰Bayer HealthCare Pharmaceuticals Inc., Dept. of Statistics, Whippany, United States of America, ¹¹Bayer Consumer Care AG, Dept. of Oncology, Basel, Switzerland, ¹²Massachusetts General Hospital Cancer Center, Dept. of Oncology, Boston, United States of America

16:05 - 16:25

mCRPC

A0635

PARP Inhibitor Plus Androgen Receptor Pathway Inhibitor Combinations for 1st Line mCRPC: A Systematic Review and Meta-Analysis

Authors: Sayyid R.K.¹, Klaassen Z.², Berlin A.³, Roy S.⁴, Bernardino R.¹, Chavarriaga J.¹, Jiang D.M.⁵, Spratt D.E.⁶, Fleshner N.E.¹, Wallis C.J.D.¹

Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Augusta University, Dept. of Urology, Augusta, United States of America, ³University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, ⁴Rush University Medical Center, Dept. of Radiation Oncology, Chicago, United States of America, ⁵University of Toronto, Dept. of Medicine, Toronto, Canada, ⁶University Hospitals, Dept. of Radiation Oncology, Cleveland, United States of America

A0636

Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer

Authors: Wang J., Zhao D., Zhao J., Li Y., Zhou F.

Institutes: Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

A0642

Design, Synthesis, and Preclinical Study of Dual Inhibitors Targeting AR-Vs and PARP1/2 in Prostate Cancer Therapy

Authors: Sihan Z., Wang S., Xia Q.

Institutes: Tongji hospital, Dept. of Urology, Wuhan, China

A0646

PPIA-regulated crotonylation of stat3 governs the immunological milieu in bone metastasis of castration-resistant prostate cancer

Authors: Zheng C.

Institutes: Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

16:25 - 16:40

Side effects of treatment

- A0648** **FRAX Spain may overestimate the need for anti-osteoporotic treatment compared to bone densitometry (DEXA) in patients with prostate cancer undergoing androgen deprivation therapy (ADT) and new antiandrogens signalling-inhibitors generation (ASI)**
Authors: Lozano V.¹, Elias F.J.¹, Buisán O.¹, Fàbregas M.¹, Suárez J.F.¹, Gifre L.², Areal J.³, Vigués F.¹
Institutes: ¹Hospital Universitari de Bellvitge, Dept. of Urology, Hospitalet de Llobregat, Spain, ²Hospital Germans Trias i Pujol, Dept. of Reumatology, Badalona, Spain, ³Hospital Germans Trias i Pujol, Dept. of Urology, Badalona, Spain
- A0637** **Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis**
Authors: Ong C.¹, Law Y.X.T.¹, Kyaw L.¹, Lim Q.Y.¹, Loke T.², Wu Q.H.¹, Tiong H.Y.¹, Chiong E.¹
Institutes: ¹National University Hospital, Dept. of Urology, Singapore, Singapore, ²Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore
- A0640** **Evaluation of Cardiovascular Events Among Men with Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis**
Authors: Matsukawa A.¹, Yanagisawa T.¹, Rajwa P.¹, Bekku K.¹, Mehdi Kardoust P.¹, Laukhtina E.¹, Klemm J.¹, Chiujdea S.¹, Fazekas T.¹, Mori K.¹, Kimura S.¹, Miki J.², Kimura T.², Shariat S.¹
Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan
- 16:40 - 16:55** **Nodal disease**
- A0649** **Effect of metastasis directed therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series.**
Authors: Mazzone E.¹, Gandaglia G.¹, Stabile A.¹, Cucchiara V.¹, Scuderi S.¹, Barletta F.¹, Nocera L.¹, Robesti D.¹, Pellegrino F.¹, Longoni M.¹, Pellegrino A.¹, Scilipoti P.¹, Cannoletta D.¹, Sorce G.¹, Samanes Gajate A.M.², Picchio M.², Ghezzi S.², Cozzarini C.³, Chiti A.², Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Nuclear Medicine, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Radiation Oncology, Milan, Italy

A0650

Oncologic Outcomes of Template vs. Radio-Guided Salvage Lymph Node Dissection for Node-Only Recurrent Prostate Cancer: Results from a Multi-Institutional Collaboration.

Authors: Bravi C.A.¹, Knipper S.², Heidenreich A.³, Fossari N.⁴, Gandaglia G.⁵, Suardi N.⁶, Osmonov D.⁷, Juenemann K.⁷, Karnes R.⁸, Kretschmer A.⁹, Budaus L.², Falkenbach F.², Buchner A.⁹, Stief C.⁹, Hiester A.¹⁰, Albers P.¹¹, Joniau S.¹², Van Poppel H.¹², Grubmuller B.¹³, Shariat S.¹³, Pfister D.³, Graefen M.², Montorsi F.⁵, Maurer T.²

Institutes: ¹The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²Martini Klinik, Dept. of Urology, Hamburg, Germany, ³Cologne, Dept. of Urology, Cologne, Germany, ⁴Lugano, Dept. of Urology, Lugano, Switzerland, ⁵San Raffaele, Dept. of Urology, Milan, Italy, ⁶Brescia, Dept. of Urology, Brescia, Italy, ⁷Kiel, Dept. of Urology, Kiel, Germany, ⁸Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁹Munich, Dept. of Urology, Munich, Germany, ¹⁰Homburg, Dept. of Urology, Homburg, Germany, ¹¹Dusseldorf, Dept. of Urology, Düsseldorf, Germany, ¹²Leuven, Dept. of Urology, Leuven, Belgium, ¹³Vienna, Dept. of Urology, Vienna, Austria

A0651

Prostatectomy vs radiotherapy for regional node positive prostate cancer

Authors: Ghaffar U.G., Sharma V., Reitano G., Basourakos S.P., Henning G.M., Karnes R.J.

Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America

Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

Urology beyond Europe

05 April 2024
10:45 - 12:45

Location Green Area, W03
Chairs J. Chueh, Taipei (TW)
X. Ma, Beijing (CN)
J Palou, Barcelona (ES)

Learning objectives

In this joint EAU - Chinese Urological Association (CUA) and Taiwanese Urological Association (TUA) session, the EAU faculty along with the urologists across the Taiwanese Strait will highlight what is new in several areas of urology: stone management, urothelial cancer and translational urology.

10:45 - 10:50	Welcome and introduction
10:50 - 11:19	Stones management
10:50 - 10:57	What's new/best in surgical stones management? To be confirmed
10:57 - 11:04	How we clean up the residual stones during RIRS? To be confirmed
11:04 - 11:19	Discussion
11:19 - 11:55	Urothelial cancer
11:19 - 11:26	Urinary markers in 2024 To be confirmed
11:26 - 11:33	UTUC in Taiwan: a data-driven analysis from the Taiwan UTUC collaboration group To be confirmed
11:33 - 11:40	New tools for the conservative management of upper urinary tract urothelial carcinoma A. Territo, Barcelona (ES)
11:40 - 11:55	Discussion
11:55 - 12:24	Urological translation studies
11:55 - 12:02	Prediction of treatment efficacy of metastatic prostate cancer with morphomic analysis S.T. Pang, Taipei (TW)
12:02 - 12:09	ctDNA guided therapy in bladder cancer To be confirmed
12:09 - 12:24	Panel discussion
12:24 - 12:27	Conclusion
	Moderator To be confirmed

Navigating urothelial carcinoma: From innovative diagnostics to therapeutic strategies

EGPT 10

**07 April 2024
15:30 - 17:00**

Location EGPT
Chairs F. Claps, Trieste (IT)
To be confirmed

15:30 - 15:51

Screen A: Urinary diagnostics in non-muscle invasive bladder cancer

P289

Effect of hematuria on the Performance of BTA stat®, UBC® Rapid Test and NMP22® as urine-based biomarker for bladder cancer detection

Authors: Weiß S.¹, Meisl C. .J.², Schlomm T.², Rabien A.², Rong D.², Hofbauer S.², Friedersdorff F.³, Sommerfeld L.³, Gagel N.³, Barski D.⁴, Otto T.⁴, Grunewald C.M.⁵, Niegisch G.N.⁵, Kramer M.W.⁶, Koch S.⁷, Linden F.⁸, Hake R.⁹, Wirtz R.M.⁸, Eidt S.⁹, Waldner M.¹⁰, Graff J.¹⁰, Jagarlamudi K.¹¹, Hallmann S.¹, Ecke T.H.¹

Institutes: ¹Helios Klinikum Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ²Charité, Dept. of Urology, Berlin, Germany, ³Evangelisches Krankenhaus Königin Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ⁴Rheinland Klinikum Neuss, Dept. of Urology, Neuss, Germany, ⁵Heinrich-Heine Universität, Dept. of Urology, Düsseldorf, Germany, ⁶Universitätsklinikum Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, ⁷Helios Klinikum Bad Saarow, Dept. of Pathology, Bad Saarow, Germany, ⁸STRATIFYER-Molecular Pathology GmbH, Dept. of Molecular Pathology, Cologne, Germany, ⁹St. Elisabeth Krankenhaus, Dept. of Pathology, Cologne, Germany, ¹⁰St. Elisabeth Krankenhaus, Dept. of Urology, Cologne, Germany, ¹¹AroCell, Dept. of R and D, Stockholm, Sweden

P267

Detection of Molecular Recurrence in Early-Stage Bladder Cancer Patients using a Urinary Tumor DNA Assay after Transurethral Resection of Bladder Tumor (TURBT)

Authors: Zhang R.¹, Hao R.², Jingyu Z.³, Di J.¹, Lei Q.¹, Feng X.², Cancan J.², Yue Z.², Xiaogang Z.², Du P.², Shidong J.², Guanglei C.¹, Haige C.¹

Institutes: ¹Renji Hospital Affiliated to Shanghai Jiaotong University, Dept. of Urology, Shanghai, China, ²Huidu Shanghai Medical Sciences Ltd, Dept. of Clinical Study, Shanghai, China, ³Renji Hospital Affiliated to Shanghai Jiaotong University, Dept. of Radiotherapy, Shanghai, China

- P262** **The urine DNA methylation assay facilitates whole course management of urothelial carcinoma in a large multicentric, prospective China cohort**
Authors: Chen X.¹, Liu Z.², Zhou L.³, Fan J.⁴, Lv Q.⁵, Wei Q.⁶, Chen H.⁷, Xu T.⁸, Tan W.⁹, Li L.⁴, Wang S.², Xu A.¹⁰, Yang J.¹¹, Liao H.¹², Fan J.¹³, Huang J.¹, Lin T.¹
Institutes: ¹Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China, ²Tongji Hospital Affiliated to Tongji University, Dept. of Urology, Shanghai, China, ³Peking University First Hospital, Dept. of Urology, Beijing, China, ⁴The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, ⁵JiangSu Province Hospital, Dept. of Urology, Nanjing, China, ⁶West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China, ⁷Renji Hospital Affiliated to Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China, ⁸Peking University People's Hospital, Dept. of Urology, Beijing, China, ⁹Southern Medical University Nanfang Hospital, Dept. of Urology, Guangzhou, China, ¹⁰Zhujiang Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China, ¹¹Chengdu University Affiliated Hospital, Dept. of Urology, Chengdu, China, ¹²Cancer Hospital of Sichuan Province, Dept. of Urology, Chengdu, China, ¹³AnchorDx Medical Co. Ltd, Dept. of Urology, Guangzhou, China
- P272** **An Innovate Segmentation System by Implementing Dilated Convolution and Red Channel Enhanced Images in Cystoscopic Images**
Authors: Mutaguchi J.¹, Morooka K.², Goto S.¹, Kobayashi S.¹, Matsumoto T.¹, Shiota M.¹, Inokuchi J.¹, Eto M.¹
Institutes: ¹Kyushu University Hospital, Dept. of Urology, Fukuoka, Japan, ²Kumamoto University, Dept. of Engineering, Kumamoto, Japan
- P264** **Development of a sensitive digital droplet PCR screening assay for the detection of GPR126 non-coding mutations in bladder cancer urine liquid biopsies**
Authors: Tivtikyan A.¹, Kamalov D.¹, Jain M.¹, Okhobotov D.¹, Vitaly D.¹, Samokhodskaya L.¹, Avdonin S.², Rakhmatullin T.², Zvereva M.³, Kamalov A.¹
Institutes: ¹Lomonosov Moscow State University, Medical Research and Educational Center, Moscow, Russia, ²Lomonosov Moscow State University, Dept. of Fundamental Medicine, Moscow, Russia, ³Lomonosov Moscow State University, Dept. of Chemistry, Moscow, Russia
- P271** **Universal Cancer-Only Marker SIX6 for the Diagnosis Universal Cancer-Only Marker SIX6 for the Diagnosis and Monitoring Early Recurrence of Urothelial Carcinoma**
Authors: Dong Y.¹, Li W.¹, Chen Q.², Xu C.², Yu W.¹
Institutes: ¹Fudan University, Institutes of Biomedical Sciences, Shanghai, China, ²Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China
- P279** **The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M**
Authors: Sun J., Zhong X-Y., Xia Q., Wang S.
Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China
-

15:51 - 16:36

Screen B: Developments for the treatment of non-muscle invasive bladder cancer

P266

Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial

Authors: Mahmud H., Luder A., Rozenswig B., Perez D., Kleinman N., Dotan Z.

Institutes: Sheba Tel-HaShomer Medical Centre, Dept. of Urology, Ramat Gan, Israel

P275

Imaging-guided photothermal therapy for bladder cancer lesions smaller than 1 millimeter expressing marker of bladder CIS

Authors: Armanetti P.¹, Locatelli I.², Venegoni C.², Alchera E.², Pederzoli F.³, Maturi M.⁴, Locatelli E.⁴, Tortorella S.⁴, Curnis F.⁵, Corti A.⁶, Lucianò R.⁷, Sanvito F.⁷, Salonia A.³, Montorsi F.³, Moschini M.², Popov V.⁸, Jose J.⁹, Comes Franchini M.⁴, Ooi E.H.¹⁰, Alfano M.¹¹

Institutes: ¹CNR Istituto di Fisiologia Clinica, Pisa, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Università Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy, ⁴University of Bologna, Dept. of Industrial Chemistry Toso Montanari, Bologna, Italy, ⁵IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology, Milan, Italy, ⁶Università Vita-Salute San Raffaele, Division of Experimental Oncology, Milan, Italy, ⁷IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, ⁸Ascend Technologies Ltd, Dept. of Engineering, Eastleigh, United Kingdom, ⁹Fujifilm Visualsonics Inc., Dept. of Imaging, Amsterdam, The Netherlands, ¹⁰Monash University Malaysia, School of Engineering, Selangor, Malaysia, ¹¹IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

P287

Pulsed electromagnetic field therapy's effect on bladder cancer cell line HT-1197

Authors: Sandberg M.¹, Whitman W.W.¹, Ross C.R.², Tsivian M.T.¹, Walker S.J.W.²

Institutes: ¹Atrium Health Wake Forest Baptist Medical Center, Dept. of Urology, Winston-Salem, United States of America, ²Wake Forest Institute for Regenerative Medicine, Dept. of Urology, Winston-Salem, United States of America

P261

Development of a porcine model of bladder cancer using the Oncopig.

Authors: Aulitzky A.¹, Wilcox Vanden Berg R.², Kim K.³, Al-Ahmadie H.³, Monette S.⁴, Shariat S.⁵, Coleman J.A.³

Institutes: ¹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Duke University, Division of Urology, Dept. of Surgery, Durham, United States of America, ³Memorial Sloan Kettering Cancer Center, Division of Urology, Dept. of Surgery, New York, United States of America, ⁴Memorial Sloan Kettering Cancer Center, Laboratory of Comparative Pathology, New York, United States of America, ⁵Medical University Vienna, Dept. of Urology, Vienna, Austria

- P285** **Subsequent therapies after intravesical BCG in patients with bladder cancer: Analysis of real-world treatment patterns**
Authors: Linghu B.¹, Sun R.², Somer R.³, Hampras S.³, Bhanvadia S.³, Scherer E.¹, Greshock J.³, Sweiti H.³
Institutes: ¹Johnson and Johnson Innovative Medicine, Dept. of Research and Development, Boston, United States of America, ²Johnson and Johnson Innovative Medicine, Dept. of Research and Development, Brisbane, United States of America, ³Johnson and Johnson Innovative Medicine, Dept. of Research and Development, Raritan, United States of America
- P277** **Is there a role for Bacillus Calmette-Güerin in very high-risk Non-Muscle Invasive Bladder carcinoma? Multicenter analysis of oncological outcomes and risk dynamics**
Authors: Subiela Henriquez J.D.¹, Krajewski W.², González-Padilla D.³, Tabora J.¹, Andrzej T.⁴, Aumatell J.L.⁵, Rodrigo E.⁶, Moschini M.⁷, Cano-Velasco J.⁸, Gallioli A.⁹, D Andrea D.¹⁰, Pilcher R.¹¹, Afferi L.¹², Del Giudice F.¹³, Albisinni S.¹⁴, Soria F.¹⁵, Laura M.¹⁶, Szydelko T.², Brasero Burgos J.¹, Sanchez Gonzalez A.¹, Artilles Medina A.¹, Gomez Dos Santos V.¹, Jimenez Cidre M.N.¹, Burgos Revilla F.J.¹
Institutes: ¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Wroclaw Medical University, Center of Excellence in Urology, Dept. of Minimally Invasive Robotic Urology, Wrocław, Poland, ³Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain, ⁴University Clinical Hospital in Opole, Institute of Health Sciences, Opole, Poland, ⁵Hospital Rey Juan Carlos, Dept. of Urology, Mostoles, Spain, ⁶Regional University Hospital, Dept. of Urology, Malaga, Spain, ⁷Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁸Hospital Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁰Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹¹Comprehensive Cancer Center Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ¹³Policlinico Umberto I Hospital, Sapienza University of Rome, Dept. of Urology, Rome, Italy, ¹⁴Tor Vergata University Hospital, Dept. of Surgical Science, Rome, Italy, ¹⁵Molinette Hospital University of Torino School of Medicine, Dept. of Surgical Science, Turin, Italy, ¹⁶The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands
- P274** **Trends in the the use of immediate postoperative intravesical chemotherapy following TURBT**
Authors: Dahmen A., Nusbaum D.J.N., Lazarovich A.L., Fialkoff J.F., Modi P.K.M., Agarwal P.K.
Institutes: University of Chicago, Division of Urology, Chicago, United States of America

- P282** **Health economic analysis of single-dose intravesical therapy after transurethral resection of bladder tumour in the Australian healthcare system**
Authors: Sathianathan N.¹, Gantz J.², Messing E.², Konety B.³, Lawrentschuk N.¹
Institutes: ¹University of Melbourne, Dept. of Urology, Melbourne, Australia, ²University of Rochester, Dept. of Urology, Rochester, United States of America, ³Allina Health, Dept. of Urology, Minneapolis, United States of America
- P280** **No impact of detrusor muscle absence in pTaHG urothelial bladder carcinoma first TURB**
Authors: Tissot G.¹, Regnier S.¹, Moschini M.², Afferi L.³, D'Andrea D.⁴, Krajewski W.⁵, Soria F.⁶, Roumiguie M.⁷, Verhoest G.⁸, Alvarez Maestro M.⁹, Mattei A.³, Montorsi F.², Shariat S.⁴, Gontero P.⁶, Xylinas E.¹
Institutes: ¹Bichat Claude Bernard Hospital, Dept. of Urology, Paris, France, ²Vita Salute University San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵Wroclaw Medical University, Dept. of Urology, Wrocław, Poland, ⁶San Giovanni Battista Hospital University of Studies of Torino, Dept. of Urology, Turin, Italy, ⁷Institut Universitaire du Cancer Toulouse-Oncopole, Dept. of Urology, Toulouse, France, ⁸Rennes University Hospital, Dept. of Urology, Rennes, France, ⁹La Paz University Hospital, Dept. of Urology, Madrid, Spain
- P276** **Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRE Trial**
Authors: Finocchiaro A.¹, Contieri R.¹, Casale P.², Buffi N.M.¹, Lazzeri M.², Lughezzani G.¹, Guazzoni G.¹, Piccolini A.¹, Paciotti M.¹, Fasulo V.¹, Saita A.², Hurle R.²
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²Humanitas Research Hospital, Dept. of Urology, Milan, Italy
- P290** **Proposal for an additional histologic grading approach for stage pT1 non-muscle-invasive bladder cancer (NMIBC) correlating with disease aggressiveness and patient outcomes**
Authors: Haas M.¹, Engelmann S.U.¹, Mayr R.¹, Gossler C.¹, Pickl C.¹, Kaelble S.¹, Yang Y.¹, Otto W.¹, Hartmann V.¹, Burger M.¹, Hartmann A.², Breyer J.¹, Eckstein M.²
Institutes: ¹University of Regensburg Caritas St. Josef Medical Centre, Dept. of Urology, Regensburg, Germany, ²Friedrich-Alexander-University Erlangen-Nuremberg, Dept. of Pathology, Erlangen, Germany

- P281** **Multi-institutional European outcomes of supervised unexperienced resident in transurethral resection of bladder cancer: the importance of a standardized program, the ENTRY project working group**
Authors: [Diana P.](#)¹, [Paciotti M.](#)², [Gallioli A.](#)¹, [Vercelli E.](#)³, [D'Agate D.](#)³, [Piccinelli M.L.](#)⁴, [Lievore E.](#)⁴, [Dagnino F.](#)², [Finocchiaro A.](#)², [Yebes Alonso A.](#)⁵, [Frego N.](#)⁶, [Bravo A.](#)¹, [Hernandez P.](#)¹, [Martinez Pineiro L.](#)⁵, [De Cobelli O.](#)⁴, [Gontero P.](#)³, [Palou J.](#)¹, [Mottrie A.](#)⁶, [Breda A.](#)¹, [Buffi N.](#)⁷
Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Humanitas Research Hospital IRCCS, Dept. of Urology, Milan, Italy, ³Città della Salute e della Scienza University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ⁴European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁵La Paz University Hospital, Dept. of Urology, Madrid, Spain, ⁶ORSI Academy, Dept. of Urology, Aalst, Belgium, ⁷Humanitas University, Biomedical Sciences, Pieve Emanuele, Italy
- P269** **Benchmarking Flemish centers for quality control indicators for transurethral resection of the bladder tumor**
Authors: [Akand M.](#)¹, [Van Bruwaene S.](#)², [Vander Eeck K.](#)³, [Baekelandt F.](#)⁴, [Van Reusel R.](#)⁵, [Muilwijk T.](#)¹, [Baekelandt L.](#)¹, [Van Cleynenbreugel B.](#)¹, [Joniau S.](#)¹, [Van Der Aa F.](#)¹
Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ³AZ Sint Blasius, Dept. of Urology, Dendermonde, Belgium, ⁴AZ Sint-Lucas Brugge, Dept. of Urology, Bruges, Belgium, ⁵AZ Turnhout, Dept. of Urology, Turnhout, Belgium
- P283** **Characteristics of bladder cancer after radiotherapy for prostate cancer**
Authors: [Rousseau S.](#)¹, [Audenet F.](#)², [Mejean A.](#)², [Descazeaud A.](#)¹
Institutes: ¹CHU Limoges, Dept. of Urology, Limoges, France, ²HEGP, Dept. of Urology, Paris, France
- P263** **Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment**
Authors: [Golijanin B.](#)¹, [Malshy K.](#)¹, [Bhatt V.](#)¹, [Lagos G.](#)², [Khaleel S.](#)¹, [Ali A.](#)³, [DeSouza A.](#)², [Chengal L.](#)³, [Mega A.](#)², [Golijanin D.](#)¹
Institutes: ¹The Minimally Invasive Urology Institute, The Miriam Hospital and Warren Alpert Medical School of Brown University, Dept. of Urology, Providence, United States of America, ²Lifespan Cancer Institute at the Miriam Hospital and Warren Alpert Medical School of Brown University, Dept. of Hematology and Oncology, Providence, United States of America, ³The Miriam Hospital. Warren Alpert Medical School of Brown University, Dept. of Pathology and Laboratory Medicine, Providence, United States of America
- 16:36 - 16:36** **Screen C:**
- 16:36 - 16:36** **Screen D:**
- 16:36 - 17:00** **Upper Urinary Tract Cancer**

- P286** **Impact of delay in diagnosis and extirpative surgery in upper tract urothelial carcinomas – a population-based study**
Authors: Liedberg F.¹, Hagberg O.¹, Häggström C.², Aljabery F.³, Gårdmark T.⁴, Hosseini A.⁵, Jahnson S.³, Jerlström T.⁶, Malmström P.U.⁷, Sherif A.⁸, Ströck V.⁹, Söderkvist K.¹⁰, Ullén A.¹¹, Holmberg L.¹², Bobjer J.¹
Institutes: ¹Institution of Translational Medicine, Lund University, Dept. of Urology Skåne University Hospital Malmö, Malmö, Sweden, ²Northern Register Centre Dept. of Public Health and Clinical Medicine Umeå University, Dept. of Surgical Sciences Uppsala University, Umeå, Sweden, ³Division of Urology, Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, ⁴Danderyd Hospital Karolinska Institute, Dept. of Clinical Sciences, Stockholm, Sweden, ⁵Karolinska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ⁶School of Medical Sciences Faculty of Medicine and Health Örebro University, Dept. of Urology, Örebro, Sweden, ⁷Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁸Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, ⁹Sahlgrenska Academy University of Gothenburg, Dept. of Urology Sahlgrenska University Hospital and Institute of Clinical Sciences, Gothenburg, Sweden, ¹⁰Umeå University, Dept. of Radiation Sciences Oncology, Umeå, Sweden, ¹¹Danderyd Hospital and Karolinska University Hospital and Karolinska Institute, Dept. of Clinical Sciences and Oncology-Pathology and Dept. of Pelvic Cancer Genitourinary Oncology, Stockholm, Sweden, ¹²Kings College and Uppsala University, School of Cancer and Pharmaceutical Sciences and Dept. of Surgical Sciences, London, United Kingdom
- P278** **Prognosis and Pathological Characteristics Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma**
Authors: Zuo W., Zhang J., Tang Q., Zhou L., Xuesong L.
Institutes: Peking University First University, Dept. of Urology, Beijing, China
- P265** **From survival to longevity: assessing upper tract urothelial carcinoma impact on life expectancy and economic strain in taiwan**
Authors: Hu W-S.¹, Lin Y.S.¹, Wang J.D.², Hsu J.Y.¹, Ou Y.C.¹, Tung M.C.¹, Chiu Y-M.³
Institutes: ¹Tungs' Taichung Metroharbor Hospital, Dept. of Urology, Taichung City, Taiwan, ²National Cheng Kung University, Dept. of Public Health, Tainan City, Taiwan, ³Tungs' Taichung Metroharbor Hospital, Big Data Research Center, Taichung City, Taiwan

- P288** **Risk factors of subsequent upper urinary tract carcinoma treated with intravesical bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: from multiple Japanese hospitals**
Authors: Numakura K.¹, Miyake M.², Kobayashi M.¹, Muto Y.¹, Sekine Y.¹, Yaoka R.³, Kobayashi T.⁴, Kojima T.⁵, Kitamura H.⁶, Nishiyama H.⁵, Fujimoto K.², Habuchi T.¹
Institutes: ¹Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ²Nara Medical University, Dept. of Urology, Nara, Japan, ³Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan, ⁴Kyoto University, Dept. of Urology, Kyoto, Japan, ⁵University of Tsukuba, Dept. of Urology, Tsukuba, Japan, ⁶University of Toyama, Dept. of Urology, Toyama, Japan
- P284** **Urological follow-up of Lynch Syndrome: UTUC incidence and mutational patterns in a dedicated outpatient clinic**
Authors: Scilipoti P., Cattafi E., Longoni M., De Angelis M., Re C., Quarta L., Bertini A., Burgio G., Avesani G., Rosiello G., Gandaglia G., Capitanio U., Salonia A., Montorsi F., Briganti A., Moschini M.
Institutes: IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy
- P270** **Integrated analysis reveals molecular features of upper tract urothelial carcinoma and prognostic value of neutrophil infiltration for adjuvant chemotherapy**
Authors: Shengming J., Junlong W., Yu W., Yao Z., Dingwei Y.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

P268

Oncologic Outcomes in Patients with Variant Histologies of Upper Tract Urothelial Cancer: Results from an International Multicenter Cohort

Authors: Pallauf M.¹, Fletcher S.A.¹, Rezaee M.¹, Roupret M.², Boorjian S.A.³, Potretzke A.M.³, Djaladat H.⁴, Ghoreifi A.⁴, Soria F.⁵, Mari A.⁶, Campi R.⁷, Khene Z.E.⁸, Kikuchi E.⁹, Rink M.¹⁰, Fujita K.¹¹, D'Andrea D.¹², Boormans J.L.¹³, Ploussard G.¹⁴, Breda A.¹⁵, Abdollah F.¹⁶, Raman J.D.¹⁷, Shariat S.F.¹², Pradere B.¹⁴, Singla N.¹

Institutes: ¹Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Pitie Salpetriere Hospital AP-HP GRC 5 Predictive Onco-Urology Sorbonne University, Dept. of Urology, Paris, France, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴University of Southern California, Institute of Urology, Los Angeles, United States of America, ⁵San Giovanni Battista Hospital University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁶Careggi Hospital University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁷Careggi Hospital University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁸Rennes University Hospital, Dept. of Urology, Rennes, France, ⁹St. Marianna University School of Medicine, Dept. of Urology, Kanagawa, Japan, ¹⁰Marienkrankenhaus Hamburg, Dept. of Urology, Hamburg, Germany, ¹¹Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, ¹²Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹³Erasmus MC Cancer Institute, Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ¹⁴La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁵Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁶Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ¹⁷Penn State Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America

P273

The impact of double-J ureteral stenting before radical cystectomy on the development of upper tract urothelial carcinoma

Authors: Mahmoud O.¹, Al-Nader M.², Krafft U.², Heß J.², Kesch C.², Tschirdewahn S.², Hadaschik B.²

Institutes: ¹South Valley University, Dept. of Urology, Qena, Egypt, ²Essen University hospital, Dept. of Urology, Essen, Germany

17:00 - 17:00

Screen F:

Prostate cancer screening at its best

Abstract session 32

07 April 2024
15:45 - 17:15

Location Green Area, eURO Auditorium 1
Chairs To be confirmed
S. Carlsson, New York (US)
C.H. Bangma, Rotterdam (NL)

15:45 - 15:47

Introduction

A0666

Why is there a need to re-think Prostate Cancer early detection?

Authors: Beyer K.¹, Leenen R.¹, Venderbos L.D.F.¹, Denijs F.¹, Helleman J.¹, Chloupkova R.², Májek O.², Briers E.³, Vasilyeva V.⁴, Gomez Rivas J.⁵, Annemans L.⁶, Vynckier P.⁶, Basu P.⁷, Chandran A.⁷, Van Den Bergh R.C.N.¹, Collen S.⁴, Stenzl A.⁴, Van Poppel H.⁸, Roobol M.J.¹

Institutes: ¹Erasmus MC Cancer Institute, Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Institute of Health Information and Statistics of the Czech Republic, National Screening Centre, Prague, Czech Republic, ³Europa Uomo, Antwerp, Belgium, ⁴European Association of Urology, Policy Office, Arnhem, The Netherlands, ⁵Clínico San Carlos University Hospital, Dept. of Urology, Madrid, Spain, ⁶Faculty of Medicine and Health Sciences, Ghent University, Economics of Health and Wellbeing, Ghent, Belgium, ⁷International Agency for Research on Cancer World Health Organization, Lyon, France, ⁸Sint Antonius Hospital, Dept. of Urology, Utrecht-Nieuwegein, The Netherlands

A0661

Prevalence and determinants of shared decision-making for psa testing in the United States

Authors: Bhojani N.¹, Miller L.E.², Zorn K.C.¹, Chughtai B.³, Elterman D.S.⁴, Bhattacharyya S.⁵, Chew B.H.⁶

Institutes: ¹University of Montreal, Dept. of Urology, Montreal, Canada, ²Miller Scientific, Dept. of Biostatistics, Johnson City, United States of America, ³Weill Cornell Medicine, Dept. of Urology, New York, United States of America, ⁴University of Toronto, Dept. of Urology, Toronto, Canada, ⁵Boston Scientific, Dept. of Health Economics and Market Access, Marlborough, United States of America, ⁶University of British Columbia, Dept. of Urology, Vancouver, Canada

A0659

Organised prostate cancer testing in Sweden – Results from the first three years of inviting 50-year-old men

Authors: Arnsrud Godtman R.¹, Jiborn T.², Wallström J.³, Akre O.⁴, Carlsson S.⁴, Nordström T.⁵, Thimansson E.⁶, Alterbeck M.⁶, Zackrisson S.⁶, Hugosson J.¹, Bjartell A.⁶, Lantz A.⁴, Bratt O.¹

Institutes: ¹Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ²Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ³Sahlgrenska Academy, University of Gothenburg, Dept. of Radiology, Gothenburg, Sweden, ⁴Karolinska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ⁵Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁶Faculty of Medicine, Lund University, Dept. of Translational Medicine, Lund, Sweden

A0665

Understanding the barriers to Prostate Cancer population-based early detection programs: the PRAISE-U BEST survey

Authors: Beyer K.¹, Leenen R.¹, Venderbos L.D.F.¹, Helleman J.¹, Denijs F.¹, Gomez Rivas J.², Vasilyeva V.³, Briers E.⁴, Chloupkova R.⁵, Májek O.⁵, Frese T.⁶, Vilaseca J.⁶, Vinker S.⁶, Vynckier P.⁷, Annemans L.⁷, Basu P.⁸, Chandran A.⁸, Van Den Bergh R.C.N.¹, Collen S.³, Van Poppel H.⁹, Roobol M.J.¹

Institutes: ¹Erasmus MC Cancer Institute, Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Clínico San Carlos University Hospital, Dept. of Urology, Madrid, Spain, ³European Association of Urology, Policy Office, Arnhem, The Netherlands, ⁴Europa Uomo, Antwerp, Belgium, ⁵Institute of Health Information and Statistics of the Czech Republic, National Screening Centre, Prague, Czech Republic, ⁶WONCA, Ljubljana, Slovenia, ⁷Faculty of Medicine and Health Sciences, Ghent University, Economics of Health and Wellbeing, Ghent, Belgium, ⁸International Agency for Research on Cancer World Health Organization, Lyon, France, ⁹Sint Antonius Hospital, Dept. of Urology, Leuven, Belgium

A0652

The Man Van Project: Second Phase Interim Results

Authors: Moghul M., Mutch F., Westaway E., Croft F., Kinsella N., Cahill D., James N.D.

Institutes: Royal Marsden Hospital, Dept. of Urology, London, United Kingdom

A0663

Effect of age at first protocolled screening on long-term outcomes in prostate cancer screening: results from a cross-sectional screening study

Authors: de Vos I.I., Remmers S., Nieboer D., Roobol M.J.

Institutes: Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands

A0667

Superiority of midlife baseline prostate-specific antigen value over psa doubling time and velocity in the prediction of lethal prostate cancer development, and mortality: A system wide analysis of a racially diverse north american cohort

Authors: Cirulli G.O.¹, Davis M.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Morrison C.¹, Tinsley S.¹, Arora S.¹, Sood A.³, Lughezzani G.⁴, Buffi N.⁴, Carrieri G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Rogers C.¹, Abdollah F.¹

Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation - Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy

A0662

Differences in quality of curative treatment and outcome in men with localised prostate cancer in the screening and control arms of the ERSPC Rotterdam

Authors: de Vos I.I., Remmers S., Roobol M.J.

Institutes: Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands

A0664

Multiplex blood-test and magnetic resonance imaging (MRI) for prostate cancer screening: Results from the 2nd screening round in the STHLM3-MRI trial

Authors: Discacciati A.¹, Abbadi A.¹, Chandra J.², Annerstedt M.³, Glaessgen A.⁴, Carlsson S.⁵, Jäderling F.⁵, Grönberg H.¹, Eklund M.¹, Nordström T.¹

Institutes: ¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Clinical Sciences Danderyd Hospital, Stockholm, Sweden, ³C-Medical, Dept. of Urology, Stockholm, Sweden, ⁴Unilabs, Dept. of Pathology, Stockholm, Sweden, ⁵Karolinska Institutet, Dept. of Molecular Medicine, Stockholm, Sweden

A0657

The Association of County-Level Prostate-Specific Antigen Screening with metastatic prostate cancer and prostate cancer mortality

Authors: Stelzl D.¹, Stone B.V.¹, Labban M.¹, Beatrice E.², Filipas D.K.¹, D'Amico A.V.³, Lipsitz S.R.¹, Choueiri T.K.⁴, Kibel A.S.¹, Cole A.P.¹, Iyer H.S.⁵, Trinh Q.D.¹

Institutes: ¹Brigham and Womens Hospital and Center for Surgery and Public Health and Harvard Medical School, Division of Urological Surgery, Boston, United States of America, ²Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ³Dana-Farber Cancer Institute Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America, ⁴Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ⁵Rutgers Cancer Institute of New Jersey, Section of Cancer Epidemiology and Health Outcomes, New Brunswick, United States of America

A0656

Can we reduce unnecessary prostate biopsies in patients with PI-RADS 3 lesions? Role of PSA density and the Stockholm 3 test

Authors: Abbadi A.¹, Eklund M.¹, Lantz A.¹, Discacciati A.¹, Chandra Engel J.², Björnebo L.¹, Falagario U.G.¹, Grönberg H.¹, Nordström T.¹

Institutes: ¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Danderyds Hospital, Dept. of Clinical Sciences, Solna, Sweden

A0655

A 20 years Follow-up Results of the Modena Screening Program for Prostate Cancer (PCa) "Progetto Uomo"(PU)

Authors: Brausi M.¹, Ferrari G.¹, Ferrari R.², Castagnetti G.³, Morselli S.¹, Ghidini N.¹, Ferrari P.¹

Institutes: ¹Hesperia Hospital, Dept. of Urology, Modena, Italy, ²University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ³Ospedale di Sassuolo, Dept. of Urology, Sassuolo, Italy

- A0653** **PROSPET-BX trial: [68Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy.**
Authors: Fasulo V.¹, Lughezzani G.¹, Lazzeri M.², Maffei D.¹, Disconzi L.³, Colombo P.⁴, Saita A.², Moretto S.¹, Finocchiaro A.¹, Peschechera R.², Casale P.², Rodari M.⁵, Guazzoni G.¹, Balzarini L.³, Buffi N.M.¹, Lopci E.⁵
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ³Humanitas Research Hospital, Dept. of Radiology, Milan, Italy, ⁴Humanitas Research Hospital, Dept. of Pathology, Milan, Italy, ⁵Humanitas Research Hospital, Dept. of Nuclear Medicine, Milan, Italy
- A0654** **The role of PSA density in the follow up of men with a negative MRI in the Göteborg 2 trial**
Authors: Möller F.¹, Månsson M.¹, Wallström J.², Hellström M.², Hugosson J.¹, Arnsrud Godtman R.¹
Institutes: ¹Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ²Sahlgrenska Academy, University of Gothenburg, Dept. of Radiology, Gothenburg, Sweden
- A0658** **The impact of prostate volume on prostate cancer detection: comparing MRI with TRUS in biopsy-naïve men**
Authors: Jianjun Y., Qiang W., Yige B.
Institutes: West China Hospital, Dept. of Urology and Institute of Urology, Sichuan, China
- A0660** **Assessing the mid-term impact of enhanced prostate cancer screening in Caucasian men with germline DNA repair pathogenic variants.**
Authors: Fasulo V.¹, Buffi N.M.¹, Casale P.², Saita A.², Hurle R.², Finocchiaro A.¹, Aljoulani M.¹, Paciotti M.¹, Asselta R.¹, Soldà G.¹, De Simone I.¹, Colombo P.³, Cieri M.³, Maura F.¹, Cavalli P.¹, Lughezzani G.¹, Lazzeri M.²
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ³Humanitas Research Hospital, Dept. of Pathology, Milan, Italy
- 17:07 - 17:10** **Expert summary**

Has focal therapy for prostate cancer become of age?

Abstract session 33

07 April 2024
15:45 - 17:15

Location Purple Area, N01
Chairs E. Barret, Paris (FR)
L. Hakim, Surabaya (ID)
To be confirmed

15:45 - 15:47

Introduction

15:47 - 16:07

Selection of candidates

A0668

The accuracy of PSMA PET/CT for assessing intraprostatic lesions in patients with prostate cancer: an evaluation of the PI-RADS, PRIMARY and PSMA-expression score

Authors: Donck E.¹, De Visschere P.², Van Praet C.¹, De Man K.², Waterschoot R.², Verbeke S.³, Hendrickx S.², Villeirs G.², Berquin C.¹, Lumen N.¹

Institutes: ¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital, Dept. of Radiology and Nuclear Medicine, Ghent, Belgium, ³Ghent University Hospital, Dept. of Pathology, Ghent, Belgium

A0675

Natural History of PIRADS-2 Lesions on Serial Multiparametric Magnetic Resonance Imaging: Real-Life Data from an Academic Center

Authors: Esen B.¹, Gurses B.², Sekmen M.¹, Kordan Y.¹, Kiremit M.C.¹, Vural M.³, Tilki D.⁴, Esen T.¹

Institutes: ¹Koç University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ²Koç University School of Medicine, Dept. of Radiology, Istanbul, Türkiye, ³American Hospital, Dept. of Radiology, Istanbul, Türkiye, ⁴Martini Klinik Prostate Cancer Center, Dept. of Urology, Istanbul, Türkiye

A0674

Oncologic Outcomes of Partial Gland Ablation using Focal Intensity Focused Ultrasound after Additional Confirmatory Transperineal Mapping Biopsy in Men with Prostate Cancer

Authors: Lee J., Chung J.H., Kang M., Sung H.H., Jeon H.G., Jeong B.C., Seo S.I., Jeon S.S., Lee H.M., Song W.

Institutes: Samsung Medical Center, Dept. of Urology, Seoul, South Korea

A0680

Lessons learned: Improved selection and treatment outcomes for Focal Therapy for early adoption to latest experience.

Authors: Rodríguez Serrano A.¹, López Vázquez D.A.¹, Cignoli D.², Linares-Espinós E.³, Lanz C.¹, Cathala N.¹, Barret E.¹, Macek P.¹, Cathelineau X.¹, Rodriguez-Sanchez L.¹

Institutes: ¹Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ²IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Lyx Institut, Dept. of Urology, Madrid, Spain

16:07 - 16:32

HIFU

A0676

A randomized non-inferiority clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinical significant prostate cancer. A Two-year follow-up.

Authors: Baco E.¹, Noor D.², Flor Galtung K.², Rud E.¹

Institutes: ¹Oslo University hospital and University of Oslo, Dept. of Urology, Oslo, Norway, ²Oslo University Hospital, Dept. of Radiology, Oslo, Norway

A0682

A novel multi-imaging based focal therapy program for prostate cancer with High Intensity Focused Ultrasound: early oncological outcomes of a single-center experience.

Authors: Maffei D.¹, Fasulo V.¹, Moretto S.¹, Adjaye E.N.Y.D.¹, Avolio P.P.¹, Contieri R.¹, Paciotti M.¹, Colombo P.G.¹, Saita A.R.², Hurle R.F.², Paolo C.², Guazzoni G.F.¹, Buffi N.M.¹, Lazzeri M.², Lughezzani G.¹

Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

A0679

High Intensity Focused Ultrasounds vs Radical Prostatectomy: carcinologic results of the HIFI study

Authors: Ploussard G.¹, Villers A.², Chevallier T.³, Houédé N.⁴, Mathieu R.⁵, Baboudjian M.⁶, Fiard G.⁷, Coloby P.⁸, Rischmann P.⁹

Institutes: ¹La Croix du Sud Clinic, Dept. of Urology, Quint-Fonsegrives, France, ²Lille University Hospital, Dept. of Urology, Lille, France, ³Nimes University Hospital, Dept. of Epidemiology and Biostatistics, Nimes, France, ⁴Nimes University Hospital, Dept. of Oncology, Nimes, France, ⁵Rennes University Hospital, Dept. of Urology, Rennes, France, ⁶Marseille University Hospital, Dept. of Urology, Marseille, France, ⁷Grenoble University Hospital, Dept. of Urology, Grenoble, France, ⁸René Dubos Hospital, Dept. of Urology, Pontoise, France, ⁹Rangueil University Hospital, Dept. of Urology, Renal Transplant and Andrology, Toulouse, France

A0678

Safety, Efficacy and Quality of Life Outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month outcomes

Authors: Yli-Pietilä E.H.M.¹, Anttinen M.¹, Mäkelä P.², Nurminen P.¹, Pouya D.³, Pärssinen H.², Sainio T.², Taimen P.⁴, Blanco Sequeiros R.², Boström P.J.¹

Institutes: ¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital, Dept. of Radiology, Turku, Finland, ³Profound Medical, Dept. of Clinical Science, Hamburg, Germany, ⁴Turku University Hospital, Dept. of Pathology, Turku, Finland

A0683

HIFU vs Radical Prostatectomy: functional results of the HIFI study

Authors: Coloby P.¹, Fiard G.², Chevallier T.³, Mathieu R.⁴, Baboudjian M.⁵, Houédé N.⁶, Villers A.⁷, Ploussard G.⁸, Rischmann P.⁹

Institutes: ¹René Dubos Hospital, Dept. of Urology, Pontoise, France, ²Grenoble University Hospital, Dept. of Urology, Grenoble, France, ³Nimes University Hospital, Dept. of Epidemiology and Biostatistics, Nimes, France, ⁴Rennes University Hospital, Dept. of Urology, Rennes, France, ⁵Marseille University Hospital, Dept. of Urology, Marseille, France, ⁶Nimes University Hospital, Dept. of Oncology, Nimes, France, ⁷Lille University Hospital, Dept. of Urology, Lille, France, ⁸La Croix du Sud Clinic, Dept. of Urology, Quint-Fonsegrives, France, ⁹Rangueil University Hospital, Dept. of Urology, Toulouse, France

16:32 - 16:57

Cryo, IRE and other energies

A0672

Focal HIFU and cryotherapy for prostate cancer: a HEAT and ICE analysis of 15-year usage trends in the United Kingdom

Authors: Light A.¹, Mayor N.¹, Cullen E.¹, Arya M.¹, Grey A.², Orczyk C.², Moore C.M.², Emberton M.², Dudderidge T.³, Hindley R.⁴, Emara A.⁴, Noureldin M.⁴, Nigam R.⁵, Viridi J.⁶, Laniado M.⁷, Mccracken S.⁸, Greene D.⁸, Ahmed H.U.¹, Shah T.T.¹

Institutes: ¹Imperial College London, Imperial Prostate Department, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵Royal Surrey NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁶Princess Alexandra Hospital NHS Trust, Dept. of Urology, Harlow, United Kingdom, ⁷Frimley Health NHS Foundation Trust, Dept. of Urology, Slough, United Kingdom, ⁸City Hospitals Sunderland NHS Foundation Trust, Dept. of Urology, Sunderland, United Kingdom

A0677

A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate Cancer

Authors: Kenigsberg A.¹, Woo H.², Fraundorfer M.³, Brennan J.⁴, Chin P.⁵, Turkbey B.¹, Choyke P.¹, Citrin D.¹, Wood B.¹, Desai P.⁶, Rairkar M.⁶, Munster P.⁷, Pinto P.A.¹

Institutes: ¹National Cancer Institute, Dept. of Urologic Oncology, Bethesda, United States of America, ²ANU College of Health and Medicine, Dept. of Urology, Canberra, Australia, ³Tauranga Hospital, Dept. of Urology, Tauranga, New Zealand, ⁴Goldfields Urology, Dept. of Urology, Bendigo, Australia, ⁵South Coast Urology, Dept. of Urology, Wollongong, Australia, ⁶Alessa Therapeutics, Dept. of Research and Development, San Carlos, United States of America, ⁷University of California San Francisco, Dept. of Medicine, San Francisco, United States of America

- A0670** **ProFocal® - novel, cooled Laser Focal Therapy. Pivotal trial results of 100 men with localised prostate cancer**
Authors: Kam J.¹, Arianayagam M.¹, Canagasingham B.¹, Goolam A.S.¹, Jeffery N.¹, Winter M.¹, Khadra M.¹, Ko R.¹, Mehan N.¹, Thangasamy I.¹, Varol C.²
Institutes: ¹Nepean Hospital, Nepean Urology Research Group, Sydney, Australia, ²Medlogical Innovations, Sydney, Australia
- A0673** **Irreversible Electroporation for Localized Prostate Cancer: Prospective Cohort Study Evaluating Local Tumor Control and Quality of Life**
Authors: Moon H.W., Bang S., Park Y.H., Bae W.J., Cho H.J., Ha U.S., Hong S.H., Kim S.W., Lee J.Y., Rhew S.A.
Institutes: Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea
- A0669** **When does focal LDR brachytherapy fail? Early lessons from Australia's LIBERATE registry**
Authors: Anderson E.¹, Smyth L.², Harkin T.¹, O'sullivan R.³, Ryan A.⁴, Lawrentshuk N.⁵, Katz D.⁶, See A.⁷, Grummet J.¹
Institutes: ¹Monash University, Dept. of Surgery, Melbourne, Australia, ²Icon Institute of Innovation and Research, Dept. of Radiotherapy, Melbourne, Australia, ³Lumus Imaging, Dept. of Radiology, Melbourne, Australia, ⁴TissuPath Specialist Pathology, Services, Melbourne, Australia, ⁵Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁶Men's Health Melbourne, Dept. of Urology, Melbourne, Australia, ⁷Icon Cancer Centre, Dept. of Radiotherapy, Melbourne, Australia
- 16:57 - 17:12** **Follow-up**
- A0671** **The Trans-Atlantic Recommendations for prostate Gland Evaluation with MRI after focal Therapy (TARGET) international consensus recommendations**
Authors: Light A.¹, Mayor N.¹, Cullen E.¹, Van Der Meulen J.², Ahmed H.U.¹, Shah T.T.¹
Institutes: ¹Imperial College London, Imperial Prostate Department, London, United Kingdom, ²London School of Hygiene and Tropical Medicine, Dept. of Health Services Research and Policy, London, United Kingdom
- A0681** **Diagnostic performance of PI-FAB (Prostate Imaging after Focal Ablation): validation of the scoring system for multiparametric MRI performed after ablative techniques for prostate cancer**
Authors: Ferriero M., Misuraca L., Mastroianni R., Tuderti G., Anceschi U., Brassetti A., Bove A., Flammia R.S., Proietti F., Bertini L., D'annunzio S., Leonardo C., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0684

The role of PSA kinetics in evaluating treatment failure after focal therapy using high-intensity focused ultrasound for primary localised prostate cancer

Authors: Moretto S.¹, Maffei D.¹, Fasulo V.¹, Adjaye E.N.A.¹, Avolio P.P.¹, Paciotti M.², Saitta C.¹, Saita A.², Hurle R.², Guazzoni G.F.¹, Casale P.², Buffi N.M.¹, Lazzeri M.², Lughezzani G.¹

Institutes: ¹Humanitas University, Dept. of Urology, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

17:12 - 17:15

Expert summary

Interventional male LUTS treatment - MiST

Abstract session 34

07 April 2024
15:45 - 17:15

Location Green Area, N04
Chairs To be confirmed
To be confirmed
To be confirmed
S. Secco, Milan (IT)

A0686

New minimally invasive techniques versus gold standard approach for middle volume (30-80 ml) prostates: a multicentre prospective randomized study

Authors: Pastore A.L.¹, Rera O.A.¹, Sequi M.B.¹, Antonioni A.¹, Valenzi F.M.¹, Suraci P.P.¹, Scalzo S.¹, Graziani D.¹, Candita G.¹, Martino G.¹, Gianfrancesco F.¹, Fuschi A.¹, Al Salhi Y.¹, Balsamo R.², Uricchio F.², De Nunzio C.³, Lombardo R.³, Sciarra A.⁴, Del Giudice F.⁴, Carbone A.¹

Institutes: ¹Sapienza University of Rome Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies Urology, Latina, Italy, ²AORN Ospedali dei Colli-Monaldi Hospital, Dept. of Urology, Naples, Italy, ³Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy, ⁴Sapienza University of Rome, Dept. of Urology, Rome, Italy

A0702

Benign prostatic hyperplasia surgical retreatment: A retrospective cohort analysis of a nationwide database

Authors: Manfredi C.¹, Licari L.¹, Bologna E.¹, Ditunno F.¹, Franco A.¹, Pandolfo S.², De Nunzio C.³, Arcaniolo D.⁴, Romero-Otero J.⁵, Cindolo L.⁶, Antonelli A.⁷, Porpiglia F.⁸, De Sio M.⁴, Autorino R.¹

Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²University of Naples Federico II, Dept. of Urology, Naples, Italy, ³Sant Andrea Hospital Sapienza University, Dept. of Urology, Rome, Italy, ⁴University of Campania Luigi Vanvitelli, Dept. of Urology, Naples, Italy, ⁵HM Hospitales, Dept. of Urology, Madrid, Spain, ⁶Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy, ⁷Azienda Ospedaliera Universitaria Integrata University of Verona, Dept. of Urology, Verona, Italy, ⁸San Luigi Gonzaga Hospital University of Turin, Dept. of Urology, Turin, Italy

A0689

Postoperative urinary incontinence following BPH surgery: insights from a comprehensive U.S. database analysis

Authors: Licari L.C.¹, Manfredi C.², Bologna E.¹, Franco A.³, Ditunno F.⁴, Pandolfo S.D.⁵, Simone G.⁶, Antonelli A.⁴, De Nunzio C.³, De Sio M.², Cherullo E.E.⁷, Autorino R.⁷

Institutes: ¹Sapienza University of Rome Policlinico Umberto I Hospital, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²University of Campania Luigi Vanvitelli, Unit of Urology, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ³Sapienza University Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ⁴Azienda Ospedaliera Universitaria Integrata Verona University of Verona, Dept. of Urology, Verona, Italy, ⁵University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ⁶Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁷Rush University, Dept. of Urology, Chicago, United States of America

A0700

Water Vapor Thermal Therapy vs. TURP for the treatment of benign prostatic obstruction: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (URAN Collaborative Group)

Authors: Asmundo M.G.R.¹, Cocci A.², Busetto G.M.³, Lo Giudice A.¹, Pezzoli M.², Sessa F.², Tuccio A.², Polverino P.², Siena G.², Cacciamani G.⁴, Castiglione F.⁵, Falcone M.⁶, Ricci M.⁶, Patruno G.⁷, Dell'Oglio P.⁸, Bertolo R.⁹, Carilli M.⁹, Durukan E.¹⁰, Russo G.I.¹

Institutes: ¹University of Catania, Dept. of Urology, Catania, Italy, ²University of Florence, Dept. of Urology, Florence, Italy, ³University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁴University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁵University College London Hospital, Dept. of Urology, London, United Kingdom, ⁶University of Turin Molinette Hospital, Dept. of Urology, Turin, Italy, ⁷San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy, ⁸ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁹San Carlo Di Nancy Hospital, Dept. of Urology, Rome, Italy, ¹⁰Copenhagen University Hospital Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark

A0699

The Rezum water vapor thermal therapy for benign prostate hypertrophy : Risk of unsuccessful trial without catheter after 7 days in a large population

Authors: Al Barajraji M.¹, Coscarella M.¹, Moussa I.¹, Naudin M.¹, Roumeguère T.²

Institutes: ¹CHU Ambroise Pare, Dept. of Urology, Mons, Belgium, ²Erasme Hospital, University Hospital of Brussels, Free University of Brussels, Dept. of Urology, Brussels, Belgium

A0695

Transurethral Intraprostatic Injections of Anesthetics (TUIA) and cortisone before rezum treatment shows full pain control and it improves post-operative dysuria

Authors: Siena G.¹, Lo Re M.¹, Nardoni S.¹, Rivetti A.¹, Polverino P.¹, Cindolo L.², Secco S.³, Gacci M.¹, Sessa F.¹

Institutes: ¹AOU Careggi, Dept. of Urology, Florence, Italy, ²Villa Stuart, Dept. of Urology, Rome, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy

A0697

Pre-operative prostate artery embolization before transurethral resection of prostate for prostate glands larger than 80 milliliters – a randomised controlled trial

Authors: Lee Y.A.¹, Neo S.H.², Ng T.K.¹, Aslim E.J.¹, Qiao Y.¹, Sim A.³, Kumar P.⁴, Chandramohan S.⁵, Chen K.¹

Institutes: ¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ³Gleneagles Medini Johor, Dept. of Urology, Johor, Malaysia, ⁴Sunway Medical Centre, Dept. of Vascular and Interventional Radiology, Selangor, Malaysia, ⁵Singapore General Hospital, Dept. of Vascular and Interventional Radiology, Singapore, Singapore

A0692

Multicenter study evaluating the safety and feasibility of Transurethral Intraprostatic Injections of Anesthetics (TUIA) delivered via an innovative catheter to perform minimally invasive surgical techniques for benign prostatic obstructions

Authors: Secco S.¹, Olivero A.¹, Sessa F.², Cindolo L.³, Chiu P.⁴, Baboudjian M.⁵, Nardoni S.², Sibona M.⁶, Lo Re M.², Lechevallier E.⁵, Destefanis P.⁶, Dell'Oglio P.¹, Tappero S.¹, Castellucci R.³, Caviglia A.¹, Palagonia E.¹, Maltzman O.¹, Chierigo F.¹, Buratto C.¹, Piccione A.¹, Galfano A.¹, Bocciardi A.¹, Gacci M.², Siena G.²

Institutes: ¹Niguarda Cà Granda Hospital, Dept. of Urology, Milan, Italy, ²Careggi University Hospital, Unit of Oncologic Minimally Invasive Urology and Andrology, Florence, Italy, ³Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy, ⁴The Chinese University of Hong Kong, S. H. Ho Urology Centre, Hong Kong, Hong Kong, ⁵Hopitaux Universitaires de Marseille Conception, Dept. of Urology, Marseille, France, ⁶AOU Città della Salute e della Scienza Ospedale Molinette, Dept. of Urology, Turin, Italy

A0693

Transperineal Laser Ablation (TPLA) and convective water vapor ablation (CWVA) for minimally invasive treatment of benign prostatic hyperplasia: a randomized controlled trial

Authors: Pacini M., Bartoletti R., Sollazzi E., Macrì G., Zucchi A., Claps F., Greco P.

Institutes: University of Pisa, Dept. of Urology, Pisa, Italy

A0688

Trans-Perineal Laser Ablation of the Prostate for the treatment of Benign Prostatic Obstruction in high surgical risk patients. One-year results from a prospective cohort of “extreme” patients

Authors: Sibona M., Vitiello F., Montefusco G., Vercelli E., Micai L., Bracco F.M., Mangione C., Colucci F., Destefanis P., Gontero P.

Institutes: A.O.U. Città della Salute e della Scienza di Torino - Molinette, Dept. of Urology, Turin, Italy

A0690

Transperineal Fusion Laser Ablation for BPH: 100 consecutive patients with 1 year results

Authors: Maiolino G.¹, Avila L.A.², Gonzalez P.G.², Gheiler E.G.², Kaufman A.K.², Bianco F.J.²

Institutes: ¹University of Perugia, Dept. of Surgical and Biomedical Sciences - Division of Urology Clinic, Perugia, Italy, ²Urological Research Network, Dept. of Urology, Miami, United States of America

- A0698** **Efficacy and safety of ultrasonography guided transperineal percutaneous laser ablation for treating benign prostatic hyperplasia: a randomized controlled clinical trial compared with transurethral resection of the prostate.**
Authors: Fu Q., Zhang W., Cao N., Meng Z., Guo Q., Xu Y., Chen L., Hu B.
Institutes: Shanghai Sixth People's Hospital, Dept. of Urology, Shanghai, China
- A0691** **Treatment of benign prostatic hyperplasia (BPH) using 3D Ultrasound-guided transperineal targeted microwave ablation (TMA): the first safety and feasibility study (BETTY trial)**
Authors: Chiu P.K-F., Lo K.L., Yee C.H., Teoh J.Y.C., Wong H.F., Kong A.W.Y., Ng C.F.
Institutes: The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong
- A0694** **MRI-guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic hyperplasia: 12-month outcomes of a phase 1-2 study**
Authors: Anttinen M.H.J.¹, Viitala A.², Doerwald P.³, Mäkelä P.², Nurminen P.¹, Pärssinen H.², Sainio T.², Taimen P.¹, Blanco Sequeiros R.², Boström P.J.¹
Institutes: ¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital, Dept. of Radiology, Turku, Finland, ³Profound Medical, Dept. of Clinical Science, Hamburg, Germany
- A0687** **Flow rate and symptom improvements maintained long-term after treatment of prostatic hypertrophy with a novel combination drug/device**
Authors: Kaplan S.A.
Institutes: Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
- A0701** **A drug-coated balloon treatment for urethral stricture: a multicenter Italian real-life study.**
Authors: Castellucci R.¹, Morselli S.², Gatti L.², Secco S.³, Scarcia M.⁴, Ludovico G.M.⁴, Spirito L.⁵, Imperatore V.⁶, Preto M.⁷, Gontero P.⁷, Persico F.⁸, Fedelini P.⁸, Trama F.⁹, Di Lauro G.⁹, Dini D.¹⁰, De Marco F.¹⁰, Cindolo L.¹
Institutes: ¹CURE Group, Dept. of Urology, Modena, Italy, ²Hesperia Hospital, Dept. of Urology, Modena, Italy, ³Niguarda Hospital, Dept. Of Urology, Milan, Italy, ⁴General Regional Hospital F. Miulli, Dept. Of Urology, Acquaviva delle Fonti, Italy, ⁵University of Campania Luigi Vanvitelli, Dept. of Woman Child and General Specialized Surgery, Unit of Urology, Naples, Italy, ⁶AORN Moscati, Dept. Of Urology, Naples, Italy, ⁷A.O.U. Città della Salute e della Scienza - Molinette Hospital - University of Turin, Dept. Of Urology, Turin, Italy, ⁸AORN A. Cardarelli, Dept. Of Urology, Naples, Italy, ⁹ASL NA2 Nord P.O. S.Maria delle Grazie, Dept. Of Urology, Pozzuoli, Italy, ¹⁰Tiberia Hospital, Dept. of Urology, Rome, Italy

A0696

Impact of treatment of BPH-related LUTS with second generation temporary implantable nitinol device (iTIND) on serum PSA: results from a multicenter prospective study (MT-06-study)

Authors: De Cillis S.T.¹, Amparore D.², Checcucci E.³, Piramide F.², Piana A.⁴, Volpi G.¹, Sica M.², Meziere J.², Schönthaler M.⁵, Robert G.⁶, Di Dio M.⁷, Cantiello F.⁸, Gómez Sancha F.⁹, Becker A.¹⁰, Terrone C.¹¹, Beverini M.¹¹, Parodi S.¹¹, De Nunzio C.¹², Muellhaupt G.¹³, Delongchamps N.B.¹⁴, Della Negra E.¹⁵, Woo H.¹⁶, Fiori C.¹, Porpiglia F.¹

Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ³Candiolo Cancer Institute FPO-IRCCS, Division of Urology, Dept. of Surgery, Candiolo, Italy, ⁴Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁵Medical Centre - University of Freiburg, Dept. of Urology, Freiburg, Germany, ⁶Bordeaux GH Pellegrin Centre Hospitalier Universitaire de Bordeaux, Dept. of Urology, Bordeaux, France, ⁷Annunziata Hospital, Division of Urology - Dept. of Surgery, Cosenza, Italy, ⁸Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁹ICUA-Clínica CEMTRO, Dept. of Urology, Madrid, Spain, ¹⁰University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹¹IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ¹²Ospedale Sant'Andrea, Sapienza University of Rome, Dept. of Urology, Rome, Italy, ¹³Cantonal Hospital St. Gallen, University of St. Gallen, Dept. of Urology, St Gallen, Switzerland, ¹⁴Cochin Hospital Assistance Publique, Hopitaux de Paris, Paris Descartes University, Dept. of Urology, Paris, France, ¹⁵Plérin Private Hospital, Dept. of Urology, Plérin, France, ¹⁶Sydney Adventist Hospital Clinical School, University of Sydney, Dept. of Urology, Sydney, Australia

A0685

The risk factors associated with the failure of prostatic urethral lift (UroLift) for benign prostatic hyperplasia: 8-years observational study.

Authors: Kim Y.U., Park S.Y., Lee R., Ha J.G., Jang J.Y., Choi J.Y., Ko Y.H., Song P.H., Moon K.H., Jung H.C.

Institutes: Yeungnam University College of Medicine, Dept. of Urology, Daegu, South Korea

Hot research topics II

Abstract session

07 April 2024
16:45 - 18:15

Location Green Area, W03
Chairs L. Dyrskjøt, Aarhus (DK)
M. Eckstein, Erlangen (DE)
To be confirmed

16:45 - 17:00

From bulk to single cell spatial analysis

A0707

The infiltration of MALT B cells could predict a poor prognosis in clear cell renal carcinoma: results from single-cell transcriptomics and spatial transcriptome

Authors: Zhu S.¹, Tian X.¹, Chang K.¹, Gan H.², Qu Y.¹, Xu W.¹, Zhang H.¹, Ye D.¹

Institutes: ¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Udan University Shanghai Cancer Center, Dept. of Oncology, Shanghai, China

A0703

Spatial mapping reveals the transcriptome and anatomic heterogeneity of human and rat corpus cavernosum

Authors: Zhao L.

Institutes: The Fifth Affiliated Hospital of Sun Yat-Sen University, Dept. of Urology, Zhuhai, China

A0708

Spatial transcriptomic clonal deconvolution identifies the 'lethal clone' in prostate cancer (PCa) as defined by ability to metastasize to lymph nodes

Authors: Yin W.¹, Figiel S.¹, He M.², Teague R.³, Anbarasan T.¹, Ranasinha N.¹, Singh R.¹, Poulouse N.¹, Doultzinos D.¹, Erickson A.¹, Loda M.⁴, Verrill C.¹, Colling R.¹, Gill P.¹, Bryant R.J.¹, Cussenot O.¹, Hamdy F.¹, Woodcock D.¹, Mills I.¹, Lundeborg J.², Lamb A.¹

Institutes: ¹University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ²KTH Royal Institute of Technology Science for Life Laboratory, Dept. of Gene Technology, Solna, Sweden, ³University of Oxford, Dept. of Cellular Pathology, Oxford, United Kingdom, ⁴Weill Cornell Medicine, Dept. of Pathology and Laboratory Medicine, New York, United States of America

17:00 - 17:15

Liquid biopsy: prognostic evaluation and treatment selection

A0705

Genomic profiling and clinical utility of circulating tumor DNA in metastatic renal cell carcinoma: Nationwide SCRUM-Japan MONSTAR SCREEN project

Authors: Kato T.¹, Matsubara N.², Yamamoto Y.¹, Ishizuya Y.¹, Shiota M.³, Eto M.³, Yasumizu Y.⁴, Tanaka N.⁴, Oya M.⁴, Osawa T.⁵, Abe T.⁵, Shinohara N.⁵, Hayashi T.⁶, Nakayama M.⁶, Kojima T.⁷, Fujisawa T.⁸, Nakamura Y.⁹, Yoshino T.⁹, Nonomura N.¹

Institutes: ¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²National Cancer Center Hospital East, Department Medical Oncology, Kashiwa, Japan, ³Kyushu University, Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, ⁴Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵Hokkaido University Graduate School of Medicine, Dept. of Urology, Sapporo, Japan, ⁶Osaka International Cancer Center, Dept. of Urology, Osaka, Japan, ⁷Aichi Cancer Center, Dept. of Urology, Nagoya, Japan, ⁸National Cancer Center Hospital East, Department Head and Neck Medical Oncology, Kashiwa, Japan, ⁹National Cancer Center Hospital East, Dept. of Gastroenterology and Gastrointestinal Oncology, Kashiwa, Japan

A0704

Rapid feedback on the effects of anticancer mitochondrially targeted tamoxifen using circulating tumor cells

Authors: Klézl P.¹, Kolostova K.², Bielikova Z.³, Stursa J.⁴, Werner L.⁴, Neuzil J.⁴, Balinthova S.⁴, Dvorakova S.⁴, Molnarova L.², Pospisilova E.², Gregusova A.¹, Sonsky J.¹, Grill R.¹, Bobek V.²

Institutes: ¹Faculty Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University, Urology Clinic, Prague, Czech Republic, ²Faculty Hospital Královské Vinohrady and 3rd Faculty of Medicine Charles University, Oncology Clinic, Prague, Czech Republic, ³General University Hospital and 1st Faculty of Medicine Charles University, Oncology Clinic, Prague, Czech Republic, ⁴Institute of Biotechnology Czech Academy of Sciences Prague, Dept. of Molecular Therapy, Vestec, Czech Republic

A0706

Prognostic value of circulating tumor cells and cell-free DNA in upper tract urothelial carcinoma

Authors: Padulles Castello B.¹, Carrasco R.², Roldan F.L.¹, Ingelmo M.², Figueras M.², Mercader C.¹, Carrascal A.¹, Muní M.¹, Mengual L.³, Izquierdo L.¹, Alcaraz A.¹

Institutes: ¹Hospital Clínic of Barcelona, Dept. of Urology, Barcelona, Spain, ²IDIBAPS, Dept. of Urology, Barcelona, Spain, ³University of Barcelona, Dept. of Biomedicine, Barcelona, Spain

Award session: New horizons in robotics and AI

Video session 11

07 April 2024
17:15 - 18:45

Location Purple Area, eURO Auditorium 2
Chairs G. Shaw, London (GB)
F. Van Der Aa, Leuven (BE)
To be confirmed

- V080** **AI Guidance in Robotic Surgery: Preliminary Video Analysis of Enhanced Surgical Performance**
Authors: Morgantini L.A.¹, Canneto R.¹, Garcia Nespolo R.², Leiderman Y.I.², Crivellaro S.¹
Institutes: ¹University of Illinois Chicago, Dept. of Urology, Chicago, United States of America, ²University of Illinois Chicago, Dept. of Ophthalmology and Visual Sciences, Chicago, United States of America
- V081** **The Single Port (SP) robotic surgical “toolbox”: a primer for beginners**
Authors: Ditonno F.¹, Pellegrino A.A.², Franco A.¹, Emerson J.¹, Manfredi C.¹, Bologna E.¹, Licari L.C.¹, Morgantini L.², Chow A.K.¹, Crivellaro S.², Autorino R.¹
Institutes: ¹Rush University, Dept. of Urology, Chicago, United States of America, ²University of Illinois Chicago, Dept. of Urology, Chicago, United States of America
- V082** **A pure single port DaVinci SP Robotic partial nephrectomy integrated with a fully functional assistant port: iFAP trocar configuration technique**
Authors: Ko Y.H., Ha J.G., Jang J.Y., Kim Y.U.
Institutes: Yeungnam University, Dept. of Urology, Daegu, South Korea
- V083** **A novel single-port robotic surgical system in RNRS-RARP**
Authors: Liu Z., Yong W., Yang L., Hua H., Yuan S., Yuanjie N.
Institutes: The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China
- V084** **Single Port radical prostatectomy comparing Shurui and da Vinci SP robots: technology illustration and intraoperative performances**
Authors: Wu Z.¹, Wang Z.¹, Wang L.¹, Patel E.², Moschovas M.C.²
Institutes: ¹First Affiliated Hospital Changhai Hospital of Naval Medical University, Dept. of Urology, Shanghai, China, ²AdventHealth Global Robotics Institute, Dept. of Urology, Orlando, United States of America
- V085** **Robot-assisted radical cystectomy with ureterocutaneostomy: surgical technique, perioperative and oncologic outcomes**
Authors: Misuraca L., Brassetti A., Anceschi U., Ferriero M., Leonardo C., D'Annunzio S., Bove A.M., Guaglianone S., Tuderti G., Mastroianni R., Chiacchio G., Flammia R.S., Proietti F., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

- V086** **A preliminary experience with metaverse surgical planning for robotic partial nephrectomy**
Authors: Checcucci E.¹, Amparore D.², Volpi G.¹, De Cillis S.T.², Alessio P.¹, Piramide F.², Piana A.³, Sica M.², Quarà A.², Gatti C.², Busacca G.², Colombo M.², Fiori C.², Porpiglia F.²
Institutes: ¹Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ²AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy
- V022** **Feasibility of image-guided navigation during robotic-assisted surgery: a prospective study**
Authors: Aguilera Saiz L.¹, Heerink W.J.¹, Groen H.C.¹, Hiep M.A.J.¹, Van Der Poel H.G.², Wit E.M.K.², Nieuwenhuijzen J.A.³, Roeleveld T.A.³, Van Leeuwen P.J.², Ruers T.J.M.¹
Institutes: ¹Netherlands Cancer Institute, Dept. of Surgical Oncology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands

Biopsy indication: role of MRI and risk calculators

Abstract session 35

07 April 2024
17:15 - 18:45

Location Green Area, N03
Chairs To be confirmed
To be confirmed
F. Sanguedolce, Barcelona (ES)

17:15 - 17:45

A0717

Risk stratification and imaging

EAU Risk stratification for prostate cancer according to systematic biopsy, target biopsy and combined biopsy results and final pathology concordance. Results from the PROMOD Study Group

Authors: Ninivaggi A.¹, Falagario U.¹, Cormio A.², Galosi A.², Carmignani L.³, Montanari E.⁴, Bove P.⁵, Gontero P.⁶, Porpiglia F.⁷, Sciarra A.⁸, Trombetta C.⁹, Bassi P.¹⁰, Simone G.¹¹, Ludovico G.¹², Mirone V.¹³, Antonelli A.¹⁴, Schips L.¹⁵, Ricapito A.¹, Busetto G.M.¹, Ficarra V.¹⁶, Boström P.J.¹⁷, De Cobelli O.¹⁸, Cormio L.¹⁹, Carrieri G.¹

Institutes: ¹University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ²Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ³IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁴IRCCS Foundation Ca Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy, ⁵San Carlo di Nancy Hospital, Dept. of Urology, Rome, Italy, ⁶Città della Salute e della Scienza di Torino Molinette Hospital, Dept. of Surgical Science, Turin, Italy, ⁷Azienda Ospedaliera Universitaria San Luigi Gonzaga, Dept. of Urology, Turin, Italy, ⁸Sapienza Rome University, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ⁹Università di Trieste, Dept. of Urology, Trieste, Italy, ¹⁰Catholic University Medical School A. Gemelli Hospital, Dept. of Urology, Rome, Italy, ¹¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹²Ente Ecclesiastico Miulli, Dept. of Urology, Acquaviva delle Fonti, Italy, ¹³University of Naples Federico II, Dept. of Urology, Naples, Italy, ¹⁴Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy, ¹⁵Università G.d'Annunzio Chieti-Pescara, Dept. of Urology, Chieti, Italy, ¹⁶University of Messina, Dept. of Urology, Messina, Italy, ¹⁷University of Turku and Turku University Hospital, Dept. of Urology, Turku, Finland, ¹⁸Istituto Europeo di Oncologia, Dept. of Urologic Cancer Surgery, Milan, Italy, ¹⁹University of Foggia and Bonomo teaching hospital, Dept. of Urology, Andria, Italy

A0720

Investigation and management of prostate cancer in patients over 70 years of age – should we reframe our thinking? An analysis of transperineal prostate biopsies at a large tertiary centre

Authors: Lim S., Soroush S., Wei G., Chu K., Harper M., Donnellan S., Ranasinghe W.

Institutes: Monash Health, Dept. of Urology, Melbourne, Australia

A0726

A new approach to data integration with AI to enhance the specificity of prostate cancer diagnosis

Authors: Moreira Da Silva N.S.¹, Vasdev N.², Budd J.¹, Yeung M.¹, Giganti F.³, Davies L.¹, Burn P.R.⁴, Hindley R.G.⁵, Ibrahim M.², Bradley A.J.⁶, Maskell G.⁶, Andreou A.⁷, Liyanage S.⁸, Persad R.⁹, Aning J.⁹, Barrett T.J.¹⁰, Hinton M.D.B.¹, Padhani A.R.¹¹, Sala E.¹², Rix A.W.¹, Shah A.¹³

Institutes: ¹Lucida Medical Ltd, Dept. of Machine Learning, Cambridge, United Kingdom, ²East and North Herts NHS Trust, Dept. of Urology, Stevenage, United Kingdom, ³University College London, Dept. of Radiology, London, United Kingdom, ⁴Somerset NHS Foundation Trust, Dept. of Radiology, Taunton, United Kingdom, ⁵Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Winchester, United Kingdom, ⁶Royal Cornwall Hospitals NHS Foundation Trust, Dept. of Radiology, Truro, United Kingdom, ⁷Royal United Hospitals Bath NHS Foundation Trust, Dept. of Radiology, Bath, United Kingdom, ⁸Mid and South Essex NHS Foundation Trust, Dept. of Radiology, Southend, United Kingdom, ⁹North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ¹⁰Cambridge University Hospitals NHS Foundation Trust, Dept. of Radiology, Cambridge, United Kingdom, ¹¹Paul Strickland Scanner Centre, Dept. of Radiology, Northwood, United Kingdom, ¹²Policlinico Universitario A. Gemelli IRCCS, Dept. of Radiology, Rome, Italy, ¹³Hampshire Hospitals NHS Foundation Trust, Dept. of Radiology, Winchester, United Kingdom

A0712

PSA-density, DRE, and PI-RADS 5: Potential surrogates for omitting prostate biopsy?

Authors: Falkenbach F.¹, Ambrosini F.², Kachanov M.³, Ortner G.¹, Maurer T.⁴, Köhler D.⁵, Beyersdorff D.⁵, Graefen M.¹, Budäus L.¹

Institutes: ¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Germany, ³University Medical Center Hamburg-Eppendorf, Institute of Human Genetics, Hamburg, Germany, ⁴University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Radiology and Nuclear Medicine, Hamburg, Germany

A0718

To biopsy or not to biopsy, that is the prostate-blem: The utility of Prostate Health Index in men with PIRADS 3 lesions

Authors: Wang K., Tsang W.C., Quek A.J.Y., Ong J.H.W., Chong D.Z.K., Wang Z., Wu Q.H., Chiong E.

Institutes: National University Hospital, Dept. of Urology, Singapore, Singapore

A0709

Risk Stratification for Avoiding Unnecessary Prostate Biopsy After Atypical Small Acinar Proliferation Detection

Authors: Kaneko M.¹, Paralkar D.¹, Ramacciotti L.S.¹, Cacciamani G.E.¹, Aron M.², Hopstone M.³, Duddalwar V.³, Gill I.S.¹, Abreu A.L.¹

Institutes: ¹University of Southern California, Institute of Urology, Center for Image-Guided Surgery Focal Therapy and Artificial Intelligence for Prostate Cancer, Los Angeles, United States of America, ²University of Southern California, Dept. of Pathology, Los Angeles, United States of America, ³University of Southern California, Dept. of Radiology, Los Angeles, United States of America

17:45 - 18:30

Risk calculators and markers

A0719

Development and external validation of new biopsy indication using Prostate Health Index Density and Prostate Image Report and Data System score

Authors: Kim J., Lee Y.H., Yoo S., Lee D., Lee S.S., Song W.H., Nam J.K., Park S.W.

Institutes: Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan-si, South Korea

A0722

Added Value of The Rotterdam Prostate Cancer Risk Calculator After a Negative Pre-Biopsy Magnetic Resonance Imaging: How many Clinically Significant Prostate Cancers Are Overlooked?

Authors: Tagalos Munoz A.C., Fernandez Conejo G., Subiela Henríquez J.D., López Plaza J.A., Fernandez Mardomingo A., Mínguez Ojeda C., Mata Alcaraz M., Rodríguez-Patrón Rodríguez R., Sanz Mayayo E., Burgos Revilla F.J.

Institutes: Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain

A0711

Intercenter variability in the accuracy of Risk calculators based on MRI parameters: Extensive external validation of 7 contemporary risk calculators.

Authors: Tocci E.¹, Falagario U.¹, Lantz A.², Carmignani L.³, Montanari E.⁴, Bove P.⁵, Gontero P.⁶, Porpiglia F.⁷, Sciarra A.⁸, Trombetta C.⁹, Bassi P.¹⁰, Simone G.¹¹, Mirone V.¹², Antonelli A.¹³, Schips L.¹⁴, Ludovico G.¹⁵, Ricapito A.¹, Busetto G.¹, Ficarra V.¹⁶, Bostrom P.¹⁷, De Cobelli O.¹⁸, Nordstrom T.¹⁹, Cormio L.²⁰, Carrieri G.¹

Institutes: ¹University of Foggia, Dept. of Urology and Kidney Transplantation, Foggia, Italy, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁴IRCCS Foundation Ca' Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy, ⁵San Carlo di Nancy Hospital, Dept. of Radiology, Rome, Italy, ⁶Molinetto Hospital, Dept of Surgical Sciences, Turin, Italy, ⁷A.O.U. San Luigi Gonzaga, Dept. of Urology, Turin, Italy, ⁸Sapienza Rome University, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ⁹Clinica Urologica, Dept. of Urology, Trieste, Italy, ¹⁰Catholic University Medical School, Dept. of Urology, Rome, Italy, ¹¹Regina Elena National Cancer Institute, Dept. of Oncologic Urology, Rome, Italy, ¹²University of Naples Federico II, Dept. of Urology, Naples, Italy, ¹³Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy, ¹⁴G. D'Annunzio, Dept. of Urology, Chieti, Italy, ¹⁵Ente Ecclesiastico Miulli, Dept. of Urology, Acquaviva delle Fonti, Italy, ¹⁶Clinica Messina, Dept. of Urology, Messina, Italy, ¹⁷University of Pori, Dept. of Urology, Pori, Finland, ¹⁸Istituto Europeo di Oncologia, Dept. of Urologic Cancer Surgery, Milan, Italy, ¹⁹Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²⁰Ospedale L. Bonomo Andria BT, Dept. of Urology, Andria, Italy

A0710

Pre-biopsy meeting as a foundation to the diagnostic prostate cancer pathway: A single unit review

Authors: Fleville S., Deeny D., O'Neill C., Safar D., Mulholland C., Subin F.

Institutes: Western Health and Social Care Trust, Dept. of Urology, Derry, United Kingdom

A0721

The Ongoing Role of DRE in the Diagnostic Pathway for Men with Suspected Prostate Cancer

Authors: Richards C., Dyer J., Cleaveland P., Tang V., Brough R., Jones C.

Institutes: Stockport NHS Foundation Trust, Dept. of Urology, Stockport, United Kingdom

A0725

Stockholm3 validation in a multi-Ethnic cohort for ProSTate cancer (SEPTA) detection: A multicentered, prospective trial

Authors: Vigneswaran H.T.¹, Eklund M.¹, Discacciati A.¹, Nordström T.¹, Hubbard R.A.², Perlis N.³, Abern M.⁴, Moreira D.⁵, Eggener S.⁶, Yonover P.⁷, Chow A.⁸, Watts K.⁹, Liss M.¹⁰, Thoreson G.¹¹, Abreu A.L.¹², Sonn G.A.¹³, Palsdottir T.¹, Plym A.¹, Wiklund F.¹, Grönberg H.¹, Murphy A.B.¹⁴

Institutes: ¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²University of Pennsylvania Perelman School of Medicine, Center for Clinical Epidemiology and Biostatistics, Philadelphia, United States of America, ³University of Toronto, Dept. of Surgery, Toronto, Canada, ⁴Duke University School of Medicine, Dept. of Urology, Durham, United States of America, ⁵University of Illinois Chicago, Dept. of Urology, Chicago, United States of America, ⁶University of Chicago, Dept. of Surgery, Chicago, United States of America, ⁷Uropartners LLC, Chicago, United States of America, ⁸Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ⁹Montefiore Medical Center, Dept. of Urology, New York, United States of America, ¹⁰University of Texas Health Science Center San Antonio, Dept. of Urology, San Antonio, United States of America, ¹¹Urology Clinics of North Texas, Dallas, United States of America, ¹²University of Southern California, Keck School of Medicine, Institute of Urology, Los Angeles, United States of America, ¹³Stanford University School of Medicine, Dept. of Urology, Palo Alto, United States of America, ¹⁴Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America

A0715

The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, single Institution series

Authors: Scilipoti P.¹, Stabile A.¹, Barletta F.¹, Cannoletta D.¹, Quarta L.¹, Pellegrino A.¹, Mazzone E.¹, Pellegrino F.¹, Scuderi S.¹, Sorce G.¹, Leni R.¹, Tenace N.², Cucchiara V.¹, Lucianò R.², Robesti D.¹, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy

A0713

Stockholm3 to predict post-operative risk and biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial

Authors: Vigneswaran H.T., Palsdottir T., Grönberg H., Nordström T., Egevad L., Eklund M.

Institutes: Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

A0714

Stockholm3 in older men; PSA values, MRI- and biopsy results.

Authors: Vigmostad M.N.¹, Vigneswaran H.T.², Gilje B.¹, Kjosavik S.¹, Palsdottir T.²

Institutes: ¹Stavanger University Hospital, Dept. of Oncology and Hematology, Stavanger, Norway, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

18:30 - 18:45

Markers PSA-PSAD

A0723

Lower than expected? Establishing a PSA density threshold

Authors: Dawson J.¹, Yassaie O.¹, Tharmaratnam K.², Garcia-Finana M.², Probert C.³, Lazarowicz H.P.¹, Cornford P.A.¹

Institutes: ¹Liverpool University Hospitals NHS Foundation Trust, Dept. of Urology, Liverpool, United Kingdom, ²University of Liverpool, Dept. of Health Data Science, Liverpool, United Kingdom, ³University of Liverpool, Institute of Systems Molecular and Integrative Biology, Liverpool, United Kingdom

A0724

Repeat PSA testing improves biopsy outcome predictions in men undergoing MRI and targeted biopsies

Authors: Davik P.¹, Elschot M.², Bathen T.², Bertilsson H.³

Institutes: ¹St Olavs Hospital, Dept. of Urology, Trondheim, Norway, ²NTNU, ISB, Trondheim, Norway, ³NTNU, IKOM, Trondheim, Norway

A0716

Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series.

Authors: Quarta L.¹, Stabile A.¹, Barletta F.¹, Mazzone E.¹, Cannoletta D.¹, Pellegrino F.¹, Sorce G.¹, Pellegrino A.¹, Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Leni R.¹, Bianchi M.¹, Longoni M.¹, Scilipoti P.¹, De Cobelli F.², Esposito A.², Gandaglia G.¹, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy

Urothelial cancer treatment: From endoscopy to robotic-assisted surgery

Video session 12

07 April 2024
17:15 - 18:45

Location Purple Area, S01
Chairs M. Musquera Felip, Barcelona (ES)
To be confirmed
To be confirmed

- V088** **A novel transurethral resection approach: a study of rotatable bi-channel en bloc resection of bladder tumor in ex vivo and in vivo porcine models**
Authors: Yao Q.¹, Yang X.², Niu H.³, Jiang H.⁴, Zhou Y.⁴, Zhu J.¹, Xue B.¹
Institutes: ¹The Second Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, ²Institute of Biomedical Engineering and Technology Chinese Academy of Sciences, Center of Optics and Health, Suzhou, China, ³The Second Affiliated Hospital of Soochow University, Dept. of Pathology, Suzhou, China, ⁴The Second Affiliated Hospital of Soochow University, Dept. of Operating Room, Suzhou, China
- V089** **Outpatient treatment of low and intermediate risk non-muscle invasive bladder tumors using transurethral ablation with diode laser (TULA). Initial experience**
Authors: Zamora Voorn P., Rodríguez Villamil L., Salgado Plonski J.J., García-Terente Fernández V., Martín Gómez L., Fernández-Pello Montes S., Rivas Del Fresno M.
Institutes: Hospital Universitario de Cabuenes, Dept. of Urology, Gijón, Spain
- V090** **Robot-assisted radical cystectomy with Hugo RAS system: Description of the setup and initial outcomes for two Italian centres**
Authors: Rocco B.M.C.¹, Sighinolfi M.C.¹, Assumma S.¹, Calcagnile T.¹, Panio E.¹, Sarchi L.¹, Turri F.¹, Sangalli M.¹, Dell'Orto P.¹, Piacentini I.¹, Terzoni S.¹, Morandi A.¹, Gaia G.², Coelho R.F.³, Moscovas M.C.⁴, Patel V.⁴, Civitella A.⁵, Prata F.⁵, Papalia R.⁵
Institutes: ¹ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ²ASST Santi Paolo e Carlo, Dept. of Gynecology, Milan, Italy, ³Istituto do Cancer, Dept. of Urology, Sao Paulo, Brazil, ⁴Global Robotic Institute, Dept. of Urology, Orlando, United States of America, ⁵Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy
- V091** **Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique**
Authors: Vaccaro C.¹, Dewulf K.², Richter K.², Branger N.², Leclercq L.², Distante A.², Djouhri M.², Rybikowski S.², Maubon T.², Walz J.², Pignot G.²
Institutes: ¹European Institute of Oncology, Dept. of Urology, Milan, Italy, ²Institut Paoli-Calmettes, Dept. of Urology, Marseille, France

- V085** **Robot-assisted radical cystectomy with ureterocutaneostomy: surgical technique, perioperative and oncologic outcomes**
Authors: Misuraca L., Brassetti A., Anceschi U., Ferriero M., Leonardo C., D'Annunzio S., Bove A.M., Guaglianone S., Tuderti G., Mastroianni R., Chiacchio G., Flammia R.S., Proietti F., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- V093** **Robotic Radical Cystectomy and Nephroureterectomy for UC in double Renal Transplant Recipient with FloRIN reconstruction**
Authors: Marquis A., Lavagno F., Allasia M., Oderda M., Livoti S., Marra G., Soria F., Gontero P.
Institutes: Molinette Hospital, University of Turin, Division of Urology. Dept. of Surgical Sciences, Turin, Italy
- V094** **“Bordeaux Neobladder”: illustration of surgical tricks and evaluation of perioperative outcomes in a referred center.**
Authors: Bianchi B.¹, Palagonia E.¹, Chiamonti F.¹, D Asimakopoulos A.², Khorrami S.¹, De Angelis M.¹, Gaston R.³, Annino F.¹
Institutes: ¹San Donato Hospital, Dept. of Urology, Arezzo, Italy, ²University of Tor Vergata, Dept. of Urology, Rome, Italy, ³Clinique Saint-Augustin, Dept. of Urology, Bordeaux, France
- V095** **Prone position posterior retroperitoneal robotic nephroureterectomy: A new approach requiring NO patient repositioning**
Authors: Lyu Q., Yang X., Cao Q., Li P.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

NMIBC: Benefits and harms of various treatment options

Abstract session 36

**07 April 2024
17:15 - 18:45**

Location Purple Area, S03
Chairs A.M. Kamat, Houston (US)
G. Kramer, Vienna (AT)
A. Masson-Lecomte, Paris (FR)

17:15 - 17:17

Introduction

A0732

Active surveillance for recurrent non-muscle invasive bladder cancer

Authors: Tokarski E.¹, Mir M.C.², Krajewski W.³, Roumigué M.⁴, Xylinas E.¹

Institutes: ¹Hôpital Bichat-Claude Bernard, Dept. of Urology, Paris, France, ²Foundation Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, ³Wroclaw Medical University, Dept. of Urology, Wrocław, Poland, ⁴CHU Toulouse, IUCT Oncopole, Dept. of Urology, Toulouse, France

A0742

The International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance.

Authors: Contieri R.¹, Tan W.S.², Buffi N.M.¹, Lughezzani G.¹, Grajales V.², Soloway M.³, Casale P.⁴, Hurle R.⁴, Kamat A.M.²

Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ³Memorial Hospital, Division of Urology, Hollywood, United States of America, ⁴IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

A0729

Outpatient laser coagulation of low-grade intermediate risk bladder tumor compared with TUR-BT, 12 months and long-term follow-up of a noninferiority RCT

Authors: Pedersen G.L.¹, Mogensen K.¹, Rosthøj S.², Hermann G.¹

Institutes: ¹Herlev-Gentofte Hospital, Dept. of Urology, Copenhagen, Denmark, ²Danish Cancer Institute, Dept. of Statistics and Data Analysis, Copenhagen, Denmark

A0734

Repeat Transurethral Resection for Non-muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era

Authors: Yanagisawa T.¹, Kawada T.², Von Deimling M.³, Matsukawa A.³, Laukhtina E.³, Rajwa P.³, Pradere B.³, D'Andrea D.³, Moschini M.⁴, Yuen-Chun Teoh J.⁵, Miki J.¹, Kimura T.¹, Shariat S.F.³

Institutes: ¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Okayama University, Graduate School of Medicine, Dept. of Urology, Okayama, Japan, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁵The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China

A0740

Correlation of quality control indicators for transurethral resection of the bladder tumor with oncological outcomes: Results from a Flemish prospective registry

Authors: Akand M.¹, Vander Eeckt K.², Van Bruwaene S.³, Van Reusel R.⁴, Baekelandt F.⁵, Muilwijk T.¹, Baekelandt L.¹, Van Cleynenbreugel B.¹, Joniau S.¹, Van Der Aa F.¹

Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²AZ Sint Blasius, Dept. of Urology, Dendermonde, Belgium, ³AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ⁴AZ Turnhout, Dept. of Urology, Turnhout, Belgium, ⁵AZ Sint-Lucas Brugge, Dept. of Urology, Bruges, Belgium

A0730

Does audit, feedback and education improve quality indicator achievement and reduce early recurrence rates in TURBT surgery for NMIBC? Results from the RESECT cluster randomised trial.

Authors: Gallagher K.M.¹, Bhatt N.², Clement K.³, Zimmermann E.⁴, Khadhour S.⁵, Gaba F.⁶, Steven M.⁷, Anbarasan T.⁸, Asif A.⁹, Light A.¹⁰, Ng A.⁹, Chan V.⁹, Nathan A.⁹, Rossi S.¹¹, Kulkarni M.¹², Cooper D.⁷, Aucott L.⁷, Gomez Rivas J.¹³, Marcq G.¹⁴, Yuen-Chun Teoh J.¹⁵, O'Brien T.¹², Nielsen M.¹⁶, Mariappan P.¹⁷, Kasivisvanathan V.⁹

Institutes: ¹Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ²Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom, ³NHS Greater Glasgow and Clyde, Dept. of Urology, Glasgow, United Kingdom, ⁴University Hospitals Plymouth, Dept. of Urology, Plymouth, United Kingdom, ⁵University of St. Andrews, School of Medicine, St. Andrews, United Kingdom, ⁶Albany Medical College, Dept. of Urology, Albany, United States of America, ⁷University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ⁸Oxford University Hospitals, Dept. of Medicine, Oxford, United Kingdom, ⁹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ¹⁰Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ¹¹Cambridge University Hospitals, Dept. of Urology, Cambridge, United Kingdom, ¹²Guy's and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹³Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ¹⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁵The Chinese University of Hong Kong, S. H. Ho Urology Centre, Dept. of Surgery, Hong Kong, Hong Kong, ¹⁶University of North Carolina Medical School, Dept. of Urology, Chapel Hill, United States of America, ¹⁷Western General Hospital, Edinburgh Bladder Cancer Surgery, Dept. of Urology, Edinburgh, United Kingdom

A0737

Impact of risk factors on oncologic outcomes in intermediate-risk non-muscle-invasive bladder cancer

Authors: Laukhtina E.¹, Klemm J.¹, Fazekas T.¹, Matsukawa A.¹, Gontero P.², Soria F.², Babjuk M.³, Teoh J.Y.C.⁴, Moschini M.⁵, Karakiewicz P.I.⁶, Abufaraj M.⁷, Comperat E.⁸, Shariat S.F.¹

Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Studies of Torino, Division of Urology, Turin, Italy, ³Charles University, Dept. of Urology, Prague, Czech Republic, ⁴The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁵IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁶University of Montreal Health Center, Division of Urology, Montreal, Canada, ⁷The University of Jordan, Division of Urology, Amman, Jordan, ⁸Medical University of Vienna, Dept. of Pathology, Vienna, Austria

A0733

Intravesical instillations in octagenarian high grade, non muscle-invasive bladder cancer patients: could they offer a real survival advantage?

Authors: Guano G., Chierigo F., Rebuffo S., Parodi S., Tappero S., Ambrosini F., Vecco F., Paola C., Granelli G., Vecchio E., Lo Monaco L.L.B., Col B., Ragno G., Mantica G., Terrone C., Borghesi M.

Institutes: IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy

A0727

Cumulative incidence of and risk factors for BCG-infection after adjuvant BCG-instillations

Authors: Holmberg L.¹, Skogmar S.², Garmo H.¹, Hagberg O.³, Häggström C.¹, Gårdmark T.⁴, Ströck V.⁵, Aljabery F.⁶, Jahnson S.⁶, Hosseini A.⁷, Jerlström T.⁸, Sherif A.⁹, Söderkvist K.¹⁰, Ullen A.¹¹, Malmström P.U.¹, Liedberg F.³

Institutes: ¹Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ²Department of Translational Medicine Lund University, Dept. of Translational Medicine Lund University, Malmö, Sweden, ³Department of Translational Medicine Lund University, Dept. of Urology Skåne University Hospital, Malmö, Sweden, ⁴Danderyd Hospital, Karolinska Institute, Dept. of Clinical Sciences, Stockholm, Sweden, ⁵Department of Urology Sahlgrenska University Hospital and Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg, Dept. of Urology Sahlgrenska University Hospital and Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg, Gothenburg, Sweden, ⁶Linköping University, Dept. of Clinical and Experimental Medicine, Division of Urology, Linköping, Sweden, ⁷Department of Urology Danderyd Hospital and Department of Molecular Medicine and Surgery Karolinska Institute, Dept. of Urology Danderyd Hospital and Dept. of Molecular Medicine and Surgery Karolinska Institute, Stockholm, Sweden, ⁸Department of Urology School of Medical Sciences Faculty of Medicine and Health Örebro University, Dept. of Urology School of Medical Sciences Faculty of Medicine and Health Örebro University, Örebro, Sweden, ⁹Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, ¹⁰Umeå University, Dept. of Radiation Sciences, Umeå, Sweden, ¹¹Karolinska Institute, Dept. of Oncology-Pathology, Stockholm, Sweden

- A0739** **Challenging the paradigm of “BCG Unresponsive” Bladder Cancer: Does additional BCG have an effect?**
Authors: Myers A., Tan W.S., Grajales V., Hwang H., Bree K.K., Navai N., Lee B.H., Dinney C.P.N., Kamat A.M.
Institutes: The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America
- A0736** **No clinical benefit from Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial (NCT03790384)**
Authors: Cicione A.F.M.¹, Lombardo R.¹, Nacchia A.¹, Simone G.¹, Pastore A.², Leonardo C.³, Franco A.¹, Tubaro A.¹, Fiasconaro D.¹, Zammitti F.¹, De Nunzio C.¹
Institutes: ¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²ICOT Sapienza University of Rome, Dept. of Urology, Latina, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- A0738** **TRUCE04: A Phase II Clinical Trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) 24)**
Authors: Hu H., Guo S., Shen C., Huang S., Zhao G., Zhang Z., Wu Z., Chen H., Chen H., Liang S., Yuanjie N.
Institutes: Second Hospital Of Tianjin Medical University, Dept. of Urology, Tianjin, China
- A0731** **First results of the phase Ib-II BladderGATE clinical trial: intravenous Atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients**
Authors: Guerrero-Ramos F.¹, De Velasco G.², Duenas M.³, Paramio J.³, García V.M.³, Gómez-Canizo C.¹, Rodríguez-Izquierdo M.¹, Hernández-Arroyo M.¹, Martín-Torres M.P.¹, Álvarez-Rodríguez P.², Suárez C.³, Morales L.⁴, Ponce S.⁵, Rodríguez-Antolín A.¹, Castellano D.²
Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain, ³CIEMAT, Molecular Oncology Unit, Madrid, Spain, ⁴Hospital Universitario 12 de Octubre, Biomedical Research Institute, Madrid, Spain, ⁵Gustave Roussy, Dept. of Innovation Therapeutics and Early Trials, Paris, France

- A0741** **Intravesical administration of Durvalumab to patients with high risk non muscle invasive bladder cancer who experience BCG failure. Final results from a phase II study by the Hellenic GU Cancer Group.**
Authors: Fragkoulis C.¹, Bamias A.², Gavalas N.², Tzannis K.³, Fragkiadis E.⁴, Pinitas A.¹, Stamatakis P.V.¹, Stathouros G.¹, Papadopoulos G.¹, Ntoumas K.¹, Stravodimos K.⁴, Mitropoulos D.⁴, Skolarikos A.⁵, Papatsoris A.⁵
Institutes: ¹GNA G. Gennimatas, Dept. of Urology, Athens, Greece, ²Attikon University Hospital National and Kapodistrian University of Athens, 2nd Propaedeutic Dept. of Internal Medicine, Athens, Greece, ³Hellenic Genito-Urinary Cancer Group, Hellenic Genito-Urinary Cancer Group, Athens, Greece, ⁴Laikon Hospital National and Kapodistrian University of Athens, 1st Urology Department, Athens, Greece, ⁵Sismanoglion Hospital National and Kapodistrian University of Athens, 2nd Urology Department, Athens, Greece
- A0728** **Intravesical electromotive mitomycin for primary high risk non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin failure: a single arm phase II multicenter prospective study.**
Authors: Di Stasi S.M.¹, Palermo G.², Capelli G.³, Totaro A.², Foschi N.², Di Stasi E.², Moosawi S.K.², Presutti S.², Racioppi M.²
Institutes: ¹Catholic University of Sacred Heart, Dept. of Urology, Rome, Italy, ²Catholic University of Sacred Heart, Dept. of Urology, Rome, Italy, ³Istituto Superiore di Sanità, Dept. of Statistics, Rome, Italy
- A0735** **Unveiling the necessity: Should (Very) high-risk NMIBC patients undergoing RC Opt for pelvic lymph node dissection? —A prospective cohort study**
Authors: Lyu Q., Yang X., Cao Q., Zhuang J.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- A0743** **Impact of Systemic Therapy in Clinical T1 Small-cell Neuroendocrine Carcinoma of the Bladder**
Authors: Myers A.¹, Moussa M.J.², Fang A.M.¹, Wilson N.³, Campbell M.T.², Guo C.C.⁴, Zhang M.⁴, Siefker-Radtke A.², Kamat A.M.¹, Alhalabi O.²
Institutes: ¹The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²The University of Texas MD Anderson Cancer Center, Dept. of GU Medical Oncology, Houston, United States of America, ³University of Michigan, Dept. of Oncology, Ann Arbor, United States of America, ⁴The University of Texas MD Anderson Cancer Center, Dept. of GU Pathology, Houston, United States of America
- 18:42 - 18:45** **Expert summary**

Complex robotic renal surgery

Video session 13

07 April 2024
17:15 - 18:45

Location Green Area, S04
Chairs To be confirmed
To be confirmed
P.J. Zondervan, Amsterdam (NL)

- V096** **The novel strategy of robotic-assisted partial nephrectomy for renal sinus tumors**
Authors: [Shao P.](#)
Institutes: The First Affiliated Hospital with Nanjing Medical University, Dept. of Urology, Nanjing, China
- V097** **Redo partial nephrectomy for local recurrence after previous nephron sparing surgery. Surgical insights and oncologic results from a high-volume robotic centre.**
Authors: [Di Maida F.](#)¹, [Grosso A.A.](#)¹, [Campi R.](#)², [Lambertini L.](#)¹, [Gallo M.L.](#)², [Cadenar A.](#)¹, [Bacchiani M.](#)¹, [Nardoni S.](#)¹, [Salamone V.](#)¹, [Coco S.](#)¹, [Paganelli D.](#)¹, [Tuccio A.](#)¹, [Mari A.](#)¹, [Masieri L.](#)¹, [Minervini A.](#)¹
Institutes: ¹University of Florence, Dept. of Urology, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ²University of Florence, Dept. of Urology, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy
- V098** **Primary Renal cell carcinoma in cross-fused ectopia in chronic kidney disease: Robot-assisted Nephron sparing surgery for a rare entity.**
Authors: [Pooleri G.K.](#), [agarwal S.](#), [Prasad V.](#), [Menon A.](#)
Institutes: Amrita Institute of Medical Sciences, Dept. of Urooncology, Kochi, India
- V099** **Retroperitoneal robot-assisted partial nephrectomy with Hugo RAS System: Surgical settings and preliminary results**
Authors: [Uleri A.](#), [Gaya J.M.](#), [Gallioli A.](#), [Bravo A.](#), [Basile G.](#), [Rodriguez-Faba O.](#), [Territo A.](#), [Sanz I.](#), [Sanchez R.](#), [Robalino J.](#), [Palou J.](#), [Breda A.](#)
Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- V100** **Robotic surgery for treatment of a renal tumor with level III vena cava tumor thrombus**
Authors: [Puig L.](#), [López Costea M.A.](#), [Sanz-Serra P.](#), [Ferreiro Pareja C.](#), [Pérez Regetti J.I.](#), [Vigués F.](#)
Institutes: Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain
- V101** **Challenging scenarios and problem-solving in robot-assisted inferior vena cava thrombectomy for Mayo level III-IV thrombi**
Authors: [Dell'Oglio P.](#), [Palagonia E.](#), [Chierigo F.](#), [Tappero S.](#), [Secco S.](#), [Maltzman O.](#), [Olivero A.](#), [Bocciardi A.M.](#), [Caviglia A.](#), [Galfano A.](#)
Institutes: ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy

V102

Re-do robot-assisted vena cava thrombectomy: Feasibility and results

Authors: Margue G.¹, Khaddad A.¹, Luyckx F.², Allenet C.¹, Yacoub M.³, Estrade V.¹, Alezra E.¹, Capon G.¹, Bladou F.¹, Robert G.¹, Gross-Goupil M.⁴, Bernhard J.C.¹

Institutes: ¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Centre Clinical SA, Dept. of Urology, Soyaux, France, ³Bordeaux University Hospital, Dept. of Pathology, Bordeaux, France, ⁴Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France

Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe

05 April 2024
10:45 - 12:45

Location
Chairs

Green Area, W06
E. Liatsikos, Patras (GR)
K.A. Mohd Ghani, Kuala Lumpur (MY)
S.V. Yrastorza, Quezon City (PH)

10:45 - 11:00

FAUA : Past, Present and Future Link between Europe and South East Asia

S.V. Yrastorza, Quezon City (PH)

11:00 - 11:15

Early radical cystectomy for high risk NMIBC. Is it better?

N.A. Md.Yusoff, Kuala Lumpur (MY)

11:15 - 11:30

Opportunities for Education, Training and Collaboration between FAUA AND EAU

E. Liatsikos, Patras (GR)

11:30 - 11:45

Application of Current recommendation and future trends of mCSPC and mCRPC treatment of Prostate Cancer in South East Asia

L. Hakim, Surabaya (ID)

11:45 - 12:00

Andropause : Perspective from Myanmar

P. Myint, Yangon Myanmar (MM)

12:00 - 12:15

Technological Exchange and Collaboration

To be confirmed

12:15 - 12:30

Advancing the treatment of penile cancer in Southeast Asia with organ-sparing techniques and sentinel node biopsy

W. Lau, Singapore (SG)

12:30 - 12:45

PCNL in children

To be confirmed

Metastatic urothelial cancer

Abstract session 37

07 April 2024
17:15 - 18:45

Location Green Area, W06
Chairs B. Ali-El-Dein, Mansoura (EG)
M. Vukovic, Podgorica (ME)
A.J Birtle, Preston (GB)

17:15 - 17:25

Antibody drug conjugates (ADC's)

A0750

Membranous NECTIN-4 expression in metastasis versus matched primary tumor more accurately predicts enfortumab vedotin response

Authors: Büttner T.¹, Zschäbitz S.², Bolenz C.³, Zengerling F.³, Heers H.⁴, Nagy D.⁵, Toma M.⁵, Kristiansen G.⁵, Ellinger J.¹, Ritter M.¹, Hartmann A.⁶, Hölzel M.⁷, Eckstein M.⁶, Klümper N.¹

Institutes: ¹University Hospital Bonn, Dept. of Urology and Paediatric Urology, Bonn, Germany, ²University Hospital Heidelberg, Dept. of Medical Oncology, Heidelberg, Germany, ³University Hospital Ulm, Dept. of Urology and Paediatric Urology, Ulm, Germany, ⁴University Hospital Marburg, Dept. of Urology, Marburg, Germany, ⁵University Hospital Bonn, Institute of Pathology, Bonn, Germany, ⁶University Hospital Erlangen, Institute of Pathology, Erlangen, Germany, ⁷University Hospital Bonn, Institute of Experimental Oncology, Bonn, Germany

A0744

Side effects of antibody-drug conjugates in the new era of tailored therapy in urologic malignancies

Authors: Tully K.H., Reike M., Bahlburg H., Brehmer M., Berg S., Noldus J., Bach P., Roghmann F.

Institutes: Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and Neurourology, Herne, Germany

17:25 - 17:45

Immune checkpoint inhibition

A0753

First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Preliminary results of the prospective CARAT registry

Authors: Goebell P.J.¹, Radkowski R.², Müller L.³, Ghasemi U.⁴, Grünwald V.⁵, Deger S.⁶, Andres-Pons A.⁷, Lennartz C.⁸, Jänicke M.⁷, Grüllich C.⁹, Staehler M.¹⁰, Gratzke C.¹¹, Potthoff K.¹²

Institutes: ¹University Clinic Erlangen, Dept. of Urology, Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany, ²Augusta-Kranken-Anstalt, Clinic for Haematology Oncology and Palliative Care, Bochum, Germany, ³Onkologie UnterEms, Leer-Emden-Papenburg, Leer, Germany, ⁴Clinic Südostbayern, Clinic Traunstein Urology, Traunstein, Germany, ⁵University Hospital Essen West-German Cancer Center Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany, ⁶Medius Clinic Ostfildern-Ruit, Clinic for Urology, Ostfildern, Germany, ⁷iOMEDICO, Dept. of Clinical Epidemiology and Health Economics, Freiburg, Germany, ⁸iOMEDICO, Dept. of Biostatistics, Freiburg, Germany, ⁹Sana Clinic Hof, Dept. of Hematology and Oncology, Hof, Germany, ¹⁰Ludwig Maximilian University of Munich, Dept. of Urology, University Hospital, Munich, Germany, ¹¹University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, ¹²iOMEDICO, Medical Department, Freiburg, Germany

A0745

Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma

Authors: Silva Diaz S.¹, Chauhan V.², Gurung A.², Nally E.², Young M.², Wells C.², Jackson-Spence F.², Szabados B.², Powles T.²

Institutes: ¹University Hospital of A Coruna, Dept. of Medical Oncology, A Coruna, Spain, ²Barts Cancer Institute, GU Oncology Team, London, United Kingdom

A0751

Pembrolizumab after platinum-based chemotherapy for treatment of metastatic bladder cancer

Authors: Richters A.¹, Van Der Heijden A.G.², Mehra N.³, Meijer R.P.⁴, Kiemeny L.A.⁵, Boormans J.L.⁶, Aben K.K.¹

Institutes: ¹The Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, The Netherlands, ²Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ³Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen, The Netherlands, ⁴University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁵Radboud University Medical Center, Dept. of Health Evidence, Nijmegen, The Netherlands, ⁶Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands

A0755

Impact of antacids on the prognosis of patients with metastatic urothelial carcinoma treated with pembrolizumab: a retrospective multicenter study

Authors: Sekito T., Katayama S., Iwata T., Kawada T., Tominaga Y., Sadahira T., Nishimura S., Bekku K., Edamura K., Kobayashi T., Kobayashi Y., Araki M.

Institutes: Okayama University Hospital, Dept. of Urology, Okayama, Japan

17:45 - 18:20

Prognosticators and predictors

A0752

Gustave Roussy Immune Score Predicts Survival Outcome of Patients with Metastatic Urothelial Carcinoma Treated with Pembrolizumab: A multicenter Study of 321 patients (YUSHIMA study)

Authors: Tanabe K.¹, Shuichiro K.¹, Katsushi N.², Junji Y.³, Yukihiro O.⁴, Tetsuo O.⁵, Ryoji T.⁶, Akira N.¹, Masataka Y.⁷, Tetsuro T.⁸, Kazutaka S.⁹, Yasuyuki S.¹⁰, Fumitaka K.¹¹, Yukio K.¹², Hajime T.¹³, Soichiro Y.¹³, Yasuhisa F.¹³

Institutes: ¹Saitama Red Cross Hospital, Dept. of Urology, Saitama, Japan, ²Kohnodai Hospital, Dept. of Urology, Chiba, Japan, ³Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ⁴Japanese Red Cross Omori Hospital, Dept. of Urology, Tokyo, Japan, ⁵JA Toride Medical Center, Dept. of Urology, Ibaraki, Japan, ⁶Tokyo Metropolitan Otsuka Hospital, Dept. of Urology, Tokyo, Japan, ⁷Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Dept. of Urology, Tokyo, Japan, ⁸Showa General Hospital, Dept. of Urology, Tokyo, Japan, ⁹Dokkyo Medical University Saitama Medical Center, Dept. of Urology, Saitama, Japan, ¹⁰Tsuchiura Kyodo General Hospital, Dept. of Urology, Ibaraki, Japan, ¹¹Tokyo Metropolitan Cancer and Infections Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, ¹²Saitama Prefectural Cancer Center, Dept. of Urology, Saitama, Japan, ¹³Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

A0754

Predictors of developing cisplatin ineligibility in a contemporary cohort of bladder cancer patients treated with radical cystectomy at an Italian National Cancer Center

Authors: Flammia R.S., Anceschi U., Brassetti A., Ferriero M., Mastroianni R., Misuraca L., Tuderti G., D'Annunzio S., Guaglianone S., Chiacchio G., Proietti F., Leonardo C., Gallucci M., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0757

TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma

Authors: Kaifeng J.¹, Zewei W.¹, Zhaopei L.², Jiejie X.³

Institutes: ¹Zhongshan Hospital Affiliated to Fudan University, Dept. of Urology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China

A0748

Impact of radiation therapy to the recurrence sites on oncological outcomes in patients who experienced local recurrence and/or pelvic lymph node metastases after radical cystectomy: A multicenter retrospective study

Authors: Fujita N.¹, Tanaka T.T.¹, Hosogoe S.H.¹, Ishii N.¹, Momota M.M.¹, Ito H.I.², Iwabuchi I.I.³, Yoneyama T.Y.¹, Hashimoto Y.H.¹, Ohyama C.O.¹, Aoki M.⁴, Hatakeyama S.H.¹

Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, ⁴Hirosaki University Graduate School of Medicine, Dept. of Radiation Oncology, Hirosaki, Japan

A0749

Gender Disparities in Clinical Outcomes of Urothelial Carcinoma Linked to X Chromosome Gene KDM6A Mutation

Authors: Liu Z.¹, Jin K.², Wang Z.², Zhu Y.¹, Xu J.³

Institutes: ¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Zhongshan Hospital of Fudan University, Dept. of Urology, Shanghai, China, ³School of Basic Medical Sciences, Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China

A0756

A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study

Authors: Lu J., Lai J., Xu C., Tianxin L.

Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China

A0747

Germline HLA-DQB1*03:01 is an independent prognostic factor for clinical outcomes in patients with urothelial cancer treated with pembrolizumab

Authors: Narita N.¹, Takahashi S.T.¹, Fujiyama N.F.², Hatakeyama S.H.³, Kobayashi T.K.⁴, Kato R.K.⁵, Naito S.N.⁶, Sobu R.¹, Mori K.¹, Mori M.¹, Sekine Y.S.¹, Kobayashi M.K.¹, Numakura K.N.¹, Saito M.S.¹, Tsuchiya N.T.⁶, Obara W.O.⁵, Habuchi T.H.¹

Institutes: ¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Akita University Hospital, Clinical Research Center, Akita, Japan, ³Hirosaki University School of Medicine, Dept. of Urology, Akita, Japan, ⁴Kyoto University School of Medicine, Dept. of Urology, Kyoto, Japan, ⁵Iwate Medical School of Medicine, Dept. of Urology, Morioka, Japan, ⁶Yamagata University School of Medicine, Dept. of Urology, Yamagata, Japan

18:20 - 18:25

Trial in progress

A0746

Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)

Authors: Powles T.¹, Grande E.², Van Der Heijden M.³, Necchi A.⁴, Iyer G.⁵, Drakaki A.⁶, Loriot Y.⁷, Sokolowski K.⁸, Zhang W.⁹, Galsky M.¹⁰

Institutes: ¹Barts Health NHS Trust, Barts Cancer Centre, London, United Kingdom, ²MD Anderson Madrid Cancer Center, Medical Oncology Program, Madrid, Spain, ³Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁴Vita-Salute San Raffaele University IRCCS San Raffaele Hospital and Scientific Institute, Dept. of Genitourinary Medical Oncology, Milan, Italy, ⁵Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, ⁶David Geffen School of Medicine, Dept. of Hematology-Oncology and Urology, Los Angeles, United States of America, ⁷Institut de Cancérologie Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, ⁸Seagen Inc., Late-Stage Clinical Development, Bothell, United States of America, ⁹Seagen Inc., Dept. of Statistics, Bothell, United States of America, ¹⁰Icahn School of Medicine at Mount Sinai, Dept. of Genitourinary Medical Oncology, New York, United States of America

Prostate Cancer Screening - Prime Time for Organized Screening Strategies?

EGPT 11

**07 April 2024
17:15 - 18:45**

Location EGPT
Chairs O. Bratt, Gothenburg (SE)
To be confirmed

17:15 - 17:15

Screen A

17:15 - 17:15

Screen B

17:15 - 17:15

Screen C

P305

Developing and comparing prostate cancer screening specific performance indicators for PRAISE-U

Authors: van Harten M.J.¹, Leenen R.C.A.², Singh D.³, Vynckier P.⁴, Meyer Andersen S.⁵, Mckinney G.⁵, Kirkegaard P.⁵, Bach Larsen M.⁵, Chandran A.³, Annemans L.⁴, Basu P.³, Collen S.⁶, Van Poppel H.⁶, Roobol M.², Willemse P.P.M.¹, Van Den Bergh R.¹

Institutes: ¹University Medical Center Utrecht, Cancer Center, Dept. of Urology, Utrecht, The Netherlands, ²Erasmuc MC Cancer Institue, Dept. of Urology, Rotterdam, The Netherlands, ³International Agency for Research on Cancer -World Health Organization, Public Health Department, Lyon, France, ⁴Ghent University, Dept. of Public Health and Primary Care, Ghent, Belgium, ⁵Randers Regional Hospital Aarhus University, University Research Clinic for Cancer Screening, Dept. of Clinical Medicine, Aarhus, Denmark, ⁶European Association of Urology, Policy Office, Arnhem, The Netherlands

P297

Prostate Assessment using Comparative Interventions – Fast MRI and Image-fusion for Cancer (IP7-PACIFIC): A prospective, multi-centre, two-by-two factorial RCT

Authors: Mayor N., Light A., Rawlins F., Cullen E., Winkler M., Shah T.S., Ahmed H.U.

Institutes: Imperial College London, Dept. of Urology, London, United Kingdom

P311

Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

Authors: Quarta L.¹, Stabile A.¹, Barletta F.¹, Mazzone E.¹, Cannoletta D.¹, Pellegrino F.¹, Sorce G.¹, Pellegrino A.¹, Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Leni R.¹, Gandaglia G.¹, Bianchi M.¹, De Cobelli F.², Brembilla G.², Roupret M.³, Karnes R.J.⁴, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy, ³Hopital Pitié-Salpêtrière - Sorbonne Université, Dept. of Urology and Predictive Onco-Urology, Paris, France, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America

- P291** **Differential impact of Prostate-Specific Antigen screening pattern on prostate cancer-mortality Among Non-Hispanic Black and Non-Hispanic White men: A large, urban health system cohort analysis**
Authors: Cirulli G.O.¹, Davis M.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Corsi N.¹, Williams E.¹, Affas R.¹, Arora S.¹, Sood A.³, Lughezzani G.⁴, Buffi N.⁴, Carrieri G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Rogers C.¹, Abdollah F.¹
Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy
- P298** **Comparing the Performance of Digital Rectal Examination and PSA as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis**
Authors: Matsukawa A.¹, Yanagisawa T.¹, Bekku K.¹, Parizi M.K.¹, Laukhtina E.¹, Klemm J.¹, Chiujdea S.¹, Keiichiro M.¹, Kimura S.¹, Fazekas T.¹, Miszczyk M.², Miki J.³, Kimura T.³, Karakiewicz P.⁴, Rajwa P.¹, Shariat S.¹
Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Maria Sklodowska-Curie National Research Institute of Oncology, Dept. of Radiotherapy and Chemotherapy, Gliwice, Poland, ³The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴University of Montreal Health Center, Division of Urology, Montreal, Canada
- P320** **Contemporary Prostate Cancer Screening Patterns Among LGBTQ+ Patients**
Authors: Alkhatib K., Leff M., Roberson D., Ding J., Lee D., Pierorazio P., Schurhamer B.
Institutes: University of Pennsylvania, Dept. of Urology, Philadelphia, United States of America
- P292** **Incidence and mortality of prostate cancer, a cohort of 564,975 patients, France 2010-2021**
Authors: Crespin H.¹, Bruyère F.¹, Lecuyer A.I.², Grammatico-Guillon L.², Laurent E.²
Institutes: ¹CHRU Tours, Dept. of Urology, Tours, France, ²CHRU Tours, Epidemiology Unit for Clinical Data in the Centre-Val de Loire - EpiDcliC, Tours, France

- P313** **Comparing PSA Screening Patterns and their role as predictor of Prostate Cancer Incidence and Mortality: a system wide analysis of a contemporary North American cohort.**
Authors: Cirulli G.O.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Davis M.¹, Tinsley S.¹, Morrison C.¹, Arora S.¹, Butaney M.¹, Sood A.³, Lughezzani G.⁴, Buffi N.⁴, Carrieri G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Rogers C.¹, Abdollah F.¹
Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation - Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy
- P296** **Prostate cancer testing in Stockholm; comparing compliance to follow up of men with elevated PSA vs elevated Stockholm3 in clinical practice between 2018 to 2020**
Authors: Palsdottir T., Vigneswaran H., Grönberg H., Nordström T.
Institutes: Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden
- P309** **Advancing prostate cancer risk stratification: is predicting positive magnetic resonance imaging (MRI) findings the preferred approach?**
Authors: Hagens M.J.¹, Mertens L.S.¹, Barwari K.¹, Aben N.², Stárková J.², Struben V.², Boellaard T.N.³, Heijmink S.W.T.J.P.³, Van Dijk - De Haan M.C.³, Van Kesteren J.¹, Van Maaren L.C.¹, Van Muilekom E.¹, Visser J.¹, Van Der Poel H.G.¹, Van Leeuwen P.J.¹
Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Digital Oncology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands
- P319** **Diagnostic validation of real world prostate cancer screening algorithms**
Authors: Hangartner K., Thüring M., Froelicher G., Obrecht F., John H., Foerster B.
Institutes: Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

- P314** **Testing Free PSA Percentage as a tool in predicting future risk of developing Prostate Cancer: a system wide analysis of a contemporary North American cohort.**
Authors: Cirulli G.O.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Davis M.¹, Morrison C.¹, Tinsley S.¹, Etta P.¹, Butaney M.¹, Sood A.³, Lughezzani G.⁴, Buffi N.⁴, Carrieri G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Rogers C.¹, Abdollah F.¹
Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation - Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy
- P303** **Is strict PSA Surveillance necessary for patients with a negative PI-RADS 4 lesion following MRI-Fusion targeted and saturation biopsies of prostate**
Authors: Tsang W.C., Lai K.W., Ong J., Wang K.Y., Quek A., Chong D., Wu Q.H., Chiong E.
Institutes: National University Hospital, Dept. of Urology, Singapore, Singapore
- P310** **Artificial intelligence-aided detection for prostate cancer with multi-modal routine health check-up data: a multi-center study**
Authors: Chen R.¹, Zhang W.², Song Z.¹, Longxin D.², Jiang Q.³, Mou W.², Lim J.⁴, Liu K.⁵, Jae Young P.⁶, Ng C.F.⁵, Aik O.T.⁴, Wei Q.⁷, Li L.⁸, We X.⁹, Chen M.¹⁰, Cao Z.³, Wang F.¹¹
Institutes: ¹Renji Hospital Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Shanghai Changhai Hospital, Dept. of Urology, Shanghai, China, ³East China University of Science and Technology, State Key Laboratory of Bioreactor Engineering, Shanghai, China, ⁴University of Malaya Medical Centre, Dept. of Urology, Kuala Lumpur, Malaysia, ⁵The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ⁶Korea University Ansan Hospital, Dept. of Urology, Soule, South Korea, ⁷West China Hospital Sichuan University, Dept. of Urology, Chengdu, China, ⁸The First Affiliated Hospital of Xian Jiaotong University, Dept. of Urology, Xian, China, ⁹The First Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, ¹⁰Zhongda Hospital Southeast University, Dept. of Urology, Nanjing, China, ¹¹First Affiliated Hospital of Guangxi Medical University, Institute of Urology and Nephrology, Nanning, China

- P293** **External validation of the Rotterdam Prostate Cancer risk calculators with and without including PHI for detection of clinically significant prostate cancer.**
Authors: [Rius Bilbao L.](#)¹, [Aguirre Larracochea U.](#)², [Valladares Gomez C.](#)³, [Remers S.](#)⁴
Institutes: ¹Galdakao Hospital, Dept. of Urology, Bilbao, Spain, ²Galdakao Hospital, Research Unit, Galdakao, Spain, ³Cruces Hospital, Dept. of Clinical Laboratory Medicine, Barakaldo, Spain, ⁴Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands
- 18:00 - 18:45** **Screen D: Trials in progress**
- P304** **ARASAFE - A randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m² (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m² (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC.**
Authors: [Von Amsberg G.](#)¹, [Roessler A.](#)², [Heers H.](#)³, [Roghmann F.](#)⁴, [Degener S.](#)⁵, [Casuscelli J.](#)⁶, [Zengerling F.](#)⁷, [Grimm M.O.](#)²
Institutes: ¹University Hospital Hamburg Eppendorf, University Cancer Center Hamburg and Martini-Klinik, Hamburg, Germany, ²University Hospital Jena, Dept. of Urology, Jena, Germany, ³University Hospital Marburg, Dept. of Urology, Marburg, Germany, ⁴University Hospital of Ruhr-University Bochum Marien Hospital, Dept. of Urology, Herne, Germany, ⁵Helios University Hospital Wuppertal, University Witten Herdecke, Dept. of Urology, Wuppertal, Germany, ⁶University Hospital Munich - Ludwig Maximilian University, Dept. of Urology, Munich, Germany, ⁷University Hospital Ulm, Dept. of Urology, Ulm, Germany
- P315** **Impact of radical prostatectomy on pelvic floor muscles: An electromyography and perineometric assessment**
Authors: [Tiwari M.](#)¹, [Ragavan N.](#)¹, [Bafna S.](#)¹, [Gopi S.](#)², [Prasanna R.](#)³, [Anrose M.](#)³
Institutes: ¹Apollo Hospitals, Dept. of Urology and UroOnoglogy, Chennai, India, ²Apollo Hospitals, Dept. of Urology, Chennai, India, ³Apollo Hospitals, Dept. of Physiotherapy, Chennai, India
- P294** **MicroUltraSound In Cancer – Active Surveillance (MUSIC-AS)**
Authors: [Albers P.](#)¹, [Wang B.](#)¹, [Broomfield S.](#)¹, [Martin A.M.](#)², [Metcalf P.](#)¹, [Tu W.](#)³, [Fung C.](#)³, [Kinnaird A.](#)¹
Institutes: ¹University of Alberta, Dept. of Surgery, Division of Urology, Edmonton, Canada, ²University of Alberta, Alberta Prostate Cancer Research Initiative, Edmonton, Canada, ³University of Alberta, Dept. of Radiology and Diagnostic Imaging, Edmonton, Canada
- P300** **Preliminary results of the CONFIRM trial: role of PSMA PET/CT in newly diagnosed prostate cancer in active surveillance prior to confirmatory biopsy**
Authors: [Liu J.](#), [Harewood L.](#), [Lawrentschuk N.](#)
Institutes: EJ Whitten Prostate Cancer Research Centre, Dept. of Urology, Melbourne, Australia
-

P295

Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS): An international, multicentre, randomised pragmatic trial

Authors: Tikkinen K.A.O.¹, Kasivisvanathan V.², Tornberg S.V.³, Hajebrahimi S.⁴, Violette P.D.⁵, Kaukonen K.M.⁶, Sallinen V.⁷, Agarwal A.⁸, Cartwright R.⁹, Lavikainen L.I.¹⁰, Tähtinen R.M.¹¹, Ng A.², Nathan A.², Kilpeläinen T.P.¹², Keane K.¹³, Ippoliti S.¹⁴, Asif A.², Ahopelto K.⁷, Aaltonen R.L.¹⁵, Sandset P.M.¹⁶, Gross P.L.¹⁷, Parpia S.¹⁸, Guyatt G.H.⁸, Devereaux P.J.¹⁹

Institutes: ¹University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ²University College London, Division of Surgery and Interventional Science, London, United Kingdom, ³University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁴Tabriz University of Medical Sciences, Dept. of Female and Functional Urology and Reconstructive Surgeries, Tabriz, Iran, ⁵Woodstock General Hospital, Dept. of Surgery and Division of Urology, Woodstock, Canada, ⁶Medbase Ltd, Medical Expert, Helsinki, Finland, ⁷Helsinki University Hospital, Dept. of Gastroenterological Surgery, Helsinki, Finland, ⁸McMaster University, Dept. of Health Research Methods and Evidence and Impact, Hamilton, Canada, ⁹Imperial College London, Dept. of Epidemiology and Biostatistics, London, United Kingdom, ¹⁰University of Helsinki, Faculty of Medicine, Helsinki, Finland, ¹¹Tampere University Hospital, Women's Hospital, Tampere, Finland, ¹²Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ¹³St. James's Hospital, Dept. of Urology, Dublin, Ireland, ¹⁴Hull University Teaching Hospitals, Dept. of Urology, Hull, United Kingdom, ¹⁵Turku University Hospital, Women's Hospital, Turku, Finland, ¹⁶University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ¹⁷McMaster University, Division of Hematology and Thromboembolism and Department of Medicine, Hamilton, Canada, ¹⁸McMaster University, Dept. of Oncology and Health Research Methods and Evidence and Impact, Hamilton, Canada, ¹⁹McMaster University, Dept. of Medicine and Dept. of Health Research Methods and Evidence and Impact, Hamilton, Canada

P301

Open-label randomised clinical trial investigating whether robot-assisted kidney transplantation can reduce surgical complications compared to open kidney transplantation (ORAKTx): Study protocol for a randomised clinical trial

Authors: Ortvad M.¹, Dagnaes J.¹, Stroomberg H.V.¹, Rohrsted M.¹, Sørensen S.S.², Røder A.¹

Institutes: ¹Copenhagen University Hospital - Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ²Copenhagen University Hospital - Rigshospitalet, Dept. of Nephrology, Copenhagen, Denmark

- P317** **89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX**
Authors: Lagaru A.¹, Takalkar A.², Higgins G.³, Kiser J.⁴, Tauchmanova L.⁵, Shah S.⁶, Vadali K.⁶, Hayward C.⁵, Crowley J.⁷
Institutes: ¹Stanford University, Dept. of Nuclear Medicine, Stanford, United States of America, ²Emory University, Dept. of Nuclear Medicine, Atlanta, United States of America, ³University of Oxford, Dept. of Oncology, Oxford, United States of America, ⁴Carilion, Dept. of Radiology, Roanoke, United States of America, ⁵Telix Pharmaceuticals, Dept. of Medical Affairs, Melbourne, Australia, ⁶Telix Pharmaceuticals, Clinical Operations, Melbourne, Australia, ⁷Carilion, Dept. of Nuclear Medicine, Roanoke, United States of America
- P312** **Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (pembro) and favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)**
Authors: Gupta S.¹, Kulkarni G.², Necchi A.³, Shore N.D.⁴, Dave H.⁵, Kapadia E.⁵, Zhao Q.⁵, Kamat A.⁶
Institutes: ¹Cleveland Clinic Taussig Cancer Center, Dept. of Genitourinary Oncology, Cleveland, United States of America, ²Princess Margaret Cancer Centre and University of Toronto, University Health Network, Toronto, Canada, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ⁴Carolina Urologic Research Center, Dept. of Oncology, Myrtle Beach, United States of America, ⁵Merck and Co Inc, Dept. of Clinical Research, Rahway, United States of America, ⁶The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America
- P299** **A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer**
Authors: Satkunasivam R.¹, Teh B.S.², Riveros C.¹, Lim K.¹, Wallis C.J.D.³, Hu S.¹, Melchiode Z.¹, Nikolos F.⁴, Miles B.J.¹, Kaushik D.¹, Chen S.H.⁴, Efsthathiou E.⁵, Chan K.S.⁴, Esnaola N.F.⁶, Sonpavde G.P.⁷
Institutes: ¹Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, ²Houston Methodist Hospital, Dept. of Radiation Oncology, Houston, United States of America, ³Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, ⁴Houston Methodist Hospital, Houston Methodist Research Institute, Houston, United States of America, ⁵Houston Methodist Hospital, Dept. of Medical Oncology, Houston, United States of America, ⁶Houston Methodist Hospital, Dept. of General Surgery, Houston, United States of America, ⁷AdventHealth Cancer Institute, Dept. of Medical Oncology, Orlando, United States of America
- P302** **A precise diagnostic method for urothelial carcinomas based on novel dual methylated DNA markers**
Authors: Wu Y.¹, Li T.², Gong Y.¹, He S.¹, Zhou L.¹, Li X.¹
Institutes: ¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Wuhan Ammunition Life-tech Company, Dept. of Urology, Wuhan, China

- P308** **SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations**
Authors: Necchi A.¹, Hussain S.A.², Loriot Y.³, de Velasco G.⁴
Institutes: ¹IRCCS San Raffaele Hospital and Scientific Institute, Head of Genitourinary Medical Oncology, Milan, Italy, ²University of Sheffield, Academic Unit of Oncology, Dept. of Oncology and Metabolism, Sheffield, United Kingdom, ³Gustave Roussy, Universite Paris Saclay, Dept. of Medical Oncology, Villejuif, France, ⁴Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain
- P316** **RJBLC-A2A008: An open-label, single-arm, multi-center study on RC48-ADC combined with toripalimab and radiotherapy as bladder-preserving therapy in HER2 overexpression muscle-invasive bladder cancer**
Authors: Ruiyun Z.¹, Lei Q.¹, Tianxiang Z.¹, Di J.¹, Jun X.², Guangyu W.³, Yanli H.⁴, Ming C.¹, Lianhua Z.¹, Haige C.¹
Institutes: ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, ²Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Pathology, Shanghai, China, ³Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Radiology, Shanghai, China, ⁴Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Radiotherapy, Shanghai, China
- P306** **RJBLC-NEBC001: A prospective, single-arm study on neoadjuvant adebrelimab plus etoposide and cisplatin in neuroendocrine bladder carcinoma**
Authors: Lei Q.¹, Tianxiang Z.¹, Di J.¹, Jun X.², Guangyu W.³, Ming C.¹, Lianhua Z.¹, Ruiyun Z.¹, Haige C.¹
Institutes: ¹Renji Hospital, Dept. of Urology, Shanghai, China, ²Renji Hospital, Dept. of Pathology, Shanghai, China, ³Renji Hospital, Dept. of Radiology, Shanghai, China
- P318** **WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.**
Authors: Bao Y.¹, Liao X.¹, Zhang P.¹, Zeng H.¹, Liu J.², Wei Q.¹
Institutes: ¹West China Hospital, Dept. of Urology, Chengdu, China, ²West China Hospital, Dept. of Biotherapy, Chengdu, China
- P307** **ProstACT GLOBAL: A Phase 3 Study Best Standard of Care With and Without 177Lu-DOTA-rosopitamab (TLX591) for Patients with PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug**
Authors: Lenzo N.¹, Hawkins C.², Gibson J.², Brown T.², Patel N.², Martina S.², Hayward C.²
Institutes: ¹GenesisCare, Dept. of Oncology, Murdoch, Australia, ²Telix Pharmaceuticals, Dept. of Medical Affairs, Indianapolis, United States of America

Semi-live session: Focal therapy for prostate cancer - How, why, when?

Thematic Session

07 April 2024
17:30 - 18:30

Location Green Area, eURO Auditorium 1
Chairs S. Crouzet, Lyon (FR)
L. Rodriguez-Sanchez, Paris (FR)

Learning objectives

By the end of the session, participants should have acquired expertise in the following:

- Understanding why focal treatments should be considered as a valid alternative option for localized prostate cancer in well-selected patients.
- Selecting a patient for potential focal therapy based on patient and prostate cancer characteristics.
- Gaining insight into the potential treatment options available for focal therapy and being aware of their limitations.
- Demonstrating proficiency in performing focal therapy using various energies or a surgical approach through four semi-live surgeries.

17:30 - 17:40

Semi-live video presentation Irreversible electroporation
C. Orczyk, London (GB)

17:40 - 17:50

Semi-live video presentation Cryotherapy
E. Barret, Paris (FR)

17:50 - 18:00

Semi-live video presentation HIFU
H.U. Ahmed, London (GB)
S. Crouzet, Lyon (FR)

18:00 - 18:10

Semi-live video presentation Partial surgical ablation
J. Olivier, Lille (FR)

18:10 - 18:15

Why not radical prostatectomy?
M. Graefen, Hamburg (DE)

18:15 - 18:30

Do we need focal therapy?
Moderator C.J. Stranne, Göteborg (SE)

18:15 - 18:30

Panel discussion

Panel E. Barret, Paris (FR)
C. Orczyk, London (GB)
M. Graefen, Hamburg (DE)
H.U. Ahmed, London (GB)
S. Crouzet, Lyon (FR)
J. Olivier, Lille (FR)

Urolithiasis: Shock wave lithotripsy and stents

Abstract session 38

07 April 2024
17:30 - 19:00

Location Purple Area, N01
Chairs M. Adhikari, Lalitpur (NP)
To be confirmed
To be confirmed

A0775

Is it safe and effective to increase the total accumulated energy by increasing the number of shock waves per session in extracorporeal shock wave lithotripsy? A prospective randomized study

Authors: Beviá Romero A.J., López-Acon D., Quereda-Flores F., Ordáz-Jurado D.G., Trassierra-Villa M., Pérez-Ardavin J., Ortiz-Salvador J.B., Castillo-Anton D.J., Espinosa J., Muñoz-Penarroja J., Puhar N., Bahilo-Mateu P., Budía-Alba A.

Institutes: Hospital Universitario y Politécnico La Fe, Dept. of Urology, Valencia, Spain

A0771

Post-SWL urinary osteopontin level and ion-activity product of CaOx are Associated with Stone Recurrence after 5-year Follow-up

Authors: Liu C-M., Liu C.J., Huang H.S.

Institutes: National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan

A0768

Break Wave™ Lithotripsy for Urolithiasis: Results of the First-In-Human International Multicenter Clinical Trial

Authors: Chew B.H.¹, Harper J.D.², Sur R.L.³, Chi T.⁴, De S.⁵, Buckley A.R.⁶, Paterson R.F.¹, Forbes C.F.¹, Hall M.K.², Kessler R.⁷, Bechis S.K.³, Woo J.R.³, Wang R.C.⁸, Bayne D.⁴, Bochinski D.⁵, Schuler T.D.⁵, Wollin T.R.⁵, Samji R.⁵, Sorensen M.D.²

Institutes: ¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²University of Washington, Dept. of Urology, Seattle, United States of America, ³University of California San Diego, Dept. of Urology, San Diego, United States of America, ⁴University of California San Francisco, Dept. of Urology, San Francisco, United States of America, ⁵University of Alberta, Dept. of Urology, Edmonton, Canada, ⁶University of British Columbia, Dept. of Radiology, Vancouver, Canada, ⁷University of Washington, Dept. of Emergency Medicine, Seattle, United States of America, ⁸University of California San Francisco, Dept. of Emergency Medicine, San Francisco, United States of America

A0761

Effect of perioperative tamsulosin on successful ureteral access sheath placement and stent-related symptom relief: a double-blind, randomized, placebo-controlled clinical trial

Authors: Nam K.H.¹, Kim D.¹, Suh J.¹, Shin J.H.², Chae H.K.³, Park H.K.¹

Institutes: ¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Ewha Womans University Mokdong Hospital, Dept. of Urology, Seoul, South Korea, ³Gangneung Asan Medical Center, Dept. of Urology, Gangneung, South Korea

A0762

Comparison of Symptom questionnaire, Stone Clearance rate, Passive Ureter Dilatation using 4.5 French vs 6 French Double J stenting for passive dilatation of unfavorable ureter

Authors: Nagabhairava M.K., Tarun J., Ramesh D., Sandeep P.

Institutes: Ms Ramaiah Hospital, Dept. of Urology, Bengaluru, India

A0760

Safety and Tolerability of Single-J vs. Double-J Stents After Ureterorenoscopy – A Randomized Trial

Authors: Laranjo Tinoco C.¹, Martins L.², Cardoso A.¹, Araújo A.S.¹, Capinha M.¹, Pinto L.¹, Coutinho A.¹, Rodrigues R.¹, Anacleto S.¹, Ribeiro J.¹, Carvalho-Dias E.¹, Mendes M.¹, Marques V.¹, Pimentel Torres J.¹, Oliveira C.¹, Alves M.¹, Mota P.¹

Institutes: ¹Hospital de Braga, Dept. of Urology, Braga, Portugal, ²University of Minho, School of Medicine, Braga, Portugal

A0764

Is shorter better? Associations between pain intensity, ureteral stent indwell time and patient factors from an international prospective registry

Authors: Forbes C.M.¹, Chew B.H.¹, Wong K.F.V.¹, Ren R.¹, Glaser A.², Taguchi K.³, Shah O.⁴, Taniel E.⁵, Amarasekera C.⁶, Hamamoto S.³, Molina W.R.⁷, Knoedler J.J.⁸, Krambeck A.E.⁶, Humphreys M.R.⁹, Stern K.L.⁹

Institutes: ¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Northwestern University, The Feinberg School of Medicine, Dept. of Urology, Glenview, United States of America, ³Nagoya City University, Dept. of Urology, Nagoya, Japan, ⁴Columbia University, Dept. of Urology, New York, United States of America, ⁵Centre Hospitalier Saint Gregoire, Dept. of Urology, Saint-Grégoire, France, ⁶Northwestern University, Dept. of Urology, Chicago, United States of America, ⁷Kansas University, Dept. of Urology, Kansas City, United States of America, ⁸Pennsylvania State University, Dept. of Urology, Hershey, United States of America, ⁹Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America

A0773

Fast track treatment of ureteral stones by short-term preoperative and postoperative stenting (FaST 6): A randomized prospective study

Authors: Hoffmann V.¹, Reicherz A.¹, Bahlburg H.¹, Brehmer M.¹, Abrams-Pompe R.S.², Noldus J.¹, Bach P.¹, Meyer C.²

Institutes: ¹Marien Hospital Herne, Dept. of Urology, Herne, Germany, ²Klinikum Herford, Dept. of Urology, Herford, Germany

A0763

Efficiency of self-expanding stents in endoscopic treatment of ureteral strictures.

Authors: Kowalski F., Kuffel B., Lipowski P., Ostrowski A., Wilamowski J., Adamwoicz J., Drewa T.

Institutes: A.Jurasz Memorial University Hospital No 1, Dept. of Urology, Bydgoszcz, Poland

A0758

Patients undergoing double J substitution with a pigtail suture stent report a significant decrease of stent-related symptoms. Results from a prospective multicenter longitudinal trial

Authors: Bosio A.¹, Ferretti S.², Alessandria E.¹, Vitiello F.¹, Vercelli E.¹, Campobasso D.², Micai L.¹, Gozzo C.¹, Bertello G.¹, Guarino G.G.², Alice C.¹, Bisconti A.¹, Fop F.¹, Gontero P.¹

Institutes: ¹AOU Città della Salute e della Scienza University Hospital, Dept. of Urology, Turin, Italy, ²AOU University Hospital, Dept. of Urology, Parma, Italy

A0766

Tria™ Ureteral Stents offer improved comfort: Results from an international prospective study

Authors: Chew B.H.¹, Forbes C.M.¹, Wong K.F.V.¹, Ren R.¹, Glaser A.², Taguchi K.³, Shah O.⁴, Taniel E.⁵, Amarasekera C.⁶, Hamamoto S.³, Molina W.R.⁷, Knoedler J.J.⁸, Krambeck A.E.⁶, Rivera M.E.⁹, Stern K.L.¹⁰, Humphreys M.R.¹⁰

Institutes: ¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Northwestern University, The Feinberg School of Medicine, Dept. of Urology, Glenview, United States of America, ³Nagoya City University, Dept. of Urology, Nagoya, Japan, ⁴Columbia University, Dept. of Urology, New York, United States of America, ⁵Centre Hospitalier Saint Gregoire, Dept. of Urology Surgery, Saint-Grégoire, France, ⁶Northwestern University, Dept. of Urology, Chicago, United States of America, ⁷University of Kansas, Dept. of Urology, Kansas City, United States of America, ⁸Pennsylvania State University, Dept. of Urology, Hershey, United States of America, ⁹Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁰Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America

A0774

Update on the use of Pigtail Suture Stents: an ongoing experience

Authors: Alessandria E., Bosio A., Vercelli E., Micai L., Gozzo C., Bertello G., Bisconti A., Gontero P.

Institutes: AOU Città della Salute e della Scienza, Dept. of Urology, Turin, Italy

A0767

In vitro and in vivo studies on bacteria and encrustation resistance of PLA-Ciprofloxacin-coating ureteral stent application

Authors: Wang Z., Han P., Lu P., Zhang W.

Institutes: Jiangsu Province Hospital, Dept. of Urology, Nanjing, China

A0769

STONE (STent Or NEphrostomy) Study: Patient-Reported Outcome Measures

Authors: Schuil H.W.¹, Hendriks N.¹, Kamphuis G.M.², Oskam B.C.H.³, Arends T.J.H.³, Duijvesz D.⁴, Van Der Heij B.⁵, Tjiam I.⁶, Scheepens W.A.⁷, d'Ancona F.C.H.⁸, Van Uhm J.I.M.⁹, Van Roijen J.H.¹⁰, Weltings S.¹¹, Van Der Meer R.W.¹², Bosmans J.E.¹³, Pelger R.C.M.⁹, Beerlage H.P.², Duijnhoven R.G.¹⁴, Schout B.M.A.¹

Institutes: ¹Alrijne Ziekenhuis, Dept. of Urology, Leiderdorp, The Netherlands, ²Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ³Meander MC, Dept. of Urology, Amersfoort, The Netherlands, ⁴Canisius-Wilhelmina Ziekenhuis, Dept. of Urology, Nijmegen, The Netherlands, ⁵Zuyderland MC, Dept. of Urology, Heerlen, The Netherlands, ⁶HagaZiekenhuis, Dept. of Urology, the Hague, The Netherlands, ⁷Catharina Ziekenhuis, Dept. of Urology, Eindhoven, The Netherlands, ⁸Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ⁹Leids Universitair Medisch Centrum, Dept. of Urology, Leiden, The Netherlands, ¹⁰Elisabeth-TweeSteden Ziekenhuis, Dept. of Urology, Tilburg, The Netherlands, ¹¹Zaans MC, Dept. of Urology, Zaandam, The Netherlands, ¹²Leids Universitair Medisch Centrum, Dept. of Interventional Radiology, Leiden, The Netherlands, ¹³Vrije Universiteit, Dept. of Health Sciences, Amsterdam, The Netherlands, ¹⁴Amsterdam UMC, Amsterdam Public Health, Methodology, Amsterdam, The Netherlands

- A0770** **Decompression of an obstructed, infected kidney- how urgent is urgent?**
Authors: Carmona O., Kleinmann N., Zilberman D.E., Dotan Z.A., Shvero A.
Institutes: Sheba Medical Center, Dept. of Urology, Tel Aviv, Israel
- A0759** **Impact of the timing of percutaneous nephrostomy on the prognosis in patients with obstructive urolithiasis with sepsis**
Authors: Koh D.H.¹, Yu J.E.¹, Kim J.B.¹, Kim H.W.¹, Kim H.J.¹, Joo Y.C.¹, Baik J.H.¹, Bae S.², Chang Y.S.¹
Institutes: ¹Konyang University, Dept. of Urology, Daejeon, South Korea, ²The Catholic University of Korea, Dept. of Urology, Seoul, South Korea
- A0765** **Retrograde ureteric stent and percutaneous nephrostomy for upper urinary tract obstruction: findings from a national consensus survey**
Authors: Quaresma V., Magalhaes F., Ferreira A.M., Marconi L., Nunes P., Figueiredo A.
Institutes: Coimbra University Hospital Centre, Dept. of Urology and Renal Transplantation, Coimbra, Portugal
- A0772** **A new innovative EPR (electronic patient records) integrated Ureteric Stent Register**
Authors: Harry D.¹, Sekhon N.¹, Masood J.¹, Buck E.², Khan I.², Parasuraman P.³, Kudhail S.⁴
Institutes: ¹Barking Havering and Redbridge NHS Trust, Dept. of Urology, London, United Kingdom, ²Barking Havering and Redbridge NHS Trust, Dept. of Information Technology, London, United Kingdom, ³Barking Havering and Redbridge NHS Trust, Business Intelligence Unit, London, United Kingdom, ⁴Barking Havering and Redbridge NHS Trust, Dept. of Admissions, London, United Kingdom

OAB / Storage LUTS

Abstract session 39

07 April 2024
17:30 - 19:00

Location Green Area, N04
Chairs To be confirmed
To be confirmed
E. Finazzi Agrò, Rome (IT)
To be confirmed

17:30 - 17:50

OAB Basic research

A0792

Immuno-Modulatory Imide Drugs (IMiDs) Inhibit Human Bladder Smooth Muscle Contraction: a Novel Drug Class in LUTS?

Authors: Tamalunas A.¹, Wendt A.¹, Springer F.¹, Rutz B.¹, Ciotkowska A.¹, Magistro G.², Nössner E.³, Stief C.G.¹, Hennenberg M.¹

Institutes: ¹LMU Hospital Munich, Dept. of Urology, Munich, Germany, ²Asklepios Westklinikum Hamburg, Dept. of Urology, Hamburg, Germany, ³Helmholtz Center Munich, Immunoanalytics Research Group Tissue Control of Immunocytes, Munich, Germany

A0789

Silencing of Rac1 and Arf6 reduces time-dependent and carbachol-induced contractions, proliferation, survival and growth in human bladder smooth muscle cells: monomeric GTPases as novel regulators of OAB-relevant bladder functions

Authors: Qian S., Hu S., Tamalunas A., Stief C.G., Hennenberg M.

Institutes: LMU University Hospital, Dept. of Urology, Munich, Germany

A0781

Interaction between periaqueductal gray and Barrington's nucleus during strong desire to void using 7 Tesla functional MRI

Authors: Knops A.¹, de Rijk M.M.¹, Kendall H. J.², Smits M.A.C.², Van Koeveeringe G.A.², Van Den Hurk J.³

Institutes: ¹Maastricht University, Dept. of Urology, Maastricht, The Netherlands, ²Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands, ³Scannexus, Ultra-High Field MRI Centre, Maastricht, The Netherlands

A0783

Genetics Of OAB Syndrome

Authors: Raison N.¹, Thompson E.², Malde S.³, Steves C.⁴, Sahai A.³

Institutes: ¹King's College London, Dept. of Surgical and Interventional Engineering, London, United Kingdom, ²University of Sussex, School of Psychology, Brighton, United Kingdom, ³Guy's and St Thomas' NHS Trust, Dept. of Urology, London, United Kingdom, ⁴King's College London, Dept. of Twin Research and Genetic Epidemiology, London, United Kingdom

17:50 - 18:05

Storage LUTS epidemiology

A0785

The Impact of Urge Urinary Incontinence on Mortality in U.S. population

Authors: Kim S., Park S.G., Lee D.H., Pak S., Lee Y.G., Cho S.T.

Institutes: Hallym University, Dept. of Urology, Seoul, South Korea

A0786

Biological age acceleration is positively associated with overactive bladder

Authors: Huang W., Lu G., Zhu G., Yang L.

Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

- A0778** **Longitudinal changes in urinary incontinence and quality of life in older community-dwelling men: 11 year data from the CHAMP study**
Authors: Makary J.¹, Chan L.¹, Naganathan V.², Blyth F.³
Institutes: ¹Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia, ²Concord Repatriation General Hospital, Centre for Education and Research on Ageing, Sydney, Australia, ³The University of Sydney, School of Public Health, Sydney, Australia
- 18:05 - 18:35** **OAB clinical**
- A0791** **Role of Body Shape and metabolic syndrome in symptoms persistence in patients undergoing transurethral resection of the prostate**
Authors: Guidotti A., Sarcinelli L., Fiasconaro D., Zammiti F., Ghezzi N., Franco A., Riolo S., Lombardo R., Tema G., Cicione A., Fuschi A., Guarnotta G., Nacchia A., Pastore A., Sciarra A., Carbone A., Franco G., Tubaro A., Santoro G., Romagnoli M., De Nunzio C.
Institutes: Sapienza University of Rome, Dept. of Urology, Rome, Italy
- A0793** **Prostate shape and intravesical prostatic protrusion assessed by Magnetic Resonance Imaging are related to urinary symptoms**
Authors: Baldassarri V., Guarnotta G., Lombardo R., Al salhi Y., Fuschi A., Pastore A.L., Nacchia A., Voglino O., Cicione A., Carbone A., Tubaro A., De Nunzio C.
Institutes: Sapienza University of Rome, Dept. of Urology, Rome, Italy
- A0787** **Differences in recovery of lower urinary tract symptoms between patients with storage-positive vs. storage-negative symptoms after laser enucleation of the prostate**
Authors: Cano Garcia C.¹, Welte M.¹, Filzmayer M.¹, Nikolov I.², Tian Z.³, Karakiewicz P.I.³, Kluth L.A.¹, Mandel P.¹, Chun F.K.H.¹, Kosiba M.¹, Becker A.¹
Institutes: ¹Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Augustinerinnen Krankenhäuser gGmbH, Dept. of Urology, Cologne, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada
- A0780** **Intravesical instillations of hyaluronic acid in the management of lower urinary tract symptoms after transurethral resection of non-muscle invasive bladder cancers: a randomized, controlled clinical study.**
Authors: Casale P.¹, Buffi N.M.², Lughezzani G.², Saita A.¹, Hurle R.¹, Finocchiaro A.², Fasulo V.², Paciotti M.², Peschechera R.¹, Benetti A.¹, Lazzeri M.¹
Institutes: ¹Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²Humanitas University, Dept. of Biomedical Sciences, Milan, Italy
- A0776** **The inhibition of uninhibited detrusor contractions through distraction task: a novel approach for characterizing detrusor overactivity during filling cystometry**
Authors: Rigole H.¹, Haudebert C.¹, Samson E.², Amiot C.², Richard C.¹, Maze S.², Hascoet J.¹, Voiry C.², Peyronnet B.¹
Institutes: ¹University of Rennes, Dept. of Urology, Rennes, France, ²University of Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France
-

A0782

A preliminary analysis of the Comparing UroLift Experience Against Rezūm (CLEAR) randomized controlled trial (RCT) suggests a superior early patient experience with UroLift

Authors: Rochester M.¹, Barber N.², Mazzarella B.³, Cantrill C.⁴, Chughtai B.⁵, Cinman A.⁶, Schiff J.⁷, Roehrborn C.⁸

Institutes: ¹Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom, ²Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom, ³Urology Austin, Dept. of Urology, Austin, United States of America, ⁴Urology San Antonio, Dept. of Urology, San Antonio, United States of America, ⁵Weill Cornell Medicine, Dept. of Urology, New York, United States of America, ⁶Tower Urology, Dept. of Urology, Los Angeles, United States of America, ⁷NYU Langone, Dept. of Urology, Garden City, United States of America, ⁸UT Southwestern, Dept. of Urology, Dallas, United States of America

18:35 - 19:00

Neuromodulation

A0777

Predictive Factors for Long-Term Response to Sacral Neuromodulation in patients with Refractory Idiopathic Overactive Bladder

Authors: Hafez S.¹, Olivier L.², Carolus B.², Biardeau X.², Perrouin-Verbe M.A.¹

Institutes: ¹Centre Hospitalo Universitaire de Nantes, Dept. of Urology, Nantes, France, ²Centre Hospitalo Universitaire de Lille, Dept. of Urology, Lille, France

A0788

Device programming, MRI utilization and safety of sacral neuromodulation through 24 months in a global post-market study

Authors: Perrouin Verbe M.A.¹, Godelocke C.², Xavier K.³, Pecha B.⁴, Burgess K.⁵, Krlin R.⁶, Michaels J.⁷, Shah S.⁸, Peyronnet B.⁹, Zaslau S.¹⁰, Noel K.¹¹, Keller D.U.J.¹², Elterman D.¹³, Nitti V.¹⁴

Institutes: ¹Centre Hospitalier Universitaire de Nantes, Dept. of Urology, Nantes, France, ²Oschner Medical Center, Dept. of Urology, New Orleans, United States of America, ³Urology Partners of North Texas, Dept. of Urology, Arlington, United States of America, ⁴First Urology, Dept. of Urology, Jeffersonville, United States of America, ⁵Prisma Health, Dept. of Urology, Greenville, United States of America, ⁶Louisiana State University Health Sciences Center, Dept. of Urology, New Orleans, United States of America, ⁷Minnesota Urology, Center for Continence Care, Woodbury, United States of America, ⁸East Coast Institute for Research LLC, Dept. of Urology, Jacksonville, United States of America, ⁹Centre Hospitalier Universitaire de Rennes, Dept. of Urology, Rennes, France, ¹⁰West Virginia University, Dept. of Urology, Morgantown, United States of America, ¹¹Medtronic, Dept. of Statistics, Minneapolis, United States of America, ¹²Medtronic, Dept. of Clinical Research, Tolochenaz, Switzerland, ¹³University of Toronto, Division of Urology, Toronto, Canada, ¹⁴University of California Los Angeles, Dept. of Female Pelvic Medicine and Reconstructive Surgery, Los Angeles, United States of America

A0790

Acute autonomic nervous system response to direct sacral nerve root stimulation in lower urinary tract dysfunction: A new approach to understand the mechanism of action of sacral nerve modulation

Authors: Biardeau X.¹, Wojtanowski A.², Tilborghs S.³, De Jonckheere J.², Vermersch P.⁴, De Wachter S.³

Institutes: ¹Lille University Hospital, Dept. of Urology, Lille, France, ²Lille University Hospital, CIC-IT, Lille, France, ³Antwerp University Hospital, Dept. of Urology, Antwerp, Belgium, ⁴Lille University Hospital, Dept. of Neurology, Lille, France

A0779

New TENS+ device for transcutaneous posterior tibial nerve stimulation: a prospective, multicenter post-market clinical study

Authors: Cornu J-N.L.¹, Donon L.², Thuillier C.³, Meyer F.⁴, Klap J.⁵, Campagne-Loiseau S.⁶, Mariadassou A.⁷, Peyronnet B.⁸

Institutes: ¹CHU de Rouen, Dept. of Urology, Rouen, France, ²Clinique Belharra, Dept. of Urology, Bayonne, France, ³CHU Grenoble-Alpes, Dept. of Urology, Grenoble, France, ⁴CHU Saint Louis, Dept. of Urology, Paris, France, ⁵Hopital Galien, Dept. of Urology, Quincy-sous-Sénart, France, ⁶CHU de Clermont-Ferrand, Dept. of Gynecology and Obstetrics, Clermont-Ferrand, France, ⁷Stimuli Technology, Dept. of Research and Development, Boulogne-Billancourt, France, ⁸CHU de Rennes, Dept. of Urology, Rennes, France

A0784

Algorithm based programming of a novel implantable tibial neuromodulation system for urge urinary incontinence

Authors: Smit M.A.C.¹, De Wachter S.², Martens F.M.³, Van Breda J. .H.M.K.⁴, Dmochowski R.⁵, Heesakkers J.F.P.A.¹

Institutes: ¹Maastricht University Medical Center, Dept. of Urology, Maastricht, The Netherlands, ²Antwerp University Hospital, Dept. of Urology, Antwerp, Belgium, ³Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁴UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁵Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America

Male LUTS: Prevention, attention, intervention

Plenary Session

08 April 2024
08:00 - 10:00

Location Green Area, eURO Auditorium 1
Chairs J-N.L. Cornu, Rouen (FR)
C. Gratzke, Freiburg (DE)

Learning objectives

The session will delve into the role of genetic predisposition, epidemiology, prevention and multidimensional impact of male LUTS. Transitioning to clinical aspects, the best experts in the field will debate on optimal medical treatments, advancements in medical management, discussing efficacy and side effects of combination therapies. Then, innovations in MiST for male LUTS will take center stage. Experts will engage in debates regarding the comparative advantages and limitations of these innovative therapies, and their role as alternative to medications or conventional surgery. The final segment will revolve around surgical interventions, as a definitive therapy for male LUTS/BPO eventually after failed MiST.

08:00 - 08:25

Epidemiology and prevention

08:00 - 08:10

Non-pharmacologic prevention of BPH: Truth and lies

M. Gacci, Florence (IT)

08:10 - 08:15

Genetic predisposition for BPH: Where do we stand?

M. Hennenberg, Munich (DE)

08:15 - 08:25

Epidemiology of male LUTS: Not only the prostate

M. Drake, London (GB)

08:25 - 08:49

Case discussion Clinical issues and daily medical challenges

08:25 - 08:28

Case presentation: Mixed symptoms in a 60 yo, 60 grams benign prostate

T. Hüscher, Mainz (DE)

08:28 - 08:35

Try alpha-blockers first / follow the leader

M. Baboudjian, Marseille Cedex (FR)

08:35 - 08:42

Try another option / think different

F. Fusco, Naples (IT)

08:42 - 08:49

Société Internationale d'Urologie (SIU) lecture A critical review: Additive effects of combination therapy - Myth or reality?

S. Gravas, Larissa (GR)

08:49 - 09:15

Debate Refining the indication of interventional therapies for male LUTS

08:49 - 08:51

Minimally invasive Surgical Therapies (MiST): What are we talking about?

S. Malde, London (GB)

08:51 - 08:58

MiST are super pills

R. Eapen, Melbourne (AU)

08:58 - 09:05

MiST are alternatives to TURP

D. Abt, Biel-Bienne (CH)

Scientific Programme - EAU24

09:05 - 09:15	Discussion: Bridging medical treatment and ablative surgery
09:15 - 09:55	Case discussion The end of the journey: Best options of BPO relief
09:15 - 09:17	Case presentation: A failed case of MiST with BPO and indication for ablative surgery - 80 gram prostate M. Creta, Solopaca (IT)
09:17 - 09:24	Perseverate: MiST after another D. Elterman, Toronto (CA)
09:24 - 09:31	Stay standard: Resection and vaporisation S. Madersbacher, Vienna (AT)
09:31 - 09:38	Enucleate: AEEP against all odds T.R.W. Herrmann, Frauenfeld (CH)
09:38 - 09:45	Innovate: Aquablation and robotics N. Barber, Camberley (GB)
09:45 - 09:55	Discussion
09:55 - 10:00	Wrap-up by chairs

Living with advanced kidney cancer

Plenary Session

08 April 2024
08:00 - 10:00

Location Purple Area, eURO Auditorium 2
Chairs S. Gillessen Sommer, Bellinzona (CH)
M.C. Mir Maresma, Valencia (ES)

Learning objectives

we will be discussing some of the current hot-topics for urologist in locally advanced and first-line metastatic kidney cancer. We will hold a debate on the real -life indications for adjuvant immunotherapy for high-risk patient after nephrectomy, including a life patient and a legal concerns of usage. We will also direct our attention toward treatment intensification for first line metastatic RCC including a debate on recent result from triplet therapy trials. Finally a state-of-the art lecture on the use of surgery and th upcoming role of SBRT in the context of oligometastatic RCC will be articulated.

08:00 - 08:01

Welcome and introduction

08:01 - 08:11

Confederación Americana de Urología (CAU) lecture Redefining role of surgery in advance kidney cancer: Surgical trade-off for metastatic kidney cancer

F. Rodriguez-Covarrubias, Mexico City (MX)

08:11 - 08:21

State-of-the-art lecture Advancements in cutting-edge SBRT therapy for oligometastatic kidney cancer

S. Siva, Melbourne (AU)

08:21 - 08:31

State-of-the-art lecture Patients priorities during mRCC therapy: Exquisite art of harmonizing patient-centric care

R. Giles, Duivendrecht (NL)

08:31 - 09:04

Debate Moving towards intensified treatment paradigms in first line metastatic kidney cancer: Triplet combinations at any cost - is more always better?

08:31 - 08:34

Case presentation

C.H.J. Muselaers, Nijmegen (NL)

08:34 - 08:44

Yes, the more the merrier

L. Albiges, Villejuif (FR)

08:44 - 08:54

No, less is more

S. Psutka, Seattle (US)

08:54 - 09:04

Discussion

Panel

S. Psutka, Seattle (US)

L. Albiges, Villejuif (FR)

C.H.J. Muselaers,
Nijmegen (NL)

09:04 - 09:14

State-of-the-art lecture Embracing the digital frontier: Symptom management through E-Health monitoring

R. Pereira Mestre, Bellinzona (CH)

09:14 - 09:24	State-of-the-art lecture Illuminating the resilient journey of kidney cancer survivorship I. Duran, Santander (ES)
09:24 - 09:34	State-of-the-art lecture Mastering the art of end-of-life care management: Harmonising dignity, comfort, and serenity in the final stages C. Schulz-Quach, Toronto (CA)
09:34 - 09:59	Debate Adjuvant immunotherapy in the legal landscape: Navigating use of IO in high-risk kidney cancer following nephrectomy - trade offs without OS advantage?
09:34 - 09:39	Case presentation L. Marandino, Milan (IT)
09:39 - 09:59	Discussion Panel T.S. O'Brien, London (GB) B. Leigh, London (GB) W. Everaerts, Leuven (BE)
09:59 - 10:00	Closing remarks

Prostate cancer screening and active surveillance – Where are we now?

ESU Course 41

08 April 2024
08:30 - 10:30

Location Purple Area, E01
Chair S. Carlsson, New York (US)

Learning objectives

- Prostate cancer is a global public health concern. While large randomised trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomised trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG Guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
- Active surveillance (AS) is now widely accepted as a management strategy for low-risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.
- The course will be interactive and include illustrative and practical clinical case discussions.

Prostate cancer screening: Where are we now?

S. Carlsson, New York (US)

Prostate cancer active surveillance: Where are we now?

R.C.N. Van Den Bergh, Utrecht (NL)

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 42

08 April 2024
08:30 - 11:30

Location Purple Area, E02
Chair O. Traxer, Paris (FR)

Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions. • To learn about equipment. • To learn about technique and indications. • To learn how to use an Holmium Laser. • To learn tips and tricks for special circumstances.

Welcome and introduction

O. Traxer, Paris (FR)

Instrumentation: Endoscopes

O. Traxer, Paris (FR)

Instrumentation: Laser and lithotripsy devices

B. Somani, Southampton (GB)

Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)

H.U. Jung, Vejle (DK)

Technique: Stones

O. Traxer, Paris (FR)

Technique: Urothelial tumours and strictures

B. Somani, Southampton (GB)

Tips and tricks and special circumstances

O. Traxer, Paris (FR)

Indications (guidelines) and clinical cases

H.U. Jung, Vejle (DK)

Conclusions

O. Traxer, Paris (FR)

Prolapse management and female pelvic floor problems

ESU Course 43

08 April 2024
08:30 - 11:30

Location Purple Area, E03
Chair V. Phé, Paris (FR)

Learning objectives

The objective of this course is to provide a complete overview of pelvic organ prolapse diagnosis, investigations (place of urodynamics) and treatment including conservative management and surgeries from open to laparoscopic and robotic approaches.

Clinical cases of POP, POP associated with stress and urge urinary incontinence and complications of surgeries will be discussed methodically.

At the end, the participants will know the diagnostic strategies, the techniques to perform POP surgeries and how to counsel the patients.

- To learn about clinical diagnosis of POP
- To learn about urodynamics and indications
- To learn step by step how to perform a sacrocolpopexy and tips and tricks
- To learn how to manage POP surgery complications

What can go wrong in the female pelvic floor support

Evaluation of female pelvic floor and basic anatomical concepts

F. Cancrini, Rome (IT)

Pelvic organ prolapse (POP) classifications and its clinical usefulness

F. Cancrini, Rome (IT)

Anterior prolapse

Pessaries

V. Phé, Paris (FR)

Vaginal approach

V. Phé, Paris (FR)

Open, laparoscopic and robotic sacrocolpopexy

V. Phé, Paris (FR)

POP and urinary incontinence

Stress incontinence and POP

F. Cancrini, Rome (IT)

Urge urinary incontinence and POP

F. Cancrini, Rome (IT)

Place of urodynamics

F. Cancrini, Rome (IT)

Interactive discussion on different clinical scenarios

Pediatric urology: Addressing challenges and improving patient care

EGPT 01

**05 April 2024
10:45 - 12:15**

Location EGPT
Chairs To be confirmed
M.S. Silay, Istanbul (TR)
To be confirmed

10:45 - 11:03

Screen A: Basic research & diagnosis

P021

Comparison of pediatric and adult patients with ureteropelvic junction obstruction in terms of nerve number, connective tissue and ganglion cell existence

Authors: Demirci D.¹, Dirik A.¹, Deniz K.², Baydilli N.¹

Institutes: ¹Erciyes University, Dept. of Urology, Kayseri, Türkiye, ²Erciyes University, Dept. of Pathology, Kayseri, Türkiye

P014

Identifying infrequent genetic changes in monozygotic twins afflicted with hypospadias via targeted panel sequencing

Authors: Kim D., Kim Y., Kim D., Kang H., Kang S., Jung Y., Choe J., Shin D., Cho J., Park J., Nam K., Song S.H., Kim K.S.

Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea

P002

Assessment of differences in the microvessel density(MVD) and growth factor levels between the inner and outer preputial skin in distal hypospadias

Authors: Prasad G.¹, Dhua A.K.¹, Kaushal S.², Prabakaran A.², Rathi H.², Goel P.¹, Agarwala S.¹, Yadav D.K.¹

Institutes: ¹All India Institute of Medical Sciences New Delhi, Dept. of Paediatric Surgery, New Delhi, India, ²All India Institute of Medical Sciences New Delhi, Dept. of Pathology, New Delhi, India

P001

Molecular biomarkers in urine which may be useful as early markers of progressive kidney damage in congenital uropathy

Authors: Krishnan N., Yadav D.K., Bajpai M.

Institutes: All India Institute of Medical Sciences, Dept. of Pediatric Surgery, New Delhi, India

P016

From pain onset to surgical decision: ultrasonographic insights into testicular torsion over a decade

Authors: Kim D., Kim Y., Kim D., Kang H., Kang S., Jung Y., Choe J., Shin D., Cho J., Park J., Nam K., Song S.H., Kim K.S.

Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea

P011

Save the Ball: Teachers teaching teens about testicular torsion in schools

Authors: McCauley N.L.¹, Ong A.², Macdonald C.³, Undre S.⁴, Green J.⁵

Institutes: ¹Royal Gwent Hospital, Dept. of Urology, Newport, United Kingdom, ²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ³Sheffield Children's NHS Foundation Trust, Dept. of Paediatric Surgery, Sheffield, United Kingdom, ⁴Lister Hospital Stevenage, Dept. of Urology, Stevenage, United Kingdom, ⁵Barts Health NHS Trust, Dept. of Urology, London, United Kingdom

11:03 - 11:21

Screen B: Testis

- P009** **Testicular location score in the retractile testis**
Authors: Chung J.M.¹, Lee S.D.¹, Cho W.Y.²
Institutes: ¹Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea, ²Dong-A University Hospital, Dept. of Urology, Busan, South Korea
- P017** **The therapeutic effects of restoring mitochondrial biogenesis by mitochondrial transplantation and pyrroloquinoline quinone maintain therapy in testicular torsion and detorsion**
Authors: Lin C.B.¹, Shih H.J.¹, Huang C.J.²
Institutes: ¹Changhua Christian Hospital, Dept. of Urology, Changhua City, Taiwan, ²Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan
- P027** **Study of abdominal testicular vessels distribution in human fetuses: anatomical basis for laparoscopic fowler-stephens surgery**
Authors: Benzi T.C., Favorito L.A., Fortuna-Costa A., Costa W.S., Sampaio F.
Institutes: State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil
- P024** **Testicular migration: when does it start the transition of the testis through the inguinal canal? Study in 169 human fetuses during the 2nd gestational trimester**
Authors: Favorito L.A., Benzi T.C., Gallo C.B.M., Sampaio F.
Institutes: State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil
- P025** **Testicular hydatides with torsion have similar anatomical features on the contra-lateral side? A morphometric study**
Authors: Favorito L.A., Sampaio F., Barbosa R.G.
Institutes: State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil
- P030** **Ultrasound for the diagnosis of testicular torsion: a systematic review and meta-analysis of diagnostic accuracy**
Authors: Alexander C.E.¹, Light A.², Chan V.³, Asif A.⁴, Clement K.⁵, Warren H.⁶, Zimmermann E.⁷, Khadouri S.⁸, Eyskens P.², Takwoingi Y.⁹, Sidhu P.¹⁰, Shah T.², Kasivisvanathan V.⁴
Institutes: ¹Luton and Duntable University Hospital, Dept. of Urology, Luton, United Kingdom, ²Imperial College London, Dept. of Urology, London, United Kingdom, ³University of Leeds, Dept. of Urology, Leeds, United Kingdom, ⁴University College London, Dept. of Urology, London, United Kingdom, ⁵NHS Greater Glasgow and Clyde, Dept. of Urology, Glasgow, United Kingdom, ⁶Guys and St Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁷Torbay and Southern Devon Health and Care NHS Trust, Dept. of Urology, Bristol, United Kingdom, ⁸NHS Fife, Dept. of Urology, Kirkcaldy, United Kingdom, ⁹University of Birmingham, University of Birmingham, Birmingham, United Kingdom, ¹⁰Kings College London, Dept. of Radiology, London, United Kingdom

11:21 - 11:33

Screen C: VUR & UTI

- P023** **Laparoscopic Lich Gregoire vesico-ureteral reimplantation training: a low cost non-biological simulation model.**
Authors: Ben Ahmed Y.¹, Boulma R.², Marzouki M.¹, Ezzine R.¹, Charieg A.¹, Nouria F.³, Jlidi S.¹, Khouni H.²
Institutes: ¹Bechir Hamza children Hospital Tunis, Dept. of Pediatric Surgery, Tunis, Tunisia, ²Internal Security Forces Hospital La Marsa, Dept. of Urology, Tunis, Tunisia, ³Bechir Hamza children Hospital Tunis, Dept. of General Surgery, Tunis, Tunisia
- P005** **The long term result of endoscopic treatment of vesicoureteric reflux using dextranomer / hyaluronic acid: 20 years experience in a single-center**
Authors: Moon D.G., Ahn S.T., Hwang W.K., Cho S.B., Kim H.J.
Institutes: Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea
- P006** **Post-operative Urinary Tract Infection in Children with Vesicoureteral Reflux: Does Pathogens and Antibiotics Resistance Change?**
Authors: Seong W.¹, Chung J.M.², Lee S.D.²
Institutes: ¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea
- P029** **Pediatric Urinary Tract Infections Following Renal Transplantation from Deceased Donors: Insights from a Singular Medical Facility**
Authors: El Helaly A.¹, Alotay A.¹, Alhagbani M.¹, Aloufi M.²
Institutes: ¹Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia, ²Prince Sultan Military Medical City, Dept. of Pediatric Nephrology, Riyadh, Saudi Arabia
- Screen D: Long-term outcomes**
- P018** **Long-term urinary and fecal outcomes in classic bladder exstrophy : what can we learn from a 20 years of experience ?**
Authors: Abdellaoui S.¹, Morel Journal N.², Cazzorla F.³, Ruffion A.², Bidault V.¹, Mouriquand P.¹, DEMEDE D.¹
Institutes: ¹Hopital Femme Mère Enfant, Dept. of Pediatric Surgery, Lyon, France, ²Hopital Pierre Benite, Dept. of Urology, Lyon, France, ³University of Grenoble-Alpes, Dept. of Infectious Disease Control, Grenoble, France
- P028** **Long-Term Outcomes After Isolated Epispadias Repair**
Authors: Bencic M., Stojanovic B., Bizic M., Djordjevic M.
Institutes: Belgrade Center for Urogenital Reconstructive Surgery, Dept. of Urology, Belgrade, Serbia
- P022** **Long-term outcomes of ileocystoplasty in children: 20 years of experience**
Authors: Rovero E.¹, Trypens A.¹, Botto N.¹, Alova I.¹, Blanc T.², Lottmann H.¹
Institutes: ¹Hopital Necker Enfants Malades, Dept. of Pediatric Surgery and Urology, Paris, France, ²Université Paris Cité, Hopital Necker Enfants Malades Department of pediatric surgery and urology, Paris, France

- P013** **Revisiting the vascular hitch procedure for crossing vessels in paediatric patients – a longitudinal institutional experience over 15 years**
Authors: Richter J.¹, Dos Santos J.¹, Sánchez C.¹, Moreno Bernardino C.¹, Romao R.², Keefe D.T.³, Chua M.E.¹, Rickard M.¹, Lorenzo A.J.¹
Institutes: ¹The Hospital for Sick Children, Division of Urology, Toronto, Canada, ²The Hospital for Sick Children, Division of General and Thoracic Surgery and Division of Urology, Toronto, Canada, ³Izaak Walton Killam Hospital for Children, Dept. of Urology, Halifax, Canada
- P003** **Comparison of two different approaches in the management of infants with primary obstructive megaureters and their long-term outcomes**
Authors: Nagabhairava M.K., Tarun J., Neehar P.
Institutes: Ms Ramaiah Hospital, Dept. of Urology, Bengaluru, India
- P012** **Chronic kidney disease (CKD) in children with Meningomyelocele (MMC): risk factors and clinical outcomes**
Authors: El Helaly A., Alotay A., Alfaddagh A., Bashareef A., Aljaafar M., Alhagbani M., alghanbar M., Nakshabandi Z., Sarhan O.
Institutes: Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia
- 11:51 - 12:03** **Screen E: Stones in children**
- P004** **Outcomes for RIRS in the setting of multiple and large renal stones (>15mm) in children: Findings from a multicenter and real-world setting**
Authors: Juliebø-Jones P.¹, Somani B.K.², Gauhar V.³, Traxer O.⁴, Fong K.Y.⁵, Castellani D.⁶, Madarriaga Y.Q.⁷, Bujons Tur A.⁷
Institutes: ¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ³Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ⁴University Tenon Hospital, Dept. of Urology, Paris, France, ⁵Yong Loo Lin School of Medicine, Dept. of Urology, Singapore, Singapore, ⁶IRCCS INRCA, Dept. of Urology, Ancona, Italy, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- P010** **Mortality and burden of disease associated with kidney stone disease in children and young persons (<20 years): Trends in Europe between 1990-2019**
Authors: Juliebø-Jones P.¹, Tzelves L.², Ulvik Y.¹, Aesøy M.¹, Beisland C.¹, Somani B.K.³
Institutes: ¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ³University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

- P007** **Quadruple-D score in the success rate of extracorporeal shock wave lithotripsy of renal stones in pediatric population**
Authors: Sendogan F.¹, Bulut M.², Canakci C.³, Dinçer E.³, Simsek B.⁴, Cetin B.⁵, Silay S.⁶, Telli O.⁷
Institutes: ¹Memorial Sisli Hospital, Dept. of Urology, Istanbul, Türkiye, ²Diyarbakir Selahaddin Eyyubi State Hospital, Dept. of Urology, Diyarbakir, Türkiye, ³Kartal Training and Research Hospital, Dept. of Urology, Istanbul, Türkiye, ⁴Liv Hospital ULUS, Dept. of Urology, Istanbul, Türkiye, ⁵Kartal Training and Research Hospital, Dept. of Pediatric Urology, Istanbul, Türkiye, ⁶Memorial Bahcelievler Hospital, Dept. of Pediatric Urology, Istanbul, Türkiye, ⁷Memorial Sisli Hospital, Dept. of Pediatric Urology, Istanbul, Türkiye
- P020** **Risk factors for the occurrence of lithiasis in the long term of pyeloplasties**
Authors: Diéguez Aguirre L., Quiroz Y., Jimenez R., Osorio J.C., Bujons A.
Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- 12:03 - 12:15** **Screen F: Miscellaneous**
- P019** **Strong parental satisfaction with the use of magnetic-end double-j ureteral stent in children**
Authors: Glenisson M.¹, Vinit N.¹, Marquant F.², Party P.¹, Nefzy L.¹, Broch A.¹, Elie C.², Lottmann H.¹, Botto N.¹, Blanc T.¹
Institutes: ¹Hopital Necker-Enfants Malades, Dept. of Pediatric Surgery and Urology, Paris, France, ²Hopital Necker-Enfants Malades, Unité de Recherche Clinique-CIC, Paris, France
- P026** **The Effect of Botulinum Toxin A in Children with Non-Neurogenic Therapy-Refractory Dysfunctional Voiding**
Authors: Hoelscher S.¹, de Angst I.¹, Buijnsters Z.¹, Bramer W.², Akkermans F.¹, Kuindersma M.¹, Scheepe J.¹, 't Hoen L.¹
Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus University Medical Center, Medical Library, Rotterdam, The Netherlands
- P008** **Pediatric renal cell carcinoma: experience of a single tertiary care center**
Authors: Hussiny M., Ghani L., Anas M., Makled N.N., Abdelmoneim M.M., Kazium Z.A.R., Dawaba M., Helmy T., T. Hafez A.
Institutes: Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt
- P015** **Posterior urethral valves (PUV) and anterior urethral valves (AUV) with and without concomitant PUV: Matched cohort study at a high-risk pediatric center**
Authors: Richter J., Dos Santos J., Sánchez C., Moreno Bencardino C., Chua M.E., Kim J.K., Khondker A., Lorenzo A.J., Rickard M.
Institutes: The Hospital for Sick Children, Division of Urology, Toronto, Canada

Advanced indications in robotic surgery

ESU Course 44

08 April 2024
08:30 - 11:30

Location Purple Area, E04
Chair A. Mottrie, Aalst (BE)

Learning objectives

Robotic surgery is expanding and is slowly but surely becoming mainstream. The tutors want to share rare indications for robotic surgery as well as very advanced cases. The focus will be on reconstructive and benign indications. It will be mainly videobased and through interactive discussions, experience and knowledge will be shared. This course is meant for robotic surgeons with an experience exceeding 100 cases. After this course, the colleagues should be able to expand their robotic program significantly.

Part 1: Reconstructive surgery

Modern management of proximal ureteric strictures (Buccal ureteroplasty, appendix, ileal interposition). Case examples.

B. McGuire, Dublin (IE)

B. Peyronnet, Rennes (FR)

Management of distal ureteric strictures (Psoas hitch, Boari Flap, Non-diverting). Case examples.

B. McGuire, Dublin (IE)

A. Mottrie, Aalst (BE)

Female AUS implantation

B. Peyronnet, Rennes (FR)

The expanding use of IDG in reconstructive urology

B. McGuire, Dublin (IE)

Panel discussion: The expanding use of IDG in reconstructive urology

Panel discussion: Follow up of patients who have undergone reconstructive procedures

Part 2: Benign and rare indications

RASP (Robotic Assisted Simple Prostatectomy)

A. Mottrie, Aalst (BE)

Bladder diverticulectomy

A. Mottrie, Aalst (BE)

Surgical approach to a non-functioning moiety in a duplex kidney

B. McGuire, Dublin (IE)

Vesicovaginal fistula

B. Peyronnet, Rennes (FR)

Vesicorectal fistula

A. Mottrie, Aalst (BE)

Sling excision and autologous sling replacement

B. Peyronnet, Rennes (FR)

Mitrofanoff

B. Peyronnet, Rennes (FR)

Redo anastomosis after failed RARP

A. Mottrie, Aalst (BE)

Conclusions

A. Mottrie, Aalst (BE)

Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 45

08 April 2024
08:30 - 11:30

Location Purple Area, E05
Chair E. Lledó García, Madrid (ES)

Learning objectives

The objectives of this course are essentially to update medical-surgical knowledge in kidney transplantation. As an area of interdisciplinary knowledge, it is important that the urologist acquires preparation for the main nephrological and urological aspects of these patients that allow to provide the best assistance. Preparation of the patient, procurement techniques, preservation, open and robotic surgery, immunosuppression therapy, diagnosis and treatment of medical & surgical complications, and prognosis in the mid and long term.

Introduction

E. Lledó García, Madrid (ES)

Selection and urological preparation of transplant recipients

E. Lledó García, Madrid (ES)

Surgical aspects of deceased donor nephrectomy

J.D.J.M. Branchereau, Nantes (FR)

Living donor nephrectomy: Technical alternatives and controversies

M. Musquera Felip, Barcelona (ES)

Preservation

E. Lledó García, Madrid (ES)

Renal transplantation. Surgical options: Tips and tricks

J.D.J.M. Branchereau, Nantes (FR)

M. Musquera Felip, Barcelona (ES)

Immunosuppression

J. Pascual, Madrid (ES)

How to diagnose and manage postoperative and long-term complications following renal transplantation. Long term survival

E. Lledó García, Madrid (ES)

J. Pascual, Madrid (ES)

Controversies on EAU Guidelines: NMIBC, RCC and strictures

Thematic Session

08 April 2024
10:45 - 12:15

Location Purple Area, eURO Auditorium 2
Chairs A. Bex, London (GB)
P. Gontero, Turin (IT)
N. Lumen, Ghent (BE)

Learning objectives

the participants should be able to:

- reflect on the grading system(s) in NMIBC
- reflect on the need for adjuvant treatment in very high-risk RCC
- reflect on the use of drug-coated balloon dilatation for recurrent short bulbar strictures

10:45 - 10:47

Introduction

P. Gontero, Turin (IT)

10:47 - 11:16

Case discussion NMIBC: The LG/HG grading system is the one that best fits clinical practice when treating non-muscle invasive urothelial carcinoma

10:47 - 10:50

Case presentation

P. Gontero, Turin (IT)

10:50 - 10:58

LG/HG is the way to go

E. Compérat, Vienna (AT)

10:58 - 11:06

A three tier system better captures tumour biology

A. Masson-Lecomte, Paris (FR)

11:06 - 11:16

Discussion

P. Gontero, Turin (IT)

11:16 - 11:45

Case discussion RCC: Offer adjuvant treatment only in patients with very high-risk for recurrence as patients with sarcomatoid dedifferentiation

11:16 - 11:19

Case presentation

To be confirmed

11:19 - 11:27

Yes

J. Bedke, Tübingen (DE)

11:27 - 11:35

No

A. Bex, London (GB)

11:35 - 11:45

Discussion

To be confirmed

11:45 - 12:14

Case discussion The recurrent short bulbar urethral stricture urethroplasty or drug coated balloon dilatation

11:45 - 11:48

Case presentation

M. Waterloos, Gent (BE)

11:48 - 11:56

Urethroplasty is the first choice

R. Dahlem, Hamburg (DE)

11:56 - 12:04

Drug-coated balloon dilatation should be attempted

S.P. Elliott, Minneapolis (US)

12:04 - 12:14

Discussion

M. Waterloos, Gent (BE)

12:14 - 12:15

Closing remarks

N. Lumen, Ghent (BE)

Medical treatment of male LUTS: From bench to bedside

Abstract session 40

**08 April 2024
10:45 - 12:15**

Location Purple Area, N01
Chairs T. Antunes Lopes, Porto (PT)
To be confirmed
To be confirmed

A0802

β -Arrestin-2-mediated promotion of contractility and stromal growth, evidenced by silencing, and correlation of β -arrestin-2 expression with voiding symptoms in patients undergoing surgery for BPH opposes predicted β -arrestin-2 functions in the prostate

Authors: Keller P., Hu S., Weinhold P., Tamalunas A., Berger L., Nicola P., Götz M., Waidelich R., Stief C.G., Hennenberg M.

Institutes: LMU University Hospital, Dept. of Urology, Munich, Germany

A0807

A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia

Authors: Lim H.¹, Shin T.J.¹, Ha J.Y.¹, Kwon S.Y.², Kim J.H.³, Lee S.W.⁴, Jeong I.G.⁵, Lee J.Y.⁶, Yoo T.K.⁷, Kim T.H.⁸, Moon D.G.⁹, Hong S.K.¹⁰, Cho J.S.¹¹, Moon H.S.¹², Lee J.W.¹³, Yun S.J.¹⁴, Jeon Y.S.¹⁵, Kang T.W.¹⁶, Moon K.H.¹⁷, Park J.S.¹⁸, Kwon T.G.¹⁹, Chung J.I.²⁰, Park S.W.²¹, Lee K.S.¹

Institutes: ¹Keimyung University Dongsan Hospital, Dept. of Urology, Daegu, South Korea, ²Dongguk University Gyeongju Hospital, Dept. of Urology, Gyeongju, South Korea, ³Severance Hospital, Dept. of Urology, Seoul, South Korea, ⁴Seoul Samsung Medical Center, Dept. of Urology, Seoul, South Korea, ⁵Seoul Asan Medical Center, Dept. of Urology, Seoul, South Korea, ⁶Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, ⁷Nowon Eulji Medical Center, Dept. of Urology, Seoul, South Korea, ⁸Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea, ⁹Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea, ¹⁰Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ¹¹Hallym University Medical Center, Dept. of Urology, Anyang, South Korea, ¹²Hanyang University Medical Center, Dept. of Urology, Seoul, South Korea, ¹³Dongguk University Medical Center, Dept. of Urology, Goyang, South Korea, ¹⁴Chungbuk National University Hospital, Dept. of Urology, Cheongju, South Korea, ¹⁵Soonchunhyang University Hospital, Dept. of Urology, Cheonan, South Korea, ¹⁶Chonnam National University Hospital, Dept. of Urology, Gwangju, South Korea, ¹⁷Yeungnam University Medical Center, Dept. of Urology, Daegu, South Korea, ¹⁸Daegu Catholic University Medical Center, Dept. of Urology, Daegu, South Korea, ¹⁹Kyungpook National University Chilgok Hospital, Dept. of Urology, Daegu, South Korea, ²⁰Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, ²¹Pusan National University Yansan Hospital, Dept. of Urology, Yangsan, South Korea

A0809

Phosphodiesterase Type 5 Inhibitor Tadalafil Reduces Prostatic Fibrosis via MiR-3126-3p/FGF9 Axis in Benign Prostatic Hyperplasia

Authors: Zhang Y., Li T., Ruan Y.

Institutes: Shanghai General Hospital, Dept. of Urology, Shanghai, China

- A0797** **Verteporfin and fasudil suppress inflammation-induced benign prostatic hyperplasia by regulating ROCK1/YAP1 pathway**
Authors: Lin D., Luo C., Wei P., Deng B., Li Z., Li K., Chen Z.
Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China
- A0799** **Activation of the cGMP/PKG/ERK signaling pathway associated with PDE5Is inhibits fibroblast activation by downregulating autophagy in early progressive benign prostatic hyperplasia**
Authors: Jin S.¹, Liu Z.L.², Xiang P.³, Fu M.¹, Zhang G.¹, Li J.X.¹, Niu Y.N.²
Institutes: ¹Beijing Tsinghua Changgung Hospital, Dept. of Urology, Beijing, China, ²Beijing Friendship Hospital, Dept. of Urology, Beijing, China, ³Beijing Tongren Hospital, Dept. of Urology, Beijing, China
- A0798** **Human Umbilical Cord-Derived Mesenchymal Stem Cells Improve Bladder Contractility and Compliance in Rats with Partial Bladder Outlet Obstruction**
Authors: Lee T.N., Chang S.-J., Hsieh T.Y., Ng K.C., Chang C.-Y., Chueh J.S.
Institutes: National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan
- A0801** **YAP and TAZ regulate gene splicing and differentiation of urinary bladder smooth muscle cells**
Authors: Liu L.¹, Martinez M.A.V.², Rippe C.², Holmberg J.², Albinsson S.², Swärd K.²
Institutes: ¹The Sixth Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangdong, China, ²Lund University, Dept. of Experimental Medical Science, Lund, Sweden
- A0810** **TGFβ1 and LIM kinases: Novel Insights into Overactive Bladder Secondary to Benign Prostate Hyperplasia**
Authors: Yu Q., Cen P., Lan H., Zhou X., Huang R., Zeng G.
Institutes: the First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China
- A0811** **Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: a US Healthcare Claims analysis**
Authors: Kaplan S.A.¹, Kaufman R.²
Institutes: ¹Icahn School at Mount Sinai, Dept. of Urology, New York, United States of America, ²Albany Medical College, Dept. of Urology, Albany, United States of America
- A0805** **Effects Of Preoperative Treatment With Phenolmicine P3 And Boisexil Dietary Supplement on Postoperative Irritative Symptoms In Patients With Middle Prostate Volume Undergoing Transurethral Prostate Surgery**
Authors: Antonioni A.¹, Valenzi F.M.¹, Rera O.A.¹, Martino G.¹, Graziani D.¹, Gianfrancesco F.¹, Candita G.¹, Sequi M.B.¹, Suraci P.P.¹, Scalzo S.¹, Fuschi A.¹, Al Salhi Y.¹, Sciarra A.², Salciccia S.², Franco G.², Di Pierro G.², Tema G.³, De Nunzio C.³, Carbone A.¹, Pastore A.L.¹
Institutes: ¹Sapienza University of Rome Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies Urology, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy
-

A0796

A prospective, randomized, open-label, parallel trial comparing the efficacy of α -blocker or 5 α -reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia

Authors: Bang S.¹, Lee K.S.¹, Yoo J.W.², Kim D.H.¹, Jeon S.³, Yang J.³, Chung B.H.¹, Koo K.C.¹

Institutes: ¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Veterans Health Service Medical Center, Dept. of Urology, Seoul, South Korea, ³Yonsei University College of Medicine, Biostatistics Collaboration Unit, Seoul, South Korea

A0808

A real-world study to evaluate disease control based on symptoms severity in Greek patients with benign prostatic hyperplasia (BPH) after 6 months of treatment under fixed dose combination (FDC) with dutasteride/tamsulosin. The PROSPERITY I study

Authors: Dimitriadis G.¹, Kalaitzis C.², Stamatiou K.³, Kotsiris D.⁴, Deirmentzoglou S.⁵, Loutriotis A.⁶, Papataxiarchou K.⁶, Tsioumas G.⁶

Institutes: ¹School of Medicine Aristotle University of Thessaloniki, First Department of Urology, Thessaloniki, Greece, ²Democritus University of Thrace, Dept. of Urology, Alexandroupolis, Greece, ³Tzaneio General Hospital, Dept. of Urology, Piraeus, Greece, ⁴Private Site, Dept. of Urology, Athens, Greece, ⁵Private Site, Dept. of Urology, Kavala, Greece, ⁶ELPEN Pharmaceutical Co. Inc., Medical Department, Athens, Greece

A0806

A randomized controlled trial comparing tadalafil/solifenacin versus tamsulosin/solifenacin combination for the treatment of benign prostatic hyperplasia with overactive bladder

Authors: Hegazy M., Ashour R., Ramez M., Wadie B.S., Nabeeh A., El-Hefnawy A.S.

Institutes: Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

A0804

A randomised, placebo-controlled study to assess the efficacy & safety of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Authors: Morsy S., Farid M., Meshref A., Rady I.

Institutes: Cairo University, Dept. of Urology, Cairo, Egypt

A0794

Efficacy and safety of fixed dose combination of silodosin and tadalafil in Indian patients with benign prostatic hyperplasia and erectile dysfunction: A phase 3 randomized clinical study

Authors: Avinash T.S.¹, Mondal P.², Chander R.³, Mandal T.⁴, Malviya J.⁵, Chaudhari H.⁶, Darakh P.⁷, Patel D.⁸, Singh V.⁹, Kumar V.¹⁰, Yadav R.¹¹, Andankar G.¹², Shah H.¹³, Jindal P.¹⁴, Patil S.¹⁵, Das S.¹⁶, Rajurkar M.¹⁷, Saha S.¹⁷, Patil D.¹⁷, Patel P.¹⁷, Ghadge P.¹⁷, Lakhwani L.¹⁷, Mehta S.¹⁷, Joglekar S.¹⁸

Institutes: ¹Sparsh Super Specialty Hospital, Dept. of Urology, Bangalore, India, ²Medical College, Dept. of Urology, Calcutta, India, ³Gandhi Hospital, Dept. of Urology, Secunderabad, India, ⁴NRS Medical College and Hospital, Dept. of Urology, Calcutta, India, ⁵Priyadarshani Nursing Home, Dept. of Urology, Mumbai, India, ⁶Oyster and Pearl Hospitals, Dept. of Urology, Pune, India, ⁷Darakh Nursing Home and Kidney Stone Center, Dept. of Urology, Aurangabad, India, ⁸V.S. General Hospital, Dept. of Urology, Ahmedabad, India, ⁹M.V. Hospital and Research Center, Dept. of Urology, Lucknow, India, ¹⁰GSVM Medical college, Dept. of Urology, Kanpur, India, ¹¹Tender Palm Hospital, Dept. of Urology, Lucknow, India, ¹²T.N. Medical College and B.Y.L. Nair Hospital, Dept. of Urology, Mumbai, India, ¹³Dr. M. K. Shah Medical College, Dept. of Urology, Ahmedabad, India, ¹⁴Opal Hospital Private Limited, Dept. of Urology, Varanasi, India, ¹⁵Medipoint Hospital Pvt. Ltd., Dept. of Urology, Pune, India, ¹⁶AMRI hospital Ltd, Dept. of Urology, Bhubaneshwar, India, ¹⁷Sun Pharma Laboratories Limited, India Clinical Research, Mumbai, India, ¹⁸Sun Pharmaceutical Industries Limited, Dept. of Urology, Mumbai, India

A0803

Can pyridostigmine bromide 60 mg improve BPH symptoms in Diabetic patients?

Authors: Yehia Abdelaziz A.¹, Ibrahim H.¹, Abuelela W.¹, Eladawy M.S.²

Institutes: ¹Cairo University, Dept. of Urology, Cairo, Egypt, ²Fayoum University, Dept. Urology, Fayoum, Egypt

A0795

Tadalafil treatment might be effective for BPH patients with metabolic syndrome.

Authors: Inamura S., Kobayashi H., Ueki K., Nishikawa T., Okubo N., Kakitsuba T., Seo W., Fukiage Y., Okumura Y., Tsutsumiuchi M., Seki M., Taga M., Fukushima M., Yokoyama O., Terada N.

Institutes: University of Fukui, Dept. of Urology, Fukui, Japan

A0800

Voiding dysfunction that developed during hospitalization improve with rehabilitation

Authors: Ohtsubo A.¹, Sagawa R.¹, Matsuo T.², Imamura R.², Sakai H.¹

Institutes: ¹Nagasaki Rosai Hospital, Dept. of Urology, Sasebo, Japan, ²Nagasaki University, Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan

Pushing the limits of active surveillance for prostate cancer?

Abstract session 41

08 April 2024
10:45 - 12:15

Location Green Area, N03
Chairs M. Baboudjian, Marseille Cedex (FR)
To be confirmed
To be confirmed
To be confirmed

10:45 - 10:47

Introduction

10:47 - 11:07

Real world data

A0828

FINPRO – A Nationwide Registry Study on Localized Prostate Cancer in Finland

Authors: Murtola T.¹, Hakkarainen T.², Lahelma M.², Pennanen P.², Pietilä M.³, Hervonen P.³, Kääriäinen O.⁴, Minn H.⁵, Nykopp T.⁴, Ronkainen H.⁶, Ettala O.⁷, Rannikko A.S.⁸

Institutes: ¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²Nordic Healthare Group, NHG Finland, Helsinki, Finland, ³Janssen-Cilag Oy, Janssen-Cilag Oy, Espoo, Finland, ⁴Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, ⁵Turku University Hospital, Dept. of Oncology, Turku, Finland, ⁶Oulu University Hospital, Dept. of Urology, Oulu, Finland, ⁷Turku University Hospital, Dept. of Urology, Turku, Finland, ⁸Helsinki University Hospital, Dept. of Urology, Helsinki, Finland

A0816

Reasons for Discontinuation of Active Surveillance and Subsequent Outcome on Radical Prostatectomy Pathology

Authors: de Vos I.I.¹, Remmers S.¹, Graefen M.², Rannikko A.S.³, Marengi C.⁴, Boevé E.R.⁵, Roobol M.J.¹

Institutes: ¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ³University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁵Franciscus Gasthuis and Vlietland, Dept. of Urology, Rotterdam, The Netherlands

A0821

Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years' experience.

Authors: Marengi C.¹, Badenchini F.¹, Avuzzi B.², Catanzaro M.A.³, Claps M.¹, Casbarra A.², Noris Chiorda B.², Guadalupi V.¹, Stellato M.¹, Nazzani S.³, Stagn S.³, Cattaneo L.⁴, Casale A.⁵, Messina A.⁵, Villa S.², Macchi A.³, Torelli T.³, Tesone A.³, Verzoni E.¹, Procopio G.¹, Rancati T.⁶, Nicolai N.³

Institutes: ¹Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Advanced Diagnostics, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Data Science, Milan, Italy

A0814

Active Surveillance for Prostate Cancer in “Real-World” Setting: Exploring Racial Disparities in Surveillance Intensity and Cancer Control Outcomes

Authors: Chiarelli G.¹, Finati M.¹, Cirulli G.O.¹, Butaney M.¹, Stephens A.¹, Arora S.¹, Morrison C.¹, Tinsley S.¹, Sood A.¹, Carrieri G.², Briganti A.³, Montorsi F.³, Lughezzani G.⁴, Buffi N.⁴, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Health System, VUI Center for Outcomes Research Analysis and Evaluation, Detroit, United States of America, ²University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ³Università Vita-Salute San Raffaele, Division of Oncology - Unit of Urology, Milan, Italy, ⁴Humanitas University, Dept. of Urology, Milan, Italy

11:07 - 11:42

De-Escalation in follow up

A0815

MRI-guided active surveillance without re-biopsy in patients with ISUP 1 and 2 prostate cancer – Results of Radical Prostatectomy and Mid-term Follow up of the prospective PROMM-AS study

Authors: Radtke J.P.¹, Al-Monajjed R.¹, Arsov C.², Valentin B.³, Ullrich T.³, Boschheidgen M.³, Hadaschik B.⁴, Giganti F.⁵, Giessing M.¹, Lopez-Cotarelo C.⁶, Rau T.⁶, Esposito I.⁶, Antoch G.³, Schimmöller L.³, Albers P.¹

Institutes: ¹University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²Elisabeth Hospital Rheydt, Dept. of Urology, Mönchengladbach, Germany, ³University Hospital Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ⁴University Hospital Essen, Dept. of Urology, Essen, Germany, ⁵University College London, Division of Surgery and Interventional Science, London, United Kingdom, ⁶University Hospital Düsseldorf, Dept. of Pathology, Düsseldorf, Germany

A0813

De-escalation of monitoring for prostate cancer active surveillance: Results of the GAP3 consortium

Authors: Tohi Y.¹, Sahrman J.M.², Arbet J.², Kato T.¹, Lee L.S.³, Peacock M.⁴, Ginsburg K.⁵, Pavlovich C.⁶, Carroll P.⁵, Bangma C.H.⁷, Sugimoto M.¹, Boutros P.C.²

Institutes: ¹Kagawa University, Dept. of Urology, Kagawa, Japan, ²Jonsson Comprehensive Cancer Center, Los Angeles, United States of America, ³Sengkang General Hospital and Singapore General Hospital, Singapore, Singapore, ⁴University of British Columbia, BC Cancer Agency, Vancouver, Canada, ⁵University California San Francisco, San Francisco, United States of America, ⁶Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ⁷Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands

A0826

MRI-guided Active Surveillance in patients with ISUP 1 prostate cancer – A multi-institutional validation of the discrimination of the PRECISE Score

Authors: Sushentsev N.¹, Wiesenfarth M.², Dixius M.³, Kastner C.⁴, Borkowetz A.⁵, Platzek I.⁶, Thomas C.⁵, Kesch C.³, Umutlu L.⁷, Reis H.⁸, Rau T.⁹, Lenders L.³, Spahn M.¹⁰, Boschheidgen M.¹¹, Antoch G.¹¹, Albers P.¹², Barrett T.¹, Schimmöller L.¹¹, Hadaschik B.³, Radtke J.P.¹²

Institutes: ¹Addenbrookes Hospital University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ²German Cancer Research Center, Division of Biostatistics, Heidelberg, Germany, ³University Hospital Essen, Dept. of Urology, Essen, Germany, ⁴Addenbrookes Hospital University of Cambridge, CamPARI Prostate Cancer Group, Cambridge, United Kingdom, ⁵Technical University Dresden, Dept. of Urology, Dresden, Germany, ⁶Technical University Dresden, Dept. of Radiology, Dresden, Germany, ⁷University Hospital Essen, Dept. of Diagnostic and Interventional Radiology, Essen, Germany, ⁸University Hospital Frankfurt, Division of Pathology, Frankfurt, Germany, ⁹University Hospital Düsseldorf, Dept. of Pathology, Düsseldorf, Germany, ¹⁰Lindenhofspital Berne, Dept. of Urology, Berne, Switzerland, ¹¹University Hospital Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ¹²University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany

A0818

A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series.

Authors: Stabile A.¹, Leni R.¹, Quarta L.¹, Mazzone E.¹, Cannoletta D.¹, Gandaglia G.¹, Pellegrino F.¹, Sorce G.¹, Pellegrino A.¹, Russo T.², Cosenza M.², Pennella R.², Brembilla G.², De Cobelli F.², Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Karnes R.J.³, Roupret M.⁴, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴AP-HP Hopital Pitié-Salpêtrière, Sorbonne Université, Dept. of Predictive Onco-Urology, Paris, France

A0812

Does The PRECISE Score Improves PI-RADS Ability to Predict Grade Reclassification in Men on Active Surveillance for Early Prostate Cancer?

Authors: Leni R.¹, Stabile A.¹, Brembilla G.², De Cobelli F.², Gandaglia G.¹, Zaurito P.¹, Santangelo A.¹, Viti A.¹, Montorsi F.¹, Vickers A.³, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy, ³Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

A0823

Should patients with PIRADS 5 lesions be recommended against active surveillance? A multicenter retrospective European study

Authors: Peyrottes A.¹, Ducrot Q.², Vitard C.³, Baudewyns A.⁴, Windisch O.⁵, Anract J.⁶, Dariane C.⁷, Tricard T.⁸, Baboudjian M.⁹, Sarkis J.¹⁰, Sadreux Y.¹¹, Oderda M.¹², De La Taille A.¹³, Olivier J.¹⁴, Brureau L.¹¹, Diamand R.⁴, Rouviere O.¹⁵, Ruffion A.³, Desgrandchamps F.¹, Roumiguie M.², Ploussard G.¹⁶, Fiard G.¹⁷

Institutes: ¹Saint-Louis Hospital, Dept. of Urology and Kidney Transplantation, Paris, France, ²Rangueil Hospital, Dept. of Urology, Toulouse, France, ³Lyon Sud Hospital, Dept. of Urology, Pierre-Bénite, France, ⁴Jules Bordet Institute, Dept. of Urology, Brussels, Belgium, ⁵Geneva University Hospitals, Division of Urology, Geneva, Switzerland, ⁶Cochin Hospital, Dept. of Urology, Paris, France, ⁷European Hospital Georges Pompidou, Dept. of Urology, Paris, France, ⁸Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ⁹Marseille University Hospital, Dept. of Urology, Marseille, France, ¹⁰Hotel-Dieu de France, Dept. of Urology, Beirut, Lebanon, ¹¹CHU de Pointe-à-Pitre, Dept. of Urology, Pointe-à-Pitre, France, ¹²Molinette Hospital, Urology Unit, Turin, Italy, ¹³Henri-Mondor Hospital, Dept. of Urology, Paris, France, ¹⁴Lille University Hospital, Dept. of Urology, Lille, France, ¹⁵Edouard Herriot Hospital, Dept. of Radiology, Lyon, France, ¹⁶La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁷Grenoble Alpes University Hospital, Dept. of Urology, Grenoble, France

A0820

PRECISE v2: Updated recommendations for reporting prostate MRI in patients on active surveillance

Authors: Englman C.¹, Maffei D.¹, Tristan B.², Clare A.³, Kirkham A.³, Giganti F.¹, Moore C.¹

Institutes: ¹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ²University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom

11:42 - 12:12

Long term outcome

A0822

Does multiparametric (mp)MRI and MRI-informed biopsy improve risk allocation of men at inclusion in Active Surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial

Authors: Marengi C.¹, Badenchini F.¹, Rancati T.², Avuzzi B.³, Messina A.⁴, Casale A.⁴, Catanzaro M.A.⁵, Claps M.¹, Casbarra A.³, Noris Chiorda B.³, Guadalupi V.¹, Stellato M.¹, Nazzani S.⁵, Stagni S.⁵, Cattaneo L.⁶, Macchi A.⁵, Villa S.³, Torelli T.⁵, Verzoni E.¹, Tesone A.⁵, Procopio G.¹, Nicolai N.⁵

Institutes: ¹Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Data Science, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiology, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Advanced Diagnostics, Milan, Italy

A0824

Adherence to recommendations in prostate cancer guidelines: Nationwide population-based study

Authors: Orrason A.W.¹, Westerberg M.², Garmo H.¹, Gedeberg R.¹, Pär S.¹

Institutes: ¹Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden, ²Uppsala University, Dept. of Mathematics, Uppsala, Sweden

A0819

Comparing functional outcomes between active surveillance vs radical prostatectomy as initial approach in newly diagnosis ISUP 1 prostate cancer.

Authors: Flammia R.S.¹, Luzzago S.², Brassetti A.¹, Mistretta F.A.², Musi G.², Salvador M.³, Brunocilla E.³, Droghetti M.³, Manfredi M.⁴, De Luca S.⁴, Porpiglia F.⁴, Tufano A.⁵, Passaro F.⁵, Perdonà S.⁵, Cormio A.⁶, Chiacchio G.¹, Galosi A.B.⁶, Scarcia M.⁷, Ludovico G.M.⁷, Cormio L.⁸, De Cobelli O.², Schiavina R.³, Leonardo C.¹, Simone G.¹

Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²IEO European institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ⁴San Luigi Gonzaga teaching Hospital University of Turin, Dept. of Oncology, Turin, Italy, ⁵IRCCS Fondazione Senatore Pascale Istituto Nazionale Tumori, Dept. of Urology, Naples, Italy, ⁶Ospedale Riuniti di Antona, Dept. of Urology, Antona, Italy, ⁷F. Miulli Hospital, Dept. of Urology, Acquaviva delle Fonti, Italy, ⁸Bonomo Teaching Hospital, Dept. of Urology, Andria, Italy

A0817

Long-term sexual health of men on active surveillance for low-risk prostate cancer – results of the Movember GAP3 consortium

Authors: Venderbos L.D.F.¹, Nieboer D.¹, Helleman J.¹, Peacock M.², Van Hemelrijck M.³, Pavlovich C.⁴, Carroll P.⁵, Roobol M.J.¹

Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²University of British Columbia, BC Cancer Agency, Vancouver, Canada, ³King's College London, UK and Guys and St Thomas NHS Foundation Trust, London, United Kingdom, ⁴Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ⁵University California San Francisco, Dept. of Urology, San Francisco, United States of America

A0825

25-year outcomes for men on active surveillance after screen detected prostate cancer in the Göteborg-1 trial

Authors: Palmstedt E., Månsson M., Hugosson J., Arnsrud Godtman R.

Institutes: Institute of Clinical Sciences, Dept. of Urology, Gothenburg, Sweden

A0827

Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage prostate cancer: the PRIAS-JAPAN study

Authors: Kato T.¹, Matsumoto R.², Yokomizo A.³, Tohi Y.¹, Fukuhara H.⁴, Fujii K.⁵, Mori K.⁶, Sato T.⁷, Inokuchi J.⁸, Hashine K.⁹, Sakamoto S.¹⁰, Kinoshita H.¹¹, Inoue K.¹², Tanikawa T.¹³, Utsumi T.¹⁴, Goto T.¹⁵, Hara I.¹⁶, Takechi Y.¹, Sugimoto M.¹

Institutes: ¹Kagawa university, Dept. of Urology, Miki-cho, Japan, ²Hokkaido University, Dept. of Renal and Genito-Urinary Surgery, Sapporo, Japan, ³Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, ⁴Kyorin University, Dept. of Urology, Tokyo, Japan, ⁵Tokyo University, Dept. of Urology, Tokyo, Japan, ⁶Jikei university, Dept. of Urology, Tokyo, Japan, ⁷Tohoku university, Dept. of Urology, Miyagi, Japan, ⁸Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁹Shikoku Cancer Center, Dept. of Urology, Matsuyama, Japan, ¹⁰Chiba university, Dept. of Urology, Chiba, Japan, ¹¹Kansai Medical University, Dept. of Urology, Osaka, Japan, ¹²Kurashiki Central Hospital, Dept. of Urology, Kurashiki, Japan, ¹³Niigata Cancer Center Hospital, Dept. of Urology, Niigata, Japan, ¹⁴Toho University Sakura Medical Center, Dept. of Urology, Chiba, Japan, ¹⁵Kyoto University, Dept. of Urology, Kyoto, Japan, ¹⁶Wakayama Medical University, Dept. of Urology, Wakayama, Japan

12:12 - 12:15

Expert summary

Advancing renal cell carcinoma care: Surgical and immunotherapy insights

Abstract session 42

08 April 2024
10:45 - 12:15

Location Green Area, N04
Chairs To be confirmed
To be confirmed
R. Flippot, Villejuif (FR)
To be confirmed

10:45 - 10:47

Introduction

A0840

Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy

Authors: Siech C.¹, Incesu R.B.², Morra S.³, Scheipner L.⁴, Baudo A.⁵, Jannello L.M.I.⁶, de Angelis M.⁷, Goyal J.A.⁸, Tian Z.⁸, Saad F.⁸, Shariat S.F.⁹, Tilki D.², Longo N.³, Carmignani L.⁵, De Cobelli O.⁶, Ahyai S.⁴, Briganti A.⁷, Mandel P.¹, Kluth L.A.¹, Chun F.K.H.¹, Karakiewicz P.I.⁸

Institutes: ¹Goethe University Frankfurt University Hospital, Dept. of Urology, Frankfurt am Main, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ³University of Naples Federico II, Dept. of Neurosciences Science of Reproduction and Odontostomatology, Naples, Italy, ⁴Medical University of Graz, Dept. of Urology, Graz, Austria, ⁵IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁶IEO European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ⁷Urological Research Institute IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ⁸University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada, ⁹Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0832

Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)

Authors: Margue G.¹, Parier B.², Albiges L.³, Klein C.¹, Pignot G.⁴, Gravis G.⁵, Bigot P.⁶, Baize N.⁷, Ingels A.⁸, Charlotte J.⁹, Audenet F.¹⁰, Vano Y.¹¹, Waeckel T.¹², Levard R.¹³, Gross-Goupil M.¹⁴, Bernhard J.C.¹

Institutes: ¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Kremlin-Bicetre Hospital - APHP, Dept. of Urology, Paris, France, ³Gustave Roussy Institute, Dept. of Medical Oncology, Paris, France, ⁴Paoli Calmettes Institute, Dept. of Urology, Marseille, France, ⁵Paoli Calmettes Institute, Dept. of Medical Oncology, Marseille, France, ⁶Angers University Hospital, Dept. of Urology, Angers, France, ⁷Angers University Hospital, Dept. of Medical Oncology, Angers, France, ⁸Henri Mondor Hospital - APHP, Dept. of Urology, Paris, France, ⁹Henri Mondor Hospital - APHP, Dept. of Medical Oncology, Paris, France, ¹⁰HEGP - APHP, Dept. of Urology, Paris, France, ¹¹HEGP - APHP, Dept. of Medical Oncology, Paris, France, ¹²Caen University Hospital, Dept. of Urology, Caen, France, ¹³Caen University Hospital, Dept. of Medical Oncology, Caen, France, ¹⁴Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France

A0838

Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place

Authors: Jurascheck L.¹, Fransen Van De Putte E.², Van Den Brink L.³, Van Der Mijn J.C.⁴, Wilgenhof S.⁴, Van Thienen J.V.⁴, Haanen J.B.A.G.⁴, Boleti E.⁵, Powles T.⁶, Zondervan P.J.³, Graafland N.M.², Bex A.¹

Institutes: ¹Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ⁴The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ⁵Royal Free NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ⁶Barts Cancer Centre, Dept. of Oncology, London, United Kingdom

A0842

The role of cytoreductive nephrectomy in metastatic clear cell carcinoma: analysis of an other-cause mortality matched population from the contemporary immunotherapy era.

Authors: Finati M.¹, Cirulli G.O.¹, Chiarelli G.¹, Tinsley S.¹, Morrison C.¹, Davis M.¹, Arora S.¹, Etta P.¹, Butaney M.¹, Akshay S.², Buffi N.³, Lughezzani G.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Bettocchi C.⁵, Carrieri G.⁵, Rogers C.⁴, Abdollah F.¹

Institutes: ¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²The James Cancer Hospital and Solove Research Institute, Ohio State's Comprehensive Cancer Center, Dept. of Urology, Columbus, United States of America, ³IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy

A0843

Impact of tumor volume on prognosis in IMDC poor risk renal cell carcinoma patients underwent cytoreductive nephrectomy

Authors: Naito H., Homare O., Tomoko H., Yu O., Yohei A., Yoichiro T., Yuki M., Takuma K., Rikiya T., Nobufumi U., Mikio S.

Institutes: Kagawa University Faculty of Medicine, Dept. of Urology, Kagawa, Japan

A0829

Prognostic factors for overall survival (OS) in patients receiving first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for advanced/metastatic renal cell carcinoma (aRCC) in a real-world setting in Germany

Authors: Bedke J.¹, Grünwald V.², Müller-Huesmann H.³, Belz H.⁴, Von Der Heyde E.⁵, Bögemann M.⁶, Strauß A.⁷, Vaz L.⁸, Bluhmki T.⁹, Herber M.¹⁰, Groetzinger S.¹⁰, Grimm M.O.¹¹

Institutes: ¹Klinikum Stuttgart, Dept. of Urology and Transplantation Surgery, Stuttgart, Germany, ²University-Hospital Essen, Dept. of Urology, Essen, Germany, ³St Josef Brothers Hospital Paderborn, Dept. of Hematology and Oncology, Paderborn, Germany, ⁴Zeisigwaldkliniken Bethanien Chemnitz, Dept. of Urology, Chemnitz, Germany, ⁵Practice for Oncology Raschplatz, Dept. of Hematology and Oncology, Hannover, Germany, ⁶University of Münster, Dept. of Urology, Münster, Germany, ⁷University of Göttingen, Dept. of Urology, Göttingen, Germany, ⁸Bristol Myers Squibb, Dept. of RWD Analytics, RWA Markets, Uxbridge, United Kingdom, ⁹Bristol Myers Squibb, Dept. of Biostatistics - Real World Evidence, Munich, Germany, ¹⁰Bristol Myers Squibb, Dept. of Medical Affairs Oncology, Munich, Germany, ¹¹Klinik und Poliklinik für Urologie, Universitätsklinikum Jena, Dept. of Urology, Jena, Germany

A0831

Improved survival in contemporary actively treated community-based metastatic clear-cell renal cell carcinoma patients

Authors: Incesu R.B.¹, Morra S.M.¹, Scheipner L.S.¹, Baudo A.¹, Jannello L.M.I.J.¹, de Angelis M.¹, Siech C.S.¹, Assad A.¹, Tian Z.T.¹, Saad F.S.¹, Shariat S.F.S.², Chun F.K.H.³, Briganti A.⁴, de Cobelli O.⁵, Carmignani L.⁶, Ahyai S.⁷, Longo N.L.⁸, Tilki D.T.⁹, Graefen M.G.⁹, Karakiewicz P.I.K.¹

Institutes: ¹University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada, ²Medical University of Vienna, Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁴IRCCS San Raffaele Scientific Institute, Unit of Urology Division of Oncology Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁵IEO European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁶IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁷Medical University of Graz, Dept. of Urology, Graz, Austria, ⁸University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ⁹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

A0833

Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old

Authors: Numakura K.¹, Kobayashi M.¹, Hatakeyama S.², Muto Y.¹, Sekine Y.¹, Sobu R.¹, Sasagawa H.¹, Akashi H.³, Kashima S.¹, Yamamoto R.¹, Nara T.¹, Saito M.¹, Narita S.¹, Ohyama C.², Habuchi T.¹

Institutes: ¹Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ³Akita University Graduate School of Medicine, Dept. of Anatomy, Akita, Japan

A0835

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

Authors: Yanagisawa T.¹, Quhal F.², Kawada T.³, Laukhtina E.², Rajwa P.², Von Deimling M.², Pradere B.², Mori K.¹, Kimura T.¹, Schmidinger M.², Shariat S.F.²

Institutes: ¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Okayama University, Graduate School of Medicine, Dept. of Urology, Okayama, Japan

A0830

The effect of treatment dose intensification on other-cause mortality in clear-cell metastatic renal cell carcinoma patients

Authors: Incesu R.B.¹, Barletta F.¹, Cano Garcia C.¹, Scheipner L.S.¹, Morra S.M.¹, Baudo A.¹, Assad A.¹, Tian Z.T.¹, Saad F.S.¹, Shariat S.F.S.², Carmignani L.³, Longo N.L.⁴, Ahyai S.⁵, Chun F.K.H.⁶, Briganti A.⁷, Tilki D.T.⁸, Graefen M.G.⁸, Karakiewicz P.I.K.¹

Institutes: ¹University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada, ²Medical University of Vienna, Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ³IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁴University of Naples Federico II, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ⁵Medical University of Graz, Dept. of Urology, Graz, Austria, ⁶University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁷IRCCS San Raffaele Scientific Institute, Unit of Urology Division of Oncology Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁸University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

A0837

Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.

Authors: Aydogdu C.¹, Paffenholz P.², Stelmach R.³, Schlack K.⁴, Roghmann F.⁵, Handke A.⁵, Mandal S.⁶, Schnabel M.⁷, Merseburger A.⁸, Ivanyi P.⁹, Tschäbitz S.³, Darr C.¹⁰, Grünwald V.¹⁰, Stief C.G.¹, Casuscelli J.¹

Institutes: ¹University Hospital LMU Munich, Dept. of Urology, Munich, Germany, ²University of Cologne Faculty of Medicine and University Hospital Cologne, Dept. of Urology and Uro-Oncology and Robot Assisted and Reconstructive Urologic Surgery, Cologne, Germany, ³Heidelberg University Hospital, Dept. of Medical Oncology of the National Center for Tumor Diseases, Heidelberg, Germany, ⁴University Hospital Münster, Dept. of Urology, Münster, Germany, ⁵University Hospital Bochum, Dept. of Urology, Herne, Germany, ⁶University of Marburg, Dept. of Urology, Marburg, Germany, ⁷Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regebsburg, Germany, ⁸University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, ⁹Hannover Medical School, Dept. of Hematology and Hemostasis and Oncology and Stem Cell Transplantation, Hannover, Germany, ¹⁰University of Duisburg-Essen and German Cancer Consortium DKTK - University Hospital Essen, Dept. of Urology, Essen, Germany

A0839

Papillary Renal Cell Carcinoma (pRCC): Outcomes Of Patients Receiving First-Line Immune-Based Combinations Or Tyrosine Kinase Inhibitors (TKIs) From The ARON-1 Study

Authors: Mollica V.¹, Massari F.¹, Fiala O.², Kucharz J.³, Molina-Cerrillo J.⁴, Seront E.⁵, Bourlon M.T.⁶, Pichler R.⁷, Myint Z.W.⁸, Kanesvaran R.⁹, Marchetti A.¹, Rosellini M.¹, Rescigno P.¹⁰, de Liano A.G.¹¹, Zakopoulou R.¹², Buti S.¹³, Porta C.¹⁴, Grande E.¹⁵, Santoni M.¹⁶

Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Medical Oncology, Bologna, Italy, ²Charles University, Dept. of Oncology and Radiotherapeutics, Pilsen, Czech Republic, ³Maria Sklodowska-Curie National Research Institute of Oncology, Dept. of Uro-oncology, Warsaw, Poland, ⁴Hospital Ramón y Cajal, Dept. of Medical Oncology, Madrid, Spain, ⁵Centre Hospitalier de Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, ⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Dept. of Hematology and Oncology, Mexico City, Mexico, ⁷Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁸University of Kentucky, Markey Cancer Center, Lexington, United States of America, ⁹National Cancer Centre Singapore, Division of Medical Oncology, Singapore, Singapore, ¹⁰Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom, ¹¹CHU Insular-Materno Infantil, Dept. of Medical Oncology, Las Palmas, Spain, ¹²National and Kapodistrian University of Athens, Dept. of Internal Medicine, Athens, Greece, ¹³University Hospital of Parma, Medical Oncology Unit, Parma, Italy, ¹⁴A.O.U. Consorziiale Policlinico di Bari, Interdisciplinary Department of Medicine, Bari, Italy, ¹⁵MD Anderson Cancer Center Madrid, Dept. of Medical Oncology, Madrid, Spain, ¹⁶Macerata Hospital, Oncology Unit, Macerata, Italy

A0836

Comparison of the Efficacy of First-line Combinations for Metastatic Clear Cell Renal Cell Carcinoma: A Propensity Score-matched Analysis of Japanese Multicenter Database

Authors: Yanagisawa T.¹, Mori K.¹, Fukuokaya W.¹, Kawada T.², Katayama S.², Uchimoto T.³, Tsujino T.³, Nishimura K.³, Adachi T.⁴, Toyoda S.⁵, Komura K.³, Takahara K.⁶, Hashimoto T.⁴, Fujita K.⁵, Azuma H.³, Ohno Y.⁴, Shiroki R.⁶, Uemura H.⁵, Araki M.², Kimura T.¹

Institutes: ¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Okayama University, Graduate School of Medicine, Dept. of Urology, Okayama, Japan, ³Osaka Medical and Pharmaceutical University, Dept. of Urology, Osaka, Japan, ⁴Tokyo Medical University, Dept. of Urology, Tokyo, Japan, ⁵Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, ⁶Fujita Health University School of Medicine, Dept. of Urology, Nagoya, Japan

A0834

Development and internal validation of a nomogram to predict five-years chest metastasis in surgically treated non metastatic renal cell carcinoma

Authors: Flammia R.S., Chiacchio G., Proietti F., Tuderti G., Mastroianni R., Brassetti A., Bove A.M., Misuraca L., D'Annunzio S., Ferriero M.C., Minore A., Basile S., Anceschi U., Costantini M., Guaglianone S., Leonardo C., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0841

Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma : oncological outcomes and predictive factors of surgical difficulties.

Authors: Pignot G.¹, Margue G.², Bigot P.³, Lang H.⁴, Balssa L.⁵, Roubaud G.⁶, Borchiellini D.⁷, Bensalah K.⁸, Schlürmann F.⁹, Ladoire S.¹⁰, Parier B.¹¹, Bernhard J.C.², Cassuto O.¹², Albiges L.¹³, Thibault C.¹⁴, Ingels A.¹⁵, Cherifi F.¹⁶, Waeckel T.¹⁷, Walz J.¹, Flippot R.¹³, Geoffrois L.¹⁸, Gravis G.¹⁹, Barthelemy P.²⁰

Institutes: ¹Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ²CHU Bordeaux, Dept. of Urology, Bordeaux, France, ³CHU Angers, Dept. of Urology, Angers, France, ⁴CHU Strasbourg, Dept. of Urology, Strasbourg, France, ⁵CHU Besançon, Dept. of Urology, Besançon, France, ⁶Institut Bergonié, Dept. of Medical Oncology, Bordeaux, France, ⁷Centre Antoine Lacassagne, Dept. of Medical Oncology, Nice, France, ⁸CHU Rennes, Hopital Pontchaillou, Dept. of Urology, Rennes, France, ⁹CHU Brest, Dept. of Medical Oncology, Brest, France, ¹⁰Centre Georges-François Leclerc, Dept. of Medical Oncology, Dijon, France, ¹¹Bicetre Hospital, Dept. of Urology, Le Kremlin-Bicêtre, France, ¹²Polyclinique St Georges, Dept. of Medical Oncology, Nice, France, ¹³Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, ¹⁴Hopital Europeen Georges Pompidou, Dept. of Medical Oncology, Paris, France, ¹⁵CHU Henri-Mondor, Dept. of Urology, Créteil, France, ¹⁶CHU Caen, Dept. of Medical Oncology, Caen, France, ¹⁷CHU Caen, Dept. of Urology, Caen, France, ¹⁸Institut de Cancérologie de Lorraine, Dept. of Medical Oncology, Vandoeuvre lès Nancy, France, ¹⁹Institut Paoli-Calmettes, Dept. of Medical Oncology, Marseille, France, ²⁰Institut de Cancérologie Strasbourg Europe, Dept. of Medical Oncology, Strasbourg, France

12:02 - 12:05

Expert summary

Overactive bladder in special situations

Thematic Session

08 April 2024
10:45 - 12:15

Location Purple Area, S01
Chairs E. Chartier-Kastler, Paris (FR)
J. Heesakkers, Maastricht (NL)

Learning objectives

Overactive Bladder is a symptom complex that according to the definition has one obligatory symptom (urgency) and three facultative symptoms (frequency, nocturia and urgency incontinence). This implies that the disorder has various ways of showing itself and the cause of the symptoms are not identified by putting the OAB label on a patient. The consequences are that causes and treatments differ according to the patient profile and that the effect of treatment on the various OAB symptoms and the syndrome as a whole varies from patient to patient.

The objective of this thematic session is to elucidate these aspect in patients with a neurogenic disease and in typical, difficult to treat, non-neurogenic clinical situations.

10:45 - 10:55

Overactive bladder in neurological diseases

10:45 - 10:55

State-of-the-art lecture **Panorama of OAB neurological dysfunction: The bladder and the brain - what the urologist needs to know?**
T.M. Kessler, Zurich (CH)

10:55 - 11:36

Rapid-fire debate **The current neurogenic OAB patient journey: What's new?**

10:55 - 11:02

The role of medications
L.P.W. Witte, Zwolle (NL)

11:02 - 11:09

Botulinum Toxin A injections: Until when should we inject?
H.C. Kuo, Hualien (TW)

11:09 - 11:16

Is there any role for neuromodulation in neurogenic OAB?
M.A. Perrouin Verbe, Nantes (FR)

11:16 - 11:36

Discussion

11:36 - 12:11

Rapid-fire debate **Daily challenges in non-neurogenic OAB: Key messages on clinical issues**

11:36 - 11:43

OAB in the irradiated bladder
A. Sahai, London (GB)

11:43 - 11:50

OAB and endometriosis
J-N.L. Cornu, Rouen (FR)

11:50 - 11:57

Persistent OAB after BPO surgery in males
M. Rieken, Zürich (CH)

11:57 - 12:04

How can we cure diabetic OAB?
C. De Nunzio, Rome (IT)

12:04 - 12:11

OAB after a mid-urethral sling
S. Arlandis, Valencia (ES)

12:11 - 12:15

Closing remarks

Innovations in biopsy and focal therapy in prostate cancer

Video session 14

08 April 2024
10:45 - 12:15

Location Purple Area, S03
Chairs To be confirmed
To be confirmed

- V103** **Holomedicine: The use of a mixed reality device to aid in transperineal prostate biopsies**
Authors: Kesavan A.¹, Gao Y.², Ng K.W.², Tay E.Y.Z.², Guo Q.², Tay H.K.L.², Tay A.H.K.², Ngiam K.Y.², Chiong E.¹, Yeo Z.²
Institutes: ¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University Health System, Dept. of Biomedical Informatics, Singapore, Singapore
- V104** **An extended reality (XRD) headset designed as a wearable monitor for transperineal procedures: applications for remote training**
Authors: Stone N.¹, Wilson M.², Griffith S.², Kim L.², Stone J.³, Vanneste B.⁴
Institutes: ¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Viomerse Inc., Dept. of Engineering, Pittsford, United States of America, ³University of Rochester Medical Center, Dept. of Neurosurgery, Rochester, United States of America, ⁴Ghent University Hospital, Dept. of Radiation Oncology, Ghent, Belgium
- V105** **MRI-TRUS Fusion Guided Prostate Biopsy: should we continue to do it? Our first hundred cases experience**
Authors: Arborea F.¹, Massenio P.², De Siati M.², Pizzuto G.², Giordano S.², Lafranceschina F.², Papapicco G.¹, Mongelli L.¹, Stellacci V.²
Institutes: ¹Università degli studi di Bari, Urologia, Bari, Italy, ²Ospedale della Murgia F. Perinei, Urologia, Altamura, Italy
- V106** **Transperineal biopsies using micro-ultrasound for prostate cancer.**
Authors: Rodríguez Socarrás M.E., Guzman Barraza J.D., Reinoso Elbers J., Gomez Rivas J.A., Carrion Monsalve D., Llanes Gonzalez L., Fernandez Del Alamo J., Ruiz Grana S., Cuadros Rivera V., Gomez Sancha F.
Institutes: Instituto de Cirugia Urologica Avanzada ICUA, Clinica Cemtro, Dept. of Urology, Madrid, Spain
- V107** **A single center evaluation of single use, disposable transperineal prostate biopsy guide with pivot feature**
Authors: Wang Y., Wilder S., Rogers C.G., Patel A.K.
Institutes: Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America
- V108** **The use of spacer in focal cryotherapy for rectal protection**
Authors: Yee C.H., Chiu P.K-F., Nicoletti R., Wong H.F., Teoh J.Y.C., Tam M.H.M., Chan Y-S., Chan C-K., Lo K.L., Chan W.H-C., Ng C.F.
Institutes: S.H. Ho Urology Centre, the Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong
- V109** **Targeted Microwaves Ablation for Localized Prostate Cancer (FOSTINE 1b): a Prospective Ablate-and-Resect Study**
Authors: Peltier A., Diamand R.
Institutes: Jules Bordet Institute, Dept. of Urology, Brussels, Belgium

V110

Single setting 3D MRI-US guided frozen section and focal cryoablation of the index lesion: oncologic and functional outcomes

Authors: Misuraca L., Brassetti A., Anceschi U., Ferriero M., Leonardo C., D'Annunzio S., Bove A.M., Guaglianone S., Tuderti G., Mastroianni R., Chiacchio G., Flammia R.S., Proietti F., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Challenging practice in continence surgery

Video session 15

08 April 2024
10:45 - 12:15

Location Green Area, S04
Chairs To be confirmed
H. Gresty, London (GB)
M.A. Perrouin Verbe, Nantes (FR)

- V111** **Robot-assisted laparoscopic artificial urinary sphincter insertion in 12 years old boy with neurogenic stress urinary incontinence**
Authors: Loubersac T.¹, De Vergie S.², Alliot H.¹, Leclair M.D.¹, Perrouin-Verbe M.A.²
Institutes: ¹University Hospital of Nantes, Dept. of Pediatric Urology, Nantes, France, ²University Hospital of Nantes, Dept. of Urology, Nantes, France
- V112** **Robotic-assisted laparoscopic implantation of artificial urinary sphincter in men with neurogenic stress urinary incontinence-Step by step technique**
Authors: Perrouin Verbe M.A., De Vergie S., Deniaud C., Paillusson D., De Guerry M-L., Rigaud J.
Institutes: Centre Hospitalo Universitaire de Nantes, Dept. of Urology, Nantes, France
- V113** **A comparative journey of Laparoscopic vs. Robotic approaches in Female Artificial Urinary Sphincter implantation**
Authors: Sanchez A., Viegas Madrid V.N., Velasco Balanza C., Casado Varela J., Saavedra Centeno M., González Rodríguez F.J., Costal M., Albers Acosta E.M., Celada Luis G., San José Manso L.A., Lopez-Fando Lavalle L.
Institutes: Hospital Universitario La Princesa, Dept. of Urology, Madrid, Spain
- V114** **The ABCs of Complicated Artificial Urinary Sphincter Insertion: The Tunical Flap Technique**
Authors: Al Saffar H., Kieran S., Deniel M.
Institutes: Peter MacCallum Cancer Centre, Dept. of Genitourinary Cancer Surgery, Melbourne, Australia
- V115** **AMS800 artificial urinary sphincter: a novel modified easier technique**
Authors: Morra I.M.¹, Ola L.¹, Dalmaso E.¹, Aimar R.¹, Ragni F.², De Cillis S.T.², Fiori C.²
Institutes: ¹AO Santa Croce e Carle Hospital, Dept. of Urology, Cuneo, Italy, ²AOU San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy
- V116** **The adjustable sling ATOMS SSP proximal implantation technique - Updated outcome of revised patients and step by step surgery video**
Authors: Queißert F., Bruecher B., Hakenes T.H., Seitzer K.S., Schrader A.J.S.
Institutes: University Hospital Muenster, Dept. of Urology and Pediatric Urology, Muenster, Germany
- V117** **Operative technique of the retro-urethral transobturator bulbar support sling**
Authors: Rehder P., Kink P., Tulchiner G., Jelisejevas L.
Institutes: Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria

V118

Vulko the New Adjustable Sling for Male Incontinence - Preliminary Results

Authors: Hübner W.A.¹, Cobreros C.², Gonzalez M.³, Olmedo J.⁴

Institutes: ¹Clinic of Korneuburg, Dept. of Urology, Kornruburg, Austria,

²Sanatorio Finochietto, Dept. of Urology, Cordoba, Argentina, ³Hospital

Italiano, Dept. of Urology, Buenos Aires, Argentina, ⁴FUCDIM, Dept. of Urology, Cordoba, Argentina

Fertility frustrations: 9 Dilemmas in men's reproductive health

Thematic Session

08 April 2024
10:45 - 12:15

Location Green Area, W01
Chairs Z. Kopa, Budapest (HU)
A. Salonia, Milan (IT)

10:45 - 10:52	Isolated teratozoospermia: Causes, work-up and management M. Dinkelman-Smit, Rotterdam (NL)
10:52 - 10:55	Discussion
10:55 - 11:02	Failed TESE: Repeat or explore donor insemination? C.F.S. Jensen, Herlev (DK)
11:02 - 11:05	Discussion
11:05 - 11:12	Ejaculatory duct obstruction: Desobstruct or TESE? V. Modgil, Manchester (GB)
11:12 - 11:15	Discussion
11:15 - 11:22	Should you perform orchidopexy in adults with cryptorchidism discovered at infertility work-up? T. Diemer, Giessen (DE)
11:22 - 11:25	Discussion
11:25 - 11:32	Should you prescribe hormonal agents to optimise sperm-retrieval? J.M. Dupree, Ann Arbor (US)
11:32 - 11:35	Discussion
11:35 - 11:42	Should you treat asymptomatic positive semen culture? L. Boeri, Milan (IT)
11:42 - 11:45	Discussion
11:45 - 11:52	Should you treat varicocele in implantation failure? N. Sofikitis, Ioannina (GR)
11:52 - 11:55	Discussion
11:55 - 12:02	Should we give nutritional supplements to men with OAT? G.I. Russo, Catania (IT)
12:02 - 12:05	Discussion
12:05 - 12:12	Should we be administering any therapy that had not shown improved live birth rate? S. Minhas, London (GB)
12:12 - 12:15	Discussion

Joint Session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Urology Beyond Europe

05 April 2024
10:45 - 12:45

Location Green Area, S06
Chairs P. Black, Vancouver (CA)
C.R. Chapple, Sheffield (GB)

10:45 - 10:50

Introduction
P. Black, Vancouver (CA)
C.R. Chapple, Sheffield (GB)

10:50 - 11:30

Bladder cancer
Moderator P. Black, Vancouver (CA)

10:50 - 11:00

State-of-the-art lecture Integrating urine markers into clinical practice
To be confirmed

11:00 - 11:14

Debate Blue-light cystoscopy at the time of TURBT remains standard of care for patients with non-muscle invasive bladder cancer

Pro D.R. Siemens, Kingston, Ontario (CA)
Con R. Heer, London (GB)

11:14 - 11:20

Panel discussion

Moderator P. Black, Vancouver (CA)
Panel D.R. Siemens, Kingston, Ontario (CA)
R. Heer, London (GB)
To be confirmed

11:20 - 11:30

State-of-the-art lecture Pelvic lymph node dissection at the time of radical cystectomy: where do we stand?
G. Kulkarni, Toronto (CA)

11:30 - 12:15

Prostate cancer
Moderator A. De La Taille, Créteil (FR)

11:30 - 11:40

State-of-the-art lecture Neoadjuvant therapy for high risk prostate cancer
N. Fleshner, Toronto (CA)

11:40 - 11:45

Case presentation: Oligometastatic prostate cancer
A. De La Taille, Créteil (FR)

11:45 - 11:55

Optimal systemic therapy
Y.Ü. Ürün, Ankara (TR)

11:55 - 12:05

Radiation of the primary and the metastases
P. Ost, Ghent (BE)

12:05 - 12:15	Panel discussion	Moderator	A. De La Taille, Créteil (FR)
		Panel	Y.Ü. Ürün, Ankara (TR) P. Ost, Ghent (BE) To be confirmed
12:15 - 12:45	Kidney cancer	Moderator	To be confirmed
12:15 - 12:25	State-of-the-art lecture	Molecular imaging of kidney tumours	
		M. Tran, London (GB)	
	Debate	Optimal management of complex renal cysts	
12:25 - 12:32	Active surveillance	To be confirmed	
12:32 - 12:39	Surgical management	A. Volpe, Novara (IT)	
12:39 - 12:45	Panel discussion	Moderator	To be confirmed
		Panel	A. Volpe, Novara (IT) M. Tran, London (GB) To be confirmed

Basic research and trials: locally advanced and metastatic bladder cancer

Abstract session 43

08 April 2024
10:45 - 12:15

Location Green Area, W03
Chairs To be confirmed
R. Seiler, Bern (CH)
A. Vlahou, Athens (GR)

10:45 - 10:47

Introduction

A0871

Bladder Cancer Patient-Derived Organoids: a new frontier for personalized therapy

Authors: Mastroianni R.¹, Frascolla C.², Donzelli S.², Pulito C.², Russo A.³, Strano S.⁴, Costantini M.¹, Blandino G.², Simone G.¹

Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Translational Oncology Research Unit, Rome, Italy, ³IRCCS Regina Elena National Cancer Institute, Pathology Unit, Rome, Italy, ⁴IRCCS Regina Elena National Cancer Institute, SAFU Unit, Rome, Italy

A0870

Patient-Derived Organoids: 3D miniature models of Bladder Cancer

Authors: Mastroianni R.¹, Frascolla C.², Donzelli S.², Orlandi G.³, Scalerà S.⁴, Ciuffreda L.⁵, Di Martino S.⁶, Russo A.⁷, Strano S.⁵, Costantini M.¹, Blandino G.², Simone G.¹

Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Translational Oncology Research Unit, Rome, Italy, ³IRCCS San Gallicano Dermatological Institute, Dept. of Microbiology and Virology, Rome, Italy, ⁴IRCCS Regina Elena National Cancer Institute, Clinical Trial Center Biostatistics and Bioinformatics, Rome, Italy, ⁵IRCCS Regina Elena National Cancer Institute, SAFU Unit, Rome, Italy, ⁶IRCCS Regina Elena National Cancer Institute, Dept. of Pathology, Rome, Italy, ⁷IRCCS Regina Elena National Cancer Institute, Pathology Unit, Rome, Italy

A0872

Prospective standardization of organoid-based pharmacotyping in urothelial carcinoma

Authors: Melzer M.K.¹, Ma Y.¹, Lindenmayer J.², Zengerling F.¹, Wezel F.¹, Günes C.¹, Kleger A.², Bolenz C.¹

Institutes: ¹Ulm University Hospital, Dept. of Urology, Ulm, Germany, ²Ulm University, Core Facility Organoids, Ulm, Germany

A0869

Bladder cancer organoids: a reliable tool for validation of in vitro new therapeutic approaches.

Authors: Decaup E.¹, Beraud C.¹, Bajeot A-S.², Gamé X.², Monjotin N.¹, Rischmann P.², Lluet P.¹, Roumiguié M.²

Institutes: ¹UROSPHERE, Dept. of Oncology, Toulouse, France, ²CHU Toulouse, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France

- A0876** **Cancer vaccine improves the efficacy of immune checkpoint inhibitor against refractory cancers**
Authors: Ueda S.¹, Ushijima M.¹, Irie A.², Senju S.², Ito K.³, Hamana H.⁴, Udaka K.⁵, Kishi H.⁴, Ogasawara K.³, Nishimura Y.², Eto M.¹
Institutes: ¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Kumamoto University, Dept. of Immunology, Kumamoto, Japan, ³Tohoku University, Dept. of Immunobiology, Sendai, Japan, ⁴Toyama University, Dept. of Immunology, Toyama, Japan, ⁵Kochi University, Dept. of Immunology, Nankoku, Japan
- A0864** **Estrogen receptor β signaling activity modulates the radio-sensitivity in bladder cancer cells**
Authors: Ide H.¹, Murakami T.¹, Kashiwagi E.², Kitaoka S.³, Komatsuda A.³, Nishimura C.³, Oya M.¹, Miyamoto H.⁴
Institutes: ¹Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Kyushu University Hospital, Dept. of Urology, Fukuoka, Japan, ³Tokyo Saiseikai Hospital, Dept. of Urology, Tokyo, Japan, ⁴University of Rochester Medical Center School of Medicine and Dentistry, Dept. of Pathology, Rochester, United States of America
- A0866** **Dynamic transition from NMIBC to MIBC in the bladder cancer rely on stiffness microenvironment determined methionine metabolism**
Authors: Yang C., Zhou Q., Chen W., Chen Y., Jiang H.
Institutes: Huashan Hospital, Dept. of Urology, Shanghai, China
- A0862** **A miRNA signature defines invasiveness with high accuracy and is associated with molecular subtypes in bladder cancer**
Authors: Eckhart L.¹, Rau S.², Eckstein M.³, Stahl P.⁴, Heinzlbecker J.², Hartmann A.³, Stöckle M.², Lenhof H.P.¹, Junker K.²
Institutes: ¹Saarland University, Center of Bioinformatics, Homburg, Germany, ²Saarland University and Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany, ³University Hospital Erlangen, Institute of Pathology, Erlangen, Germany, ⁴Saarland University and Saarland University Medical Center, Institute of Pathology, Homburg, Germany
- A0867** **Germline variants linked to ovarian and bladder cancer in females: Is ovary sparing radical cystectomy an option?**
Authors: Davis L.¹, Calaway A.¹, Avulova S.², Correa A.³, Kutikov A.³, Magee D.³, Uzzo R.³, Ponsky L.¹, Abbosh P.³, Bukavina L.³
Institutes: ¹University Hospitals Cleveland Medical Center, Dept. of Urology, Cleveland, United States of America, ²Albany Medical Center, Dept. of Urology, Albany, United States of America, ³Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America
- A0865** **Tumor infiltrating CD39+ CD8+ T cells mediate anti-tumor immunity and determine better prognosis in bladder cancer**
Authors: Zhao Z., Zhu W., Jin Q., Guo H., Yang R.
Institutes: Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China
-

A0874

The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC)

Authors: Tateo V.¹, Gibb E.A.², Mercinelli C.¹, Raggi D.¹, Cigliola A.¹, Patanè D.A.¹, Crupi E.¹, Giannatempo P.³, Colecchia M.⁴, Moschini M.⁵, Avesani G.⁵, Briganti A.⁵, Montorsi F.⁵, Santini D.⁶, Necchi A.¹

Institutes: ¹IRCCS San Raffaele Hospital, Dept. of Oncology, Milan, Italy, ²Veracyte, Dept. of Bladder Cancer, Vancouver, Canada, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Oncology, Milan, Italy, ⁴IRCCS San Raffaele Hospital, Dept. of Pathology, Milan, Italy, ⁵IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁶Policlinico Umberto I La Sapienza, Dept. of Oncology, Milan, Italy

A0875

Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC)

Authors: Mercinelli C.¹, Raggi D.¹, Cigliola A.¹, Tateo V.¹, Patanè D.A.¹, Crupi E.², Colecchia M.³, Moschini M.⁴, Re C.⁴, Avesani G.⁴, Briganti A.⁴, Montorsi F.⁴, Ross J.S.⁵, Graf R.⁶, Pavlick D.C.⁷, Necchi A.¹

Institutes: ¹IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ²Vita-Salute San Raffaele University, Dept. of Medical Oncology, Milan, Italy, ³IRCCS San Raffaele Hospital, Dept. of Pathological Anatomy, Milan, Italy, ⁴IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁵SUNY Upstate Medical University, Dept. of Pathology, Syracuse, United States of America, ⁶Foundation Medicine Inc., Dept. of Biomedical Science, Boston, United States of America, ⁷Foundation Medicine Inc., Pathology and Cancer Genomics Departments, Cambridge, United States of America

A0861

Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

Authors: Nakauma-González J.A.¹, Bahlinger V.², Van Doeveren T.¹, Van De Werken H.J.G.³, Helleman J.¹, Pasanisi J.⁴, Masliah Planchon J.⁴, Bieche I.⁴, Wilhelm T.⁴, Lara M.F.⁵, García-Morales L.⁶, Eckstein M.², Stöhr R.², Sikic D.⁷, García Muñoz I.⁸, Prieto Cuadra J.D.⁸, Lozano M.J.⁹, Álvarez M.¹⁰, Matas-Rico E.¹⁰, Hartmann A.², Herrera-Imbroda B.¹⁰, Allory Y.¹¹, Boormans J.L.¹

Institutes: ¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²University Hospital Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, ³Erasmus MC Cancer Institute, Dept. of Immunology, Rotterdam, The Netherlands, ⁴Institut Curie, Dept. of Genetics, Paris, France, ⁵Málaga University, Dept. of Surgical Specialties, Biochemistry and Immunology, Málaga, Spain, ⁶Reina Sofía University Hospital, Dept. of Urology, Córdoba, Spain, ⁷Friedrich-Alexander-University Erlangen-Nuremberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, ⁸Hospital Universitario Virgen de la Victoria, Dept. of Pathological Anatomy, Málaga, Spain, ⁹Málaga University, Dept. of Pathology, Málaga, Spain, ¹⁰Instituto de Investigación Biomédica de Málaga, Genitourinary Cancer Translational Research Group, Málaga, Spain, ¹¹Institut Curie, Dept. of Pathology, Paris, France

A0868

Amiodarone, an anti-arrhythmic drug, is a new repurposed drug for bladder cancer therapy

Authors: [Roa F.J.](#)¹, [Roubelakis M.G.](#)², [Paschidis K.](#)², [Van Creij N.C.H.](#)¹, [Makridakis M.](#)³, [Tserga A.](#)³, [Vlahou A.](#)³, [Santer F.R.](#)¹, [Holm P.S.](#)⁴, [Hoffmann M.J.](#)⁵, [Puhr M.](#)¹, [Mokou M.](#)⁶, [Frantzi M.](#)⁶, [Latosinska A.](#)⁶, [Mischak H.](#)⁶, [Culig Z.](#)¹, [Pichler R.](#)¹

Institutes: ¹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ²National and Kapodistrian University of Athens, Laboratory of Biology, Athens, Greece, ³Academy of Athens, Biomedical Research Foundation, Athens, Greece, ⁴Medical University of Innsbruck, Dept. of Oral and Maxillofacial Surgery, Innsbruck, Austria, ⁵Heinrich Heine University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ⁶Mosaiques Diagnostics, Dept. of Biomarker Research, Hannover, Germany

A0873

Single-cell RNA-seq analysis reveals the role of tumor-associated neutrophils and neutrophil extracellular traps in upper tract urothelial carcinoma

Authors: [Wang Y.](#)¹, [Shen X.E.](#)², [Gu D.](#)¹, [Shen Y.F.](#)³, [Fan L.J.](#)², [Ruan J.](#)⁴, [Zhao P.](#)⁴, [Li M.Z.](#)¹, [Huang Y.T.](#)¹, [Long X.Z.](#)¹

Institutes: ¹The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ²Zhejiang University, Institute of Bioinformatics, Hangzhou, China, ³The First Affiliated Hospital Zhejiang University School of Medicine, Dept. of Laboratory Medicine, Hangzhou, China, ⁴The First Affiliated Hospital Zhejiang University School of Medicine, Dept. of Medical Oncology, Hangzhou, China

A0860

Assessment of cancer cell invasion and high-throughput screenings in a novel ex vivo murine bladder tissue model

Authors: [Gunes C.](#), [Liu J.](#), [Jiang W.](#), [Wang X.](#), [Azoitei A.](#), [Melzer M.](#), [Wezel F.](#), [Bolenz C.](#)

Institutes: Ulm University, Dept. of Urology, Ulm, Germany

A0863

Urachal (U) and Non-Urachal (NU) adenocarcinomas (adenoCA) of the bladder: A comparative comprehensive genomic profiling (CGP) study

Authors: [Cigliola A.](#)¹, [Basnet A.](#)², [Jacob J.](#)³, [Bratslavsky G.](#)³, [Cheng L.](#)⁴, [Grivas P.](#)⁵, [Kamat A.M.](#)⁶, [Spiess P.E.](#)⁷, [Dean P.](#)⁸, [Lin D.I.](#)⁸, [Ross J.S.](#)⁸, [Necchi A.](#)¹

Institutes: ¹IRCCS San Raffaele Hospital, Dept. of Oncology, Milan, Italy, ²SUNY Upstate Medical University, Division of Hematology Oncology, New York, United States of America, ³SUNY Upstate Medical University, Dept. of Urologic Surgery Oncology, New York, United States of America, ⁴Warren Alpert Medical School of Brown University, Lifespan Academic Medical Center, Dept. of Pathology and Laboratory Medicine, Providence, United States of America, ⁵University of Washington, Dept. of Medicine Division of Medical Oncology, Washington, United States of America, ⁶The UT M D Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁷Moffitt Cancer Center, Dept. of GU Oncology, Florida, United States of America, ⁸Foundation Medicine, Dept. of Pathology and Cancer Genomics, Cambridge, United Kingdom

12:12 - 12:15

Expert summary

R. Seiler, Bern (CH)

Andrology: Male infertility and hypogonadism

Abstract session 44

08 April 2024
10:45 - 12:15

Location Green Area, W06
Chairs To be confirmed
To be confirmed
To be confirmed

10:45 - 10:47

Introduction

10:47 - 11:12

Diagnostic innovation

A0883

DeepSperM: A machine learning based model that facilitates sperm identification through touch print smear cytology of testicular specimen from patients with azoospermia

Authors: Hsu C.H.¹, Tsai C.H.¹, Chen W-J.¹, Huang I.S.¹, Peng Y.C.², Ko M.C.³, Tu E.³, Huang W.J.¹

Institutes: ¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Pathology and Laboratory Medicine, Taipei, Taiwan, ³Taiwan AI Labs, Dept. of Medical Imaging, Taipei, Taiwan

A0890

Innovation in clinical diagnosis of male infertility: validation study and a 6-month experience using whole exome sequencing

Authors: D'Hauwers K.W.¹, Oud M.S.², Van Der Heijden G.W.³, Timmermans R.G.J.², Van De Vorst M.², Hofste T.², de Leeuw N.², Smeets D.F.C.M.², Ramos L.³, Faas B.H.W.², Westra D.²

Institutes: ¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ²Radboud University Medical Center, Dept. of Human Genetics, Nijmegen, The Netherlands, ³Radboud University Medical Center, Dept. of Obstetrics and Gynecology, Nijmegen, The Netherlands

A0882

Karyotype alterations and Y chromosome microdeletion prevalence among patients with nonobstructive azoospermia - findings from a large multi-center cross-sectional study

Authors: Pozzi E.¹, Venigalla G.², Raymo A.², Ila V.², Belladelli F.¹, Bertini A.¹, Corsini C.¹, Raffo M.¹, Negri F.¹, D'Arma A.¹, Montorsi F.¹, Ramasamy R.², Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Desai Sethi Urology Institute, Dept. of Urology, Miami, United States of America

A0879

Predictors of Abnormal DNA Fragmentation Index and Successful Pregnancy

Authors: Nguyen V., Fan A., Patel D.P., Hsieh T.C.

Institutes: University of California San Diego, Dept. of Urology, San Diego, United States of America

A0887

Potential of testis-derived circular RNAs in seminal plasma to predict the outcome of microdissection testicular sperm extraction in patients with idiopathic non-obstructive azoospermia

Authors: Song N., Ji C.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

11:12 - 11:42

Male infertility in context

A0877

May Assisted Reproductive Techniques outcomes impact on overall health parameters in infertile men?

Authors: Belladelli F.¹, Pozzi E.¹, Corsini C.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Ventimiglia E.¹, Fallara G.², Boeri L.³, Capogrosso P.⁴, Dehò F.⁴, d'Arma A.¹, Pagliardini L.⁵, Papaleo E.⁵, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ⁴ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy, ⁵IRCCS Ospedale San Raffaele, Dept. of Obstetrics and Gynaecology, Milan, Italy

A0885

Revealing the disability and illness burden in infertile men: key findings from a long-term longitudinal study utilizing the Years Lived with Disability metric

Authors: Negri F.¹, Pozzi E.¹, Bertini A.¹, Raffo M.¹, Belladelli F.¹, Corsini C.¹, Cattafi F.¹, Oddo M.¹, Malvestiti M.¹, Boeri L.², Fallara G.³, Ventimiglia E.¹, Capogrosso P.⁴, Dehò F.⁴, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ³European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁴ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy

A0888

Long-term comorbidity trends among men with primary infertility: findings from a long term comprehensive longitudinal study

Authors: Pozzi E.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Belladelli F.¹, Corsini C.¹, Cattafi F.¹, Malvestiti M.¹, Candela L.¹, Fallara G.², Ventimiglia E.¹, Boeri L.³, Capogrosso P.⁴, Dehò F.⁴, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ⁴ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy

A0884

The incidence of male breast cancer in Klinefelter's syndrome and its proposed mechanisms

Authors: Cook B.D., Nayar S.

Institutes: King's College London, FoLSM, London, United Kingdom

A0881

Exploring the landscape of idiopathic Non-Obstructive Azoospermia at two tertiary referral centers: BMI as a Significant Predictor of Hormonal Profiles and Implications for Medical Intervention

Authors: Pozzi E.¹, Venigalla G.², Raymo A.², Ila V.², Negri F.¹, Boeri L.³, Bertini A.¹, Belladelli F.¹, Corsini C.¹, D'Arma A.¹, Francesco M.¹, Andrea S.¹, Ranjith R.²

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Desai Sethi Urology Institute, Dept. of Urology, Miami, United States of America, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy

A0878

Unravelling familial ties: elevated sperm DNA fragmentation index in infertile men and familial cancer susceptibility

Authors: Belladelli F.¹, Pozzi E.¹, Bertini A.¹, Corsini C.¹, Raffo M.¹, Negri F.¹, Cattafi F.¹, Ventimiglia E.¹, Fallara G.², Matloob R.¹, Boeri L.³, Capogrosso P.⁴, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ⁴ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy

A1106

Cardiac structure and function in men with erectile dysfunction

Authors: Durukan E.¹, Jensen C.F.S.D.¹, Dons M.², Sengeløv M.², Landler N.E.², Skaarup K.G.², Østergren P.B.¹, Sønksen J.¹, Biering-Sørensen T.², Fode M.¹

Institutes: ¹Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ²Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Cardiology, Gentofte, Denmark

11:42 - 11:47

Outcomes

A0889

Reproductive outcomes in infertile couples undergoing intracytoplasmic sperm injection with a male partner exhibiting chromosomal translocation or inversion

Authors: Wu Y-L., Huang I.S., Huang E.Y.H., Chen W-J., Tsai C.H., Huang W.J.S.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

11:47 - 12:07

Hypogonadism and testosterone therapy

A0893

Are reference intervals for free testosterone in healthy men reliable also in men with erectile dysfunction? Findings from a cross-sectional study

Authors: Boeri L.¹, Pozzi E.², Belladelli F.², Bertini A.², Corsini C.², Raffo M.², Negri F.², Oddo M.², Candela L.², Fallara G.³, Capogrosso P.⁴, Zahiti L.⁵, Mattei A.⁵, Dehò F.⁴, Montanari E.¹, d'Arma A.¹, Montorsi F.², Salonia A.²

Institutes: ¹Fondazione IRCCS Ca Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ³European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁴ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy, ⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland

A0880

Effectiveness of long-term testosterone therapy for up to 15 years on erectile function and sexual activity in men with functional hypogonadism

Authors: Haider A.¹, Haider K.S.¹, Doros G.², Traish A.³

Institutes: ¹Praxis Dr.Haider, Praxis Dr. Haider, Bremerhaven, Germany, ²Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, ³Boston University School of Medicine, Dept. of Biochemistry and Dept. of Urology, Boston, United States of America

A0891

Is testosterone replacement therapy effective and safe even for eugonadal men with symptom of late onset hypogonadism?

Authors: Ishikawa K.¹, Sano M.¹, Anno Y.¹, Taniguchi A.¹, Kure A.¹, Uesaka Y.¹, Nozaki T.¹, Shirai M.¹, Kobayashi K.², Horie S.³, Tsujimura A.¹

Institutes: ¹Juntendo University Urayasu Hospital, Dept. of Urology, Urayasu, Japan, ²D Clinic Tokyo, Dept. of Urology, Tokyo, Japan, ³Juntendo University Graduate School of Medicine, Dept. of Urology, Tokyo, Japan

A0892

Chatbots vs andrologists : testing 25 clinical cases

Authors: Perrot O.¹, Schirmann A.L.¹, Vidant A.¹, Guillot-Tantay C.¹, Izard V.¹, Leuret T.¹, Boillot B.¹, Mesnard B.¹, Lebacle C.², Francois-Xavier M.¹

Institutes: ¹Foch Hospital, Dept. of Urology, Suresnes, France, ²Kremlin-Bicetre Hospital, Dept. of Urology, Kremlin Bicetre, France

12:07 - 12:12

Hormones and gender

A0886

Transgender men can achieve adequate muscular development through low-dose testosterone therapy: A Long-term Study on Body Composition Changes

Authors: Tominaga Y.¹, Kobayashi T.¹, Matsumoto Y.², Moriwake T.¹, Sadahira T.¹, Katayama S.¹, Iwata T.¹, Nishimura S.¹, Bekku K.¹, Edamura K.¹, Kobayashi Y.¹, Watanabe M.³, Araki M.¹

Institutes: ¹Okayama University, Dept. of Urology, Okayama, Japan, ²Good Life Hospital, Dept. of Urology, Hiroshima, Japan, ³Okayama University, Center for Innovative Clinical Medicine, Okayama, Japan

12:12 - 12:15

Expert summary

Adverse pathology at pathology, imaging for risk assessment and local staging

EGPT 12

**08 April 2024
10:45 - 12:15**

Location EGPT
Chairs R.J. Bryant, Oxford (GB)
To be confirmed

10:45 - 10:57

P335

Screen A: Significance of Intraductal or cribriform patterns at biopsy

The Individual and Combined role of MRI and PSMA PET/CT For Predicting Seminal Vesicle Invasion: A Prospective Multi-Center Study.

Authors: Kang S.¹, Sitharthan D.², Treacy P.J.³, Karunaratne S.³, Bird J.³, Alexander K.³, Leslie S.⁴, Chan L.⁵, Steffens D.³, Thanigasalam R.⁴

Institutes: ¹The University of Sydney, Faculty of Medicine and Health, Sydney, Australia, ²Bankstown Hospital, Dept. of Urology, Sydney, Australia, ³Royal Prince Alfred Hospital, Surgical Outcomes Research Centre, Sydney, Australia, ⁴Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia, ⁵Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia

P347

Cribriform pattern associated lymphatic metastases detected by prostate-specific membrane antigen in post-radical prostatectomy biochemically recurrent patients

Authors: Marques Bernardino R.M.¹, Sayyid R.¹, Zizo A.D.¹, Cockburn J.¹, Leao R.², Berjaoui M.¹, Metser U.³, Berlin A.⁴, Van Der Kwast T.⁵, Fleshner N.¹

Institutes: ¹University of Toronto Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Portugal, ²Hospital Cuf Coimbra, Coimbra, Portugal, ³University of Toronto, Princess Margaret Cancer Centre, Dept. of Imagiology, Toronto, Canada, ⁴University of Toronto, Princess Margaret Cancer Centre, Dept. of Radiation Oncology, Toronto, Canada, ⁵University of Toronto, Princess Margaret Cancer Centre, Dept. of Pathology, Toronto, Canada

P333

The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate: from whole mount histology to [68Ga]Ga-PSMA-11 PET/CT

Authors: Zheng H.¹, Shan P.², Binyu W.¹, Yao F.², Fengjiao Y.³, Shuyue A.³, Feng W.³, Junlong Z.¹, Hongqian G.¹, Xuefeng Q.¹

Institutes: ¹Nanjing University Medical School Affiliated Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²Nanjing University Medical School Affiliated Drum Tower Hospital, Dept. of Pathology, Nanjing, China, ³Nanjing First Hospital, Dept. of Nuclear Medicine, Nanjing, China

- P346** **Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases through 18F-DCFPyL-PSMA-PET/CT Scans in Pre-Treatment Prostate Cancer Patients**
Authors: Marques Bernardino R.M.¹, Sayyid R.¹, Lajkosz K.², Al-Daqqaq Z.¹, Cockburn J.¹, Leao R.³, Metser U.⁴, Berlin A.⁴, Van Der Kwast T.⁵, Fleshner N.¹
Institutes: ¹University of Toronto, Princess Margaret Cancer Centre, Division of Urology, Dept. of Surgical Oncology, Toronto, Canada, ²University of Toronto, Princess Margaret Cancer Centre, Dept. of Statistics, Toronto, Canada, ³Cuf Hospitais, Dept. of Urology, Lisbon, Portugal, ⁴University of Toronto, Princess Margaret Cancer Centre, Joint Department of Medical Imaging, Toronto, Canada, ⁵University of Toronto, Dept. of Laboratory Medicine and Pathobiology, Toronto, Canada
- 10:57 - 11:15** **Screen B: Imaging and prediction of adverse pathology events**
- P321** **Association between PSMA PET intraprostatic SUVmax and post radical prostatectomy pathology: A systematic review and meta-analysis**
Authors: Chen D., Huang S., Papa N., Lawrentschuk N., Murphy D.G., Perera M.
Institutes: Peter MacCallum Cancer Centre, Dept. of Cancer Surgery, Melbourne, Australia
- P348** **Value of 68Ga-PSMA PET/CT compared to mpMRI for primary tumor characterization based on radical prostatectomy histopathology**
Authors: Lim J.S.¹, Yun O.J.¹, Kang J.H.¹, Lee S.H.¹, Kang J.K.¹, Jo I.², Chung J-W.¹, Ha Y.S.¹, Choi S.H.¹, Lee J.N.¹, Kim B.S.¹, Jeong S.Y.², Kim H.T.¹, Kim T.H.¹, Yoo E.S.¹, Kwon T.G.¹
Institutes: ¹Kyungpook National University School of Medicine, Dept. of Urology, Daegu, South Korea, ²Kyungpook National University School of Medicine, Dept. of Nuclear Medicine, Daegu, South Korea
- P343** **Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-labeled PSMA-ligand positron emission tomography/computed tomography and multiparameter magnetic resonance imaging: A Single-centre, Prospective, Single-arm Trial**
Authors: Niu S.¹, Wang B.J.¹, Liu Y.C.², Wang H.Y.³, Ding X.H.⁴, Zhang X.¹
Institutes: ¹Chinese PLA General hospital, Dept. of Urology, Beijing, China, ²Chinese PLA General hospital, Dept. of Nuclear Medicine, Beijing, China, ³Chinese PLA General hospital, Dept. of Radiology, Beijing, China, ⁴Chinese PLA General hospital, Dept. of Pathology, Beijing, China

- P340** **Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant Prostate cancer.**
Authors: Emmett L.¹, Papa N.², Hope T.³, Fendler W.⁴, Calais J.⁵, Burger I.⁶, Eiber M.⁷, Barbato F.⁴, Moon D.⁸, Xue A.⁹, Franklin A.¹⁰, Thompson J.¹¹, Rasiah K.¹², Frydenberg M.⁹, Yaxley J.¹³, Buteau J.¹⁴, Liu V.¹, Nguyen A.¹, Hsiao E.¹⁵, Stricker P.¹¹, Hofman M.¹⁴, Kasivisvanathan V.¹⁶, Roberts M.¹⁰, Murphy D.⁸
Institutes: ¹St Vincent's Hospital Sydney Australia, Dept. of Theranostics and Nuclear Medicine, Sydney, Australia, ²Garvan Institute of Medical Research, Dept. of Statistics, Sydney, Australia, ³University of California, Dept. of Radiology and Biomedical Imaging, San Francisco, United States of America, ⁴University of Duisburg-Essen, Dept. of Nuclear medicine, Essen, Germany, ⁵David Geffen School of Medicine at UCLA, Dept. of Molecular and Medical Pharmacology, Los Angeles, United States of America, ⁶Kantonsspital, Dept. of Nuclear Medicine, Baden Baden, Switzerland, ⁷Technical University Munich, Dept. of Nuclear Medicine, Munich, Germany, ⁸Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ⁹Monash University, Dept. of Surgery, Melbourne, Australia, ¹⁰Royal Brisbane and Womens Hospital, Dept. of Urology, Brisbane, Australia, ¹¹St Vincent's Hospital Sydney Australia, Dept. of Urology, Sydney, Australia, ¹²Royal North Shore Hospital, Dept. of Urology, Sydney, Australia, ¹³The Wesley Hospital, Dept. of Urology, Brisbane, Australia, ¹⁴Peter MacCallum Cancer Centre, Dept. of Nuclear Medicine, Melbourne, Australia, ¹⁵Royal North Shore Hospital, Dept. of Nuclear Medicine, Sydney, Australia, ¹⁶University College London, Division of Surgery and Interventional Science, London, United Kingdom
- P342** **Correlation of intraprostatic SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.**
Authors: Preisser F., Nohe F., Maurer T., Graefen M., Tilki D.
Institutes: University Hospital Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany
- P330** **PSMA-PET vs. conventional imaging for preoperative staging high-risk PCa patients underwent surgery for cN0M0 disease**
Authors: Bianchi L.¹, Valerio M.², Novello Q.², Balestrazzi E.¹, Bevilacqua F.¹, Nanni L.¹, Droghetti M.¹, Piazza P.¹, Gandaglia G.³, Ceci F.⁴, Farolfi A.⁵, Fanti S.⁵, Briganti A.³, Montorsi F.³, Schiavina R.¹, Brunocilla E.¹
Institutes: ¹IRCCS Azienda Ospedaliero-universitaria di Bologna, Division of Urology, Bologna, Italy, ²Geneva University Hospital, University of Geneva, Dept. of Urology, Geneva, Switzerland, ³IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Experimental Oncology Urological Research Institute, Milan, Italy, ⁴IEO European Institute of Oncology IRCCS, Division of Nuclear Medicine, Milan, Italy, ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, Italy

11:15 - 11:30

Screen C: Imaging and risk of progression

- P327** **Validation of the EAU Risk Groups for Radical Prostatectomy Prostate Cancer Patients Who Experienced Biochemical Recurrence Restaged with PSMA PET Imaging and Development of a Novel Tool**
Authors: Longoni M.¹, Barletta F.M.¹, Gandaglia G.¹, Mazzone E.¹, Stabile A.¹, Robesti D.¹, Quarta L.¹, Bandini M.¹, Cucchiara V.¹, Pellegrino F.¹, Scuderi S.¹, Cirulli G.O.¹, Scilipoti P.¹, Bianchi M.¹, Samanes Gajate A.M.², Picchio M.², Chiti A.², Karakiewicz P.I.³, Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ³Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada
- P323** **PI-RADS score 5 is a strong predictor for rapid prostate cancer specific death**
Authors: Shadbahr T.¹, Pylväläinen J.¹, Hoffström J.¹, Kenttämies A.², Mirtti T.¹, Laajala T.D.¹, Rannikko A.¹
Institutes: ¹University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland, ²Helsinki University Hospital, Dept. of Radiology, Helsinki, Finland
- P349** **Multi-Institutional Development and Validation of a Radiomic Model to Predict Prostate Cancer Recurrence following Radical Prostatectomy**
Authors: Huynh L.¹, Bonebrake B.¹, Tran J.², Marasco J.¹, Ahlering T.², Wang S.¹, Baine M.¹
Institutes: ¹University of Nebraska Medical Center, Dept. of Radiation Oncology, Omaha, United States of America, ²University of California Irvine, Dept. of Urology, Orange, United States of America

P338

Can We Rely on Available Models Predicting Pathological Outcomes in Prostate Cancer Patients Staged With 68-Ga PSMA-PET/CT? External Validation of the Existing Nomograms for Extracapsular Extension and Seminal Vesicle Invasion at Radical Prostatectomy and Development of a Novel Tool Including Intraprostatic SUVmax

Authors: Scuderi S.L.A.¹, Rajwa P.², Gomez-Rivas J.³, Bianchi L.⁴, Kesch C.³, Darr C.³, Guo H.⁵, Zhuang J.⁵, Zattoni F.⁶, Fendler W.⁷, Marra G.⁸, Huebner N.⁹, Joniau S.¹⁰, Schiavina R.¹¹, Mattei A.¹², Fiori C.¹³, Porpiglia F.¹³, Picchio M.¹⁴, Chiti A.¹⁴, Van Den Bergh R.¹⁵, Shariat S.², Montorsi F.¹⁶, Briganti A.¹⁶, Gandaglia G.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Essen University Hospital, Dept. of Urology, Essen, Germany, ⁴IRCCS Azienda ospedaliero universitaria di Bologna, Division of Urology, Bologna, Italy, ⁵Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Jiangsu, China, ⁶University of Padua, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy, ⁷Essen University Hospital, Dept. of Nuclear Medicine, Essen, Germany, ⁸Città della Salute e della Scienza University of Turin, Dept. of Urology, Turin, Italy, ⁹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁰University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹¹IRCCS Azienda ospedaliero universitaria di Bologna, Dept. of Urology, Bologna, Italy, ¹²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ¹³San Luigi Hospital University of Turin, Division of Urology, Dept. of Oncology School of Medicine, Turin, Italy, ¹⁴IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹⁵Antonius Hospital Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹⁶IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

P331

Accuracy of the MRI 5-point Likert score to predict extra-prostatic extension and seminal vesicle invasion in patients undergoing radical prostatectomy for prostate cancer and development of a new MRI-based nomogram.

Authors: Pellegrino F.¹, Falagario U.G.¹, Proietti F.², Brasetti A.², Hagman A.¹, Briganti A.³, Montorsi F.³, Carrieri G.⁴, Lantz A.¹, Akre O.¹, Aly M.¹, Egevad L.⁵, Jaderling F.¹, Wiklund P.¹

Institutes: ¹Karolinska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ³IRCCS San Raffaele Hospital, Unit of Urology, Division of Oncology, Milan, Italy, ⁴University of Foggia, Dept. of Urology, Foggia, Italy, ⁵Karolinska Institute, Dept. of Oncology and Pathology, Stockholm, Sweden

11:30 - 11:48

Screen D: Imaging for detection

- P332** **The value of 68Ga-PSMA PET/MRI for classifying PI-RADS 3 lesions on multiparametric MRI: a prospective single-center study**
Authors: Shi J.¹, Li D.Y.², Chen M.X.¹, Fu Y.³, Peng S.³, Zhang Q.¹, Liang J.¹, Lu Q.¹, Lu J.M.², Ai S.Y.⁴, Wang F.⁴, Qiu X.F.¹, Guo H.Q.¹
Institutes: ¹The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Dept. of Radiology, Nanjing, China, ³The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Dept. of Pathology, Nanjing, China, ⁴The Affiliated Nanjing First Hospital of Nanjing Medical University, Dept. of Nuclear Medicine, Nanjing, China
- P337** **DEPROMP-Study: PSMA-PET/CT Prior to Prostate Biopsy: Enhancing Prostate Cancer Detection and Personalized Management**
Authors: Krausewitz P.¹, Gaertner F.C.², Essler M.², Attenberger U.³, Luetkens J.³, Kristiansen G.⁴, Ohlmann C.H.⁵, Hauser S.¹, Ellinger J.¹, Ritter M.¹
Institutes: ¹University Hospital Bonn, Dept. of Urology, Bonn, Germany, ²University Hospital Bonn, Dept. of Nuclear Medicine, Bonn, Germany, ³University Hospital Bonn, Dept. of Radiology, Bonn, Germany, ⁴University Hospital Bonn, Institute of Pathology, Bonn, Germany, ⁵Johanniter Hospital Bonn, Dept. of Urology, Bonn, Germany
- P322** **Comparison of the Incidence of Clinically Significant Prostate Cancer in Patients With Isolated Peripheral vs Transitional Zone PIRADS 3 Lesions**
Authors: Malshy K., Ochsner A., Ortiz R., Golijanin B., Khaleel S., Eaton S., Golijanin D., Hyams E.
Institutes: The Miriam Hospital, Warren Alpert Medical School of Brown University, Minimally Invasive Urology Institute, Providence, United States of America
- P350** **Do 5-alpha reductase inhibitors influence the features of suspicious lesions on magnetic resonance imaging and targeted biopsy results for prostate cancer diagnosis?**
Authors: Savin Z., Shem-Tov Dlugy A., Mendelson T., Lifshitz K., Mano R., Keren-Paz G., Bar-Yosef Y., Yossepowitch O., Dekalo S.
Institutes: Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel
- P326** **Decoding Clinically Significant Prostate Cancer in Biopsy Naïve Patients: A Machine Learning Approach from a tertiary referral center**
Authors: Dagnino F. D.¹, Saitta C.S.¹, Puri D.P.², Meagher M.M.², Yuen K.Y.², Afari J.A.², Derweesh I.H.², Fasulo V. .F.¹, Paciotti M. .P.³, Saita A.³, Hurle R.H.³, Lazzeri M.L.³, Buffi N.M.¹, Casale P.³, Lughezzani G. .L.¹
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ²UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ³IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

- P329** **How can we reduce the rates of false positive findings at mpMRI? The pivotal role of Urologist expertise assessed in a large, single center series**
Authors: Pellegrino A.¹, Stabile A.¹, Quarta L.¹, Barletta F.¹, Mazzone E.¹, Cannoletta D.¹, Pellegrino F.¹, Sorce G.¹, Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Leni R.¹, Cirulli G.O.¹, Longoni M.¹, Scilipoti P.¹, De Angelis M.¹, De Cobelli F.², Esposito A.², Gandaglia G.¹, Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy
- 11:48 - 12:00** **Screen E: Imaging for local staging**
- P341** **Determining an optimal SUVmax cut-off for detection of intra-prostatic radiorecurrent prostate cancer using 68Ga-PSMA-11 PET/CT**
Authors: Light A.¹, Lazic S.², Houghton K.², Bayne M.¹, Connor M.J.¹, Mayor N.¹, Tam H.², Ahmed H.U.¹, Shah T.T.¹, Barwick T.D.²
Institutes: ¹Imperial College London, Imperial Prostate Department, London, United Kingdom, ²Imperial College Healthcare NHS Trust, Dept. of Imaging, London, United Kingdom
- P324** **Impact of magnetic resonance imaging scan and image acquisition protocol in detecting clinically significant prostate cancer at biopsy: results from the PROMOD working group**
Authors: Fanelli A.¹, Finati M.¹, Falagario U.G.¹, Lantz A.², Jambor I.³, Carmignani L.⁴, Montanari E.⁵, Bove P.⁶, Gontero P.⁷, Sciarra A.⁸, Trombetta C.⁹, Bassi P.¹⁰, Simone G.¹¹, Mirone V.¹², Antonelli A.¹³, Schips L.¹⁴, Busetto G.M.¹, Bettocchi C.¹, Ferro M.¹⁵, Bostrom P.¹⁶, Nordstrom T.¹⁷, De Cobelli O.¹⁵, Cormio L.¹, Carrieri G.¹
Institutes: ¹University of Foggia, Dept. Of Urology and Kidney Transplantation, Foggia, Italy, ²Karolinska University Hospital Solna, Dept. of Urology, Stockholm, Sweden, ³University of Turku, Dept. of Radiology, Turku, Finland, ⁴IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁵IRCCS Foundation Ca Granda Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy, ⁶San Carlo di Nancy Hospital, Dept. of Urology, Rome, Italy, ⁷Città della Salute e della Scienza di Torino Molinette Hospital, Dept. of Surgical Sciences, Turin, Italy, ⁸Sapienza Rome University, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ⁹Clinica Urologica di Trieste, Dept. Of Urology, Trieste, Italy, ¹⁰Catholic University Medical School A. Gemelli, Dept. of Urology, Rome, Italy, ¹¹National Cancer Institute, Dept. of Oncologic Urology Regina Elena, Rome, Italy, ¹²University of Naples Federico II, Dept. Of Urology, Naples, Italy, ¹³Azienda Ospedaliera Universitaria Integrata di Verona, UOC Urologia, Verona, Italy, ¹⁴Università G. d' Annunzio, Dept. Of Urology, Chieti, Italy, ¹⁵Istituto Europeo di Oncologia, Dept. of Urologic Cancer Surgery, Milan, Italy, ¹⁶University of Turku and University Hospital, Dept. of Urology, Turku, Finland, ¹⁷Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

P345 **Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission**

Authors: Vis A.¹, Meijer D.¹, Roberts M.J.², Siriwardana A.R.², Morton A.², Yaxley J.W.², Samaratunga H.³, Emmett L.⁴, Van Der Ven P.M.⁵, Heymans M.W.⁵, Nieuwenhuijzen J.A.¹, Van Der Poel H.G.⁶, Van Donswijk M.L.⁷, Boellaard T.N.⁸, Schoots I.G.⁸, Stricker P.⁹, Haynes A.M.¹⁰, Oprea-Lager D.E.¹¹, Coughlin G.D.¹², Van Leeuwen P.J.⁶

Institutes: ¹VU, Dept. of Urology, Amsterdam, The Netherlands, ²Royal Brisbane and Women's Hospital, Dept. of Urology, Brisbane, Australia, ³University of Queensland, Faculty of Medicine, Brisbane, Australia, ⁴University of New South Wales, St Vincent' Clinical School, Kensington, Australia, ⁵VU, Dept. of Epidemiology and Data Science, Amsterdam, The Netherlands, ⁶Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁷Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁸Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ⁹St. Vincent's Prostate Cancer Centre, St. Vincent's Clinic, Sydney, Australia, ¹⁰The Garvan Institute of Medical Research, Australian Prostate Cancer Research Centre, Sydney, Australia, ¹¹VU, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ¹²Wesley Hospital, Dept. of Urology, Brisbane, Australia

P336 **The Next Generation Trial: Assessing 18F-PSMA-1007 Positron Emission Tomography and Magnetic Resonance Imaging in the primary staging of prostate cancer patients**

Authors: Mookerji N.¹, Pfanner T.², Hui A.², Huang G.¹, Broomfield S.¹, Dean L.¹, Adam B.³, Dromparis P.³, Albers P.¹, Fung C.², Tamm A.², Kinnaird A.¹

Institutes: ¹University of Alberta, Dept. of Surgery, Edmonton, Canada, ²University of Alberta, Dept. of Radiology, Edmonton, Canada, ³University of Alberta, Dept. of Pathology, Edmonton, Canada

12:00 - 12:15 **Screen F: Suspicious imaging and negative biopsies**

P328 **What happens to patients with a PI-RADS 5 lesion and a negative prostate biopsy? Long term follow up of a single institutional experience.**

Authors: Pacioti M.¹, Cella L.², Maffei D.², Avolio P.P.², Aljoulani M.², Arena P.², Saitta C.², Uleri A.², Diana P.², Contieri R.², Dagnino F.², Frego N.², De Carne F.², Beatrice E.², Fasulo V.¹, Hurle R.¹, Saita A.¹, Lazzeri M.¹, Casale P.¹, Buffi N.², Lughezzani G.²

Institutes: ¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²Humanitas University, Dept. of Biomedical Sciences, Milan, Italy

- P334** **Negative MRI rules out clinically significant prostate cancer regardless of PI-RADS era**
Authors: Shadbahr T.¹, Pylväläinen J.², Hoffström J.¹, Kenttämies A.³, Mirtti T.⁴, Laajala T.D.¹, Rannikko A.S.⁵
Institutes: ¹University of Helsinki, Research Program in Systems Oncology, Faculty of Medicine, Helsinki, Finland, ²Helsinki University Hospital, Dept. of Radiology, HUS Diagnostic Center, Helsinki, Finland, ³University of Helsinki, Dept. of Radiology, HUS Diagnostic Center, Helsinki, Finland, ⁴Helsinki University Hospital, Dept. of Pathology, HUS Diagnostic Center, Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Urology, Helsinki, Finland
- P339** **Negative fusion biopsy in PIRADS 3-5 cases: what comes next in real world clinical practice?**
Authors: Flammia R.S.¹, Proietti F.¹, Chiacchio G.¹, D'Annunzio S.¹, Misuraca L.¹, Brassetti A.¹, Bove A.M.¹, Ferriero M.C.¹, Minore A.¹, Basile S.¹, Anceschi U.¹, Tuderti G.¹, Mastroianni R.¹, Guaglianone S.¹, Sequi M.B.², Al Salhi Y.², Leonardo C.¹, Valenzi F.M.², Carbone A.², Pastore A.², Simone G.¹
Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²ICOT Center, Dept. of Urology, Latina, Italy
- P344** **Long-Term follow-up after initial negative prostate biopsy: Comparison of conventional TRUS against mpMRI-fusion biopsies**
Authors: Scherer T.¹, Alshazly K.¹, Bieri U.¹, Kaufmann B.¹, Schmid F.¹, Wettstein M.¹, Saba K.², Mortezaei A.³, Eberli D.¹, Poyet C.¹
Institutes: ¹University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ²Klinik Hirslanden Aarau, Dept. of Urology, Aarau, Switzerland, ³University Hospital Basel, Dept. of Urology, Basel, Switzerland
- P325** **PROSPET-BX trial: [G8Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy**
Authors: Maffei D.¹, Lughezzani G.¹, Lazzeri M.², Fasulo V.¹, Arena P.¹, Disconzi L.³, Colombo P.¹, Saita A.², Hurle R.F.², Guazzoni G.F.¹, Balzarini L.³, Rodari M.⁴, Casale P.², Buffi N.M.¹, Lopci E.⁴
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ³IRCCS Humanitas Research Hospital, Dept. of Radiology, Milan, Italy, ⁴IRCCS Humanitas Research Hospital, Dept. of Nuclear Medicine, Milan, Italy

Surgical, non-surgical and systemic treatment of localized muscle-invasive bladder cancer

Abstract session 58

08 April 2024
11:00 - 12:30

Location Purple Area, E01
Chairs To be confirmed
P. Mariappan, Edinburgh (GB)
G. Marcq, Lille (FR)

11:00 - 11:02

Introduction

11:02 - 11:47

Peri-operative systemic therapy in MIBC

A0910

The impact of cigarette smoking on response rate and survival in patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy and radical cystectomy

Authors: [Kräuter J.](#), Laukhtina E., Shariat S.F.

Institutes: Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0897

Thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is associated with a lower risk of venous thromboembolism and bleeding, a multicentric retrospective study

Authors: [Antonelli L.](#)¹, [Afferi L.](#)¹, [Leonardo C.](#)², [Borghesi M.](#)³, [Antonelli A.](#)⁴, [Tully K.](#)⁵, [Umari P.](#)⁶, [Albisinni S.](#)⁷, [Mari A.](#)⁸, [Pichler R.](#)⁹, [Claps F.](#)¹⁰, [Teoh J.Y.C.](#)¹¹, [Schulz G.B.](#)¹², [Soria F.](#)¹³, [Poyet C.](#)¹⁴, [Alrumayyan M.](#)¹⁵, [Rink M.](#)¹⁶, [Zamboni S.](#)¹⁷, [Campi R.](#)¹⁸, [Mertens L.](#)¹⁹, [Roupret M.](#)²⁰, [Lavalley L.](#)²¹, [Moschini M.](#)²², [Fankhauser C.D.](#)¹

Institutes: ¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Sapienza University of Rome, Dept. of Urology, Rome, Italy, ³IRCCS Ospedale Policlinico S. Martino, Dept. of Urology, Genoa, Italy, ⁴Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ⁵Marien Hospital Herne, Dept. of Urology and Neurourology, Bochum, Germany, ⁶St. George University Hospital, Dept. of Urology, London, United Kingdom, ⁷Hopital Universitaire de Bruxelles, Dept. of Urology, Brussels, Belgium, ⁸Careggi Hospital, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ⁹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁰University of Trieste, Dept. of Medicine Surgery and Health Sciences, Trieste, Italy, ¹¹The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, China, ¹²LMU Munich, Dept. of Urology, Munich, Germany, ¹³AOU città della Salute e della Scienza di Torino, Division of Urology, Turin, Italy, ¹⁴University Hospital Zürich, Dept. of Urology, Zürich, Switzerland, ¹⁵Princess Margaret Cancer Centre, Division of Urology, Toronto, Canada, ¹⁶Marienkrankenhaus Hamburg, Dept. of Urology, Hamburg, Germany, ¹⁷ASST Spedali Civili di Brescia, Division of Urology, Brescia, Italy, ¹⁸Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹⁹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²⁰Pitie-Salpêtrière Hospital, Dept. of Urology, Paris, France, ²¹University of Ottawa and Ottawa Hospital Research Institute, Division of Urology, Ottawa, Canada, ²²Vita-Salute San Raffaele, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

- A0900** **Feasibility and oncological outcome of patients achieving non-invasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy for bladder preservation strategy in muscle-invasive bladder cancer**
Authors: Onishi T.¹, Inaba S.¹, Shibahara T.¹, Suguno Y.², Inoue T.², Kato M.³, Kojima T.³
Institutes: ¹Ise Redcross hospital, Dept. of Urology, Ise, Japan, ²Mie University Hospital, Dept. of Urology, Tsu, Japan, ³Aichi Cancer Center, Dept. of Urology, Nagoya, Japan
- A0903** **Impact of maximal transurethral resection prior to neoadjuvant chemotherapy on oncological outcomes in patients who undergo radical cystectomy: A multicenter retrospective study**
Authors: Fujita N.¹, Tanaka T.T.¹, Hosogoe S.H.¹, Ishii N.I.¹, Momota M.M.¹, Ito H.I.², Iwabuchi I.I.³, Yoneyama T.Y.¹, Hashimoto Y.H.¹, Ohyama C.O.¹, Hatakeyama S.H.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan
- A0901** **First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).**
Authors: Mercinelli C.¹, Basile G.², Raggi D.¹, Cigliola A.¹, Tateo V.¹, Patanè D.A.¹, Crupi E.³, Costa De Padua T.¹, Colecchia M.⁴, Colombo R.², Moschini M.², Re C.², Avesani G.², Brembilla G.⁵, De Cobelli F.⁵, Briganti A.², Pavlick D.C.⁶, Ross J.S.⁷, Montorsi F.², Necchi A.¹
Institutes: ¹IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Vita-Salute San Raffaele University, Dept. of Medical Oncology, Milan, Italy, ⁴IRCCS San Raffaele Hospital, Dept. of Pathological Anatomy, Milan, Italy, ⁵IRCCS San Raffaele Hospital, Dept. of Radiology, Milan, Italy, ⁶Foundation Medicine Inc., Pathology and Cancer Genomics Departments, Cambridge, United States of America, ⁷SUNY Upstate Medical University, Dept. of Pathology, Syracuse, United States of America
- A0904** **Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node-positive bladder cancer: results of a prospective study**
Authors: Lyu Q., Yang X., Cao Q., Zhuang J.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A0896

The optimal number of induction chemotherapy cycles in cN+ bladder cancer

Authors: [von Deimling M.](#)¹, Mertens L.S.², Furrer M.³, Li R.⁴, Tendijck G.A.H.², Taylor J.⁵, Crocetto F.⁶, Maas M.⁷, Mari A.⁸, Pichler R.⁹, Moschini M.¹⁰, Tully K.H.¹¹, Laukhtina E.¹², Del Giudice F.¹³, Marcq G.¹⁴, Velev M.¹⁵, Gallioi A.¹⁶, Fisch M.¹, Black P.C.⁷, Lotan Y.⁵, Spiess P.E.⁴, Kiss B.³, Shariat S.F.¹², Pradere B.¹⁷

Institutes: ¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³University of Bern, Dept. of Urology, Bern, Switzerland, ⁴H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, ⁵University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁶University of Naples, Dept. of Neurosciences Reproductive Sciences and Odontostomatology, Naples, Italy, ⁷University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁸University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁰Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy, ¹¹Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ¹²Medical University Vienna, Dept. of Urology, Vienna, Austria, ¹³Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁴Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ¹⁵Université Paris-Saclay, Dept. of Cancer Medicine, Villejuif, France, ¹⁶Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁷Urosud La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

A0902

Stratifying the risk of disease progression among surgically treated muscle invasive bladder cancer eligible for adjuvant nivolumab

Authors: [Flammia R.S.](#), Proietti F., Anceschi U., Misuraca L., Ferriero M.C., Chiacchio G., Tuderti G., Mastroianni R., Brassetti A., Bove A.M., D'Annunzio S., Guaglianone S., Leonardo C., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0894

Dissecting the genomic, immunophenotypic and therapeutic implications of FAT1 loss muscle-invasive bladder cancer

Authors: [Wang Z.](#)¹, Kaifeng J.¹, Zhaopei L.², Jiejie X.³

Institutes: ¹Zhongshan Hospital Affiliated to Fudan University, Dept. of Urology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China

11:47 - 11:57

Bladder-sparing treatment in patients with MIBC

A0908

Radical Cystectomy versus Trimodal Therapy for Non-metastatic Muscle-Invasive Bladder Cancer: analysis of an Other-cause Mortality Matched Cohort

Authors: Finati M.¹, Cirulli G.O.¹, Chiarelli G.¹, Stephens A.², Tinsley S.¹, Butaney M.¹, Arora S.¹, Sood A.³, Buffi N.⁴, Lughezzani G.⁴, Briganti A.⁵, Montorsi F.⁵, Busetto G.M.⁶, Carrieri G.⁶, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, Ohio State's Comprehensive Cancer Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy, ⁶University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy

A0907

Tetramodal bladder-preservation therapy incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymphnode dissection for muscle-invasive bladder cancer: long-term oncologic outcomes of 201 patients

Authors: Tanaka H.¹, Fujiwara M.¹, Hasegawa A.¹, Tanaka H.¹, Suzuki K.¹, Kimura T.¹, Yasujima R.¹, Ito T.¹, Ikeda R.¹, Matsumoto S.¹, Yoshitomi K.¹, Kobayashi M.¹, Nakamura Y.¹, Fan B.¹, Chen W.¹, Ishikawa Y.¹, Fukuda S.¹, Waseda Y.¹, Yoshida S.¹, Yoshimura R.², Kihara K.¹, Fujii Y.¹

Institutes: ¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Tokyo Medical and Dental University, Dept. of Radiation Oncology, Tokyo, Japan

11:57 - 12:27

Surgical techniques of radical cystectomy for MIBC

A0899

The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: Results from the GRAND study

Authors: Pyrgidis N., Volz Y., Ebner B., Kazmierczak P., Enzinger B., Hermans J., Semmler M., Buchner A., Stief C., Schulz G.B.

Institutes: University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

A0905

The effect of Robot-Assisted Radical Cystectomy (RARC) on peritoneal metastasis in patients with muscle-invasive bladder cancer

Authors: Yoneyama F.¹, Hatakeyama S.¹, Tabata R.², Fujita N.¹, Yamamoto H.¹, Yoneyama T.¹, Sato S.², Oyama C.¹

Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Ageo Central General Hospital, Dept. of Urology, Ageo, Japan

A0909

Surgical technique and perioperative outcomes of Robot-Assisted Radical Cystectomy with the Hugo™ RAS: is it ready for prime time?

Authors: Prata F.¹, Tedesco F.¹, Iannuzzi A.¹, Ragusa A.¹, Civitella A.¹, Pira M.¹, D'Addurno G.¹, Basile S.¹, Callè P.¹, Travino A.¹, Fantozzi M.¹, Tuzzolo P.¹, Cacciatore L.¹, Testa A.¹, Raso G.¹, Pino M.¹, Ricci M.¹, Muto G.², Anceschi U.³, Simone G.³, Muto G.⁴, Scarpa R.M.¹, Papalia R.¹

Institutes: ¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²Unit of Oncologic Minimally-Invasive Urology and Andrology of Careggi Hospital, Dept. of Experimental and Clinical Medicine, Florence, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy

A0898

DaBlCa-16: The MOSAIC trial - A randomized study investigating retrosigmoid versus conventional ileal conduit in robot-assisted radical cystectomy - feasibility and 90-day postoperative complications

Authors: Brandt S.¹, Körner S.K.¹, Milling R.V.L.¹, Nielsen N.K.¹, Kingo P.S.¹, Joensen U.N.M.², Bro L.³, Jensen T.K.³, Livbjerg A.H.⁴, Knud F.⁴, Vrang M.L.⁵, Vangedal M.⁵, Lam G.W.⁵, Jensen J.B.¹

Institutes: ¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Copenhagen University Hospital Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ³Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁴Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁵Herlev and Gentofte University Hospital, Dept. of Urology, Copenhagen, Denmark

A0895

Impact of transvaginal specimen extraction on urinary continence after robot-assisted radical cystectomy and intracorporeal orthotopic neobladder

Authors: Mastroianni R., Tuderti G., Anceschi U., Bove A.M., Brassetti A., D'Annunzio S., Ferriero M., Flammia R.S., Misuraca L., Proietti F., Anselmi M., Guaglianone S., Leonardo C., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0906

Systematic review of clinical outcomes and step-by-step description of orthotopic bladder reconstruction following robot-assisted radical cystectomy

Authors: Piramide F.¹, Turri F.², Amparore D.¹, Fallara G.³, De Groote R.⁴, Wuernschimmel C.⁵, Di Maida F.⁶, Liakos N.⁷, Pellegrino F.⁸, Andras I.⁹, Mastroso A.¹⁰, Bianchi R.³, Galfano A.¹¹, Minervini A.⁶, Simone G.¹², Briganti A.⁸, De Cobelli O.³, Gaston R.¹⁰, Montorsi F.⁸, Wiklund P.¹³, Porpiglia F.¹, Mottrie A.⁴, Larcher A.⁸, Dell'Oglio P.¹¹

Institutes: ¹AOU San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy, ²ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ³IEO European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁴OLV Hospital, Dept. of Urology, Aalst, Belgium, ⁵Lucerne Cantonal Hospital, Dept. of Urology, Lucerne, Switzerland, ⁶Careggi Hospital, Dept. of Urology, Florence, Italy, ⁷Medical Faculty and Medical Centre of the University of Freiburg, Dept. of Urology, Freiburg, Germany, ⁸IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁹Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ¹⁰Clinique Saint-Augustin, Dept. of Urology, Bordeaux, France, ¹¹ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ¹²IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹³Karolinska University Hospital, Dept. of Urology, Solna, Sweden

12:27 - 12:30

Expert summary

Urogenital reconstruction

Abstract session 59

08 April 2024
12:00 - 13:30

Location Purple Area, E02
Chairs L. De Kort, Utrecht (NL)
S. Kulkarni, Pune (IN)
To be confirmed
To be confirmed

12:00 - 12:25

Urethral Strictures: Basic Research

A0924

The superiority of hypoxic to normoxic adipose-derived stem cells culture in inducing IL-10, FGF-2 and preventing fibrotic tissue formation in a urethra model

Authors: [Pramana I.B.P.](#)¹, [Widiana I.G.R.](#)², [Duarsa G.W.K.](#)³, [Mahadewa T.G.B.](#)⁴

Institutes: ¹Faculty of Medicine Udayana University - Udayana University Teaching Hospital, Dept. of Urology, Denpasar, Indonesia, ²Faculty of Medicine Udayana University - Prof I.G.N.G. Ngoerah General Hospital, Dept. of Internal Medicine, Denpasar, Indonesia, ³Faculty of Medicine Udayana University - Prof I.G.N.G. Ngoerah General Hospital, Dept. of Urology, Denpasar, Indonesia, ⁴Faculty of Medicine Udayana University - Prof I.G.N.G. Ngoerah General Hospital, Dept. of Neurosurgery, Denpasar, Indonesia

A0916

Single-cell transcriptome profiling of foreskin lesions from male genital lichen sclerosus urethral strictures patients

Authors: [Zhang R.](#), Xiu X., Yu Z., Song L.

Institutes: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

A0912

Transcriptomic analysis reveals inflammatory and oxidative stress subtypes in prepuce lesions of Male Genital Lichen Sclerosus-Associated Urethral Stricture patients and explores their histological and clinical correlations

Authors: [Xianjie X.](#)¹, [Juan T.](#)², [Guangyu M.](#)¹, [Zhenwei Y.](#)¹, [Ruihang Z.](#)¹, [Wei Y.](#)¹, [Qiang F.](#)¹, [Lujie S.](#)¹

Institutes: ¹Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Pathology, Shanghai, China

A0923

Establishment of epithelial organoids for urethral tissue engineering purposes

Authors: [De Graaf P.](#)¹, [Griffioen A.](#)¹, [Slaats G.G.G.](#)², [de Kort L.M.O.](#)¹

Institutes: ¹University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ²University Medical Center Utrecht, Dept. of Nephrology, Utrecht, The Netherlands

A0927

Novel 3D bioprinting for urethral reconstruction

Authors: Olsen Ekerhult A.T.¹, Ortac M.², Nie W.³, Mahajan N.³, Zhao W.³, Chandra P.³, Atala A.³

Institutes: ¹Institute of Clinical Sciences, Gothenburg University, Dept. of Urology at Sahlgrenska University Hospital, Gothenburg, Sweden, ²Istanbul University, Medical Faculty, Istanbul, Türkiye, ³Wake Forest Institute of Regenerative Medicine, Dept. of Urology, Winston-Salem, United States of America

12:25 - 13:05

Urethral strictures: Clinic

A0911

Kulkarni versus the standard dorsal Approach for Buccal Mucosal Graft Urethroplasty: Does Sexual Function Matter?

Authors: Tharwat Abdelghafour A., Maarouf A.

Institutes: Zagazig University, Dept. of Urology, Zagazig, Egypt

A0919

Incidence and management of BPH surgery-related urethral stricture: results from a large U.S. database

Authors: Licari L.C.¹, Manfredi C.², Bologna E.¹, Franco A.³, Ditunno F.⁴, Antonelli A.⁴, De Sio M.², Cindolo L.⁵, De Nunzio C.³, Cherullo E.E.⁶, Leonardo C.⁷, Autorino R.⁶

Institutes: ¹Sapienza University of Rome Policlinico Umberto I Hospital, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²University of Campania Luigi Vanvitelli, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ³Sapienza University Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ⁴Azienda Ospedaliera Universitaria Integrata Verona University of Verona, Dept. of Urology, Verona, Italy, ⁵Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy, ⁶Rush University, Dept. of Urology, Chicago, United States of America, ⁷Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0915

28 Years of Expertise: Optimizing Treatment Strategies for Pelvic Fractures and Complex Urethral Injuries with a Comprehensive Approach

Authors: Ocampo M.A., Kulkarni S.B., Navarro J., Talpallikar A., Baroth P., Bhadranavar S., Joshi P.M.

Institutes: UROKUL Kulkarni Uro Surgery Institute, Dept. of Reconstructive Urology, Pune, India

A0928

Novel drug injectable urethral catheter set with hyaluronic acid for patient satisfaction, pain, clinical convenience, and stricture prevention after transurethral surgery: a multicenter randomized single-blind clinical trial

Authors: Kim S.J.¹, Han Kyu C.², Wook N.², Jong Yeon P.², Sang Hyun P.³, Jae-Seung C.³, Cheol Kyu O.³, Sangjun Y.⁴, Min Chul C.⁴, Hyeon J.⁴, Seong Cheol K.⁵, Sungchan P.⁵, Won Ik S.³, Jae Il C.³, Chan Ho L.³, Kweonsik M.³, Jimin C.⁶, Jungyo S.¹, Bumjin L.¹, Dalsan Y.¹

Institutes: ¹Ulsan University, Dept. of Urology, Seoul, South Korea, ²Ulsan University, Dept. of Urology, Gangneung, South Korea, ³Inje University, Dept. of Urology, Busan, South Korea, ⁴Seoul National University, Dept. of Urology, Seoul, South Korea, ⁵Ulsan University, Dept. of Urology, Ulsan, South Korea, ⁶Dong-A University, Dept. of Management and Information, Busan, South Korea

- A0926** **Elimination of post-operative oral care pathways does not increase complications in buccal mucosal graft urethroplasty**
Authors: Foreman J.¹, Krughoff K.², Dvergsten T.¹, Sury K.¹, Lentz A.¹, Peterson A.¹
Institutes: ¹Duke University, Dept. of Urology, Durham, United States of America, ²Oregon Urology Institute, Dept. of Urology, Springfield, United States of America
- A0922** **The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 3-year results**
Authors: Elliott S.P.¹, Coutinho K.², Roberston K.³, DeLong J.⁴, Virasoro R.⁵
Institutes: ¹University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ²New Jersey Urology, Dept. of Urology, Millburn, United States of America, ³Cheapeake Urology, Dept. of Urology, Hanover, United States of America, ⁴MultiCare Urology, Dept. of Urology, Puyallup, United States of America, ⁵Eastern Colorado Veterans Affairs Hospital, Dept. of Urology, Colorado Springs, United States of America
- A0920** **Results of oral mucosa graft urethroplasty in the penil urethra with or without reconstruction of the meatus**
Authors: Borisenkov M., Beier J., Pandey A.
Institutes: Sana Klinikum Hof, Dept. of Urology, Hof, Germany
- A0917** **Effect of Inferior Alveolar plus Buccal Nerve Block on Postoperative Morbidity at Buccal Mucosal Graft Harvest Site: A Prospective Double-Blind Randomised Controlled Trial**
Authors: Mandal S., Nayak P., das k M., Ram P., Tarigopula V., Singh G A., G R.
Institutes: All India Institute of Medical Sciences Bhubaneswar, Dept. of Urology, Bhubaneswar, India
- 13:05 - 13:15** **Gender affirmation surgery**
- A0913** **Evaluation of urethral complications in a large cohort following transmasculine gender affirmation surgery**
Authors: Gobbo A., Christopher N.A., Li V.Y., Ralph D.J., Lee W.G.
Institutes: University College of London Hospitals, Dept. of Andrology, London, United Kingdom
- A0914** **Quality of life and sexual satisfaction after metoidioplasty in transmen**
Authors: Stojanovic B., Bizic M., Bencic M., Djordjevic M.L.
Institutes: School of Medicine University of Belgrade, Dept. of Urology, Belgrade, Serbia
- 13:15 - 13:30** **Reconstructive urology: miscellaneous**
- A0918** **Volume variability in orthotopic neobladder: the Impact of the ileal width and the AADAPT formula tested on the animal model.**
Authors: Annino F.¹, Bianchi B.¹, Chiaramonti F.¹, Verdelli L.¹, Alteri L.², Di Costanzo R.¹, Khorrami S.¹, Asimakopoulos A.²
Institutes: ¹Azienda Toscana Sud Est San Donato Hospital, Dept. of Urology, Arezzo, Italy, ²Fondazione PTV Policlinico Tor Vergata, Dept. of Urology, Rome, Italy
-

A0921

Comparative Effectiveness of Surgical Treatments for Recurrent Obstruction Following Failed Pyeloplasty: A Multicenter, Prospective Registry Study

Authors: Xiong S.¹, Zhang L.¹, Li Z.¹, Zhang P.², Zhu H.³, Wang B.⁴, Zhou L.¹, Li X.¹

Institutes: ¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Emergency General Hospital, Dept. of Urology, Beijing, China, ³Beijing Jiangong Hospital, Dept. of Urology, Beijing, China, ⁴Beijing Miyun District Hospital, Dept. of Urology, Beijing, China

A0925

Ex-vivo bladder model for evaluation of optimum applied pressure and number of artificial urinary sphincter cuffs to achieve continence

Authors: Shokri P.¹, Ziaee S.A.M.Z.¹, Borumandnia N.¹, Tabatabaei S.T.²

Institutes: ¹Shahid Beheshti University of Medical Sciences, Dept. of Urology, Tehran, Iran, ²TABA Health, Dept. of Urology, Newton, United States of America

Kidney transplantation

Abstract session 60

07 April 2024
16:45 - 18:15

Location Green Area, W01
Chairs To be confirmed
To be confirmed
To be confirmed
J.D. Olsburgh, London (GB)

A0945

Impact of the number of organs retrieved during multiple organ procurement on short and long term renal graft function.

Authors: Ghestem T.¹, Uhl M.¹, Taha F.², Kaulanjan K.³, Goujon A.⁴, Beretta A.⁵, Papet J.P.⁶, Dupuis H.⁶, Panis A.⁷, Peyrottes A.⁸, Lemaire A.⁹, Clement L.¹⁰, Bettler L.¹¹, Pues M.¹², Joncour C.², Stempfer G.³, Waeckel T.¹³, De Sousa P.¹

Institutes: ¹CHU Amiens-Picardie, Dept. of Urology, Amiens, France, ²CHU de Reims, Dept. of Urology, Reims, France, ³CHU de Pointe-à-Pitre, Dept. of Urology, Pointe-à-Pitre, France, ⁴CHU de Rennes, Dept. of Urology, Rennes, France, ⁵CHU de Lyon, Dept. of Urology, Lyon, France, ⁶CHU de Rouen, Dept. of Urology, Rouen, France, ⁷CHU de Créteil, Dept. of Urology, Paris, France, ⁸Hopital Européen Georges Pompidou, Dept. of Urology, Paris, France, ⁹Hopital Saint Louis, Dept. of Urology, Paris, France, ¹⁰CHU de Nancy, Dept. of Urology, Nancy, France, ¹¹CHU de Dijon, Dept. of Urology, Dijon, France, ¹²CHU de Lille, Dept. of Urology, Lille, France, ¹³CHU de Caen, Dept. of Urology, Caen, France

A0936

Analysing rejected kidney offers - are your own rules justified?

Authors: Putz J., Baunacke M., Becker S.M., Thomas C.
Institutes: Medical Faculty Carl Gustav Carus TU Dresden, Dept. of Urology, Dresden, Germany

A0943

TransplantAFUF: Impact of BMI and the iliocutaneous distance on renal transplant prognosis.

Authors: Joncour C.¹, Seizilles De Mazancourt E.², Kaulanjan K.K.³, Goujon A.⁴, Berretta A.², Papet J.⁵, Dupuis H.⁵, Panis A.⁶, Lemaire A.⁷, Uhl M.⁸, Larose C.⁹, Ghestem T.⁸, Escoffier A.¹⁰, Bettler L.¹⁰, Pues M.¹¹, Stempfer G.³, Warckel T.¹², Larré S.¹, Taha F.¹

Institutes: ¹CHU de Reims, Dept. of Urology, Reims, France, ²CHU de Lyon, Dept. of Urology, Lyon, France, ³CHU de Pointe-à-Pitre, Dept. of Urology, Pointe-à-Pitre, France, ⁴CHU de Rennes, Dept. of Urology, Rennes, France, ⁵CHU de Rouen, Dept. of Urology, Rouen, France, ⁶CHU de Créteil, Dept. of Urology, Créteil, France, ⁷Hopital Saint Louis, Dept. of Urology, Paris, France, ⁸CHU d'Amiens, Dept. of Urology, Amiens, France, ⁹CHU de Nancy, Dept. of Urology, Nancy, France, ¹⁰CHU de Dijon, Dept. of Urology, Dijon, France, ¹¹CHU de Lille, Dept. of Urology, Lille, France, ¹²CHU de Caen, Dept. of Urology, Caen, France

A0938

Questioning minimum annual caseload requirements for kidney transplantation (KT): low-volume centers show better graft function after deceased-donor KT in German total population quality assurance data from 2006 to 2021

Authors: Reimold P.¹, Aksoy C.¹, Beckmann J.¹, Zacharis A.¹, Groeben C.¹, Karschuck P.¹, Eisenmenger N.², Geks J.³, Flegar L.¹, Huber J.¹

Institutes: ¹Philipps-University Marburg, Dept. of Urology, Marburg, Germany, ²Reimbursement Institute, Reimbursement Institute, Hürth, Germany, ³Philipps-University Marburg, Dept. of General Surgery, Marburg, Germany

A0929

Kidney transplant in patients with unique blood transfusion preferences: a study of ethical and clinical aspects at a specialized institution

Authors: García Formoso N., Herrero Blanco E., Alonso Mediavilla E., Ballesterro Diego R., Campos Juanatey F., Velilla Díez G., García Herrero J., Sánchez Gil M., Azcárraga Aranegui G., Latatu Córdoba M.Á., Expósito Ibáñez E., Domínguez Esteban M., Zubillaga Guerrero S., Gutiérrez Banos J.L.

Institutes: Marques de Valdecilla University Hospital, Dept. of Urology, Santander, Spain

A0931

Proposal of a Standardized Training Curriculum for Open and Robot-assisted Kidney Transplantation

Authors: Pecoraro A.¹, Territo A.², Boissier R.³, Hevia V.⁴, Prudhomme T.⁵, Piana A.⁶, Banuelos B.⁷, Serni S.¹, Breda A.², Campi R.¹

Institutes: ¹Careggi University Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³La Conception University Hospital, Dept. of Urology and Renal Transplantation, Marseille, France, ⁴Hospital Ramón y Cajal, Dept. of Urology, Madrid, Spain, ⁵Rangueil University Hospital, Dept. of Urology, Kidney Transplantation and Andrology, Toulouse, France, ⁶San Luigi Gonzaga Hospital, Division of Urology, Turin, Italy, ⁷University Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain

A0933

Implementation of robot-assisted kidney transplantation in surgical practice at referral European transplant Centres: An audit within the ERUS-RAKT working group

Authors: Pecoraro A.¹, Campi R.¹, Gallioli A.², Territo A.², Basile G.², Gaya J.M.², Etcheverry B.³, Vignolini G.¹, Prudhomme T.⁴, Ortved M.⁵, Zeuschner P.⁶, Garcia-Baquero R.⁷, Fornara P.⁶, Rohrsted M.⁵, Doumerc N.⁴, Serni S.¹, Breda A.²

Institutes: ¹Careggi University Hospital, Unit of Urological Minimally Invasive Robotic Surgery and Kidney Transplantation, Florence, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ⁴University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, ⁵Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark, ⁶Medical Faculty of Martin Luther University Halle-Wittenberg, Clinic of Urology and Transplantation, Halle, Germany, ⁷Hospital Universitario Puerta del Mar, Kidney Transplant Unit, Cádiz, Spain

A0934

Robot-assisted kidney transplantation: 8-year European experience

Authors: Territo A.¹, Pecoraro A.², Campi R.², Gallioli A.¹, Basile G.¹, Gaya J.M.¹, Etcheverry B.³, Musquera M.⁴, Lopez De Mesa Rodriguez B.⁴, Prudhomme T.⁵, Vignolini G.², Volpe A.⁶, Garcia-Baquero R.⁷, Kocak B.⁸, Idu M.⁹, Fornara P.¹⁰, Rohrsted M.¹¹, Doumerc N.⁵, Decaestecker K.¹², Serni S.², Vignes F.³, Alcaraz A.⁴, Breda A.¹

Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Careggi University Hospital, Unit of Urological Minimally Invasive Robotic Surgery and Kidney Transplantation, Florence, Italy, ³Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ⁴Hospital Clinic-IDIBAPS, Dept. of Urology, Barcelona, Spain, ⁵University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, ⁶University of Eastern Piedmont, Division of Urology, Novara, Italy, ⁷Hospital Universitario Puerta del Mar, Kidney Transplant Unit, Cádiz, Spain, ⁸Koç University Hospital Organ Transplant Center, Dept. of Urology, Istanbul, Türkiye, ⁹Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands, ¹⁰Medical Faculty of Martin Luther University Halle-Wittenberg, Clinic of Urology and Transplantation, Halle, Germany, ¹¹Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark, ¹²University Hospital Ghent, ERN eUROGEN Accredited Centre, Dept. of Urology, Ghent, Belgium

A0932

Trifecta in robot-assisted kidney transplantation (RAKT) from living donors: the ERUS-RAKT experience

Authors: Gallioli A.¹, Pecoraro A.², Campi R.², Territo A.¹, Gaya J.M.¹, Berquin C.³, Etcheverry B.⁴, Musquera M.⁵, Prudhomme T.⁶, Vignolini G.², Vangeneugden J.³, Volpe A.⁷, Garcia-Baquero R.⁸, Kocak B.⁹, Idu M.¹⁰, Fornara P.¹¹, Rohrsted M.¹², Alcaraz A.⁵, Doumerc N.⁶, Vignes F.⁴, Decaestecker K.³, Serni S.², Breda A.¹

Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Careggi University Hospital, Unit of Urological Minimally Invasive Robotic Surgery and Kidney Transplantation, Florence, Italy, ³University Hospital Ghent, ERN eUROGEN Accredited Centre, Dept. of Urology, Ghent, Belgium, ⁴Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ⁵Hospital Clinic-IDIBAPS, Dept. of Urology, Barcelona, Spain, ⁶University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, ⁷University of Eastern Piedmont, Division of Urology, Novara, Italy, ⁸Hospital Universitario Puerta del Mar, Kidney Transplant Unit, Cádiz, Spain, ⁹Koç University Hospital, Dept. of Urology, Istanbul, Türkiye, ¹⁰Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands, ¹¹Medical Faculty of Martin Luther University Halle-Wittenberg, Clinic of Urology and Transplantation, Halle, Germany, ¹²Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark

A0940

Orthotopic Robot-Assisted Kidney Transplantation: Experience from the ERUS-RAKT Group

Authors: Etcheverry Giadrosich B.R.¹, Lozano V.¹, Fiol M.¹, Pérez J.I.¹, Buisan O.¹, Gaya J.M.², Pecoraro A.², Doumerc N.³, Sallusto F.³, Suárez J.F.¹, Prudhomme T.³, Breda A.², Vigués F.¹

Institutes: ¹Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³Centre Hospitalier Universitaire Rangueil, Dept. of Urology, Toulouse, France

A0935

Post-operative surgical complications of renal transplantation in the elderly

Authors: Beretta A.¹, Badet L.¹, Kaulanjan K.², Goujon A.³, Papet J.⁴, Dupuis H.⁴, Panis A.⁵, Peyrottes A.⁶, Lemaire A.⁷, Uhl M.⁸, Larose C.⁹, Ghestem T.⁸, Bettler L.¹⁰, Pues M.¹¹, Joncour C.¹², Stempfer G.², Waeckel T.¹³, Taha F.¹², Matillon X.¹, Seizilles De Mazancourt E.¹

Institutes: ¹HCL, Dept. of Urology and Kidney Transplantation, Lyon, France, ²Hospital of Pointe a Pitre, Dept. of Urology, Pointe-à-Pitre, France, ³University Hospital of Rennes, Dept. of Urology, Rennes, France, ⁴University Hospital of Rouen, Dept. of Urology, Rouen, France, ⁵University Hospital of Créteil, Dept. of Urology, Paris, France, ⁶European Hospital Georges Pompidou, Dept. of Urology, Paris, France, ⁷Saint Louis Hospital, Dept. of Urology, Paris, France, ⁸University Hospital of Amiens, Dept. of Urology, Amiens, France, ⁹University Hospital of Nancy, Dept. of Urology, Nancy, France, ¹⁰University Hospital of Dijon, Dept. of Urology, Dijon, France, ¹¹University Hospital of Lille, Dept. of Urology, Lille, France, ¹²University Hospital of Reims, Dept. of Urology, Reims, France, ¹³University Hospital of Caen, Dept. of Urology, Caen, France

A0939

Complications and outcomes of percutaneous drainage in the treatment of lymphocele after renal transplantation.

Authors: Boiko O.¹, Mutsinzi G.², Navarro A.¹, Maldonado A.¹, Reyes E.¹, Martin S.¹, Llorente A.I.¹, Iliuta F.¹, Sanz J.¹, Gonzalez D.¹, Rodriguez A.¹, Garcia A.¹, Olano I.¹, Padilla J.¹, Carlevaris A.¹, Boiko M.³, Arruza A.¹

Institutes: ¹University Hospital of Cruces, Dept. of Urology, Barakaldo, Spain, ²Hospital of San Eloy, Dept. of Urology, Barakaldo, Spain, ³Clinic Androcentr, Dept. of Urology, Kyiv, Ukraine

A0944

Evaluation of oxygenation modalities for marginal renal transplants in a porcine model.

Authors: Lévy S.¹, Loiseau E.², Mesnard B.³, Brunet S.², Bernadet S.², Minault D.², Hervouet J.², Blancho G.², Drouin S.⁴, Darius T.⁵, Prudhomme T.¹, Branchereau J.³

Institutes: ¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²Nantes Université, Inserm Unit 1064, Nantes, France, ³CHU Hotel-Dieu, Dept. of Urology, Nantes, France, ⁴Hopital Pitie Salpetriere, Dept. of Urology, Paris, France, ⁵Cliniques Universitaires Saint-Luc, Dept. of Surgery and Abdominal Transplantation, Brussels, Belgium

A0937

Assessment of kidney graft quality during normothermic machine perfusion using NMR spectroscopy as a valuable tool

Authors: Putz J.¹, Steinhauser C.¹, Yakac A.E.¹, Füssel S.¹, Thomas C.¹, Markgraf W.², Kromnik S.², Döcke A.², Talhofer P.², Thiele C.², Malberg H.², Jonas S.³, Mirschink P.³, Funk A.M.³

Institutes: ¹Medical Faculty Carl Gustav Carus TU Dresden, Dept. of Urology, Dresden, Germany, ²TU Dresden, Institute of Biomedical Engineering, Dresden, Germany, ³Medical Faculty Carl Gustav Carus TU Dresden, Institute for Clinical Chemistry and Laboratory Medicine, Dresden, Germany

A0941

Assessment of compliance with recommendations for the use of renal infusion machines and the consequences of their non-application

Authors: Larose C.¹, Seizilles De Mazancourt E.², Taha F.³, Kaulanjan K.⁴, Goujon A.⁵, Beretta A.², Papet J.⁶, Dupuis H.⁶, Panis A.⁷, Peyrottes A.⁸, Lemaire A.⁹, Uhl M.¹⁰, Ghestem M.¹⁰, Bettler L.¹¹, Poes M.¹², Joncour C.³, Stempfer G.⁴, Waeckel T.¹³, Hubert J.¹, Eschwege P.¹, Mazeaud C.¹

Institutes: ¹CHRU Nancy, Dept. of Urology, Nancy, France, ²CHU de Lyon, Dept. of Urology, Lyon, France, ³CHU de Reims, Dept. of Urology, Reims, France, ⁴CHU de Pointe-à-Pitre, Dept. of Urology, Pointe-à-Pitre, France, ⁵CHU de Rennes, Dept. of Urology, Rennes, France, ⁶CHU de Rouen, Dept. of Urology, Rouen, France, ⁷CHU de Créteil, Dept. of Urology, Créteil, France, ⁸Georges Pompidou, Dept. of Urology, Paris, France, ⁹Hopital Saint Louis, Dept. of Urology, Paris, France, ¹⁰CHU Amiens, Dept. of Urology, Amiens, France, ¹¹CHU de Dijon, Dept. of Urology, Dijon, France, ¹²CHU Lille, Dept. of Urology, Lille, France, ¹³CHU de Caen, Dept. of Urology, Caen, France

A0946

Robot-assisted pyelo-ureterostomy for complex ureteral strictures in kidney transplant patients: A very successful option

Authors: Vangeneugden J.¹, Berquin C.¹, Desender L.², Randon C.², Van Laecke S.³, Nagler E.³, Peeters P.³, Vanmassenhove J.³, Vanommeslaeghe F.³, Van Praet C.¹, Decaestecker K.¹

Institutes: ¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital, Dept. of Thoracic and Vascular Surgery, Ghent, Belgium, ³Ghent University Hospital, Dept. of Nephrology, Ghent, Belgium

A0942

Robotic Surgery for the Management of Urinary Tract Complications Following Kidney Transplantation

Authors: Lozano V., Etcheverry B., Fiol M., Fàbregas M., Riera L., Sanz P., Buisán O., Castells M., Vigués F.

Institutes: Hospital Universitari de Bellvitge, Dept. of Urology, Hospitalet de Llobregat, Spain

A0930

Impact of Timing of Rejection Cardiovascular Events in Living Donor Kidney Transplantation: A Multicenter Retrospective Study

Authors: Okamoto T.¹, Hamaya T.¹, Matsuura T.M.², Saito M.S.³, Nishida H.N.⁴, Maita S.M.⁵, Murakami R.M.⁶, Hatakeyama S.H.¹, Tomita H.T.⁶, Tsuchiya N.T.⁴, Obara W.O.², Habuchi T.H.³, Ohyama C.O.¹

Institutes: ¹Hirosaki University, Dept. of Urology, Hirosaki, Japan, ²Iwate Medical University, Dept. of Urology, Morioka, Japan, ³Akita University, Dept. of Urology, Akita, Japan, ⁴Yamagata University, Dept. of Urology, Yamagata, Japan, ⁵Iwate Prefectural Isawa Hospital, Dept. of Urology, Isawa, Japan, ⁶Hirosaki University, Dept. of Cardiology and Nephrology, Hirosaki, Japan

How to get away from positive surgical margins during prostatectomy?

Abstract session 61

08 April 2024
12:00 - 13:30

Location Purple Area, E04
Chairs S. Knipper, Berlin (DE)
M. Moussa, Beirut (LB)
D. Murphy, Melbourne (AU)

12:00 - 12:02

Introduction

12:02 - 12:17

Margins and Retzius-sparing RP

A0948

Predictors of positive surgical margins and site-specific analysis after Retzius-sparing and antegrade robotic radical prostatectomy in trainees' cohorts: results of a multicentric experience

Authors: Anceschi U.¹, Basile S.¹, Dell'Oglio P.², Prata F.¹, Flammia R.S.¹, Vecchio E.², Olivero A.², Tuderti G.¹, Brassetti A.¹, Ferriero M.¹, Bove A.M.¹, Mastroianni R.¹, Zampa A.¹, Spadaro G.¹, Proietti F.¹, Tappero S.², Secco S.², Martiriggiano M.², Guaglianone S.¹, Leonardo C.¹, Galfano A.², Bocciardi A.M.², Simone G.¹

Institutes: ¹IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²ASST Niguarda Hospital, Dept. of Urology, Milan, Italy

A0958

Retzius-sparing robot-assisted radical prostatectomy for large prostate volumes: surgical and functional outcomes

Authors: Maltzman O., Tappero S., Caviglia A., Chierigo F., Piccione A., Vecchio E., Martiriggiano M., Cellini V., Palagonia E., Buratto C., Olivero A., Napoli G., Barbieri M., Strada E., Di Trapani D., Petralia G., Secco S., Bocciardi A.M., Galfano A., Dell'Oglio P.

Institutes: ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy

A0949

Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score matched analysis

Authors: Qian J.¹, Fu Y.², Marra G.³, Zhang F.⁴, Wu X.⁵, Li D.⁶, Xu L.⁴, Qiu X.⁴, Gan W.⁴, Guo H.⁴

Institutes: ¹Nanjing Medical University Affiliated Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²Medical School of Nanjing University Affiliated Drum Tower Hospital, Dept. of Pathology, Nanjing, China, ³San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ⁴Medical School of Nanjing University Affiliated Drum Tower Hospital, Dept. of Urology, Nanjing, China, ⁵Medical School of Nanjing University Affiliated Drum Tower Hospital, Dept. of Anesthesiology, Nanjing, China, ⁶Medical School of Nanjing University Affiliated Drum Tower Hospital, Dept. of Radiology, Nanjing, China

12:17 - 12:47

MRI and augmented reality

A0957

Preoperative MRI to assess the anatomical location of positive surgical margin at robot-assisted radical prostatectomy (RARP)

Authors: van der Graaf S.H.¹, Sweere V.¹, Veerman H.¹, Boellaard T.N.², Schoots I.G.³, Wit E.M.K.¹, Roeleveld T.A.⁴, Nieuwenhuijzen J.A.⁵, Vis A.N.⁵, Beerlage H.P.⁵, Van Der Poel H.G.⁶, Van Leeuwen P.J.⁶

Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ³Erasmus University Medical Center, Dept. of Radiology and Nuclear Medicine, Rotterdam, The Netherlands, ⁴Noordwest Ziekenhuisgroep, Dept. of Urology, Alkmaar, The Netherlands, ⁵Amsterdam University Medical Centers Location VUmc, Dept. of Urology, Amsterdam, The Netherlands, ⁶Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands

A0951

Is it safe to perform contralateral nerve sparing in high-risk prostate cancer with unilateral lesions on multiparametric magnetic resonance image?

Authors: Cheng Y.¹, Fu Y.F.², Li D.Y.³, Lu J.L.³, Huang H.H.¹, Peng S.P.², Zhang S.Z.¹, Qiu X.Q.¹, Guo H.G.¹

Institutes: ¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Pathology, Nanjing, China, ³Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Radiology, Nanjing, China

A0955

Deep learning model for real-time semantic segmentation during intraoperative robotic prostatectomy

Authors: Il In P., Sung Gon P., Ji Won K., Min Jung K., Donghyun L., Sung Tae C., Young Goo L., Pak S.

Institutes: Hallym University College of Medicine, Dept. of Urology, Seoul, South Korea

A0953

A phase III prospective randomized trial to evaluate the impact of augmented reality during robot-assisted radical prostatectomy on the rates of postoperative surgical margins

Authors: Luzzago S.¹, Mistretta F.A.¹, Fontana M.¹, Piccinelli M.L.¹, Jannello L.M.I.¹, Lievore E.¹, Bianchi R.¹, Ferro M.¹, Brescia A.¹, Bottero D.¹, Graps G.¹, Guglielmo O.¹, Renne G.², Ivanova M.², Fusco G.M.³, Jereczek-Fossa B.A.⁴, Marvaso G.⁴, Musi G.¹, de Cobelli O.¹

Institutes: ¹European Institute of Oncology, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Pathology, Milan, Italy, ³Università di Napoli Federico II, Dept. of Urology, Naples, Italy, ⁴European Institute of Oncology, Dept. of Radiotherapy, Milan, Italy

A0952

A prospective randomized controlled study on reducing positive surgical margin in robot assisted radical prostatectomy using holographic imaging intraoperative navigation guided intraoperative frozen section technology: Preliminary results

Authors: Wang X.¹, Lv Z.T.¹, Wang M.¹, Zhang Y.Q.¹, Zhang Y.G.¹, Liu L.T.², Zhang W.², Li C.M.³, Zhu S.C.¹, Wang J.Y.¹, Liu M.¹

Institutes: ¹Beijing Hospital, Dept. of Urology, Beijing, China, ²Beijing Hospital, Dept. of Pathology, Beijing, China, ³Beijing Hospital, Dept. of Radiology, Beijing, China

A0950

The effect of preoperative MRI on oncological outcomes following radical prostatectomy: a 12-year follow-up of a randomized controlled trial

Authors: Noor D.¹, Baco E.², Galtung K.F.¹, Berge V.², Lauritzen P.M.¹, Eri L.M.², Rud E.¹

Institutes: ¹Oslo University Hospital, Dept. of Radiology, Oslo, Norway, ²Oslo University Hospital, Dept. of Urology, Oslo, Norway

12:47 - 13:22

Real time evaluation of margins and new technology

A0962

Diffuse reflectance spectroscopy during prostatectomy; towards intraoperative margin assessment.

Authors: de Roode L.M.¹, de Boer L.¹, Da Silva Guimares M.², Van Leeuwen P.³, Van Der Poel H.³, Dashtbozorg B.¹, Ruers T.¹

Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek, Dept. of Image-Guided Surgery, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek, Core Facility Molecular Pathology and Biobanking, Amsterdam, The Netherlands, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, The Netherlands

A0954

Intraoperative evaluation of surgical margins during robot-assisted radical prostatectomy: comparison between fluorescence confocal microscopy and frozen section analysis with final pathology as standard reference

Authors: Luzzago S.¹, Mistretta F.A.¹, Piccinelli M.L.¹, Fallara G.¹, Fontana M.¹, Tozzi M.¹, Zago A.¹, Tallini M.¹, Cordima G.¹, Ferro M.¹, Bottero D.¹, Ivanova M.², Fusco N.², Renne G.², Musi G.¹, de Cobelli O.¹

Institutes: ¹European Institute of Oncology, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Pathology, Milan, Italy

A0961

Centralized prostatectomy with intra-operative NeuroSAFE surgical margin assessment improves surgical margin control

Authors: Kroon L.¹, Remmers S.², Busstra M.³, Gan M.³, Klaver S.³, Rietbergen J.³, Van Der Slot M.A.², Hollemans E.¹, Kweldam C.F.³, Bangma C.², Roobol M.², Van Leenders G.¹

Institutes: ¹Erasmus Medical Center, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ³Anser, Prostate Clinic, Rotterdam, The Netherlands

A0959

Five-year oncological results of intra-operative frozen section (Neurosafe) during robotic-assisted radical prostatectomy

Authors: Fonseca P.¹, Ogbechie C.¹, Adam S.¹, Haidar O.¹, Jinaraj A.¹, Ocallaghan M.², Hennessey D.³, Rabinowitz J.¹, Brodie A.¹, Kinnear N.¹, Lane T.¹, Vasdev N.¹, Adshead J.¹

Institutes: ¹Lister Hospital Stevenage, Division of Robotic Urology, Dept. of Urology, Stevenage, United Kingdom, ²Flinders Medical Centre, Dept. of Urology, Adelaide, Australia, ³Mercy University Hospital, Dept. of Urology, Cork, Ireland

A0960

Accuracy of fluorescence confocal microscopy for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement

Authors: Almeida-Magana R.¹, Au M.¹, Al-Hammouri T.², Mathew M.³, Dinneen K.³, Freeman A.³, Haider A.³, Vreuls W.⁴, Shaw G.²

Institutes: ¹University College London, Dept. of Targeted Intervention, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Histopathology, London, United Kingdom, ⁴Canisius Wilhelmina Hospital, Dept. of Pathology, Nijmegen, The Netherlands

A0947

Robot-assisted radical prostatectomy with Hugo™ RAS System: perioperative outcomes from the largest multicentric series.

Authors: Prata F.¹, Totaro A.², Montanaro F.³, Sighinolfi C.⁴, Mottaran A.⁵, Civitella A.¹, Bientinesi R.², Gandi C.², Iannuzzi A.¹, Marino F.², Veccia A.³, Piazza P.⁵, Ragusa A.¹, Russo P.², Scarciglia E.², Tedesco F.¹, Schiavina R.⁵, Rocco B.⁴, Brunocilla E.⁵, Antonelli A.³, Sacco E.², Bassi P.², Scarpa R.M.¹, Papalia R.¹

Institutes: ¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²Fondazione Policlinico Universitario A. Gemelli, IRCCS Università Cattolica del Sacro Cuore, Dept. of Urology, Rome, Italy, ³Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ⁴ASST Santi Paolo e Carlo University of Milan, Dept. of Urology, Milan, Italy, ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy

A0956

Evaluation of the minimum volume standard for radical prostatectomies in the Netherlands: centralization of care and surgical outcomes over time

Authors: van der Starre C.M.¹, Aben K.K.H.¹, Van Leeuwen P.J.², Busstra M.³, de Jong I.J.⁴, Heesterman B.L.¹, Somford D.M.⁵

Institutes: ¹Netherlands Comprehensive Cancer Organisation, Dept. of Research and Development, Utrecht, The Netherlands, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁴University Medical Center Groningen, Dept. of Urology, Groningen, The Netherlands, ⁵Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands

13:22 - 13:25

Expert summary

Urolithiasis: Percutaneous nephrolithotomy

Abstract session 62

08 April 2024
12:00 - 13:30

Location Purple Area, E05
Chairs B.H. Chew, Vancouver (CA)
To be confirmed
To be confirmed
A. Sierra Del Rio, Barcelona (ES)

- A0970** **Application of optical tracking sensing technology in fusion of image puncture and 3D navigation lithotripsy of ultrasound-guided PCNL**
Authors: Liu Y.B.¹, Song H.F.², Li J.X.²
Institutes: ¹Beijing Tsinghua Changgung Hospital 2.Peking University First Hospital, Dept. of Urology, Beijing, China, ²Beijing Tsinghua Changgung Hospital, Dept. of Urology, Beijing, China
- A0966** **The utility of Augmented Reality in planning renal access for PCNL**
Authors: Lasmanovich R.¹, Dagan M.², Carmona O.¹, Zilberman D.¹, Dotan Z.¹, Kleinman N.¹, Shvero A.¹
Institutes: ¹Sheba medical center, Dept. of Urology, Ramat Gan, Israel, ²Sheba Medical Center, The Engineering Medical Research Lab, Ramat Gan, Israel
- A0969** **Ultrasonographic guided Robotic-assisted percutaneous renal puncture: a feasibility study.**
Authors: Piro A.¹, Eissa A.², Resca S.¹, Vella J.¹, Ientile R.¹, de Faveri A.¹, Di Bari S.¹, Ferraguti F.³, Bazzani S.³, Secchi C.³, Ferretti S.¹, Puliatti S.¹, Micali S.¹, Bianchi G.¹
Institutes: ¹University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²Tanta University, Dept. of Urology, Faculty of Medicine, Tanta, Egypt, ³University of Modena and Reggio Emilia, Dept. of Sciences and Methods for Engineering, Modena, Italy
- A0978** **Impact of Renal Access Angles and Speed of Nephroscope Retrieval Movements on the Vortex Effect**
Authors: Ito W., Prokop D., Valadon C., Whiles B., Neff D., Duchene D., Molina W.
Institutes: The University of Kansas Medical Center, Dept. of Urology, Kansas, United States of America
- A0967** **Comparing anterior and posterior calyx approach in supine percutaneous nephrolithotomy**
Authors: Ricapito A.¹, Gupta K.², Yaghoobian A.², Khargi R.², Connors C.², Atallah W.², Carrieri G.¹, Gupta M.²
Institutes: ¹University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
- A0964** **Supine Tubeless Upper Pole PCNL under Spinal Anaesthesia: Safety, Feasibility and Outcomes from a Tertiary Endourology centre**
Authors: Kumar N.¹, Somani B.²
Institutes: ¹Ford Hospital and Research Centre, Dept. of Urology, Patna, India, ²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

- A0968** **A comparison on safety and efficacy between 24 Fr versus 18 Fr pneumatic balloon dilators for percutaneous treatment of renal stones between 10 and 20 mm: results from a contemporary cohort**
Authors: Perri D.¹, Besana U.¹, Pacchetti A.¹, Morini E.¹, Mazzoleni F.¹, Verzotti E.¹, Romero Otero J.², Gozen A.S.³, Rocco B.⁴, Bozzini G.¹
Institutes: ¹Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²12 de Octubre University Hospital, Dept. of Urology, Madrid, Spain, ³SLK-Kliniken, Dept. of Urology, Heilbronn, Germany, ⁴ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy
- A0972** **Prospective Comparative study of Thulium Fiber Laser Vs Holmium laser with Moses technology for kidney stone in Percutaneous Nephrolithotomy: A Randomised controlled single-center trial**
Authors: Singh A., Ganpule A.G., Sabnis R.B., Desai M.
Institutes: Muljibhai Patel Urological Hospital, Dept. of Urology, Nadiad, India
- A0974** **Vacuum-assisted mini-percutaneous nephrolithotomy is associated with lower rates of infectious complications compared to standard procedures in low-risk patients: a single-center experience**
Authors: Zanetti S.P., Nizzardo M., Nardini S., Marmiroli A., Quistini A., Roberto D., Scanferla E., Molteni S., Longo F., Albo G., De Lorenzis E., Montanari E., Boeri L.
Institutes: Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy
- A0975** **Effect of tranexamic acid irrigation on perioperative blood loss during mini-percutaneous nephrolithotomy: A double-blind, randomized controlled clinical trial**
Authors: Prohsoontorn O., Ketsuwan C.
Institutes: Faculty of Medicine, Ramathibodi Hospital, Dept. of Urology, Bangkok, Thailand
- A0971** **Nomogram Predicting Acute Kidney Injury Following Percutaneous Nephrolithotomy: An Observational Study.**
Authors: Chawla A.K., Goli A., Viswanath K., Pillai S., Hegde P.
Institutes: Manipal, Dept. of Urology and Renal transplant, Manipal, India
- A0976** **Frailty impact on post-operative complications and resource utilization following mini-PCNL using the modified 5 item frailty index (MFI-5) score**
Authors: Sureka S., Baid A., Singh U.P., Yadav A., Rastogi S., Pathak A., Kadlepla Mutt P.
Institutes: SGPGI, Dept. of Urology, Lucknow, India
- A0979** **Impact of duration of pre-operative antibiotics on SIRS / urosepsis rates following PNL for non-staghorn renal stones: A randomized controlled study**
Authors: Mete U.¹, Deshpande R.¹, Bhadada S.², Taneja N.³, Mavuduru R.¹, Bora G.¹
Institutes: ¹PGIMER, Dept. of Urology, Chandigarh, India, ²PGIMER, Dept. of Endocrinology, Chandigarh, India, ³PGIMER, Dept. of Microbiology, Chandigarh, India
- A0973** **Stone cultures performed during PCNL could accurately predict post-operative septic complications: a single tertiary centre experience**
Authors: Ripa F., Zanetti S.P., Boeri L., De Lorenzis E., Longo F., Albo G., Montanari E.
Institutes: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy
-

- A0963** **Significance of renal pelvis urine gram stain, systemic inflammation index, white blood cell ratios and guy stone score in predicting post operative fever after mpcnl: A prospective observational study**
Authors: Harina J., Aquino T., Bardelosa Iiii J.G., Yanga T.M., Guiang A.
Institutes: Jose R Reyes Memorial Medical Center, Dept. of Urology, Manila, Philippines
- A0965** **Intraoperative cone beam computed tomography increases single procedure stone free rates in percutaneous nephrolithotomy: results of a randomized controlled trial.**
Authors: Kingma R.A., Altobelli E., Bus M.T.J., de Jong I.J., Roemeling S.
Institutes: University Medical Center Groningen, Dept. of Urology, Groningen, The Netherlands
- A0977** **Totally X-ray-free tubeless mini-percutaneous nephrolithotomy in supine position: Is tomorrow already here?**
Authors: Safaev Y., Mukhtarov S., Nasirov F.
Institutes: Republican Specialized Scientific and Practical Medical Center of Urology, Dept. of Surgery, Tashkent, Uzbekistan
- A0980** **Enhancing Patient Understanding and Satisfaction through Video Consent in Percutaneous Nephrolithotomy (PCNL)**
Authors: Esperto F., Testa A., Iannuzzi A., Cacciatore L., Deanesi N., Calle' P., Tedesco F., Ragusa A., Salerno A., Papalia R., Scarpa R.M.
Institutes: Fondazione Campus Bio-Medico of Rome, Dept. of Urology, Rome, Italy

The cutting edge of partial nephrectomy: Robotic precision, surgical advances, and virtual realities

Abstract session 63

08 April 2024
12:00 - 13:30

Location
Chairs

Purple Area, E06
To be confirmed
T. Toshio, Tokyo (JP)
A. Volpe, Novara (IT)

12:00 - 12:02

Introduction

A0993

Off-clamp versus on-clamp robotic partial nephrectomy: A systematic review and meta-analysis of randomized trials and matched studies

Authors: Fong K.Y.¹, Lim B.J.H.², Chan Y.H.¹, Castellani D.³, Chen K.², Tay K.J.², Ho H.S.S.², Yuen J.S.P.², Aslim E.J.², Teoh J.⁴, Gan V.H.L.², Lim E.J.²

Institutes: ¹National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, ²Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ³Università Politecnica delle Marche, Urology Unit, Ancona, Italy, ⁴The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, China

A0996

Does the single-layer technique with soft coagulation versus the double-layer technique in robot-assisted partial nephrectomy affect postoperative outcomes for complex tumors?

Authors: Shiozaki K.¹, Fukawa T.², Hashimoto K.³, Kadoriku F.⁴, Fukuta K.¹, Utsunomiya S.¹, Kita S.⁵, Sasaki Y.², Daizumoto K.², Seto K.¹, Tomita R.², Izumi K.⁵, Kusuhara Y.², Ninomiya I.⁴, Nakanishi R.¹, Yamamoto Y.², Yamaguchi K.², Izaki H.¹, Naroda T.³, Okamoto K.⁴, Yamanaka M.⁵, Takahashi M.², Furukawa J.²

Institutes: ¹Tokushima Central Prefectural Hospital, Dept. of Urology, Tokushima, Japan, ²Tokushima University Graduate School of Biomedical Sciences, Dept. of Urology, Tokushima, Japan, ³Kochi Red Cross Hospital, Dept. of Urology, Kochi, Japan, ⁴Ehime Central Prefectural Hospital, Dept. of Urology, Matsuyama, Japan, ⁵Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan

A0986

Preclinical survival study comparing a new poly (2-oxazoline) based hemostatic sealing patch vs. standard renorrhaphy after partial nephrectomy.

Authors: Farinha R.J.¹, Zondervan P.², De Groote R.³, Roozen E.⁴, Bender J.⁵, Head S.⁵, Mottrie A.¹

Institutes: ¹ORSI Academy, Dept. of Urology, Melle, Belgium, ²Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ³OLV, Dept. of Urology, Aalst, Belgium, ⁴Radboud UniversityCenter, Dept. of Surgery, Nijmegen, The Netherlands, ⁵GATT Technologies, Dept. of Technology, Nijmegen, The Netherlands

- A0990** **Investigating the impact of suture-less technique on percentage of preserved parenchyma after off-clamp robot-assisted partial nephrectomy**
Authors: Flammia R.S.¹, Ruggiero S.², Brassetti A.¹, Proietti F.¹, Chiacchio G.¹, Mastroianni R.¹, Tuderti G.¹, Misuraca L.¹, D'Annunzio G.¹, Anceschi U.¹, Ferriero M.C.¹, Bove A.M.¹, Minore A.¹, Basile S.¹, Guaglianone S.¹, Leonardo C.¹, Simone G.¹, Vidiri A.²
Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Dept. of Radiology and Diagnostics Imaging, Rome, Italy
- A0991** **Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorrhaphy: Analyses of an experienced surgeon**
Authors: Toshio T.¹, Yoshida K.¹, Iizuka J.¹, Fukuda H.¹, Kobari Y.¹, Kondo T.²
Institutes: ¹Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, ²Tokyo Women's Medical University Hospital Adachi Medical Center, Dept. of Urology, Tokyo, Japan
- A0984** **Single-port vs multi-port robot-assisted partial nephrectomy: a single center propensity-score matched analysis**
Authors: Licari L.C.¹, Bologna E.¹, Franco A.², Ditunno F.³, Manfredi C.⁴, Coogan C.⁵, Cherullo E.E.⁵, Vourganti S.⁵, Chow A.K.⁵, Autorino R.⁵
Institutes: ¹Sapienza University of Rome Policlinico Umberto I Hospital, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²Sapienza University Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ³Azienda Ospedaliera Universitaria Integrata Verona University of Verona, Dept. of Urology, Verona, Italy, ⁴University of Campania Luigi Vanvitelli, Unit of Urology, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ⁵Rush University, Dept. of Urology, Chicago, United States of America
- A0994** **Prospective comparison between da vinci and hugo ras platforms in robot-assisted partial nephrectomy**
Authors: Hevia Palacios V.¹, García Rojo E.¹, Brime Menendez R.¹, Feltes Ochoa J.A.¹, Justo Quintas J.¹, Lista Mateos F.¹, Calzas Montalvo C.¹, Bozzini G.², Romero Otero J.¹
Institutes: ¹HM Sanchinarro, Dept. of Urology, Madrid, Spain, ²Sant Anna Hospital, Dept. of Urology, Como, Italy

- A0982** **Robot-assisted partial nephrectomy using the new Hugo™ RAS System versus traditional Da Vinci platform: a propensity score-matched comparison of perioperative and functional outcomes.**
Authors: Prata F.¹, Tedesco F.¹, Iannuzzi A.¹, Ragusa A.¹, Civitella A.¹, Pira M.¹, D'Addurno G.¹, Basile S.¹, Callè P.¹, Travino A.¹, Fantozzi M.¹, Tuzzolo P.¹, Cacciatore L.¹, Minore A.¹, Testa A.¹, Raso G.¹, Pino M.¹, Ricci M.¹, Muto G.², Anceschi U.³, Simone G.³, Muto G.⁴, Scarpa R.M.¹, Papalia R.¹
Institutes: ¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²Unit of Oncologic Minimally-Invasive Urology and Andrology of Careggi Hospital, Experimental and Clinical Medicine, Florence, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy
- A0989** **Transperitoneal and retroperitoneal robot-assisted partial nephrectomy with a novel robotic system: initial experience from a tertiary care referral centre**
Authors: Chierigo E., Caviglia A., Palagonia E., Cellini V., Maltzman O., Buratto C., Vecchio E., Olivero A., Barbieri M., Piccione A., Napoli G., Strada E., Petralia G., Secco S., Di Trapani D., Tappero S., Bocciardi A.M., Galfano A., Dell'Oglio P.
Institutes: ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy
- A0997** **Outcomes of the MP1000 system for robot-assisted partial nephrectomy: A multicenter randomized controlled trial**
Authors: Yu G., Yang Y., Xu Z.
Institutes: PLA General Hospital, Dept. of Urology, Beijing, China
- A0995** **Robot-assisted partial nephrectomy with the on demand Dexter™ robotic system: the first twenty cases**
Authors: Fontanier T., Robin H., Hugues G., Ali Benali N., Bodet M.L., Mignot H., Forgues A., Emeriau D., Thillou D.
Institutes: CH de Saintonge, Dept. of Urology, Saintes, France
- A0983** **Real-time feature tracking and segmentation in urologic robotic assisted surgery: an artificial intelligence based platform**
Authors: Canneto R.¹, Morgantini L.A.¹, Garcia Nespolo R.², Leiderman Y.I.², Crivellaro S.C.¹
Institutes: ¹University of Illinois Chicago, Dept. of Urology, Chicago, United States of America, ²University of Illinois Chicago, Illinois Eye and Ear Infirmary, Dept. of Ophthalmology and Visual Sciences, Chicago, United States of America
- A0992** **A novel 3D deep learning model to automatically demonstrate renal vasculature segmentation and its validation in nephron-sparing surgery**
Authors: Shao P.
Institutes: The First Affiliated Hospital with Nanjing Medical University, Dept. of Urology, Nanjing, China

A0985

Deep-learning approach to renal parenchyma detection: a first step towards augmented reality to guide robot-assisted partial nephrectomy

Authors: Khaddad A.¹, Bartoli A.², Chandelon K.², Margue G.¹, Desternes J.², Bourdel N.³, Bernhard J.C.¹

Institutes: ¹Bordeaux University Hospital Center, Dept. of Urology and Kidney Transplantation, Bordeaux, France, ²Clermont Auvergne University, Dept. of Computer Science, Clermont-Ferrand, France, ³Clermont Auvergne University, Dept. of Gynecology and Obstetrics, Clermont-Ferrand, France

A0987

Deep Learning Automated Phase Recognition in Robot-Assisted Partial Nephrectomy

Authors: Mezzina M.¹, Peraire Loes M.¹, Simoens J.¹, Debbaut C.², Ferraguti F.³, Van Praet C.⁴, De Groote R.⁵, Decaestecker K.⁶, Mottrie A.¹, De Backer P.¹

Institutes: ¹ORSI Academy, Dept. of Urology, Ghent, Belgium, ²Ghent University, IBiTech BioMMeda, Ghent, Belgium, ³University of Modena and Reggio Emilia, Dept. of Sciences and Methods for Engineering, Modena, Italy, ⁴Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁵OLV Hospital, Dept. of Urology, Aalst, Belgium, ⁶AZ Maria Middelaers, Dept. of Urology, Ghent, Belgium

A0988

Robotic Assisted Partial Nephrectomy with Metaverse based surgical planning: a single center preliminary experience

Authors: Piramide F.¹, De Cillis S.T.¹, Amparore D.¹, Checcucci E.², Piana A.³, Volpi G.², Sica M.¹, Verri P.¹, Burgio M.¹, Meziere J.¹, Quarà A.¹, Cisero E.¹, Busacca G.¹, Marsero L.¹, Colombo M.¹, Mandaletti M.¹, Mesterca A.G.¹, Ortenzi M.¹, Ribolzi B.S.¹, Di Dio M.⁴, Manfredi M.¹, Fiori C.¹, Porphiglia F.¹

Institutes: ¹AOU San Luigi Gonzaga University of Turin, Dept of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁴Annunziata Hospital Division of Urology, Dept. of Surgery, Cosenza, Italy

A0981

Surgeon skill is associated with positive surgical margins in robot-assisted partial nephrectomy: Results of a video-based evaluation

Authors: Wang Y.¹, Wilder S.¹, Hijazi M.², Mirza M.², Van Til M.², Maatman T.³, Ghani K.R.², Lane B.R.⁴, Rogers C.G.¹, Michigan Urological Surgery Improvement Collaborative M.²

Institutes: ¹Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ²University of Michigan Medical School, Dept. of Urology, Ann Arbor, United States of America, ³Michigan Urological Clinic, Dept. of Urology, Grand Rapids, United States of America, ⁴Corewell Health Hospital System, Dept. of Urology, Grand Rapids, United States of America

Rapid-fire debates: Kidney cancer

Thematic Session

08 April 2024
12:30 - 14:00

Location Green Area, eURO Auditorium 1
Chairs A. Breda, Barcelona (ES)
M.C. Mir Maresma, Valencia (ES)

12:30 - 12:45	cT1a SRM turns into pT3a with positive margins, what's next? Moderator Z . Wu, Shanghai (CN)
12:30 - 12:31	Case presentation Z . Wu, Shanghai (CN)
12:31 - 12:35	Surveillance P.M. Pierorazio, Philadelphia (US)
12:35 - 12:39	Radical nephrectomy V. Ficarra, Messina (IT)
12:39 - 12:45	Discussion/Q&A
12:45 - 13:00	How do we manage a patient with complex cystic renal mass (Bosniak III/IV)? Moderator S. Dabestani, Lund (SE)
12:45 - 12:46	Case presentation S. Dabestani, Lund (SE)
12:46 - 12:50	Surveillance E. Roussel, Leuven (BE)
12:50 - 12:54	Surgery R. Campi, Florence (IT)
12:54 - 13:00	Discussion/Q&A
13:00 - 13:15	Follow-up after pT1a clear cell RCC: Do we save lives with intense follow-up imaging? Moderator A. Volpe, Novara (IT)
13:00 - 13:01	Case presentation A. Volpe, Novara (IT)
13:01 - 13:05	No imaging at all C. Beisland, Bergen (NO)
13:05 - 13:09	Guidelines imaging L. Oliveira Marconi, Coimbra (PT)
13:09 - 13:15	Discussion/Q&A
13:15 - 13:30	Should we do lymph node dissection for clinical high-risk RCC: What template is appropriate? Moderator U. Capitanio, Milan (IT)
13:15 - 13:16	Case presentation U. Capitanio, Milan (IT)
13:16 - 13:20	No T. Kuusk, London (GB)

13:20 - 13:24	Unilateral RPLND C. Palumbo, Novara (IT)
13:24 - 13:30	Discussion/Q&A
13:30 - 13:45	Adjuvant immunotherapy after pT3a F IV /N0 at nephrectomy: Is that real high-risk for all? Moderator M-O. Grimm, Jena (DE)
13:30 - 13:31	Case presentation M-O. Grimm, Jena (DE)
13:31 - 13:35	Yes T. Powles, London (GB)
13:35 - 13:39	No L. Albiges, Villejuif (FR)
13:39 - 13:45	Discussion/Q&A
13:45 - 14:00	Does scalpel play a role in intermediate risk metastatic RCC? Moderator R. Flippot, Villejuif (FR)
13:45 - 13:46	Case presentation R. Flippot, Villejuif (FR)
13:46 - 13:50	Upfront CN C.K. Bensalah, Rennes (FR)
13:50 - 13:54	dCN A. Bex, London (GB)
13:54 - 14:00	Discussion/Q&A

Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS) Urology beyond Europe

Urology Beyond Europe

05 April 2024
10:45 - 12:45

Location Purple Area, E02
Chairs M.A. Khan, Islamabad (PK)
J.L. Vásquez, Copenhagen (DK)

Learning objectives

This session will collaboratively endeavor to provide an overview of the latest developments in the training of Minimally Invasive Surgery (MIS) for BPH and management of kidney cancer (RCC) and upper tract UC with the aim of optimising patient care.

10:45 - 10:50

Welcome and introductions

M.A. Khan, Islamabad (PK)

MIS for BPH

Moderators I. Memon, Hyderabad (PK)
T.A. Sami, Birmingham (GB)

10:50 - 11:00

Training models for MIS in BPH

A. Dhanasekaran, Birmingham (GB)

11:00 - 11:10

Current best evidence for MIS in BPH

G.I. Russo, Catania (IT)

11:10 - 11:20

Current practice pattern of BPH management in Pakistan

M.I. Nazir, Lahore (PK)

11:20 - 11:35

Q & A

11:35 - 12:40

Management of RCC

Moderators M. Aslam, Scotland (GB)
R. Campi, Florence (IT)

11:35 - 11:45

New technologies in the management of RCC

N. Azawi, Havdrup (DK)

11:45 - 11:55

Management in small renal masses: An update

M. Ather, Karachi (PK)

11:55 - 12:05

Pattern of presentation and diagnostic challenges in RCC

To be confirmed

12:05 - 12:15

The role of partial nephrectomy in the management of RCC

R.G. Bertolo, Verona (IT)

12:15 - 12:25

Challenging clinical case mRCC

Y. Rasheed, Karachi (PK)

12:25 - 12:40

Debate On clinical case

12:40 - 12:45

Conclusion

F. Mumtaz, London (GB)

Familial and hereditary cancer syndromes in urology

Thematic Session

08 April 2024
12:30 - 14:00

Location Purple Area, eURO Auditorium 2
Chairs P. Albers, Düsseldorf (DE)
C.H. Bangma, Rotterdam (NL)

Learning objectives

Session "Familial and hereditary cancer syndromes in urology"

Genetic factors may contribute to the initiation and progression of various urologic malignancies based on germ line mutations. Some of these urologic cancers are related to a larger syndromes involving multiple organs. For the urologic clinician it is important to know in which cases to initiate genetic screening. In this session the relation between a positive family history and germ line related urologic malignancies is highlighted for prostate, kidney, and bladder cancer. Based on best available knowledge, this will provide recommendations for genetic work-up, treatment, and follow-up in patients and their family members.

12:30 - 12:32

Introduction: Relevance and epidemiology of familial cancer syndromes in urology

C.H. Bangma, Rotterdam (NL)

12:32 - 12:40

What is the relation between family history and germ line mutation?

K. Hemminki, Heidelberg (DE)

12:40 - 12:48

What does a urologist need to know starting germ line screening?

M. Ausems, Utrecht (NL)

12:48 - 13:06

Familial prostate cancer

12:48 - 12:56

Familial prostate cancer

A. Morgans, Boston (US)

12:56 - 12:58

Case presentation: 35 yrs, BRCA 2 +, no previous history

P. Rajwa, Zabrze (PL)

12:58 - 13:06

Panel discussion Genetic work-up, treatment, follow-up recommendation

13:06 - 13:24

Familial kidney cancer

13:06 - 13:14

Familial kidney cancer

P. Mulders, Nijmegen (NL)

13:14 - 13:16

Case presentation: 45 yrs, history of papRCC I with organ-preserving surgery, now recurrence in both kidneys

E. Roussel, Leuven (BE)

13:16 - 13:24

Panel discussion Genetic work-up, treatment, follow-up recommendation

13:24 - 13:42

Lynch syndrome

13:24 - 13:32

Lynch syndrome

M. Gebauer Madsen, Aarhus N (DK)

13:32 - 13:34	Case presentation: 30 yrs, HNPCC E. Laukhtina, Vienna (AT)
13:34 - 13:42	Panel discussion Urological work-up, interdisciplinary care, follow-up recommendations
13:42 - 14:00	Debate Routine genetic testing for familial cancer syndromes
13:42 - 13:47	Yes R. Giles, Duivendrecht (NL)
13:47 - 13:52	No A.S. Rannikko, Helsinki (FI)
13:52 - 14:00	Discussion

Male LUTS diagnosis - clinical issues

Abstract session 45

08 April 2024
12:30 - 14:00

Location Purple Area, N01
Chairs To be confirmed
To be confirmed
To be confirmed
To be confirmed

A1000

Evaluation Of Nocturia In Patients Affected By Severe Obstructive Sleep Apnea Syndrome By Nocturnal Bladder Capacity Index.

Authors: Pastore A.L.¹, Al Salhi Y.¹, Sequi M.B.¹, Suraci P.P.¹, Rera A.¹, Valenzi F.M.¹, Antonioni A.¹, Martino G.¹, Candita G.¹, Graziani D.¹, Scalzo S.¹, Gianfrancesco F.¹, Fuschi A.¹, De Nunzio C.², Cicione A.², De Berardinis E.³, Sciarra A.³, Carbone A.¹

Institutes: ¹Sapienza University of Rome Faculty of Pharmacy and Medicine, Dept. of Medico Surgical Sciences and Biotechnologies Urology, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology, Rome, Italy

A1006

Regular sleep habits with appropriate bedtime prolong hours to undisturbed sleep and reduce nocturnal urine volume per hour.

Authors: Okumura Y.¹, Nobukawa S.², Ishibashi T.³, Takahashi T.³, Ueki K.¹, Nishikawa T.¹, Okubo N.¹, Kakitsuba T.¹, Seo W.¹, Fukiage Y.¹, Kobayashi H.¹, Tsutsumiuchi M.¹, Seki M.¹, Inamura S.¹, Taga M.¹, Fukushima M.¹, Yokoyama O.¹, Terada N.¹

Institutes: ¹University of Fukui, Dept. of Urology, Fukui, Japan, ²Chiba Institute of Technology, Dept. of Information Engineering, Chiba, Japan, ³University of Fukui, Dept. of Psychiatry, Fukui, Japan

A1010

The association between testosterone deficiency and nocturia in patients over 60 years with cardiovascular diseases

Authors: Kim S., Park S.G., Lee D.H., Pak S., Lee Y.G., Cho S.T.

Institutes: Hallym University Kangnam Sacred Heart Hospital, Dept. of Urology, Seoul, South Korea

A1011

Causal relationship between lower urinary tract symptoms and frailty: The chicken or the egg dilemma

Authors: Hosogoe S.¹, Fujita N.², Okamoto T.², Yamamoto H.², Yoneyama T.², Hashimoto Y.², Ohyama C.², Hatakeyama S.²

Institutes: ¹Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan

A1017

The Influence of Dietary Habits on Male Lower Urinary Tract Symptoms: Differential Influence of Water Intake on Voiding Symptoms and Storage Symptoms

Authors: Park J.¹, Choi W.S.², Son H.³

Institutes: ¹Konkuk University Medical center, Dept. of Urology, Seoul, South Korea, ²Konkuk University School of Medicine, Dept. of Urology, Seoul, South Korea, ³Seoul National University Boramae hospital, Dept. of Urology, Seoul, South Korea

- A1012** **Mobile app-based versus conventional uroflowmetry: Is your home toilet the new uroflowmetry lab?**
Authors: Kumar S., Manoj K.
Institutes: All India Institute of Medical Sciences New Delhi, Dept. of Urology, New Delhi, India
- A1014** **Transitional Voided volume: a new parameter for assessing home uroflowmetry**
Authors: De Win G.¹, Peters M.², Pauwels J.², Van Beeck Morales E.², Vermandel A.¹, Van Dongen S.³, De Wachter S.¹
Institutes: ¹University Hospital Antwerp, Dept. of Urology, Antwerp, Belgium, ²University of Antwerp, Faculty of Medicine and health sciences, Antwerp, Belgium, ³University of Antwerp, Dept. of Biology, Antwerp, Belgium
- A1009** **Twelve-year follow-up observation of idiopathic detrusor underactivity in the elderly living in community: Treatment and urodynamic changes**
Authors: Jeong S.J.¹, Kim J.S.², Song S.H.¹, Lee H.S.¹, Nam J.H.¹, Park H.J.¹, Park J.H.¹, Chung Y.S.¹
Institutes: ¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Seoul National University College of Medicine, Dept. of Medicine, Seoul, South Korea
- A1002** **Developing Dual AI Models Using Non-Invasive Clinical Parameters to Aid in Male Bladder Outlet Obstruction Diagnosis and Minimize the Need for Invasive Video-Urodynamic Studies**
Authors: Tsai C.Y.¹, Tian J.H.², Kuo H.C.³
Institutes: ¹Far Eastern Memorial Hospital, Division of Urology, Dept. of Surgery, New Taipei, Taiwan, ²Hualien Tzu Chi Hospital, Dept. of Medical Research, Hualien, Taiwan, ³Hualien Tzu Chi Hospital, Dept. of Urology, Hualien, Taiwan
- A1007** **Can Clinical Prostate Score (CLIPS) be used as a useful adjunct for predicting success in minimal invasive surgical therapy (MIST) of the prostate?**
Authors: Pek G., Law T., Tay W.K., Chiong E., Chua W.J., Consigliere D., Tsang W.C.
Institutes: National University Hospital, Dept. of Urology, Singapore, Singapore
- A1016** **In how many patients invasive urodynamics should be omitted? Data from a single center database analysed on the basis of the UPSTREAM trial findings.**
Authors: Rosato E., Finazzi Agrò E., Di Rocco F., Cerrelli G., Mancini M.C., Turbanti A., Pletto S., Orecchia L.
Institutes: Università degli Studi di Roma Tor Vergata, Dept. of Surgical Sciences, Rome, Italy
- A0999** **The diagnostic role of prostatic urethral angle in diagnosis of bladder neck dysfunction in men with lower urinary tract symptoms and small prostate volume**
Authors: Chang T-L., Jiang Y.H., Jhang J.F., Liu M.C., Yang C.C., Kuo H.C.
Institutes: Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan
-

- A1005** **Voiding symptoms are aggravated by decreasing glandular content and by increasing stromal/epithelial ratio in patients undergoing surgery for BPH, independently from prostate size**
Authors: Keller P., Hu S., Weinhold P., Tamalunas A., Berger L., Nicola P., Götz M., Waidelich R., Stief C.G., Hennenberg M.
Institutes: LMU University Hospital, Dept. of Urology, Munich, Germany
- A1008** **Identification of programmed cell death (PCD) associated genes in diagnosing benign prostatic hyperplasia and prostate cancer by integrated bioinformatics analysis and machine learning**
Authors: Jie C., Bo C., Dehong C.
Institutes: West China Hospital, Dept. of Urology, Chengdu, China
- A1003** **Both activator and inhibitor of transient receptor potential mucolipin 1 (TRPML1) inhibit contractions induced by various stimuli in human prostate smooth muscle**
Authors: Hu S., Eitelberger N., Müderrisoglu A.E., Hennenberg M., Stief C.G., Tamalunas A.
Institutes: LMU Hospital Munich, Dept. of Urology, Munich, Germany
- A1015** **Novel Concepts of Post-receptor Signaling: Phospholipase C (PLC) Plays an Important Role in Prostate Cell Proliferation, Viability, and Cytoskeletal Organization**
Authors: Tamalunas A., Vigodski V., Eitelberger N., Trieb M., Rutz B., Chiotkowska A., Stief C.G., Hennenberg M.
Institutes: LMU Hospital Munich, Dept. of Urology, Munich, Germany
- A1004** **Concentration-dependent antagonism of α 1-adrenergic smooth muscle contractions in human prostate tissues, and bidirectional effects on stromal cell growth by the dual β - and α 1-adrenergic antagonist carvedilol**
Authors: Hu S., Tamalunas A., Waidelich R., Stief C.G., Hennenberg M.
Institutes: LMU University Hospital, Dept. of Urology, Munich, Germany
- A1001** **Phospholipase C (PLC) is a crucial mediator of agonist-induced smooth muscle contraction in the lower urinary tract**
Authors: Tamalunas A., Vigodski V., Eitelberger N., Trieb M., Hu S., Rutz B., Chiotkowska A., Stief C.G., Hennenberg M.
Institutes: LMU Hospital Munich, Dept. of Urology, Munich, Germany
- A0998** **Over-expression of LEDGF/p75 in HEp-2 cells enhances autoimmune IgG response in patients with benign prostatic hyperplasia - a novel diagnostic approach with therapeutic consequence?**
Authors: Liedke V.¹, Rose L.², Hiemann R.¹, Nasser A.³, Rödiger S.¹, Bonaventura A.⁴, Winkler L.¹, Sowa M.², Stöckle M.⁴, Schierack P.¹, Junker K.⁴, Roggenbuck D.¹
Institutes: ¹Brandenburg University of Technology Cottbus-Senftenberg, Faculty Environment and Natural Sciences, Senftenberg, Germany, ²GA Generic Assays GmbH, GA Generic Assays GmbH, Blankenfelde-Mahlow, Germany, ³Medipan GmbH, Medipan GmbH, Blankenfelde-Mahlow, Germany, ⁴Saarland University and Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany
- A1013** **LIM kinase inhibitor: a novel pharmacological strategy in the treatment of mixed symptoms in mixed LUTS?**
Authors: Yu Q., Cen P., Lan H., Zhou X., Huang R., Zeng G.
Institutes: the First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China
-

NMIBC: From diagnosis to prognosis

Abstract session 46

08 April 2024
12:30 - 14:00

Location Green Area, N03
Chairs A. Chkhotua, Tbilisi (GE)
R. Järvinen, Helsinki (FI)
To be confirmed
S. Shariat, Vienna (AT)

A1020

A Fully Automated Novel Urine Cytology Support Artificial Intelligence System for the Prediction of Histological High-grade Urothelial Carcinoma: External Validation Study

Authors: [Kaneko M.](#)¹, Harada Y.¹, Tsuji K.¹, Paralkar D.², Fujihara A.¹, Ueno K.³, Nakanishi M.³, Konishi E.⁴, Takamatsu T.⁵, Horiguchi G.⁶, Teramukai S.⁶, Ito-Ihara T.⁷, Abreu A.L.⁸, Ukimura O.¹

Institutes: ¹Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ²University of Southern California, Dept. of Pathology and Urology, Los Angeles, United States of America, ³KYOCERA Communication Systems Co. Ltd, Corporate R and D Department, Kyoto, Japan, ⁴Kyoto Prefectural University of Medicine, Dept. of Surgical Pathology, Kyoto, Japan, ⁵Kyoto Prefectural University of Medicine, Dept. of Medical Photonics, Kyoto, Japan, ⁶Kyoto Prefectural University of Medicine, Dept. of Biostatistics, Kyoto, Japan, ⁷Kyoto Prefectural University of Medicine, Dept. of Clinical and Translational Research Center, Kyoto, Japan, ⁸University of Southern California, Dept. of Urology and Radiology, Los Angeles, United States of America

A1019

A viable alternative to Urine Cytology in Urothelial Cancer Detection: a non-inferiority trial

Authors: Manera A.¹, [Morselli S.](#)¹, Baria E.², Cicchi R.², Liaci A.¹, Moscardi L.¹, Gajo L.¹, D'Amico A.¹, Bardina Galiana L.¹, Campi R.¹, Sebastianelli A.¹, Pavone F.S.³, Nesi G.⁴, Ribal M.J.⁵, Serni S.¹, Gacci M.¹

Institutes: ¹University of Florence, Experimental and Clinical Medicine, Florence, Italy, ²National Research Council, INO - Istituto Nazionale di Ottica, Sesto Fiorentino, Italy, ³University of Florence, Physics, Sesto Fiorentino, Italy, ⁴University of Florence, Dept. of Health Sciences, Florence, Italy, ⁵Hospital Clínic de Barcelona, Dept. of Uro-Oncology, Barcelona, Spain

A1034

Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial

Authors: [Junlong W.](#)¹, Yuda L.², Kaiwei Y.³, Xiao L.⁴, Huina W.⁴, Tingting Y.⁴, Ran T.⁴, Jing G.⁴, Feng L.⁴, Shanbo C.⁴, Wei Y.³, Hailong H.², Dingwei Y.¹

Institutes: ¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²The Second Affiliated Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ³Peking University First Hospital, Dept. of Urology, Beijing, China, ⁴Acornmed Biotechnology, Research and Development Center, Beijing, China

A1032

A prospective, comparative, within-patient controlled multicenter phase III study comparing blue light cystoscopy versus white light cystoscopy for the detection of bladder cancer using modern HD 4K equipment

Authors: Li H.Z.¹, Hu H.L.², Huang J.³, Ma L.L.⁴, Zhang S.D.⁴, Guo J.M.⁵, Liu X.H.⁶, Guo Y.L.⁷, Wen J.¹, Zhang H.X.⁴, Jiang S.⁵, He W.³, Liu C.³, Yuan X.L.⁸, Haefner M.⁹, Weber B.-C.⁹, Young-Halvorsen K.¹⁰

Institutes: ¹Peking Union Medical College Hospital, Dept. of Urology, Beijing, China, ²Second Affiliated Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ³Sun Yat-Sen Memorial Hospital of Zhongshan University, Dept. of Urology, Guangzhou, China, ⁴Peking University Third Hospital, Dept. of Urology, Beijing, China, ⁵Sun Yat-sen Hospital Fudan University, Dept. of Urology, Shanghai, China, ⁶Peoples Hospital of Wuhan University, Dept. of Urology, Wuhan, China, ⁷The Central Hospital of Wuhan, Dept. of Urology, Wuhan, China, ⁸Jiangsu Yahong Meditech Co, Development Dept., Taizhou, China, ⁹Richard Wolf GmbH, Clinical Affairs Department, Knittlingen, Germany, ¹⁰Photocure ASA, Dept. of Clinical Development and Medical Affairs, Oslo, Norway

A1027

Photodynamic diagnosis (PDD) directed biopsies vs white light bladder mapping in patients with positive cytology and negative preoperative workup: an international multicenter retrospective study

On behalf of the European Association of Urology Young Academic Urologist Urothelial Working Group

Authors: Colucci C.F.¹, Soria F.¹, Livoti S.¹, Rosazza M.¹, Dutto D.¹, Marcq G.², Jarry E.², Mertens L.³, Moschini M.⁴, Deangelis M.⁴, Longoni M.⁴, Hurle R.⁵, Mancon S.⁵, Pichler R.⁶, Lackner F.⁶, Montorsi F.⁴, Gontero P.¹

Institutes: ¹AOU Città della Salute e della Scienza di Torino University of Turin School of Medicine, Dept. of Urology, Turin, Italy, ²Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Surgical Oncology, Dept. of Urology, Amsterdam, The Netherlands, ⁴Urological Research Institute IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁵Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Dept. of Urology, Rozzano Milan, Italy, ⁶Comprehensive Cancer Center Innsbruck CCCI Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria

A1028

Leveraging deep learning for real-time detection of bladder tumor in cystoscopy: a multi-center retrospective study

Authors: Li Y.¹, Ji Z.¹, Lv J.², Zhang H.³, Sun Y.¹, He C.⁴, Ye Z.¹

Institutes: ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dept. of Urology, Beijing, China, ²The Sixth Hospital of Beijing, Dept. of Urology, Beijing, China, ³Beijing Longfu Hospital, Dept. of Urology, Beijing, China, ⁴Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

A1021

A breakthrough non-invasive tool for early detection of bladder cancer in human urine: evaluation of a novel compact spectrometer.

Authors: Prata F.¹, Civitella A.¹, Basile S.¹, Iannuzzi A.¹, Tedesco F.¹, Ragusa A.¹, D'Addurno G.¹, Tuzzolo P.¹, Travino A.¹, Muto G.², Anceschi U.³, Simone G.³, Ciarrocchi D.⁴, Camerini C.⁴, Zompanti A.⁴, Muto G.⁵, Scarpa R.M.¹, Pennazza G.⁴, Santonico M.⁶, Papalia R.¹

Institutes: ¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²Unit of Oncologic Minimally-Invasive Urology and Andrology of Careggi Hospital, Experimental and Clinical Medicine, Florence, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴Unit of Electronics for Sensor Systems of Campus Bio-Medico University, Dept. of Engineering, Rome, Italy, ⁵GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy, ⁶Unit of Electronics for Sensor Systems of Campus Bio-Medico University, Dept. of Science and Technology for Sustainable Development and One Health, Rome, Italy

A1018

A novel Bladder Cancer diagnostic technique based on urine multimodal spectroscopy

Authors: Morselli S.¹, Manera A.¹, Baria E.², Cicchi R.², Liaci A.¹, Moscardi L.¹, Gajo L.¹, D'Amico A.¹, Bardina Galiana L.¹, Campi R.¹, Sebastianelli A.¹, Pavone F.S.³, Nesi G.⁴, Ribal M.J.⁵, Serni S.¹, Gacci M.¹

Institutes: ¹University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ²National Research Council, INO - Istituto Nazionale di Ottica, Sesto Fiorentino, Italy, ³University of Florence, Dept. of Physics, Sesto Fiorentino, Italy, ⁴University of Florence, Dept. of Health Sciences, Florence, Italy, ⁵Hospital Clínic de Barcelona, Dept. of Uro-Oncology, Barcelona, Spain

A1023

The impact of centralized uropathology review in the management of bladder cancer patients at the time of transurethral resection of the bladder

Authors: Robesti D.¹, Moschini M.¹, Tenace N.P.², Burgio G.¹, Re C.¹, Leni R.¹, De Angelis M.¹, Scilipoti P.¹, Pellegrino F.¹, Cannoletta D.¹, Gandaglia G.¹, Fossati N.³, Gallina A.³, Doglioni C.², Colecchia M.², Salonia A.¹, Montorsi F.¹, Briganti A.¹, Lucianò R.²

Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Division of Oncology - Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy, ³Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Dept. of Urology, Lugano, Switzerland

A1026

Unlocking the potential of urinary mutation and methylation biomarkers: A Game-Changing approach to optimizing candidates of NMIBC for Repeated TURBT - A prospective multicenter study

Authors: Lyu Q., Yang X., Cao Q.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A1031

Molecular subtyping, ADC assessment and FGFR testing reveals potential for co-targeting of FGFR3 with TROP2 & NECTIN4 – preview of Bladder BRIDGister.

Authors: Wirtz R.¹, Weber A.², Schubert T.², Kastner L.³, Friedersdorff F.⁴, Barski D.⁵, Otto T.⁵, Waldner M.⁶, Graff J.⁶, Veltrup E.¹, Linden F.¹, Schwandt M.¹, Hake R.⁷, Eidt S.⁶, Roggisch J.⁸, Koch S.⁸, Heidenreich A.³, Schanzenbach C.², Weissbach R.², Ecke T.⁹

Institutes: ¹STRATIFYER Molecular Pathology GmbH, Dept. of Translational Science, Cologne, Germany, ²Biotype GmbH, Dept. of Diagnostics, Dresden, Germany, ³University Clinic Cologne, Dept. of Urology, Cologne, Germany, ⁴Evangelisches Krankenhaus Königin Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ⁵Rheinlandklinikum, Dept. of Urology, Neuss, Germany, ⁶St. Elisabeth Hospital, Dept. of Urology, Cologne, Germany, ⁷Institute of Pathology at the St. Elisabeth Hospital, Dept. of Uropathology, Cologne, Germany, ⁸Helios Hospital, Institute of Pathology, Bad Saarow, Germany, ⁹Helios Hospital, Dept. of Urology, Bad Saarow, Germany

A1030

Prognostic Value of Micrometric Substaging in pT1 Bladder Cancer Patients Treated with En Bloc Transurethral Resection

Authors: Yanagisawa T.¹, Sato S.², Hayashida Y.³, Okada Y.⁴, Matsukawa A.¹, Iwatani K.¹, Shimoda M.², Takahashi H.², Kimura T.¹, Shariat S.F.⁵, Miki J.¹

Institutes: ¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²The Jikei University School of Medicine, Dept. of Pathology, Tokyo, Japan, ³National Hospital Organization Ureshino Medical Center, Dept. of Urology, Saga, Japan, ⁴Saitama Medical Center, Dept. of Urology, Saitama, Japan, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria

A1035

The importance of being grade 3 in primary non-muscle invasive bladder cancer

Authors: Beijert I.J.¹, Oskar O.², Gårdmark T.³, Holmberg L.⁴, Häggström C.⁴, Johnston A.⁵, Trail M.⁶, Hamid S.⁶, Dreyer B.A.⁷, Padovani L.⁸, Garau R.⁸, Hasan R.⁸, Ahmad I.⁵, Hendry D.⁵, Compérat E.M.⁹, Burger M.¹⁰, Gontero P.¹¹, Ribal M.J.¹², Van Der Kwast T.H.¹³, Babjuk M.¹⁴, Sylvester R.J.¹⁵, Mariappan P.⁸, Liedberg F.¹⁶, Van Rhijn B.W.G.¹⁷

Institutes: ¹Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands, ²Lund University, Institution of Translational Medicine, Malmö, Sweden, ³Danderyd Hospital Karolinska Institute, Dept. of Clinical Sciences, Stockholm, Sweden, ⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁵Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ⁶Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ⁷Victoria Hospital, Dept. of Urology, Kirkcaldy, United Kingdom, ⁸Western General Hospital, Edinburgh Bladder Cancer Surgery, Dept. of Urology, Edinburgh, United Kingdom, ⁹Tenon Hospital AP-HP Sorbonne University, Dept. of Pathology, Paris, France, ¹⁰Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹¹Città della Salute e della Scienza University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ¹²European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands, ¹³Princess Margaret Cancer Center University of Toronto, Laboratory Medicine Program, Toronto, Canada, ¹⁴Teaching Hospital Motol and 2nd Faculty of Medicine Charles University, Dept. of Urology, Prague, Czech Republic, ¹⁵European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands, ¹⁶Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ¹⁷Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands

A1033

Grade heterogeneity of NMIBC: Does it affect the outcomes of the intermediate and high risk patients treated with adequate adjuvant BCG?

Authors: Karaburun M.C.¹, Serbes E.D.², Akpınar C.¹, Obaid K.¹, Gogus C.¹, Kiremitci S.², Enneli D.², Baltacı S.¹, Suer E.¹

Institutes: ¹Ankara University, Dept. of Urology, Ankara, Türkiye, ²Ankara University, Dept. of Pathology, Ankara, Türkiye

A1025

The genetic information of non muscle invasive bladder cancer associated with recurrence

Authors: Lim D., Lee H.Y., Gu J.S., Gu H.M., Cho H.J., Kim T.H., Lim E., Jung Y.W., Park M.Y., Park K., Kang T.W., Oh K.J., Kim S.O., Yu S.H.

Institutes: Chonnam National University Medical School, Dept. of Urology, Gwangju, South Korea

A1022

Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle Invasive Bladder Cancer

Authors: Scheipner L., Zurl H., Altziebler J.V., Pichler G.P., Schöpfer-Schwab S., Jasarevic S., Gaisl M., Pohl K.C., Pumberger K., Andlar S., Hutterer G.C., Bele U., Leitsmann C., Leitsmann M., Augustin H., Zigeuner R., Ahyai S., Mischinger J.

Institutes: Medical University of Graz, Dept. of Urology, Graz, Austria

A1029

Lymphovascular invasion as prognostic factor in patients with T1 high-grade non-muscle-invasive bladder cancer

Authors: Laukhtina E.¹, Klemm J.¹, Fazekas T.¹, Matsukawa A.¹, Gontero P.², Soria F.², Babjuk M.³, Teoh J.Y.C.⁴, Moschini M.⁵, Karakiewicz P.I.⁶, Abufaraj M.⁷, Comperat E.⁸, Shariat S.F.¹

Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Studies of Torino, Division of Urology, Turin, Italy, ³Charles University, Dept. of Urology, Prague, Czech Republic, ⁴The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁵IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁶University of Montreal Health Center, Division of Urology, Montreal, Canada, ⁷The University of Jordan, Division of Urology, Amman, Jordan, ⁸Medical University of Vienna, Dept. of Pathology, Vienna, Austria

A1024

Pragmatic Clinico-pathological sub-classification of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) with multicentre validation

Authors: Mariappan P.¹, Johnston A.², Trail M.³, Hamid S.³, Hollins G.⁴, Dreyer B.A.⁵, Ramsey S.⁶, Padovani L.¹, Garau R.¹, Guerrero Enriquez J.⁷, Simpson H.⁵, Hasan R.¹, Sharpe C.⁸, Thomas B.G.¹, Maresca G.⁹, Boden A.¹⁰, Bhatt J.², Ahmad I.², Nandwani G.M.³, Chaudhry A.H.⁸, Khan R.S.¹⁰, Dimitropoulos K.⁹, Graham C.¹¹, Hendry D.²

Institutes: ¹Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ²Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ³Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ⁴University Hospital Ayr, Dept. of Urology, Ayr, United Kingdom, ⁵Victoria Hospital, Dept. of Urology, Kirkcaldy, United Kingdom, ⁶Raigmore Hospital, Dept. of Urology, Inverness, United Kingdom, ⁷The University of Edinburgh, Edinburgh Medical School, Edinburgh, United Kingdom, ⁸Dumfries and Galloway Royal Infirmary, Dept. of Urology, Dumfries, United Kingdom, ⁹Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, ¹⁰University Hospital Monklands, Dept. of Urology, Airdrie, United Kingdom, ¹¹The University of Edinburgh, Edinburgh Clinical Research Facility, Edinburgh, United Kingdom

Frontiers in renal cell carcinoma management: Surgical strategies and prognostic insights

Abstract session 47

08 April 2024
12:30 - 14:00

Location	Green Area, N04
Chairs	To be confirmed
	To be confirmed
	To be confirmed
	To be confirmed

A1052

Sutureless purely off-clamp Robot-assisted partial nephrectomy in solitary kidney: comparison of perioperative, pathologic and functional outcomes with renorrhaphy technique

Authors: Tuderti G., Mastroianni R., Misuraca L., Bove A., Anceschi U., Flammia R.S., Proietti F., D'Annunzio S., Brassetti A., Ferriero M., Guaglianone S., Leonardo C., Simone G.

Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A1038

Management and predictive factors of unplanned open conversion during minimally invasive renal tumor surgery

Authors: Branger N.¹, Doumerc N.², Bigot P.³, Knipper S.¹, Pignot G.¹, Audenet F.⁴, Bruyère F.⁵, Fontenil A.⁶, Parier B.⁷, Champy C.⁸, Roupret M.⁹, Waeckel T.¹⁰, Surlemont L.¹¹, Guy L.¹², Vignot L.¹³, Khene Z.E.¹⁴, Bernhard J.C.¹⁵

Institutes: ¹Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ²CHU Toulouse, Dept. of Urology, Toulouse, France, ³CHU Angers, Dept. of Urology, Angers, France, ⁴Hopital européen Georges Pompidou, Dept. of Urology, Paris, France, ⁵CHU Tours, Dept. of Urology, Tours, France, ⁶CHU Nimes, Dept. of Urology, Nimes, France, ⁷Kremlin Bicetre, Dept. of Urology, Paris, France, ⁸Hopital Henri Mondor, Dept. of Urology, Créteil, France, ⁹La Pitié Salpêtrière, Dept. of Urology, Paris, France, ¹⁰CHU Caen, Dept. of Urology, Caen, France, ¹¹CHU Rouen, Dept. of Urology, Rouen, France, ¹²CHU Clermont-Ferrand, Dept. of Urology, Clermont-Ferrand, France, ¹³CHU Nice, Dept. of Urology, Nice, France, ¹⁴CHU Rennes, Dept. of Urology, Rennes, France, ¹⁵CHU Bordeaux, Dept. of Urology, Bordeaux, France

A1046

Robotic partial nephrectomy in patients with a solitary kidney – a multicenter analysis

Authors: Katzendorn O.¹, Faraj Tabrizi P.¹, Schiefelbein F.², Schoen G.³, Wiesinger C.⁴, Pfuner J.⁴, Ubrig B.⁵, Gloger S.⁵, Nuhn P.⁶, Eraky A.⁶, Wagner C.⁷, Ayanle A.⁷, Kesch C.⁸, Al-Nader M.⁸, Hadaschik B.A.⁸, Fuhrmann C.¹, Kuczyk M.A.¹, Siemer S.⁹, Stöckle M.⁹, Zeuschner P.⁹, Harke N.N.¹

Institutes: ¹Hannover Medical School, Dept. of Urology and Urological Oncology, Hannover, Germany, ²Klinikum Wuerzburg Mitte, Missioklinik, Dept. of Urology, Wuerzburg, Germany, ³Urologische Klinik Muenchen - Planegg, Dept. of Urology, Munich, Germany, ⁴Klinikum Wels-Grieskirchen GmbH, Dept. of Urology, Wels, Austria, ⁵University Witten-Herdecke - Augusta-Kranken-Anstalt Bochum, Chair and Department of Urology, Bochum, Germany, ⁶University of Schleswig-Holstein Campus Kiel, Dept. of Urology, Kiel, Germany, ⁷St. Antonius Hospital Gronau, Dept. of Urology, Gronau, Germany, ⁸University Hospital Essen, Dept. of Urology, Essen, Germany, ⁹Saarland University, Dept. of Urology and Pediatric Urology, Homburg Saar, Germany

A1047

Impact of Positive Surgical Margin after Radical and Partial Nephrectomy for Renal Cell Carcinoma: A Multicenter Analysis.

Authors: Saitta C.¹, Cerrato C.¹, Capitanio U.², Autorino R.³, Beatrici E.⁴, Pandolfo S.³, Meagher M.¹, Antonelli A.⁵, Veccia A.⁵, Amparore D.⁶, Simone G.⁷, Tuderti G.⁷, Lughezzani G.⁴, Buffi N.⁴, Tanaka H.⁸, Pati D.⁹, Master V.⁹, Fujii Y.⁸, Porpiglia F.⁶, Montorsi F.², Derweesh I.¹

Institutes: ¹UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Rush Medical Univeristy, Dept. of Urology, Chicago, United States of America, ⁴IRCCS Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ⁵University of Verona, Dept. of Urology, Verona, Italy, ⁶San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁷IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁸Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ⁹Emory Medical Center, Dept. of Urology, Atlanta, United States of America

A1041

Comparison of outcomes between radical nephrectomy and partial nephrectomy in cT2 renal cell carcinoma: a KORCC registry propensity score matching

Authors: Chung Y.S.¹, Jung Kwon K.¹, Seok-Soo B.¹, Sung Kyu H.¹, Sangchul L.¹, Cheol K.², Chang Wook J.², Seok Ho K.³, Sung Hoo H.⁴, Ji Youl L.⁴, Yong-June K.⁵, Jinsoo C.⁶, Eu Chang H.⁷, Tae Gyun K.⁸, Hae Seong L.¹, Jun Hyeon N.¹, Jeong Keun S.¹, Jeong Won P.¹

Institutes: ¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnamsi, South Korea, ²Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ³Korea University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁴The Catholic University of Korea, College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University Hospital, Dept. of Urology, Cheongju, South Korea, ⁶National Cancer Center, Dept. of Urology, Goyang, South Korea, ⁷Chonnam National University Medical School, Dept. of Urology, Gwangju, South Korea, ⁸Kyungpook National University Chilgok Hospital, Dept. of Urology, Daegu, South Korea

A1051

Outcomes of partial and radical nephrectomy in patients with pathological T3a upstaging of clinical T1 renal cell carcinoma: an analysis from the International Marker Consortium for Renal Cancer (INMARC) Cohort

Authors: Fukuda S.¹, Kobayashi M.¹, Chen W.¹, Fujiwara M.¹, Nakamura Y.¹, Ishikawa Y.¹, Nakayama A.², Meagher M.³, Patil D.⁴, Waseda Y.¹, Tanaka H.¹, Yoshida S.¹, Saito K.², Derweesh I.H.³, Master V.A.⁴, Fujii Y.¹

Institutes: ¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Dokkyo Medical University Saitama Medical Center, Dept. of Urology, Saitama, Japan, ³University of California San Diego, Dept. of Urology, San Diego, United States of America, ⁴Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America

A1040

Comparative analysis of oncological and functional outcomes of radical and partial nephrectomy in pT3aN0M0 renal cell carcinoma: A multicenter propensity score-matched analysis

Authors: Saitta C.¹, Nguyen M.¹, Capitanio U.², Autorino R.³, Afari J.¹, Tanaka H.⁴, Patil D.⁵, Meagher M.¹, Mansour M.¹, Puri D.¹, Yuen K.¹, Mantovani M.⁶, Piccolini A.⁷, Garofano G.⁷, Cerrato C.¹, Antonelli A.⁸, Larcher A.², Porpiglia F.⁹, Montorsi F.², Fujii Y.⁴, Master V.⁵, Lughezzani G.⁷, Buffi N.⁷, Derweesh I.¹

Institutes: ¹UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ²San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Virginia Commonwealth University, Dept. of Urology, Richmond, United States of America, ⁴Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ⁵Emory Medical University, Dept. of Urology, Atlanta, United States of America, ⁶Humanitas University, Dept. of Biomedical Sciences, Rozzano, Italy, ⁷Humanitas Clinical Research Hospital, Dept. of Urology, Rozzano, Italy, ⁸University of Verona School of Medicine, Dept. of Urology, Verona, Italy, ⁹San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy

- A1048** **Prognostic Significance of the Site of Invasion in pT3a Renal Cell Carcinoma**
Authors: [Lee H.Y.](#)¹, Nam K.H.¹, Kim D.¹, Park J.J.¹, Kim D.¹, Suh J.¹, Kang M.², Seo S.I.², Jeong C.W.³, Kwak C.³, Song C.¹
Institutes: ¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Samsung medical center, Dept. of Urology, Seoul, South Korea, ³Seoul National University College of Medicine, Dept. of Urology, Seoul, South Korea
- A1053** **On-Clamp vs Off-Clamp Robotic Partial Nephrectomy to Treat pT3a Renal Cancers: A Multicenter Analysis**
Authors: [Brassetti A.](#)¹, Cartolano S.¹, Iuculano S.¹, Capecchi L.¹, Cacciatore L.¹, Bove A.M.¹, Proietti F.¹, Ferriero M.C.¹, Flammia R.S.¹, Tuderti G.¹, Mastroianni R.¹, Anceschi U.¹, Misuraca L.¹, D'Annunzio S.¹, Guaglianone S.¹, Leonardo C.¹, Amparore D.², Porphiglia F.², Simone G.²
Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy
- A1045** **Node positive non-clear cell renal cell carcinoma: oncological outcomes and genomic insights**
Authors: [Eismann L.](#)¹, Zucker M.², Dawidek M.¹, Reese S.¹, Posada Calderon L.¹, Aulitzky A.¹, Stief C.³, Coleman J.¹, Kotecha R.⁴, Carlo M.⁴, Chen Y.⁵, Reznik E.², Russo P.¹, Hakimi A.¹
Institutes: ¹MSKCC, Dept. of Urology, New York, United States of America, ²MSKCC, Dept. of Computational Oncology, New York, United States of America, ³LMU, Dept. of Urology, Munich, Germany, ⁴MSKCC, Dept. of Medical Oncology, New York, United States of America, ⁵MSKCC, Dept. of Pathology, New York, United States of America
- A1043** **Does Timing from Diagnosis to Surgery Impact Oncologic Outcomes in Patients with Nonmetastatic Clear-cell Renal Cell Carcinoma and Tumor Thrombus?**
Authors: [Khene Z-E.](#)¹, Bernhard J.C.², Bigot P.³, Bensalah K.¹
Institutes: ¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Bordeaux, Dept. of Urology, Bordeaux, France, ³Angers, Dept. of Urology, Angers, France
- A1049** **Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis**
Authors: [Liu Z.](#)
Institutes: Peking University Third Hospital, Dept. of Urology, Beijing, China
- A1044** **Prognostic factor and cancer-specific survival of the surgically managed renal cell carcinoma with venous thrombus: Thirty-year experience of single tertiary medical center**
Authors: [Lee H.Y.](#), Nam K.H., Kim D., Park J.J., Kim D., Lim B., Song C., You D., Jeong I.G., Hong J.H., Hong B., Ahn H., Suh J.
Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea

- A1042** **The impact of histological variants on oncological outcomes after surgical resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-Institutional Study**
Authors: Khene Z-E.¹, Fleury R.¹, Bigot P.², Bernhard J.C.³, Bensalah K.¹
Institutes: ¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Angers, Dept. of Urology, Angers, France, ³Bordeaux, Dept. of Urology, Bordeaux, France
- A1037** **Defining a caseload threshold for safe management of inferior vena cava tumor thrombus in renal cell carcinoma patients: German total population data with 3,700 cases from 2006 to 2020.**
Authors: Martin T., Koch R., Haak L., Flegar L., Reimold P., Huber J., Groebe C.
Institutes: Philipps-University Marburg, Dept. of Urology, Marburg, Germany
- A1039** **Robotic versus Open Level III-IV Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis**
Authors: Liangyou G., Xin M., Xu Z.
Institutes: Chinese PLA General Hospital, Dept. of Urology, Beijing, China
- A1036** **NODESAFE nomogram: A novel score system to predict lymph node involvement at the time of nephrectomy or nodal recurrence in non-metastatic renal cell carcinoma**
Authors: Saitta C.¹, Cerrato C.¹, Afari J.¹, Tanaka H.², Patil D.³, Yuen K.¹, Wang L.¹, Roberts J.¹, Meagher M.¹, Puri D.¹, Nguyen M.¹, Hakimi K.¹, Masaki K.², Shohei F.², Lughezzani G.⁴, Buffi N.⁴, Fujii Y.², Master V.³, Derweesh I.¹
Institutes: ¹UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ²Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ³Emory Medical Center, Dept. of Urology, Atlanta, United States of America, ⁴IRCCS Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy

A1050

The comparison of prognostic models accuracy in non-metastatic papillary renal cell carcinoma undergoing curative surgical treatments: An analysis from international multi-institutional papillary renal cell carcinoma database

Authors: Erdem S.¹, Campi R.², Klatte T.³, Capitanio U.⁴, Bertolo R.⁵, Roussel E.⁶, Amparore D.⁷, Pavan N.⁸, Wu Z.⁹, Mir M.C.¹⁰, Kara O.¹¹, Carbonara U.¹², Marchioni M.¹³, Anceschi U.¹⁴, Pazir Y.¹⁵, Muselaers S.¹⁶, Marandino L.¹⁷, Palumbo C.¹⁸, Warren H.¹⁹, Diana P.²⁰, Simone G.¹⁴, Minervini A.²¹, Serni S.², Ozcan F.¹

Institutes: ¹Istanbul University, Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Türkiye, ²University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Dept. of Experimental and Clinical Medicine, Florence, Italy, ³Helios Klinikum Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Urology Division of Experimental Oncology, Milan, Italy, ⁵University of Verona Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁶University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁷University of Turin San Luigi Gonzaga Hospital, Dept. of Oncology Division of Urology, Orbassano, Italy, ⁸University of Palermo, Dept. of Surgical Oncological and Stomatological Sciences Section of Urology, Palermo, Italy, ⁹Changhai Hospital, Naval Medical University, Dept. of Urology, Changhai, China, ¹⁰IMED Hospital, Dept. of Urology, Valencia, Spain, ¹¹Kocaeli University School of Medicine, Dept. of Urology, Kocaeli, Türkiye, ¹²University of Bari, Unit of Andrology and Kidney Transplantation, Dept. of Emergency and Organ Transplantation Urology, Bari, Italy, ¹³SS. Annunziata Hospital G. D'Annunzio University, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ¹⁴IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁵Istanbul University, Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Türkiye, ¹⁶Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ¹⁷Royal Marsden NHS Foundation Trust, Skin and Renal Unit, London, United Kingdom, ¹⁸University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy, ¹⁹University College London, Specialist Centre for Kidney Cancer Royal Free Hospital, Dept. of Urology, London, United Kingdom, ²⁰IRCCS Humanitas Clinic, Dept. of Urology, Milan, Italy, ²¹University of Florence, Unit of Urological Oncologic Minimally-Invasive Robotic Surgery and Andrology, Florence, Italy

Restoration of lower urinary tract functioning after oncological treatments

Thematic Session

08 April 2024
12:30 - 14:00

Location Purple Area, S01
Chairs F.C. Burkhard, Bern (CH)
C. Harding, Newcastle upon Tyne (GB)

Learning objectives

This session will explore three commonly encountered scenarios in functional and reconstructive urology:

- Post-prostatectomy incontinence
- Mesh insertion in patients with previous radiation treatment
- Reconstruction after radical cystectomy in the female patient..

Attendees will learn about the treatment options available and factors which may influence choice of surgery and hear from experts regarding their preferences. Patient factors which influence treatment choice will also be highlighted. The eagerly awaited data from the SATURN registry will be presented.

12:30 - 13:02

Rapid-fire debate Difficult post prostatectomy incontinence

12:30 - 12:32

Case presentation: Post prostatectomy incontinence + radiation therapy and proven UUI an SUI

L. Moris, Leuven (BE)

12:32 - 12:37

Medical and non invasive solutions are the best and the safest

F. Cruz, Porto (PT)

12:37 - 12:42

Try Pro-ACT balloons

To be confirmed

12:42 - 12:47

Male slings are possible

M. Tutolo, Milan (IT)

12:47 - 12:52

Sphincter is the best

F. Van Der Aa, Leuven (BE)

12:52 - 13:02

Discussion

13:02 - 13:12

State-of-the-art lecture Results of SATURN trial on complicated PPI treatment

L. De Kort, Utrecht (NL)

13:12 - 13:27

Case discussion SUI surgery in female with pelvic radiation history: Are synthetic mid-urethral sling indicated?

13:12 - 13:14

Case presentation

M.A. Cerruto, Verona (IT)

13:14 - 13:19

Yes

G. Karsenty, Marseille (FR)

13:19 - 13:24

No

P.E. Zimmern, Dallas (US)

13:24 - 13:27

Conclusion

M.A. Cerruto, Verona (IT)

13:27 - 13:42

Rapid-fire debate Reconstruction after radical cystectomy in females

Scientific Programme - EAU24

- 13:27 - 13:32 **Introduction: Reconstruction after radical cystectomy in females, from pelvic exenteration to organ-sparing**
V. Phé, Paris (FR)
- 13:32 - 13:37 **Privilege ileal conduit**
N. Thiruchelvam, Cambridge (GB)
- 13:37 - 13:42 **Propose neobladder**
S.T. De Cillis, Turin (IT)
- 13:42 - 13:52** **Neobladder with continent urinary diversion: Why, when and how?**
T.J. Greenwell, London (GB)

Biopsy route and methods of targeting

Abstract session 48

08 April 2024
12:30 - 14:00

Location Purple Area, S03
Chairs To be confirmed
To be confirmed
To be confirmed
T. Roumequere, Brussels (BE)

12:30 - 12:32

Introduction

12:32 - 12:42

MRI/US Fusion methods

A1068

Transperineal prostatic targeted biopsy utilizing fusion technique: An institutional case series

Authors: Abatangelo G., Minja A., Scremin E., Nigro F., Benedetto G., Bratti E., Cattaneo F., Sguotti P.

Institutes: Ospedale San Bortolo, Dept. of Urology, Vicenza, Italy

A1061

Comparative study between cognitive fusion targeted prostate biopsy technique and software-based magnetic resonance imaging-ultrasonography image-fusion targeted prostate biopsy technique in a high-volume hospital

Authors: Calzas Montalvo C., Sopena Sutil R., Juste Álvarez S., Gil Moradillo J., Garcia Gonzalez L., Rodriguez-Izquierdo Jimenez M., García Gómez B., Duarte Ojeda J.M., Caro González M.A.D.P., De la Calle Moreno A., Gonzalez Ginel I., García-Rayó Encinas C., Rodriguez Antolín A.

Institutes: Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain

12:42 - 13:32

Biopsy route

A1057

Transperineal prostate biopsy: An international Delphi consensus for best clinical practices

Authors: Storino Ramacciotti L.¹, Cacciamani G.E.¹, Kaneko M.¹, Rodler S.¹, Strauss D.¹, Rais-Bahrami S.², Wysock J.³, Tafuri A.⁴, Polascik T.J.⁵, Gill I.¹, Abreu A.L.¹

Institutes: ¹University of Southern California, Institute of Urology, Los Angeles, United States of America, ²University of Alabama, Dept. of Urology, Alabama, United States of America, ³New York University, Dept. of Urology, New York, United States of America, ⁴University of Verona, Dept. of Urology, Verona, Italy, ⁵Duke University Medical Center, Dept. of Urology, Durham, United States of America

A1062

Comparison between 14G and 18G needle in performing transperineal prostate biopsies: preliminary results on sample quality, patient discomforts and complications rates from a non-inferiority randomized trial

Authors: Panunzio A.¹, Tafuri A.¹, Rizzo M.¹, Fasano C.², Zacheo F.¹, Orlando R.¹, Mancini A.¹, De Carlo F.¹, Di Cosmo F.¹, Luperto E.¹, Greco F.³, Giordano L.³, Maglietta A.², Pagliarulo V.¹

Institutes: ¹Vito Fazzi Hospital, Dept. of Urology, Lecce, Italy, ²Vito Fazzi Hospital, Dept. of Pathology, Lecce, Italy, ³Vito Fazzi Hospital, Dept. of Radiology, Lecce, Italy

- A1069** **Freehand Single-Port Access Transperineal Ultrasound Guided Biopsy versus Transrectal Ultrasound Guided Prostate Biopsy Under Local Anesthesia: A Randomized Prospective, Cross-Sectional Study**
Authors: Yadao J.E.G., Del Rio R., Madrona E.P., Tan K.M., Alpas M., Macalalag M.E.
Institutes: Veterans Memorial Medical Center, Dept. of Urology, Quezon City, Philippines
- A1054** **MRI/TRUS fusion-guided transperineal versus transrectal prostate biopsy: A large, multiracial and ethnically diverse cohort**
Authors: Storino Ramacciotti L., Kaneko M., Rodler S., Mohideen M., Aron M., Hopstone M., Cacciamani G.E., Gill I., Abreu A.L.
Institutes: University of Southern California, Institute of Urology, Los Angeles, United States of America
- A1063** **Retrospective analysis of the learning curve for transperineal robotic-assisted prostate biopsy**
Authors: Sigle A., Hackländer A., Himmelsbach R.J., Weishaar M., Morlock J., Grabbert M., Gratzke C., Jilg C.A.
Institutes: University Hospital Freiburg, Dept. of Urology, Freiburg, Germany
- A1070** **Grid-based cognitive diagnostic transperineal prostatic biopsies without transrectal ultrasound imaging**
Authors: Sahni D.S.¹, Morrison J.², Leung H.³
Institutes: ¹NHS Greater Glasgow and Clyde, Dept. of Urology, Glasgow, United Kingdom, ²NHS Greater Glasgow and Clyde, Dept. of Radiology, Glasgow, United Kingdom, ³University of Glasgow, School of Cancer Sciences, Glasgow, United Kingdom
- A1058** **Learning Curve Analysis in Transperineal MRI/TRUS Fusion Prostate Biopsy: Impact and Outcomes**
Authors: Kaneko M.¹, Ramacciotti L.S.¹, Paralkar D.¹, Jadvar D.S.¹, Cacciamani G.E.¹, Desai M.¹, Aron M.¹, Aron M.², Hopstone M.³, Gill I.S.¹, Abreu A.L.¹
Institutes: ¹University of Southern California, Institute of Urology, Center for Image-Guided Surgery Focal Therapy and Artificial Intelligence for Prostate Cancer, Los Angeles, United States of America, ²University of Southern California, Dept. of Pathology, Los Angeles, United States of America, ³University of Southern California, Dept. of Radiology, Los Angeles, United States of America
- A1056** **Trans perineal precision point prostate biopsies: A paradigm shift in prostate cancer diagnosis. A retrospective analysis of 1000 cases.**
Authors: Anwar B., Quddus B.Q., Rao P., Khan S., Islam J.U., Ghiblawi S.
Institutes: Blackpool Victoria Hospital, Dept. of Urology, Blackpool, United Kingdom
- A1060** **Prospective per-target analysis of the added value of probe-tethered access cannulas in cognitive transperineal prostate biopsy of MRI targets**
Authors: Orecchia L., Germani S., Colalillo G., Fasano A., Ricci M., Rosato E., Asimakopoulos A.D., Albisinni S., Finazzi Agrò E., Miano R.
Institutes: AOU Policlinico Tor Vergata, University of Rome Tor Vergata, Dept. of Urology, Rome, Italy
-

- A1059** **Transperineal vs. Transrectal MRI/TRUS Fusion Biopsy: A Comparative Analysis of Index Cancer Characterization in Radical Prostatectomy Specimens**
Authors: Kaneko M.¹, Paralkar D.¹, Ramacciotti L.S.¹, Jadvar D.S.¹, Cacciamani G.E.¹, Hopstone M.², Djaladat H.¹, Desai M.¹, Aron M.¹, Aron M.³, Gill I.S.¹, Abreu A.L.¹
Institutes: ¹University of Southern California, Institute of Urology, Center for Image-Guided Surgery Focal Therapy and Artificial Intelligence for Prostate Cancer, Los Angeles, United States of America, ²University of Southern California, Dept. of Radiology, Los Angeles, United States of America, ³University of Southern California, Dept. of Pathology, Los Angeles, United States of America
- 13:32 - 13:57** **Trans perineal biopsy route and anesthesia**
- A1064** **Does inhalational methoxyflurane (Penthrox®) improve pain control during local anaesthetic transperineal biopsy of the prostate?**
Authors: Whiting D., Yousaf A., Adamou C., Darlington D., Papadopoulos D., Carbonara U., Kusuma M., Patil K., Moschonas D., Perry M., Abou Chedid W.
Institutes: Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom
- A1066** **Perineal infiltration of bupivacaine at the time of transperineal prostate biopsy. Does it reduce pain in the recovery bay?**
Authors: Al-Khanaty A.¹, Mcgrath S.², Qin K.¹, Perera M.¹, Papa N.³, Bolton D.¹, Lawrentschuk N.⁴
Institutes: ¹Austin Health, Dept. of Urology, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Dept. of Urology, Melbourne, Australia, ³The University of Melbourne, School of Public Health and Preventative Medicine, Melbourne, Australia, ⁴The Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia
- A1065** **Transperineal fusion biopsies in the office setting: Impact of Sufentanil**
Authors: Pluchino A., Lopez Prieto A., Avila L.A., Gonzalez P.G., Egui-Benatuil G., Pluchino S.P., Bianco F.
Institutes: Urological Research Network, Dept. of Urology, Miami Lakes, United States of America
- A1055** **Local anaesthetic transperineal prostate biopsy: what is the learning curve?**
Authors: Mayor N., Salih A., Inder M., Light A.J.W., Eldred-Evans D., Bertonecchi Tanaka M., Connor M.J., Shah T.T., Ahmed H.U.
Institutes: Imperial College London, Dept. of Urology, London, United Kingdom
- A1067** **Clinical evaluation of office-based MR-guided transperineal prostate biopsies without the use of antibiotic prophylaxis**
Authors: Boesen L.¹, Nørgaard N.¹, Bisbjerg R.¹, Al-Hamadani M.M.N.¹, Sjölin C.S.¹, Løgager V.B.²
Institutes: ¹Herlev Gentofte University Hospital, Dept. of Urology and Urological Research, Herlev, Denmark, ²Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark
- 13:57 - 14:00** **Expert summary**
-

Identifying, preventing and managing complications

Video session 16

08 April 2024
12:30 - 14:00

Location Green Area, S04
Chairs R. Gaston, Bordeaux Cedex (FR)
To be confirmed
To be confirmed

- V119** **Nightmare surgical scenario during robotic nephroureterectomy for unexpected ureteral endometriosis infiltrating the external iliac artery**
Authors: Roggero L.R., Brancelli C., Corghi G., Migliorini F., Cerruto M.A., Bertolo R.G., Veccia A., Antonelli A.
Institutes: Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy
- V120** **Variations in Promontory Anatomy Complicating Robotic Sacrocolpopexy**
Authors: Zimmern P.E.¹, Souders C.², Goueli R.¹, Trivedi H.¹, Khatri G.¹
Institutes: ¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America
- V121** **Robotic parastomal hernia repair after radical cystectomy**
Authors: Fabregas Drnda M., Perez-Reggeti J.I., Lozano V., Suarez J.F., Vignes F.
Institutes: Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain
- V122** **Face-To-Face Robot-Assisted and Laparoscopic Complex Vesicovaginal Fistula Repair**
Authors: Miranda M.¹, Leitao T.¹, Fernandes M.¹, Ye A.¹, Chambino J.¹, Osório F.², Maes K.³, Palma Dos Reis J.¹
Institutes: ¹Centro Hospitalar Universitário Lisboa Norte, Dept. of Urology, Lisbon, Portugal, ²Hospital da Luz Lisboa, Dept. of Gynaecology, Lisbon, Portugal, ³Hospital da Luz Lisboa, Dept. of Urology, Lisbon, Portugal
- V123** **Robotic re-exploration in post robot assisted radical cystectomy mechanical bowel obstruction: It is feasible**
Authors: Khanna A., Singh A., Vasudev V., Pratihari S., Rawal S.
Institutes: Rajiv Gandhi Cancer Institute and Research Centre, Dept. of Urology and Robotic Surgery, New Delhi, India
- V124** **Buccal Mucosa Endo-laparoscopic repair of Vesico-urethral stenosis after Radical Prostatectomy**
Authors: Smets H., Brits T., De Wachter S., De WIn G.
Institutes: University hospital Antwerp, Dept. of Urology, Antwerp, Belgium
- V125** **Robot assisted retzius sparing trans-vesical pull-through technique for reconstruction of vesicourethral anas**
Authors: Koshmelev A., Monod P.C., Baranova E.O., Zhivov A.V.
Institutes: Ilyinskaya Hospital, Dept. of Urology, Moscow, Russia

V126

Robotic Vesico-Urethral Anastomosis Re-fashioning after Urinary Leak following Radical Robotic Prostatectomy

Authors: Al-Bermani O.¹, Day E.¹, Tzelves L.¹, Olphert J.¹, So C.², Tandogdu Z.¹, Shaw G.¹, Lamb B.¹

Institutes: ¹University College London Hospital, Dept. of Urology, London, United Kingdom, ²University College London Hospital, Dept. of Radiology, London, United Kingdom

Transgender surgery

Thematic Session

08 April 2024
12:30 - 14:00

Location Green Area, W01
Chairs R. Djinic, Belgrade (RS)
S.C. Morgenstern, Frankfurt am Main (DE)

Learning objectives

This session gives an update on transgender surgery for the Urologist. The various techniques for male to female including the inversion technique and when this goes wrong the alternative vaginoplasty options. The common types of female to male affirmation surgery will be discussed including metoidioplasty, forearm flap phalloplasty and latissimus dorsi flaps. These surgeries have high complication rates and so separate talks will be given on this, in particular urethral complications. The final stage of prosthetics will be updated

12:30 - 12:32	Introduction
12:32 - 12:40	Tips and tricks: Microsurgery, flap technology and cosmetics To be confirmed
12:40 - 13:07	Male-to-Female: Sex Reassignment Surgery (SRS)
12:40 - 12:48	An overview N. Morel Journal, Lyon (FR)
12:48 - 12:56	M2F SRS: Penile Inversion Surgery - Techniques C. Trombetta, Trieste (IT)
12:56 - 13:04	Re-do Vaginoplasty - Rectosigmoid, Skin, Peritoneum... S. Krege, Essen (DE)
13:04 - 13:07	Discussion
13:07 - 13:41	Female-to-Male: Sex Reassignment Surgery (SRS)
13:07 - 13:15	Male genital reconstruction - Metoidioplasty: New advances W.G. Lee, London (GB)
13:15 - 13:23	Radial forearm flap phalloplasty: Advantages and disadvantages M. Falcone, Torino (IT)
13:23 - 13:31	Latissimus dorsi phalloplasty B. Spiridonescu, Bucharest (RO)
13:31 - 13:41	Panel discussion
13:41 - 13:49	Urethral reconstruction and complications in total phalloplasty G. Pigot, Amsterdam (NL)
13:49 - 13:57	Prosthesis implantation in total phalloplasty: Options and complications D.J. Ralph, London (GB)
13:57 - 14:00	Discussion and closure

Basic research and trials: localized and locally advanced prostate cancer

Abstract session 49

08 April 2024
12:30 - 14:00

Location Green Area, W03
Chairs To be confirmed
To be confirmed
G. Van Der Pluijm, Leiden (NL)
To be confirmed

A1073

Population genetics identifies distinct subsets of prostate cancer risk variants between men of European, African and East Asian ancestry

Authors: Molokwu C.¹, Useh E.², Venugopal S.³

Institutes: ¹Bradford Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Bradford, United Kingdom, ²University College London, Dept. of Cell and Gene Therapy, London, United Kingdom, ³The Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Dept. of Urology, Liverpool, United Kingdom

A1078

Folate receptor 2-positive tumor-associated macrophages exert immunosuppressive function in prostate cancer

Authors: Zhou Q., Ou Y., Dai X., Zhang J., Yang C., Zhang L., Jiang H.

Institutes: Huashan Hospital Fudan University, Dept. of Urology, Shanghai, China

A1079

Urinary-exosomal transcript markers for discriminating indolent from aggressive disease of prostate cancer patients under active surveillance

Authors: Borkowetz A., Gräfe S., Thomas C., Fuessel S., Erdmann K.

Institutes: Technische Universität Dresden, Dept. of Urology, Dresden, Germany

A1084

Analysis of transcriptomic data reveals the landscape of cholesterol metabolism in prostate cancer and impact of related signature on survival.

Authors: An Y., Sun J.X., Xu J.Z., Liu C.Q., Zhang S.H.

Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

A1082

The Interplay between Zonal Microenvironments and Cancer Development in the Prostate

Authors: Ali A.¹, Murtuza S.², Lee D.², Sachdeva A.³, Hart C.³, Azhar F.³, Mevel R.⁴, Elumalai T.⁵, Rajendran I.⁶, Jain Y.⁷, Clarke N.³, Oliveira P.⁸, Choudhury A.², Bristow R.⁹, Baena E.¹⁰

Institutes: ¹Cancer Research UK Manchester Institute, Dept. of Translational Oncogenomics and Prostate Oncobiology, Manchester, United Kingdom, ²University of Manchester, School of Health Sciences, Manchester, United Kingdom, ³University of Manchester, GU Cancer Research Group, Manchester, United Kingdom, ⁴Cancer Research UK Manchester Institute, Dept. of Stem Cell Biology, Manchester, United Kingdom, ⁵Cambridge University Hospitals NHS Foundation Trust, Dept. of Oncology, Cambridge, United Kingdom, ⁶Cambridge University Hospitals NHS Foundation Trust, Dept. of Radiology, Cambridge, United Kingdom, ⁷The Christie NHS Foundation Trust, Dept. of Radiology, Manchester, United Kingdom, ⁸The Christie NHS Foundation Trust, Dept. of Pathology, Manchester, United Kingdom, ⁹Cancer Research UK Manchester Institute, Dept. of Translational Oncogenomics, Manchester, United Kingdom, ¹⁰Cancer Research UK Manchester Institute, Dept. of Prostate Oncobiology, Manchester, United Kingdom

A1086

Whole exome sequencing analysis in low-risk prostate cancer patients with known family history. Implication for active surveillance.

Authors: Cucchiara V., Gandaglia G., Stabile A., Mazzone E., Leni R., Scilipoti P., Longoni M., Viti A., Santangelo A., Montorsi F., Briganti A.

Institutes: IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

A1087

Utilizing patient-derived organoids of prostate cancer to predict functional homologous recombination repair deficiency and targeted therapy response

Authors: Elsesy M.E.¹, Oh-Hohenhorst S.J.², Oing C.¹, Eckhardt A.¹, Burdak-Rothkamm S.¹, Alawi M.³, Müller C.³, Schüller U.⁴, Maurer T.², Von Amsberg G.², Petersen C.¹, Rothkamm K.¹, Mansour W.Y.¹

Institutes: ¹University Medical Center Hamburg-Eppendorf, Dept. of Radiotherapy and Radiooncology, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ³University Medical Center Hamburg-Eppendorf, Bioinformatics Core, Hamburg, Germany, ⁴University Medical Center Hamburg-Eppendorf, Institute of Neuropathology, Hamburg, Germany

A1074

Endothelial-mesenchymal transition in the cancer microenvironment promotes neuroendocrine differentiation of prostate cancer

Authors: Kageyama T.¹, Kato M.², Sekito S.¹, Sugino Y.¹, Sasaki T.¹, Masui S.¹, Nishikawa K.¹, Murakawa Y.³, Inoue T.¹

Institutes: ¹Mie University, Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan, ²Aichi Cancer Center Hospital, Dept. of Urology, Nagoya, Japan, ³Kyoto University, Institute for the Advanced Study of Human Biology, Kyoto, Japan

- A1071** **Cholesterol metabolism reprogramming induces the secretion of MDK to promote M2 polarization of macrophages and promotes the progression of prostate cancer**
Authors: Peng S.R., [Huang H.](#)
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- A1083** **Assessing Epigenetic Features Associated with Lymph Node Metastases in Prostate Cancer**
Authors: [Bandini M.](#)¹, Zaurito P.¹, Barletta F.¹, Cirulli G.O.¹, Lucianò R.², Giannese F.³, Scotti G.M.³, Cucchiara V.¹, Stabile A.¹, Mazzone E.¹, Oneto C.³, Sorce G.¹, Tenace N.P.², Scarfò F.², Brembilla G.⁴, Esposito A.⁴, Morelli M.³, Lazarevic D.³, De Cobelli F.⁴, Doglioni C.², Tonon G.³, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Center for Omics Sciences, Milan, Italy, ⁴Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy
- A1081** **Variable anti-cancer effects of statins in androgen-insensitive prostate cancer and increased sensitivity of docetaxel-resistant cells to lipophilic statins via the AKT pathway**
Authors: [Oh-Hohenhorst S.J.](#)¹, Gu J.¹, Elsesy M.E.², Mansour W.Y.², Fabian F.¹, Schumacher U.³, Lange T.³, Hohenhorst J.L.¹, Saad F.⁴, Graefen M.¹, Tilki D.¹
Institutes: ¹University Medical Center Hamburg Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Dept. of Radiotherapy and Radiooncology, Hamburg, Germany, ³University Medical Center Hamburg-Eppendorf, Institut for Anatomy and Experimental Morphology, Hamburg, Germany, ⁴Centre Hospitalier de l'Université de Montréal, Dept. of Urology, Montreal, Canada
- A1085** **Mimicking physiological conditions to optimize the development of prostate cancer patient-derived organoids**
Authors: Dolgos R.¹, [Parmentier R.](#)¹, Bubendorf L.², Seifert H.³, Mortezaei A.³, Rentsch C.³, Le Magnen C.¹
Institutes: ¹University Hospital Basel, University Basel, Dept. of Urology - Institute of Medical Genetics and Pathology - Dept. of Biomedicine, Basel, Switzerland, ²University Hospital Basel, University Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland, ³University Hospital Basel, Dept. of Urology, Basel, Switzerland
- A1075** **Development and validation of a novel prostate-specific membrane antigen-targeted near infrared imaging agent S0456@PBP-EVs for fluorescence guided surgery in prostate cancer**
Authors: [Sun J.](#), Luan Y., Xia Q., Xu J., Wang S.
Institutes: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China
-

- A1080** **Targeting cofilin 1 reverses the immunotherapy-induced cold phenotype in prostate cancer through cellular cytoskeletal reorganization**
Authors: Le L., Zihua W.
Institutes: Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China
- A1077** **Investigating the STING pathway in the prostate cancer tumour immune microenvironment and radiosensitivity**
Authors: Chan C.Y.¹, Kwon J.¹, Murphy E.A.¹, Phyu S.M.¹, Shigemori K.¹, Mills I.G.², Bryant R.J.², Parkes E.E.¹
Institutes: ¹University of Oxford, Dept. of Oncology, Oxford, United Kingdom, ²University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
- A1076** **Enhancing novel multimodality therapy for prostate cancer, combining radiotherapy, vascular-targeted photodynamic therapy, and anti-CD73 immunotherapy**
Authors: Sjoberg H.T.¹, Macklin S.¹, Philippou Y.¹, Murphy E.A.¹, Tullis I.², Jones K.², Stribbling S.², Preise D.³, Agemy L.³, Yechezkel T.³, Giaccia A.², Mills I.G.¹, Muschel R.², Vojnovic B.², Scherz A.³, Hamdy F.C.¹, Bryant R.J.¹
Institutes: ¹University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ²University of Oxford, Dept. of Oncology, Oxford, United Kingdom, ³The Weizmann Institute of Science, Dept. of Plant and Environmental Sciences, Rehovot, Israel
- A1072** **Single-cell Secretion Analysis Unveils Autocrine IL11-mediated Resistance to Docetaxel in Prostate Cancer via Activation of the JAK3/STAT4 Pathway.**
Authors: Cheng B.S., Huang H.
Institutes: Sun Yat sen Memorial Hospital Sun Yat-sen University, Dept. of Urology, Guangzhou, China

Male sexual dysfunction: Advancing medical therapy

Abstract session 50

08 April 2024
12:30 - 14:00

Location	Green Area, W06
Chairs	To be confirmed
	To be confirmed
	To be confirmed

12:30 - 12:45

RCTs in andrology: can we change practice?

A1103

Early Recovery of Erectile Function After Intrafascial Nerve Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Randomized Comparison of PDE5Is vs. Prostaglandin (PG) vs. Combination Therapy (PGE + PDE5Is)

Authors: Candita G.¹, Suraci P.P.¹, Rera O.A.¹, Sequi M.B.¹, Valenzi F.M.¹, Antonioni A.¹, Scalzo S.¹, Martino G.¹, Gianfrancesco F.¹, Graziani D.¹, Al Salhi Y.¹, Fuschi A.¹, De Nunzio C.², Nacchia A.², Sciarra A.³, Franco G.³, Carbone A.¹, Pastore A.L.¹

Institutes: ¹Sapienza University of Rome, Dept. of Medical Surgical Sciences And Biotechnologies Sapienza University Of Rome , Latina, Italy, ²Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology, Rome, Italy

A1094

PRePED study: a randomised, double-blind controlled trial to evaluate the efficacy of intracavernosal infusion of platelet rich plasma (PRP) against control (platelet poor plasma) in the treatment of vasculogenic erectile dysfunction. Preliminary results

Authors: Fernandez Pascual E.¹, Curvo R.², Centeno Soto G.³, Martínez-Ballesteros C.⁴, Turo Antona J.⁴, Prieto L.⁴, Carballido J.⁴, Avendano Solá C.³, Bueno J.L.⁵, Martínez-Salamanca J.I.⁴

Institutes: ¹Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ²Hospital Universitario del Sureste, Dept. of Urology, Arganda, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda, Dept. of Clinical Pharmacology, Majadahonda, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Dept. of Urology, Majadahonda, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda, Dept. of Hematology, Majadahonda, Spain

A1092

Treatment of Erectile Dysfunction using Digital Health Applications (DiGA) - Results of a Prospective, Randomized, Controlled, Single-Blind Study (RCT) (EDDIG Study)

Authors: Zitzmann M.¹, Cremers J.¹, Krallmann C.¹, Dreger N.M.², Raschke R.³, Khaljani E.⁴, Maxeiner A.⁵, Miller K.⁶, Wiemer L.⁷, Kliesch S.¹

Institutes: ¹University Clinics Muenster, Dept. of Clinical and Surgical Andrology, Muenster, Germany, ²Urologie am Malkasten, Dept. of Urology, Düsseldorf, Germany, ³Urological Practice Urology-Teltow, Dept. of Urology, Teltow, Germany, ⁴Uro-Werder, Dept. of Urology, Werder-Havel, Germany, ⁵Fasanus, Dept. of Urology, Berlin, Germany, ⁶Charite, Dept. of Urology, Berlin, Germany, ⁷Kranus Health, Dept. of Development, Munich, Germany

12:45 - 13:20

Erectile dysfunction and its clinical correlates

- A1098** **A Novel Machine Learning-based Risk Classification For Vascular Damage In Men With Erectile Dysfunction**
Authors: Belladelli F.¹, Pozzi E.¹, Corsini C.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Cattafi F.¹, Oddo M.¹, Malvestiti M.¹, Ramadani R.¹, Candela L.¹, Capogrosso P.², Boeri L.³, Zahiti L.⁴, Mattei A.⁴, d'Arma A.¹, Dehò F.², Montorsi F.¹, Salonia A.¹
Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi - University of Insubria, Dept. of Urology, Varese, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore - University of Milan, Dept. of Urology, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland
- A1096** **Reassessing Cardiovascular Risk Stratification in Men with Erectile Dysfunction: Beyond the Princeton Consensus**
Authors: Lorigo J.¹, Ramalho A.R.¹, Figueiredo B.R.¹, Tavares Silva E.T.S.¹, Afonso Mendes P.¹, Figueiredo A.F.¹, Gomes D.²
Institutes: ¹Centro Hospitalar e Universitário de Coimbra, Dept. of Urology, Coimbra, Portugal, ²USF Serra da Lousã, Faculty of Medicine of University of Coimbra, Coimbra, Portugal
- A1091** **A paradoxical association between asthma and erectile dysfunction: A bidirectional Mendelian randomization study**
Authors: Lyu X.Y., Xu X.Y., Luo D.Y.
Institutes: West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China
- A1095** **Erectile Dysfunction after COVID-19 Infection in Egyptian Individuals: An Observational Longitudinal Study.**
Authors: Zoeir A.¹, Khaled O.¹, Hanteera M.², Eltatawy H.¹
Institutes: ¹Tanta University, Dept. of Urology, Tanta, Egypt, ²Tanta University, Dept. of Pulmonology, Tanta, Egypt
- A1090** **Artificial Intelligence in Andrology. Can we predict long-term erectile dysfunction following COVID-19?**
Authors: Natal F.¹, Conde Redondo M.C.¹, Sierrasesumaga Martin N.¹, Garcia Vina A.², Marfil Pena C.³, Bahillo Martinez A.⁴, Tamayo Velasco A.⁵, Jojoa M.⁴, Tamayo Gomez E.⁶
Institutes: ¹Clinic University Hospital, Dept. of Urology, Valladolid, Spain, ²Rio Hortega University Hospital, Dept. of Urology, Valladolid, Spain, ³Santa Barbara Hospital, Dept. of Urology, Soria, Spain, ⁴University of Valladolid, Valladolid, Spain, ⁵Clinic University Hospital, Dept. of Haematology and Hemotherapy Service, Valladolid, Spain, ⁶University of Valladolid, Dept. of Surgery, Valladolid, Spain
- A1105** **More negative sexual self-concept in middle-aged men with sexual dysfunctions: results of the Bavarian Men's Health-Study**
Authors: Herkommer K.¹, Meissner V. .H.¹, Soehne V.¹, Dinkel A.², Jahnen M.¹, Schiele S.¹, Kron M.³, Gschwend J.E.¹
Institutes: ¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Psychosomatic Medicine and Psychotherapy, Munich, Germany, ³University of Ulm, Institute of Epidemiology and Medical Biometrics, Ulm, Germany
-

A1089

Limitations of IIEF-15 in the preoperative assessment of patients undergoing surgery for prostate disease

Authors: Maiolino G., Paladini A., Mucciardi F., La Mura R., Rizzo D., Russo M., Tancredi A., Guadagni L., Mangione P., Cochetti G.
Institutes: University of Perugia, Urology Clinic, Perugia, Italy

13:20 - 13:35

Assessing the effects of therapy beyond erectile hardness

A1097

The Effects of PDE5i on Psychological Well-Being in ED Patients

Authors: Belladelli F.¹, Pozzi E.¹, Bertini A.¹, Corsini C.¹, Raffo M.¹, Negri F.¹, Oddo M.¹, Candela L.¹, Capogrosso P.², Boeri L.³, Zahiti L.⁴, Mattei A.⁴, d'Arma A.¹, Dehò F.², Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi - University of Insubria, Dept. of Urology, Varese, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore - University of Milan, Dept. of Urology, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland

A1099

Duration of untreated ED is associated with overall impoverishment of male sexual function

Authors: Belladelli F.¹, Pozzi E.¹, Corsini C.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Cattafi F.¹, Oddo M.¹, Malvestiti M.¹, Ramadani R.¹, Candela L.¹, Capogrosso P.², Boeri L.³, Zahiti L.⁴, Mattei A.⁴, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi - University of Insubria, Dept. of Urology, Varese, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore - University of Milan, Dept. of Urology, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland

A1104

Treatment adherence disparities in men with primary erectile dysfunction: a comparative study of psychogenic and organic cases

Authors: Corsini C.¹, Pozzi E.¹, Belladelli F.¹, Bertini A.¹, Raffo M.¹, Negri F.¹, Cattafi F.¹, Malvestiti M.¹, Candela L.¹, Capogrosso P.², Boeri L.³, Zahiti L.⁴, Mattei A.⁴, Dehò F.², d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi, Dept. of Urology, Varese, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore, Dept. of Urology, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland

13:35 - 14:00

Premature ejaculation

A1100

Premature and delayed ejaculation: an update of latency time and comparison between male and female perception in the largest cohort of study up to day

Authors: Lo Re M.¹, Lo Giudice A.², Pezzoli M.¹, Gajo L.¹, Giunti D.³, Polloni G.⁴, Russo G.I.², Di Dio M.⁵, Minervini A.¹, Cocci A.¹

Institutes: ¹AOU Careggi, Dept. of Urology, Florence, Italy, ²University of Catania, Dept. of Urology, Catania, Italy, ³Centro integrato sessuologia clinica Il Ponte, Dept. of Sessuology, Florence, Italy, ⁴Centre of Pshycology, Dept. of Pshycology, Como, Italy, ⁵SS Annunziata Hospital, Dept. of Surgery, Dept. of Urology, Cosenza, Italy

- A1088 Ejaculatory duct obstruction: A single centre experience over 14 years**
Authors: Schirmann A., Leung C., Chiriaci G., Katelaris A., Allen C., Ralph D., Sangster P.
Institutes: University College London Hospital, Dept. of Andrology, London, United Kingdom
- A1093 Prospective and comparative study to evaluate the impact of the male masturbation device "Controleyac®" by Androgenital® on premature ejaculation: Functional results, safety, and satisfaction assessment**
Authors: Alonso Isa M.^{1,3}, García Gómez B.², Garcia Rojo E.³, Pena Vallejo H.⁴, Caro González M.A.D.P.⁴, Juste Álvarez S.⁴, Calzas Montalvo C.⁴, Sopena Sutil R.⁴, Rodríguez Antolín A.⁴, Romero Otero J.³
Institutes: ¹Hospital 12 de Octubre Hm Puerta del Sur and Roc Clinic, Dept. of Urology, Madrid, Spain, ²Hospital 12 de Octubre Hm Montepincipe and Roc Clinic, Dept. of Urology, Madrid, Spain, ³HM Sanchinarro and ROC Clinic, Dept. of Urology, Madrid, Spain, ⁴Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain
- A1102 Multicentre Study On Premature Ejaculation Treatment with Pelvic Floor Muscle Rehabilitation: Analysis of 5 Years Results.**
Authors: Pastore A.L.¹, Maruccia S.², Suraci P.P.¹, Rera A.¹, Sequi M.B.¹, Valenzi F.M.¹, Antonioni A.¹, Scalzo S.¹, Candita G.¹, Martino G.¹, Gianfrancesco F.¹, Al Salhi Y.¹, Fuschi A.¹, De Nunzio C.³, Lombardo R.³, Del Giudice F.⁴, Sciarra A.⁴, Di Pierro G.⁴, Franco G.⁴, Carbone A.¹
Institutes: ¹Sapienza University of Rome, Dept. of Medico Surgical Sciences and Biotechnologies Urology, Latina, Italy, ²ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ³Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy, ⁴Sapienza University of Rome, Dept. of Urology, Rome, Italy
- A1101 Evaluation of factors associated with premature ejaculation: logistical regression on the largest cohort of male patients ever studied**
Authors: Lo Re M.¹, Lo Giudice A.², Pezzoli M.¹, Gajo L.¹, Giunti D.³, Russo G.I.², Polloni G.⁴, Di Dio M.⁵, Minervini A.¹, Cocci A.¹
Institutes: ¹AOU Careggi, Dept. of Urology, Florence, Italy, ²University of Catania, Dept. of Urology, Catania, Italy, ³Centro integrato sessuologia clinica Il Ponte, Dept. of Sessuology, Florence, Italy, ⁴Centre of Pshycology, Dept. of Pshycology, Como, Italy, ⁵SS Annunziata Hospital, Dept. of Surgery, Dept. of Urology, Catania, Italy

Penile cancer: The importance of partnering with patients in procuring data

Patient information session - Roundtable

05 April 2024
11:30 - 12:30

Location Green Area, W08
Chair To be confirmed

Learning objectives

In this session we discuss:

- 1) How we can best anticipate the unmet needs of long-term survivorship for penile cancer taking in to account the unique psychological, psychosocial, and psychosexual impact that the disease will have.
- 2) How can we maintain best practice when all curative treatment will involve surgery to the penis and men may opt for less invasive treatment outside of the MDT recommendation.
- 3) A potentially ground-breaking initiative which could enable quicker identification of penile cancer via a novel algorithmic mobile phone app. How a focus group of patient advocates have helped shape this project by providing support and constructive criticism strengthening its fitness for purpose.

11:30 - 11:35

Welcome and introduction

To be confirmed

11:35 - 11:50

Procuring patient data

A. Parnham, Manchester (GB)

B.E. Ayres, London (GB)

11:50 - 12:05

Shared decision-making

To be confirmed

To be confirmed

12:05 - 12:15

Mobile phone app to identify potential penile cancer

L. Schneidewind, Rostock (DE)

12:15 - 12:30

Q&A and closing

To be confirmed

Urolithiasis: Endoscopic Intervention

EGPT 13

08 April 2024
12:30 - 14:00

Location	EGPT
Chairs	To be confirmed
	To be confirmed
	To be confirmed

12:30 - 12:54

Screen A: Outcome of intervention

P356

Comparison of STONE, CROES, and RIRS Scoring Systems in Predicting Outcomes of Retrograde Intrarenal Surgery in Horseshoe Kidneys: A Single-Center Experience

Authors: Keles A., Arikan O., Demirtas B., Cicek M., Yildirim A.

Institutes: Istanbul Medeniyet University, School of Medicine, Goztepe Prof Dr Suleyman Yalcin City Hospital, Dept. of Urology, Istanbul, Türkiye

P358

Which is a better predictor for the safety and efficacy of retrograde intrarenal surgery; stone size or volume? A study of rirsearch study group

Authors: Yazici C.M.¹, Siddikoglu D.², Ozman O.³, Cinar O.⁴, Akgul H.M.¹, Cakir H.⁵, Basatac C.⁶, Sancak E.B.⁷, Baseskioglu B.⁸, Onal B.⁹, Akpinar H.⁶

Institutes: ¹Tekirdag Namik Kemal University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ²Canakkale Onsekiz Mart University School of Medicine, Dept. of Biostatistics, Canakkale, Türkiye, ³Gaziosmanpasa Training and Research Hospital, Clinic of Urology, Istanbul, Türkiye, ⁴Zonguldak Bulent Ecevit University, School of Medicine, Dept. of Urology, Zonguldak, Türkiye, ⁵Acibadem Fulya Hospital, Clinic of Urology, Istanbul, Türkiye, ⁶Group Florence Nightingale Hospitals, Clinic of Urology, Istanbul, Türkiye, ⁷Canakkale Onsekiz Mart University School of Medicine, Dept. of Urology, Canakkale, Türkiye, ⁸Acibadem Eskisehir Hospital, Clinic of Urology, Eskisehir, Türkiye, ⁹Istanbul University-Cerrahpasa Medical Faculty, Dept. of Urology, Istanbul, Türkiye

P369

A Machine Learning Approach Using Stone Volume to Predict Stone-Free Status after Uteroscopy for Kidney Stones

Authors: Ripa F.¹, Vigneswaran G.², Teh R.², Pietropaolo A.³, Modi S.², Somani B.³

Institutes: ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²University Hospital Southampton NHS Foundation Trust, Dept. of Interventional Radiology, Southampton, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

P351

Perioperative outcomes of same-session bilateral versus unilateral ureteroscopy for stone removal: Results from the GRAND study

Authors: Pyrgidis N., Chaloupka M., Ebner B., Stief C., Weinhold P., Marcon J., Schulz G.B.

Institutes: University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

- P354** **Incidence, risk factors and persistence of acute kidney injury following ureteroscopy and laser lithotripsy: Results from a tertiary care referral center**
Authors: Candela L.¹, Villa L.¹, Ventimiglia E.¹, Trevisani F.¹, Corsini C.¹, Robesti D.¹, D'Arma A.¹, Traxer O.², Montorsi F.¹, Salonia A.¹
Institutes: ¹Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Hopital Tenon Sorbonne Université GRC n 20 Lithiase Renale, Dept. of Urology, Paris, France
- P363** **Is Bladder Catheterization Necessary After Ureteroscopy and DJ Stent Placement? A Randomized Prospective YAU Endourology & Urolithiasis Study**
Authors: Sener T.E.¹, Ozgur G.¹, Cetin M.¹, Pietropaolo A.², Tzelves L.³, Esperto F.⁴, Tanidir Y.¹
Institutes: ¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ³University College of London Hospital, Dept. of Urology, London, United Kingdom, ⁴Campus Bio-Medico University, Dept. of Urology, Rome, Italy
- P364** **"Who's at risk? New postoperative hydronephrosis in ureteroscopy patients without prior hydronephrosis"**
Authors: Fernandez Moncaleano G.¹, Becker R.E.N.¹, Meah S.¹, Daignault-Newton S.¹, Thelus J.M.¹, Ross J.¹, Sarle R.², Wenzler D.³, Seifman B.⁴, Ghani K.R.¹, Dauw C.A.¹
Institutes: ¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Sparrow Medical Group, Dept. of Urology, Lansing, United States of America, ³Comprehensive Urology, Dept. of Urology, Royal Oak, United States of America, ⁴Michigan Institute of Urology, Dept. of Urology, West Bloomfield, United States of America
- P359** **Video gaming and surgical proficiency: Investigating the impact of video gaming experience to Flexible Ureteroscopy (FURS) among post-graduate medical interns**
Authors: Yanga T.M., Aquino T., Harina L., Guiang E., Lorenzo E.I.S., Kalbit R.H.
Institutes: Jose R. Reyes Memorial Medical Center, Dept. of Urology, Manila City, Philippines
- 12:54 - 13:21** **Screen B: The battle between thulium fiber and Holmium: YAG laser**
- P370** **Safety and Outcomes of Ureterorenoscopy with High-Power Thulium Yag Laser for Urolithiasis: First Case Series in our High-Volume institution**
Authors: Esperto F., Cacciatore L., Tedesco F., Salerno A., Prata F., Basile S., Testa A., Raso G., Ricci M., Savia S.M., D'Addurno G., Papalia R., Scarpa R.M.
Institutes: Fondazione Policlinico Campus Bio-Medico, Dept. of Urology, Rome, Italy

- P367** **Prospective randomized trial comparing high power Holmium:YAG and thulium fiber laser for retrograde ureteroscopy: preliminary clinical results, environmental noise analysis, and surgeon satisfaction**
Authors: Vergamini L.¹, Glazyrine V.¹, Ito W.¹, Du H.E.², Sardu M.E.², Whiles B.¹, Neff D.¹, Duchene D.¹, Molina W.R.¹
Institutes: ¹University of Kansas, Dept. of Urology, Kansas City, United States of America, ²University of Kansas, Dept. of Statistics, Kansas City, United States of America
- P373** **Who is the winner? Superpulsed Thulium Fiber Laser Vs. Pulse Modulated High Power Holmium:YAG Laser For Retrograde Intrarenal Surgery: A Randomized Control Trial**
Authors: Ricapito A.¹, Gupta K.², Yaghoubian A.², Khargi R.², Connors C.², Atallah W.², Gupta M.²
Institutes: ¹University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
- P360** **Thulium:YAG (Yttrium Aluminium Garnet) pulsed laser vs Holmium:YAG laser in RIRS (retrograde intrarenal surgery): a comparative prospective study**
Authors: Carbonaro B., Mondino P., Filocamo M.T., Rosso D., Rossi R., Polledro P., Borsa R., Cordara G., Coppola P.
Institutes: SS Annunziata, Dept. of Urology, Savigliano, Italy
- P376** **Tantalizing Thulium vs Hallowed Holmium : A Prospective Randomized Controlled Trial comparing The Efficacy & Efficiency of Thulium Fiber Laser And Holmium: Yttrium Aluminium Garnet Laser for Stone Lithotripsy during Retrograde Intrarenal Surgery for Renal Calculus of 1 to 2 cm**
Authors: Nanavati P., Wani A., Tak G., Ragoori D., Reddy P.C., Chiruvella M.
Institutes: Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India
- P368** **Thulium fiber laser versus high-power Holmium:YAG laser in mini-endoscopic combined intrarenal surgery for treatment of kidney stones: a practical comparison**
Authors: Vergamini L.¹, Ito W.¹, Choi N.¹, Valadon C.¹, Du H.E.², Sardu M.E.², Whiles B.¹, Neff D.¹, Duchene D.¹, Molina W.R.¹
Institutes: ¹The University of Kansas, Dept. of Urology, Kansas City, United States of America, ²The University of Kansas, Dept. of Statistics, Kansas City, United States of America
- P357** **Thulium Laser Lithotripsy for Retrograde Intra-Renal Surgeries : YAG or Fiber ? a prospective evaluation**
Authors: Panthier F., Solano C.S., Kutchukian S.K., Candela L., Doizi S., Corrales Acosta M., Chicaud M., Traxer O.T.
Institutes: Tenon Hospital AP-HP Sorbonne University, Dept. of Urology GRC20, Paris, France
- P355** **Holmium versus Thulium laser for Renal Stone Lithotripsy during Retrograde Intrarenal Surgery: Outcomes from a prospective multicenter study**
Authors: Cabrera Meiras F., Duque Ruiz G.I., García Rojo E., Calzas Montalvo C., Espinales Castro G.M., Saenz Calzada D., Sánchez Guerrero C., Pérez Fentes D.A., Romero Otero J.
Institutes: ROC Clinic, HM Hospitales, Dept. of Urology, Madrid, Spain

- P362** **Is “kidney stone calculator” efficient in predicting ureteroscopic lithotripsy duration? A ho:yag and thulium fiber lasers comparative analysis**
Authors: Chicaud M.¹, Kutchukian S.², Doizi S.³, Audenet F.⁴, Berthe L.⁵, Yonneau L.⁶, Leuret T.⁶, Timsit M.O.⁴, Méjean A.⁴, Candela L.³, Corrales M.³, Descazeaud A.¹, Traxer O.³, Panthier F.³
Institutes: ¹CHU Limoges, Dept. of Urology, Limoges, France, ²CHU Poitiers, Dept. of Urology, Poitiers, France, ³Hopital Tenon, Dept. of Urology, Paris, France, ⁴Hopital Europeen Georges Pompidou, Dept. of Urology, Paris, France, ⁵Arts et Métiers ParisTech, Laboratoire PIMM UMR 8006 CNRS, Paris, France, ⁶Hopital Foch, Dept. of Urology, Paris, France
- 13:21 - 13:39** **Screen C: New technology**
- P361** **The ILY® robotic system for flexible ureteroscopy: first italian case series in a single center**
Authors: Quarà A.¹, Cossu M.¹, Poggio M.¹, Amparore D.¹, Checcucci E.², De Cillis S.T.¹, Piramide F.¹, Volpi G.², Piana A.³, Sica M.¹, Verri P.¹, Burgio M.¹, Busacca G.¹, Marsero L.¹, Mesterca A.G.¹, Ortenzi M.¹, Garzena V.¹, Turcan A.¹, Ferrando L.¹, Manfredi M.¹, Di Dio M.⁴, Fiori C.¹, Porphiglia F.¹
Institutes: ¹AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁴Annunziata Hospital, Division of Urology - Dept. of Surgery, Cosenza, Italy
- P378** **Stone size guidance of robotic RIRS, Zamenix**
Authors: Song K-S.¹, Hong S.H.², Jang J.H.¹, Kim J.¹, Park H.³, Lee D.¹, Kong D.¹, Kim J.¹, Kim J.¹, Kwon D.S.⁴, Cho S.Y.³
Institutes: ¹ROEN Surgical, Research Institute, Daejeon, South Korea, ²Seoul National University, College of Medicine, Seoul, South Korea, ³Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ⁴Korea Advanced Institute of Science and Technology, Dept. of Mechanical Engineering, Daejeon, South Korea
- P366** **Retrograde intrarenal surgery using the ILY robotic flexible ureteroscope: a single centre experience**
Authors: Krajewski W.¹, Nowak Ł.N.¹, Chorbińska J.C.H.¹, Pisarski S.P.², Łaskiewicz J.Ł.², Tomczak W.T.², Małkiewicz B.M.¹, Szydełko T.S.¹
Institutes: ¹University Center of Excellence in Urology, Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ²Wrocław Medical University, University Center of Excellence in Urology, Wrocław, Poland

- P371** **Fluid dynamics within the renal cavities during endoscopic stone surgery: Does the position of the flexible ureteroscope and ureteral access sheath affect the outflow rate?**
Authors: Tsaturyan A.¹, Keller E.X.², Peteinaris A.³, Faria-Costa G.⁴, Pietropaolo A.⁵, Ballesta Martinez B.³, Tatanis V.³, Eugenio Ventimiglia E.⁶, Esperto F.⁷, Sener T.E.⁸, De Conninck V.⁹, Emiliani E.¹⁰, Hameed B.M.Z.¹¹, Talso M.¹², Mykoniatis I.¹³, Tzelves L.¹⁴, Kallidonis P.³
Institutes: ¹Erebouni Medical Center, Dept. of Urology, Yerevan, Armenia, ²University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ³University of Patras, Dept. of Urology, Patras, Greece, ⁴Unidade Local de Saúde de Matosinhos, Dept. of Urology, Matosinhos, Portugal, ⁵University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁶IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁷Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy, ⁸Marmara University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ⁹AZ Klina, Dept. of Urology, Brasschaat, Belgium, ¹⁰Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹¹Father Muller Medical College, Dept. of Urology, Karnataka, India, ¹²Luigi Sacco University Hospital, Dept. of Urology, Milan, Italy, ¹³Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ¹⁴University College Hospital London, Dept. of Urology, London, United Kingdom
- P353** **Comparative analysis of light sources and illumination in flexible ureteroscopy: fundamental findings from a PEARLS analysis**
Authors: Kwok J.L.¹, De Coninck V.², Corrales M.³, Sierra A.⁴, Panthier F.³, Ventimiglia E.⁵, Gauhar V.⁶, Schmid F.⁷, Hunziker M.⁷, Poyet C.⁷, Traxer O.³, Eberli D.⁷, Keller E.X.⁷
Institutes: ¹University Hospital Zurich and Tan Tock Seng Hospital, Dept. of Urology, Singapore and Zurich, Switzerland, ²AZ Klina, Dept. of Urology, Brasschaat, Belgium, ³Hopital Tenon, Sorbonne Université GRC n20 Groupe de Recherche Clinique sur la Lithiase Urinaire, Paris, France, ⁴Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain, ⁵IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ⁶Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ⁷University Hospital Zurich, Dept. of Urology, Zürich, Switzerland
- P379** **Washing out stone dust: does ureteroscopic irrigation work?**
Authors: Yang B.¹, Ray A.², Zhang J.², Turney B.¹
Institutes: ¹University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ²Boston Scientific Corporation, Dept. of Urology, Marlborough, United States of America
- 13:39 - 14:00** **Screen D: What is the best approach for stones?**

- P375** **PUrE RCT 1: Clinical and cost-effectiveness of Flexible Ureterorenoscopy and Extracorporeal Shockwave Lithotripsy for lower pole stones ≤10 mm**
Authors: Wiseman O.¹, Smith R.D.², Starr K.³, Aucott L.⁴, Hernández R.⁵, Thomas R.E.⁶, Maclennan S.⁷, Clark T.⁸, Maclennan G.⁶, Mcrae D.⁶, Bell V.⁶, Cotton S.⁶, Gall Z.⁹, Turney B.¹⁰, McClinton S.⁷
Institutes: ¹Cambridge University Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ²University College Hospitals NHS Foundation Trust, Stone and Endourology Unit, London, United Kingdom, ³University of Warwick, Warwick Medical School, Warwick, United Kingdom, ⁴University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ⁵University of Aberdeen, Health Economics Research Unit, Aberdeen, United Kingdom, ⁶University of Aberdeen, CHaRT Health Services Research Unit, Aberdeen, United Kingdom, ⁷University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁸PPI, Academic Urology Unit, Aberdeen, United Kingdom, ⁹Stockport NHS Foundation Trust, Dept. of Urology, Stockport, United Kingdom, ¹⁰University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
- P380** **PUrE RCT 2: Clinical and cost-effectiveness of FURS and Percutaneous Nephrolithotomy for lower pole stones 10-25mm**
Authors: Smith R.D.¹, Wiseman O.², Starr K.³, Aucott L.⁴, Hernández R.⁵, Thomas R.E.⁶, Maclennan S.⁷, Clark T.⁸, Maclennan G.⁶, Mcrae D.⁶, Bell V.⁶, Cotton S.⁶, Gall Z.⁹, Turney B.¹⁰, McClinton S.⁷
Institutes: ¹University College Hospitals NHS Foundation Trust, Stone and Endourology Unit, London, United Kingdom, ²Cambridge University Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ³University of Warwick, Warwick Medical School, Warwick, United Kingdom, ⁴University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ⁵University of Aberdeen, Health Economics Research Unit, Aberdeen, United Kingdom, ⁶University of Aberdeen, CHaRT Health Services Research Unit, Aberdeen, United Kingdom, ⁷University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁸PPI, Academic Urology Unit, Aberdeen, United Kingdom, ⁹Stockport NHS Foundation Trust, Dept. of Urology, Stockport, United Kingdom, ¹⁰University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
- P352** **Retrograde Intrarenal Surgery (RIRS) Versus Mini-Percutaneous Nephrolithotripsy (Mini-PCNL) In Treatment Of Renal Stones 1.5 to 2 cm in Diameter Using Holmium Laser : A Prospective Randomized Study**
Authors: Singh H.M., Prakash J.V.S., Thiruvarul P.V., Vetrichandar S., Arun Kumar P., Natarajan V.
Institutes: Stanley Medical College, Dept. of Urology, Chennai, India
- P377** **Efficacy and Patient Satisfaction Of Flexible Ureteroscopy, Semirigid Ureteroscopy And Extracorporeal Shockwaves Lithotripsy In The Management Of Proximal Ureteric Stones .5 to 1.5 cm: A Randomized Trial**
Authors: Tharwat Abdelghafour A.¹, Maarouf A.²
Institutes: ¹Zagazig University, Dept. of Urology, Zagazig, Egypt, ²Zagazig University, Dept. of Urology, Zagazig, Egypt

- P374** **Miniaturized percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of renal calculi larger than 20 mm: A propensity score-matched analysis**
Authors: Sakly A., Ben Taher S., Zakhama W., Hamza M., Sidhom W., Binous Y.
Institutes: Tahar Sfar University Hospital, Dept. of Urology, Mahdia, Tunisia
- P372** **Laparoendoscopic Rendezvous Ureterolithotomy for Unilateral Upper Tract Stones in the Galdakao Modified Supine Valdivia Position**
Authors: Huang C.H., Chen I.H.A., Yu C.C.
Institutes: Kaohsiung Veterans General Hospital, Dept. of Surgery, Kaohsiung, Taiwan
- P365** **Comparison of Transperitoneal Laparoscopic Ureterolithotomy, Retrograde Flexible Ureteroscopy, and Mini- percutaneous Antegrade Ureteroscopic Lithotripsy in the Management of Large Proximal Ureteral Stones (1.5-2 cm): A Prospective Randomized Trial.**
Authors: Zoeir A., Zaghloul T., Mamdoh H., Mousa A., Gameel T., Eltatawy H., Ragab M., Abo-Elenein M.
Institutes: Tanta University, Dept. of Urology, Tanta, Egypt

Semi-live session: Hypospadias challenges

Thematic Session

05 April 2024
12:00 - 13:00

Location Green Area, eURO Auditorium 1
Chairs P. Hoebeke, Ghent (BE)
U.K. Kennedy, Zurich (CH)

Learning objectives

After this session, you will have gained insight into the complexity of treating complicated hypospadias. To be competent for offering this treatment to patients, an experience with and knowledge of multiple reconstructive techniques is necessary.

12:00 - 12:12

Semi-live video presentation Flaps & grafts in hypospadias repair, where do we use them?

Y.T. Soygür, Ankara (TR)

12:12 - 12:15

Discussion

12:15 - 12:27

Semi-live video presentation Management of chordee during hypospadias repair

M. Castagnetti, Padua (IT)

12:27 - 12:30

Discussion

12:30 - 12:42

Semi-live video presentation Management of hypospadias complications

A. El-Ghoneimi, Paris (FR)

12:42 - 12:45

Discussion

12:45 - 12:57

Semi-live video presentation Management of hypospadias cripples

M. Fisch, Hamburg (DE)

12:57 - 13:00

Discussion

Advanced course on urethral stricture surgery

ESU Course 07

05 April 2024
12:00 - 15:00

Location Purple Area, E01
Chair L. Martínez-Piñeiro , Madrid (ES)

Learning objectives

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow-up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged. Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.

P. Nyirády, Budapest (HU)

Penile urethroplasty. Lichen sclerosus.

P. Nyirády, Budapest (HU)

Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.

F. Campos Juanatey, Santander (ES)

Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).

L. Martínez-Piñeiro , Madrid (ES)

Female urethroplasty

F. Campos Juanatey, Santander (ES)

Discussion / Cases

F. Campos Juanatey, Santander (ES)

L. Martínez-Piñeiro , Madrid (ES)

P. Nyirády, Budapest (HU)

Surgical complications during laparoscopic/robotic urological procedures: Prevention, diagnosis, management and complications

ESU Course 08

05 April 2024
12:00 - 15:00

Location Purple Area, E03
Chair B.M.C. Rocco, Milan (IT)

Learning objectives

- The risk of complication is a major issue for laparoscopic and robotic surgeons; the knowledge of complication is key to maximize the safety of urological procedures.

- The course provides a comprehensive overview about the topic, summarizing how to prevent, recognize, grade and fix surgical issues. - An interactive video session will merge trainees' and experts' experience to approach minor, major and harmful drawback of common urological interventions.

Introduction - Aims of the course

B.M.C. Rocco, Milan (IT)

Lectures: Frequency, risk factors, prevention and key aspects

Vascular lesions

A.E. Canda, Istanbul (TR)

Intestinal lesions

B.M.C. Rocco, Milan (IT)

Urinary, neuronal and solid organ lesions

T. Tokas, Hall In Tirol (AT)

How to minimize the risk of complications in robotic surgery? - Tricks of the trade

B.M.C. Rocco, Milan (IT)

Risk factors and grading of complications: The patient's and the surgeon's factor

T. Tokas, Hall In Tirol (AT)

How to train complications management: Tips and tricks from the training models

A.E. Canda, Istanbul (TR)

Video presentation and case management - A video collection from experts

A.E. Canda, Istanbul (TR)

T. Tokas, Hall In Tirol (AT)

Questions and answers

B.M.C. Rocco, Milan (IT)

Dealing with the challenge of infection in urology

ESU Course 10

05 April 2024
12:00 - 15:00

Location Purple Area, E05
Chair Z. Tandođdu, London (GB)

Learning objectives

This ESU course on infection diseases provides a broad, up-to-date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biological principles and strategies to treat urogenital tract infections from benign infections to life-threatening infections will be discussed in this course:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
- Uncomplicated and recurrent cystitis.
- Complicated urinary tract infections.
- Urosepsis and Fournier gangrene.
- Male genital tract infections.

Introduction

Z. Tandođdu, London (GB)

Classification of urinary tract infection (UTI) and surgical field contamination categories as a basis for treatment and prophylaxis

Z. Tandođdu, London (GB)

Low-grade and recurrent UTI

J. Kranz, Aachen (DE)

Male genital infections: Epididymitis and urethritis

J. Medina-Polo, Madrid (ES)

Hospital acquired UTI and antibiotic resistance

Z. Tandođdu, London (GB)

Perioperative prophylaxis with special focus on prostate biopsies

J. Medina-Polo, Madrid (ES)

Sepsis and Fournier's gangrene

J. Kranz, Aachen (DE)

Robotic renal surgery

ESU Course 11

05 April 2024
12:00 - 15:00

Location Purple Area, E06
Chair B.J. Challacombe, London (GB)

Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained in a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons expect:

- Video-based step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

Introduction

B.J. Challacombe, London (GB)

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

Robotic pyeloplasty: Multichannel or single technique

A. Antonelli, Verona (IT)

Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques

A. Antonelli, Verona (IT)

Partial nephrectomy II: Step 4: Different tumour resection techniques

R. De Groot, Aalst (BE)

Partial nephrectomy III: Step 5: Different renography techniques

B.J. Challacombe, London (GB)

Partial nephrectomy IV: Special and difficult indications

R. De Groot, Aalst (BE)

Partial nephrectomy V: Complication management and new tools

R. De Groot, Aalst (BE)

Wrap up and conclusions

B.J. Challacombe, London (GB)

Advanced endourology in non-standard patients with urolithiasis

ESU Course 12

05 April 2024
12:00 - 15:00

Location Purple Area, E07
Chair G.M. Kamphuis, Amsterdam (NL)

Learning objectives

The course will discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients. The course will cover:

- Horseshoe kidney, caliceal diverticula duplicate urinary system
- Pregnancy and complex metabolic patients
- After bladder substitution/ileal conduit/reimplantation
- Transplanted kidneys and spinal malformation

Introduction

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: Horseshoe kidneys

E. Emiliani, Barcelona (ES)

Urolithiasis in urinary system anomalies: Calyceal diverticula stones

S. Doizi, Paris (FR)

Urolithiasis in pregnancy

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation

E. Emiliani, Barcelona (ES)

Medullary sponge kidneys

S. Doizi, Paris (FR)

Urolithiasis in transplant kidneys

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney

S. Doizi, Paris (FR)

Bilateral stone treatment; Do's and don'ts

E. Emiliani, Barcelona (ES)

Patients with relative contraindications: Spinal and skeletal malformations

G.M. Kamphuis, Amsterdam (NL)

Joint session of the European Association of Urology (EAU) and Iranian Urological Association (IUA)

Urology beyond Europe

05 April 2024
12:30 - 14:30

Location Purple Area, S03
Chairs M. Babjuk, Prague (CZ)
S.J. Hosseini, Tehran (IR)

12:30 - 12:35

Introduction

12:35 - 13:10

Endourology

Moderators

To be confirmed

S.J. Hosseini, Tehran (IR)

12:35 - 12:50

Laparoscopy in management of kidney tumors

To be confirmed

12:50 - 13:05

The optimal energy source and technique of TURB

M. Babjuk, Prague (CZ)

13:05 - 13:10

Discussion

13:10 - 13:45

Andrology

Moderators

M. Babjuk, Prague (CZ)

To be confirmed

13:10 - 13:25

Surgical management of penile curvatures

S. Minhas, London (GB)

13:25 - 13:40

Surgical treatments of priapism

To be confirmed

13:40 - 13:45

Discussion

13:45 - 14:10

Pediatric urology

Moderators

M. Babjuk, Prague (CZ)

S.J. Hosseini, Tehran (IR)

13:45 - 14:00

The management of vesicoureteral reflux in childhood

G. Bogaert, Leuven (BE)

14:00 - 14:10

Discussion

14:10 - 14:15

Closing remarks

Refining technique and technology in robotic partial nephrectomy

Video session 02

05 April 2024
12:30 - 14:00

Location Green Area, S04
Chairs To be confirmed
U. Capitanio, Milan (IT)
To be confirmed

- V009** **Techniques for optimizing functional results of Da Vinci XI nephron sparing surgery**
Authors: Bujoreanu E.C.¹, Petrut B.²
Institutes: ¹Medicover Hospital, Dept. of Urology, Cluj-Napoca, Romania, ²Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania
- V010** **Technical approach for consistent outcomes for resection and reconstruction in minimally invasive partial nephrectomy**
Authors: Brodie B., Lee A., Ho H.
Institutes: Singapore General Hospital, Dept. of Urology, Singapore, Singapore
- V011** **The “wheelbarrow technique” for partial nephrectomy of endophytic small renal mass**
Authors: Brodie B., Lee A., Ho H.
Institutes: Singapore General Hospital, Dept. of Urology, Singapore, Singapore
- V012** **Challenges to the development of a surgical support system for robot-assisted partial nephrectomy using highly versatile augmented reality**
Authors: Sawada A.¹, Magaribuchi T.², Hamada A.², Masui K.², Koeda M.³, Kamoto T.¹
Institutes: ¹Miyazaki University, Dept. of Urology, Miyazaki, Japan, ²Kyoto University, Dept. of Urology, Kyoto, Japan, ³Okayama Prefectural University, Dept. of Human Information Engineering, Okayama, Japan
- V013** **Purely Off-clamp RAPN for cT2b renal mass**
Authors: Misuraca L., Brassetti A., Anceschi U., Ferriero M., Leonardo C., D'Annunzio S., Bove A.M., Guaglianone S., Tuderti G., Mastroianni R., Chiacchio G., Flammia R.S., Proietti F., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- V014** **Sutureless robot assisted partial nephrectomy: feasibility and surgical technique (UroCCR n°158)**
Authors: Margue G., Blanco A., Klein C., Khaddad A., Estrade V., Alezra E., Capon G., Bladou F., Robert G., Bernhard J.C.
Institutes: Bordeaux University Hospital, Dept. of Urology, Bordeaux, France
- V015** **Sutureless Off-clamp Robotic partial Nephrectomy in solitary kidney: surgical technique, perioperative, pathologic and functional outcomes**
Authors: Tuderti G., Mastroianni R., Misuraca L., Bove A., Anceschi U., Flammia R.S., Proietti F., D'Annunzio S., Brassetti A., Iuculano S., Pula M., Ferriero M., Guaglianone S., Leonardo C., Simone G.
Institutes: IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

V016

Single-port robotic retroperitoneal partial nephrectomy: initial series in Spain

Authors: Vazquez-Martul D., Altez Fernández C., Díaz Pedrouzo A., Ponce Díaz J.L., Barbagelata López A., Chantada Abal V.

Institutes: A Coruna University Hospital, Dept. of Urology, A Coruna, Spain

Biopsy targeting pathology results and markers

EGPT 02

**05 April 2024
12:30 - 14:00**

Location EGPT
Chairs To be confirmed
E. Linares Espinós, Madrid (ES)

Screen A: Biopsy, imaging for detection, risk prediction, targeting and route

- P036** **Association between MRI-detected tumor ADC and risk of 5-year biochemical recurrence after radical prostatectomy.**
Authors: Piccinelli M.L.¹, Mistretta F.A.¹, Luzzago S.¹, Alessi S.², Marvaso G.³, Lievore E.¹, Vaccaro C.¹, Guglielmo O.¹, Graps G.¹, Fontana M.¹, Bianchi R.¹, Brescia A.¹, Bottero D.¹, Ferro M.¹, Jereczek-Fossa B.A.³, Petralia G.², Musi G.¹, De Cobelli O.¹
Institutes: ¹European Institute of Oncology, Dept. of Urologic Surgery, Milan, Italy, ²European Institute of Oncology, Dept. of Radiology, Milan, Italy, ³European Institute of Oncology, Division of Radiation Oncology, Milan, Italy
- P046** **The Role of Artificial Intelligence for the Detection of Clinically Significant Prostate Cancer at Multiparametric Magnetic Resonance Imaging**
Authors: Quarta L.¹, Scuderi S.¹, Gandaglia G.¹, Stabile A.¹, Marzorati C.¹, Russo T.², Brembilla G.², Camisassa E.², Leni R.¹, Cucchiara V.¹, Bianchi M.¹, Cannoletta D.², Zaurito P.¹, Barletta F.¹, Cosenza M.², Robesti D.¹, Mazzone E.¹, De Cobelli F.², Montorsi F.¹, Briganti A.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy
- P051** **Impact of Volume Difference Between 3D Transrectal Ultrasound and MRI Segmentation on the Outcome of fusion MRI-Targeted Prostate Biopsy.**
Authors: Lenfant L.¹, Beitone C.², Troccaz J.², Roupret M.¹, Seisen T.¹, Renard-Penna R.³, Voros S.², Mozer P.C.¹
Institutes: ¹Hopital Pitié Salpêtrière - AP-HP- Sorbonne Université, Dept. of Urology, Paris, France, ²Université Grenoble Alpes - CNRS - INSERM - Grenoble INP, TIMC-GMCAO, Grenoble, France, ³Hopital Pitié Salpêtrière - AP-HP- Sorbonne Université, Dept. of Radiology, Paris, France
- P043** **Comparing the Diagnostic Accuracy of mpMRI and MicroUS for Detecting Clinically Significant Prostate Cancer in Patients with Previous Negative Prostate Biopsy**
Authors: Frego N., Fasulo V., Maffei D., Arena P., Avolio P.P., Chiarelli G., Beatrici E., Sordelli F., De Carne F., Garofano G., Dagnino F., Aljoulan M., Paciotti M., Saita A.R., Lazzeri M., Hurle R., Buffi N.M., Casale P., Lughezzani G.
Institutes: IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

- P031** **Micro-ultrasound guided prostate biopsies: evaluation of PRI-MUS score in a high-volume experience.**
Authors: Maffei D.¹, Avolio P.P.¹, Moretto S.¹, Piccolini A.¹, Aljoulani M.¹, Dagnino F.¹, Paciotti M.¹, Hurle R.F.², De Carne F.¹, Saita A.R.², Guazzoni G.F.¹, Buffi N.M.¹, Lazzeri M.², Lughezzani G.¹
Institutes: ¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy
- P035** **Can "Artificial Intelligence" improve cancer detection in transperineal MRI-TRUS fusion biopsies of the prostate?**
Authors: Günzel K.¹, Hamm C.², Schlegel J.¹, Ozimek T.¹, Luckau J.¹, Busch J.¹, Magheli A.¹, Hinz S.¹
Institutes: ¹Vivantes Klinikum Am Urban, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Radiology, Berlin, Germany
- P052** **Transperineal approach is safer than transrectal approach in MRI-ultrasound fusion prostate biopsy: an analysis using propensity score matching**
Authors: Tanaka H., Kobayashi M., Yoshitomi K., Fan B., Fujiwara M., Nakamura Y., Ishikawa Y., Fukuda S., Waseda Y., Tanaka H., Yoshida S., Fujii Y.
Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan
- P050** **Validation of the PRIMARY system for 68Ga-PSMA-11 PET/CT interpretation for detection of intra-prostatic radiorecurrent prostate cancer**
Authors: Light A.¹, Lazic S.², Houghton K.², Bayne M.¹, Connor M.J.¹, Mayor N.¹, Tam H.², Ahmed H.U.¹, Shah T.T.¹, Barwick T.D.²
Institutes: ¹Imperial College London, Imperial Prostate Department, London, United Kingdom, ²Imperial College Healthcare NHS Trust, Dept. of Imaging, London, United Kingdom
- Screen B: Grading issues at biopsy**

- P045** **Proportion of Gleason 8-10 prostate cancer found on biopsy and tumor aggressiveness in matched cohorts of men in Asia and Western countries.**
Authors: Dong L.¹, Lajkosz K.², Sanchez-Salas R.³, Tiwari R.V.⁴, Zhu Y.², Dias dos Santos C.P.⁵, Dong B.¹, Pan J.¹, Chan A.⁶, Woon D.⁷, Kulkarni G.⁷, Perlis N.⁷, Hamilton R.⁷, Klotz L.⁸, Wallis C.J.D.⁶, Macek P.³, Tay K.J.⁹, Toi A.¹⁰, Finelli A.⁷, Fleshner N.E.⁷, Cathelineau X.³, Van Der Kwast T.H.¹¹, Xue W.¹, Zlotta A.R.⁶
Institutes: ¹Renji Hospital - Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Princess Margaret Cancer Centre, Dept. of Biostatistics, Toronto, Canada, ³McGill University Health Centre, Dept. of Surgery, Montreal, Canada, ⁴Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ⁵L Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁶Mount Sinai Hospital - University of Toronto, Dept. of Surgery, Toronto, Canada, ⁷University Health Network, Dept. of Surgical Oncology, Toronto, Canada, ⁸Sunnybrook Health Sciences Centre, Division of Urology, Toronto, Canada, ⁹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁰University Health Network, Dept. of Medical Imaging, Toronto, Canada, ¹¹University Health Network, Dept. of Pathology, Toronto, Canada
- P041** **Predictors of Adverse Pathological Features following Robotic Radical Prostatectomy in patients with Low-risk Prostate Cancer**
Authors: Reddy S.K.¹, Covas Moschovas M.¹, Shady S.¹, Gamal A.¹, Rogers T.¹, Sandri M.², Harvey T.¹, Robinson K.¹, Patel V.¹
Institutes: ¹AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²University of Brescia, Data Methods and Statistics, Brescia, Italy
- P054** **MRI-Targeted Biopsy in Biopsy-Naïve Patients and the Risk of Overtreatment: A Grading Issue**
Authors: Jabbour T.¹, Peltier A.¹, Rocq L.², Sirtaine N.², Lefebvre Y.³, Bourgeno H.A.¹, Baudewyns A.¹, Roumeguere T.¹, Diamand R.¹
Institutes: ¹Jules Bordet Institute-Erasme Hospital HUB, Dept. of Urology, Brussels, Belgium, ²Jules Bordet Institute-Erasme Hospital HUB, Dept. of Pathology, Brussels, Belgium, ³Jules Bordet Institute-Erasme Hospital HUB, Dept. of Radiology, Brussels, Belgium
- P042** **The quantification of GSP4 volume is superior to ISUP GG classification and %GSP4 for predicting adverse outcomes in radical prostatectomy patients**
Authors: Scuderi S.L.A.¹, Tin A.², Stabile A.¹, Mazzone E.¹, Quarta L.¹, Zaurito P.¹, Ciabattini M.¹, Cosenza A.¹, Brancaccio M.¹, Leni R.¹, Klug J.³, Porwal S.³, Tenace N.P.⁴, Lucianò R.⁴, Gandaglia G.¹, Eastham J.A.³, Montorsi F.¹, Briganti A.¹, Vickers A.J.³
Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America, ³Memorial Sloan Kettering Cancer Center, Urology Service - Dept. of Surgery, New York, United States of America, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy

- P038** **Stage-specific survival among men with prostate cancer in the Nordic countries 2004-2016 - the NORDCAN survival studies**
Authors: Larsen S.B.¹, Lundberg F.E.², Friis S.³, Birgisson H.⁴, Andersson T.M.L.², Engholm G.³, Lambert P.C.², Lambe M.², Pettersson D.⁵, Ólafsdóttir E.⁴, Johannesen T.B.⁶, Kønig S.M.³, Johansson A.L.V.², Mørch L.S.⁷
Institutes: ¹Copenhagen University Hospital - Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³Danish Cancer Institute, Dept. of Cancer Epidemiology and Surveillance, Copenhagen, Denmark, ⁴Icelandic Cancer Registry, Reykjavik, Iceland, ⁵National Board of Health and Welfare, Swedish Cancer Registry, Stockholm, Sweden, ⁶Cancer Registry of Norway, Oslo, Norway, ⁷Danish Cancer Institute, Dept. of Cancer Therapeutics, Copenhagen, Denmark
- P053** **Characteristics of tumor immune microenvironment in locally advanced prostate cancer not detected by imaging**
Authors: Yanai Y.¹, Kosaka T.², Mikami S.³, Arai M.², Watanabe K.², Yasumizu Y.², Takeda T.², Matsumoto K.², Oya M.²
Institutes: ¹Saitama City Hospital, Dept. of Urology, Saitama, Japan, ²Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ³Keio University School of Medicine, Dept. of Diagnostic Pathology, Tokyo, Japan
- Screen C: PSA as a predictor of treatment outcomes**
- P055** **Impact on P-score on treatment and long-term outcomes in men with prostate cancer**
Authors: Röbeck P.¹, Berglund E.², Dragomir A.³, Häggman M.¹, Ladjevard S.¹
Institutes: ¹Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden, ²Prostatype Genomics AB, Dept. of Technology, Solna, Sweden, ³Uppsala University Hospital, Dept. of Pathology, Uppsala, Sweden
- P033** **Development and validation of a new personalized algorithmic model for PSA analysis : PROSTia**
Authors: Larose C.¹, Mazeaud C.¹, Eschwege P.¹, Tomic J.¹, Martelin N.²
Institutes: ¹CHRU Nancy, Dept. of Urology, Nancy, France, ²Prostperia, Dept. of Prostperia, Nancy, France
- P034** **Prostate biopsy features and risk of biochemical recurrence after robot-assisted radical prostatectomy: High-Volume Tertiary Care Hospital experience**
Authors: Collà Ruvolo C., Sorce G., Freco N., Ticonosco M., Rebuffo S., Pissavini A., Belmonte M., De Naeyer G., D Hondt F., De Groote R., Mottrie A.
Institutes: Onze-Lieve-Vrouweziekenhuis, Dept. of Urology, Aalst, Belgium

- P040** **Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men**
Authors: Chiarelli G.¹, Davis M.¹, Stephens A.¹, Finati M.¹, Cirulli G.¹, Morrison C.¹, Sood A.², Carrieri G.³, Briganti A.⁴, Montorsi F.⁴, Lughezzani G.⁵, Buffi N.⁵, Rogers C.¹, Abdollah F.¹
Institutes: ¹Henry Ford Health System, VUI Center for Outcomes Research Analysis and Evaluation, Detroit, United States of America, ²MD Anderson, Dept. of Urology, Houston, United States of America, ³University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁴Università Vita-Salute San Raffaele, Division of Oncology - Unit of Urology, Milan, Italy, ⁵Humanitas University, Dept. of Urology, Milan, Italy
- Screen D: Neoadjuvant systemic treatment to locally advanced stages**
- P059** **Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients.**
Authors: Devos G.T.¹, Tosco L.¹, Baldewijns M.², Giesen A.¹, Gevaert T.², Goffin K.³, Petit V.⁴, Mai C.⁴, Raskin Y.¹, Van Haute C.¹, De Meerleer G.⁵, Berghen C.⁵, Devlies W.¹, Claessens F.⁶, Van Poppel H.¹, Everaerts W.¹, Joniau S.¹
Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium, ³University Hospitals Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ⁴University Hospitals Leuven, Dept. of Radiology, Leuven, Belgium, ⁵University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium, ⁶University Hospitals Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium
- P047** **Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: a subanalysis of the ARNEO trial**
Authors: Giesen A.¹, Devos G.¹, Tosco L.¹, Baekelandt L.¹, Baldewijns M.², Gevaert T.¹, Goffin K.³, Petit V.⁴, Mai C.⁴, Raskin Y.¹, Van Haute C.¹, Goeman L.⁵, De Meerleer G.⁶, Berghen C.⁶, Devlies W.¹, Claessens F.⁷, Van Poppel H.¹, Everaerts W.¹, Joniau S.¹
Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium, ³University Hospitals Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ⁴University Hospitals Leuven, Dept. of Radiology, Leuven, Belgium, ⁵KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ⁶University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium, ⁷KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium
- Screen E: Incidence at histology, after pandemic, risks factors**

- P056** **Outcome for men diagnosed with prostate cancer at cystoprostatectomy performed for bladder cancer. Nationwide, population-based study**
Authors: Scilipoti P.¹, Liedberg F.², Garmo H.³, Stattin P.³, Westerberg M.³
Institutes: ¹IRCCS San Raffaele Hospital, Division of Experimental Oncology-Unit of Urology, Milan, Italy, ²Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ³Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
- P048** **Incidental Prostate Cancer In Patients Treated For Benign Prostatic Hyperplasia: Analysis From A Contemporary National Dataset**
Authors: Bologna E.¹, Licari L.C.¹, Franco A.², Ditunno F.³, Manfredi C.⁴, De Nunzio C.², Antonelli A.³, De Sio M.⁴, Leonardo C.⁵, Cindolo L.⁶, Cherullo E.E.⁷, Autorino R.⁷
Institutes: ¹Sapienza University Rome Policlinico Umberto I Hospital, Dept. of Maternal-Child and Urological Sciences, Rome, Italy, ²Sant'Andrea Hospital Sapienza University, Dept. of Urology, Rome, Italy, ³Azienda Ospedaliera Universitaria Integrata Verona University of Verona, Dept. of Urology, Verona, Italy, ⁴University of Campania Luigi Vanvitelli, Unit of Urology, Dept. of Woman Child and General and Specialized Surgery, Naples, Italy, ⁵Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁶Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy, ⁷Rush University, Dept. of Urology, Chicago, United States of America
- P044** **The rebound effect of diagnosis of csPCa, after Covid-19 pandemic**
Authors: Fanelli A.¹, Falagario U.G.¹, Guzzi F.¹, Ninivaggi A.¹, Montrone L.¹, Selvaggio O.¹, Annese P.¹, Busetto G.M.¹, Bettocchi C.¹, Sanguedolce F.², Cormio L.¹, Carrieri G.¹
Institutes: ¹University of Foggia, Dept. Of Urology and Kidney Transplantation, Foggia, Italy, ²University of Foggia, Dept. of Clinical and Experimental Medicine, Foggia, Italy
- P057** **Long-term Analysis of Treatment Decision Regret: Importance of the decision-making process and postoperative HRQOL after treatment for early-stage prostate cancer.**
Authors: Osawa T.¹, Sato M.², Nishioka K.³, Miyazaki T.³, Takahashi S.³, Mori T.³, Hashimoto T.³, Miyata H.¹, Matsumoto R.¹, Abe T.¹, Ohashi K.², Murai S.¹, Ito Y.M.⁴, Shinohara N.¹
Institutes: ¹Hokkaido University, Dept. of Urology, Sapporo, Japan, ²Hokkaido University, Faculty of Health Sciences, Sapporo, Japan, ³Hokkaido University, Dept. of Radiation Oncology, Sapporo, Japan, ⁴Hokkaido University Hospital, Clinical Research and Medical Innovation Center, Sapporo, Japan
- P058** **Association of proton pump inhibitors cumulative use with prostate cancer risk and adverse outcomes: A population-based analysis**
Authors: Sayyid R.K.¹, Tiwari R.¹, Zhang B.², Wilton A.², Lajkosz K.¹, Cockburn J.¹, Bernardino R.¹, Al-Rumayyan M.¹, Al-Daqqaq Z.³, Seskin R.², Fleshner N.E.¹
Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Institute for Clinical Evaluative Sciences, Dept. of Epidemiology, Toronto, Canada, ³University of Toronto, Faculty of Medicine, Toronto, Canada
-

Screen F: supportive care

P037 Effect of Smoking on Prostate Cancer Survivors' Long-Term Quality of Life and Function: A longitudinal analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study

Authors: Nguyen D.D.¹, Barocas D.A.², Huang L.C.³, Zhiguo Z.³, Koyama T.³, Penson D.F.², Goodman M.⁴, Hamilton A.S.⁵, Wu X.C.⁶, Paddock L.E.⁷, Stroup A.⁷, O'neil B.B.⁸, Hoffman K.E.⁹, Wallis C.J.D.¹

Institutes: ¹University of Toronto, Division of Urology, Toronto, Canada, ²Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America, ³Vanderbilt University Medical Center, Dept. of Biostatistics, Nashville, United States of America, ⁴Emory University Rollins School of Public Health, Dept. of Epidemiology, Atlanta, United States of America, ⁵Keck School of Medicine, University of Southern California, Dept. of Preventative Medicine, Los Angeles, United States of America, ⁶Louisiana State University New Orleans School of Public Health, Dept. of Epidemiology, New Orleans, United States of America, ⁷Cancer Institute of New Jersey - Rutgers Health, Dept. of Epidemiology, New Brunswick, United States of America, ⁸University of Utah Health, Dept. of Urology, Utah, United States of America, ⁹The University of Texas MD Anderson Center, Dept. of Radiation Oncology, Texas, United States of America

P032 Smoking and Exercise are Independently Associated with Mental Health in Prostate Cancer

Authors: Alkhatib K.¹, Roberson D.¹, Briggs L.², Matulewicz R.³, Guzzo T.¹, Pierorazio P.¹

Institutes: ¹University of Pennsylvania, Dept. of Urology, Philadelphia, United States of America, ²Mayo Clinic, Dept. of Urology, Phoenix, United States of America, ³Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America

P039 Association of Area of Deprivation Index with Prostate Cancer incidence and lethality over a contemporary North American cohort..

Authors: Finati M.¹, Cirulli G.O.¹, Chiarelli G.¹, Stephens A.², Davis M.¹, Tinsley S.¹, Butaney M.¹, Arora S.¹, Morrison C.¹, Sood A.³, Buffi N.⁴, Lughezzani G.⁴, Salonia A.⁵, Briganti A.⁵, Montorsi F.⁵, Bettocchi C.⁶, Carrieri G.⁶, Rogers C.¹, Abdollah F.¹

Institutes: ¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, Ohio State's Comprehensive Cancer Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy, ⁶University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy

P049

A Multi-Institutional Prospective Cohort Study Evaluating Mental Wellbeing in Prostate Cancer: The MIND-P Study

Authors: Brunckhorst O.¹, Liszka J.¹, James C.¹, Fanshawe J.², Hammadeh M.², Thomas R.³, Khan S.⁴, Sheriff M.⁵, Ahmed H.⁶, Van Hemelrijck M.⁷, Muir G.⁸, Stewart R.⁹, Dasgupta P.¹, Ahmed K.¹

Institutes: ¹King's College London, MRC Centre for Transplantation, London, United Kingdom, ²Queen Elizabeth Hospital, Dept. of Urology, London, United Kingdom, ³Bedfordshire Hospitals NHS Foundation Trust, The Primrose Oncology Unit, Bedford, United Kingdom, ⁴East Surrey Hospital, Dept. of Urology, Redhill, United Kingdom, ⁵Medway NHS Foundation Trust, Dept. of Urology, Gillingham, United Kingdom, ⁶Imperial College London, Imperial Prostate Department, London, United Kingdom, ⁷King's College London, Dept. of Translational Oncology and Urology Research, London, United Kingdom, ⁸King's College Hospital, Dept. of Urology, London, United Kingdom, ⁹King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.01

05 April 2024
12:45 - 13:40

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.02

05 April 2024
12:45 - 13:40

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.03

**05 April 2024
12:45 - 13:40**

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Challenge the EAU Guidelines: Oligometastatic bladder cancer

Thematic Session

05 April 2024
13:00 - 14:30

Location Purple Area, eURO Auditorium 2
Chairs A. Masson-Lecomte, Paris (FR)
J.A. Witjes, Nijmegen (NL)

Learning objectives

In this session a relative new phenomenon is discussed: oligo metastatic disease in bladder cancer.

There are several issues need attention: Is the metastasis synchronous or metachronous; what is the best imaging tool; what is the best therapeutic approach: surgery, radiation, systemic therapy or a combination; can we use markers to predict (oligo)-metastatic disease? All these issues will be discussed by experts in their filed during this interesting session to provide you with the best possible insights.

13:00 - 13:02

Introduction

A. Masson-Lecomte, Paris (FR)

13:02 - 13:12

State-of-the-art lecture Consensus statement of ESMO, ESTRO and EAU

A. Bamias, Athens (GR)

13:12 - 13:17

Case presentation

J.A. Witjes, Nijmegen (NL)

13:17 - 13:27

State-of-the-art lecture What is the best imaging for diagnosis and follow up: MRI, CT, PET?

V. Panebianco, Rome (IT)

13:27 - 13:37

State-of-the-art lecture In which cases is surgery the best option?

G. Thalmann, Bern (CH)

13:37 - 13:47

State-of-the-art lecture In which cases we should consider radiotherapy?

N. James, London (GB)

13:47 - 13:57

State-of-the-art lecture Should we add systemic therapy?

R. Cathomas, Chur (CH)

13:57 - 14:17

Discussion

14:17 - 14:27

State-of-the-art lecture Can we use markers to decide on which local or systemic treatment or systemic therapy and in follow up?

L.S. Mertens, Amsterdam (NL)

14:27 - 14:30

Closing remarks

J.A. Witjes, Nijmegen (NL)

Controversies in paediatric urology

Thematic Session

05 April 2024
13:00 - 14:30

Location Purple Area, N01
Chairs J.S.L.T. Quaedackers, Groningen (NL)
M.S. Silay, Istanbul (TR)

Learning objectives

Join us for an informative pediatric urology session, where experts discuss the latest advancements in diagnosing and treating urological conditions in children. Learn about innovative techniques, compassionate care, and the importance of early intervention for pediatric urology issues in this concise and engaging session.

13:00 - 13:05	The usefulness of artificial intelligence in paediatric urology B. Haid, Linz (AT)
13:05 - 13:10	Urological interventions in the fetal period: What should we know? O. Telli, Istanbul (TR)
13:10 - 13:20	State-of-the-art lecture How can we improve treatment success of children with monosymptomatic enuresis nocturna? G. Bogaert, Leuven (BE)
13:20 - 13:30	European Society for Paediatric Urology (ESPU) lecture Management of sphincter insufficiency in children A. Faure, Marseille (FR)
13:30 - 13:35	Discussion with the audience
13:35 - 14:00	Case discussion Undescended testis
13:35 - 13:37	Clinical case presentation M.I Dönmez, Istanbul (TR)
13:37 - 13:52	Round table discussion A. Bujons Tur, Barcelona (ES) R.J.M. Lammers, Groningen (NL) G. Bogaert, Leuven (BE)
13:52 - 13:55	Summary from the EAU guidelines To be confirmed
13:55 - 14:00	Discussion with the audience
14:00 - 14:30	Debate Surgical management of duplicated ureters Moderator A-F. Spinoit, Ghent (BE)
14:00 - 14:02	Introduction A-F. Spinoit, Ghent (BE)
14:02 - 14:07	Heminephrectomy M.S. Skott, Aarhus (DK)
14:07 - 14:12	Uretero-ureterostomy L.A. 't Hoen, Rotterdam (NL)
14:12 - 14:17	Ureteral reimplantation N. Baydilli, Kayseri (TR)

Scientific Programme - EAU24

14:17 - 14:22	Ureteral clipping F. O'Kelly, Dublin (IE)
14:22 - 14:25	Expert summary A-F. Spinoit, Ghent (BE)
14:25 - 14:30	Discussion with the audience

Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

**05 April 2024
13:00 - 15:30**

Location Green Area, N03
Chairs P. Albers, Düsseldorf (DE)
Y. Tomita, Niigata (JP)

Learning objectives

The aim of this session is to provide the audience an insight in specific topics of current clinical practice in urology. The selected themes this year are “Renal cancer” and “Renal transplantation.” For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of renal cancer and renal transplantation based on the actual EAU-Guidelines.

13:00 - 13:05

Introduction
Y. Tomita, Niigata (JP)

13:05 - 13:50

Renal cancer
Moderators C.K. Bensalah, Rennes (FR)
H. Miyake, Kobe (JP)

13:05 - 13:15

Robot-assisted partial nephrectomy
A. Minervini, Florence (IT)

13:15 - 13:25

Presurgical systemic therapy and subsequent cytoreductive nephrectomy
H. Tanaka, Tokyo (JP)

13:25 - 13:50

Panel discussion

Panel	M.C. Mir Maresma, Valencia (ES) A. Bex, London (GB) R. Tomida, Tokushima (JP) S. Ishikawa, Niigata (JP)
--------------	--

13:50 - 14:40

JUA Abstract presentations
Moderators P. Albers, Düsseldorf (DE)
Y. Tomita, Niigata (JP)

13:50 - 13:55

Abstract 1: Androgen deprivation therapy reduces the risk of bladder hemorrhage in patients undergoing radiotherapy

Presenter	To be confirmed
------------------	-----------------

13:55 - 14:00	Abstract 2: Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: A retrospective observational study using propensity score matching	Presenter	To be confirmed
14:00 - 14:05	Abstract 3: Delta-radiomics analysis in comparison to radiomics analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma	Presenter	To be confirmed
14:05 - 14:10	Abstract 4: Geriatric nutritional risk index predicts postoperative complications in elderly patients undergoing robot-assisted radical cystectomy	Presenter	To be confirmed
14:10 - 14:15	Abstract 5: Serum serotonin levels as a potential risk factor for overactive bladder in a community-dwelling population	Presenter	To be confirmed
14:15 - 14:20	Abstract 6: Analysis of ctDNA hotspot mutations in non-coding lesion improves early prediction of recurrence in muscle-invasive bladder cancer (MIBC)	Presenter	To be confirmed
14:20 - 14:25	Abstract 7: Procedural safety of aquablation for benign prostatic hyperplasia in Japanese men	Presenter	To be confirmed

14:25 - 14:30	Abstract 8: Restoring spermatogenic potential of aging mice by miRNA-enriched exosomes from conditioned medium of human exfoliated deciduous dental pulp-derived stem cells	Presenter	To be confirmed
14:30 - 14:35	Abstract 9: Contralateral patent processus vaginalis in pediatric patients with a unilateral nonpalpable testis	Presenter	To be confirmed
14:35 - 14:40	Summary by moderators		
14:40 - 15:25	Renal transplantation		
	Moderators	A. Alcaraz, Barcelona (ES) M. Tasaki, Niigata (JP)	
14:40 - 14:50	New tools for rejection diagnosis		
	T. Hirai, Tokyo (JP)		
14:50 - 15:00	Update in robotic assisted kidney transplantation		
	A. Breda, Barcelona (ES)		
15:00 - 15:25	Panel discussion	Panel	A. Breda, Barcelona (ES) A. Alcaraz, Barcelona (ES) T. Hirose, Sapporo (JP) To be confirmed
15:25 - 15:30	Closing remarks by JUA President		
	M. Eto, Fukuoka (JP)		

Unveiling the unseen: Management of small tumours in penile and testis cancer

Thematic Session

05 April 2024
13:00 - 14:30

Location Purple Area, S01
Chairs O.R. Brouwer, Amsterdam (NL)
A. Lorch, Zürich (CH)

Learning objectives

While the focus is often on more advanced disease, adequate and early diagnosis of rare urological cancers may be equally important and challenging. This session will feature state of the art lectures and discussions on small testicular masses, including fertility considerations and the potential role of miR-371a-3p for early stage testicular cancer patients. In addition, the state of the art insights on how to manage a patient with a micrometastasis in the sentinel node will be debated.

13:00 - 13:25

Case discussion Incidental testicular mass detected in infertility work-up

13:00 - 13:05

Case presentation

M. Gül, Konya (TR)

13:05 - 13:10

Radical orchidectomy

T. Tandstad, Trondheim (NO)

13:10 - 13:15

Partial orchidectomy

P. Paffenholz, Cologne (DE)

13:15 - 13:20

Monitor

A. Terbuch, Graz (AT)

13:20 - 13:25

Discussion

13:25 - 13:35

State-of-the-art lecture Work-up of an indeterminate testicular mass

A. Muneer, London (GB)

13:35 - 13:45

State-of-the-art lecture Do we fully understand testicular dysgenesis syndrome yet?

M.M. Fode, Herlev (DK)

13:45 - 13:55

State-of-the-art lecture Fertility options and considerations in testis cancer patients

P. Sangster, London (GB)

13:55 - 14:05

State-of-the-art lecture miR-371a-3p in active surveillance in stage I testis cancer: Finally ready for clinical practice?

C. Fankhauser, Lucerne (CH)

14:05 - 14:10

Discussion

14:10 - 14:30

Case discussion Micrometastasis on DSNB

14:10 - 14:15

Case presentation

M.T.A. Vreeburg, Amsterdam (NL)

14:15 - 14:20

Inguinal lymphadenectomy

C. Protzel, Schwerin (DE)

Scientific Programme - EAU24

14:20 - 14:25

Monitor

A. Parnham, Manchester (GB)

14:25 - 14:30

Discussion

Joint Session of the European Association of Urology (EAU), the Arab Association of Urology (AAU) and the Pan-African Urological Surgeons Association (PAUSA)

Urology beyond Europe

05 April 2024
13:00 - 15:30

Location **Chairs**

Green Area, W01
M. Moussa, Beirut (LB)
J. N'Dow, Aberdeen (GB)
J. Rassweiler, Krems - Stein (DE)
A.S. Zribi, Tunis (TN)

Learning objectives

Define ejaculation sparing techniques and explain available methods. Stay updated on evolving research and innovations. Patient counseling before penile implant and identify criteria for patient selection. Recognize specific issues in Africa - Diagnosis barriers, limited resources, and cultural consideration.

Case discussion on erectile dysfunction

Introduction

J. Rassweiler, Krems - Stein (DE)
M. Moussa, Beirut (LB)
A.S. Zribi, Tunis (TN)

13:00 - 13:40

Urolithiasis

Moderators

To be confirmed
M. Jalloh, Dakar (SN)
J. Rassweiler, Krems - Stein (DE)

13:00 - 13:10

ECRIS

C.M. Scoffone, Turin (IT)

13:10 - 13:20

FURS

Y.M. Al-Hallaq, Baghdad (IQ)

13:20 - 13:30

An analysis of Tunisian urinary calculi based on their epidemiological characteristics and chemical composition. From 2001 to 2021

K. Bouzid Ghazzi, Tunis (TN)

13:30 - 13:40

Case presentation on urolithiasis

To be confirmed

13:40 - 14:20

Prostate cancer

Moderators

To be confirmed
To be confirmed
To be confirmed

13:40 - 13:50

Early detection of Prostate cancer

To be confirmed

13:50 - 14:00

Early continence after robotic radical prostatectomy

A. El Hajj, Beirut (LB)

- 14:00 - 14:10 **New clinical research and clinical development in prostate cancer in Sub Saharian Africa**
M. Jalloh, Dakar (SN)
To be confirmed
- 14:10 - 14:20 **Case based discussion: Pathways to diagnosis of prostate cancer**
A.S. Zribi, Tunis (TN)
- 14:20 - 15:00** **Men's health**
Moderators M. Moussa, Beirut (LB)
 To be confirmed
 N. Sofikitis, Ioannina (GR)
- 14:20 - 14:30 **Ejaculation sparing techniques**
T. Bach, Hamburg (DE)
- 14:30 - 14:40 **Inflatable penile prosthesis, patient satisfaction revisited**
To be confirmed
- 14:40 - 14:50 **Management of urethral strictures in Africa: Challenges and solutions**
A. Mbassi, Yaoundé (CM)
- 14:50 - 15:00 **Case presentation men's health**
J. Feghali, Beirut (LB)
- 15:00 - 15:40** **Renal transplantation session**
Moderators To be confirmed
 To be confirmed
 Y.M. Osman, Mansoura (EG)
- 15:00 - 15:10 **Patient selection in renal transplantation, EAU guideline**
To be confirmed
- 15:10 - 15:20 **Multiple arteries in live donor renal transplantation**
Y.M. Osman, Mansoura (EG)
- 15:20 - 15:30 **Surgical complications of renal transplantation: risk factors and impact on transplant survival. Cases based discussion**
To be confirmed
- 15:30 - 15:40 J. Rassweiler, Krems - Stein (DE)

Counsel and improve functional results after radical prostatectomy

Abstract session 1

05 April 2024
13:00 - 14:30

Location Green Area, W03
Chairs T. Höfner, Linz (AT)
I. Minčík, Presov (SK)
To be confirmed
K. Touijer, New York (US)

13:00 - 13:30

Identify patients at risk for poor outcome

A0017

How many procedures are necessary during the learning curve of robot-assisted radical prostatectomy to improve trifecta achievement for organ-confined prostate cancer? Results from a multicentric series

Authors: [Anceschi U.](#)¹, Basile S.¹, Dell'Oglio P.², Oderda M.³, Al-Hammouri T.⁴, Puglisi M.⁵, Iannuzzi A.¹, Olivero A.², Tuderti G.¹, Mattevi D.⁵, Allasia M.³, Bove A.M.¹, Tappero S.², Secco S.², Martiriggiano M.², Albisinni S.⁶, Galfano A.², Bocciardi A.M.², Gontero P.³, Shaw G.⁴, Luciani L.G.⁵, Cai T.⁵, Quackels T.⁷, Simone G.¹

Institutes: ¹IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²ASST - Niguarda Hospital, Dept. of Urology, Milan, Italy, ³Molinette Hospital - University of Turin, Dept. of Urology, Turin, Italy, ⁴University College London Hospital NHS, Dept. of Urology, London, United Kingdom, ⁵APSS - Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ⁶Fondazione Policlinico Tor Vergata, University of Rome, Dept. of Urology, Rome, Italy, ⁷Erasmus Hospital, University of Bruxelles, Dept. of Urology, Brussels, Belgium

A0005

Self-reported comorbidities and associated psychological factors as part of patient-reported outcome measures (PROMs) in long-term survivors after radical prostatectomy

Authors: [Herkommer K.](#)¹, Schlichte A. .N. .J. .H.¹, Klorek T.¹, Peter C.¹, Jahnen M.¹, Dinkel A.², Schiele S.¹, Lunger L.¹, Schulwitz H.¹, Gschwend J. .E.¹

Institutes: ¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Psychosomatic Medicine and Psychotherapy, Munich, Germany

A0003

Temporal validation of an artificial intelligence tool (SEPERA) to inform nerve-sparing strategy during radical prostatectomy and comparison against urologists

Authors: Pickel L.¹, Zhang K.¹, Booth R.¹, Shahid A.¹, Ringa M.², Ali A.², Chan A.³, Perlis N.⁴, Hamilton R.J.⁴, Fleshner N.E.⁴, Finelli A.⁴, Johnson A.E.W.⁵, Kulkarni G.S.⁴, Feifer A.², Zlotta A.R.³, [Kwong J.](#)⁶

Institutes: ¹University of Toronto, Temerty Faculty of Medicine, Toronto, Canada, ²Trillium Health Partners, Division of Urology, Dept. of Surgery, Mississauga, Canada, ³Mount Sinai Hospital - Sinai Health System, Division of Urology, Dept. of Surgery, Toronto, Canada, ⁴Princess Margaret Cancer Centre - University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada, ⁵University of Toronto, Dalla Lana School of Public Health, Toronto, Canada, ⁶University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada

- A0002** **Predictors of early continence in robot-assisted radical prostatectomy: The role of prostate lobe asymmetry**
Authors: Di Bello F., Morra S., Pezone G., Collà Ruvolo C., Fraia A., La Rocca R., Napolitano L., Creta M., Longo N., Califano G.
Institutes: Università degli studi di Napoli Federico II, Neuroscience reproductive science and odontostomatology, Naples, Italy
- A0014** **Trifecta and Pentafecta after robot-assisted laparoscopic prostatectomy with bladder neck sparing and maximal urethral length preservation in patients with large prostates (>100cc)**
Authors: Alberti A., Nicoletti R., Dibilio E., Resta G.R., Makrides P., Caneschi C., Ciaralli E., Cifarelli A., D'Amico A., Paganelli D., Saladino M., Mazzola L., Lo Re M., Polverino P., Rivetti A., Facchiano D., Spatafora P., Sebastianelli A., Campi R., Serni S., Gacci M., Sessa F.
Institutes: University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy
- A0016** **Stratification of potency after robotic-assisted radical prostatectomy based on age and degree of nerve-sparing**
Authors: Kinnear N.¹, Fonseca P.¹, Jinaraj A.¹, Rabinowitz J.¹, Adam S.¹, Ogbechie C.¹, Haidar O.¹, Hennessey D.², Brodie A.¹, Lane T.¹, Vasdev N.¹, Adshead J.¹
Institutes: ¹Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ²Mercy University Hospital, Dept. of Urology, Cork, Ireland
- 13:30 - 13:55** **Prepare for the worst?**
- A0009** **Multimodal prehabilitation before robotic-assisted radical prostatectomy. A randomised controlled trial. Preliminary results**
Authors: Carbonell E.¹, Dana F.², Tena B.², Sebjo R.³, Salinas R.³, Romano B.⁴, Sisó M.⁴, Capitán D.², Terès S.⁴, Gath F.³, Sanguino A.¹, Sureda Riera J.¹, Mercader C.¹, Vendrell M.², Musquera M.¹, Laxe S.³, Martínez-Pallí G.², Ribal M.J.¹, Alcaraz A.¹, Vilaseca A.¹
Institutes: ¹Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clínic de Barcelona, Dept. of Anesthesiology, Barcelona, Spain, ³Hospital Clínic de Barcelona, Dept. of Physical medicine and Rehabilitation, Barcelona, Spain, ⁴Hospital Clínic de Barcelona, Dept. of Endocrinology and Nutrition, Barcelona, Spain
- A0011** **Intra-operative frozen section during robotic-assisted laparoscopic prostatectomy is associated with superior 1-year potency and continence and equivalent biochemical recurrence**
Authors: Kinnear N., Haidar O., Ogbechie C., Adam S., Fonseca P., Jinaraj A., Brodie A., Vasdev N., Lane T., Adshead J.
Institutes: Lister Hospital, Dept. of Urology, Stevenage, United Kingdom
- A0007** **Surgical Planning in Robotic Assisted Radical Prostatectomy (RALP): A Quality improvement (QI) project to improve Nerve-sparing (NS) outcomes**
Authors: Tandogdu Z.¹, Dickinson L.¹, Day E.¹, Tarim K.¹, Kelkar A.¹, Sridhar A.¹, Ta A.¹, Lamb B.¹, So C.W.², Collins J.¹, Rajan P.¹, Sooriakumaran P.¹, Nathan S.¹, Briggs T.¹, Allen C.², Shaw G.¹, Kelly J.¹
Institutes: ¹University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²University College London Hospital, Dept. of Uro-Radiology, London, United Kingdom

- A0015** **Functional Outcomes of Hypothermic RARP: A Randomized, Multicenter, Single-Blinded Study**
Authors: Han J.H.¹, Jeong C.W.¹, Jeong S.H.¹, Chung J.H.², Lee S.C.³, Byun S.S.³, Kwak C.¹, Jeon S.S.²
Institutes: ¹Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ²Samsung Medical Center, Dept. of Urology, Seoul, South Korea, ³Seoul National University Bundang Hospital, Dept. of Urology, Seoul, South Korea
- A0013** **Comparative Analysis of Early Functional Outcomes Following the Hood Technique vs. Standard Nerve Sparing Technique during RARP**
Authors: Khanmammadova N.¹, Cumpapas A.D.¹, Jiang D.¹, Gevorkyan R.², Epino M.¹, Chu T.¹, Gao A.¹, Afyouni A.S.¹, O'leary M.¹, Nguyen T.T.³, Fung C.¹, Nguyen C.¹, Ali S.N.¹, Shahait M.⁴, Lee D.I.¹
Institutes: ¹University of California Irvine, Dept. of Urology, California, United States of America, ²University of Southern California, Keck School of Medicine, California, United States of America, ³University of Medicine and Pharmacy, Dept. of Urology, Ho Chi Minh, Vietnam, ⁴Clemenceau Medical Center, Dept. of Urology, Dubai, United Arab Emirates
- 13:55 - 14:25** **Tools to improve outcome**
- A0004** **Short-term follow-up shows superior continence after robotic radical prostatectomy: Results from 16,839 German routine care patients.**
Authors: Butea-Bocu M.C., Beyer B., Müller G.
Institutes: Kliniken Hartenstein, Center for Urological Rehabilitation, Bad Wildungen, Germany
- A0010** **A Retrospective Concomitant Nonrandomized Comparison of Testosterone Replacement Therapy Versus No Treatment: Erectile Function Recovery in Older Hypogonadal Men Post-RARP.**
Authors: Gevorkyan R., Hammad M.A.M., Tran J., Fung C., Barham D.W., Yafi F., Ahlering T.
Institutes: University of California Irvine, Dept. of Urology, Orange, United States of America
- A0006** **A new approach to prostate cancer survivorship care following radical prostatectomy (RP)**
Authors: MacAskill F.E.N., Gharbieh S., Sandher A., Torres C., Sandher R., Taylor C., Yap T., Shabbir M., Sahai A.
Institutes: Guy's Hospital, Dept. of Urology, London, United Kingdom
- A0001** **The impact of prostate cancer ADT and EBRT follow-up treatment on patient-reported quality of life – results from the EUPROMS 2.0 follow-up study**
Authors: Venderbos L.D.F.¹, Remmers S.¹, Deschamps A.², Dowling J.², Carl E-G.², Perreira-Azevedo N.³, Roobol M.J.¹
Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Europa Uomo, Antwerp, Belgium, ³Entre o Douro e Vouga Medical Center, Dept. of Urology, Santa Maria da Feira, Portugal
- A0012** **Preservation of Neurovascular Bundles in High-Risk Prostate Cancer Patients: Long-Term Oncological Outcomes from a High-Volume Tertiary Center**
Authors: Frego N., Ticonosco M., Sorce G., Collà Ruvolo C., Rebuffo S., Pissavini A., Belmonte M., De Naeyer G., De Groote R., D'Hondt F., Mottrie A.
Institutes: Onze-Lieve-Vrouweziekenhuis, Dept. of Urology, Aalst, Belgium
-

A0008

Impact of Nerve-Sparing on Urinary Continence following Robot-Assisted Radical Prostatectomy: results from a High-Volume Tertiary Care Hospital

Authors: Pissavini A., Sorce G., Ticonosco M., Frego N., Collà Ruvolo C., Rebuffo S., Belmonte M., De Groote R., De Naeyer G., D Hondt F., Mottrie A.

Institutes: Onze-Lieve-Vrouweziekenhuis, Dept. of Urology, Aalst, Belgium

A0412

Current practice and unmet training needs in Robotic-assisted radical prostatectomy: investigation from the Junior ERUS / YAU working group

Authors: Covas Moschovas M.¹, Bravi C.², Dell'Oglio P.³, Turri F.⁴, De Groote R.⁵, Liakos N.⁶, Wenzel M.⁷, Wurnschimmel C.⁸, Di Maida F.⁹, Piramide F.¹⁰, Andras I.¹¹, Breda A.¹², Mottrie A.⁵, Patel V.¹, Larcher A.¹³

Institutes: ¹AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁴ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ⁵OLV Hospital, ORSI Academy, Dept. of Urology, Aalst, Belgium, ⁶University of Freiburg Medical Centre, Dept. of Urology, Freiburg, Germany, ⁷University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁸Luzerner Kantonsspital, Dept. of Urology, Luzerner, Switzerland, ⁹University of Florence, Dept. of Urology, Florence, Italy, ¹⁰University of Turin, Dept. of Urology, Turin, Italy, ¹¹Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ¹²Autonoma University of Barcelona, Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, ¹³San Raffaele Hospital, Dept. of Urology, Milan, Italy

Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

05 April 2024
13:00 - 15:00

Location Green Area, W06
Chairs R. Hovhannisyanyan, Yerevan (AM)
H. Van Poppel, Leuven (BE)

Introduction

13:00 - 13:40

Andrology

Moderator

To be confirmed

13:00 - 13:10

Methods of surgical sperm extraction in the assisted reproductive technology (ART) programme and the specifics of patient preparation

D. Fanarjyan, Yerevan (AM)

13:10 - 13:20

The prevalence of sexual disorders in Tashkent

S. Shavakhabov, Tashkent (UZ)

13:20 - 13:30

Male infertility: did we learn from the past?

N. Sofikitis, Ioannina (GR)

13:30 - 13:40

Our experience in penile implantation

Z. Khakimkhodzhaev, Bishkek (KG)

13:40 - 14:20

Minimally invasive urology

Moderator

To be confirmed

13:40 - 13:50

The impact of different techniques of dorsal venous complex management during laparoscopic radical prostatectomy on oncological and functional results

A. Pertia, Tbilisi (GE)

13:50 - 14:00

ORSI training center: Robots, the sky is the limit?

A. Mottrie, Aalst (BE)

14:00 - 14:10

Surgical recovery of long-term pelvic defects of ureters

S. Kussymzhanov, Almaty (KZ)

14:10 - 14:20

Interstitial cystitis and bladder pain syndrome

To be confirmed

14:20 - 14:40

Screening prostate cancer

Moderator

To be confirmed

14:20 - 14:30

Screening of prostate cancer: Georgian experience

A. Chkhotua, Tbilisi (GE)

14:30 - 14:40

EU and Council recommendation

H. Van Poppel, Leuven (BE)

Upper urinary tract cancer: Challenges in molecular and clinical diagnosis

Abstract session 2

05 April 2024
13:00 - 14:30

Location Green Area, S06
Chairs To be confirmed
To be confirmed
S. Füssel, Dresden (DE)

13:00 - 13:02

Introduction

13:02 - 13:27

Staging of upper tract urothelial carcinoma

A0018

pT3 Upper Tract Urothelial Carcinoma of the Renal Pelvis: Validating the Prognostic Significance of Subclassification

Authors: Oberneder K., Laukhtina E., Shariat S.F.

Institutes: Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0030

Prognostic impact of a novel pathologic T3 subclassification in patients with upper urinary tract cancer undergoing radical nephroureterectomy

Authors: Tsai Y-C., Chou Y.J.

Institutes: Taipei Tzu Chi Hospital, Dept. of Urology, New Taipei City, Taiwan

A0024

Preoperative Multivariable Model for the Prediction of Non-organ Confined Upper Tract Urothelial Carcinoma in Taiwanese population

Authors: Huang Y.P.¹, Huang E.Y.H.², Li C.C.³, Chung H-J.², Huang T.H.², Wei T.C.², Fan Y.H.², Lin C.C.², Lin T.P.², Kuo J.Y.², Lu S.H.², Chang Y-H.², Lin A.T.L.², Huang W.J.²

Institutes: ¹Fu Jen Catholic University Hospital, Dept. of Urology, New Taipei City, Taiwan, ²Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ³Taipei Veterans General Hospital, Dept. of Radiology, Taipei, Taiwan

A0028

Incidence of potential candidates for kidney-sparing surgery in upper tract urothelial carcinoma : analysis using radical nephroureterectomy specimens

Authors: Matsumoto S., Waseda Y., Kimura T., Suzuki K., Hasegawa A., Tanaka H., Ikeda R., Yoshitomi K., Chen W., Fan B., Kobayashi M., Fujiwara M., Nakamura Y., Ishikawa Y., Fukuda S., Tanaka H., Yoshida S., Fujii Y.

Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

A0031

Development and validation of a novel nomogram to predict lymph node invasion in upper tract urothelial carcinoma

Authors: Saitta C.¹, Meagher M.F.², Autorino R.³, Porpiglia F.⁴, Bell S.⁵, Abdollah F.⁶, Simone G.⁷, Yong C.⁸, Lughezzani G.², Afari J.¹, Tozzi M.⁹, Jacob T.¹⁰, Ghoreifi A.¹¹, Wang L.¹², Margulis V.¹⁰, Sundaram C.⁸, Djaladat H.¹¹, Mehrazin R.¹³, Gonzalzo M.¹⁴, Buffi N.², Wu Z.¹², Ferro M.⁹, Derweesh I.¹

Institutes: ¹UC San Diego Health system, Dept. of Urology, San Diego, United States of America, ²UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ³VCU Health, Dept. of Urology, Richmond, United States of America, ⁴University of Turin, Dept. of Urology, Turin, Italy, ⁵Lewis Katz School of Medicine, Dept. of Urology, Philadelphia, United States of America, ⁶Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ⁷IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁸Indiana University, Dept. of Urology, Indianapolis, United States of America, ⁹European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ¹⁰University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹¹Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ¹²Shanghai Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ¹³Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁴Desai Sethi Urology Institute, Dept. of Urology, Miami, United States of America

13:27 - 13:57

Molecular landscape of upper tract urothelial carcinoma

A0020

Preoperative plasma levels of transforming growth factor beta and its prognostic influence on disease outcomes after radical nephroureterectomy

Authors: Alimohammadi A., Laukhtina E., Oberneder K., Ofner H., Franke J., D'Andrea D., Shariat S.

Institutes: Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0019

Mutational characteristics of advanced urothelial carcinoma in a high-prevalence area for aristolochic acid-associated urinary tract cancers

Authors: Tung H-T.¹, Jou Y.C.², Tsai H.T.¹, Tzai T.S.³, Tsai Y.S.¹

Institutes: ¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²St Martin De Porres Hospital, Dept. of Urology, Chai-Yi, Taiwan, ³An-Nan Hospital, Dept. of Urology, Tainan, Taiwan

A0026

Hematoxylin-eosin Staining Based Immune Microenvironment Subtypes to Guide Prognostic Stratification for Locally Progressive Upper Tract Urothelial Carcinoma

Authors: Xu C.¹, Zhong W.², Wu D.², Huang Y.¹, Li X.³, Lin T.², Huang J.², Zhou L.¹, Li X.¹

Institutes: ¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China, ³Peking University First Hospital, Dept. of Radiation Oncology, Beijing, China

- A0033** **The genomic landscape and clinical relevance in Chinese patients with upper tract urothelial carcinoma**
Authors: Junlong W., Shengming J., Jian P., Shanshan W., Dingwei Y.
Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- A0022** **Performance of Urinary Comprehensive Genomic Profiling in Patients with Upper Tract Urothelial Carcinoma**
Authors: Pallauf M.¹, Broenimann S.¹, Fischer D.S.², Hamlington B.², Biocca V.T.², Levin T.G.², Mcconkey D.J.³, Singla N.¹
Institutes: ¹Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Convergent Genomics, Dept. of Convergent Genomics, South San Francisco, United States of America, ³Johns Hopkins University School of Medicine, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, United States of America
- A0034** **Implication of central pathology review in multi-center study of upper tract urothelial cancer**
Authors: Chou Y.J., Tsai Y.C.
Institutes: Taipei Tzu Chi Hospital, Division of Urology, New Taipei City, Taiwan
- 13:57 - 14:27** **Endoscopic management of upper tract urothelial carcinoma**
- A0023** **Intraoperative diagnosis of upper tract urothelial carcinoma with ex-vivo confocal laser microscopy during ureteroscopy**
Authors: Territo A.¹, Basile G.¹, Gallioli A.¹, Gaya J.M.¹, Verri P.¹, Robalino J.¹, Bravo A.¹, Izquierdo P.¹, Hernandez P.¹, Diana P.¹, Pecoraro A.¹, Berquin C.¹, Afferi L.¹, Rodriguez-Faba O.¹, Algaba F.², Palou J.¹, Breda A.¹
Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Pathology, Barcelona, Spain
- A0032** **Stenting versus nephrostomy tubes for bladder cancer associated with hydronephrosis: Does stenting increase the incidence of upper tract urothelial carcinoma by retrograde tumor cell seeding?**
Authors: Wettstein M.S., Bernardino R.M., Randhawa H., Kwong J.C.C., Cheung D.C., Aminoltejari K., Fleshner N.E., Zlotta A.R., Kulkarni G.S.
Institutes: University of Toronto, Division of Urology, Toronto, Canada
- A0027** **Diagnostic role of ureteroscopy and oncological outcome in patients clinically suspected of upper tract carcinoma in situ**
Authors: Katayama S., Iwata T., Kawada T., Tominaga Y., Sadahira T., Nishimura S., Edamura K., Bekku K., Kobayashi T., Kobayashi Y., Araki M.
Institutes: Okayama University Hospital, Dept. of Urology, Okayama, Japan
- A0025** **Systematic biopsies of the upper tract: a tool to improve the diagnostic accuracy of ureteroscopy and characterization of upper tract urothelial cancer**
Authors: Gallioli A.¹, Basile G.¹, Territo A.¹, Dieguez L.¹, Izquierdo P.¹, Aumatell J.¹, Pecoraro A.¹, Lauwers C.¹, Berquin C.¹, Gaya J.M.¹, Sanguedolce F.¹, Gavrillov P.¹, Algaba F.², Palou J.¹, Breda A.¹
Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Pathology, Barcelona, Spain
-

A0021

Oncologic outcomes of endoscopic management of upper tract urothelial carcinoma: a systematic review and pooled analysis from the EAU-YAU Urothelial Working Group

Authors: Gallioli A.¹, Uleri A.¹, Mertens L.², Tedde A.¹, Moschini M.³, Del Giudice F.⁴, Soria F.⁵, Laukhtina E.⁶, José Daniel S.⁷, Krajewski W.⁸, D'Andrea D.⁶, Mari A.⁹, Marcq G.¹⁰, Mori K.¹¹, Teoh J.¹², Afferi L.¹³, Basile G.¹, Territo A.¹, Sanguedolce F.¹, Breda A.¹, Pradere B.¹⁴

Institutes: ¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁴Sapienza University of Rome Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ⁵University of Turin and Città della Salute e della Scienza, Surgical Sciences, Turin, Italy, ⁶Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Dept. of Urology, Madrid, Spain, ⁸Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ⁹University of Florence and Careggi Hospital, Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹⁰Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ¹²S.H. Ho Urology Centre and The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ¹³Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹⁴Urosud La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

A0029

Decisional and prognostic impact of diagnostic ureteroscopy in high-risk upper tract urothelial carcinoma: a multi-institutional collaborative analysis (ROBUUST collaborative group)

Authors: Ditunno F.¹, Veccia A.¹, Montanaro F.¹, Pettenuzzo G.¹, Costantino S.¹, Franco A.², Wu Z.³, Correa A.⁴, Margulis V.⁵, Djaladat H.⁶, Simone G.⁷, Derweesh I.H.⁸, Abdollah F.⁹, Nirmish S.¹⁰, Ferro M.¹¹, Porpiglia F.¹², Checcucci E.¹², Gonzalگو M.L.¹³, Perdonà S.¹⁴, Mehrazin R.¹⁵, Sundaram C.P.¹⁶, Autorino R.², Antonelli A.¹

Institutes: ¹University of Verona, Dept. of Urology, Verona, Italy, ²Rush University, Dept. of Urology, Chicago, United States of America, ³Naval Medical University, Dept. of Urology, Shanghai, China, ⁴Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁵University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁶Norris Comprehensive Cancer Center University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁷IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁸UC San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ⁹Vattikuti Urology Institute Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ¹⁰John Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ¹¹European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ¹²University of Turin San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ¹³University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁴Istituto Nazionale Tumori Fondazione Pascale, Dept. of Urology, Naples, Italy, ¹⁵Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁶Indiana University, Dept. of Urology, Indianapolis, United States of America

14:27 - 14:30

Expert summary

Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

05 April 2024
13:00 - 15:00

Location Purple Area, E02
Chairs S.K. Hong, Seongnam (KR)
A.S. Merseburger, Lübeck (DE)

Learning objectives

This session will address a variety of hot urology topics with the help of specialists and key opinion leaders from South Korea and Europe. Delegates can expect detailed and up-to-date coverage of topics like andrology, voiding difficulty, and urological cancers including prostate cancer and urothelial cancer. In this session some of the regional similarities and differences in approaches will be explored.

Welcome and introduction

J.H. Hong, Seoul (KR)

13:00 - 13:40

Urothelial cancer

Moderators A. Breda, Barcelona (ES)
S.H. Kang, Seoul (KR)

13:00 - 13:10

Is perioperative intravesical chemotherapy necessary for surgical treatment of UTUC?

T. Choi, Seoul (KR)

13:10 - 13:20

Active surveillance in NMIBC: When and how?

S.I. Jung, Gwangju (KR)

13:20 - 13:30

Single-port robotic radical cystectomy: Tips & tricks

A. Breda, Barcelona (ES)

13:30 - 13:40

Panel discussion

Panel E.N. Xylinas, Paris (FR)
Y.J. Kim, Cheongju (KR)
T.H. Kim, Daegu (KR)
To be confirmed

13:40 - 14:20

Voiding dysfunction, andrology

Moderators K-S. Lee, Seoul (KR)
V. Phé, Paris (FR)

13:40 - 13:50

The appropriate grafting material in the surgical treatment of Peyronie's disease: Collagen fleece (TachoSil) vs. Bovine Pericardium vs. Saphenous Vein?

M.G. Park, Seoul (KR)

13:50 - 14:00

Optimal evaluation and management in patients with post-prostatectomy incontinence

H.J. Byun, Daegu (KR)

14:00 - 14:10

Current status of minimally invasive surgical therapies for BPH

T.R.W. Herrmann, Frauenfeld (CH)

14:10 - 14:20	Panel discussion	Panel	T.R.W. Herrmann, Frauenfeld (CH) K. Park, Kwangju (KR) J.S. Shim, Seoul (KR) J.H. Lee, Seoul (KR)
14:20 - 15:00	Prostate cancer Moderators		B.A. Hadaschik, Essen (DE) K.J. Joo, Seoul (KR)
14:20 - 14:30	Risk-adapted strategy for screening and early detection in prostate cancer		J. Walz, Marseille (FR)
14:30 - 14:40	Updates and best strategy for biochemical recurrence after radical prostatectomy		H.H. Han, Seoul (KR)
14:40 - 14:50	How does PSMA PET-CT change our clinical practice in the management of prostate cancer?		B.A. Hadaschik, Essen (DE)
14:50 - 15:00	Panel discussion	Panel	J. Walz, Marseille (FR) J.H. Hong, Seoul (KR) P.H. Song, Daegu (KR) J. Suh, seoul (KR) J.H. Han, Seoul (KR)

Updates and controversies - Urolithiasis, female and male LUTS guidelines 2024: What has changed?

ESU Course 09

05 April 2024
13:00 - 15:00

Location Purple Area, E04
Chair A.K. Nambiar, Newcastle-upon-Tyne (GB)

Learning objectives

This course will focus on three non-oncology Guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis) and there will be a brief review of the EAU Guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

Welcome and introduction

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Urolithiasis guideline: New diagnostic algorithms, best clinical practice in urinary stone intervention, how and how often to follow up and time to discharge urinary stone patients after treatment

R. Geraghty, Newcastle upon Tyne (GB)

Non-neurogenic male LUTS guideline: Updates and controversies

J-N.L. Cornu, Rouen (FR)

Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2024

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Inflammatory bladder

Patient information session - Roundtable

05 April 2024
13:30 - 14:30

Location **Chairs**

Green Area, W08
D.A.W. Janssen, Nijmegen (NL)
Patient Advocate - J.M. Meijlink, Naarden (NL)

Learning objectives

We want to generate attention for the burden and lack of guidelines for inflammatory bladder diseases. We will focus on BPS/IC, chronic radiation induced cystitis and ketamine induced cystitis. The burden, experienced by patients and the nuances in healthcare management will be discussed. This roundtable will give patients and clinical care experts in this field a platform on how to improve healthcare for these underdiagnosed and often sub optimally treated patients.

13:30 - 13:35

Welcome & introduction

D.A.W. Janssen, Nijmegen (NL)

13:35 - 13:50

IC/BPS

D.A.W. Janssen, Nijmegen (NL)
Patient Advocate - J.M. Meijlink, Naarden (NL)

13:50 - 14:05

Radiotherapy/radiation cystitis

13:50 - 13:55

A patient view to talk about their experience

To be confirmed

13:55 - 14:05

An expert view on treatments

L.M. Renström Koskela, Stockholm (SE)

14:05 - 14:20

Ketamine cystitis: Affects and addiction

W. Van Der Sanden, Utrecht (NL)

14:20 - 14:30

Q&A and closing

D.A.W. Janssen, Nijmegen (NL)

Hands-on Training in MRI fusion biopsy

HOT 1.17

05 April 2024
13:30 - 16:45

Location Orange Area, HOT 3
Chair To be confirmed

Learning objectives

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. The Hands-on Training in MRI Fusion Biopsy is designed to help participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

The course provides an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. After presentations on During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

The training is designed to be 2 hours, including a short introduction, presentation of different approaches, and a rotation of training at each station.

13:30 - 13:35

Introduction

13:35 - 13:50

Different MRI-Ultrasound technical approaches available

13:50 - 14:20

Demonstration: How to perform a transperineal biopsy

14:20 - 16:20

Hands-on training at stations

16:20 - 16:30

Closing remarks, Q&A

Hands-on Training in MRI fusion biopsy

HOT 2.25

06 April 2024
09:00 - 12:15

Location Orange Area, HOT 3
Chair To be confirmed

Learning objectives

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. The Hands-on Training in MRI Fusion Biopsy is designed to help participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

The course provides an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. After presentations on During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

The training is designed to be 2 hours, including a short introduction, presentation of different approaches, and a rotation of training at each station.

09:00 - 09:05

Introduction

09:05 - 09:20

Different MRI-Ultrasound technical approaches available

09:20 - 09:50

Demonstration: How to perform a transperineal biopsy

09:50 - 11:50

Hands-on training at stations

11:50 - 12:00

Closing remarks, Q&A

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.05

05 April 2024
13:45 - 14:40

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.06

05 April 2024
13:45 - 14:40

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.10

05 April 2024
13:45 - 14:40

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Harnessing technology in urology: From remote monitoring to AI-enhanced robotic interventions

Video session 03

05 April 2024
14:15 - 15:45

Location Green Area, S04
Chairs To be confirmed
To be confirmed
F. Porpiglia, Turin (IT)

- V017** **Use of TYTOCARE device for home telemonitoring in patients undergoing radical cystectomy: Comparative analysis of early post-operative outcomes**
Authors: Amparore D.¹, Quarà A.¹, De Cillis S.¹, Colombo M.¹, Garzena V.¹, Verri P.¹, Poggio M.¹, Checcucci E.², Piana A.³, Piramide F.¹, Volpi G.², Sica M.¹, Burgio M.¹, Meziere J.¹, Marsero L.¹, Sterrantino A.¹, Ziani N.¹, Turcan A.¹, Manfredi M.¹, Fiori C.¹, Porpiglia F.¹
Institutes: ¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy
- V018** **Artificial Intelligence 3D Augmented Reality guided RARP v.s. Artificial Intelligence 3D Augmented Reality guided RARP v.s. Cognitive MRI intervention: ad interim analysis of RIDERS Trial**
Authors: Checcucci E.¹, De Cillis S.T.², Amparore D.², Volpi G.¹, Gatti C.², Paolo A.¹, Piramide F.², Piana A.³, Cisero E.², Ortenzi M.², Sterrantino A.², Busacca G.², De Luca S.², Rescigno P.⁴, Manfredi M.², Stura I.⁵, Migliaretti G.⁵, Piazzolla P.¹, Fiori C.², Porpiglia F.²
Institutes: ¹Candiolo Cancer Institute FPO-IRCCS, Division of Urology, Dept. of Surgery, Candiolo, Italy, ²AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ⁴University of Turin, Dept. of Oncology, Turin, Italy, ⁵School of Medicine - University of Turin, Dept. of Molecular Biotechnology and Health Sciences, Orbassano, Italy
- V019** **3D-models assistance during robot-assisted renal artery aneurysm removal**
Authors: Amparore D.¹, Piramide F.¹, Verri P.¹, Barbuto S.¹, Checcucci E.², De Cillis S.T.¹, Piana A.³, Volpi G.², Sica M.¹, Burgio M.¹, Meziere J.¹, Busacca G.¹, Cisero E.¹, Quarà A.¹, Marsero L.¹, Mandaletti M.¹, Gatti C.¹, Ortenzi M.¹, Trapella G.¹, Ferrando L.¹, Manfredi M.¹, Fiori C.¹, Porpiglia F.¹
Institutes: ¹AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy
- V020** **Robotic ureteroplasty for retrocaval ureter with three-dimensional images navigation: technique and outcomes**
Authors: Xiang W., Yiming Z., Zhihua L., Xinfei L., Silu C., Guanpeng H., Mancheng X., Kunlin Y., Liqun Z., Kai Z., Xuesong L.
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

- V021 **Robot assisted 3D model & indocyanine guided ureteral reimplantation in renal transplant patients:**
- 4 emblematic cases from our series.**
Authors: Lavagno F., Allasia M., Oderda M., Marquis A., D Agate D., Mangione C., Greco A., Pasquale G., Bosio A., Gontero P.
Institutes: Molinette Hospital and University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy
- V022 **Feasibility of image-guided navigation during robotic-assisted surgery: a prospective study**
- Authors:** Aguilera Saiz L.¹, Heerink W.J.¹, Groen H.C.¹, Hiep M.A.J.¹, Van Der Poel H.G.², Wit E.M.K.², Nieuwenhuijzen J.A.³, Roeleveld T.A.³, Van Leeuwen P.J.², Ruers T.J.M.¹
Institutes: ¹Netherlands Cancer Institute, Dept. of Surgical Oncology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands
- V086 **A preliminary experience with metaverse surgical planning for robotic partial nephrectomy**
- Authors:** Checcucci E.¹, Amparore D.², Volpi G.¹, De Cillis S.T.², Alessio P.¹, Piramide F.², Piana A.³, Sica M.², Quarà A.², Gatti C.², Busacca G.², Colombo M.², Fiori C.², Porpiglia F.²
Institutes: ¹Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ²AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ³Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy
- V024 **Super-selective clamping guided by 3D augmented reality during robot assisted partial nephrectomy: A single center experience**
- Authors:** Spena G.¹, Tufano A.¹, Izzo A.¹, Quarto G.¹, Grimaldi G.¹, Castaldo L.¹, Franzese D.¹, Passaro F.¹, Muscariello R.¹, Del Prete P.², Perdonà S.¹
Institutes: ¹Istituto Nazionale Tumori 'Fondazione G. Pascale' IRCCS, Dept. of Uro-Gynaecological Oncology, Division of Urology, Naples, Italy, ²Istituto Nazionale Tumori 'Fondazione G. Pascale' IRCCS, Dept. of Scientific Management, Naples, Italy

Urogenital reconstruction

EGPT 03

**05 April 2024
14:15 - 15:45**

Location EGPT
Chairs To be confirmed
T.L.C. Kuo, Singapore (SG)
To be confirmed

14:15 - 14:36

Screen A: Urethral strictures

P084

Delineating functional outcomes and patient-reported treatment satisfaction after perineal urethrostomy as last resort management of complex anterior urethral strictures

Authors: Klemm J.¹, Dahlem R.¹, König F.¹, Shariat S.F.², Marks P.¹, Fisch M.¹, Vetterlein M.W.¹

Institutes: ¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria

P064

Management Patterns of Male Urethral Stricture Disease Among Urologists: What Do the Guidelines Say? What Do Urologists Do?

Authors: Deger M.¹, Cebeci O.O.², ATES T.¹, Geyik S.³, Girgin R.⁴, Bozkurt O.⁵

Institutes: ¹Cukurova University, Dept. of Urology, Adana, Türkiye, ²Kocaeli Derince Training and Research Hospital, Dept. of Urology, Kocaeli, Türkiye, ³Aksaray University, Dept. of Urology, Aksaray, Türkiye, ⁴Zonguldak Bulent Ecevit University, Dept. of Urology, Zonguldak, Türkiye, ⁵Dokuz Eylul University, Dept. of Urology, Izmir, Türkiye

P061

Efficacy analysis of Da Vinci robot-assisted laparoscopic Y-V cystoplasty for anastomotic stricture after radical prostatectomy for prostate cancer—experience from a single urinary tract repair center

Authors: Fu Q., Huang J., Hu X., Song L.

Institutes: Shanghai Sixth People's Hospital, Dept. of Urology, Shanghai, China

P069

Non-bulb transecting vessel - sparing excision and primary anastomosis (EPA). Dorsal approach for proximal bulbar and membranous strictures.

Authors: Dahamshy M., Sidi A., Tsivian A.

Institutes: Wolfson Medical Center, Dept. of Urologic Surgery, Holon, Israel

P072

Mucosal sparing augmented non-transecting urethroplasty (msANTA) : Game changer In the management of non traumatic Bulbar urethral strictures

Authors: Bafna S., Ragavan N., Jain N., Ganesan T.

Institutes: Apollo Hospitals, Dept. of Urology, Chennai, India

P077

Long-term Follow-up and Success Rate of Ventral Inlay Buccal Mucosal Graft Urethroplasty vs Dorsal onlay Buccal Mucosal Graft Urethroplasty for Female Urethral Stricture Disease.

Authors: Mandal S., das k M., Nayak P., G R., Ram P., Singh G A.

Institutes: All India Institute of Medical Sciences Bhubaneswar, Dept. of Urology, Bhubaneswar, India

- P076** **Does tobacco exposure, preoperative oral health, and buccal mucosal graft histology have a effect on postoperative pain scores at harvest site? A Prospective Observational**
Authors: Mandal S.¹, Nayak P.¹, Das M.¹, Ayyanar P.², T V.¹, Singh G A.¹
Institutes: ¹All India Institute of Medical Sciences Bhubaneswar, Dept. of Urology, Bhubaneswar, India, ²All India Institute of Medical Sciences Bhubaneswar, Dept. of Pathology, Bhubaneswar, India
- 14:36 - 14:54** **Screen B: Sexual dysfunction**
- P080** **Qualitative assessment of patient-reported outcomes in urinary and sexual function in patient after perineal urethrostomy**
Authors: Neuville P.¹, Zhang X.¹, Hwang C.¹, Moore M.², Hagedorn J.¹, Skokan A.J.¹
Institutes: ¹University of Washington, Dept. of Urology, Seattle, United States of America, ²University of Washington, Harborview Injury Prevention and Research Center, Seattle, United States of America
- P087** **Our outcomes of an improved penile venous surgery in patients with venogenic erectile dysfunction**
Authors: Gvasalia B.R.¹, Chesnov D.A.², Babaev M.U.², Gorobets Y.P.², Dukuzov D.A.², Chelidze I.D.², Pushkar D.Y.²
Institutes: ¹American Hospital Tbilisi MSUMD, Dept. of Urology, Tbilisi, Georgia, ²MSUMD, Dept. of Urology, Moscow, Russia
- P067** **Efficacy of transobturator vaginal tape (TVT-O) in the treatment of Coital Incontinence.**
Authors: Gubbiotti M.¹, Rosadi S.¹, Giommoni V.¹, Rubilotta E.²
Institutes: ¹Ospedale Santa Maria alla Gruccia, Dept. of Urology, Montevarchi, Italy, ²AOUI Verona, Dept. of Urology, Verona, Italy
- P081** **Does a separate blood supply to the urethra decrease complications in transmasculine gender affirmation surgery? Outcomes of radial artery urethroplasty in a large cohort**
Authors: Gobbo A., Christopher N.A., Li V.Y., Ralph D.J., Lee W.G.
Institutes: University College of London Hospitals, Dept. of Andrology, London, United Kingdom
- P088** **Novel strategy for Combining penile erection restoration and factual girth enhancement based on de novo penile fibrovascular assembly**
Authors: Chung C-H.¹, Hsu G.², Chueh J.³, Tsai M.-H.⁴
Institutes: ¹Taipei Municipal Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, ²National Taiwan University Hospital, Microsurgical Potency Reconstruction and Research Center, Taipei, Taiwan, ³National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ⁴China Medical University, Dept. of Anatomy, Taichung, Taiwan
- P089** **Effect of alpha-adrenoceptor antagonists on sexual function: A systematic review and meta-analysis**
Authors: Gherabi N.¹, Buchholz N.², Trinchieri A.²
Institutes: ¹University of Algiers, Dept. of Medicine, Algiers, Algeria, ²U-merge Ltd., Dept. of Urology, London, United Kingdom
- 14:54 - 15:06** **Screen C: Urogenital reconstruction: preclinical**
-

- P068** **Shared genetic etiology and causality between Hunner-type interstitial cystitis and autoimmune disorders: A large-scale genome-wide cross-trait analysis**
Authors: Lyu X.Y., Fan Y., Xu X.Y., Luo D.Y.
Institutes: West China Hospital - Sichuan University, Dept. of Urology, Chengdu, China
- P063** **Functionality and tolerability of magnetic artificial urinary sphincter in canine incontinence model**
Authors: Tabatabaei S.¹, Shokri P.S.², Ziaee S.A.M.², Pedram M.S.³, Dehghan M.M.³, Shakhssalim N.²
Institutes: ¹Taba Health, Dept. of Urology, Newton, United States of America, ²Shahid Beheshti University of Medical Sciences, Dept. of Urology and Nephrology, Tehran, Iran, ³Tehran University of Medical Science, Dept. of Surgery and Radiology, Tehran, Iran
- P078** **Paclitaxel coated ureteral balloon for ureteroscopic thermal injury induced ureteral stenosis in porcine model: a preclinical study.**
Authors: Li X.¹, Zhang P.², Zhao F.¹, Xu L.¹, Zhihua L.¹, Yang K.¹, Li X.¹
Institutes: ¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Emergency General Hospital, Dept. of Urology, Beijing, China
- P083** **Decellularization and recellularization of human foreskin for tissue engineering applications**
Authors: Kuniakova M.¹, Novotna O.N.², Galfiova P.G.³, Kovac J.K.¹, Bujdak P.⁴, Trebaticky B.T.⁴, Danisovic L.¹, Žižan S.⁴
Institutes: ¹Faculty of Medicine, Comenius University, Institute of Medical Biology and Clinical Genetics, Bratislava, Slovakia, ²Faculty of Medicine, Comenius University, Dept. of Pediatric Urology, Bratislava, Slovakia, ³Faculty of Medicine, Comenius University, Institute of Histology and Embryology, Bratislava, Slovakia, ⁴Faculty of Medicine, Comenius University, Dept. of Urology, Bratislava, Slovakia
- 15:06 - 15:30** **Screen D: Urogenital reconstruction: miscellaneous**
- P070** **Systematic review and meta-analysis of the outcomes of robot-assisted surgery in complex neuro-urological interventions**
Authors: Geretto P.¹, De Cillis S.², Abdelghani B.³, Phé V.³
Institutes: ¹University of Turin, Neuro-Urology, Turin, Italy, ²San Luigi University Hospital, Dept. of Urology, Turin, Italy, ³Tenon Academic Hospital-aphp, Dept. of Urology, Paris, France
- P079** **Combined endoscopic and robot-assisted repair of vesicovaginal fistula and bladder endometriosis: Role of peritoneal flap**
Authors: Albo G.¹, Ciamarra F.², Jannello L.², Pagliarulo V.³, Quistini A.², Boeri L.², Zanetti S.P.², De Lorenzis E.², De Mitri R.³, Scanferla E.², Longo F.², Garcia M.⁴, Montanari E.¹
Institutes: ¹University of Milan, Dept. of Clinical Sciences and Community Health, Milan, Italy, ²Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³Vito Fazzi Hospital, Urology Unit, Lecce, Italy, ⁴Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America

- P074** **Combined robot-assisted and endoscopic treatment of ureteral strictures: functional outcomes in a single center experience**
Authors: Berra M., Bondonno G., Portè F., Sogni F., Ceratti G., Pesce D.P., Palumbo C., Volpe A.
Institutes: University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy
- P065** **Bladder elongation psoas hitch does not negatively affect voiding function**
Authors: Sury K., Grimaud L., Salvino M., Livingston A., Foreman J., Lentz A., Peterson A.
Institutes: Duke University, Dept. of Urology, Durham, United States of America
- P082** **Short-term Morbidity and Long-term Functional Outcomes of the T Plasty for Salvage Reconstruction of Recalcitrant Bladder Neck Stenosis**
Authors: König E., Dahlem R., Marks P., Kühnke L., Klemm J., Fisch M., Vetterlein M.W.
Institutes: University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- P085** **Long-term results of Subtrigonal Inlay Patch (SIP) Technique for recurrent bladder neck contractures**
Authors: Bozkurt O., Sarikaya E., Sen V., Demir O., Esen A.A.
Institutes: Dokuz Eylul University, Dept. of Urology, Izmir, Türkiye
- P075** **Iatrogenic or recurrent Bladder Neck contracture treated by the Palminteri Ferrari technique: a new way to approach a frustrating condition**
Authors: Palminteri E.¹, Morselli S.², Cindolo L.², Toso S.², Rabito S.², Ferrari R.², Gatti L.², Ferrari G.²
Institutes: ¹Center for Urethral and Genitalia Reconstructive Surgery, Dept. of Urology, Turin, Italy, ²CURE Group, Dept. of Urology, Modena, Italy
- P073** **Pudendal entrapment syndrome: the earliest diagnosis, the best surgical result**
Authors: Piana A.¹, Alba S.¹, Cuzari S.², Perugia C.², Greco A.¹, Chiaradia F.¹, Sidoti F.¹, Jacopo L.¹, Zappalà G.¹, Cappa M.²
Institutes: ¹Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ²Fabia Mater Clinic, Dept. of Urology, Rome, Italy
- 15:30 - 15:45** **Screen E: Complex reconstructive pathology**
- P060** **The Portuguese Navy Radiation-induced Cystitis (PNRC) scale: Validation of a novel clinical radiation-induced cystitis classification**
Authors: Ribeiro De Oliveira T.M.¹, Henriques Pereira S.², D Espiney Amaro C.³, Sousa Castro A.¹, Gomes Monteiro P.¹, Cardoso Felicio J.¹, Biyani C.S.⁴
Institutes: ¹Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ²Lisbon Medical Academic Center, Dept. of Urology, Lisbon, Portugal, ³Armed Forces Hospital, Underwater and Hyperbaric Medicine Centre, Lisbon, Portugal, ⁴Leeds Teaching Hospitals NHS Trust, Dept. of Urology, Leeds, United Kingdom
-

- P062** **Prior radiotherapy is an independent predictor for major postoperative complications in patients undergoing urinary diversion for non-malignant indications**
Authors: Haugland J., Bergesen A.K., Roth I., Hjelle K.M., Beisland C., Juliebø-Jones P., Gudbrandsdottir G.
Institutes: Haukeland University Hospital, Dept. of Urology, Bergen, Norway
- P071** **Urosymphyseal fistula and pubic osteomyelitis in prostate cancer survivors – a complex disease requiring extensive and specialized treatment**
Authors: Smeyers L.¹, Borremans J.¹, Van Der Aa F.¹, Herteleer M.², Joniau S.¹
Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Traumatology, Leuven, Belgium
- P086** **Comparing Lifespan of Artificial Urinary Sphincters in Preirradiated Patients: Transcorporal vs. Standard Placement**
Authors: Malshy K.¹, Marthi S.², Ortiz R.¹, Golijanin B.¹, Miller K.¹, Hartsell L.², Cancian M.¹
Institutes: ¹The Miriam Hospital, Warren Alpert Medical School of Brown Urology, Minimally Invasive Urology Institute, Providence, United States of America, ²Emory University Hospital, Dept. of Urology, Attleboro, United States of America
- P066** **Correlation between early recovery of urinary continence and length of spared urethra after robotic assisted radical prostatectomy: a prospective multicenter study**
Authors: Valenzi F.M.¹, Fuschi A.¹, Al Salhi Y.¹, Suraci P.P.¹, Scalzo S.¹, Antonioni A.¹, Rera O.A.¹, Sequi M.B.¹, Graziani D.¹, Gianfrancesco F.¹, Martino G.¹, Candita G.¹, Sciarra A.², Moriconi M.², De Nunzio C.³, Tema G.³, Zucchi A.⁴, Pacini M.⁴, Carbone A.¹, Pastore A.L.¹
Institutes: ¹Sapienza University of Rome Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies Urology, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy, ⁴University of Pisa, Dept. of Urology, Pisa, Italy

Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology Beyond Europe

**05 April 2024
14:45 - 16:45**

Location Purple Area, eURO Auditorium 2
Chairs A.R. Rodriguez, Winston Salem (US)
A. Stenzl, Tübingen (DE)

Learning objectives

The session provides an update including interactive discussion of the present imaging, diagnosis, staging and management of prostate cancer, bladder cancer, and kidney cancer, as well as, demonstration of new techniques related to the surgical treatment of benign prostatic hyperplasia and renal stones. All these topics will be presented and discussed by recognized experts representatives from both the EAU and CAU. The session aims to show aspects from different health care systems with respect to the management of malignant and benign genitourinary diseases.

14:45 - 14:46

Introduction

A. Stenzl, Tübingen (DE)
A.R. Rodriguez, Winston Salem (US)

Prostate cancer: Diagnosis – Staging

14:46 - 14:56

Prostate MRI the new gold standard: How, when, in whom

M. Wroclawski, Sao Paulo (BR)

14:56 - 15:06

Update on PSMA PET/CT: When does its use in staging have an impact on survival?

W. Fendler, Essen (DE)

15:06 - 15:16

Debate Transperineal prostate biopsy the new gold standard

Pro C. Gratzke, Freiburg (DE)
Con R.R. Tourinho Barbosa, Paris (FR)

15:16 - 15:31

Prostate cancer: Treatment

15:16 - 15:21

Indications, advantages and disadvantages of focal treatment modalities

R. Sanchez-Salas, Montreal (CA)

15:21 - 15:26

How reliable are imaging modalities for focal treatment

To be confirmed

15:26 - 15:31

Discussion

15:31 - 15:56

Discussion Bladder Cancer

15:31 - 15:41	Debate Extended lymphadenectomy for bladder cancer is not necessary	Pro	J.E. Gschwend, Munich (DE)
		Con	H. Zampolli, São Paulo (BR)
15:41 - 15:51	Role of immunotherapy in bladder cancer M. Babjuk, Prague (CZ)		
15:51 - 15:56	Discussion		
15:56 - 16:21	Tips and tricks: Kidney cancer		
15:56 - 16:06	Laparoscopic partial nephrectomy G. Vitagliano, Buenos Aires (AR)		
16:06 - 16:16	Robotic partial nephrectomy V. Ficarra, Messina (IT)		
16:16 - 16:21	Discussion		
16:21 - 16:31	Tips and tricks: BPH		
16:21 - 16:31	Pitfalls in laser enucleation T.R.W. Herrmann, Frauenfeld (CH)		
16:31 - 16:41	Tips and tricks: Endourology		
16:31 - 16:41	Mini percutaneous nephrolithotomy N. Bernardo, Buenos Aires (AR)		
16:41 - 16:45	Conclusion		

Immunotherapy

Thematic Session

05 April 2024
14:45 - 16:15

Location Purple Area, N01
Chairs P. Black, Vancouver (CA)
S.K. Pal, Duarte (US)

14:45 - 15:25

Kidney cancer

14:45 - 14:55

Immune checkpoint therapy in kidney cancer: Have we reached the limit?

U. Vogl, Bellinzona (CH)

14:55 - 15:05

Selecting patients for immunotherapy: Tissue based biomarkers vs. IMDC classification

To be confirmed

15:05 - 15:15

What is new in perioperative therapy in kidney cancer

A. Bex, London (GB)

15:15 - 15:17

Case presentation

R. Flippot, Villejuif (FR)

15:17 - 15:25

Panel discussion

15:25 - 15:55

Bladder cancer

15:25 - 15:35

Immunotherapy beyond BCG in NMIBC

D. Raggi, Milan (IT)

15:35 - 15:45

Perioperative immune checkpoint inhibition in MIBC

B. Szabados, London (GB)

15:45 - 15:55

Response to immune checkpoints in different histological and molecular subtypes

To be confirmed

15:55 - 16:05

Biomarkers beyond PDL1 for predicting response to checkpoint inhibition in bladder cancer

A. Necchi, Milan (IT)

16:05 - 16:15

Novel approaches to immunotherapy in GU cancers: What comes next?

To be confirmed

Navigating the landscape: Testicular carcinoma across stages

Abstract session 3

05 April 2024
14:45 - 16:15

Location Purple Area, S01
Chairs T. Kuliš, Zagreb (HR)
To be confirmed
P. Paffenholz, Cologne (DE)

14:45 - 15:05

Tumor micro-environment

A0039

New definition of the “Growing teratoma syndrome” based on molecular subtyping and novel biomarkers

Authors: Pongratanakul P.¹, Bremmer F.², Pauls S.³, Poschmann G.³, Kresbach C.⁴, Stephan A.⁵, Parmaksiz F.⁵, Skowron M.A.⁵, Paffenholz P.⁶, Stühler K.³, Schüller U.⁴, Ströbel P.², Heidenreich A.⁶, Che Y.⁷, Albers P.⁷, Nettersheim D.⁵

Institutes: ¹University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²University Medical Center Göttingen, Institute of Pathology, Göttingen, Germany, ³Heinrich Heine University Düsseldorf, Molecular Proteomics Laboratory, Düsseldorf, Germany, ⁴University Hospital Hamburg-Eppendorf, Institute of Neuropathology, Hamburg, Germany, ⁵University Hospital Düsseldorf, Urological Research Laboratory, Düsseldorf, Germany, ⁶University of Cologne, Dept. of Urology, Cologne, Germany, ⁷University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany

A0044

A single-cell analysis reveals intra-tumor heterogeneity and immune environment of testicular seminoma

Authors: Wang W.¹, Chen G.², Yang L.²

Institutes: ¹West China Hospital Sichuan University, Dept. of Urology, Institute of Urology, Chengdu, China, ²West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu Sichuan P. R. China., Dept. of Urology and Pelvic Surgery, Chengdu, China

A0043

Predictive value of immune genes related to RAS/KIT mutations in the response of TGCT to cisplatin-based chemotherapy and immunotherapy

Authors: Song N., Ji C.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A0041

Primary retroperitoneal germ-cell tumors (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)

Authors: Nazzani S.¹, Giannatempo P.², Bernasconi V.¹, Silvani C.¹, Mego M.³, Taglialatela I.², Bimbatti D.⁴, Secondino S.⁵, De Giorgi U.⁶, Claps M.², Biasoni D.¹, Catanzaro M.¹, Zimatore M.², Torelli T.¹, Stagni S.¹, Macchi A.¹, Tesone A.¹, Pedrazzoli P.⁵, Basso U.⁴, Procopio G.², De Braud F.², Nicolai N.¹

Institutes: ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Oncology, Milan, Italy, ³Comenius University and National Cancer Institute of Slovakia, Dept. of Oncology, Bratislava, Slovakia, ⁴Istituto Oncologico Veneto, Dept. of Oncology, Padua, Italy, ⁵Fondazione IRCCS Policlinico San Matteo, Dept. of Oncology, Pavia, Italy, ⁶IRCCS Istituto Romagnolo per lo Studio dei Tumori, Dept. of Oncology, Meldola, Italy

15:05 - 15:35

Optimizing diagnosis and management of stage I and indeterminate lesions

A0040

MRI in the diagnosis of indeterminate testicular lesions- a game changer?

Authors: Törzsök P.¹, Deininger S.², Lusuardi L.², Abenhardt M.², Oswald D.², Forstner R.³, Meissnitzer M.³, Deininger C.⁴, Hecht S.³, Brandtner H.³

Institutes: ¹Széchenyi István University, Dept. of Health and Sport Sciences, Győr, Hungary, ²Paracelsus Medical University, Dept. of Urology and Andrology, Salzburg, Austria, ³Paracelsus Medical University, Dept. of Radiology, Salzburg, Austria, ⁴Paracelsus Medical University, Institute of Tendon and Bone Regeneration, Salzburg, Austria

A0046

miRNA as a liquid biomarker to detect malignancy in small testicular masses.

Authors: Chavarriaga J.¹, Langleben C.¹, Lobo J.², Nappi L.³, Yousef G.M.⁴, Janfaza S.³, Tavares N.T.², Ding Q.⁴, Bobrowski A.¹, Prendeville S.⁴, Anson-Cartwright L.¹, Jeronimo C.², Wagner H.⁵, Jarvi K.⁶, O'malley M.⁷, Leao R.⁸, Lajkosz K.¹, Hamilton R.¹

Institutes: ¹Princess Margaret Cancer Centre, Dept. of Surgery, Division of Urology, Toronto, Canada, ²Hospitais e Clínicas, Dept. of Laboratory Medicine and Pathobiology, Porto, Portugal, ³University of British Columbia, Dept. of Medical Oncology, Vancouver, Canada, ⁴University Health Network, Dept. of Laboratory Medicine and Pathobiology, Toronto, Canada, ⁵University Health Network, UHN Biospecimen Services, Toronto, Canada, ⁶Mount Sinai Hospital, Dept. of Surgery, Division of Urology, Toronto, Canada, ⁷University Health Network, Joint Department of Medical Imaging, Toronto, Canada, ⁸CUF Hospitais e Clínicas, Dept. of Urology, Coimbra, Portugal

A0051

Predicting metastatic relapse in clinical stage I seminoma germ cell tumors using artificial intelligence on histopathological slides

Authors: Khoraminia F.¹, Kwakkenbos K.¹, Van Leenders G.J.L.H.², Zuiverloon T.C.M.¹, Alberts A.¹

Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus University Medical Center, Dept. of Pathology, Rotterdam, The Netherlands

- A0038** **Long-term outcomes of surveillance of clinical stage I pure teratoma of the testicle**
Authors: Chavarriaga J.¹, Clark R.¹, Atenafu E.², Anson-Cartwright L.¹, Hamilton R.J.¹
Institutes: ¹Princess Margaret Cancer Centre, Dept. of Surgery, Division of Urology, Toronto, Canada, ²Princess Margaret Cancer Centre, Dept. of Biostatistics, Toronto, Canada
- A0050** **Utility of Circulating Tumor DNA in Patients with Different Stages of Testicular Cancer**
Authors: Ben David R., Tillu N., Attalla K., Waingankar N., Galsky M., Wiklund P., Mehrazin R., Sfakianos J.
Institutes: Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
- A0037** **Inconsistency in the assessment of retroperitoneal lymph node metastasis in testicular cancer patients: influence on clinical stage, therapy and relapse rate**
Authors: Strauch A.¹, Nestler K.², Schoch J.¹, Kubitscheck L.², Waldeck S.², Schmelz H.¹, Nestler T.¹
Institutes: ¹Federal Armed Forces Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ²Federal Armed Forces Hospital Koblenz, Institute of Diagnostic and Interventional Radiology, Koblenz, Germany
- 15:35 - 16:00** **The role and impact of RPLND in metastatic germ cell tumors**
- A0035** **Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour, a multicenter retrospective cohort study**
Authors: Antonelli L.¹, Heidenreich A.², Bagrodia A.³, Branger N.⁴, Cazzaniga W.⁵, Clinton T.N.⁶, Daneshmand S.⁷, Djaladat H.⁷, Eggener S.⁸, Hamilton R.J.⁹, Ho M.⁸, Sexton W.J.¹⁰, Nazzani S.¹¹, Nicol D.⁵, Nicolai N.¹¹, Olson K.¹², Paffenholz P.², Porter J.¹³, Singla N.¹⁴, Stroup S.P.¹⁵, Tachibana I.¹⁶, Terbuch A.¹⁷, Cary C.¹⁶, Fankhauser C.D.¹
Institutes: ¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Faculty of Medicine and University Hospital Cologne, Dept. of Urology, Cologne, Germany, ³San Diego and The University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁴Institut Paoli-Calmettes, Dept. of Surgical Oncology, Marseille, France, ⁵The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁶Brigham and Women Hospital, Dept. of Urology, Boston, United States of America, ⁷Kenneth Norris Jr. Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁸University of Chicago Medical Center, Dept. of Urology, Chicago, United States of America, ⁹University of Toronto, Dept. of Urology, Toronto, Canada, ¹⁰H. Lee Moffitt Cancer Center, Dept. of Genitourinary Oncology, Tampa, United States of America, ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, Urologic Oncology Unit, Milan, Italy, ¹²Mayo Clinic, Dept. of Urology, Scottsdale, United States of America, ¹³Swedish Medical Group, Dept. of Urology, Seattle, United States of America, ¹⁴The James Buchanan Brady Urological Institute, Dept. of Urology and Oncology, Baltimore, United States of America, ¹⁵Naval Medical Center San Diego, Dept. of Urology, California, United States of America, ¹⁶Indiana University School of Medicine, Dept. of Urology, Indiana, United States of America, ¹⁷Medical University of Graz, Division of Oncology, Graz, Austria
-

A0045

Primary retroperitoneal lymph node dissection in marker positive testicular cancer

Authors: Chavarriga J.¹, Mousa A.¹, Burrafato Z.¹, Atenafu E.², Anson-Cartwright L.¹, Langleben C.¹, Jewett M.¹, Hamilton R.¹

Institutes: ¹Princess Margaret Cancer Centre, Dept. of Surgery, Division of Urology, Toronto, Canada, ²Princess Margaret Cancer Centre, Dept. of Biostatistics, Toronto, Canada

A0048

Association of radiographic and pulmonary functional changes in patients receiving polychemotherapy including bleomycin

Authors: Frey L.¹, Grunwald S.¹, Duwe G.¹, Frey L.J.¹, Korczynski D.², Sparwasser P.³, Dotzauer R.¹, Haferkamp A.¹, Brandt M.P.¹

Institutes: ¹University Medical Center Mainz, Dept. of Urology, Mainz, Germany, ²University Medical Center Mainz, Dept. of Pneumology, Mainz, Germany, ³University Medical Center Tübingen, Dept. of Urology, Tübingen, Germany

A0047

Retrospective analysis on oncological results of postchemotherapeutic residual tumor resection in patients with metastatic seminoma following systemic chemotherapy

Authors: Steinbach C., Paffenholz P., Pfister D., Heidenreich A.

Institutes: University Clinic Cologne, Dept. of Urology, Cologne, Germany

A0036

Risk factors for relapse in non-seminomatous testicular cancer after post-chemotherapy retroperitoneal lymph node dissection with viable residual cancer

Authors: Antonelli L.¹, Ardizzone D.¹, Tachibana I.², Adra N.², Cary C.², Sexton W.J.³, Bagrodia A.⁴, Mego M.⁵, Daneshmand S.⁶, Nicolai N.⁷, Nazzani S.⁷, Heidenreich A.⁸, Paffenholz P.⁸, Saoud R.⁹, Eggener S.⁹, Oswald N.¹⁰, Tryakin A.¹¹, Naoun N.¹², Cazzaniga W.¹³, Nicol D.¹³, Gerdtsson A.¹⁴, Tandstad T.¹⁵, Fizazi K.¹², Fankhauser C.D.¹

Institutes: ¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Indiana University School of Medicine, Dept. of Urology, Indiana, United States of America, ³H. Lee Moffitt Cancer Center, Dept. of Urology, Tampa, United States of America, ⁴San Diego and The University of Texas Southwestern, Dept. of Urology, Texas, United States of America, ⁵Comenius University, Dept. of Oncology, Bratislava, Slovakia, ⁶Keck School of Medicine, Dept. of Urology, Los Angeles, United States of America, ⁷Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁸Faculty of Medicine and University Hospital Cologne, Dept. of Urology, Cologne, Germany, ⁹University of Chicago Medical Center, Dept. of Urology, Chicago, United States of America, ¹⁰Mayo Clinic, Dept. of Urology, Scottsdale, United States of America, ¹¹N.N. Blokhin Russian Cancer Research Center, Dept. of Urology, Moscow, Russia, ¹²Institut Gustave Roussy, Dept. of Oncology, Villejuif, France, ¹³The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹⁴Karolinska Institutet, Dept. of Urology, Stockholm, Sweden, ¹⁵St. Olavs University Hospital, Dept. of Urology, Trondheim, Norway

16:00 - 16:15

Testis cancer survival and survivorship

A0042

Ejaculatory dysfunction (EjD) after retroperitoneal lymph node dissection (RPLND) for testicular cancer (TC)

Authors: Conduit C.¹, Lewin J.¹, Hong W.², Ahmad G.³, Sim I.W.⁴, Leonard M.⁵, O'haire S.¹, Moody M.¹, Hutchinson A.⁶, Lawrentschuk N.⁷, Thomas B.⁷, Dhillon H.⁸, Tran B.¹

Institutes: ¹Peter MacCallum Cancer Centre, Dept. of Medical Oncology, Melbourne, Australia, ²Walter and Eliza Hall Institute of Medical Research, Dept. of Personalised Oncology, Melbourne, Australia, ³Royal Children's Hospital, Dept. of Andrology, Melbourne, Australia, ⁴Monash Health, Dept. of Endocrinology, Clayton, Australia, ⁵The Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Consumer Advocacy Panel, Sydney, Australia, ⁶University of South Australia, Behaviour-Brain-Body Research Centre, Adelaide, Australia, ⁷Royal Melbourne Hospital, Dept. of Surgery, Melbourne, Australia, ⁸University of Sydney, Dept. of Psychology, Sydney, Australia

A0049

The Empower Pathway: an innovative approach to delivering personalised care for testicular cancer survivors

Authors: Holwell R., Champion P., Nicol D., Huddart R., Reid A., Cazzaniga W., Kinsella N., Kirk C., Drain M.

Institutes: The Royal Marsden, Dept. of Urology, London, United Kingdom

A0052

Hospital anxiety and depression scale (HADS) scores trends among testicular cancer patients, a single institute longitudinal study

Authors: Alkhatib K., Roberson D., Guzzo T., Pierorazio P.

Institutes: University of Pennsylvania, Dept. of Urology, Philadelphia, United States of America

Biopsy strategy: targeted only or along with systematic?

Abstract session 4

05 April 2024
14:45 - 16:15

Location Purple Area, S03
Chairs J.M. Norris, London (GB)
G.Y. Robert, Bordeaux (FR)
To be confirmed

14:45 - 14:47

Introduction

14:47 - 15:07

Targeted biopsy only

A0066

Prostate cancer detection rate with MRI-targeted biopsy alone using outpatient transperineal prostate biopsy.

Authors: Avolio P.P., Hassan T., Addar A., Alshamsi H., Mcpherson V., Loutochin O., Anidjar M., Sanchez-Salas R.

Institutes: McGill University Health Centre, Division of Urology, Montreal, Canada

A0054

Targeted Biopsy and Overgrading of MRI lesions in Prostate Cancer: Does it Lead to Overtreatment?

Authors: Uleri A.¹, Baboudjian M.¹, Diamand R.², Beauval J.B.³, Touzani A.³, Roche J.B.⁴, Lacetera V.⁵, Roumeguère T.², Simone G.⁶, Benamran D.⁷, Fourcade A.⁸, Gondran-Tellier B.¹, Fiard G.⁹, Peltier A.², Ploussard G.³

Institutes: ¹North Hospital Aix-Marseille University APMH, Dept. of Urology, Marseille, France, ²Jules Bordet Institute Université, Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, ³La Croix du Sud Hopital, Dept. of Urology, Quint-Fonsegrives, France, ⁴Clinique Saint-Augustin, Dept. of Urology, Bordeaux, France, ⁵Azienda Ospedaliera Ospedali Riuniti Marche Nord, Dept. of Urology, Pesaro, Italy, ⁶IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁷Geneva University Hospitals, Dept. of Urology, Geneva, Switzerland, ⁸Hopital Cavale Blanche CHRU Brest, Dept. of Urology, Brest, France, ⁹Grenoble Alpes University Hospital, Dept. of Urology, Grenoble, France

A0053

Can we avoid systematic biopsies for prostate cancer diagnosis in multiparametric magnetic resonance imaging (mpMRI) targeted biopsies?

Authors: Calzas Montalvo C., Sopena Sutil R., Juste Álvarez S., Gil Moradillo J., García González L., Rodriguez-Izquierdo Jimenez M., García González B., Caro González M.A.D.P., De la Calle Moreno A., García-Rayó Encinas C., González Ginel I., Rodriguez Antolín A.

Institutes: Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain

A0056

Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging

Authors: Yun S.W., Tae Il N., Seok Ho K., Jun C., Ji Sung S., Sung Gu K.

Institutes: Anam Hospital Korea University College of Medicine, Dept. of Urology, Seoul, South Korea

15:07 - 16:12

Along with systematic biopsies

A0063

The clinical utility of contralateral systematic biopsies in men with unilateral MRI foci undergoing office-based transperineal MRI-guided biopsies

Authors: Boesen L.¹, Nørgaard N.¹, Bisbjerg R.¹, Al-Hamadani M.M.N.¹, Sjölin C.S.¹, Løgager V.B.²

Institutes: ¹Herlev Gentofte University Hospital, Dept. of Urology and Urological Research, Herlev, Denmark, ²Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark

A0065

Targeted with perilesional biopsy should be considered as the new standard for the diagnosis of clinically significant prostate cancer. A Systemic Review & Meta-analysis

Authors: Sanguedolce F.¹, Tedde A.², Lauwers C.N.G.², Panarello M.², Basile G.³, Gallioli A.⁴, Berquin C.⁵, Pecoraro A.⁶, Robalino J.⁴, Bravo A.⁴, Massimo M.², Baboudjian M.⁷, Schoots I.G.⁸, Padhani A.R.⁹, Palou J.⁴, Breda A.⁴

Institutes: ¹Fundacio Puigvert AND Università degli Studi di Sassari, Dept. of Urology AND Dept of Medicine Surgery and Pharmacy, Barcelona AND Sassari, Spain, ²Università degli Studi di Sassari, Dept of Medicine Surgery and Pharmacy, Sassari, Italy, ³IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁴Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁵Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁶Careggi Hospital University of Florence, Dept of Urology, Florence, Italy, ⁷North Academic Hospital of Marseille, Dept. of Urology, Marseille, France, ⁸Erasmus University Medical Centre, Dept. of Radiology and Nuclear Medicine, Rotterdam, The Netherlands, ⁹Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, Northwood, United Kingdom

A0058

Is Ipsilateral Systematic Biopsy Combined With Targeted Biopsy the Optimal Substitute for Bilateral Systematic Biopsy Combined With Targeted Biopsy? A Systematic Review and Meta-analysis.

Authors: Wu Q., Tu X., Zhang C., Bao Y., Wei Q.

Institutes: West China Hospital Sichuan University, Dept. of Urology, Chengdu, China

A0069

The impact of systematic sampling on prostate biopsy results

Authors: Ayerra Pérez H., Barba Abad J.F., Herrera Aranda N., Arce Cuatango P., San Martín Vilarino P., Duque Martínez I., García De Garayo Pires N., Pinto Martín R., Tolosa Eizaguirre E., Moctezuma Velázquez J., Campà Bortoló J.M., Extramiana Cameno J.

Institutes: Araba University Hospital, Dept. of Urology, Vitoria-Gasteiz, Spain

A0068

The added value of side specific systematic biopsy in patients diagnosed by magnetic resonance imaging-targeted prostate biopsy

Authors: Bourgeno H-A.¹, Jabbour T.¹, Baudewyns A.¹, Simone G.², Fourcade A.³, Fournier G.³, Oderda M.⁴, Gontero P.⁴, Bernal-Gomez A.⁵, Roche J.B.⁵, Abou Zahr R.⁶, Ploussard G.⁶, Fiard G.⁷, Halinski A.⁸, Rysankova K.⁹, Dariane C.¹⁰, Anract J.¹¹, Taha F.¹², Windish O.¹³, Assenmacher G.¹⁴, Guenzel K.¹⁵, Roumequere T.¹, Peltier A.¹, Diamand R.¹

Institutes: ¹Hopital Universitaire de Bruxelles, Dept. of Urology, Brussels, Belgium, ²IRCCS National Cancer Institute, Dept. of Urology, Rome, Italy, ³CHRU Brest, Dept. of Urology, Brest, France, ⁴Città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy, ⁵Clinique Saint-Augustin, Dept. of Urology, Bordeaux, France, ⁶La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ⁷Grenoble Alpes University Hospital, Dept. of Urology, Grenoble, France, ⁸Private Medical Center Klinika Wisniowa, Dept. of Urology, Zielona Góra, Poland, ⁹University Hospital Ostrava, Dept. of Urology, Ostrava, Czech Republic, ¹⁰Hopital Européen Georges Pompidou, Dept. of Urology, Paris, France, ¹¹Hopital Cochin, Dept. of Urology, Paris, France, ¹²Centre Hospitalier Universitaire de Reims, Dept. of Urology, Reims, France, ¹³Hopitaux Universitaires de Genève, Dept. of Urology, Geneva, Switzerland, ¹⁴Cliniques de l'Europe-Saint Elisabeth, Dept. of Urology, Brussels, Belgium, ¹⁵Vivantes Klinikum am Urban, Dept. of Urology, Berlin, Germany

A0060

The suitability of hemi-ablation for patients diagnosed with localised prostate cancer following multiparametric MRI targeted and non-targeted transperineal prostate biopsy

Authors: Reddy D.T., Eldred- Evans D., Winkler M., Shah T., Ahmed H.
Institutes: Imperial College London, Dept. of Surgery and Oncology, London, United Kingdom

A0062

The POET Trial – PrOspective Evaluation of a new perilesional Template for systematic prostate biopsy

Authors: Sigle A.¹, Halbich J.G.¹, Himmelsbach R.¹, Glienke M.¹, Moosmann M.¹, Kerrutt A.¹, Franz J.¹, Binder N.², Bronsert P.³, Engel H.⁴, Oerther B.⁴, Grabbert M.¹, Jilg C.A.¹, Gratzke C.¹

Institutes: ¹University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, ²University Hospital Freiburg, Institute of General Practice and Family Medicine, Freiburg, Germany, ³University Hospital Freiburg, Institute of Pathology, Freiburg, Germany, ⁴University Hospital Freiburg, Dept. of Radiology, Freiburg, Germany

A0055

Optimizing the Number of Systematic Cores During MRI Target Biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial

Authors: Cannoletta D.¹, Stabile A.¹, Barletta F.M.¹, Quarta L.¹, Mazzone E.¹, Gandaglia G.¹, Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Leni R.¹, Cirulli G.O.¹, Sorce G.¹, Pellegrino F.¹, Bianchi M.¹, De Cobelli F.², Brembilla G.², Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Radiology, Milan, Italy

A0061

When Does Systematic Biopsy Information Matter The Most? Identifying Independent Predictors Of Disease Downgrading At Radical Prostatectomy In high grade Prostate Cancer Based On A Large Multi-Institutional Series.

Authors: Sorce G.¹, Stabile A.¹, Longoni M.¹, Scilipoti P.¹, Ploussard G.², Marra G.³, Valerio M.⁴, Campi R.⁵, Minervini A.⁵, Serni S.⁵, Moschini M.¹, Marquis A.³, Beauval J.B.⁶, Rakauskas A.⁷, Van Der Bergh R.⁸, Rahota R.G.², Soeterik T.⁸, Roumiguè M.⁶, Guo H.⁹, Mattei A.¹⁰, Gontero P.³, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ³Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ⁴Lausanne University Hospital, Dept. of Urology, Lausanne, Switzerland, ⁵University of Florence - Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ⁶Toulouse University Hospital, Dept. of Urology and Renal Transplantation, Toulouse, France, ⁷Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ⁸University Medical Centre Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁹Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹⁰Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland

A0057

The significant added value of concomitant systematic prostate biopsies in addition to targeted sampling in patients with previous negative biopsies. Implications for accurate staging predictions from a large multi-institutional series.

Authors: Robesti D.¹, Pellegrino F.¹, Stabile A.¹, Barletta F.¹, Scuderi S.¹, Ploussard G.², Marra G.³, Valerio M.⁴, Campi V.⁵, Minervini A.⁵, Marquis A.⁶, Viti A.¹, Beauval J.B.⁷, Rakauskas A.⁴, Van Den Bergh R.⁸, Rahota R.G.², Soeterik T.⁸, Roumiguè M.⁷, Guo H.⁹, Mattei A.¹⁰, Gontero P.³, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Saint Jean Languedoc - La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ³Città della Salute e della Scienza - University of Turin, Dept. of Urology, Turin, Italy, ⁴Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ⁵Careggi Hospital - University of Florence, Dept. of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ⁶San Giovanni Battista Hospital - University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁷CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, ⁸Antonius Hospital Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁹Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹⁰Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland

A0067

The role of ipsilateral and contralateral systematic biopsy in MRI-ultrasound fusion biopsy

Authors: Guo H.¹, Ng C.F.², Chiu P.K-F.²

Institutes: ¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Prince of Wales Hospital, S. H. Ho Urology Centre, Dept. of Surgery, Hong Kong, Hong Kong

A0064

Diagnostic accuracy of Multiparametric Magnetic Resonance Imaging (mpMRI), Targeted and Systematic Prostate Biopsy for the Detection of Cribriform Growth Pattern in Patients with Clinical-Localized Prostate Cancer

Authors: Piasentin A.¹, Rossin G.¹, Traunero F.¹, Ongaro L.¹, Sernaglia G.¹, Biasatti A.¹, Rizzo M.¹, Zucchi A.², Bartoletti R.², Liguori G.¹, Bertolotto M.³, Trombetta C.¹, Claps F.¹

Institutes: ¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Pisa, Dept. of Translational Research and New Technologies, Pisa, Italy, ³University of Trieste, Dept. of Radiology, Trieste, Italy

A0059

A nomogram to predict lymphnode involvement in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI as unique high-risk feature

Authors: Bravi C.A.¹, Paciotti M.², Balestrazzi E.³, Piro A.⁴, Piramide F.⁵, Peraire M.⁶, Rebuffo S.⁶, Sorce G.⁶, Collà Ruvolo C.⁶, Frego N.⁶, Ticonosco M.⁶, Belmonte M.⁶, Pissavini A.⁶, De Groote R.⁶, De Naeyer G.⁶, Dall'Oglio P.⁷, Minervini A.⁸, Di Maida F.⁸, Schiavina R.³, Porpiglia F.⁵, Moschovas M.C.⁹, Patel V.⁹, Montorsi F.¹⁰, Mottrie A.⁶

Institutes: ¹Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²Humanitas Research Hospital IRCCS, Dept. of Urology, Rozzano, Italy, ³IRCCS Azienda Ospedaliero Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ⁴Ospedale Policlinico e Nuovo Ospedale Civile S.Agostino Estense Modena University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁵University of Turin San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁶Onze-Lieve-Vrouwziekenhuis Hospital, ORSI Academy, Dept. of Urology, Aalst, Belgium, ⁷ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁸Careggi Hospital and University of Florence, Dept. of Urology, Florence, Italy, ⁹University of Central Florida UCF, Dept. of Urology, Florida, United States of America, ¹⁰San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

16:12 - 16:15

Expert summary

Urolithiasis: Imaging and conservative management

Abstract session 5

05 April 2024
14:45 - 16:15

Location Green Area, W03
Chairs N. Abid, Lyon (FR)
To be confirmed
To be confirmed
To be confirmed

A0077

Trends in Kidney Stone Prevalence among US Adults from the NHANES Database

Authors: [Bhojani N.](#)¹, Miller L.E.², Bhattacharyya S.³, Chew B.H.⁴

Institutes: ¹University of Montreal, Dept. of Urology, Montreal, Canada, ²Miller Scientific, Dept. of Biostatistics, Johnson City, United States of America, ³Boston Scientific, Dept. of Health Economics and Market Access, Marlborough, United States of America, ⁴University of British Columbia, Dept. of Urology, Vancouver, Canada

A0073

The impact of kidney stone disease on quality of life in high-risk stone formers

Authors: [Assad A.](#)¹, Raizenne B.¹, El-Yamani M.E.M.¹, Almousa S.¹, Bechis S.K.², Sur R.L.², Nakada S.Y.³, Streeper N.M.⁴, Pais Jr. V.M.⁵, Sivalingam S.⁶, Chew B.H.⁷, Andonian S.⁸, Bhojani N.¹

Institutes: ¹CHUM, Dept. of Surgery, Montreal, Canada, ²University of California San Diego, Dept. of Surgery, San Diego, United States of America, ³University of Wisconsin School of Medicine and Public Health, Dept. of Surgery, Madison, United States of America, ⁴Pennsylvania State University College of Medicine, Dept. of Surgery, Philadelphia, United States of America, ⁵Dartmouth Hitchcock Medical Center, Dept. of Surgery, Lebanon, United States of America, ⁶Glickman Urological and Kidney Institute, Dept. of Surgery, Cleveland, United States of America, ⁷University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁸McGill University Health Center, Dept. of Urology, Montreal, Canada

A0075

Utilizing artificial intelligence to anticipate urolithiasis risk in general population

Authors: [Gimenez B.](#), Larenas F., Reyes A., Cortes C., Fulla J.

Institutes: Universidad de Chile, Dept. of Urology, Santiago, Chile

A0071

Dose optimization by deep learning tool in various CT protocols for urolithiasis: a physical human phantom study

Authors: Wee C.B.¹, Tae J.H.², Chang I.H.², Kim T.H.², Myung S.C.², Choi J.², Kim J.H.², Kim J.W.², Lee Y.S.², [Choi S.Y.](#)²

Institutes: ¹Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea, ²Chung-Ang University, Dept. of Urology, Seoul, South Korea

A0083

Quality of information and appropriateness of Open AI outputs for lithiasis management

Authors: [Guercio A.](#), Sarcinelli L., Romagoli M., Riolo S., Nacchia A., Lombardo R., Tema G., Guarnotta G., Cicione A., Pastore A., Al Salhi Y., Franco G., Sciarra A., Tubaro A., Carbone A., De Nunzio C.

Institutes: Sapienza University of Rome, Dept. of Urology, Rome, Italy

- A0072** **Comparison of automated kidney stone size measurement and volumetry in photon counting CT compared to 3rd generation dual energy CT and physically measurements**
Authors: Nestler T.¹, Stoll R.¹, Schmelz H.¹, Schoch J.¹, Hesse A.², Nestler K.³, Smolka K.³, Spornitz K.³, Overhoff D.³, Waldeck S.³
Institutes: ¹Federal Armed Services Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ²University Stone Center University Hospital Bonn, Dept. of Urology, Bonn, Germany, ³Federal Armed Services Hospital Koblenz, Dept. of Radiology, Koblenz, Germany
- A0085** **Radiomics-based Multi-class Classification for Composition of Urolithiasis on Non-Contrast Computed Tomography.**
Authors: Jeong S.¹, Lee K.S.¹, Lee J.H.¹, Kim L.N.², Kim H.Y.³
Institutes: ¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Yonsei University College of Medicine, Dept. of Integrative Medicine, Seoul, South Korea, ³Yonsei University College of Medicine, Dept. of Biomedical System Informatics, Seoul, South Korea
- A0087** **Multi-Energy Photon-Counting Computed Tomography: A Novel Technique to Determine Kidney Calculi Composition**
Authors: Wang B.¹, Li J.¹, Xing Y.²
Institutes: ¹Beijing Tsinghua Changgung Hospital, Dept. of Urology, Beijing, China, ²Tsinghua University, Dept. of Engineering Physics, Beijing, China
- A0076** **Evaluation of the clinical significance of radiological signs of stone impaction in predicting spontaneous stone passage**
Authors: Popiolek M.M.¹, Sahlén K.², Lidén M.³, Sundqvist P.¹, Wagenius M.⁴, Jendeberg J.³
Institutes: ¹Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ²Uppsala University Hospital, Surgical Sciences Section of Radiology, Uppsala, Sweden, ³Örebro University Hospital, Dept. of Radiology, Örebro, Sweden, ⁴Helsingborgs Hospital, Dept. of Urology, Helsingborg, Sweden
- A0078** **Factors Affecting Radiation Exposure In Patients Undergoing Endoscopic Treatment For Urolithiasis**
Authors: Sugrue D.D.¹, Ryan F.², Courtney M.¹, Horan M.¹, Ryan P.¹, Mcloughlin L.C.¹, Lonergan P.E.¹, Manecksha R.¹
Institutes: ¹St. James's Hospital, Dept. of Urology, Dublin, Ireland, ²Tallaght University Hospital, Dept. of Urology, Dublin, Ireland
- A0079** **Caveats against the use of ultrasound as the primary imaging modality in pediatric urolithiasis.**
Authors: Abbas M.¹, Jaber J.¹, Raisin G.¹, Kuint R.², Kocherov S.¹, Zahrkov E.², Kafka I.¹, Chertin B.¹
Institutes: ¹Shaare Zedek Medical Center, Dept. of Urology and Pediatric Urology, Jerusalem, Israel, ²Shaare Zedek Medical Center, Dept. of Radiology, Jerusalem, Israel

- A0080** **Acoustic Radiation Force Impulse Image for Evaluation of Parenchyma Elasticity in Acute Hydronephrotic Kidney: A Preliminary Report**
Authors: Chen J-C.¹, Lu S.Y.¹, Wang H.K.², Lin T.P.¹, Huang W.J.¹
Institutes: ¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Radiology, Taipei, Taiwan
- A0081** **Screening for Clinically Significant Nephrolithiasis Based on Simple Health Checkup Clinical and Urine Parameters in General Populations: Machine Learning Models and Multi-hospital Study**
Authors: Chen H.¹, Chen Y-C.², Wu W.J.², Juan Y.S.², Wei P.S.³, Lee J.T.⁴, Kao C.Y.³
Institutes: ¹Kaohsiung Municipal Ta-Tung Hospital, Dept. of Urology, Kaohsiung, Taiwan, ²Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan, ³National Sun Yat-Sen University, Dept. of Electrical Engineering, Kaohsiung, Taiwan, ⁴National Sun Yat-Sen University, School of Medicine, Kaohsiung, Taiwan
- A0070** **Optimal timing of surgical intervention after diagnosis of upper urinary tract stones: a perspective from renal function preservation**
Authors: Yuma W., Riko I., Shunya M., Kasumi Y., Bo F., Masaki K., Motohiro F., Yuki N., Yudai I., Shohei F., Hajime T., Soichiro Y., Yasuhisa F.
Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan
- A0082** **Results of treatment of patients with urolithiasis during gestation**
Authors: Kotov S.V., Perov R., Nizin P.
Institutes: Pirogov Russian National Research Medical University, Urology and Andrology of Medical Faculty, Moscow, Russia
- A0086** **Decision Regret Analysis of patients opting for early Ureteroscopy versus a trial of Medical Expulsive Therapy after Shared Decision Making for management of ureteric calculi ≤ 10mm: Final results from the DRAUMET study**
Authors: Singh A., Chawla A.K., Viswanath K.V., Pillai S.P., Hegde P.H.
Institutes: KMC Manipal, Dept. of Urology and Renal transplant, Manipal, India
- A0084** **Histopathological evaluation of Holmium:YAG Laser Injury to human ureter during urolithiasis surgery**
Authors: O'Meara S.¹, Sheehan K.², Fay J.², O'grady T.², Croghan S.M.³, Hogan D.³, O'brien F.J.⁴, Davis N.³
Institutes: ¹Royal College of Surgeons of Ireland, Dept. of Surgery, Dublin, Ireland, ²Royal College of Surgeons of Ireland, Dept. of Pathology, Dublin, Ireland, ³Beaumont Hospital, Dept. of Urology and Transplant Surgery, Dublin, Ireland, ⁴Royal College of Surgeons of Ireland, Dept. of Tissue Engineering and Research Group, Dublin, Ireland

A0074

Kidney stone analysis: An EAU section of urolithiasis (EULIS) survey on current practices and perspectives worldwide

Authors: Stoots S.J.M.¹, Somani B.K.², Durutovic O.³, Cavadas V.⁴, Secker A.⁵, Jung H.U.⁶, Ulvik Ø.⁷, Ingimarsson J.⁸, Tefik T.⁹, Sener E.¹⁰, Dragos L.¹¹, Tailly T.¹², Popiolek M.¹³, Bin Hamri S.¹⁴, Gauhar V.¹⁵, Hameed Z.¹⁶, Rivas J.G.¹⁷, Bhojani N.¹⁸, Seitz C.¹⁹, Beerlage H.P.¹, de Jonge R.²⁰, Kamphuis G.M.¹

Institutes: ¹Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands, ²University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³University Clinical Center of Serbia, Dept. of Urology, Belgrade, Serbia, ⁴Porto Hospital Centre, Dept. of Urology, Porto, Portugal, ⁵Medical Center University of Muenster, Dept. of Urology, Muenster, Germany, ⁶Urological Research Centre, Lillebaelt Hospital, University of Southern Denmark, Dept. of Urology, Fredericia, Denmark, ⁷Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ⁸Maine Medical Center, Dept. of Urology, South Portland, United States of America, ⁹Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Türkiye, ¹⁰Marmara University School of Medicine, Dept. of Urology, Istanbul, Türkiye, ¹¹Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ¹²University Hospital of Ghent, Dept. of Urology, Ghent, Belgium, ¹³Faculty of Medicine and Health, Örebro University, Dept. of Urology, Örebro, Sweden, ¹⁴Ministry of the National Guard Health Affairs King Saud Bin Abdulaziz University for Health Sciences King Abdullah International Medical Research Center, Dept. of Urology, Riyadh, Saudi Arabia, ¹⁵Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁶Kasturba Medical College Manipal Manipal Academy of Higher Education, Dept. of Urology, Manipal, India, ¹⁷Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ¹⁸Centre Hospitalier de l'Université de Montréal, Dept. of Urology, Montreal, Canada, ¹⁹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²⁰Amsterdam University Medical Centers, Dept. of Laboratory Medicine, Amsterdam, The Netherlands

Upper urinary tract cancer: Risk stratification and new treatment modalities

Abstract session 6

05 April 2024
14:45 - 16:15

Location Green Area, S06
Chairs J.L. Domínguez Escrig, Valencia (ES)
To be confirmed
To be confirmed

14:45 - 15:10

Minimal invasive surgery of upper tract urothelial carcinoma

A0093

Change in Kidney Function after Endoscopic Management of Upper Tract Urothelial Cancer – Results from the EndoUTUC Collaboration

Authors: Pallauf M.¹, Broenimann S.¹, Agrawal P.¹, Herrera-Caceres J.O.², Small A.³, Raskolnikov D.³, Kleinmann N.⁴, Shvero A.⁴, Matin S.F.⁵, Labbate C.⁵, Kaimakliotis H.⁶, Tachibana I.⁶, Linehan J.⁷, Choe J.⁷, Shah O.⁸, Movassaghi M.⁸, Huang W.⁹, Persily J.⁹, Perecman A.¹⁰, Canes D.¹⁰, Potretzke A.M.¹¹, Rodriguez R.¹¹, Raman J.D.², Singla N.¹

Institutes: ¹Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Penn State Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, ³Montefiore Medical Center Albert Einstein College of Medicine, Montefiore Department of Urology, New York, United States of America, ⁴Sheba Medical Center The Sackler School of Medicine, Dept. of Urology, Ramat Gan, Israel, ⁵The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶Indiana University Medical Center, Dept. of Urology, Indianapolis, United States of America, ⁷Providence Specialty Medical Group, Dept. of Urology, Santa Monica, United States of America, ⁸Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ⁹New York University Grossman School of Medicine, Dept. of Urology, New York, United States of America, ¹⁰Lahey Hospital and Medical Center, Dept. of Urology, Burlington MA, United States of America, ¹¹Mayo Clinic, Dept. of Urology, Rochester, United States of America

A0095

"Twenty-Year Follow-Up of Large-Volume Low-Grade Urothelial Carcinoma: Long-Term Outcomes in Patients Undergoing Ureteroscopic versus Nephroureterectomy Therapy"

Authors: Verhovsky G., Fishman A.I.F., Debeatham W., Grasso M.G.
Institutes: New York Medical College, Dept. of Urology, Sleepy Hollow, United States of America

A0089

Open versus Minimally Invasive Nephroureterectomy in Octogenarians: An Analysis of Surgical Approach Trends, Outcomes and Survival Analysis with Propensity Matching

Authors: Trecarten S.¹, Bhandari M.², Abdel-Aziz A.¹, Noel O.¹, Liss M.¹, Dursun F.¹, Robert S.¹, Mansour A.¹

Institutes: ¹University of Texas Health Science Center San Antonio, Dept. of Urology, San Antonio, United States of America, ²University of Texas Health Science Center San Antonio, Dept. of Population Health Sciences, San Antonio, United States of America

A0104

Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (ROBUUST collaborative analysis)

Authors: Ditunno F.¹, Franco A.¹, Wu Z.², Wang L.², Correa A.³, Margulis V.⁴, Djaladat H.⁵, Veccia A.⁶, Simone G.⁷, Tuderti G.^{7, 8}, Derweesh I.H.⁹, Abdollah F.¹⁰, Singla N.¹¹, Ferro M.¹², Porpiglia F.¹³, Checcucci E.¹³, Amparore D.¹³, Gonzalgo M.L.¹⁴, Perdonà S.⁸, Tufano A.⁸, Mehrazin R.¹⁵, Sundaram C.P.¹⁶, Antonelli A.⁶, Autorino R.¹

Institutes: ¹Rush University, Dept. of Urology, Chicago, United States of America, ²Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ³Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁵Norris Comprehensive Cancer Center University of Southern California, Institute of Urology, Los Angeles, United States of America, ⁶University of Verona, Dept. of Urology, Verona, Italy, ⁷IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁸Istituto Nazionale Tumori Fondazione Pascale, Dept. of Urology, Naples, Italy, ⁹UC San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ¹⁰Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ¹¹John Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, United States of America, ¹²European Institute of Oncology IRCCS, Division of Urology, Milan, Italy, ¹³University of Turin San Luigi Gonzaga Hospital, Division of Urology, Turin, Italy, ¹⁴University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁵Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁶Indiana University, Dept. of Urology, Indianapolis, United States of America

A0092

Robot-assisted radical nephroureterectomy for locally advanced upper tract urothelial carcinoma. Is it ready for prime time? A snapshot from the Junior ERUS/Young Academic Urologist Working Group on Robot-assisted Surgery

Authors: Di Maida F.¹, Bravi C.A.², De Groote R.³, Piramide F.⁴, Turri F.⁵, Wenzel M.⁶, Sharma G.⁷, Würnschimmel C.⁸, Andras I.⁹, Lambert E.¹⁰, Dell'Oglio P.¹¹, Moschovas M.C.¹², Campi R.¹³, Liakos N.¹⁴, Mari A.¹, Carbin Joseph D.D.¹⁵, Paciotti M.¹⁶, Sorce G.¹⁷, Montorsi F.¹⁷, Briganti A.¹⁷, Mottrie A.³, Minervini A.¹, Larcher A.¹⁷

Institutes: ¹University of Florence, Dept. of Urology, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ²The Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Onze-Lieve-Vrouwziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ⁴San Luigi Gonzaga Hospital - University of Turin, Dept. of Urology, Orbassano, Italy, ⁵ASST Santi Paolo e Carlo - University of Milan, Dept. of Urology, Milan, Italy, ⁶Goethe University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁷Medanta The Medicity, Dept. of Urology, Gurgaon, India, ⁸Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁹Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ¹⁰Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ¹¹ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ¹²AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ¹³University of Florence, Dept. of Urology, Unit of Urologic Robotic Minimally-Invasive Surgery and Renal Transplantation, Florence, Italy, ¹⁴University of Freiburg, Dept. of Urology, Freiburg, Germany, ¹⁵Stokes Centre for Urology - Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, ¹⁶Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, ¹⁷IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy

15:10 - 15:35

Systemic treatment for upper tract urothelial carcinoma

A0094

Neoadjuvant disitamab vedotin combined with tislelizumab for locally advanced upper urinary tract carcinoma: A pilot study for a phase II trial.

Authors: Bao Y., Liao X., Wei Q.

Institutes: West China Hospital, Dept. of Urology, Chengdu, China

A0090

Real-world data: call for paradigm shift towards neoadjuvant chemotherapy in patients with Upper Tract Urothelial Carcinoma treated with Nephroureterectomy - Analysis of the ROBUUST Registry

Authors: Tuderti G.¹, Proietti F.¹, Wu Z.², Franco A.³, Abdollah F.⁴, Finati M.⁴, Ferro M.⁵, Tozzi M.⁵, Porpiglia F.⁶, Checcucci E.⁷, Margulis V.⁸, Singla N.⁹, Derweesh I.H.¹⁰, Correa A.¹¹, Gonzalgo M.L.¹², Mehrazin R.¹³, Sundaram C.P.¹⁴, Tufano A.¹⁵, Perdonà S.¹⁵, Djaladat H.¹⁶, Ditonno F.¹⁷, Antonelli A.¹⁷, Autorino R.³, Simone G.¹

Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴Vattikuti Urology Institute-Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ⁵European Institute of Oncology IEO-IRCCS, Dept. of Urology, Milan, Italy, ⁶University of Turin-San Luigi Gonzaga Hospital, Division of Urology, Turin, Italy, ⁷Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ⁸University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁹The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ¹⁰UC San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ¹¹Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America, ¹²Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ¹³Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁴Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁵Fondazione 'G. Pascale' IRCCS, Dept. of Uro-Gynaecology, Naples, Italy, ¹⁶Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Dept. of Urology, Los Angeles, United States of America, ¹⁷University of Verona, Dept. of Urology, Verona, Italy

A0096

Genomic Tumor Correlates of Clinical Outcomes Following Kidney-Sparing Chemoradiation Therapy for upper tract urothelial carcinoma

Authors: Gu C., Ye D.W.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

A0101

Real-world outcomes of first-line systematic treatment in advanced Upper Urinary Tract Urothelial Carcinoma patients with renal impairment: YUSHIMA-04 study

Authors: Kimura T.¹, Fujiwara M.¹, Matsumoto S.¹, Yoshitomi K.¹, Kobayashi M.¹, Fan B.¹, Nakamura Y.¹, Ishikawa Y.¹, Fukuda S.¹, Waseda Y.¹, Tanaka H.¹, Yoshida S.¹, Takazawa R.², Sakai Y.³, Koga F.⁴, Saito K.⁵, Yano M.⁶, Tsukamoto T.⁷, Okuno T.⁸, Kageyama Y.⁹, Otsuka Y.¹⁰, Nagahama K.¹¹, Fujii Y.¹

Institutes: ¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Tokyo Metropolitan Ohtsuka Hospital, Dept. of Urology, Tokyo, Japan, ³Tsuchiura Kyodo General Hospital, Dept. of Urology, Ibaraki, Japan, ⁴Tokyo Metropolitan Komagome Hospital, Dept. of Urology, Tokyo, Japan, ⁵Dokkyo Medical University Saitama Medical Center, Dept. of Urology, Saitama, Japan, ⁶Tamananbu Regional Hospital, Dept. of Urology, Tokyo, Japan, ⁷Showa General Hospital, Dept. of Urology, Tokyo, Japan, ⁸JA TORIDE MEDICAL CENTER, Dept. of Urology, Ibaraki, Japan, ⁹Saitama Cancer Center, Dept. of Urology, Saitama, Japan, ¹⁰Omori Red Cross Hospital, Dept. of Urology, Tokyo, Japan, ¹¹Kohnodai Hospital National Center for Global Health and Medicine, Dept. of Urology, Chiba, Japan

A0088

Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients

Authors: Morra S.¹, Incesu R.B.¹, Scheipner L.¹, Baudo A.¹, Jannello L.M.I.¹, Siech C.¹, DE ANGELIS M.¹, Tian Z.¹, Califano G.², Colla' Ruvolo C.², Creta M.², Saad F.¹, Shariat S.³, Chun F.⁴, De Cobelli O.⁵, Musi G.⁵, Briganti A.⁶, Tilki D.⁷, Ahyai S.⁸, Carmignani L.⁹, Longo N.², Karakiewicz P.I.¹

Institutes: ¹Cancer Prognostics and Health Outcomes Unit, Dept. of Urology, Montreal, Canada, ²University of Naples Federico II, Dept. of Neurosciences Science of Reproduction and Odontostomatology, Naples, Italy, ³Medical University of Vienna, Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ⁴University Hospital Frankfurt- Goethe University Frankfurt am Main, Dept. of Urology, Frankfurt, Germany, ⁵European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁶San Raffaele, Dept. of Urology, milan, Italy, ⁷Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ⁸Medical University of Graz, Dept. of Urology, Graz, Austria, ⁹San Donato milanese, Dept. of Urology, Milan, Italy

15:35 - 15:55

Outcomes after treatment for upper tract urothelial carcinoma

A0091

Real-world management of high-risk Upper Tract Urothelial Carcinoma: level of adherence to EAU guidelines- Analysis of the ROBUUST Registry

Authors: Tuderti G.¹, Proietti F.¹, Wu Z.², Franco A.³, Abdollah F.⁴, Finati M.⁴, Ferro M.⁵, Tozzi M.⁵, Porpiglia F.⁶, Checcucci E.⁷, Margulis V.⁸, Singla N.⁹, Derweesh I.H.¹⁰, Correa A.¹¹, Gonzalzo M.L.¹², Mehrazin R.¹³, Sundaram C.P.¹⁴, Tufano A.¹⁵, Perdonà S.¹⁵, Djaladat H.¹⁶, Ditunno F.¹⁷, Antonelli A.¹⁷, Autorino R.³, Simone G.¹

Institutes: ¹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴Vattikuti Urology Institute-Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ⁵European Institute of Oncology IEO-IRCCS, Division of Urology, Milan, Italy, ⁶University of Turin-San Luigi Gonzaga Hospital, Division of Urology, Turin, Italy, ⁷Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ⁸University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁹The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ¹⁰UC San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ¹¹Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America, ¹²Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ¹³Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁴Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁵Fondazione 'G. Pascale' IRCCS, Uro-Gynecological Department, Naples, United States of America, ¹⁶Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Dept. of Urology, Los Angeles, United States of America, ¹⁷University of Verona, Dept. of Urology, Verona, Italy

A0099

The Long-term Outcome of Nephron-Sparing Surgery versus Radical Nephroureterectomy for Organ-Localized Upper Urinary Tract Urothelial Carcinoma: A Population-based Study of 1969 Patients

Authors: Ruiyi D., Jianhui J.H., Yu C.J., Kan K.

Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

A0098

Validating and extending pre-operative renal scintigraphy predictions for post-nephrectomy renal function changes beyond upper urinary tract urothelial carcinoma

Authors: Su K.-S., Huang Y.H., Ku M.H., Chen W-R., Huang T.H., Wei T.C., Huang I.S., Fan Y.H., Lin C.C., Lin T.P., Chung H-J., Kuo J.Y., Chang Y-H., Lin T.L., Huang J.S.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

A0102

Oncological outcomes and preoperative predictors of disease recurrence in upper tract urothelial carcinoma patients treated with distal ureterectomy: results from a large national cohort

Authors: Rosazza M.¹, Soria F.¹, Livoti S.¹, Dutto D.¹, Colucci F.¹, De Lorenzis E.², Foschi N.³, Mantica G.⁴, Ambrosini F.⁴, Campi R.⁵, Serni S.⁵, Moscardi L.⁵, Chiancone F.⁶, Amparore D.⁷, Lucarelli G.⁸, Lasorsa F.⁸, Gontero P.¹

Institutes: ¹AOU Città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy, ²Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Urology, Rome, Italy, ⁴IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ⁵Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁶A.O.R.N. A. Cardarelli, Dept. of Urology, Naples, Italy, ⁷San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy, ⁸University of Bari Aldo Moro, Urology Andrology and Kidney Transplantation Unit, Bari, Italy

15:55 - 16:15

Risk stratification of upper tract urothelial carcinoma

A0100

Risk of upper tract urothelial carcinoma recurrence following non-muscle invasive bladder cancer: A retrospective, multi-institutional analysis of 3,036 patients

Authors: Kwong J.¹, Ringa M.², Al-Daqqaq Z.³, Chelliahpillai Y.³, Lee S.³, Kim K.³, Ali A.², Wettstein M.S.¹, Chan A.⁴, Perlis N.⁵, Lee J.Y.⁵, Hamilton R.J.⁵, Fleshner N.E.⁵, Finelli A.⁵, Feifer A.², Kulkarni G.S.⁵, Zlotta A.R.⁴

Institutes: ¹University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada, ²Trillium Health Partners, Division of Urology, Dept. of Surgery, Mississauga, Canada, ³University of Toronto, Temerty Faculty of Medicine, Toronto, Canada, ⁴Mount Sinai Hospital - Sinai Health System, Division of Urology, Dept. of Surgery, Toronto, Canada, ⁵University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada

A0103

Head-to-head comparison of the American Urological Association and European Association of Urology risk stratification models of upper tract urothelial carcinoma

Authors: Basile G., Gallioli A., Territo A., Berquin C., Sanz I., Casadevall M., Farré A., Pecoraro A., Lauwers C., Afferi L., Gaya J.M., Sanguedolce F., Huguet J., Palou J., Breda A.

Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain

A0097

Interleukin-6 and its soluble receptor as predictors of disease outcomes after radical nephroureterectomy in patients with upper tract urothelial carcinoma

Authors: Ofner H.¹, Laukhtina E.¹, D'Andrea D.¹, Klemm J.², Matsukawa A.³, Roupert M.⁴, Teoh J.Y.C.⁵, Nyirady P.⁶, Chlosta P.⁷, Abufaraj M.⁸, Babjuk M.⁹, Margulis V.¹⁰, Shariat S.F.¹

Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴Sorbonne University, Dept. of Urology, Paris, France, ⁵The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁶Semmelweis University, Dept. of Urology, Budapest, Hungary, ⁷Jagiellonian University, Dept. of Urology, Cracow, Poland, ⁸University of Jordan, Dept. of Special Surgery, Amman, Jordan, ⁹Charles University, Dept. of Urology, Prague, Czech Republic, ¹⁰University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

A0105

Impact of lymphovascular invasion on survival of surgically treated patients with Upper Tract Urothelial Carcinoma: A nationwide analysis

Authors: Cirulli G.O.¹, Corsi N.¹, Rakic I.¹, Finati M.¹, Chiarelli G.¹, Stephens A.², Davis M.¹, Tinsley S.¹, Sood A.³, Lughezzani G.⁴, Buffi N.⁴, Carrieri G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Rogers C.¹, Abdollah F.¹

Institutes: ¹VUI Center for Outcomes Research Analysis and Evaluation - Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴IRCCS Humanitas Research Hospital - Humanitas University, Dept. of Urology, Milan, Italy, ⁵University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ⁶IRCCS Ospedale San Raffaele - Vita-Salute San Raffaele University - Division of Oncology Unit of Urology, Dept. of Urology, Milan, Italy

Use of digital technology & data-driven shared decision making

Patient information session - Roundtable

05 April 2024
14:45 - 15:45

Location Green Area, W08
Chair E. Rogers, Roscommon (IE)

Learning objectives

- 1) Participants will learn about the transformative impact of digital technology and artificial intelligence on patient advocacy and decision-making.
- 2) The roundtable will explain how using multiple communication channels (digital, face-to-face, print, etc.) can support informed patient decisions, and optimise communication using AI and digital innovations.
- 3) Attendees will learn about the legal challenges and considerations in digital health and data usage.

14:45 - 14:50

Introduction
E. Rogers, Roscommon (IE)

14:50 - 15:00

Digital technology in patient advocacy and decision-making
L. Makaroff, Chinnor (GB)

15:00 - 15:05

The role of omnichannel strategies in informed decision-making
To be confirmed

15:05 - 15:10

Enhancing patient empowerment through digital platforms
M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

15:10 - 15:15

Empowering patients in health management via digital tools
To be confirmed

15:15 - 15:25

Legal considerations in digital health and data usage
To be confirmed

15:25 - 15:40

Interactive discussion and Q&A
Moderator E. Rogers, Roscommon (IE)

15:40 - 15:45

Concluding remarks and future directions
E. Rogers, Roscommon (IE)

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.07

05 April 2024
14:45 - 15:40

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.09

05 April 2024
14:45 - 15:40

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.11

05 April 2024
14:45 - 15:40

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Evidence-based medicine in urology

Thematic Session

05 April 2024
15:00 - 16:30

Location Green Area, N04
Chairs A. Briganti, Milan (IT)
K.A.O. Tikkinen, Helsinki (FI)

Learning objectives

In this session featuring urologic examples, attendees will learn about:

- i) Advantages and disadvantages of surrogate endpoints
- ii) How to assess the certainty of evidence and its impact on decision-making
- iii) Analyzing heterogeneity and conducting subgroup analyses
- iv) The significance of non-inferiority trials and network meta-analyses
- v) Understanding the principles and applications of platform trials
- vi) Pros and cons of fixed-effect vs. random-effects models for meta-analyses
- vii) Patients' values & preferences, and the importance of trustworthy guidelines

15:00 - 15:01

Introduction

15:01 - 15:15

Debate Surrogate endpoints

15:01 - 15:06

Pro

A. Martini, Houston (US)

15:06 - 15:11

Con

R. Breau, Ottawa (CA)

15:11 - 15:13

Rebuttal - pro

A. Martini, Houston (US)

15:13 - 15:15

Rebuttal - con

R. Breau, Ottawa (CA)

15:15 - 15:22

Certainty of evidence

D.A. González-Padilla, Madrid (ES)

15:22 - 15:29

Moving from evidence to the decisions

P. Dahm, Minneapolis (US)

15:29 - 15:36

Heterogeneity in systematic reviews

H. Van der Worp, Groningen (NL)

15:36 - 15:43

Subgroup analysis in randomised trials

T.P. Kilpeläinen, Helsinki (FI)

15:43 - 15:50

Non-inferiority trial

S.V. Tornberg, Helsinki (FI)

15:50 - 15:57

Platform trials

N. James, London (GB)

Scientific Programme - EAU24

15:57 - 16:04	Network meta-analysis A.K. Puerto Niño, Bogota (CO)
16:04 - 16:18	Debate Fixed-effect vs. random-effects models for meta-analysis
16:04 - 16:09	Pro fixed H. Mostafaei, Vienna (AT)
16:09 - 16:14	Pro random A. Halme, Helsinki (FI)
16:14 - 16:16	Rebuttal - pro H. Mostafaei, Vienna (AT)
16:16 - 16:18	Rebuttal - con A. Halme, Helsinki (FI)
16:18 - 16:23	Patients' values and preferences S. Malde, London (GB)
16:23 - 16:28	Trustworthy guidelines P.D. Violette, Woodstock (CA)
16:28 - 16:30	Closing remarks

Pediatric urology: Emerging trends in surgical techniques and innovations

Abstract session 7

05 April 2024
15:45 - 17:15

Location Green Area, W01
Chairs To be confirmed
R.J.M. Lammers, Groningen (NL)
To be confirmed

A0113

Descent: Departmental evaluation of scrotal imaging considering european and national testicle guidelines

Authors: Bernstein D. E.¹, Manning H.², Jain K.², Chang S.², Cherian A.³, Undre S.²

Institutes: ¹Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, London, United Kingdom, ²East and North Hertfordshire Hospitals NHS Trust, Dept. of Urology, Stevenage, United Kingdom, ³Great Ormond Street Hospital, Dept. of Urology, London, United Kingdom

A0108

The impact of health care on outcomes of suspected testicular torsion: Results from the GRAND study

Authors: Pyrgidis N., Apfelbeck M., Stredele R., Rodler S., Kidess M., Volz Y., Weinhold P., Stief C., Marcon J., Schulz G.B., Chaloupka M.

Institutes: University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

A0107

Role of different urinary biomarkers in the differentiation of ureteropelvic junction obstruction from transient hydronephrosis

Authors: Banerjee A.¹, Ashwin R.¹, Babu R.¹, Perungo S.²

Institutes: ¹Sri Ramachandra Institute of Higher Education and Research, Dept. of Pediatric Urology, Chennai, India, ²Sri Ramachandra Institute of Higher Education and Research, Dept. of Pediatric Nephrology, Chennai, India

A0116

Early prenatal detection of LUTO is associated with increased risk of kidney transplantation - a multi-institutional trans-atlantic experience

Authors: Richter J.¹, Harper L.², Pecorelli S.², Good H.³, Dos Santos J.¹, Shinar S.⁴, Van Mieghem T.⁴, Lorenzo A.J.¹, Rickard M.¹

Institutes: ¹The Hospital for Sick Children, Division of Urology, Toronto, Canada, ²University Hospital Pellegrin-Enfants- CHU de Bordeaux, Dept. of Pediatric Surgery and Urology, Bordeaux, France, ³University of Toronto, Faculty of Medicine, Toronto, Canada, ⁴Mount Sinai Hospital, Dept. of Obstetrics and Gynecology, Division of Maternal and Fetal Medicine, Toronto, Canada

A0106

Effect of overnight bladder drainage on posterior urethral valve sequelae: A randomized controlled trial

Authors: Elkashef A., Abdelhalim A., Dawaba M.S., Hafez A.T.

Institutes: Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

A0119

The Optimal Urethral Coverage in Hypospadias repair: Dartos Fascia versus Tunica Vaginalis Flap? A Randomized Controlled Trial

Authors: Ramez M., Hashem A., Helmy T., Dawaba M., Bazeed M.A.

Institutes: Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt

A0122

Long-term functional outcomes of voiding after hypospadias repair: A single-center retrospective comparative study

Authors: Nishio H.¹, Mizuno K.¹, Sakata T.², Matsumoto D.², Kato T.², Kamisawa H.², Kurokawa S.², Nakane A.², Maruyama T.², Yasui T.², Hayashi Y.¹

Institutes: ¹Nagoya City University Graduate School of Medical Sciences, Dept. of Pediatric Urology, Nagoya, Japan, ²Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

A0123

Long-term outcomes and genotype to phenotype correlation in children with Denys Drash syndrome: a national cohort study

Authors: Glenisson M.¹, Grapin M.², Blanc T.¹, Hogan J.³, Aurelle M.⁴, Roussey G.⁵, Mouche A.⁶, Rousset-Rouviere C.⁷, Novo R.⁸, Faudeux C.⁹, Fila M.¹⁰, Vrillon I.¹¹, Cloarec S.¹², Simon T.¹³, Harambat J.R.¹⁴, Martinez Casado E.¹⁵, Boyer O.², Dorval G.¹⁶, Sarnacki S.¹

Institutes: ¹Hopital Necker-Enfants Malades, Dept. of Pediatric Surgery and Urology, Paris, France, ²Hopital Necker-Enfants Malades, Dept. of Pediatric Nephrology, Paris, France, ³Hopital Robert Debré, Dept. of Pediatric Nephrology, Paris, France, ⁴Hospices Civils de Lyon, Dept. of Pediatric Nephrology, Lyon, France, ⁵Centre Hospitalier Universitaire de Nantes, Dept. of Pediatric Nephrology, Nantes, France, ⁶Hopital Armand Trousseau, Dept. of Pediatric Nephrology, Paris, France, ⁷Hopital La Timone, Dept. of Pediatric Nephrology, Marseille, France, ⁸Hopital Jeanne de Flandre, Dept. of Pediatric Nephrology, Lille, France, ⁹CHU de Nice, Dept. of Pediatric Nephrology, Nice, France, ¹⁰CHU de Montpellier, Dept. of Pediatric Nephrology, Montpellier, France, ¹¹CHU de Nancy, Dept. of Pediatric Nephrology, Nancy, France, ¹²Hopital Pédiatrique de Clocheville, Dept. of Pediatric Nephrology, Tours, France, ¹³Hopital des Enfants de Toulouse, Dept. of Pediatric Nephrology, Toulouse, France, ¹⁴CHU de Bordeaux, Dept. of Pediatric Nephrology, Bordeaux, France, ¹⁵CHU de Rouen, Dept. of Pediatric Nephrology, Rouen, France, ¹⁶Hopital Necker-Enfants Malades, Genomic Medicine Service, Paris, France

A0115

Transitional outcomes of children who have undergone Cohen ureteroneocystostomy for the treatment of vesicoureteral reflux to adulthood

Authors: Oktar T., Selvi I., Dönmez M.I., Gürcan M., Aydinoglu A.T., Ziylan O.

Institutes: Istanbul University, Istanbul Faculty of Medicine, Dept. of Pediatric Urology, Istanbul, Türkiye

A0120

Mitrofanoff's channel procedure : what can we learn from a 20-year experience ?

Authors: Amar S.¹, Bidault V.², Hameury F.², Mouriquand P.D.E.², Demède D.²

Institutes: ¹Gatien de Clocheville Hospital, Paediatric Surgery Unit, Tours, France, ²Women Mother and Child Hospital, Paediatric Surgery Unit, Lyon, France

A0112

Day surgery for transperitoneal versus retroperitoneal robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction in children. A multicentre study

Authors: Trypens A.¹, Faure A.², Merdrignac V.³, Duchesne C.⁴, Rod J.³, Ballouhay Q.⁵, Abbo O.⁶, Botto N.¹, Arnaud A.⁴, Blanc T.¹

Institutes: ¹Necker Enfants Malades Hospital, Dept. of Pediatric Surgery and Urology, Paris, France, ²CHU Timone Enfants, Dept. of Pediatric Urology, Marseille, France, ³Caen University Hospital, Dept. of Pediatric Surgery, Caen, France, ⁴CHU Rennes, Dept. of Pediatric Surgery, Rennes, France, ⁵Limoges University Hospital, Dept. of Pediatric Surgery, Limoges, France, ⁶CHU Toulouse, Dept. of Pediatric Surgery, Toulouse, France

A0117

Robotic-assisted laparoscopy surgery (RALS) in children weighing 10kg or less: results of a multicentric study

Authors: Faure A.¹, BALLOUHEY Q.², Gastaldi P.¹, Botto N.³, Rod J.⁴, Arnaud A.⁵, Abbo O.⁶, Blanc T.³

Institutes: ¹APHM Aix Marseille Univeristy Timone Enfants, Dept. of Pediatric Urology, Marseille, France, ²CHU Limoges, Dept. of Pediatric Surgery, Limoges, France, ³AP-HP Hopital Necker Enfants Malades, Dept. of Pediatric Surgery, Paris, France, ⁴CHU Caen, Dept. of Pediatric Surgery, Caen, France, ⁵CHU Rennes, Dept. of Pediatric Surgery, Rennes, France, ⁶CHU Toulouse, Dept. of Pediatric Surgery, Toulouse, France

A0109

Major factors contributing to surgical success in pediatric patients with VUR who underwent laparoscopic or robot-assisted extravesical ureteral reimplantation

Authors: Hayashi Y.H.¹, Mizuno K.M.¹, Nishio H.N.¹, Matsumoto D.M.², Sakata T.S.³, Kamisawa H.K.⁴, Nakane A.⁵, Kurokawa S.K.⁴, Maruyama T.M.⁶, Tozawa K.T.⁷, Yasui T.Y.³

Institutes: ¹Nagoya City University Graduate School of Medical Sciences, Dept. of Pediatric Urology, Nagoya, Japan, ²Nagoya City University West Medical Center, Dept. of Urology, Nagoya, Japan, ³Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ⁴Anjo Kosei Hospital, Dept. of Urology, Anjo, Japan, ⁵Gamagori City Hospital, Dept. of Urology, Gamagori, Japan, ⁶Nagoya City University East Medical Center, Dept. of Urology, Nagoya, Japan, ⁷Nagoya City University Graduate School of Medical Sciences, Dept. of Medical Safety Management, Nagoya, Japan

- A0110** **Retroperitoneal versus transperitoneal robotic-assisted laparoscopic nephron sparing surgery for renal tumor in children. A multicentre study.**
Authors: Grosman J.¹, Glenisson M.², Joseph S.³, Faure A.⁴, Philippe-Chomette P.², Arnaud A.⁵, Loiselet K.⁶, Aquilina L.⁵, Planchamp T.³, Abbo O.³, Blanc T.¹
Institutes: ¹Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Dept. of Pediatric Surgery and Urology, Paris, France, ²Hopital Robert Debré, Assistance Publique Hopitaux de Paris, Dept. of Pediatric Surgery, Paris, France, ³Hopital des Enfants de Toulouse, Dept. of General Pediatric Surgery, Toulouse, France, ⁴Hopitaux Universitaires de Marseille, Assistance Publique Hopitaux de Marseille, Dept. of Pediatric Surgery and Urology, Marseille, France, ⁵CHU Rennes, Dept. of Pediatric Surgery, Rennes, France, ⁶Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Dept. of Pediatric Radiology, Paris, France
- A0118** **Maximizing robotic extravesical ureteral reimplantation success: the synergistic impact of ureteral adventitia inclusion and robust distal end detrusorraphy sutures**
Authors: Kim D., Kim Y., Kim D., Kang H., Kang S., Jung Y., Choe J., Shin D., Cho J., Park J., Nam K., Song S.H., Kim K.S.
Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea
- A0121** **Robot-assisted laparoscopic adrenalectomy: extended application in children**
Authors: Glenisson M.¹, Taghavi K.², Loiselet K.³, Fiorenza V.¹, Cornet M.¹, Capito C.¹, Vinit N.¹, Sarnacki S.¹, Blanc T.¹
Institutes: ¹Hopital Necker-Enfants Malades, Dept. of Pediatric Surgery and Urology, Paris, France, ²Monash Children Hospital, Dept. of Pediatric Urology, Melbourne, Australia, ³Hopital Necker-Enfants Malades, Dept. of Pediatric Radiology, Paris, France
- A0114** **Pediatric obesity and development of the penis and testi**
Authors: Chung J.M.¹, Lee D.¹, Lee S.D.¹, Lee D-G.²
Institutes: ¹Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea, ²Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Dept. of Urology, Seoul, South Korea
- A0111** **Efficacy and safety of mirabegron compared with solifenacin in treatment of non-neurogenic voiding dysfunction in children: A randomized controlled trial**
Authors: Mansour I., El-Hefnawy A., Abd Elhalim A., Laymon M., Dawaba M.
Institutes: Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.13

05 April 2024
15:45 - 16:40

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.14

05 April 2024
15:45 - 16:40

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.15

05 April 2024
15:45 - 16:40

Location

Orange Area, HOT 1

The future of urology: From carbon footprint to artificial intelligence

Plenary Session

06 April 2024
08:00 - 10:00

Location Green Area, eURO Auditorium 1
Chairs T. Knoll, Sindelfingen (DE)
A. Stenzl, Tübingen (DE)

Learning objectives

In urology we are facing an increasing challenge with more and more non-reusable material applied in surgery and other interventional techniques. This will cause a considerable use of resources for production and transport. Thus, possible advantages for patients as well as treating physicians outweigh the burden on climate and use of raw materials? Will, on the other hand, better education, application of artificial intelligence leading to a better indication of certain interventions? Leaders in the field of training, education, digitalization and other aspects of future changes in urology will give you a nice perspective of what is coming up over the next 10 years.

08:00 - 08:02

Introduction

T. Knoll, Sindelfingen (DE)

08:02 - 08:12

State-of-the-art lecture Training in urology: How do we adapt to the changing future?

A. Gallagher, Melle (BE)

08:12 - 08:22

State-of-the-art lecture Female perspective in urology: How are the residency programs changing?

V. Phé, Paris (FR)

08:22 - 08:32

State-of-the-art lecture How should I prepare to become a leader in urology?

F. Montorsi, Milan (IT)

08:32 - 09:37

Artificial intelligence in urology: Where are now?

Moderator M.R. Cooperberg, San Francisco (US)

08:32 - 08:42

State-of-the-art lecture Using digital twins to support multiple stages of the patient journey

To be confirmed

08:42 - 08:52

State-of-the-art lecture Image-guided navigation systems in urological surgery

A. Breda, Barcelona (ES)

08:52 - 09:02

State-of-the-art lecture Artificial Intelligence in prostate cancer imaging

M. De Rooij, Nijmegen (NL)

09:02 - 09:12

State-of-the-art lecture Metaverse in urology: Fiction or reality

F. Porpiglia, Turin (IT)

09:12 - 09:22

State-of-the-art lecture How do I see the urology theatre of 2030?

P. Dasgupta, London (GB)

09:22 - 09:37

Discussion: The role of AI

09:37 - 09:57

Best way to reduce carbon footprint in urology

Moderator K.A.O. Tikkinen, Helsinki (FI)

Scientific Programme - EAU24

09:37 - 09:42	US perspective S. Loeb, New York (US)
09:42 - 09:47	EU perspective A. Leliveld-Kors, Groningen (NL)
09:47 - 09:57	Discussion
09:57 - 10:00	Closing remarks

Risk-adapted screening and treatment of screen-detected prostate cancer

Plenary Session

06 April 2024
08:00 - 10:00

Location Purple Area, eURO Auditorium 2
Chairs P. Albers, Düsseldorf (DE)
A. Villers, Lille (FR)

08:00 - 08:05	Patients' perspective of risk-adapted screening strategy in Europe E-G. Carl, Tornesch (DE)
08:05 - 08:13	Implementation of personalised screening strategies for cancers in Europe H.J. De Koning, Rotterdam (NL)
08:13 - 08:21	Implementation of risk-adapted screening strategy in Europe - PRAISE-U M.J. Roobol, Rotterdam (NL)
08:21 - 08:29	Genetic predisposition to prostate cancer D. Stoppa-Lyonnet, Paris (FR)
08:29 - 08:37	Society of Urologic Oncology (SUO) lecture Update on biomarkers and US risk-adapted screening strategy A.S. Kibel, Boston (US)
08:37 - 08:47	Don't screen for prostate cancer: The new UK perspective? F.C. Hamdy, Oxford (GB)
08:47 - 09:30	Case discussion Risk adapted screening for prostate cancer in Europe
08:47 - 08:52	MRI only (ReImagine trial - UK prostate health check) C. Moore, London (GB)
08:52 - 08:57	PSA only (PROBASE - the German Screening Trial in young men) B.A. Hadaschik, Essen (DE)
08:57 - 09:02	PSA + MRI (OPT - the Swedish nationwide screening strategy) O. Bratt, Gothenburg (SE)
09:02 - 09:07	PSA + Risk calculators + MRI (the EAU screening algorithm) K. Beyer, London (GB)
09:07 - 09:12	PSA + blood-based biomarkers + MRI (ProScreen - the Finish screening trial) A.P. Auvinen, Tampere (FI)
09:12 - 09:17	PSA+MRI+Targeted biopsies only (Gothenburg-2 trial) J. Hugosson, Gothenburg (SE)
09:17 - 09:20	Case presentation: Elevated PSA, familial risk M. Maggi, Rome (IT)
09:20 - 09:30	The best and pragmatic way of personalised diagnosis of prostate cancer C.H. Bangma, Rotterdam (NL)
09:30 - 10:00	Debate Treatment of screen-detected prostate cancer
09:30 - 09:34	Case presentation: 50 yrs, MCCL < 6mm ISUP 2, 10% GP4, BRCA2 + E. Linares Espinós, Madrid (ES)

Scientific Programme - EAU24

09:34 - 09:42

Active surveillance

O. Yossepowitch, Tel-Aviv (IL)

09:42 - 09:50

Curative treatment

R. Coelho, Sao Paulo (BR)

09:50 - 10:00

Familial prostate cancer: Does it influence the screening and management?

A. Morgans, Boston (US)

Oligometastatic prostate cancer

ESU Course 13

06 April 2024
08:30 - 10:30

Location Purple Area, E01
Chair S. Joniau, Leuven (BE)

Learning objectives

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis-directed therapy.
- Understand opportunities and challenges in individualising care of the oligometastatic prostate cancer patient.

Introduction: Oligometastatic prostate cancer as a diagnosis

S. Joniau, Leuven (BE)

Surgery of primary oligometastatic prostate cancer (N1/M1)

S. Joniau, Leuven (BE)

Surgery for recurrent nodal metastasis with updates on molecular/PET imaging

A. Briganti, Milan (IT)

Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates

T. Zilli, Genève (CH)

Further cases (case illustrations throughout)

A. Briganti, Milan (IT)

S. Joniau, Leuven (BE)

T. Zilli, Genève (CH)

Discussion and conclusion

S. Joniau, Leuven (BE)

Urinary tract and genital trauma

ESU Course 14

06 April 2024
08:30 - 11:30

Location Purple Area, E02
Chair N. Kitrey, Ramat Gan (IL)

Learning objectives

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore to understand and follow the basic principles is needed.

The ESU urological trauma course details the epidemiology, mechanism of action, diagnosis, and management of urogenital trauma (renal, ureteric, bladder, urethra, and external genitalia). The course is based on the peer-reviewed annually-updated EAU Guidelines on urological trauma. Interactive case-based discussion will highlight the key points of trauma management.

Introduction

N. Kitrey, Ramat Gan (IL)

General trauma

N. Kitrey, Ramat Gan (IL)

Renal trauma

E.K. Mayer, London (GB)

Ureteral trauma

N. Lumen, Ghent (BE)

Bladder trauma

E.K. Mayer, London (GB)

Urethral trauma

N. Lumen, Ghent (BE)

Genital trauma

N. Kitrey, Ramat Gan (IL)

Questions and answers

Update EAU Guidelines 2024 - Renal, bladder and prostate cancer: What has changed?

ESU Course 15

06 April 2024
08:30 - 11:30

Location Purple Area, E03
Chair H.G. Van Der Poel, Amsterdam (NL)

Learning objectives

During the course, recent practice changing alterations in the EAU Guidelines will be discussed. Based on the clinical recommendations, the highlights of the guidelines on prostate, renal and bladder cancer changed in the 2022 updates, will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

Introduction

H.G. Van Der Poel, Amsterdam (NL)

Update renal cancer: Localised

A. Volpe, Novara (IT)

Discussion

Update renal cancer: Metastasised

A. Volpe, Novara (IT)

Discussion

Update bladder cancer: Non-muscle invasive

J.L. Domínguez Escrig, Valencia (ES)

Discussion

Update bladder cancer: Muscle invasive

J.L. Domínguez Escrig, Valencia (ES)

Discussion

Update prostate cancer: Localised

N. Grivas, Ioannina (GR)

Discussion

Update prostate cancer: Metastasised

N. Grivas, Ioannina (GR)

Discussion

Male prosthetic urology

ESU Course 16

06 April 2024
08:30 - 11:30

Location Purple Area, E04
Chair A. Muneer, London (GB)

Learning objectives

This is a state of the art course on the use of prosthetics in the management of erectile dysfunction and urinary incontinence. The main learning objectives are:

- Step-by-step preparation and insertion of a penile prosthesis
- Complications and difficult situations for IPP
- Step-by-step options and techniques in the surgical management of incontinence
- Complications and difficult situations for GSI management

Introduction to biofilms and prosthetic infections

A. Muneer, London (GB)

Penile prosthesis

Different types of prosthesis

A. Muneer, London (GB)

Theatre set-up and preparation of patients

A. Muneer, London (GB)

Surgical techniques and intraoperative complications

I. Moncada Iribarren, Madrid (ES)

The difficult implant: Peyronie's, priapism, fibrosis

J. Romero-Otero, Madrid (ES)

Revision surgery and post operative complications

J. Romero-Otero, Madrid (ES)

Prosthetic surgery for male urinary incontinence

AUS: Indications, types, techniques and complications

I. Moncada Iribarren, Madrid (ES)

Slings: Indications, types, techniques and complications

S. Malde, London (GB)

Neuromodulation devices

S. Malde, London (GB)

Future of prosthetic urology

I. Moncada Iribarren, Madrid (ES)

Robotic-assisted laparoscopic prostatectomy

ESU Course 17

06 April 2024
08:30 - 11:30

Location Purple Area, E05
Chair A. De La Taille, Créteil (FR)

Learning objectives

The objectives are to explain, using videos and step-by-step explanations, robotic assisted radical prostatectomy with three presenters using three different approaches: Transperitoneal, preperitoneal and retzius-sparing techniques.

General principles regarding port placement, prostate anatomy and surgical landmarks will be also reminded considering the different possible options and the different types of robotic systems used. Finally, the course will present the possible intraoperative risks of complications and how-to-manage-them strategies. This course will be interactive including direct and/or multichoice questions to the audience.

Introduction

A. De La Taille, Créteil (FR)

Robotic radical prostatectomy with da Vinci systems

Operative protocol: Operative room organisation, side docking
F. Annino, Arezzo (IT)

Operative protocol; Ways of access port placements: TransPeritoneal

A. Haese, Hamburg (DE)

Operative protocol; Ways of access port placements; PrePeritoneal
A. De La Taille, Créteil (FR)

Operative protocol; Ways of access port placements: Retzius-sparing

F. Annino, Arezzo (IT)

Anatomical reminders

F. Annino, Arezzo (IT)

Technique of lymphadenectomy

A. Haese, Hamburg (DE)

Robotic prostatectomy: How I do it

A. Haese, Hamburg (DE)

F. Annino, Arezzo (IT)

A. De La Taille, Créteil (FR)

How I manage bleeding/Lymphocele/ureter repair

F. Annino, Arezzo (IT)

Operative complications

How I manage urine leakage

A. Haese, Hamburg (DE)

How I manage bladder strictures

A. De La Taille, Créteil (FR)

Robotic-assisted radical prostatectomy with other systems

A. De La Taille, Créteil (FR)

Conclusion

A. De La Taille, Créteil (FR)

Treatment of localised renal masses tips and tricks

ESU Course 18

06 April 2024
08:30 - 11:30

Location Purple Area, E06
Chair A. Minervini, Florence (IT)

Learning objectives

- Learn tips and tricks for successfully managing challenging cases of localised renal tumours through interactive case discussion
- Become familiar with the current standards of minimally-invasive surgical techniques and ablative therapies for localized renal tumours
- Understand the benefits of robotics and 3D reconstruction for surgical conservative treatment in challenging scenarios through interactive cases and surgical videos
- Review and analyse the patterns and predictors of recurrence in localized RCC through analysis of clinical trial evidence

Partial nephrectomy: Indications and surgical steps

M.J. Ribal Caparros, Barcelona (ES)

Radical Nephrectomy: Indications and surgical steps

A. Minervini, Florence (IT)

Ablative treatment: Technologies, indications and results

D. Enikeev, Vienna (AT)

Discussion

Surgical treatment in challenging cases and bilateral renal tumours

A. Minervini, Florence (IT)

Ablative treatment in challenging cases: Tips and tricks

D. Enikeev, Vienna (AT)

Adjuvant therapy in localised RCC: Patterns and predictors of recurrence and evidences from clinical trials

M.J. Ribal Caparros, Barcelona (ES)

Interactive case reports discussion

M.J. Ribal Caparros, Barcelona (ES)

D. Enikeev, Vienna (AT)

A. Minervini, Florence (IT)

Complications in endourology: Causes, management and prevention

ESU Course 19

06 April 2024
08:30 - 11:30

Location Purple Area, E07
Chair V.M.J. De Coninck, Brasschaat (BE)

Learning objectives

The aims and objectives of this course are to provide a complete overview of complications related to endourological procedures.

- Extracorporeal shock wave lithotripsy (ESWL)
- Retrograde intrarenal surgery (RIRS)
- Percutaneous nephrolithotomy (PCNL)
- Transurethral resection of the bladder (TURB) and prostate (TURP), anatomical endoscopic enucleation of the prostate (AEEP), cystolithotripsy/cystolitholapaxy, internal urethrotomy/urethral dilation

This ESU course has the goal to fill the knowledge gap for early identification of complications during endourological procedures and to describe their management, in order to prevent further harm. At the end of the course, the participants will be able to increase their knowledge about complications in endourology and to identify them according to their etiology. They will also know how most endourological complications can be managed and prevented. Lastly, clinicians will use the increased knowledge to provide better care to their patients.

Extracorporeal shock wave lithotripsy

E.X. Keller, Zürich (CH)

RIRS

V.M.J. De Coninck, Brasschaat (BE)

PCNL

E.X. Keller, Zürich (CH)

TURB, TURP, AEEP, cystolithotripsy/cystolitholapaxy

K. Lehrich, Berlin (DE)

Internal urethrotomy, urethral dilation

K. Lehrich, Berlin (DE)

Complications related to fluoroscopy and imaging

V.M.J. De Coninck, Brasschaat (BE)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.01

06 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.02

06 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.03

06 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

YUORDay24: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part I

Special Session

06 April 2024 10:00 - 14:00	Location Chairs	Green Area, W06 E. Checcucci, Candiolo (IT) J.L. Vásquez, Copenhagen (DK)
10:00 - 10:15	Welcome and introduction	
10:15 - 11:00	European Urology Scholarship Programme (EUSP) Moderators Y. Abu Ghanem, London (GB) U.G. Falagario, Foggia (IT) A.S. Merseburger, Lübeck (DE)	
10:15 - 10:25	Updates on the EUSP programmes and how to apply A.S. Merseburger, Lübeck (DE)	
10:25 - 10:35	How to successfully apply for a one year scholarship G. Jenster, Rotterdam (NL)	
10:35 - 10:45	What are the value proposition of a scholarship program for the YUO, EAU, and our patients? J.L. Vásquez, Copenhagen (DK)	
10:45 - 10:50	Report of the best scholars clinical and basic research A.S. Merseburger, Lübeck (DE)	
10:50 - 11:00	Best scholar winner: Presentation and award To be confirmed	
11:00 - 12:00	Surgery tips and tricks Moderators To be confirmed A. Goujon, Paris (FR) A. Khelif, Mons (BE)	
11:00 - 11:10	Gain the access to the retroperitoneum with retroperitoneoscopic approach F. Porpiglia, Turin (IT)	
11:10 - 11:15	Discussion	
11:15 - 11:25	How to maximise the quality of TURB and avoid intraoperative risks J Palou, Barcelona (ES)	
11:25 - 11:30	Discussion	
11:30 - 11:40	Percutaneous kidney puncture: Tips and tricks for an efficient and safe procedure S. Proietti, Milan (IT)	
11:40 - 11:45	Discussion	
11:45 - 11:55	Testicular cancer surgery C. Fankhauser, Lucerne (CH)	
11:55 - 12:00	Discussion	
12:00 - 13:00	New technologies for young surgeons and scientists	

Moderators L. Baekelandt, Leuven (BE)
E. Checcucci, Candiolo (IT)
A. Rautio, Tallinn (EE)

- 12:00 - 12:10 **The importance of 3D models for planning and navigation in kidney surgery**
D. Amparore, Turin (IT)
- 12:10 - 12:15 **Discussion**
- 12:15 - 12:25 **Aquablation: Advantages and drawbacks of a new instrument**
T.R.W. Herrmann, Frauenfeld (CH)
- 12:25 - 12:30 **Discussion**
- 12:30 - 12:40 **Artificial intelligence for prostate cancer: From imaging to histology**
To be confirmed
- 12:40 - 12:45 **Discussion**
- 12:45 - 12:55 **ChatGPT for clinics and academics**
G. Cacciamani, Los Angeles (US)
- 12:55 - 13:00 **Discussion**
- 13:00 - 14:00** **Nightmare cases: Clinical case discussion**
Moderators L. Afferi, Luzern (CH)
D.M. Carrión Monsalve, Madrid (ES)
V. Quaresma, Coimbra (PT)
- 13:00 - 13:20 **Case I: Complete obstruction of a double-layered polytetrafluoroethylene membrane – covered self-expandable segmental metallic stent (UVENTA) due to encrustation**
A. Pietropaolo, Southampton (GB)
E. Papadimitriou, Athens (GR)
- 13:20 - 13:40 **Case II: Fournier’s Gangrene after circumcision – if you not only lose your prepuce**
To be confirmed
F. Aschwanden, Lucerne (CH)
- 13:40 - 14:00 **Case III: Laparoscopic radical prostatectomy - it’s never too late for a complication**
R. Gaston, Bordeaux Cedex (FR)
K. Gkeka, Patras (GR)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.05

06 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.06

06 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.07

06 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Future-proofing urology: Affordable medicine and Artificial Intelligence

Abstract session 8

06 April 2024
10:15 - 11:45

Location Purple Area, S01
Chairs To be confirmed
To be confirmed
P. De Backer, Ghent (BE)
J. Gómez Rivas, Madrid (ES)

10:15 - 10:45

Affordable medicine and accessible care

A0140

Cost comparison of reusable and single-use cystoscopes: A systematic literature review and meta-analysis

Authors: [Birkedal A.C.O.](#)¹, [Mahmalji W.](#)², [Dehlholm-Lambertsen E.](#)¹

Institutes: ¹Ambu Limited United Kingdom, Dept. of Marketing - Health Economic Market Access, Cambridgeshire, United Kingdom, ²Hereford County Hospital, Dept. of Urology, Hereford, United Kingdom

A0137

Office-based endoscopic urological procedures under local anesthesia: Evaluation of feasibility, pain, and patient preference

Authors: [Ricapito A.](#)¹, [Gupta K.](#)², [Khargi R.](#)², [Yaghoubian A.](#)², [Atallah W.](#)², [Carrieri G.](#)¹, [Gupta M.](#)²

Institutes: ¹University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

A0125

A Cost-Consequence Analysis of the Man Van Project: Comparing Prostate-specific Antigen Testing on a Nurse-led Mobile Service with Primary Care

Authors: [Moghul M.](#)¹, [Yi D.](#)², [Croft F.](#)¹, [Mutch F.](#)¹, [Westaway E.](#)¹, [Kinsella N.](#)¹, [Cahill D.](#)¹, [James N.D.](#)¹

Institutes: ¹Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ²Imperial College London, Convergence Science Centre, London, United Kingdom

A0131

Virtual care as a tool to improve health equity? A U.S. national racial and ethnic analysis of telemedicine utilization among cancer patients and survivors during COVID-19

Authors: [Cortese B.D.](#)¹, [Alkhatib K.Y.](#)¹, [Harmatz I.M.](#)¹, [Leff M.A.](#)¹, [Mclauchlan N.](#)¹, [Michel K.F.](#)¹, [Roberson D.S.](#)¹, [Schurhamer B.](#)¹, [Lee D.J.](#)¹, [Guzzo T.J.](#)¹, [Pierorazio P.M.](#)¹, [Talwar R.](#)²

Institutes: ¹University of Pennsylvania Health System, Dept. of Surgery, Division of Urology, Philadelphia, United States of America, ²Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America

A0126

Current Expectations And Opinions On Single Port Robotic Surgery: Preliminary Analysis Of a Survey Among European Experts (SPARC Collaborative Group)

Authors: Ditonno F.¹, Licari L.C.¹, Franco A.¹, Bologna E.¹, Manfredi C.¹, Soputro N.², Ramos-Carpinteyro R.², Kaouk J.², Amhed M.³, Stifelman M.D.³, Nelson R.J.⁴, Badani K.K.⁵, Crivellaro S.⁶, Autorino R.¹

Institutes: ¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²Glickman Urological and Kidney Institute Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ³Hackensack University Medical Center, Dept. of Urology, Hackensack, United States of America, ⁴McLaren Macomb Hospital, Dept. of Urology, Mount Clemens, United States of America, ⁵Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁶University of Illinois Chicago, Dept. of Urology, Chicago, United States of America

A0127

Characteristics and trends of industry-sponsored research funding to urologists in the United States between 2014 and 2022

Authors: Nguyen D.D.¹, Muramaya A.², Nguyen A.L.V.³, Murad L.⁴, Kulkarni G.S.¹, Bhojani N.⁵, Satkunasivam R.⁶, Trinh Q.D.⁷, Wallis C.J.D.¹

Institutes: ¹University of Toronto, Division of Urology, Toronto, Canada, ²Icahn School of Medicine at Mount Sinai, Dept. of Population Health Science and Policy, New York, United States of America, ³University of Western Ontario, Schulich School of Medicine and Dentistry, Windsor, Canada, ⁴McGill University, Faculty of Medicine and Health Sciences, Montreal, Canada, ⁵Centre Hospitalier de l'Université de Montréal, Division of Urology, Montreal, Canada, ⁶Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, ⁷Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America

10:45 - 11:00

AI in diagnosis: pathology

A0138

Multi-modal deep learning model for predicting homologous recombination deficiency in prostate cancer: an international multi-cohort study

Authors: Chen R.¹, Zhang Q.², Zhang W.³, Na T.⁴, Zhu Y.⁴, Deng L.³, Han W.³, Zhu L.³, Li Y.⁵, Wang X.⁶, Yang Y.⁷, Zhang W.³, Lai Y.³, Wang Y.³, Min Q.³, Dong Z.³, Huamao Y.³, Wang L.³, Gao X.³

Institutes: ¹Renji Hospital Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Shanghai Changhai Hospital, Dept. of Radiology, Shanghai, China, ³Shanghai Changhai Hospital, Dept. of Urology, Shanghai, China, ⁴Shanghai Changhai Hospital, Dept. of Pathology, Shanghai, China, ⁵Daping Hospital Army Medical University, Dept. of Urology, Chongqing, China, ⁶First Affiliated Hospital School of Medicine, Dept. of Urology, Hangzhou, China, ⁷Nanjing Jinling Hospital Nanjing University School of Medicine, Dept. of Clinical Laboratory, Nanjing, China

A0129

Deep Learning Unveils Molecular Footprints in Histology: Predicting Molecular Subtypes from Bladder Cancer Histology Slides

Authors: Khoraminia F.¹, de Jong C.¹, Akram F.², Litjens G.³, Jansen M.D.C.¹, Nakauma Gonzalez A.¹, Lichtenberg D.¹, Stubbs A.², Khalili N.³, Zuiverloon T.C.M.¹

Institutes: ¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC Cancer Institute, Dept. of Pathology and Clinical Bioinformatics, Rotterdam, The Netherlands, ³Radboud University Medical Center, Dept. of Pathology, Nijmegen, The Netherlands

A0132

Intelligent discrimination between Normal and Cancerous Human Urothelial Cells by using Electrical Impedance analyzed by Combination of Microflow Cytometry and Machine Learning

Authors: Kim H.W.¹, Jang K.¹, Shin D.G.¹, Lee J.Z.¹, Kim S.², Ra S.², Kim K.², Ryu Y.², Kim W.³, Park Y.²

Institutes: ¹Pusan National University School of Medicine, Dept. of Urology, Busan, South Korea, ²Chonnam National University, Dept. of Mechanical Design Engineering, Yeosu, South Korea, ³Korea Electronics Technology Institute, Smart Sensor Research Center, Seongnam, South Korea

11:00 - 11:30

AI in diagnosis: imaging and other

A0141

Harnessing artificial intelligence for enhanced renal analysis: automated detection of hydronephrosis and precise kidney segmentation

Authors: Alexa R.¹, Kranz J.¹, Murillo L.F.C.², Kramann R.³, Kuppe C.³, Sanyal R.³, Hayat S.³, Hoffmann M.¹, Saar M.¹

Institutes: ¹RWTH Aachen University, Dept. of Urology and Pediatric Urology, Aachen, Germany, ²RWTH Aachen University, Robotic Systems Engineering, Aachen, Germany, ³RWTH Aachen University, Dept. of Nephrology Rheumatology Clinical Immunology and Hypertension, Aachen, Germany

A0136

Can artificial neural network models improve estimation of glomerular filtration rate?

Authors: Zafari T.¹, Kishore K.², Kwok R.¹, Lottfaliany M.³, Poon A.⁴, Torkamani N.⁵, Macisaac R.⁶, Churilov L.¹, Ekinici E.¹

Institutes: ¹University of Melbourne, Melbourne Medical School, Melbourne, Australia, ²Austin Health and The University of Melbourne, Data Analytics Research and Evaluation Centre, Melbourne, Australia, ³Deakin University, The Institute for Mental and Physical Health and Clinical Translato, Melbourne, Australia, ⁴Austin Health and University of Melbourne, Dept. of Molecular Imaging and Therapy, Melbourne, Australia, ⁵Austin Health, Dept. of Endocrinology, Melbourne, Australia, ⁶St Vincents Hospital Melbourne and University of Melbourne, Dept. of Endocrinology and Diabetes, Melbourne, Australia

A0128

Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods

Authors: Saikali S.¹, Khosravi P.², Boger M.¹, Jaber A.R.¹, Covas Moschovas M.¹, Rogers T.¹, Reddy S.¹, Gamal A.¹, Venkataraman S.³, Patel E.¹, Patel V.¹

Institutes: ¹AdventHealth Global Robotics Institute, Dept. of Uro-oncology, Celebration, United States of America, ²New York City College of Technology, Dept. of Biological Sciences, New York, United States of America, ³Promaxo, Dept. of Clinical Research and Strategy, Oakland, United States of America

A0133

Data processing pipeline and artificial intelligence (AI) for autonomous fusion in transperineal prostate biopsies

Authors: Cianflone F.¹, Maris B.², Alessandro V.¹, Artoni F.¹, Montanaro F.¹, Pettenuzzo G.¹, Cerruto M.A.¹, Fiorini P.², Antonelli A.¹

Institutes: ¹University of Verona - Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ²University of Verona, Dept. of Engineering for Innovation Medicine, Verona, Italy

A0130

Development of pT classification prediction system in UTUC using deep-learning

Authors: Daizumoto K.¹, Osafune N.¹, Torii K.², Nishimura R.³, Uehara H.⁴, Nishiyama M.¹, Kobayashi S.¹, Yutaro S.¹, Tomida R.¹, Ueno Y.¹, Kusuhara Y.¹, Fukawa T.¹, Yamaguchi K.¹, Yamamoto Y.¹, Takahashi M.¹, Furukawa J.¹

Institutes: ¹Tokushima University Graduate School of Biomedical Sciences, Dept. of Urology, Tokushima, Japan, ²Tokushima University, Center for Design-Oriented AI Education and Research, Tokushima, Japan, ³Tokushima University, Dept. of Technology Industrial and Social Science, Tokushima, Japan, ⁴Tokushima University, Dept. of Pathology, Tokushima, Japan

A0135

Artificial Intelligence Based Personalized Oncological Outcome Prediction Model for Upper Urinary Tract Urothelial Carcinoma After Radical Nephroureterectomy: Development and Multi-Center Validation

Authors: Kim D.¹, Nam K.H.¹, Lee H.Y.¹, Lim B.¹, Kim D.¹, Jeong Y.¹, Jeong I.G.¹, Park J.J.¹, You D.¹, Hong J.H.¹, Song C.¹, Ku J.H.², Hong B.¹, Ahn H.¹, Kim H.³, Suh J.¹

Institutes: ¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Seoul National University Hospital Seoul National University College of Medicine, Dept. of Urology, Seoul, South Korea, ³Hallym University Sacred Heart Hospital, Dept. of Urology, Anyang, South Korea

11:30 - 11:45

AI facilitating surgery

A0134

AI-based classification and segmentation method for bladder cancer from cystoscopic image: preliminary study

Authors: Hwang W. K.¹, Kim H.J.¹, Jo S.B.¹, Ahn S.T.¹, Oh M.M.¹, Park H.S.¹, Moon D.G.¹, Choi I.², Yang Z.², Cho H.Y.³, Kim J.W.¹

Institutes: ¹Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea, ²Korea University Guro Hospital, Dept. of Radiology, Seoul, South Korea, ³Korea University Anam Hospital, Dept. of Pathology, Seoul, South Korea

A0124

A.I. instrument tracking during proficiency-based progression training: Does instrument velocity really matter?

Authors: Simoens J.¹, Mottrie A.¹, Hofman J.¹, Besi G.², Ferraguti F.², De Wel O.³, Puliatti S.⁴, De Groot R.⁵, Gallagher A.¹, De Backer P.¹

Institutes: ¹ORSI Academy, Dept. of Urology, Melle, Belgium, ²University of Modena and Reggio Emilia, Dept. of Science and Methods of Engineering, Modena, Italy, ³Barco, Healthcare, Kortrijk, Belgium, ⁴University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁵Onze-Lieve-Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium

A0139

Evaluation of an extended reality (XR) headset designed for remote training, resident surgery observation and as a wearable monitor for minimally invasive surgery (MIS)

Authors: Stone N.¹, Griffith S.², Wilson M.², Stone J.³

Institutes: ¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Viomerse, Dept. of Engineering, Pittsford, United States of America, ³University of Rochester Medical Center, Dept. of Neurosurgery, Rochester, United States of America

Penile cancer treatment and penile reconstruction

Video session 04

06 April 2024
10:15 - 11:45

Location Green Area, S04
Chairs H.M. Alnajjar, London (GB)
L. Barreto, Nitra (SK)
To be confirmed

- V025** **Hyperrealistic 3D models for the practice of andrological surgical procedures. A new paradigm?**
Authors: García Herrero J., Campos Juanatey E., Calleja Hermosa P., Varea Malo R., Alonso Mediavilla E., García Formoso N., Sánchez Gil M., Azcárraga Aranegui G., Expósito Ibáñez E., Latatu Córdoba M.A., Arnaiz Jiménez F., Domínguez Esteban M., Zubillaga Guerrero S., Gutiérrez Banos J.L.
Institutes: Hospital Universitario Marqués de Valdecilla, Dept. of Urology, Santander, Spain
- V026** **No Scalpel Nesbit. Novel method of Nesbit's procedure with a carbon dioxide (CO2) laser.**
Authors: Chomicz A., Pawlowska-Krajka E.K.
Institutes: LUX MED Pulawska Hospital, Dept. of Urology, Warsaw, Poland
- V027** **A Novel Technique of Penile Preservation: Local Excision of Proximal Corporal Sarcoma and Left to Right Corporo-corporostomy.**
Authors: Bhagat S.K.¹, Saurabh N.², Suresh A.³
Institutes: ¹Fortis Hospital Mulund, Dept. of Urology and Renal transplant, Mumbai, India, ²Rajiv Gandhi Cancer Institute and Research Centre, Dept. of Urooncology, New Delhi, India, ³Belarusian State Medical University, Minsk, Belarus
- V028** **Perineoscopic urethroscopy in penile cancer patients**
Authors: Bravo Balado A.C., Sánchez R.L., Hernández P., Robalino J., Gaya J.M., Breda A., Rosales A.
Institutes: Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain
- V029** **Fused Double-Cylinder Penile Prosthesis Placement After Phalloplasty Without Urethral Lengthening: A Novel Technique Using A 2-Piece IPP**
Authors: Sandhu S.¹, Mallavarapu S.¹, Stelmar J.², Smith S.¹, Garcia M.¹
Institutes: ¹Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ²University of California San Diego, Dept. of Medicine, San Diego, United States of America
- V030** **Video Comparative Analysis of Modern Dynamic Sentinel Node Biopsy Techniques in European Referral Centres: Practices, Variations, and Opportunities for Research**
Authors: Yan S.¹, Fankhauser C.², Ayres B.¹, Watkin N.¹, Longoni M.³, Bandini M.³
Institutes: ¹St George's University Hospital, Dept. of Urology, London, United Kingdom, ²Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ³San Raffaele Hospital, Dept. of Urology, Milan, Italy

V031 **Robot-Assisted Video-Endoscopic Inguinal Lymph Node Dissection (RAVEIL):**

Description of Technique

Authors: Diamand R., Peltier A.

Institutes: Jules Bordet Institute, Dept. of Urology, Brussels, Belgium

V032 **Robot-assisted Inguinal Lymphadenectomy with the Hugo™ RAS System: surgical set-up and initial experience.**

Authors: Berquin C., Gaya J.M., Basile G., Pecoraro A., Gallioli A., Lauwers C., Casadevall M., Sanz I., Izquierdo P., Territo A., Gavrillov P., Rosales A., Palou J., Breda A.

Institutes: Fundació Puigvert, Dept. of Urology, Barcelona, Spain

Progress and controversies in oncological urology

Meeting of the EAU Section of Oncological Urology (ESOU)

06 April 2024
10:30 - 13:10

Location Purple Area, N01
Chair M. Rouprêt, Paris (FR)

Learning objectives

To strengthen the leading role of European urologists in providing care to patients with genitourinary malignancies.

To recognize the value of multidisciplinary collaborations between urologists, medical oncologists, radiation oncologists, and other stakeholders involved in the multifaceted care of patients with genitourinary malignancies.

To navigate the evolving landscape of multimodal, minimally invasive and technologically advanced therapeutic options with the aim to implement personalized pathways of care across the wide spectrum of genitourinary malignancies stage by stage.

10:30 - 10:35

Welcome and introduction

M. Rouprêt, Paris (FR)
G. Giannarini, Udine (IT)

10:35 - 11:20

Session I: Hot topics in oncological urology

Moderators G. Giannarini, Udine (IT)
M. Rouprêt, Paris (FR)

10:35 - 10:45

Prostate: Options and challenges in the management of oligometastatic prostate cancer in the PSMA-PET era

C. Sweeney, Adelaide (AU)

10:45 - 10:50

Questions & answers

10:50 - 11:00

Which future for immunotherapy in localised kidney cancer?

R. Campi, Florence (IT)

11:00 - 11:05

Questions & answers

11:05 - 11:15

The current role of surgery in metastatic testicular cancer

C. Fankhauser, Lucerne (CH)

11:15 - 11:20

Questions & answers

11:20 - 11:35

European Urology Oncology lecture

11:20 - 11:23

Introduction

M. Rouprêt, Paris (FR)

11:23 - 11:35

Survivorship considerations across the spectrum of genitourinary oncology

A. Morgans, Boston (US)

Session II: Common problems in oncological urology

Moderators G. Giannarini, Udine (IT)
M.C. Mir Maresma, Valencia (ES)

11:35 - 12:05

Case-based debate High-risk biochemical recurrence after radical prostatectomy

11:35 - 11:40	Case presentation C.V. Kesch, Essen (DE)
11:40 - 11:50	Treat without imaging B. Tombal, Brussels (BE)
11:50 - 12:00	Treat after imaging A. De La Taille, Créteil (FR)
12:00 - 12:05	Discussion
12:05 - 12:35	Case-based debate Metastatic bladder cancer at diagnosis: Complete response after systemic treatment and subsequent bladder recurrence pT1 High Grade
12:05 - 12:10	Case presentation M. Moschini, Milan (IT)
12:10 - 12:20	Cystectomy P. Gontero, Turin (IT)
12:20 - 12:30	2nd line metastatic treatment To be confirmed
12:30 - 12:35	Discussion
12:35 - 13:05	Case-based debate Clear cell renal carcinoma T3c with lung micronodules
12:35 - 12:40	Case presentation M. von Deimling, Hamburg (DE)
12:40 - 12:50	Treatment systemic first R. Flippot, Villejuif (FR)
12:50 - 13:00	Surgery first M.C. Mir Maresma, Valencia (ES)
13:00 - 13:05	Discussion
13:05 - 13:10	Closing remarks M.C. Mir Maresma, Valencia (ES) G. Giannarini, Udine (IT)

Controversies and dilemmas in reproductive and sexual medicine: From the laboratory to the clinic and from the operating theater back to the laboratory

Meeting of the EAU Section of Andrological Urology (ESAU)

06 April 2024 10:30 - 13:30	Location Chair	Green Area, N03 N. Sofikitis, Ioannina (GR)
10:30 - 10:31	Welcome	N. Sofikitis, Ioannina (GR)
10:31 - 11:01	State of the art lectures in reproductive medicine Moderators	G. Corona, Bologna (IT) M.M. Fode, Herlev (DK)
10:31 - 10:41	Are there any evidence based lifestyle recommendations we can give to men from infertile couples	A. Salonia, Milan (IT)
10:41 - 10:51	Which pharmaceutical treatments are contraindicated in men who wish to become fathers	A. Giwercman, Malmö (SE)
10:51 - 11:01	Sparing surgery of the testis: Indications, Techniques and Outcomes	S. Minhas, London (GB)
11:01 - 11:11	State of the art lectures in sexual medicine Moderators	C. Bettocchi, Foggia (IT) D.J. Ralph, London (GB)
11:01 - 11:11	The role of extracorporeal shock wave therapy in andrology	J. Rassweiler, Krems - Stein (DE)
11:11 - 11:21	State of the art lectures in male endocrinology Moderators	To be confirmed P. Verze, Salerno (IT)
11:11 - 11:21	Is testosterone first choice therapy in obese hypogonadal men?	H. Behre, Halle (DE)
11:21 - 11:31	State of the art debates in reconstructive surgery Moderators	G.I. Russo, Catania (IT) A. Salonia, Milan (IT)
11:21 - 11:31	Penile surgery can increase the penile length: Aesthetic fact?	To be confirmed
11:31 - 11:41	State of the art lectures in assisted reproductive technology for the treatment of azoospermia Moderators	To be confirmed To be confirmed
11:31 - 11:41	Do we really need spermatozoa to generate healthy human offspring?	N. Sofikitis, Ioannina (GR)
11:41 - 12:05	Surgery in motion 1: Surgery for the treatment of male infertility	

	Moderators	F. Dimitriadis, Thessaloniki (GR) F. Fusco, Naples (IT)
11:41 - 11:48	Does micro-TESE remains the gold standard for testicular sperm recovery in non-obstructed azoospermic males?	M. Dinkelman-Smit, Rotterdam (NL)
11:48 - 11:55	Microsurgical aspiration of epididymal sperm from obstructed azoospermic males	A.B. Altay, Izmir (TR)
11:55 - 12:02	Tips and tricks on the surgical treatment of recurrent varicocele	S. Çayan, Mersin (TR)
12:02 - 12:05	Discussion	
12:05 - 12:23	Surgery in motion 2: Surgery for the treatment of male infertility	
	Moderators	M. Boiko, Kyiv (UA) A. Khelaia, Tbilisi (GE)
12:05 - 12:12	Surgery of the ejaculatory ducts: Indications and results	A. Muneer, London (GB)
12:12 - 12:19	Microsurgical aspiration of sperm from the vas deferens	A. Zachariou, Ioannina (GR)
12:19 - 12:23	Discussion	
12:23 - 12:54	Testicular cancer and male reproductive health-optimizing outcomes	
	Moderators	To be confirmed S. Minhas, London (GB)
12:23 - 12:32	Testicular dysgenesis: Its role in male reproductive health and testicular cancer - What is the evidence?	To be confirmed
12:32 - 12:40	Fertility preservation in men with testis cancer: The onco TESE, technique and outcomes	Z. Kopa, Budapest (HU)
12:40 - 12:49	The hypothalamo-pituitary testicular axis in men with testicular cancer	G. Corona, Bologna (IT)
12:49 - 12:54	Discussion	
12:54 - 13:28	Lectures and surgery in motion 3: Penile surgery	
	Moderator	P.A.S. Vendeira, Porto (PT)
12:54 - 13:01	Indications for longitudinal incision of the tunica for Peyronie's disease	A. Kadioglu, Istanbul (TR)
13:01 - 13:08	Ischemic priapism: Placement of the IPP at an early stage	C. Bettocchi, Foggia (IT)
13:08 - 13:17	Ischemic priapism: Placement of the IPP at a late stage/complications	D.J. Ralph, London (GB)
13:17 - 13:24	Ischemic priapism: Tips and tricks in diagnosis and treatment	D. Hatzichristou, Thessaloniki (GR)

13:24 - 13:28

Discussion

13:28 - 13:30

Conclusions

N. Sofikitis, Ioannina (GR)

Understanding tumour and patient biology for optimised treatment

Thematic Session

06 April 2024
10:30 - 12:00

Location Green Area, N04
Chairs L. Dyrskjøt, Aarhus (DK)
K. Junker, Homburg (DE)

10:30 - 10:34	Welcome and introduction
10:34 - 10:46	State-of-the-art lecture Perspectives of antibody-drug conjugates for specific tumour targeting: An overview P. Black, Vancouver (CA)
10:46 - 11:43	Tumour focused
10:46 - 10:56	Nectin-4—drug conjugates (in metastatic urothelial carcinomas): The right drug for everyone? N. Klümper, Bonn (DE)
10:56 - 11:06	Rationale of PARP inhibitors in combination with novel hormonal agents in PC: Do we still need BRCA testing? To be confirmed
11:06 - 11:16	miRNAs: New biomarkers for tailored treatment of testicular germ cell tumours? J. Lobo, Porto (PT)
11:16 - 11:26	Molecular imaging: From diagnostics to theranostics (general overview) W. Fendler, Essen (DE)
11:26 - 11:43	Discussion
11:43 - 11:55	State-of-the-art lecture The impact of aging on cancer progression and therapeutic response A. Gomes, Tampa (US)
11:55 - 12:00	Discussion

Benign prostatic hyperplasia and Female incontinence

Meeting of the EAU Section of Functional Urology (ESFU)

06 April 2024
10:30 - 13:30

Location Purple Area, S03
Chair F. Cruz, Porto (PT)

Learning objectives

The most prevalent conditions urologists involved in functional urology are Benign Prostatic Hyperplasia and Urinary Incontinence. BPH will be object of in-depth scrutiny including diagnosis, different forms of treatments and respective long term outcomes. The information will be applied in a debate of two cases. Urinary incontinence will be object of a lecture that will examine health policies in Europe. Artificial Urinary Sphincter use in men and women and Posterior Tibial Nerve Stimulation will also be addressed in the session.

10:30 - 10:35

Welcome and introduction

Moderators F. Cruz, Porto (PT)
To be confirmed

10:35 - 10:45

Female urinary incontinence in Europe

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

10:45 - 11:45

BPH Session: One treatment fits all or personalised medicine?

Moderators F. Cruz, Porto (PT)
To be confirmed

10:45 - 10:55

When do we need urodynamics to study a male patient with BPE and LUTS?

M. Tutolo, Milan (IT)

10:55 - 11:05

How can we anticipate we are pushing too far medical treatment, in monotherapy or combination?

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

11:05 - 11:15

Do we have long terms results to say that minimally invasive urethral stents came to age?

N. Mangir, Ankara (TR)

11:15 - 11:25

Rezum, aquablation or the good old TURP?

A.K. Nambiar, Newcastle-upon-Tyne (GB)

11:25 - 11:35

Doctor, tell me about the risk of incontinence after HOLEP vs. other forms of pro enucleation

T. Antunes Lopes, Porto (PT)

11:35 - 11:45

Why so many patients are on medical treatment after BPH/BPE surgery?

V. Phé, Paris (FR)

Case presentation with a debate

Moderator J. Heesakkers, Maastricht (NL)

11:45 - 11:50

Case 1

J. Heesakkers, Maastricht (NL)

11:50 - 11:55

Case 2

J. Heesakkers, Maastricht (NL)

11:55 - 12:15	Debate/discussion
12:15 - 13:00	ESFFU invites other Societies Moderators S. Arlandis, Valencia (ES) T. Tarcan, Üsküdar/ İstanbul (TR)
12:15 - 12:30	ICS lecture AUS and urinary incontinence: are we arriving to the end of gender discrimination? E. Chartier-Kastler, Paris (FR)
12:30 - 12:45	SUFU Lecture What is new in the treatment of BPS/IC? To be confirmed
12:45 - 13:00	SINUG Lecture Cognitive dysfunction with long term anticholinergic medication: Real or a hype? P. Blasco Hernández, Sevilla (ES) Debate Botulinum toxin A or posterior tibial nerve stimulation to treat incontinence in my multiple sclerosis patient? Moderators F.C. Burkhard, Bern (CH) E. Finazzi Agrò, Rome (IT)
13:00 - 13:10	Botulinum toxin A A. Apostolidis, Thessaloniki (GR)
13:10 - 13:20	Posterior tibial nerve stimulation K-D. Sievert, Detmold (DE)
13:20 - 13:25	Discussion
13:25 - 13:30	Closing remarks F. Cruz, Porto (PT)

Urinary tract and prostatic infections in the office and outpatient setting: A realistic guidance for everyday practice

Meeting of the EAU Section of Urologists in Office (ESUO)

06 April 2024
10:30 - 13:30

Location Green Area, W01
Chairs H. Brenneis, Pirmasens (DE)
F. Dimitriadis, Thessaloniki (GR)

Learning objectives

Urinary tract and prostatic infections (UTPIs) are the most frequent cause of office and outpatient clinic visits accounting for numerous hospitalizations. Distinguished clinical physicians and scientists joined forces to present a comprehensive resource guide to current diagnostic and treatment modalities for a broad spectrum of clinical issues relevant to UTPIs. State-of-the-art lectures on novel strategies such as the Artificial Intelligence guide antibiotic choice, low-risk pregnant women with UTIs, and the role of hygienic measures against COVID-19 on infective complications after urological interventions will be presented. Finally, the relationship between chronic prostatitis and male sexual function and fertility will be discussed.

10:30 - 10:33

Welcome and introduction

F. Dimitriadis, Thessaloniki (GR)

10:33 - 11:46

Urinary Tract Infections in the office and the outpatient setting

Moderators A. Zachariou, Ioannina (GR)
L.P. Zapala, Warsaw (PL)

10:33 - 10:46

State-Of-The-Art lecture: Can novel strategies guide antibiotic choice in recurrent UTIs and improve antimicrobial stewardship?
F.M.E. Wagenlehner, Giessen (DE)

10:46 - 10:56

Markers and most common pathogens of male genital infections
M. Benyó, Debrecen (HU)

10:56 - 11:06

UTIs in everyday urology practice: Practical guidance
J. Keehnen, Rotterdam (NL)

11:06 - 11:16

The real "face" of E.coli: Why it is so problematic to finally "kill" it!
A. Khelaia, Tbilisi (GE)

11:16 - 11:26

Catheter-associated urinary tract infections and how to handle
P. Tsafrakidis, Limassol (CY)

11:26 - 11:39

State-Of-The-Art lecture: Low-risk pregnant women with urinary tract infections. How to handle and what is the risk of preterm birth?
S.E. Geerlings, Amsterdam (NL)

11:39 - 11:46

Discussion

11:46 - 12:33

Chronic prostatitis in the office and the outpatient setting
Moderators M. Benyó, Debrecen (HU)
T.H. Kuru, Köln (DE)

11:46 - 11:56

Chronic prostatitis: Does it really exist and what can we do?
H. Brenneis, Pirmasens (DE)

- 11:56 - 12:06 **Sexual function consequences in patients with chronic prostatitis**
A. Zachariou, Ioannina (GR)
- Debate Does Evidence-Based Medicine suggest a connection between chronic prostatitis and male infertility?**
- 12:06 - 12:16 **Yes, there is a connection**
F. Dimitriadis, Thessaloniki (GR)
- 12:16 - 12:26 **No, there is no significant connection**
S. Minhas, London (GB)
- 12:26 - 12:33 **Discussion**
- 12:33 - 13:22 Infective complications in office-based urological interventions**
Moderators S.M. Haensel, Rotterdam (NL)
A. Verit, Istanbul (TR)
- 12:33 - 12:45 **State-Of-The-Art lecture: What is the role of hygienic measures against COVID-19 on infective complications after urological interventions?**
R. Bartoletti, Pisa (IT)
- 12:45 - 12:55 **Prostate biopsy: With or without antibiotic prophylaxis?**
T.H. Kuru, Köln (DE)
- 12:55 - 13:05 **Lowering the risk of infections in patients undergoing urologic procedures in the office setting**
L.P. Zapala, Warsaw (PL)
- 13:05 - 13:15 **UTI associated with stents, stones, or foreign bodies that cannot be urgently removed**
W. Krajewski, Wrocław (PL)
- 13:15 - 13:22 **Discussion**
- 13:22 - 13:29 Helmut Haas Award**
Moderator S.M. Haensel, Rotterdam (NL)
- 13:22 - 13:27 **Presentation of the award-winning work by the winner**
To be confirmed
- 13:27 - 13:30 **Closing remarks**
H. Brenneis, Pirmasens (DE)

Advancing urothelial cancer care: From molecular subtyping to enhanced imaging techniques

Abstract session 9

06 April 2024
10:30 - 12:00

Location Green Area, W03
Chairs S. Crabb, Southampton (GB)
T-X. Lin, Guangzhou (CN)
S.V. Lindsborg, Aarhus (DK)

10:30 - 10:32

Introduction

10:32 - 11:07

Improving diagnostic modalities in MIBC

A0143

The Optimal Way to Determine Kidney Function for Cisplatin-based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A European Association of Urology Young Academic Urologists Urothelial Cancer Working Group Multi-institutional Study

Authors: Pichler R.¹, Fritz J.², Mari A.³, Cadenar A.³, Von Deimling M.⁴, Del Giudice F.⁵, Leonardo C.⁵, Bologna E.⁵, Mori K.⁶, Rana T.⁷, De Santis M.⁷, Klatter T.⁷, Erber B.⁷, Lackner F.¹, Kronbichler A.⁸, Fisch M.⁴, Moschini M.⁹, Pradere B.¹⁰, Mertens L.S.¹¹

Institutes: ¹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Medical University of Innsbruck, Institute of Medical Statistics and Informatics, Innsbruck, Austria, ³University of Florence, Dept. of Experimental and Clinical Medicine Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁵Sapienza University of Rome Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ⁶The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁷Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ⁸Medical University of Innsbruck, Dept. of Internal Medicine IV, Innsbruck, Austria, ⁹IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ¹⁰La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands

A0158

MBC Trial – MRI before cystoscopy incorporating novel diffusion kurtosis imaging and tumour contact length

Authors: Shanmugasundaram R.¹, Palma C.¹, Ni K.¹, Song K.¹, Moses D.², De Silva S.³, Thompson J.¹

Institutes: ¹St George Hospital, Dept. of Urology, Sydney, Australia, ²University of NSW, School of Biomedical Engineering, Sydney, Australia, ³University of NSW, Faculty of Medicine, Sydney, Australia

- A0149** **Theranostics in chemotherapy resistant MIBC by instillation of FAP & CXCR4 radioligands into the bladder - the Bladder BRIDGister experience**
Authors: Wirtz R.¹, Kastner L.², Friedersdorff F.³, Schlomm T.⁴, Barski D.⁵, Otto T.⁵, Waldner M.⁶, Graff J.⁶, Veltrup E.¹, Linden F.¹, Schwandt M.¹, Hake R.⁷, Eidt S.⁷, Roggisch J.⁸, Rieger C.², Koch S.⁸, Klatte T.⁹, Ecke T.⁹, Heidenreich A.², Greifenstein L.¹⁰, Baum R.P.¹⁰
Institutes: ¹STRATIFYER Molecular Pathology GmbH, Dept. of Translational Science, Cologne, Germany, ²University Clinic Cologne, Dept. of Urology, Cologne, Germany, ³Evangelisches Krankenhaus Königin Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ⁵Rheinlandklinikum, Dept. of Urology, Neuss, Germany, ⁶St. Elisabeth Hospital, Dept. of Urology, Cologne, Germany, ⁷Institute of Pathology at the St. Elisabeth Hospital, Dept. of Urology, Cologne, Germany, ⁸Helios Hospital, Institute of Pathology, Bad Saarow, Germany, ⁹Helios Hospital, Dept. of Urology, Bad Saarow, Germany, ¹⁰Curanosticum Wiesbaden-Frankfurt, Theranostics, Wiesbaden, Germany
- A0150** **MRI-based machine learning radiomics for preoperative prediction of HER2 status in urothelial bladder carcinoma**
Authors: Lyu Q., Yang X., Cao Q., Yu R.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- A0142** **Quantitative MRI Parameters Providing the Novel Value in Discriminating Muscle-Invasive Bladder Cancer**
Authors: Yoshida S.¹, Kimura K.², Ikeda M.², Fukui K.², Tsuchiya J.², Nakamura Y.¹, Waseda Y.¹, Tanaka H.¹, Tateishi U.², Fujii Y.¹
Institutes: ¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Tokyo Medical and Dental University, Dept. of Diagnostic Radiology and Nuclear Medicine, Tokyo, Japan
- A0151** **Inclusion of apparent diffusion coefficient value in Vesical Imaging Reporting and Data System improves accuracy of diagnosis of muscle-invasive bladder cancer**
Authors: Lyu Q., Yang X., Cao Q., Liu P.
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- A0155** **Assessment of the value of frozen section analysis if the macroscopic appearance of the ureter is normal: Case-control study**
Authors: Kerroumi S.¹, Ouanezar C.O.¹, Lansari A.D.¹, Bazzi T.A.¹, Hafaf M.H.¹, Neuzillet Y.N.², Soorojebally Y.S.², Leuret T.L.², Yousfi M.D.Y.¹
Institutes: ¹Faculty of Medicine of Oran, Dept. of Urology, Oran, Algeria, ²Hospital Foch, Dept. of Urology, Paris, France
- 11:07 - 11:22** **Variant histologies of MIBC**

A0145

Molecular, immunohistochemical and clinical determinants of urothelial carcinoma of the bladder with nested subtype

Authors: Koll F.J.¹, Basar M.², Chen Z.³, Tin A.L.⁴, Alam S.M.⁵, Tallman J.E.⁵, Clinton T.N.⁵, Whiting K.⁴, Chen J.F.², Sarungbam J.², Sirintrapun S.J.², Gopalan A.², Chen Y-B.², Fine S.W.², Tickoo S.K.², Pietzak E.⁵, Iyer G.⁶, Rosenberg J.E.⁶, Bajorin D.F.⁶, Bochner B.H.⁵, Reuter V.E.², Gao S.P.⁷, Solit D.B.⁷, Al-Ahmadie H.²

Institutes: ¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Memorial Sloan Kettering Cancer Center, Dept. of Pathology, New York, United States of America, ³Weill Cornell Medicine, Physiology Biophysics and Systems Biology Program, New York, United States of America, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America, ⁵Memorial Sloan Kettering Cancer Center, Urology Service - Dept. of Surgery, New York, United States of America, ⁶Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, ⁷Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States of America

A0144

Squamous Metaplasia: A risk we should factor into bladder cancer follow up?

Authors: Leighton J., Holmes S., Nambiar A.

Institutes: Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom

A0153

Clinical characteristics and oncologic outcomes of bladder neuroendocrine carcinoma in a contemporary, multi-institutional cohort

Authors: Zaffuto E.¹, Leni R.², Pini G.M.³, Nicolini L.³, Gianazza S.⁴, Maragliano R.³, Franzi F.³, Famoso G.³, Capogrosso P.¹, Giancesini G.¹, Carcano G.⁴, Briganti A.², Montorsi F.², Colecchia M.⁵, Uccella S.³, Dehò F.¹

Institutes: ¹Ospedale di Circolo and Macchi Foundation Insubria University, Dept. of Urology, Varese, Italy, ²IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Division of Oncology, Unit of Urology, Milan, Italy, ³Ospedale di Circolo and Macchi Foundation Insubria University, Dept. of Pathology, Varese, Italy, ⁴Ospedale di Circolo and Macchi Foundation Insubria University, Dept. of Surgery, Varese, Italy, ⁵IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Dept. of Pathology, Milan, Italy

11:22 - 11:57

Refining the prognosis of MIBC

A0154

Evaluating the use of One-Step Nucleic Acid Amplification (OSNA) for detecting lymph node metastases in urothelial carcinoma of the bladder – First results of an ongoing, self-controlled study

Authors: Michalik B.¹, Engels S.¹, Dirks L.¹, Henke R.P.², Wawroschek F.¹, Winter A.¹

Institutes: ¹Carl von Ossietzky University Oldenburg, University Hospital for Urology, Oldenburg, Germany, ²Institute of Pathology Oldenburg, Oldenburg, Germany

A0157

Molecular subtyping for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients.

Authors: De Jong J.J.¹, Lotan Y.², Proudfoot J.³, Daneshmand S.⁴, Svatek R.⁵, Narayan V.⁶, Shreyas Subhash J.⁶, Li R.⁷, Inman B.⁸, Wright J.⁹, Shah P.¹⁰, Gibb E.¹¹

Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ³Veracyte, Dept. of Research and Development, San Francisco, United States of America, ⁴University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁵UT Health, Dept. of Urology, San Antonio, United States of America, ⁶Emory University, Dept. of Urology, Atlanta, United States of America, ⁷Moffitt Cancer Center, Dept. of Urology, Tampa, United States of America, ⁸Duke University, Dept. of Urology, North Carolina, United States of America, ⁹University of Washington, Dept. of Urology, Washington, United States of America, ¹⁰Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹¹Veracyte, Bladder Cancer Program, Vancouver, Canada

A0152

The prognostic significance of the presence of Lead, Cadmium, Aluminum and Zinc and expression of FGFR3, GATA3 and Cytokeratin 5/6 markers in bladder cancer tissue

Authors: Ali-El-Dein B.¹, Abdelrahim M.¹, Elkady M.E.¹, Mortada W.I.¹, Zakaria M.M.¹, Tarabay H.H.¹, Gomaa I.M.¹, Atteya M.¹, Elgamal M.¹, Mosbah A.¹, Attia A.¹, Abdelgawad M.²

Institutes: ¹Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Dept. of Urology, Mansoura, Egypt, ²Toshka Urology and Endoscopy Center, Dept. of Urology, Mansoura, Egypt

A0146

Prognostic Influence of Preoperative Plasma Levels of Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) on Disease Outcomes Following Radical Cystectomy

Authors: Oberneder K.¹, Klemm J.², Schuetfort V.², Laukhtina E.¹, Shariat S.F.¹

Institutes: ¹Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0156

The stroma-rich consensus bladder cancer subtype correlates with improved prognosis after neoadjuvant immunotherapy and radical cystectomy

Authors: De Jong J.J.¹, Reike M.², Szabados B.³, Hakansson A.⁴, Necchi A.⁵, Powles T.⁶, Gibb E.⁷

Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Marien Hospital Herne, Dept. of Urology, Herne, Germany, ³Barts Cancer Institute, Dept. of Urology, London, United Kingdom, ⁴Veracyte, Dept. of Research and Development, San Francisco, United States of America, ⁵Ospedale San Raffaele, Dept. of Medical Oncology, San Raffaele, Italy, ⁶Barts Cancer Institute, Dept. of Medical Oncology, London, United Kingdom, ⁷Veracyte, Bladder Cancer Program, Vancouver, Canada

A0147

Positive ctDNA Status Before Radical Cystectomy Predicts Lymph Node Status and Pathological Upstaging

Authors: Ben David R.¹, Cumarasamy S.¹, Alerasool P.², Neeraja T.¹, Joran R.¹, Galsky M.³, Kaufmann B.¹, Kyrollis A.¹, Mehrazin R.¹, Wiklund P.¹, Sfakianos J.¹

Institutes: ¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²New York Medical College, School of Medicine, New York, United States of America, ³Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, United States of America

A0148

Development and validation of a highly specific digital PCR test using hypermethylated circulating tumor DNA in invasive urothelial carcinoma

Authors: Prost D.¹, Haberstick M.², Lavollé A.³, Taly V.⁴, Laurent-Puig P.², Beinse G.⁵, Thibault C.², Audenet F.⁶

Institutes: ¹St Joseph Hospital, Dept. of Urology, Paris, France, ²European Hospital Georges Pompidou, Dept. of Oncology, Paris, France, ³Hospital Andre Mignot, Dept. of Urology, Versailles, France, ⁴Cordeliers Research Center, Dept. of Personalized Medicine, Paris, France, ⁵Cochin Hospital, Dept. of Oncology, Paris, France, ⁶European Hospital Georges Pompidou, Dept. of Urology, Paris, France

11:57 - 12:00

Expert summary

Innovations and challenges in the management of urological infections

EGPT 4

06 April 2024
10:30 - 12:00

Location	EGPT
Chairs	To be confirmed
	To be confirmed
	To be confirmed

10:30 - 10:42

Screen A: Basic research

P093

The postmenopausal urinary metabolome is associated with recurrent UTI and urobiome ecology.

Authors: Neugent M.¹, Hulyalkar N.¹, Lutz K.², Li Q.³, Zimmern P.⁴, Shulaev V.⁵, De Nisco N.¹

Institutes: ¹The University of Texas at Dallas, Dept. of Biological Sciences, Richardson, United States of America, ²The University of Texas Southwestern Medical Center, Peter O'Donnel Jr. School of Public Health, Dallas, United States of America, ³The University of Texas at Dallas, Dept. of Mathematical Sciences, Richardson, United States of America, ⁴The University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁵The University of North Texas, Dept. of Biological Sciences, Denton, United States of America

P094

Associations between potential renal acid load and urine PH in postmenopausal women with recurrent UTI

Authors: Chavez J.C.¹, Williams K.², Shah A.², Christie A.L.³, Zimmern P.E.²

Institutes: ¹Healthy Lifestyles Healthy Futures, Dept. of Nutritional Services, Knoxville, United States of America, ²University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ³University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center Biostatistics, Dallas, United States of America

P092

Identification of urinary cytokines to distinguish between asymptomatic bacteriuria and urinary tract infection

Authors: Basu U.¹, Ebrahimzadeh T.¹, Zimmern P.E.², De Nisco N.J.¹

Institutes: ¹The University of Texas at Dallas, Dept. of Biological Sciences, Richardson, United States of America, ²The University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

P095

Tissue distribution of Ceftazidime-Avibactam in kidney tissue in healthy rats and pigs using a microdialysis technique.

Authors: Vallée M.¹, Moreau J.², Lamarche I.², Barc C.³, Kasal-Hoc N.³, Mirfendereski H.², Aranzana-Climent V.², Couet W.², Cazenave-Roblot F.⁴, Marchand S.²

Institutes: ¹Poitiers University Hospital, Dept. of Urology and Kidney Transplantation, Poitiers, France, ²Poitiers University, Inserm U1070 PHAR2, Poitiers, France, ³INRAE Centre Val de Loire, UE1277 Experimental Infectiology Platform, Nouzilly, France, ⁴Poitiers University Hospital, Dept. of Infectious Disease, Poitiers, France

10:42 - 11:00

Screen B: Markers

- P113** **Association between elevated plasma thrombin-antithrombin complex levels and severe acute kidney injury development in urological sepsis**
Authors: Fujita N.¹, Momota M.M.¹, Soma O.S.¹, Noro D.N.¹, Yoneyama T.Y.¹, Hashimoto Y.H.¹, Yoshikawa K.Y.², Ohyama C.O.¹, Hatakeyama S.H.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Mutsu General Hospital, Dept. of Urology, Mutsumi, Japan
- P112** **Endothelial glycocalyx injury is a risk factor for disseminated intravascular coagulation development in urological sepsis**
Authors: Fujita N.¹, Tobisawa Y.T.², Yoneyama T.Y.¹, Momota M.M.¹, Soma O.S.¹, Noro D.N.¹, Yoneyama T.Y.¹, Hashimoto Y.H.¹, Yoshikawa K.Y.³, Ohyama C.O.¹, Hatakeyama S.H.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University Hospital, Dept. of Urology, Gifu, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsumi, Japan
- P114** **Comparison of qSOFA score and SIRS criteria for assessing the risk for severe acute kidney injury development and mortality in febrile urinary tract infection**
Authors: Fujita N.¹, Momota M.M.¹, Soma O.S.¹, Noro D.N.¹, Ito H.I.², Yoneyama T.Y.¹, Hashimoto Y.H.¹, Yoshikawa K.Y.³, Ohyama C.O.¹, Hatakeyama S.H.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsumi, Japan
- P117** **Persistently elevated urinary inflammatory biomarkers may predict recurrence of recurrent urinary tract infection in women**
Authors: Jiang Y-H., Jhang J.F., Chang T-L., Liu M-C., Yang C.C., Kuo H.C.
Institutes: Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan
- P091** **Prediction of urinary tract infection combining sysmex UF-5000I urine fluorescence flow cytometry with urinalysis – a single center study in Vietnam**
Authors: Trang V.A.V.¹, Truyen T.T.T.², Tran N.T.U.³, Tran N.H.U.³, Dinh T.K.H.³, Huynh T.T.³, Le H.G.³, Huynh V.T.V.³, Nguyen H.T.A.³, Ho D.B.H.³, Le T.B.N.³, Tu M.N.³, Hong T.K.N.³, Huynh T.T.³, Lieu P.T.³, Huynh N.L.³, Dang T.B.N.³, Nguyen T.H.D.², Nguyen M.T.², Doan D.T.³, Nguyen P.C.H.¹, Tran V.H.¹
Institutes: ¹Pham Ngoc Thach University of Medicine, Faculty of Medicine, Ho Chi Minh, Vietnam, ²Nam Can Tho University, Faculty of Medicine, Can Tho, Vietnam, ³Binh Dan Hospital, Laboratory, Ho Chi Minh, Vietnam

- P097** **Plasma hyaluronan levels predict major adverse cardiovascular events in urological sepsis**
Authors: Momota M.¹, Fujita N.¹, Tobisawa Y.², Yoneyama T.³, Soma O.¹, Noro D.¹, Ito H.⁴, Yoshikawa H.⁵, Ohyama C.¹, Hatakeyama S.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, ³Hirosaki University Graduate School of Medicine, Dept. of Glycotechnology, Center for Advanced Medical Research, Hirosaki, Japan, ⁴Aomori Rosai Hospital Hachinohe Japan, Dept. of Urology, Hachinohe, Japan, ⁵Mutsu General Hospital, Dept. of Urology, Mutsu, Japan
- 11:00 - 11:12** **Screen C: Diagnosis**
- P107** **Comparing the accuracy of UTISA and ACSS questionnaires in diagnosing acute uncomplicated cystitis in women**
Authors: Chou Y.J., Yang S.S.D.
Institutes: Taipei Tzu Chi Hospital, Division of Urology, New Taipei City, Taiwan
- P110** **Bacteriuria and urosepsis in patients with stented ureters: predictors of infection & when not to treat**
Authors: Batura D.¹, Elswefy M.¹, Chouhan R.², Bassett P.³, Gopal Rao G.²
Institutes: ¹London North West University Hospitals NHS Trust London, Dept. of Urology, London, United Kingdom, ²London North West University Hospitals NHS Trust London, Dept. of Microbiology, London, United Kingdom, ³Statsconsultancy Ltd, Dept. of Medical Statistics, Amersham, United Kingdom
- P115** **Why underrepresentation costs lives: First results from a high-volume multi-institutional study in Germany about risk factors for mortality in Fournier gangrene**
Authors: Rieger C.¹, Hübers M.¹, Pfister D.¹, Schleifer S.², Hirsch J.², Kranz J.³, Gerdes B.⁴, Pantea V.⁵, Chachin A.⁵, Träger M.⁶, Glienke M.⁶, Henniges P.⁷, Vetterlein M.W.⁸, Klemm J.⁸, Roghmann F.⁹, Dellino M.⁹, Jany U.¹⁰, Tylingr M.¹¹, Al Assali K.¹², Patroi P.¹³, Mayr R.¹⁴, Engelmann S.¹⁴, Schneidewind L.¹⁵, Heidenreich A.¹
Institutes: ¹University of Cologne, Dept. of Urology, Cologne, Germany, ²University of Augsburg, Dept. of Urology, Augsburg, Germany, ³University Hospital RWTH Aachen, Dept. of Urology, Aachen, Germany, ⁴Charité-Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ⁵University Hospital Essen, Dept. of Urology, Essen, Germany, ⁶University of Freiburg, Dept. of Urology, Freiburg, Germany, ⁷University Hospital Göttingen, Dept. of Urology, Göttingen, Germany, ⁸University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁹Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ¹⁰Medical School University of Leipzig, Dept. of Urology, Leipzig, Germany, ¹¹University Hospital Schleswig-Holstein Campus Lübeck, Dept. of Urology, Lübeck, Germany, ¹²University Hospital Magdeburg, Dept. of Urology, Magdeburg, Germany, ¹³University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ¹⁴Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹⁵University Medical Center Rostock, Dept. of Urology, Rostock, Germany
-

- P102** **Reduction of antibiotic use around prostatic biopsy in a prostate cancer network**
Authors: Bangma C.H.¹, Rietbergen J.², Klaver S.³, Busstra M.¹, Planken E.⁴, Pelger R.⁵, Andel van G.⁶, Aussems P.⁷, Venderbos L.¹, Borggreven N.¹, Raaymakers R.⁸, Merks B.⁹
Institutes: ¹Erasmus University Medical Centre, Dept. of Urology, Rotterdam, The Netherlands, ²Franciscus Gasthuis, Dept. of Urology, Rotterdam, The Netherlands, ³Maasstadziekenhuis, Dept. of Urology, Rotterdam, The Netherlands, ⁴Admiraal de Ruyter Ziekenhuis, Dept. of Urology, Goes, The Netherlands, ⁵Leiden University Medical Centre, Dept. of Urology, Leiden, The Netherlands, ⁶Onze Lieve Vrouwe Gasthuis, Dept. of Urology, Amsterdam, The Netherlands, ⁷Reinier de Graaf Gasthuis, Dept. of Urology, Delft, The Netherlands, ⁸Albert Schweizer Ziekenhuis, Dept. of Urology, Dordrecht, The Netherlands, ⁹Haaglanden Medisch Centrum, Dept. of Urology, Den Haag, The Netherlands
- 11:12 - 11:24** **Screen D: Screening**
- P104** **Asymptomatic Bacteriuria prior to Partial and Radical nephrectomy: To screen or not to screen?**
Authors: Ayoub E.¹, Kutchukian S.¹, DINH A.², Bigot P.³, Robin H.¹, Bernardeau S.¹, DUCOUSSO H.¹, Gondran-Tellier B.⁴, Françot M.⁵, DE VERGIE S.⁵, Chapuis M.⁶, Bureau L.⁶, Lechevallier E.⁴, Poussot B.⁷, Borojeni S.⁸, Kosseifi F.⁸, Gaullier M.⁷, Thibault T.⁷, Baboudjian M.⁴, Rigaud J.⁵, Karray O.⁹, DESCAZEAUD A.¹⁰, Bruyère F.¹¹, Vallée M.¹
Institutes: ¹Poitiers University Hospital, Dept. of Urology, Poitiers, France, ²Garches Hospital, Dept. of Infectious Disease, Paris, France, ³Angers university hospital, Dept. of Urology, Angers, France, ⁴Aix-Marseille University Hospital, Dept. of Urology, Aix-Marseille, France, ⁵Nantes University Hospital, Dept. of Urology, Nantes, France, ⁶Guadeloupe University Hospital, Dept. of Urology, Pointe-à-Pitre, France, ⁷Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ⁸Saint Joseph hospital, Dept. of Urology, Paris, France, ⁹Pontoise Hospital, Dept. of Urology, Pontoise, France, ¹⁰Limoges University Hospital, Dept. of Urology, Limoges, France, ¹¹Tours University Hospital, Dept. of Urology, Tours, France
- P109** **The prevalence and genotype distribution of Human Papillomaviruses among Korean females**
Authors: Jo S.B., Kim H.J., Hwang W.K., Lee H.S., Ahn S.T., Kim J.W., Oh M.M., Park H.S., Moon D.G.
Institutes: Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea
- P108** **The prevalence and genotype distribution of Human Papillomaviruses among Men in Korea**
Authors: Jo S.B., Kim H.J., Hwang W.K., Lee H.S., Ahn S.T., Kim J.W., Oh M.M., Park H.S., Moon D.G.
Institutes: Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea
- P116** **Reducing infectious complications after transrectal prostate biopsy: significance of rectal swab ESBL/MRGN screening and tailored antibiotic treatment**
Authors: Ortner G., Fritz V., Schachtner J., Nagele U., Tokas T.
Institutes: LKH Hall, Dept. of Urology, Hall in Tirol, Austria

11:24 - 11:39

Screen E: Miscellaneous

P103

Catheter Associated Urinary Tract Infections-Online questionnaire (CAUTI-On): status quo in central European urological care

Authors: Bausch K.¹, Arbelaez E.¹, Zünti I.¹, Tschudin Sutter S.², Halbeisen F.S.³, Seifert H.H.¹

Institutes: ¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²University Hospital Basel, Dept. of Infectious Disease, Basel, Switzerland, ³University Hospital Basel, Dept. of Clinical Epidemiology, Basel, Switzerland

P098

Radiomics analysis using non-contrast computed tomography for predicting HDU admission in patients with acute pyelonephritis

Authors: Horie T., Fujiwara M., Hasegawa A., Kimura T., Suzuki K., Tanaka H., Ito T., Yasujima R., Ikeda R., Matsumoto S., Yoshitomi K., Kobayashi M., Nakamura Y., Chen W., Fan B., Ishikawa Y., Fukuda S., Waseda Y., Tanaka H., Yoshida S., Fujii Y.

Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

P119

Real time urinary tract infection diagnosis and antimicrobial susceptibility testing within <90 Minutes

Authors: Halachmi S.¹, Sprints S.¹, Jiang X.², Borkum T.², Massad-Ivanir N.², Segal E.²

Institutes: ¹Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, ²Technion Israeli Institute of Technology, Dept. of Biotechnology and Food Engineering, Haifa, Israel

P105

Quality of information and appropriateness of Open AI outputs for urinary tract infections

Authors: Romagnoli M., Riolo S., Santoro G., Lombardo R., Tema G., Nacchia A., Guarnotta G., Cicione A., Pastore A., Al Salhi Y., Carbone A., Franco G., Sciarra A., Tubaro A., De Nunzio C.

Institutes: Sapienza University of Rome, Dept. of Urology, Rome, Italy

P096

Propolis - a natural material for antimicrobial and anti-encrustation coating on ureteral stents

Authors: Yang L., Zhao Y., Chen G., Yushanjiang S.

Institutes: West China Forth Hospital, Dept. of Urology Pelvic Surgery and Andrology, Chengdu, China

11:39 - 12:00

Screen F: Complications

P106

Assessing the Influence of Recurrent Urinary Tract Infections on Sexual Function: A case-control study

Authors: Medina-Polo J.¹, Guntinas-Castillo A.², Calzas-Montalvo C.¹, Caro-González M.A.D.P.¹, Arrébola-Pajares A.¹, Juste-Álvarez S.¹, de la Calle-Moreno A.¹, Romero-Otero J.³, Rodríguez-Antolín A.¹

Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²HM Hospitals, Dept. of Gynecology, Madrid, Spain, ³HM Hospitals and ROC Clinic, Dept. of Urology, Madrid, Spain

P118

Pathogen Species Are the Risk Factors for Postoperative Infection of Patients with Transurethral Resection of the Prostate: A Retrospective Study

Authors: Lin J.¹, Yang Z.¹, Fu H.², Ye L-F.¹

Institutes: ¹Fujian Provincial Hospital, Dept. of Urology, Fuzhou, China, ²Fujian Provincial Hospital, Clinical Laboratory, Fuzhou, China

- P111** **Role of serum immunoglobulin N-glycans in endothelial glycocalyx injury in urological sepsis**
Authors: Fujita N.¹, Yoneyama T.Y.¹, Tobisawa Y.T.², Momota M.M.¹, Soma O.S.¹, Noro D.N.¹, Yoneyama T.Y.¹, Hashimoto Y.H.¹, Ohyama C.O.¹, Hatakeyama S.H.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University Hospital, Dept. of Urology, Gifu, Japan
- P100** **Comparison of Urinary Tract Infection Rates with and without Prophylactic Antibiotics in Transperineal Prostate Biopsy: An Updated Systematic Review and Meta-Analysis**
Authors: Jun D.Y.¹, Jeong J.Y.², Moon Y.J.³, Cho S.⁴, Lee J.Y.¹, Jung H.D.⁴
Institutes: ¹Severance Hospital. Urological Science Institute. Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²National Health Insurance Service Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ³Kyungpook National University Hospital, Dept. of Urology, Daegu, South Korea, ⁴Inje University Ilsan Paik Hospital, Dept. of Urology, Goyang, South Korea
- P101** **The impact of exposure to ileal feces during intracorporeal urinary diversion: cultivable microbiota of the distal ileum**
Authors: Zennami K.¹, Nukaya T.¹, Ishikawa K.², Takenaka M.¹, Ichino M.¹, Takahara K.¹, Sasaki H.¹, Kusaka M.³, Sumitomo M.¹, Shiroki R.¹
Institutes: ¹Fujita Health University, Dept. of Urology, Toyoake, Japan, ²Fujita Health University Bantane Hospital, Dept. of Urology, Nagoya, Japan, ³Fujita Health University Okazaki Medical Center, Dept. of Urology, Okazaki, Japan
- P099** **Antimicrobial Prophylaxis in Robot assisted laparoscopic radical Prostatectomy: A Systematic Review**
Authors: Falkensammer E.¹, Erenler E.², Bjerklund Johansen T.E.³, Tzelvels L.⁴, Schneidewind L.S.⁵, Yuan Y.Y.⁶, Koves B.K.⁷, Tandogdu Z.T.⁸
Institutes: ¹Klinikum Wels-Grieskirchen GmbH, Dept. of Urology, Wels, Austria, ²Koç University, Istanbul, Türkiye, ³University of Oslo, Dept. of Urology, Oslo, Norway, ⁴National and Kapodistrian University of Athens Sismanogleio General Hospital, Dept. of Urology, Athens, Greece, ⁵University Greifswald, Dept. of Urology, Greifswald, Germany, ⁶McMaster University, Health Sciences Centre, Ontario, Canada, ⁷South-Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ⁸University College London Hospitals, Dept. of Urology, London, United Kingdom
- P090** **Analysis of Urinary Tract Infections (UTI) complications after Radical Cystectomy: Results from a single center study and Improvement of ERAS protocol**
Authors: Lorusso V.¹, Le Quellec A.¹, Rion C.¹, Pacchetti A.¹, Doisy L.¹, Lannes F.¹, Sypre D.¹, Branger N.¹, Maubon T.¹, Rybikowski S.¹, Granata A.M.², Gregori A.², Pignot G.¹, Walz J.¹
Institutes: ¹Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ²ASST Fatebenefratelli-Sacco Hospitals, Dept. of Urology, Milan, Italy
-

EAU Policy Office: PRAISE U project on early detection of PCa - what U need to know

Thematic Session

06 April 2024
10:45 - 12:15

Location
Chairs

Purple Area, eURO Auditorium 2
P. Albers, Düsseldorf (DE)
H. Van Poppel, Leuven (BE)

10:45 - 11:00	State of play of PCa early detection across the EU including the new European Joint Action on Cancer Screening M.J. Roobol, Rotterdam (NL)
11:00 - 11:10	Results of European needs assessment: What countries require in terms of early detection R.C.A. Leenen, Rotterdam (NL)
11:10 - 11:20	Tailoring success: Strategies for prostate cancer screening implementation across diverse health systems in Europe A. Chandran, Lyon (FR)
11:20 - 11:40	Piloting early detection programmes: The opportunities and challenges A. Patasius, Vilnius (LT) M. Otero Garcia, Vigo (ES)
11:40 - 11:50	The importance of data needed to inform cancer early detection policy: The Czech experience O. Majek, Brno (CZ)
11:50 - 12:00	What role for the EAU Evidence Hub? P. Cornford, Liverpool (GB)
12:00 - 12:10	Joining the dots from diagnosis to treatment: Update from EU initiatives on comprehensive cancer centres T. Albrecht, Ljubljana (SI)
12:10 - 12:15	Session take home messages P. Albers, Düsseldorf (DE) H. Van Poppel, Leuven (BE)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.09

06 April 2024
11:00 - 11:55

Location Orange Area, HOT 1

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.10

06 April 2024
11:00 - 11:55

Location Orange Area, HOT 1

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.11

06 April 2024
11:00 - 11:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in prostate MRI reading for urologists

HOT 2.29

06 April 2024
09:30 - 13:00

Location Orange Area, HOT 5
Chair V. Kasivisvanathan, London (GB)

Learning objectives

The MRI Reading Course is designed as a half-day or full-day live or online training.

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

09:30 - 09:35

Course Overview

V. Kasivisvanathan, London (GB)

09:35 - 09:45

Lecture: The importance of prostate MRI to the Urologist

V. Kasivisvanathan, London (GB)

09:45 - 10:15

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

M. Pecoraro, Rome (IT)

10:15 - 10:45

Lecture: Interactive case discussion – reporting MRI using PI-RADS

To be confirmed

10:45 - 10:50

Introduction to the software for MRI interpretation

J. Walz, Marseille (FR)

10:50 - 11:20

Diagnosis I: Practical MRI diagnosis

11:20 - 11:50

Review of the findings I

M. Pecoraro, Rome (IT)

11:50 - 12:20

Diagnosis II: Practical MRI diagnosis

12:20 - 12:50

Review of the findings II

To be confirmed

12:50 - 13:00

Discussion, feedback, & closure

J. Walz, Marseille (FR)

Hands-on Training in Prostate MRI reading for urologists

HOT 2.30

06 April 2024
15:15 - 18:45

Location Orange Area, HOT 5
Chair V. Kasivisvanathan, London (GB)

Learning objectives

The MRI Reading Course is designed as a half-day or full-day live or online training.

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

15:15 - 15:20

Course Overview

15:20 - 15:30

Lecture: The importance of prostate MRI to the Urologist

15:30 - 16:00

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

M. De Rooij, Nijmegen (NL)

16:00 - 16:30

Lecture: Interactive case discussion – reporting MRI using PI-RADS

F. Giganti, London (GB)

16:30 - 16:35

Introduction to the software for MRI interpretation

V. Kasivisvanathan, London (GB)

16:35 - 17:05

Diagnosis I: Practical MRI diagnosis

J. Gómez Rivas, Madrid (ES)

17:05 - 17:35

Review of the findings I

M. De Rooij, Nijmegen (NL)

17:35 - 18:05

Diagnosis II: Practical MRI diagnosis

J. Gómez Rivas, Madrid (ES)

18:05 - 18:35

Review of the findings II

F. Giganti, London (GB)

18:35 - 18:45

Discussion, feedback, & closure

Hands-on Training in Prostate MRI reading for urologists

HOT 3.37

07 April 2024
09:00 - 12:30

Location Orange Area, HOT 5
Chair F. Sanguedolce, Barcelona (ES)

Learning objectives

The MRI Reading Course is designed as a half-day or full-day live or online training.

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

09:00 - 09:05

Course Overview

F. Sanguedolce, Barcelona (ES)

09:05 - 09:15

Lecture: The importance of prostate MRI to the Urologist

F. Sanguedolce, Barcelona (ES)

09:15 - 09:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

J.A. Hernández Mancera, Barcelona (ES)

09:45 - 10:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

V. Panebianco, Rome (IT)

10:15 - 10:20

Introduction to the software for MRI interpretation

C.V. Kesch, Essen (DE)

10:20 - 10:50

Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

Review of the findings I

J.A. Hernández Mancera, Barcelona (ES)

11:20 - 11:50

Diagnosis II: Practical MRI diagnosis

11:50 - 12:20

Review of the findings II

V. Panebianco, Rome (IT)

12:20 - 12:30

Discussion, feedback, & closure

C.V. Kesch, Essen (DE)

Hands-on Training in Prostate MRI reading for urologists

HOT 4.02

08 April 2024
09:00 - 12:30

Location Orange Area, HOT 5
Chair To be confirmed

Learning objectives

The MRI Reading Course is designed as a half-day or full-day live or online training.

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

09:00 - 09:05

Course Overview

To be confirmed

09:05 - 09:15

Lecture: The importance of prostate MRI to the Urologist

To be confirmed

09:15 - 09:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

J.A. Hernández Mancera, Barcelona (ES)

09:45 - 10:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

V. Panebianco, Rome (IT)

10:15 - 10:20

Introduction to the software for MRI interpretation

To be confirmed

10:20 - 10:50

Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

Review of the findings I

J.A. Hernández Mancera, Barcelona (ES)

11:20 - 11:50

Diagnosis II: Practical MRI diagnosis

11:50 - 12:20

Review of the findings II

V. Panebianco, Rome (IT)

12:20 - 12:30

Discussion, feedback, & closure

To be confirmed

Hands-on Training in Urodynamics

HOT 2.28

06 April 2024
15:15 - 18:15

Location Orange Area, HOT 3
Chair A. Garcia Mora, Mexico City (MX)

Learning objectives

Description:

This Hands-on Training is designed for participants to improve their skills in urodynamics, with an emphasis on practical aspects. Participants will have the opportunity to practice each step of the UDS procedure, including set up, running a test, troubleshooting, and interpretation.

Training aim

The primary objective of this course is to enhance participants' skills in urodynamics, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in UDS procedures.

15:15 - 15:35

Introduction

A. Garcia Mora, Mexico City (MX)

15:35 - 15:55

Hands-on Training: Rotation

A. Gammie, Bristol (GB)

15:55 - 16:25

Setting Up

A. Gammie, Bristol (GB)

16:25 - 16:55

Running a test

P. Geretto, torino (IT)

16:55 - 17:15

Hands-on Training: Rotation

17:15 - 17:45

Troubleshooting

To be confirmed

17:45 - 18:15

Interpretation

C. Ochoa Vargas, Bristol (GB)

Hands-on Training in Urodynamics

HOT 3.34

07 April 2024
10:00 - 13:00

Location Orange Area, HOT 3
Chair A. Garcia Mora, Mexico City (MX)

Learning objectives

Description:

This Hands-on Training is designed for participants to improve their skills in urodynamics, with an emphasis on practical aspects. Participants will have the opportunity to practice each step of the UDS procedure, including set up, running a test, troubleshooting, and interpretation.

Training aim

The primary objective of this course is to enhance participants' skills in urodynamics, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in UDS procedures.

10:00 - 10:20

Introduction

A. Garcia Mora, Mexico City (MX)

10:20 - 10:40

Hands-on Training: Rotation

10:40 - 11:10

Setting Up

A. Gammie, Bristol (GB)

11:10 - 11:40

Running a test

F. Cancrini, Rome (IT)

11:40 - 12:00

Hands-on Training: Rotation

12:00 - 12:30

Troubleshooting

L. Thomas, Bristol (GB)

12:30 - 13:00

Interpretation

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

Hands-on Training in PSMA/PET image reading for urologists

HOT 1.18

05 April 2024
13:00 - 16:30

Location Orange Area, HOT 5

Learning objectives

The Hands-on Training in PSMA/PET image reading for urologists provides training in PET imaging for prostate cancer with an emphasis on PSMA. The course aims to help urologists understand the role PET imaging plays in the management of patients with prostate cancer and how to interpret the images. The training addresses how prostate PET imaging works, what different tracers might be used for prostate cancer, and how to use the information generated by PET (i.e. in clinical decision making or modifying management of patients). The course will cover initial staging, staging at recurrence, and the use of PET imaging for radioligand treatment. The current limitations and pitfalls of PET imaging will be critically assessed and discussed.

Training aim

The primary objective of this course is to develop practical skills needed to implement PSMA/PET into practice.

13:00 - 13:10	Importance of PSMA/PET imaging to the Urologist and introduction to the course To be confirmed
13:10 - 13:25	Overview of PET-tracers and radioligands To be confirmed
13:25 - 13:40	Principles of PET reading in Prostate Cancer To be confirmed
13:40 - 13:55	Current data on PET imaging in newly diagnosed prostate cancer To be confirmed
13:55 - 14:15	Review of PSMA/PET images for initial prostate cancer staging To be confirmed
14:15 - 14:25	Discussion of Role of PSMA/PET for initial staging To be confirmed
14:25 - 14:40	Current data on PET imaging in recurrent prostate cancer To be confirmed
14:40 - 15:20	Review of PSMA/PET images of prostate cancer recurrence To be confirmed
15:20 - 15:30	Discussion of Role of PSMA/PET for Recurrence F. Sanguedolce, Barcelona (ES)
15:30 - 15:45	Current data on the role of PET imaging for selection of radioligand therapy To be confirmed
15:45 - 16:05	Review of PSMA/PET images of advanced prostate cancer To be confirmed
16:05 - 16:15	Discussion of Role of PSMA/PET and radioligand therapy for advanced disease F. Sanguedolce, Barcelona (ES)

16:15 - 16:25

Pitfalls and limitations of PSMA/PET

To be confirmed

16:25 - 16:30

Summary and Close

F. Sanguedolce, Barcelona (ES)

Hands-on Training in Urological ultrasound

HOT 3.33

07 April 2024
14:00 - 17:00

Location	Orange Area, HOT 3
Chairs	P. Martino, Bari (IT) V. Scattoni, Milan (IT)
Tutors	To be confirmed C.B. Maccagnano, Milan (IT)

Learning objectives

Description:

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

Training aim

- Understanding standard operating procedures
- Proficiency in imaging techniques
- Identification of normal anatomy
- Recognition of pathological findings
- Integration of innovative ultrasound technologies
- Practical hands-on experience

14:00 - 14:05

Introduction

P. Martino, Bari (IT)

14:05 - 14:20

Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder

V. Scattoni, Milan (IT)

14:20 - 14:40

Innovative ultrasound of the kidney and bladder: Normal and pathological findings

A.B. Galosi, Ancona (IT)

14:40 - 15:00

Standard operating procedure for ultrasound examination genital organs: Prostate and testis

P. Martino, Bari (IT)

15:00 - 15:15

Innovative ultrasound of prostate and testis: Normal and pathological findings

T. Loch, Flensburg (DE)

15:15 - 17:00

Hands-on Training: Kidney and bladder / Prostate & testis

Hands-on Training in Urological ultrasound

HOT 4.01

08 April 2024
09:30 - 12:30

Location Orange Area, HOT 3
Chairs P. Martino, Bari (IT)
V. Scattoni, Milan (IT)
Tutors To be confirmed
C.B. Maccagnano, Milan (IT)

Learning objectives

Description:

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

Training aim

- Understanding standard operating procedures
- Proficiency in imaging techniques
- Identification of normal anatomy
- Recognition of pathological findings
- Integration of innovative ultrasound technologies
- Practical hands-on experience

09:30 - 09:35

Introduction

P. Martino, Bari (IT)

09:35 - 09:50

Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder

V. Scattoni, Milan (IT)

09:50 - 10:10

Innovative ultrasound of the kidney and bladder: Normal and pathological findings

To be confirmed

10:10 - 10:30

Standard operating procedure for ultrasound examination genital organs: Prostate and testis

P. Martino, Bari (IT)

10:30 - 10:45

Innovative ultrasound of prostate and testis: Normal and pathological findings

T. Loch, Flensburg (DE)

10:45 - 12:30

Hands-on Training: Kidney and bladder / Prostate & testis

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.13

07 April 2024
11:00 - 11:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.18

07 April 2024
14:00 - 14:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.23

07 April 2024
15:00 - 15:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.28

07 April 2024
16:00 - 16:55

Location Orange Area, HOT 1

Learning objectives

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

E-BLUS Exam

HOT 3.16

**07 April 2024
14:00 - 14:30**

Location

Orange Area, HOT 1

E-BLUS

HOT 3.20

07 April 2024
14:30 - 15:00

Location

Orange Area, HOT 1

E-BLUS

HOT 3.21

07 April 2024
15:00 - 15:30

Location

Orange Area, HOT 1

E-BLUS Exam

HOT 3.25

**07 April 2024
15:30 - 16:00**

Location

Orange Area, HOT 1

E-BLUS Exam

HOT 3.26

**07 April 2024
16:00 - 16:30**

Location

Orange Area, HOT 1

E-BLUS Exam

HOT 3.30

**07 April 2024
16:30 - 17:00**

Location

Orange Area, HOT 1

ESTs1 Exam

HOT 3.17

07 April 2024
14:00 - 14:55

Location

Orange Area, HOT 1

ESTs1 Exam

HOT 3.22

07 April 2024
15:00 - 15:50

Location

Orange Area, HOT 1

ESTs1 Exam

HOT 3.27

07 April 2024
16:00 - 16:55

Location

Orange Area, HOT 1

EAU24 Live surgery

Special session

06 April 2024
10:30 - 18:00

Location Green Area, eURO Auditorium 1

10:30 - 11:00

Part 1a

Channel 1 HoLEP + MOSES Technology

To be confirmed

Channel 2 Semi-live: RIRS procedure LithoVue SU scope and Moses Technology

To be confirmed

Channel 3 ECIRS procedure with LithoVue SU scope and Moses Technology

To be confirmed

To be confirmed

Channel 4 Part I: Stone lithotripsy

To be confirmed

11:00 - 11:30

Part 1b

Channel 1 GreenLight

To be confirmed

Channel 2 Semi-live: Rezum

To be confirmed

Channel 3 PRU (AMS 800 & AMS 700 - combined procedure)

To be confirmed

Channel 4 Part II: Stone lithotripsy

To be confirmed

11:30 - 12:00

Part 2a

Channel 1 Part I: PCNL

To be confirmed

To be confirmed

To be confirmed

Channel 2 Pre-recorded: BPH

Moderator To be confirmed

Channel 3 ECIRS/SBES - TFL (Fiber Dust) + Holmium (Cyber Ho)

To be confirmed

To be confirmed

Channel 4 BPH HoLEP - Virtual Basket (Cyber Ho 150)

To be confirmed

12:00 - 12:30

Part 2b

Channel 1 Part II: PCNL

To be confirmed

To be confirmed

Channel 2 Semi-live: Bladder tumour

To be confirmed

Channel 3 RIRS - Holmium Virtual Basket (Cyber Ho)

To be confirmed

Channel 4 ThuFlep - TFL (Fiber Dust)

To be confirmed

12:30 - 13:00

Part 3

Channel 1 Thulium Laser Enucleation of the Prostate (ThuFLEP) with SOLTIVE™ System

To be confirmed

Channel 2 Semi-live: Minimally invasive BPH treatment with iTind

To be confirmed

Channel 3 Endoscopic Combined Intrarenal Surgery (ECIRS) with SOLTIVE thulium fiber laser

To be confirmed

To be confirmed

To be confirmed

Channel 4 Pre-recorded: New technology (15 min.)

Moderator To be confirmed

Channel 4 Semi-live: Mini-PCNL - TFL (Fiber Dust) - (15 min.)

To be confirmed

13:00 - 13:30

Part 4

Channel 1 Flexible Ureteroscopic Lithotripsy with SOLTIVE thulium fiber laser

To be confirmed

Channel 2 Semi-live: NMIBC treatment with Narrow Band Imaging (NBI) & Plasma+

To be confirmed

Channel 3 Laparoscopic partial nephrectomy

To be confirmed

Channel 4 Semi-live: BPH - TFL Vs Holmium - TFL (Fiber Dust) + Holmium (Cyber Ho 100) - (15 min.)

To be confirmed

To be confirmed

To be confirmed

Channel 4 Pre-recorded: Mini-ECIRS -TFL (Fiber Dust) + Holmium (Cyber Ho) - (15 min.)

Moderator To be confirmed

13:30 - 14:00

Part 5

Channel 1 BipolIEP

To be confirmed

Channel 2 Semi-live: UTUC using Flex-XC1 and MultiLASE TFL

To be confirmed

Channel 3 RIRS

To be confirmed

Channel 4 Semi-live: DISS (Direct-in-scope-suction) RIRS with SUCTION scope

To be confirmed

14:00 - 15:00

Part 6

To be confirmed

To be confirmed

15:00 - 15:30

Part 7

Channel 1 Radical prostatectomy

To be confirmed

Channel 2 Semi-live: Cystectomy

To be confirmed

To be confirmed

Channel 2 Pre-recorded: Partial nephrectomy

Moderator To be confirmed

Channel 3 Partial nephrectomy

To be confirmed

Channel 4 Semi-live: RARP

To be confirmed

15:30 - 17:00

Part 8

Channel 1 Kidney Partial nephrectomy

To be confirmed

To be confirmed

Channel 2 Pre-recorded:

Radical prostatectomy (extraperitoneal approach) - (45 min.)

Moderator To be confirmed

Channel 2 Semi-live: Benign prostatectomy (transvesical approach) - (45 min.)

To be confirmed

Channel 3 Radical prostatectomy

To be confirmed

Channel 4 Semi-live: Kidney

To be confirmed

17:00 - 17:30

Part 9

Channel 1 Semi-live: Lithiasis

To be confirmed

Channel 2 Semi-live: Stone management and ureterorenoscopy

To be confirmed

Channel 3 Invisible PNL

To be confirmed

Channel 4 Semi-live: Hydrogel Method with MediNik

To be confirmed

17:30 - 18:00

Part 10

Channel 4 Advanced AEEP with TFL and Piranha Morcellator

To be confirmed

ESU/ESUT Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 1.04

05 April 2024
12:45 - 13:40

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 1.08

05 April 2024
13:45 - 14:40

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 1.12

05 April 2024
14:45 - 15:40

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 1.16

05 April 2024
15:45 - 16:40

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.04

06 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.08

06 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.12

06 April 2024
11:00 - 11:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.16

06 April 2024
12:00 - 12:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.20

06 April 2024
15:30 - 16:25

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 2.24

06 April 2024
16:30 - 17:25

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.04

07 April 2024
09:00 - 09:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.09

07 April 2024
10:00 - 10:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.14

07 April 2024
11:00 - 11:55

Location

Orange Area, HOT 1

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.19

07 April 2024
14:00 - 14:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.24

07 April 2024
15:00 - 15:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Transurethral treatment - Step 3 (HoLEP)

HOT 3.29

07 April 2024
16:00 - 16:55

Location Orange Area, HOT 1

Learning objectives

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of Holmium Laser Enucleation of the Prostate (HoLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in HoLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

Training aim

The primary objective of this course is to enhance participants' skills in HOLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Hands-on Training in Sacral Neuromodulation (SNM)

HOT 2.26

06 April 2024
09:30 - 11:00

Location Orange Area, HOT 4
Chair V. Phé, Paris (FR)

Learning objectives

This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

Training aim

The primary objective of this course is to enhance participants' skills in sacral neuromodulation, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in SNM procedures.

- Hands-on Training.
- Operating area setup and organization.
- The management of equipment
- Standardized technical approach of a urological procedure.
- Management of critical details related to an urological procedure.

09:30 - 09:30

Introduction

09:30 - 11:00

Percutaneous Nerve Evaluation Station 1

M. Tutolo, Milan (IT)

09:30 - 11:00

Percutaneous Nerve Evaluation Station 2

M.G. Çulha, Istanbul (TR)

09:30 - 11:00

Percutaneous Nerve Evaluation Station 3

To be confirmed

09:30 - 11:00

Advanced Station 1

C. Ochoa Vargas, Bristol (GB)

09:30 - 11:00

Advanced Station 2

S. Arlandis, Valencia (ES)

09:30 - 11:00

Advanced Station 3

C. Harding, Newcastle upon Tyne (GB)

09:30 - 11:00

Programming Station

L. Thomas, Bristol (GB)

Hands-on Training in Sacral Neuromodulation (SNM)

HOT 2.27

06 April 2024
11:15 - 12:45

Location Orange Area, HOT 4
Chair V. Phé, Paris (FR)

Learning objectives

This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

Training aim

The primary objective of this course is to enhance participants' skills in sacral neuromodulation, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in SNM procedures.

- Hands-on Training.
- Operating area setup and organization.
- The management of equipment
- Standardized technical approach of a urological procedure.
- Management of critical details related to an urological procedure.

11:15 - 12:45

Introduction

11:15 - 12:45

Percutaneous Nerve Evaluation Station 1

To be confirmed

11:15 - 12:45

Percutaneous Nerve Evaluation Station 2

M.G. Çulha, Istanbul (TR)

11:15 - 12:45

Percutaneous Nerve Evaluation Station 3

To be confirmed

11:15 - 12:45

Advanced Station 1

C. Ochoa Vargas, Bristol (GB)

11:15 - 12:45

Advanced Station 2

A. Kaufmann, Mönchengladbach (DE)

11:15 - 12:45

Advanced Station 3

J-N.L. Cornu, Rouen (FR)

11:15 - 12:45

Programming Station

L. Thomas, Bristol (GB)

Hands-on Training in Non-Technical Skills (NTS)

HOT 3.35

07 April 2024
13:45 - 15:30

Location Orange Area, HOT 4
Chair N. Raison, London (GB)

Learning objectives

The Hands-on Training in Non-Technical Skills (NTS) focuses on a wide range of cognitive, reflective, and social abilities that complement the technical expertise of professionals, facilitating safe and effective performance in dynamic and high-stakes environments. Non-technical skills such as communication, teamwork, and decision-making are central to the safety and efficiency of patient care, preventing adverse effects, errors, managing emergencies, and fostering a culture of safety. During this course, expert faculty will simulate common complex or stressful operating room scenarios. Delegates will participate these scenarios to practice the specific skills necessary to navigate the complexities of the operating room, such as communicating effectively, work collaboratively, maintain situational awareness, and making timely and informed decisions.

Training aim

The primary objective of this course is to enhance participants' non-technical skills focusing on key aspects such as leadership, communication, teamwork, collaboration, situational awareness, and decision-making. By the end of the course, attendees should feel more confident in applying these skills to their daily practice.

13:45 - 13:55

Introduction to Non-Technical Skills

N. Raison, London (GB)

13:55 - 14:05

Principles of Non-Technical Skills

S.M. Haensel, Rotterdam (NL)

14:05 - 15:10

Hands-on Training

15:10 - 15:30

Debrief

G. Zanovello, Verona (IT)

Hands-on Training in Non-Technical Skills (NTS)

HOT 3.36

07 April 2024
15:45 - 17:30

Location Orange Area, HOT 4
Chair To be confirmed

Learning objectives

The Hands-on Training in Non-Technical Skills (NTS) focuses on a wide range of cognitive, reflective, and social abilities that complement the technical expertise of professionals, facilitating safe and effective performance in dynamic and high-stakes environments. Non-technical skills such as communication, teamwork, and decision-making are central to the safety and efficiency of patient care, preventing adverse effects, errors, managing emergencies, and fostering a culture of safety. During this course, expert faculty will simulate common complex or stressful operating room scenarios. Delegates will participate these scenarios to practice the specific skills necessary to navigate the complexities of the operating room, such as communicating effectively, work collaboratively, maintain situational awareness, and making timely and informed decisions.

Training aim

The primary objective of this course is to enhance participants' non-technical skills focusing on key aspects such as leadership, communication, teamwork, collaboration, situational awareness, and decision-making. By the end of the course, attendees should feel more confident in applying these skills to their daily practice.

15:45 - 15:55

Introduction to Non-Technical Skills

To be confirmed

15:55 - 16:05

Principles of Non-Technical Skills

S.M. Haensel, Rotterdam (NL)

16:05 - 17:10

Hands-on Training

17:10 - 17:30

Debrief

G. Zanovello, Verona (IT)